

---

American Transplant Congress  
Meeting Office  
1120 Route 73, Suite 200  
Mount Laurel, NJ 08054  
Telephone: 856-439-0500  
Fax: 856-439-0525



---

# Table of Contents

Day-at-a-Glance and Program .....	5
Oral Abstracts .....	312
Poster Abstracts .....	591
Index by Author.....	1168
Index by Keyword .....	1206



**AMERICAN TRANSPLANT CONGRESS**  
**Day-at-a-Glance, Saturday, June 1, 2019**

---

Saturday, June 1

**1:00 pm – 5:30 pm     In-Depth Symposia**

---

- Page 6*            **HLA – Beyond the Basics of A, B, and DR**  
*Ballroom A*
- Page 6*            **The Changing Landscape of Liver Transplantation**  
*Ballroom C*
- Page 7*            **Leadership Bootcamp: Growth, Sustainability and Fiscal Management of Transplant Programs**  
*Room 312*
- Page 7*            **The Basics of Heart & Lung Transplantation: Clinical Perspectives and Evidence-Based Management**  
*Room 306*
- Page 8*            **Managing Kidney Renal Allograft Failure to Re-Transplantation (KRAFT): Challenges and Opportunities**  
*Room 311*
- Page 9*            **The Multidisciplinary Team: Solving Problems in the Modern World**  
*Room 310*
- Page 9*            **Transplant Infectious Disease**  
*Ballroom B*
- Page 10*           **Molecular Dissection of Rejection**  
*Room 304*
- Page 11*           **Basic Science for the Clinician – Transplant Rejection**  
*Room 302*

**5:30 pm            Congress Begins**

---

**5:30 pm – 7:30 pm     Opening Reception with Exhibits**

---

*Hall C/D*

**5:30 pm – 7:30 pm     Poster Session A**

---

**Presenters in Attendance**

*Hall C/D*

# AMERICAN TRANSPLANT CONGRESS

Program, Saturday, June 1, 2019

---

## In-Depth Symposia (Additional Fee)

1:00 pm – 5:30 pm

### HLA-Beyond the Basics of A, B, and Dr

#### **Ballroom A**

Moderators: Elaine Reed, PhD, University of California Los Angeles Health, Los Angeles, CA. Peter Nickerson, MD, FRCPC, University of Manitoba, Winnipeg, MB, Canada.

- 1:00 pm **Antibody Mediated Injury Through the Pathologist's Lens –What Does Suspicious Mean?**  
*Lynn Cornell, MD, Mayo Clinic, Rochester, MN, USA.*
- 1:20 pm **Audience Discussion**
- 1:30 pm **Antibody Mediated Injury from the Nephrologist's Perspective: Current Dilemmas and Future Directions**  
*Darshana Dadhania, MD, MS, Weill Cornell Medicine, New York City, NY, USA.*
- 1:50 pm **Audience Discussion**
- 2:00 pm **Accommodation to Antibodies**  
*Elaine Reed, PhD, University of California Los Angeles Health, Los Angeles, CA, USA.*
- 2:20 pm **Audience Discussion**
- 2:30 pm **Debate-PRO: Monitoring for Donor Specific Antibody on a Routine Basis Is Necessary!**  
*Peter Nickerson, MD, FRCPC, University of Manitoba, Winnipeg, MB Canada.*
- 2:40 pm **Debate-CON: Monitoring for Donor Specific Antibody on a Routine Basis is NOT Necessary!**  
*Howard Gebel, PhD, Emory University, Atlanta, GA, USA.*
- 2:50 pm **Debate - PRO: Rebuttal**  
*Peter Nickerson, MD, FRCPC, University of Manitoba, Winnipeg, MB, Canada.*
- 2:55 pm **Debate - CON: Rebuttal**  
*Howard Gebel, PhD, Emory University, Atlanta, GA, USA.*
- 3:00 pm **Audience Discussion**

## Coffee Break

3:10 pm – 3:30 pm

- 3:30 pm **Algorithms for Epitope Matching**  
*Vasilis Kosmoliaptis, MD, PhD, University of Cambridge, Cambridge, England.*
- 3:50 pm **Audience Discussion**
- 4:00 pm **Reviewing Available Data on Outcomes**  
*James Cooper, MD, University of Colorado, Aurora, CO, USA.*
- 4:20 pm **Audience Discussion**
- 4:30 pm **Comprehensive Tour of Non-HLA Antibodies**  
*Matthew Everly, PharmD, Terasaki Research Institute, Los Angeles, CA, USA.*
- 4:50 pm **Audience Discussion**
- 5:00 pm **Clinical Relevance of Non-HLA Antibodies**  
*Dany Anglicheau, MD, PhD, Necker-Children Malades Hospital, Paris, France.*
- 5:20 pm **Audience Discussion**

### The Changing Landscape of Liver Transplantation

#### **Ballroom C**

Moderators: Mike Abecassis, MD, MBA, Northwestern Medicine, Feinberg School of Medicine, Chicago, IL, USA. David Goldberg, MD, MSCE, University of Pennsylvania, Philadelphia, PA, USA.

- 1:00 pm **Challenges of NASH and Obesity**  
*Kymerly Watt, MD, Mayo Clinic, Rochester, MN, USA.*
- 1:20 pm **Audience Discussion**
- 1:30 pm **Challenges of Retransplantation**  
*Carlos O. Esquivel, MD, PhD, Stanford Abdominal Transplantation, Stanford, CA, USA.*
- 1:50 pm **Audience Discussion**
- 2:00 pm **The Increasing Burden of Renal Disease**  
*Patricia Sheiner, MD, FACS, Hartford Hospital, Hartford, CT, USA.*
- 2:20 pm **Audience Discussion**

# AMERICAN TRANSPLANT CONGRESS

Program, Saturday, June 1, 2019

Saturday, June 1

2:30 pm **How to Transplant Low MELD Patients**  
*Alan Langnas, DO, University of Nebraska, Omaha, NE, USA.*

2:50 pm **Audience Discussion**

## Coffee Break

3:00 pm – 3:30 pm

3:30 pm **New and Extended Indications for LT in the Future**  
*Marwan Abouljoud, MD, Henry Ford Hospital, Detroit, MI, USA.*

3:50 pm **Audience Discussion**

4:00 pm **The Future of the Liver Transplant Workforce - Surgeon Perspective**  
*Mike Engelsbe, MD, University of Michigan, Ann Arbor, MI, USA.*

4:15 pm **The Future of the Liver Transplant Workforce - Mid-level Provider Perspective**  
*Georgeine Smith, MHS, MS, The Hospital of the University of Pennsylvania, Philadelphia, PA, USA.*

4:30 pm **The Future of the Liver Transplant Workforce - Hepatologist Perspective**  
*Robert Brown, MD, MPH, Weill Cornell Medical College, New York, NY, USA.*

4:45 pm **The Future of Liver Transplant Workforce Panel Discussion**

## Leadership Bootcamp: Growth, Sustainability and Fiscal Management of Transplant Programs

### Room 312

Moderators: *John Gutowski, FACHE, University of Colorado Health, Aurora, CO, USA. Laura Stillion, MHA, FACHE, The Ohio State University Wexner Medical Center, Columbus, OH, USA.*

1:00 pm **Playing Small Ball: Administrative and Clinical Challenges**  
*Marc Garfinkel, MD, SIU School of Medicine, Springfield, IL, USA.*

1:30 pm **Audience Discussion**

1:40 pm **Innovations in Growth and Marketing**  
*Jennifer Milton, RN, MBA, University Transplant Center, San Antonio, TX, USA.*

2:10 pm **Audience Discussion**

2:20 pm **Pros and Cons of Transplant Models: Institutes and Service Lines**  
*Jason Vanatta, MD, Cleveland Clinic Florida, Weston, FL, USA.*

2:50 pm **Audience Discussion**

## Coffee Break

3:00 pm – 3:30 pm

3:30 pm **Common Errors in Medicare Cost Report Preparation**  
*Ed Zavala, MBA, Vanderbilt University Medical Center, Nashville, TN, USA.*

4:00 pm **Audience Discussion**

4:10 pm **Implications for Staffing of the Long-Term Care of Transplant Patients**  
*Laura Stillion, MHA, FACHE, The Ohio State University Wexner Medical Center Columbus, OH, USA.*

4:40 pm **Audience Discussion**

## The Basics of Heart & Lung Transplantation: Clinical Perspectives and Evidence-Based Management

### Room 306

Moderators: *Kevin Daly, MD, Boston Children's Hospital, Boston, MA, USA. Jon Kobashigawa, MD, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, USA.*

1:00 pm **Primary Graft Failure in Heart Transplantation**  
*Maryjane Farr, MD, Columbia University Medical Center, New York, NY, USA.*

1:20 pm **Management of Common Post-Transplant Complications**  
*Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA.*

1:40 pm **Mechanical Circulatory Support as a Bridge to Heart Transplantation**  
*Jeff Teuteberg, MD, Stanford University, Stanford, CA, USA.*

2:00 pm **Evaluation for Heart Transplant Candidacy: Key Concepts**  
*Donna Mancini, MD, Mount-Sinai, New York, NY, USA.*

# AMERICAN TRANSPLANT CONGRESS

Program, Saturday, June 1, 2019

---

**2:20 pm Monitoring, Diagnosis and Treatment of Rejection in Heart Transplantation**

*Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA.*

**2:40 pm Panel Discussion**

**Coffee Break**

---

**3:00 pm – 3:30 pm**

**3:30 pm – 5:30 pm**

*Moderators: Sangeeta Bhorade, MD, Northwestern Medicine, Chicago, IL, USA. Daniel Dilling, MD, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA.*

**3:30 pm Evaluation for Lung Transplant Candidacy: Key Concepts**

*Jonathan Singer, MD, MS, UCSF, San Francisco, CA, USA.*

**3:50 pm The Use of Mechanical Assist Devices in Bridging to Lung Transplantation**

*Marty Zamora, MD, University of Colorado Denver, Denver, CO, USA.*

**4:10 pm Primary Graft Failure in Lung Transplantation**

*Jeffrey D. Edelman, MD, University of Washington, Seattle, WA, USA.*

**4:30 pm Monitoring, Diagnosis and Treatment of Rejection in Lung Transplantation**

*Deborah Levine, MD, University of Texas Health Science Center San Antonio, San Antonio, TX, USA.*

**4:50 pm Management of Common Post-Transplant Complications**

*Marie Budev, DO, The Cleveland Clinic, Cleveland, OH, USA.*

**5:10 pm Panel Discussion**

**Managing Kidney Renal Allograft Failure to Re-Transplantation (KRAFT): Challenges and Opportunities**

**Room 311**

*Moderators: Martha Pavlakis, MD, Beth Israel Deaconess Medical Center, Boston, MA, USA. Jim Rice, MD, Scripps, La Jolla, CA, USA.*

**1:00 pm Managing CKD V in Recipients with Failing Kidney Allografts: Are Transplant Nephrologists Up to the Task?**

*Robert Gatson, MD, University of Alabama, Birmingham, AL, USA.*

**1:30 pm Audience Discussion**

**1:40 pm Increased Mortality in Recipients with a Failed Kidney Allograft: Why so High?**

*John Gill, MD, MS, Providence Health Care, Vancouver, BC, Canada.*

**2:10 pm Audience Discussion**

**2:20 pm Outcomes of Renal Re-transplantation**

*Todd Pesavento, MD, The Ohio State University, Columbus, OH, USA.*

**2:50 pm Audience Discussion**

**Coffee Break**

---

**3:00 pm – 3:30 pm**

**3:30 pm The Changing Face of Sensitization in Recipients with Failing Kidney Allograft**

*Carrie Schinstock, MD, Mayo Clinic, Rochester, MN, USA.*

**2:50 pm Audience Discussion**

**4:10 pm Collaborative Relationship: Is it Possible to Improve Care of Recipients with Failing Kidney Allografts?**

*James Rice, MD, Scripps Clinic and Green Hospital, La Jolla, CA, USA.*

**4:40 pm Audience Discussion**



# AMERICAN TRANSPLANT CONGRESS

Program, Saturday, June 1, 2019

---

Saturday, June 1

## The Multidisciplinary Team: Solving Problems in the Modern World

### Room 310

1:00 pm – 3:00 pm

Moderators: Brenda Kowinski, MSN, RN, CCTC, NATCO, Indianapolis IN, USA. Joyce Trompeta, PhD, PNP, University of California, San Francisco, CA, USA.

1:00 pm **Undocumented Immigrants: Transplant Center Responsibilities; Strategies to Handle Difficult Situation; Legal and Fiscal Concerns**  
*Luke Preczewski, BS, Jackson Health System, Miami, FL, USA.*

1:20 pm **Audience Discussion**

1:30 pm **Media and Judicial Influence on OPTN Organ Allocation Policy**  
*Stuart Sweet, MD, PhD, Washington University, St. Louis, MO, USA.*

1:50 pm **Audience Discussion**

2:00 pm **Transplanting HepC+ to HepC-: What are the financial implications?**  
*Cameron Wolfe, MBBS, MPH, Duke University Medical Center, Durham, NC, USA.*

2:20 pm **Audience Discussion**

2:30 pm **Chronic Sorrow**  
*Stacia Hays, DNP, CPNP, University of Florida, Gainesville, FL, USA.*

2:50 pm **Audience Discussion**

## Coffee Break

3:00 pm – 3:30 pm

3:30 pm – 5:35 pm

Moderators: Tiffany Buda, RSN, BSN, Cleveland Clinic, Cleveland, OH, USA. Linda Ohler, New York University Langone Health, New York, NY, USA.

3:30 pm **Development of APP Staffing Models, Supporting Inpt and Outpt Tx Service lines**  
*Karen Kerepesi, PA, Cleveland Clinic, Cleveland, OH, USA.*

3:50 pm **Audience Discussion**

3:55 pm **APN as Gatekeeper in Diagnosis of Cardiac Primary Dysfunction**  
*Maureen Flattery, MD, VCU Health, Richmond, VA, USA.*

4:15 pm **Audience Discussion**

4:20 pm **Avoiding the ER: APP-Run Post-Transplant Urgent Care Clinics**  
*Rebecca Duke, APRN-CNP, DNP, Northwestern Memorial Hospital, Chicago, IL, USA.*

4:40 pm **Audience Discussion**

4:45 pm **No Urine? No Problem! APP-Run DGF Clinics**  
*Brenda Muth, NP, University of Wisconsin, Madison, WI, USA.*

5:05 pm **Audience Discussion**

5:10 pm **Development of Clinic Transplant Pharmacist Services: Who, What, When, and Where**  
*Lisa Potter, PharmD, BCPS, University of Chicago Medicine, Chicago, IL, USA.*

5:30 pm **Audience Discussion**

## Transplant Infectious Disease

### Ballroom B

1:00 pm – 2:00 pm

Moderators: Camille Kotton, MD, Massachusetts General Hospital, Boston, MA, USA. Jonathan Hand, MD, Ochsner Medical Center, New Orleans, LA, USA.

1:00 pm **Managing Infections in Transplant Candidates: Overview of Pre-Transplant Evaluation**  
*Judith Anesi, MD, University of Pennsylvania, Philadelphia, PA, USA.*

1:20 pm **Managing Infections in Transplant Candidates: MDROs- Treatment and Does it Affect Candidacy?**  
*Ghady Haidar, MD, University of Pittsburgh Medical Center Pittsburgh, PA, USA.*

1:40 pm **Managing Infections in Transplant Candidates: LVAD Infections**  
*Christine Koval, MD, Cleveland Clinic, Cleveland OH, USA.*

# AMERICAN TRANSPLANT CONGRESS

Program, Saturday, June 1, 2019

---

**2:00 pm – 3:00 pm**

*Moderators: Susanna Tan, MD, Stanford University, Stanford, CA, USA. Nicole Theodoropoulos, MD, MS, University of Massachusetts, Worcester, MA, USA.*

**2:00 pm Managing Complicated Infections in Transplant Recipients: Managing Post-Transplant TB**

*Aruna Subramaniam, MD, Stanford University, Stanford, CA, USA.*

**2:20 pm Managing Complicated Infections in Transplant Recipients: Managing BK-Updates in Therapeutic Options**

*Hans Hirsch, MD, MSc, University of Basel, Basel, Switzerland.*

**2:40 pm Managing Complicated Infections in Transplant Recipients: Non-Aspergillus Moulds**

*Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada.*

**3:00 pm Audience Discussion**

## Coffee Break

**3:15 pm – 3:45 pm**

**3:45 pm – 4:45 pm**

*Moderators: Emily Blumberg, MD, FAST, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. Monica Ardura, DO, MSCS, Nationwide Children's Hospital & The Ohio State University, Columbus, OH, USA.*

**3:45 pm T1D is a Team Sport!: The Cutting Edge Surgeons Perspective of Managing Post-Transplant Infections**

*Abhinav Humar, MD, University of Pittsburgh, Pittsburgh, PA, USA.*

**4:05 pm T1D is a Team Sport!: A Day in the Life-The Pharmacist's Role in Management of SOT Infections**

*Gregory Malat, PharmD, Hahnemann University Hospital, Philadelphia, PA, USA.*

**4:25 pm T1D is a Team Sport!: Tell me Why-The 'Path' to Diagnosis of SOT Infections**

*Maricar Malinis, MD, Yale University School of Medicine, New Haven, CT, USA.*

**4:45 pm Cases in Transplant Infections-Stump The Expert**

*Lara Danziger-Isakov, MD, MPH, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.*

**4:50 pm Cases in Transplant Infections-Stump The Expert**

*Nicole Theodoropoulos, MD, MS, University of Massachusetts Medical School, Worcester, MA, USA.*

**4:55 pm Cases in Transplant Infections-Stump The Expert**

*Lillian Abbo, MD, University of Miami/Jackson Health System, Miami, FL, USA.*

**5:00 pm Cases in Transplant Infections-Stump The Expert**

*Shirish Huprikar, MD, The Mount Sinai Hospital, New York, NY, USA.*

**5:05 pm Cases in Transplant Infections-Stump The Expert**

*Jonathan Hand, MD, Ochsner Medical Center, New Orleans, LA, USA.*

**5:10 pm Cases in Transplant Infections-Stump The Expert**

*Fernanda Silveira, MD, University of Pittsburgh and UPMC, Pittsburgh, PA, USA.*

**5:15 pm Audience Discussion**

## Molecular Dissection of Rejection

### **Room 304**

**1:00 pm – 3:00 pm**

*Moderators: Christopher Blosser, MD, University of Washington Division of Nephrology, Seattle, WA, USA. Lorenzo Gallon, MD, Northwestern University, Chicago, IL, USA.*

**1:00 pm Molecular Approaches to Chronic Allograft Injury**

*Enver Akalin, MD, FAST, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.*

**1:20 pm Audience Discussion**

**1:30 pm Biomarkers in Graft Rejection**

*Manikkam Suthanthiran, MD, Weill Cornell Medicine, New York, NY, USA.*

**1:50 pm Audience Discussion**

# AMERICAN TRANSPLANT CONGRESS

Program, Saturday, June 1, 2019

---

Saturday, June 1

**2:00 pm Single Cell Approaches to Rejection**  
*Emmanuel Zorn, PhD, Columbia University Medical Center, New York, NY, USA.*

**2:20 pm Audience Discussion**

**2:30 pm Epigenetic and Transplantation**  
*Valeria Mas, PhD, University of Virginia School of Medicine, Charlottesville, VA, USA.*

**2:50 pm Audience Discussion**

## Coffee Break

---

**3:00 pm – 3:30 pm**

**3:30 pm – 5:30 pm**  
*Moderators: Loren Gragert, PhD, Tulane University School of Medicine, New Orleans, LA, USA. Lorenzo Gallon, MD, Northwestern University, Chicago, IL, USA.*

**3:30 pm DNA Biomarkers of Graft Rejection**  
*Minnie Sarwal, PhD, MD, UCSF, San Francisco, CA, USA.*

**3:50 pm Audience Discussion**

**4:00 pm Linking Molecular Signatures of Rejection to Histology**  
*Philip Halloran, MD, University of Alberta, Edmonton, AB, Canada.*

**4:20 pm Audience Discussion**

**4:30 pm Learning from Large Genomic Studies in Transplantation**  
*Brendan Keating, D. Phil, University of Pennsylvania, Philadelphia, PA, USA.*

**4:50 pm Audience Discussion**

**5:00 pm B Cell Biomarkers for Transplantation**  
*David Rothstein, MD, University of Pittsburgh, Pittsburgh, PA, USA.*

**5:20 pm Audience Discussion**

## Basic Science for the Clinician-Transplant Rejection

### Room 302

*Moderators: Arjang Djamali, MD, MS, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. Basset El Essawy, M.B.B.Ch, MSc, Transplant Research Center-Brigham and Women's Hospital- Harvard, Boston, MA, USA.*

**1:00 pm Costimulation for Clinicians**  
*Andrew Adams, MD/PhD, Emory University, Atlanta, GA, USA.*

**1:20 pm Audience Discussion**

**1:30 pm Diagnosis of AMR - What the Clinician Needs to Know**  
*Jacqueline O'Leary, MD, MPH, UT Southwestern Medical Center, Dallas, TX, USA.*

**1:50 pm Audience Discussion**

**2:00 pm Basic Science of B Cell Mediated Rejection from a Clinician's View**  
*Stanley Jordan, MD, Cedars-Sinai Medical Center, West Hollywood, CA, USA.*

**2:20 pm Audience Discussion**

**2:30 pm T Cell Subsets - What a Clinician Needs to Know**  
*Xounrong Luo, MD, PhD, Duke University, Durham, NC, USA.*

**2:50 pm Audience Discussion**

## Coffee Break

---

**3:00 pm – 3:30 pm**

**3:30 T Regs in Transplantation**  
*Anil Chandraker, MD, Brigham and Women's Hospital, Boston, MA, USA.*

**3:50 pm Audience Discussion**

**4:00 pm Complement Inhibition in Transplantation**  
*Rex Neal-Smith, MD, PhD, Massachusetts General Hospital, Boston, MA, USA.*

**4:20 Audience Discussion**

**4:30 pm Innate Immune System for Clinicians**  
*Martin Oberbarnscheidt, MD, PhD, University of Pittsburgh, Pittsburgh, PA, USA.*

**AMERICAN TRANSPLANT CONGRESS**  
**Program, Saturday, June 1, 2019**

---

**4:50 Audience Discussion**

**5:00 pm Endothelial Biology**  
*David Briscoe, MD, Boston Children's  
Hospital and Harvard Medical School  
Boston, MA, USA.*

**5:20 pm Audience Discussion**

**Congress Begins**

---

**Opening Reception with Exhibits**

---

*Hall C/D*  
5:30 pm – 7:30 pm

**Poster Session A – Presenters in  
Attendance**

---

*Hall C/D*  
5:30 pm – 7:30 pm

**Poster Viewing: 5:30 pm - 7:30 pm**  
**Presenters in Attendance: 5:30 pm - 7:30 pm**

**Poster Session A can be found on  
pages 149-190.**

# AMERICAN TRANSPLANT CONGRESS

## Day-at-a-Glance, Sunday, June 2, 2019

---

**7:00 am – 8:15 am Sunrise Interactive**  
*(Continental Breakfast Included)*

Page 17 **Non-Tuberculous Mycobacteria in Lung Transplant Recipients**  
Room 306

Page 17 **Can We Solve the Organ Discard Problem?**  
Ballroom A

Page 17 **Immunosuppression in 2019 and Beyond: Considerations for CNJ Conversion**  
Ballroom B

Page 18 **Trying to Avoid Intestinal Transplantation in the Patient with Short Gut Syndrome**  
Room 206

Page 18 **Acute Liver Failure: We Came, We Saw, Have We Conquered?**  
Ballroom C

Page 18 **Keeping it Real, the Motto of ‘One Transplant for Life’. Addressing the Unmet Need of Post Transplant Education and Communication**  
Room 311

Page 18 **Approach to Desensitization Pre and Post Heart Transplantation**  
Room 310

Page 19 **A to Z in HIV to HIV Kidney Transplantation**  
Room 312

Page 19 **Gender Disparity in Transplantation**  
Room 208

Page 19 **Expanding the Lung Donor Pool While Optimizing Patient Outcomes**  
Room 313

Page 19 **Pediatric Kidney Transplantation: Barriers to Success**  
Room 210

Page 20 **Optimizing Management of the Metabolic Syndrome After Liver Transplantation**  
Room 309

**7:00 am – 8:15 am Sunrise Didactic**  
*(Continental Breakfast Provided)*

Page 20 **Tissue Engineering in Transplantation**  
Room 302

Page 20 **Antibody Functions in Tissues & Regulations**  
Room 304

**8:15 am – 8:30 am Break**

**8:30 am – 9:30 am Plenary Session I**

Page 21 *Veterans Auditorium*

**9:30 am – 9:45 am Joint Award Session**

Page 21 *Veterans Auditorium*

**9:45 am – 10:00 am ASTS Research Grants**

Page 21 *Veterans Auditorium*

**10:00 am – 10:15 am ASTS Pioneer Award**

Page 21 *Veterans Auditorium*

**10:15 am – 10:30 am AST Awards**

Page 21 *Veterans Auditorium*

**10:30 am – 10:45 am AST Lifetime Achievement Award**

Page 22 *Veterans Auditorium*

**10:45 am – 11:15 am Coffee Break in the Exhibit Hall**  
*Hall C/D*

Sunday, June 2

**AMERICAN TRANSPLANT CONGRESS**  
**Day-at-a-Glance, Sunday, June 2, 2019**

---

**11:15 am – 12:45 pm Midday Interactive**

---

- Page 22*      **Personalized Medicine in Transplantation: Can We Move the Needle?**  
*Room 313*
- Page 22*      **Lung Transplantation: From Bench to Bedside and Back**  
*Room 206*
- Page 22*      **Are Donors After Cardiac Death Underutilized in Pediatric Transplant Recipients?**  
*Room 210*
- Page 23*      **Personalized Immunosuppression and Infectious Risk: Joint ATC-ESCMID/ESOT Session**  
*Ballroom B*
- Page 23*      **Controversies in KPD**  
*Room 302*

**11:15 am – 12:45 pm Midday Didactic**

---

- Page 23*      **When to Sound the Alarm: Tough Risk-Benefit Decisions for Journals, Pharma and the FDA**  
*Room 310*
- Page 24*      **T Cell Mediated Rejection: Where are we in 2019?**  
*Veterans Auditorium*
- Page 24*      **Renal Issues in Cardiac Transplantation**  
*Room 208*
- Page 24*      **Bench to Bedside: B Cells in Transplantation**  
*Room 304*
- Page 25*      **EBV and Post-Transplant Lymphoproliferative Disease: Emerging Data & Pediatric Consensus Guidelines**  
*Ballroom C*
- Page 25*      **Revisiting DOAC Anticoagulation in Transplantation**  
*Room 312*

- Page 25*      **Tipping the Scale in Our Favor: The Steatoic Donor Liver**  
*Room 311*
- Page 25*      **Silent Chronic Graft Injury After Liver Transplantation: Evidence for TCMR and/or AMR?**  
*Room 309*
- Page 26*      **Platelets in the Immune Response**  
*Room 306*
- Page 26*      **Tregs-Bench to Bedside**  
*Ballroom A*

**12:45 pm – 1:00 pm Break**

---

**1:00 pm – 2:15 pm Sponsored Satellite Symposia**

---

Satellite Symposia are open to all registered Congress attendees. Satellite Symposia take place at the Sheraton Boston Hotel. Please check the ATC website, [www.atcmeeting.org](http://www.atcmeeting.org), or ATC mobile app (ATC19) for the full Satellite Symposia program listing.

*Page 26*      *Sheraton Boston Hotel*

**1:00 pm – 2:15 pm Luncheon Workshops**

---

*(Additional Fees - Limited Ticketed Events)*

- Page 26*      **Obesity in Kidney Transplantation: Donors and Recipients**  
*Room 109*
- Page 26*      **New Transplant Medical Director: Roles, Responsibilities & Challenges**  
*Room 110*
- Page 26*      **Differentiating ‘Difficult Patients’ and ‘Patients in Difficult Situations’ in Urgent Organ Failure**  
*Cafe, Across from Hall A Registration*



# AMERICAN TRANSPLANT CONGRESS

## Day-at-a-Glance, Sunday, June 2, 2019

---

<i>Page 26</i>	<b>Where Have You Been All My Life? The Living Donor with Infectious Disease</b> <i>Room 108</i>	<i>Page 36</i>	<b>Endothelial Cell Biology</b> <i>Room 310</i>
<b>1:30 pm – 4:30 pm      Transplantation In Depth (Basic)</b>		<i>Page 37</i>	<b>Ischemia Reperfusion &amp; Organ Rehabilitation I</b> <i>Room 313</i>
<i>Page 27</i>	<b>The Next New Thing- Basic Pathways to Emerging Therapeutics</b> <i>Room 302</i>	<i>Page 38</i>	<b>Tolerance: Clinical Studies</b> <i>Room 208</i>
<b>2:15 pm – 2:30 pm      Break</b>		<i>Page 39</i>	<b>Medley of Heart Transplantation Topics</b> <i>Room 206</i>
<b>2:30 pm – 4:00 pm      Concurrent Oral Abstract Sessions</b>		<i>Page 40</i>	<b>Non-Organ Specific: Organ Preservation/Ischemia Reperfusion Injury</b> <i>Room 209</i>
<i>Page 27</i>	<b>Kidney Complications: Late Graft Failure I</b> <i>Veterans Auditorium</i>	<b>2:30 pm – 5:30 pm      Student Program</b>	
<i>Page 28</i>	<b>Kidney Deceased Donor Allocation I</b> <i>Ballroom B</i>	<i>Page 40</i>	<b>The Science, The Art, and The Allure of Transplantation</b> <i>Room 210</i>
<i>Page 29</i>	<b>Kidney Donor Selection / Management Issues I</b> <i>Ballroom C</i>	<b>4:00 pm – 4:30 pm      Coffee Break in the Exhibit Hall</b>	
<i>Page 30</i>	<b>Kidney Immunosuppression: Desensitization</b> <i>Ballroom A</i>	<i>Hall C/D</i>	
<i>Page 31</i>	<b>Kidney Technical</b> <i>Room 304</i>	<b>4:30 pm – 6:00 pm      Concurrent Oral Abstract Sessions</b>	
<i>Page 32</i>	<b>Liver: Immunosuppression and Rejection</b> <i>Room 312</i>	<i>Page 41</i>	<b>Kidney Immunosuppression: Novel Regimens and Drug Minimization I</b> <i>Veterans Auditorium</i>
<i>Page 33</i>	<b>PTLD/Malignancies: All Topics</b> <i>Room 312</i>	<i>Page 42</i>	<b>Kidney Acute Antibody Mediated Rejection</b> <i>Ballroom B</i>
<i>Page 34</i>	<b>Biomarkers, Immune Monitoring and Outcomes I</b> <i>Room 306</i>	<i>Page 43</i>	<b>Kidney: Cardiovascular and Metabolic I</b> <i>Ballroom C</i>
<i>Page 35</i>	<b>Tissue Engineering &amp; Technology</b> <i>Room 309</i>	<i>Page 44</i>	<b>Kidney Living Donor: Quality and Selection</b> <i>Ballroom A</i>
		<i>Page 45</i>	<b>Kidney: Pediatrics I</b> <i>Room 304</i>

Sunday, June 2

**AMERICAN TRANSPLANT CONGRESS**  
**Day-at-a-Glance, Sunday, June 2, 2019**

---

- Page 46*      **Liver: MELD, Allocation and Donor Issues (DCD/ECD) I**  
*Room 312*
- Page 47*      **Liver Transplant Oncology**  
*Room 311*
- Page 48*      **Lymphocyte Biology - Basic**  
*Room 306*
- Page 49*      **Histocompatibility and Immunogenetics**  
*Room 309*
- Page 50*      **B-cell / Antibody / Autoimmunity**  
*Room 310*
- Page 51*      **Vaccines and Viruses**  
*Room 313*
- Page 51*      **Psychosocial and Treatment Adherence**  
*Room 208*
- Page 52*      **Setting the Table for Success after Lung Transplantation**  
*Room 206*
- Page 53*      **Pancreas and Islet: All Topics I**  
*Room 209*

**5:45 pm – 7:45 pm      ASTS Town Hall & Reception**

---

*Hall A*

**6:00 pm – 7:00 pm      Poster Session B**  
**Presenters in Attendance**

---

*Hall C/D*



# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

## Sunrise Symposia: Interactive (Continental Breakfast Included)

7:00 am – 8:15 am

### Non-Tuberculous Mycobacteria in Lung Transplant Recipients

#### Room 306

Moderators: Scott Palmer, MD, MHS, Duke University, Durham, NC. Aruna Subramanian, MD, Stanford University, Stanford, CA, USA.

7:00 am **Epidemiology and Management of Non-Tuberculous Mycobacteria in Lung Transplant Recipients**  
*Michele Morris, MD, University of Miami Miller School of Medicine, Miami Florida, USA.*

7:20 am **Debate - Pro: Mycobacterium Abscessus and Lung Transplant: To Transplant or Not to Transplant**  
*Ricardo La Hoz, MD, UT Southwestern Medical Center Dallas, TX, USA.*

7:35 am **Debate - Con: Mycobacterium Abscessus and Lung Transplant: To Transplant or Not to Transplant**  
*Joshua Mooney, MD, MS, Stanford University, Stanford, CA, USA.*

7:50 am **Debate - Pro: Rebuttal**  
*Ricardo La Hoz, MD, UT Southwestern Medical Center, Dallas, TX, USA.*

7:55 am **Debate - Con: Rebuttal**  
*Joshua Mooney, MD, MS, Stanford University, Stanford, CA, USA.*

8:00 am **Audience Discussion**

### Can We Solve the Organ Discard Problem?

#### Ballroom A

Moderators: Ryutaro Hirose, MD, University of California San Francisco, San Francisco, CA, USA. David Klassen, MD, UNOS, Richmond, VA, USA.

7:00 am **Who Can Tolerate a Marginal Kidney? Predicting Survival After Transplantation**  
*Dory Segev, MD, PhD, Johns Hopkins University, Baltimore, MD, USA.*

7:20 am **PHS Risk Status: Time for a Change?**  
*Cameron Wolfe, MBBS(Hons), MPH, Duke University Medical Center, Durham, NC, USA.*

7:40 am **Can we Predict Organ Discard?**  
*Darren Stewart, MS, UNOS, Richmond, VA, USA.*

8:00 am **Panel Discussion**

### Immunosuppression in 2019 and Beyond: Considerations for CNJ Conversion

#### Ballroom B

Moderators: Ahmed Aljedai, Pharm. D., MBA, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. Simon Tremblay, PharmD, MS, University of Cincinnati, Cincinnati, OH, USA.

7:00 am **Conversion to Improve Adherence: Change in Formulation or Agent**  
*Mary Moss Chandran, PharmD, BCPS, Children's Hospital Colorado, Denver, CO, USA.*

7:15 am **Conversion to improve Adherence: Psychosocial Factors and Therapy**  
*John Peipert, PhD, Northwestern Medicine, Chicago, IL, USA.*

7:30 am **Conversion to Improve Renal Function in Patients with Persistent Renal Dysfunction: Change to mTOR Inhibitor**  
*Yasir Qazi, MD, Keck Med Center at USC, Los Angeles, CA, USA.*

7:45 am **Conversion to Improve Renal Function in Patients with Persistent Renal Dysfunction: Change to Belatacept**  
*Patricia West-Thielke, PharmD, BCPS, University of Illinois of Chicago, Chicago, IL, USA.*

8:00 am **Panel Discussion**

Sunday, June 2

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

## Trying to Avoid Intestinal Transplantation in the Patient with Short Gut Syndrome

### Room 206

Moderators: Cal Matsumoto, MD, MedStar Health, Washington, DC, USA. Thomas Schiano, MD, The Mount Sinai Medical Center, New York, NY, USA.

**7:00 am Can I Use Diet and Medications? – Multidisciplinary Medical Management of the Patient with Intestinal Failure**  
Syed-Mohammed Jafri, MD, Henry Ford Hospital, Detroit, MI, USA.

**7:20 am Surgical Management - Can I Do Surgery to Prevent Future Transplant?**  
George Mazariegos, MD, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.

**7:40 am While Trying to Avoid a Transplant, How Do We Treat the Complications from Intestinal Failure and TPN?**  
Maria Cristina Segovia, MD, Duke University Hospital, Chapel Hill, NC, USA.

**8:00 am Panel Discussion**

## Acute Liver Failure: We Came, We Saw, Have We Conquered?

### Ballroom C

Moderators: Catherine Frenette, MD, FAST, Scripps Center for Organ Transplant, La Jolla, CA, USA. Daniel Ganger, MD, FACP, Northwestern Medicine, Chicago, IL, USA.

**7:00 am 20 years of Contributions to ALF Management: An Update from the ALFSG**  
Daniel Ganger, MD, FACP, Northwestern Medicine, Chicago, IL, USA.

**7:20 am Does My ALF Patient Need a Liver Transplant?**  
William Bernal, MD, FRCP, Liver Intensive Therapy Unit, Kings College Hospital London, England..

**7:40 am Successful Management of the Patient with Acute Liver Failure and When is it Futile?**  
Constantine Karvellas, MD, SM, University of Alberta, Edmonton, AB, Canada.

**8:00 am Panel Discussion**

## Keeping it Real, the Motto of 'One Transplant for Life'. Addressing the Unmet Need of Post-Transplant Education and Communication

### Room 311

Moderators: Anita Patel, MD, Henry Ford Transplant Institute, Detroit, MI. Milagros Samaniego, Henry Ford Transplant Institute, Detroit, MI, USA.

**7:00 am Improve Access For Patients Away From the Primary Transplant Center: Telemedicine and Mobile Clinics**  
Richard Formica, MD, Yale School of Medicine, New Haven, CT, USA.

**7:15 am Educating and Communicating with Community Specialists, Primary Care Providers, Care Partners and Patients – How Do Canadians Do This?**  
Marcelo Cantarovich, MD, Professor of Medicine, McGill University Health Centre Research Institute, Montreal, Quebec.

**7:30 am Insurance Organizations and Ensurance of Transplant Health Care, Role of Lobbying and Legislation**  
Matthew Cooper, MD, Professor of Surgery, Medstar Georgetown Transplant Institute, Washington, DC, USA.

**7:45 am Taking Transplant Medicine to the Community: Outreach models, Communication and Educational Endeavors**  
Marwan Abouljoud, MD, Henry Ford Hospital, Detroit, MI, USA.

**8:00 am Panel Discussion**

## Approach to Desensitization Pre and Post Heart Transplantation

### Room 310

Moderators: Monica Colvin, MD, MS, Frankel Cardiovascular Center- Michigan Medicine, Midland, MI, USA. Josef Stehlik, MD, MPH, University of Utah School of Medicine Salt Lake City, UT, USA.

**7:00 am Understanding Regulation of Antibody Production**  
Annette Jackson, PhD, Duke University, Durham, NC, USA.

**7:20 am Emerging Therapies for Desensitization**  
Jignesh Patel, MD, PhD, Cedars-Sinai, Beverly Hills, CA, USA.

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

**7:40 am Managing De Novo DSA After Heart Transplantation**

*Robert Cole, MD, Emory University, Atlanta, GA, USA.*

**8:00 am Panel Discussion**

**A to Z in HIV to HIV Kidney Transplantation**

**Room 312**

*Moderators: Shirish Huprikar, MD, The Mount Sinai Hospital, New York, NY. Peter Stock, MD, PhD, University of San Francisco California, San Francisco, CA, USA.*

**7:00 am Getting Over the Hump: Barriers of HIV Pre-kidney Transplant Evaluation**

*Dong Heun Lee, MD, Drexel University, Philadelphia, PA, USA.*

**7:20 am Pumping Up the Pool: Soliciting HIV+ Kidney Donors**

*Christine Durand, MD, Johns Hopkins School of Medicine Baltimore, MD, USA.*

**7:40 am In the Home Stretch: Successful HIV Post-Kidney Transplant Care**

*Deirdre Sawkinski, MD, University of Pennsylvania, Philadelphia, PA, USA.*

**8:00 am Panel Discussion**

**Gender Disparity in Transplantation**

**Room 208**

*Moderators: Mitra Nadim, MD, FASN, University of Southern California, Los Angeles, CA, USA. Elizabeth Chua, MD, FASN, Va Baptist Medical Center, Montgomery, VA, USA.*

**7:00 am Donor-Recipient Gender Mismatch in Liver Transplantation**

*Elizabeth Pomfret, MD, PhD, University of Colorado Anschutz Medical Campus Aurora, CO, USA.*

**7:20 am Gender Differences in Post Transplant Outcomes**

*Susan Orloff, MD, FACS, Oregon Health & Science University, Portland, OR*

**7:40 am Access to Care and Social Determinants in Kidney Transplantation**

*Milda Saunders, MD, MPH, University of Chicago Medicine, Chicago, IL, USA.*

**8:00 am Panel Discussion**

**Expanding the Lung Donor Pool While Optimizing Patient Outcomes**

**Room 313**

*Moderators: Marie Budev, DO, The Cleveland Clinic, Cleveland, OH, USA. Daniel Dilling, MD, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA.*

**7:00 am Using Ex Vivo Lung Perfusion for Functionally Impaired and Standard Donor Lungs**

*Marcelo Cypel, MD, MSc, University of Toronto, Toronto, ON.*

**7:15 am High Risk Donors and Post-Transplant Recipient Outcomes**

*Carli Lehr, MD, Cleveland Clinic, Cleveland, OH, USA.*

**7:30 am HIV and Hepatitis C Donors – Nuts and Bolts of How to Use Them in Lung Transplantation**

*Christine Koval, MD, Cleveland Clinic, Cleveland, OH, USA.*

**7:45 am Pushing the Envelope: When to Consider the Extended Criteria Donor?**

*Ken McCurry, MD, Cleveland Clinic, Cleveland, OH, USA.*

**8:00 am Panel Discussion**

**Pediatric Kidney Transplantation: Barriers to Success**

**Room 210**

*Moderators: Eileen Brewer, MD, Texas Children's Hospital/Baylor College of Medicine, Houston, TX, USA. Rouba Garro, MD, Emory University, Atlanta, GA, USA.*

**7:00 am Pediatric Nonadherence**

*Thomas Nevins, MD, University of Minnesota Department of Pediatrics, Saint Paul, MN, USA.*

**7:20 am Transplanting Children with FSGS - Diagnosis, Prevention and Management of Recurrence**

*Priya Verghese, MD, University of Minnesota, Minneapolis, MN, USA.*

**7:40 am Cardiovascular Risk in Pediatric Kidney Recipients: Burden and Impact**

*Michael Seifert, MD, MSCI, University of Alabama School of Medicine, Birmingham, AL, USA.*

Sunday, June 2

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

8:00 am Panel Discussion

## Optimizing Management of the Metabolic Syndrome After Liver Transplantation

### Room 309

Moderators: James N Fleming, PharmD, Medical University of South Carolina, Charleston, SC, USA.  
Kymberly Watt, MD, Mayo Clinic, Rochester, MN, USA.

7:00 am **Cardiovascular Disease Risk Factor Optimization After Liver Transplantation: Do's, Don'ts and Drug Management (Clinician Perspective)**

Lisa VanWagner, MD MSc, Northwestern Medicine, Chicago, IL, USA.

7:10 am **Cardiovascular Disease Risk Factor Optimization After Liver Transplantation: Do's, Don'ts and Drug Management (Pharmacist Perspective)**

Erin Ticehurst, PharmD, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

7:20 am Audience Discussion

7:25 am **Prevention and Management of Obesity After Liver Transplantation: Implications for Immunosuppression (Clinician Perspective)**

Angela Fitch, MD, Massachusetts General Hospital, Boston, MA, USA.

7:35 am **Prevention and Management of Obesity after Liver Transplantation: Implications for Immunosuppression (Pharmacist Perspective)**

Tiffany Kaiser, PharmD, University of Cincinnati, Cincinnati, OH, USA.

7:45 am Audience Discussion

7:50 am **Practical Strategies for Glucose Control and Diabetes Prevention after Liver Transplant: Where Are We Now? (Clinician Perspective)**

Nicholas Lim, MD, University of Minnesota, Minneapolis, MN, USA.

8:00 am **Practical Strategies for Glucose Control and Diabetes Prevention after Liver Transplant: Where Are We Now? (Pharmacist Perspective)**

Jeong Park, MS, PharmD, University of Michigan, Ann Arbor, MI, USA.

8:10 am Audience Discussion

## **Sunrise Symposia: Didactic (Continental Breakfast Included)**

7:00 am – 8:15 am

### Tissue Engineering in Transplantation

#### Room 302

Moderators: Jeffrey Fair, MD, University of Texas Medical Branch, Galveston, TX, USA. Jason Wertheim, MD, PhD, Northwestern University, Chicago, IL, USA.

7:00 am **Nano-Intervention of Organs to Improve Outcome of Organ Transplant**  
Satish Nadig, MD, PhD, FACS, Medical University of South Carolina, Charleston, SC, USA.

7:20 am Audience Discussion

7:25 am **Advanced Regenerative Manufacturing Institute: Technologies to Make the Tissues of Tomorrow**  
Su Ryon Shin, PhD, Harvard University, Cambridge, MA, USA.

7:45 am Audience Discussion

7:50 am **Manufacturing a New Population of Cell Types for Organ Engineering and Transplantation**  
Jan Jensen, PhD, Trailhead Biosystems Inc., Cleveland, OH, USA.

8:10 am Audience Discussion

### Antibody Functions in Tissues & Regulations

#### Room 304

Moderators: Melissa Yeung, MD, Harvard Medical School, Boston, MA, USA. Philip Halloran, University of Alberta, Edmonton, AB, Canada.

7:00 am **Antibody Accommodation in Tissues**  
Elaine Reed, PhD, University of California Los Angeles Health, Los Angeles, CA, USA.

7:20 am Audience Discussion



# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

Sunday, June 2

**7:25 am Antibody Functionality Through Glycosylation**  
*Robert Anthony, PhD, Massachusetts General Hospital & Harvard School of Medicine, Boston, MA, USA.*

**7:45 am Audience Discussion**

**7:50 am Antibody Functions in Grafts**  
*Emmanuel Zorn, PhD, Columbia University Medical Center, New York, NY, USA.*

**8:10 am Audience Discussion**

## Break

**8:15 am**

## Plenary Session I

**8:30 AM - 9:45 AM**

### Veterans Auditorium

*Chairs: Dixon Kaufman, MD, PhD, President, ASTS, Madison, WI and Dianne McKay, MD, FAST, President, AST, La Jolla, CA.*

**8:30 AM Role of Innate Allorecognition Pathways in Mouse Renal Allograft Rejection (Abstract #1)**  
*D. Zhao<sup>1</sup>, H. Dai<sup>1</sup>, K. Abou-Daya<sup>1</sup>, A. Williams<sup>1</sup>, M. Oberbarnscheidt<sup>1</sup>, X. Li<sup>2</sup>, F. Lakkis<sup>1</sup>, <sup>1</sup>Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Houston Methodist Hospital Immunobiology & Transplant Science Center, Houston, TX*

**8:45 AM Oxygenated Hypothermic Machine Perfusion of Kidneys Donated after Circulatory Death: An International Randomised Controlled Trial (Abstract #2)**  
*I. Jochmans<sup>1</sup>, H. S. Hofker<sup>2</sup>, L. Davies<sup>3</sup>, S. Knight<sup>3</sup>, J. Pirenne<sup>1</sup>, R. J. Ploeg<sup>3</sup>, - on behalf of COPE and participating centres<sup>4</sup>, <sup>1</sup>Abdominal Transplant Surgery, University Hospitals Leuven, Leuven, Belgium, <sup>2</sup>University Medical Center Groningen, Groningen, Netherlands, <sup>3</sup>University of Oxford, Oxford, United Kingdom, <sup>4</sup>Belgium, Netherlands, United Kingdom*

**9:00 AM Discovery and Validation of an Early Post-Transplant Biomarker Model Predictive of Chronic Kidney Disease in Liver Transplant Recipients (Abstract #3)**

*J. Levitsky<sup>1</sup>, S. Asrani<sup>2</sup>, G. Klintmalm<sup>2</sup>, T. Schiano<sup>2</sup>, A. Moss<sup>3</sup>, K. Chavin<sup>4</sup>, C. Miller<sup>5</sup>, L. Zhao<sup>6</sup>, K. Guo<sup>6</sup>, N. Bridges<sup>7</sup>, J. Odum<sup>7</sup>, M. Brown<sup>7</sup>, D. Ikle<sup>8</sup>, B. Armstrong<sup>8</sup>, M. Abecassis<sup>9</sup>, <sup>1</sup>Gastroenterology and Hepatology, Northwestern University, Chicago, IL, <sup>2</sup>Baylor, Dallas, TX, <sup>3</sup>Mayo Arizona, Phoenix, AZ, <sup>4</sup>Case Western, Cleveland, OH, <sup>5</sup>Cleveland Clinic, Cleveland, OH, <sup>6</sup>Northwestern University, Chicago, IL, <sup>7</sup>NIAID, Bethesda, MD, <sup>8</sup>Rho, Chapel Hill, NC, <sup>9</sup>Comprehensive Transplant Center, Northwestern University, Chicago, IL*

**9:15 AM Bcl-2 Inhibition with Venetoclax Promotes Induction of Mixed Chimerism and Renal Allograft Tolerance without Severe Myelosuppression in Non-Human Primate (Abstract #4)**

*H. Sasaki<sup>1</sup>, D. Ma<sup>1</sup>, T. Oura<sup>1</sup>, A. Dehnadi<sup>1</sup>, I. Rosales<sup>2</sup>, B. Cosimi<sup>1</sup>, P. Cippa<sup>3</sup>, T. Fehr<sup>3</sup>, T. Kawai<sup>1</sup>, <sup>1</sup>Surgery, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Pathology, Massachusetts General Hospital, Boston, MA, <sup>3</sup>Medicine, University of Zurich, Zurich, Switzerland*

## Joint Award Session

**9:30 am – 9:45 am**

*Veterans Auditorium*

### ASTS Research Grants

**9:45 am – 10:00 am**

*Veterans Auditorium*

### ASTS Pioneer Award

**10:00 am – 10:15 am**

*Veterans Auditorium*

### AST Awards

**10:15 am – 10:30 am**

*Veterans Auditorium*

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

## **AST Lifetime Achievement Award**

10:30 am – 10:45 am

*Veterans Auditorium*

## **Coffee Break in the Exhibit Hall**

10:45 am – 11:15 am

*Hall C/D*

## **Midday Symposia Interactive**

11:15 am – 12:45 pm

### **Personalized Medicine in Transplantation: Can We Move the Needle?**

#### **Room 313**

*Moderators: John Gill, PhD, University of Colorado Medicine, Aurora, CO, USA. Michelle Josephson, MD, University of Chicago Medicine, Chicago, IL, USA.*

**11:15 am Is There a Role for More Personalized Organ Allocation/Donor and Recipient Matching?**

*John Friedewald, MD, FAST, Northwestern University, Chicago, IL, USA.*

**11:35 am Could More Personalized Immunosuppression Work?**

*Eugene DePasquale, MD, UCLA Health, Santa Monica, CA, USA.*

**11:55 am What is the iBox and How Can it Help?**

*Alexandre Loupy, MD, PhD, Paris Transplant Group, Paris, France.*

**12:15 am Can Omics Assist Us in Moving Personalized Medicine in Transplantation?**

*Minni Sarwal, PhD, MD, UCSF, San Francisco, CA, USA.*

**12:35 pm Panel Discussion**

### **Lung Transplantation: From Bench to Bedside and Back**

#### **Room 206**

*Moderators: Scott Palmer, MD, MHS, Duke University, Durham, NC, USA. Jonathan Singer, MD, MS, University of California San Francisco, San Francisco, CA, USA.*

**11:15 am Basic Mechanisms of Lung Transplant Rejection: New Insights from Pre-Clinical Models**

*Daniel Kreisel, MD, PhD, Washington University, St Louis, MO, USA.*

**11:30 am Acute and Humoral Rejection After Lung Transplantation: Risk Factors and Mechanisms**

*Ramsey Hachem, MD, Washington University School of Medicine, St. Louis, MO, USA.*

**11:45 am CLAD: Emerging Phenotypes and New Insights into Mechanisms and Treatments**

*John Belperio, MD, UCLA, Los Angeles, CA, USA.*

**12:00 pm Lung Transplantation and the Microbiome**

*Sangeeta Bhorade, MD, Northwestern-Feinberg School of Medicine, Chicago IL, USA.*

**12:15 pm The Unique Problem of CMV in Lung Transplant: Challenges and Solutions**

*Laurie Snyder, MD, MHS, Duke University, Durham, NC, USA.*

**12:30 pm Panel Discussion**

### **Are Donors After Cardiac Death Underutilized in Pediatric Transplant Recipients?**

#### **Room 210**

*Moderators: Walter Andrews, MD, Children's Mercy Hospital, Kansas City, MO. Amy Gallo, MD, Stanford University, Palo Alto, CA, USA.*

**11:15 am A Historical Look at the Use of Donors After Cardiac Death in Pediatric Liver and Kidney Transplant**

*Christine Hwang, MD, UT Southwestern Medical Center, Dallas, TX, USA.*

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

**11:30 am Debate - Pro: Using Donors after Cardiac Death in Pediatric Liver and Kidney Transplant Recipients**

*Jorge Reyes, MD, University of Washington, Seattle, WA, USA.*

**11:45 am Debate - Con: Using Donors after Cardiac Death in Pediatric Liver and Kidney Transplant Recipients**

*Paul Grimm, MD, Stanford University, Stanford, CA, USA.*

**12:00 am Rebuttal: Pro**

*Jorge Reyes, MD, University of Washington, Seattle, WA, USA.*

**12:15 am Rebuttal: Con**

*Paul Grimm, MD, Stanford University, Stanford, CA, USA.*

**12:30 pm Panel Discussion**

## **Personalized Immunosuppression and Infectious Risk: Joint ATC-ESCMID/ESOT Session**

### **Ballroom B**

*Moderators: Oriol Manuel, MD, University Hospital of Lausanne, Lausanne, Switzerland. Nicolas Mueller, MD, University Hospital Zurich, Zurich, Switzerland.*

**11:15 am Underlying Infectious Risk: Genetics**

*Pierre-Yves Bochud, MD, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.*

**11:35 am Audience Discussion**

**11:45 am Acquired Infectious Risk: Impact of Standard & Novel Immunosuppression (Proteosomes, Checkpoint Inhibitors, CAR-T)**

*Jay Fishman, MDM, Massachusetts General Hospital-Harvard Medical School, Boston, MA, USA.*

**12:05 pm Audience Discussion**

**12:15 pm Measuring “Net State” and Pathogen-Specific Immunity**

*Oriol Manuel, MD, CHUV, Lausanne, Suisse.*

**12:35 pm Audience Discussion**

## **Controversies in KPD**

### **Room 302**

*Moderators: Marian Charlton, RN, SRN, New York Presbyterian-Weill Cornell Medicine, New York, NY, USA. Jeffrey Veale, MD, UCLA, Los Angeles, CA, USA.*

**11:15 am Debate - Pro: Family Vouchers: Expanding Kidney Transplantation and the Next Great Thing!**

*Matthew Cooper, MD, Professor of Surgery, Washington, DC, USA.*

**11:35 am Debate - Con: Family Vouchers: Coercion and the End of Non-Directed Donation!**

*Keren Ladin, PhD, MSc, Tufts University, Medford, MA, USA.*

**11:55 am Pro: Rebuttal**

*Matthew Cooper, MD, Professor of Surgery, Washington, DC, USA.*

**12:10 pm Con: Rebuttal**

*Keren Ladin, PhD, MSc, Tufts University, Medford, MA, USA.*

**12:25 pm Audience Discussion**

## **Midday Symposia: Didactic**

**11:15 am – 12:45 pm**

### **When to Sound the Alarm: Tough Risk-Benefit Decisions for Journals, Pharma and the FDA**

#### **Room 310**

*Moderators: Flavio Vincenti, MD, UCSF, San Francisco, CA, USA. Shirish Huprikar, MD, The Mount Sinai Hospital, New York, NY, USA.*

**11:15 am The Role of the Journal in Keeping the Public Informed**

*Lindsey Baden, MD, Brigham and Women’s Hospital, Boston, MA.*

**11:35 am Audience Discussion**

**11:45 am Decision Making in Drug Development**

*Karen Smirnakis, MD, PhD, Vice President, Head of Global Medical Safety, Global Safety and Regulatory Sciences, Biogen, Cambridge, MA, USA.*

**12:05 pm Audience Discussion**

Sunday, June 2

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

**12:15 pm How the FDA Assess Risk and Benefits**  
*Edward Cox, MD, MPH, U.S. Food and Drug Administration, Silver Spring, MD, USA.*

**12:35 pm Audience Discussion**

## **T Cell Mediated Rejection: Where are we in 2019?**

### **Veterans Auditorium**

*Moderators: Sundaram Hariharan, MD, Starzl Transplant Institute, Pittsburgh, PA. David Rush, MD, University of Manitoba, Winnipeg, MB. Canada.*

**11:15 am Borderline Rejection After Kidney Transplantation - Is it Borderline?**  
*Rajil B. Mehta, MD, FASN, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.*

**11:35 am Audience Discussion**

**11:45 am Impact of HLA Epitope Matching on T-Cell Mediated Rejection**  
*Peter Nickerson, MD, FRCPC, University of Manitoba, Winnipeg, MB, Canada.*

**12:05 pm Audience Discussion**

**12:15 pm Cross Talk Between B and T Cells and its Influence on TCMR**  
*Arjang Djarnali, MD, MS, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.*

**12:35 pm Audience Discussion**

## **Renal Issues in Cardiac Transplantation**

### **Room 208**

*Moderators: Teresa DeMarco, MD, University of California, San Francisco, San Francisco, CA, USA. Indranee Rajapreyar, MD, University of Alabama Birmingham, Birmingham, AL, USA.*

**11:15 am Assessing the Need for Heart Versus Combined Cardiac and Kidney Transplantation in Systolic Heart Failure Patients with Chronic Kidney Disease: A Transplant Cardiologist's Perspective**  
*Monica Colvin, MD, MS, Frankel Cardiovascular Center- Michigan Medicine, Midland, MI, USA.*

**11:35 am Assessing the Need for Heart Versus Combined Cardiac and Kidney Transplantation in Systolic Heart Failure Patients with Chronic Kidney Disease: A Transplant Nephrologist's Perspective**  
*Roy Bloom, MD, University of Pennsylvania, Philadelphia, PA, USA.*

**11:55 am Timing of Renal Transplantation After Cardiac Transplantation in Listed Heart and Kidney Recipients**  
*David Foley, MD, University of Wisconsin, Madison, WI, USA.*

**12:15 pm Renal Protective Strategies After Cardiac Transplantation**  
*Jose Tallaj, MD, University of Alabama Birmingham School of Medicine, Birmingham, AL, USA.*

**12:35 pm Panel Discussion**

## **Bench to Bedside: B Cells in Transplantation**

### **Room 304**

*Moderators: Kenneth Newell, MD, PhD, Emory University, Atlanta, GA, USA. William Burlingham, PhD, University of Wisconsin, Madison, WI, USA.*

**11:15 am Basic: B Cells in Antigen Presentation**  
*Anita Chong, PhD, The University of Chicago, Chicago, IL.*

**11:35 am Audience Discussion**

**11:45 am Translational - Blunting Damage from Pre-Transplant DSA**  
*E. Steve Woodle, MD, University of Cincinnati, Cincinnati, OH, USA.*

**12:05 pm Audience Discussion**

**12:15 pm Clinical: Breg Therapy: Is Now the Time?**  
*Claudia Mauri, PhD, University College London, London, England.*

**12:35 pm Audience Discussion**



# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

## EBV and Post-Transplant Lymphoproliferative Disease: Emerging Data & Pediatric Consensus Guidelines

### Ballroom C

Moderators: Vikas Dharnidharka, MD, MPH, Washington University School of Medicine, St. Louis, MO, USA. Michael Green, MD, MPH, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

#### 11:15 am **New Understandings of Pathogenesis and Immune Response to Epstein Barr Virus Infection and EBV-Associated PTLD in Solid Organ Transplant Recipients**

Olivia Martinez, PhD, Stanford University School of Medicine, Stanford, CA, USA.

#### 11:35 am **Audience Discussion**

#### 11:45 am **Persistent EBV Viremia: Lend Me a Hand**

Upton Allen, MBBS, MSc, Sick Kids- The Hospital of Sick Children, Toronto, ON.

#### 12:05 pm **Audience Discussion**

#### 12:15 pm **The International Pediatric Transplant Association's EBV/PTLD Consensus Guidelines**

Steve Webber, MBChB, Vanderbilt University School of Medicine, Nashville, TN, USA.

#### 12:35 pm **Audience Discussion**

## Revisiting DOAC Anticoagulation in Transplantation

### Room 312

Moderators: Jeong Park, MS, PharmD, University of Michigan, Ann Arbor, MI, USA. Georgina Waldman, PharmD, Heart Transplant at Massachusetts General Hospital, Boston, MA, USA.

#### 11:15 am **Optimizing DOAC therapy in Pre-and Post- Transplant Patients**

David M. Salerno, PharmD, New York-Presbyterian Hospital, New York, NY, USA.

#### 11:40 am **Measuring and Reversal of DOACs**

Alicia Lichvar, PharmD, BCPS, College of Pharmacy-Chicago Rockford, Chicago, IL, USA.

#### 12:05 pm **Challenging Pre-Transplant Cases and DOAC Management**

Patrick Klem, PharmD, University of Colorado Hospital, Denver, CO, USA.

#### 12:30 pm **Audience Discussion**

## Tippling the Scale in Our Favor: The Steatoic Donor Liver

### Room 311

Moderators: Kristopher Croome, MD, Mayo Clinic Florida, Jacksonville, FL, USA. Jean Edmond, MD, Columbia University, New York, NY, USA.

#### 11:15 am **How much Steatosis is There? The Donor Frozen Section Biopsy**

Oyedele Adeyi, MD, FCAP, University of Toronto, Toronto, Ontario.

#### 11:35 am **Audience Discussion**

#### 11:45 am **Macrosteatosis: How Far Can You Go?**

George Loss, MD, FACS, Ochsner Health System, New Orleans, LA, USA.

#### 12:05 pm **Audience Discussion**

#### 12:15 pm **ASTS Scientific Studies Committee: Multicenter Trial in the Standardization of Steatosis**

Benjamin Philosophie, MD, Johns Hopkins Hospital, Baltimore, MD, USA.

#### 12:35 pm **Audience Discussion**

## Silent Chronic Graft Injury After Liver Transplantation: Evidence for TCMR and/or AMR?

### Room 309

Moderators: John Levisky, MD, Northwestern, Chicago, IL. Jacqueline O'Leary, MD, MPH, UT Northwestern, Dallas, TX, USA.

#### 11:15 am **Antibody-Mediated Rejection: Can We Confidently Diagnose and Treat It Yet?**

Patricia Campbell, MBChB, FRCP(C), University of Alberta, Edmonton, AB, Canada.

#### 11:35 am **Audience Discussion**

#### 11:45 am **Inflammation and Fibrosis in Clinically Ideal Liver Transplant Recipients: The Tip of the Iceberg?**

Sandy Feng, MD, PhD, UCSF, San Francisco, CA, USA.

Sunday, June 2

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

12:05 pm Audience Discussion

12:15 pm **Mechanistic Insight into Chronic Graft Injury: What are Rational Therapies?**

*Alberto Sanchez-Fueyo, MD, Kings College, London, England.*

12:35 pm Audience Discussion

## **Platelets in the Immune Response**

### **Room 306**

*Moderators: Qizhen Shi, PhD, Medical College of Wisconsin, Milwaukee, WI, USA. Irene Kim, MD, Cedars-Sinai, Beverly Hills, CA, USA.*

11:15 am **Immune Regulatory Role of Platelets**

*Craig Morrell, DVM, PhD, University of Rochester, Rochester, NY, USA.*

11:35 am Audience Discussion

11:45 am **Platelets as Inflammatory Mediators**

*Karin Hoffmeister, MD, Blood Research Institute, Milwaukee, WI, USA.*

12:05 pm Audience Discussion

12:15 pm **Platelets in Alloimmune Rejection**

*William W. Baldwin, III, MD, PhD, Lerner Research Institute Cleveland Clinic, Cleveland, OH, USA.*

12:35 pm Audience Discussion

## **Tregs-Bench to Bedside**

### **Ballroom A**

*Moderators: Peter Heeger, MD, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Qizhi Tang, PhD, UCSF, San Francisco, CA, USA.*

11:15 am **Tregs Optimization**

*Wayne Hancock, MD, PhD, University of Pennsylvania & Children's Hospital of Philadelphia, Philadelphia, PA, USA.*

11:35 am Audience Discussion

11:45 am **Treg Survival and Death**

*Jamil Azzi, MD, Harvard Medical School, Boston, MA, USA.*

12:05 pm Audience Discussion

12:15 pm **Tregs on Trial**

*Qizhi Tang, PhD, UCSF, San Francisco, CA, USA.*

12:35 pm Audience Discussion

## **Break**

12:45 pm – 1:00 pm

## **Sponsored Satellite Symposia**

1:00 pm – 2:15 pm

Satellite Symposia are open to all registered Congress attendees. Satellite Symposia take place at the Sheraton Boston Hotel. Please check the ATC website, [www.atcmeeting.org](http://www.atcmeeting.org), or ATC mobile app (ATC19) for the full Satellite Symposia program listing

## **Luncheon Workshops (Additional Fee)**

1:00 pm – 2:15 pm

### **Obesity in Kidney Transplantation: Donors and Recipients**

#### **Room 109**

*Moderators: Tayyab Diwan, MD, University of Cincinnati, Cincinnati, OH, USA. Jayme Locke, MD, MPH, University of Alabama at Birmingham, Birmingham, AL, USA.*

### **New Transplant Medical Director: Roles, Responsibilities & Challenges**

#### **Room 110**

*Moderators: Francis Weng, MD, Saint Barnabas Medical Center, Livingston, NJ, USA. Christian Larsen, MD, Emory University, Atlanta, GA, USA.*

### **Differentiating 'Difficult Patients' and 'Patients in Difficult Situations' in Urgent Organ Failure**

#### **Cafe, Across from Hall A Registration**

*Moderators: Kristin Kuntz, PhD, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Heather Brusckwein, PsyD, University of Virginia, Charlottesville, VA, USA.*

### **Where Have You Been All My Life? The Living Donor with Infectious Disease**

#### **Room 108**

*Moderators: Ricardo La Hoz, MD, UT Southwestern Medical Center, Dallas, TX, USA. Clarisse Machado, PhD, Institute of Tropical Medicine, University of Sao Paulo, Sao Paulo, Brazil.*

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

## Transplantation In Depth (Basic) The Next New Thing-Basic Pathways to Emerging Therapeutics

1:30 pm – 4:00 pm

### Room 302

Moderators: *Maria-Lusia Alegre, MD, PhD, The University of Chicago, Chicago, IL, USA. Jerzy Kupiec-Weglinski, MD, PhD, UCLA, Los Angeles, CA, USA.*

**1:30 pm TNF alpha**

*Peter Heeger, MD, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.*

**1:50 pm Audience Discussion**

**2:00 pm CAR T Cells**

*Megan Levings, PhD, University of British Columbia, Vancouver, BC, Canada.*

**2:20 pm Audience Discussion**

**2:30 pm Epigenetic Drugs and Immune Regulation**

*Wayne Hancock, MD, PhD, University of Pennsylvania & Children's Hospital of Philadelphia, Philadelphia, PA, USA.*

**2:50 pm Audience Discussion**

**3:00 pm Trained Immunity in Macrophages - Relevance to Transplant**

*Jordi Ochando, PhD, Mount Sinai, New York, NY, USA.*

**3:20 pm Audience Discussion**

**3:30 pm Nanobodies in Immune Regulation**

*Andrew Woodham, PhD, Harvard Medical School - Boston Children's Hospital, Boston, MA, USA.*

**3:50 pm Audience Discussion**

### Break

2:15 pm – 2:30 pm

## Concurrent Oral Abstract Sessions

2:30 pm – 4:00 pm

### Kidney Complications: Late Graft Failure I

#### Veterans Auditorium

Chairs: *D. Cohen, Columbia University Med Ctr, New York, NY and V. Kirchner, University of Minnesota, Minneapolis, MN*

**2:30 PM Impact of Glomerulitis at 4-Month Biopsy on Long Term Kidney Allograft Outcomes (Abstract #5)**

*M. Whigham, G. Mour, M. Buras, S. Sukumaran Nair, A. Jaramillo, D. Ramon, R. Heilman, Mayo Clinic, Phoenix, AZ*

**2:42 PM Population-Based Modeling of Prototypes and Determinants of Allograft Function Trajectories after Kidney Transplantation: Impact for Patient Monitoring and Risk Stratification (Abstract #6)**

*M. Raynaud<sup>1</sup>, O. Aubert<sup>1</sup>, M. Naesens<sup>2</sup>, I. Juric<sup>3</sup>, N. Basic<sup>3</sup>, N. Kamar<sup>4</sup>, E. Huang<sup>5</sup>, S. Jordan<sup>5</sup>, B. Orandi<sup>6</sup>, D. Segev<sup>6</sup>, M. Stegall<sup>7</sup>, E. Morelon<sup>8</sup>, M. Giral<sup>9</sup>, E. Bailly<sup>10</sup>, E. Akalin<sup>11</sup>, G. Gupta<sup>12</sup>, M. Ladrière<sup>13</sup>, M. Buchler<sup>10</sup>, P. Reese<sup>14</sup>, C. Lefaucheur<sup>1</sup>, A. Loupy<sup>1</sup>, <sup>1</sup>Paris, France, <sup>2</sup>Leuven, Belgium, <sup>3</sup>Zagreb, Croatia, <sup>4</sup>Toulouse, France, <sup>5</sup>Los Angeles, CA, <sup>6</sup>Baltimore, MD, <sup>7</sup>Rochester, MN, <sup>8</sup>Lyon, France, <sup>9</sup>Nantes, France, <sup>10</sup>Tours, France, <sup>11</sup>New York, NY, <sup>12</sup>Richmond, VA, <sup>13</sup>Nancy, France, <sup>14</sup>Philadelphia, PA*

**2:54 PM Mortality and Morbidity in Kidney Transplant Recipients with a Failing Graft (Abstract #7)**

*N. N. Lam<sup>1</sup>, D. J. Boyne<sup>2</sup>, R. R. Quinn<sup>2</sup>, P. C. Austin<sup>3</sup>, B. R. Hemmelgarn<sup>2</sup>, P. Campbell<sup>1</sup>, G. A. Knoll<sup>4</sup>, L. Tibbles<sup>2</sup>, S. Yilmaz<sup>2</sup>, H. Quan<sup>2</sup>, P. Ravani<sup>2</sup>, <sup>1</sup>University of Alberta, Edmonton, AB, Canada, <sup>2</sup>University of Calgary, Calgary, AB, Canada, <sup>3</sup>ICES, Toronto, ON, Canada, <sup>4</sup>University of Ottawa, Ottawa, ON, Canada*

Sunday, June 2

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

**3:06 PM Room for Optimism; Improvement in Long-Term Patient and Graft Survival of Kidney Transplants in the United States over the past Three Decades (Abstract #8)**

C. Wu, A. Rana, N. Galvan, C. O'Mahony, J. Goss, B. Murthy, *Division of Abdominal Transplantation, Baylor College of Medicine, Houston, TX*

**3:18 PM The Graft and Patient Survival of Kidney Transplantation According to Ethnicity in US Kidney Transplant Recipients (Abstract #9)**

H. Shin<sup>1</sup>, Y. Kim<sup>1</sup>, Y. Jung<sup>1</sup>, H. Rim<sup>1</sup>, A. Chandraker<sup>2</sup>, <sup>1</sup>*Internal Medicine, Kosin University College of Medicine, Gospel Hospital, Busan, Korea, Republic of,* <sup>2</sup>*Internal Medicine, Harvard Medical School Brigham & Women's Hospital, Boston, MA*

**3:30 PM CMV Risk Status Remains a Relevant Risk Factor for Long-Term Outcomes (Abstract #10)**

G. Karadkhele, W. Zhang, C. P. Larsen, *Emory University, Atlanta, GA*

**3:42 PM Bisphosphonates Effectively Improve the Long Term Renal Transplant Outcomes; A Single Center Retrospective Study (Abstract #11)**

S. Song<sup>1</sup>, K. Huh<sup>2</sup>, H. Choi<sup>3</sup>, J. Lee<sup>2</sup>, D. Kim<sup>2</sup>, Y. Kim<sup>2</sup>, M. Kim<sup>2</sup>, S. Kim<sup>2</sup>, D. Joo<sup>2</sup>, B. Kim<sup>3</sup>, <sup>1</sup>*Surgery, Ewha Womans University, Seoul, Korea, Republic of,* <sup>2</sup>*Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of,* <sup>3</sup>*Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of*

## Kidney Deceased Donor Allocation I

### Ballroom B

*Chairs: L. Kayler, Erie County Medical Center, Buffalo, NY and R. Parsons, Emory University School of Medicine, Atlanta, GA*

**2:30 PM National Landscape of Hope Act Transplant Candidates and Recipients in the United States (Abstract #12)**

A. R. Wilk<sup>1</sup>, R. Hunter<sup>2</sup>, M. A. McBride<sup>2</sup>, D. K. Klassen<sup>2</sup>, <sup>1</sup>*Research, United Network for Organ Sharing, Richmond, VA,* <sup>2</sup>*United Network for Organ Sharing, Richmond, VA*

**2:42 PM Regional Disparities In The Transplant Rates Across Unos Regions Pre- And Post-kidney Allocation System Policy Implementation (Abstract #13)**

A. C. Perez-Ortiz, E. Heher, N. Elias, *Massachusetts General Hospital, Boston, MA*

**2:54 PM Changes in Kidney Offer Acceptance for Pediatric Candidates Post-KAS (Abstract #14)**

M. Bowring, K. Jackson, J. Garonzik-Wang, D. Segev, A. Massie, *Johns Hopkins University, Baltimore, MD*

**3:06 PM Impact of Donor Hepatitis C Virus Infection on Kidney Transplant Outcomes in the Direct Acting Antiretroviral Era: Time to Revise the KDPI? (Abstract #15)**

R. M. Cannon, E. G. Davis, L. Mackelaite, H. Dave, M. Eng, C. M. Jones, *University of Louisville, Louisville, KY*

**3:18 PM Exploring the Drivers of the Early Decline in One-Year Patient Survival after KAS (Abstract #16)**

K. Lindblad, A. Wilk, D. Stewart, *UNOS, Richmond, VA*



# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

Sunday, June 2

**3:30 PM Longer-Term Outcomes for Hepatitis C Virus Negative Recipients of Kidneys from Hepatitis C Virus Nucleic Acid Test Positive Donors: The THINKER Trial (Abstract #17)**

P. Reese<sup>1</sup>, P. Abt<sup>1</sup>, E. Blumberg<sup>1</sup>, R. Bloom<sup>1</sup>, D. Sawinski<sup>1</sup>, P. Porrett<sup>1</sup>, A. Woodards<sup>1</sup>, K. Reddy<sup>1</sup>, V. van Deerlin<sup>1</sup>, R. Hasz<sup>2</sup>, M. Levine<sup>1</sup>, R. McLean<sup>1</sup>, A. Sicilia<sup>1</sup>, D. Goldberg<sup>1</sup>, <sup>1</sup>University of Penn, Philadelphia, PA, <sup>2</sup>Gift of Life, Philadelphia, PA

**3:42 PM Accelerating Kidney Allocation: Simultaneously Expiring Offers (Abstract #18)**

M. Kosztowski<sup>1</sup>, M. Mankowski<sup>2</sup>, S. Raghavan<sup>3</sup>, J. Garonzik-Wang<sup>1</sup>, D. Axelrod<sup>4</sup>, D. L. Segev<sup>1</sup>, S. E. Gentry<sup>1</sup>, <sup>1</sup>Johns Hopkins University, Baltimore, MD, <sup>2</sup>King Abdullah University of Science and Technology, Thuwal, Saudi Arabia, <sup>3</sup>University of Maryland, College Park, MD, <sup>4</sup>University of Iowa, Iowa City, IA

## Kidney Donor Selection / Management Issues I

### Ballroom C

Chairs: H. Gritsch, University of California Los Angeles (Urology), Los Angeles, CA. and M. Hobeika, Houston Methodist, Houston, TX

**2:30 PM Transplantation of Kidneys from Hepatitis C Infected Donors to Hepatitis C Negative Recipients (Abstract #19)**

M. Z. Molnar, O. Cseprekal, M. Yazawa, M. Talwar, V. Balaraman, V. Mas, D. Maluf, R. Helmick, L. Campos, N. Nezakatgoo, C. Eymard, P. Horton, R. Verma, A. Jenkins, C. R. Handley, H. Snyder, C. Cummings, U. A. Agbim, B. Maliakkal, S. K. Satapathy, S. P. Nair, J. D. Eason, Methodist University Hospital Transplant Institute, Memphis, TN

**2:42 PM Hope in Action: A Multicenter Prospective Study of HIV to HIV Kidney Transplantation (Abstract #20)**

C. Durand<sup>1</sup>, S. Huprikar<sup>2</sup>, M. Bowring<sup>3</sup>, D. Brown<sup>1</sup>, B. Haydel<sup>4</sup>, N. Desai<sup>3</sup>, F. Naqvi<sup>1</sup>, R. Friedman-Moraco<sup>5</sup>, N. Turgeon<sup>6</sup>, V. Stosor<sup>7</sup>, J. Charette<sup>7</sup>, S. Mehta<sup>8</sup>, J. Husson<sup>9</sup>, A. Gilbert<sup>10</sup>, M. Cooper<sup>11</sup>, C. Butkus-Small<sup>12</sup>, G. Gupta<sup>13</sup>, S. Mehta<sup>14</sup>, O. Adebisi<sup>15</sup>, P. Chin-Hong<sup>16</sup>, P. Stock<sup>17</sup>, A. Massie<sup>3</sup>, S. Florman<sup>4</sup>, D. Segev<sup>3</sup>, <sup>1</sup>Medicine, Johns Hopkins University, Baltimore, MD, <sup>2</sup>Medicine, Mount Sinai, New York, NY, <sup>3</sup>Surgery, Johns Hopkins University, Baltimore, MD, <sup>4</sup>Surgery, Mount Sinai, New York, NY, <sup>5</sup>Medicine, Emory University, Atlanta, GA, <sup>6</sup>Surgery, Emory University, Atlanta, GA, <sup>7</sup>Medicine, Northwestern University, Chicago, IL, <sup>8</sup>Medicine, University of Alabama, Birmingham, AL, <sup>9</sup>Medicine, University of Maryland, Baltimore, MD, <sup>10</sup>Medicine, Georgetown University, Washington DC, DC, <sup>11</sup>Department of Surgery, Georgetown University, Washington DC, DC, <sup>12</sup>Medicine, Cornell University, New York, NY, <sup>13</sup>Medicine, Virginia Commonwealth University, Richmond, VA, <sup>14</sup>Medicine, New York University, New York, NY, <sup>15</sup>Medicine, Indiana University, Indianapolis, IN, <sup>16</sup>Medicine, University of California at San Francisco, San Francisco, CA, <sup>17</sup>Surgery, University of California at San Francisco, San Francisco, CA

**2:54 PM Hope Act Donors With Organs Recovered For Transplant: The First Two Years (Abstract #21)**

W. A. Werbel, O. Kusemiju, B. Barnaba, M. Bowring, B. Doby, C. Kirby, R. Fernandez, Y. Eby, J. Miller, D. Brown, S. Seaman, D. Ostrander, A. Tobian, D. Segev, C. M. Durand, Johns Hopkins University, Baltimore, MD

**AMERICAN TRANSPLANT CONGRESS**  
**Program, Sunday, June 2, 2019**

---

**3:06 PM Outcomes in Non-A1 and Non A1 B to B Deceased Donor Renal Transplantation Are Comparable to B Donor Renal Transplants (Abstract #22)**  
A. Brar, L. Kwon, A. Gruessner, F. Tedla, R. Gruessner, N. Sumrani, D. John, J. Renz, M. O. Salifu, *SUNY Downstate Medical Center, Brooklyn, NY*

**3:18 PM Did COIIN Cohort A Maintain Graft Survival Performance While Increasing Moderate to High KDPI Transplants? (Abstract #23)**  
J. Foutz, R. J. Carrico, K. Sisaithong, H. Tosoc-Haskell, D. Klassen, *Research, United Network for Organ Sharing, Richmond, VA*

**3:30 PM Significant Increase in Moderate to High KDPI Kidney Transplants Using a Multi-Operational Approach: Results from the COIIN (Collaborative Innovation and Improvement Network) Initiative (Abstract #24)**  
T. Pesavento<sup>1</sup>, J. Foutz<sup>2</sup>, K. Sisaithong<sup>2</sup>, D. Klassen<sup>2</sup>, L. Stillion<sup>1</sup>, A. Rajab<sup>1</sup>, R. Pelletier<sup>3</sup>, K. Washburn<sup>1</sup>, H. Tosoc-Haskell<sup>2</sup>, <sup>1</sup>*Ohio State University, Columbus, OH*, <sup>2</sup>*UNOS, Richmond, VA*, <sup>3</sup>*Robert Wood Johnson, New Brunswick, NJ*

**3:42 PM Long-Term Outcomes Following Uncontrolled Donation after Cardiac Death Kidney Transplantation: Opportunity for Increasing Donor Pool? (Abstract #25)**  
R. A. Choudhury, K. Prins, D. Yoeli, H. B. Moore, T. L. Nydam, *Transplant Surgery, University of Colorado, Aurora, CO*

**Kidney Immunosuppression: Desensitization**

**Ballroom A**

*Chairs: A. Djamali, University of Wisconsin-Madison, Madison, WI and A. Vo, Cedars Sinai Medical Ctr, Los Angeles, CA*

**2:30 PM Costimulation Blockade Modulates Humoral Responses in Highly Sensitized Transplant Recipients (Abstract #26)**  
J. Kwun, B. Ezekian, P. Schroder, M. Manook, J. Yoon, M. Mulvihill, K. Freischlag, J. Yi, S. Knechtle, *Surgery, Duke Transplant Center, Durham, NC*

**2:42 PM Evaluation of the Safety and Tolerability of Clazakizumab® (Anti-IL-6 Monoclonal) as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (nct03380962) (Abstract #27)**  
A. A. Vo, N. Ammerman, E. Huang, A. Peng, R. Najjar, S. Sethi, S. Williamsons, C. Myers, K. Lim, J. Choi, S. C. Jordan, *Cedars Sinai Medical Ctr, Los Angeles, CA*

**2:54 PM Long-Term Outcomes of Eculizumab-Treated Positive Crossmatch Recipients: Allograft Survival, Histologic Findings, and Natural History of the Donor-Specific Antibodies (Abstract #28)**  
C. Schinstock, A. Bentall, S. Byron, L. Cornell, M. Everly, M. Gandhi, M. Stegall, *Mayo Clinic, Rochester, MN*

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

**3:06 PM Safety and Efficacy of Imlifidase in Highly-Sensitized Kidney Transplant Patients: Results from a Phase 2 Study (Abstract #29)**

S. C. Jordan<sup>1</sup>, C. Legendre<sup>2</sup>, N. Desai<sup>3</sup>, T. Lorant<sup>4</sup>, M. Bengtsson<sup>4</sup>, L. Laxmyr<sup>5</sup>, B. Lonze<sup>6</sup>, A. Vo<sup>1</sup>, K. J. Wood<sup>7</sup>, C. Kjellman<sup>5</sup>, R. A. Montgomery<sup>6</sup>, <sup>1</sup>*Cedars-Sinai Medical Center, Los Angeles, CA*, <sup>2</sup>*Hopital Necker, Paris, France*, <sup>3</sup>*Johns Hopkins University, Baltimore, MD*, <sup>4</sup>*Uppsala University, Uppsala, Sweden*, <sup>5</sup>*Hansa Medical AB, Lund, Sweden*, <sup>6</sup>*NYU Langone Health Transplant Institute, New York, NY*, <sup>7</sup>*University of Oxford, Oxford, United Kingdom*

**3:18 PM Anti-HLA IgM Antibodies Are Reduced in Highly-HLA Sensitized Patients Transplanted after Imlifidase (IdeS) Treatment (Abstract #30)**

X. Zhang<sup>1</sup>, S. Jordan<sup>2</sup>, <sup>1</sup>*HLA and Immunogenetics Laboratory, Comprehensive Transplant Center, Cedars-Sinai Health System, Los Angeles, CA*, <sup>2</sup>*Comprehensive Transplant Center, Cedars-Sinai Health System, Los Angeles, CA*

**3:30 PM Eight-Year Outcomes Following ABO-Incompatible Kidney Transplantation Performed after Desensitization by Antigen-Unspecific Immunoabsorption Devices (Abstract #31)**

C. Speer<sup>1</sup>, F. Kälble<sup>1</sup>, L. Pego da Silva<sup>1</sup>, C. Nusschag<sup>1</sup>, M. Schaiher<sup>1</sup>, C. Süsal<sup>2</sup>, C. Sommerer<sup>1</sup>, M. Zeier<sup>1</sup>, C. Morath<sup>1</sup>, <sup>1</sup>*Nephrology, University of Heidelberg, Heidelberg, Germany*, <sup>2</sup>*Immunology, University of Heidelberg, Heidelberg, Germany*

**3:42 PM Bortezomib Based Induction Therapy Decreases Delayed Graft Function in High Risk Kidney Transplantation (Abstract #32)**

K. Mahendran<sup>1</sup>, N. Koizumi<sup>2</sup>, J. K. Melancon<sup>1</sup>, <sup>1</sup>*Transplant Institute, The George Washington University, Washington, DC*, <sup>2</sup>*Schar School of Policy and Government, George Mason University, Arlington, VA*

## Kidney Technical

**Room: 304**

*Chairs: N. Turgeon, Emory University, Atlanta, GA and R. Heilman, Mayo Clinic, Phoenix, AZ.*

**2:30 PM Robotic-Assisted versus Open Techniques for Living Donor Kidney Transplant Recipients: A Comparison Using Propensity Score Analysis (Abstract #33)**

F. Tinney, J. Stracke, S. Nagai, L. Malinzak, T. McEvoy, S. Mohamed Ilias, A. Yoshida, *Transplant Institute, Henry Ford Hospital, Detroit, MI*

**2:42 PM Single Cell Sequencing of Human Kidney Allograft (Abstract #34)**

H. Yang<sup>1</sup>, H. Suryawanshi<sup>2</sup>, M. Lagman<sup>1</sup>, M. Lubetzky<sup>1</sup>, A. Alonso<sup>1</sup>, S. Seshan<sup>1</sup>, T. Tuschl<sup>2</sup>, M. Suthanthiran<sup>1</sup>, T. Muthukumar<sup>1</sup>, <sup>1</sup>*Weill Cornell Medicine, New York, NY*, <sup>2</sup>*Rockefeller University, New York, NY*

**2:54 PM Enhanced Recovery after Surgery Protocols in Kidney Transplantation: Time to Change Practice? (Abstract #35)**

A. M. Elsabbagh, I. Ghoneim, A. Moiz, D. Mckenny, M. A. Zawaideh, *St. Vincent Abdominal Transplant Center, St. Vincent Hospital, Indianapolis, IN*

**3:06 PM Robotic Assisted Kidney Transplant Outcomes in Obese Candidates (Abstract #36)**

I. G. Tzvetanov, K. A. Tulla, O. T. Okoye, C. Di Bella, P. Di Cocco, J. A. Almario Alvarez, M. Spaggiari, E. Benedetti, *University of Illinois at Chicago, Chicago, IL*

**3:18 PM Simultaneous Robotic Kidney Transplantation and Bariatric Surgery for Morbidly Obese Patients with End-Stage Renal Failure (Abstract #37)**

P. West-Thielke, K. A. Tulla, O. T. Okoye, J. A. Almario Alvarez, M. Spaggiari, I. G. Tzvetanov, E. Benedetti, *University of Illinois at Chicago, Chicago, IL*

Sunday, June 2

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

**3:30 PM Robotic-Assisted versus Open-Kidney Transplantation in Non-Obese Recipients (Abstract #38)**  
P. R. Modi, B. Pal, S. Singla, R. Chauhan, V. Kothari, A. Mishra, M. Modi, B. Butala, V. Kute, H. Patel, V. Trivedi, *Transplantation Surgery and Urology, Institute of Kidney Diseases and Research Centre, Ahmedabad, India*

**3:42 PM The Safety of Surveillance and Indication Biopsies in Kidney Transplantation: A Series of 2000 Biopsies (Abstract #39)**  
A. S. Naik<sup>1</sup>, Y. Huang<sup>2</sup>, D. M. Cibrik<sup>3</sup>, E. Shaban<sup>1</sup>, M. McGuire<sup>1</sup>, C. Boyer<sup>1</sup>, S. P. Norman<sup>1</sup>, <sup>1</sup>*Internal Medicine/Nephrology, Univ of Michigan Medical Ctr, Ann Arbor, MI*, <sup>2</sup>*Internal Medicine/Nephrology, Univ of California Davis, Sacramento, CA*, <sup>3</sup>*Internal Medicine/Nephrology, Kansas University Medical Center, Kansas City, KS*

## Liver: Immunosuppression and Rejection

### Room: 312

*Chairs: M. Russo, and Carolinas Medical Center, Charlotte, NC and S. Feng, University of California, San Francisco, San Francisco, CA*

**2:30 PM Early Use of Everolimus Plus Reduced Tacrolimus vs Standard Tacrolimus in De Novo Livertransplant Recipients: 12 Months Efficacy and Safety Data from HEPHAISTOS Study (Abstract #40)**  
B. Nashan<sup>1</sup>, P. Schemmer<sup>1</sup>, H. Schlitt<sup>1</sup>, A. Pascher<sup>1</sup>, C. Klein<sup>1</sup>, U. Neumann<sup>1</sup>, I. Kroeger<sup>2</sup>, P. Wimmer<sup>2</sup>, F. Braun<sup>1</sup>, <sup>1</sup>*Study Group, Hephaistos, Germany*, <sup>2</sup>*Novartis Pharma GmbH, Nuernberg, Germany*

**2:42 PM IgG4 Subclass Class 2 Donor Specific Antibody (DSA) is Associated with Subclinical Rejection in Stable Pediatric Liver Transplant (LT) Recipients with Normal Liver Tests (Abstract #41)**  
A. Jackson<sup>1</sup>, S. Kanaparthi<sup>2</sup>, B. Burrell<sup>3</sup>, D. Lucas<sup>4</sup>, R. Vega<sup>4</sup>, A. J. Demetris<sup>5</sup>, S. Feng<sup>6</sup>, <sup>1</sup>*Surgery, Duke University, Durham, NC*, <sup>2</sup>*The Immune Tolerance Network, Bethesda, MD*, <sup>3</sup>*Immune Tolerance Network, Bethesda, MD*, <sup>4</sup>*Medicine, Johns Hopkins University, Baltimore, MD*, <sup>5</sup>*Pathology, University of Pittsburgh, Pittsburgh, PA*, <sup>6</sup>*Surgery, University of California San Francisco, San Francisco, CA*

**2:54 PM Frailty Associated with Increased Rates of Acute Cellular Rejection within 3 Months after Liver Transplantation (Abstract #42)**  
L. Fozouni, A. Lebsack, Y. Mohamad, C. Freise, P. Stock, J. Lai, *UCSF, San Francisco, CA*

**3:06 PM Late Acute Rejection Increases Risk Of Graft Failure In Ldlr Recipients: Data From The A2all Cohort (Abstract #43)**  
H. J. Braun, J. L. Dodge, J. D. Grab, S. M. Syed, G. R. Roll, C. E. Freise, J. P. Roberts, N. L. Ascher, *University of California, San Francisco, San Francisco, CA*

**3:18 PM Impact Of Delayed Kidney Transplantation On Positive Crossmatch Liver Kidney Transplantation (Abstract #44)**  
Z. Rokop, C. Kubal, B. Ekser, R. Mangus, J. Fridell, P. Mihaylov, W. Goggins, *Department of Surgery, Indiana University Hospital, Indianapolis, IN*

**3:30 PM Early Tacrolimus Trough Concentration Variability Could Predict Rejection in Pediatric Liver Transplantation: A Single-Center and Retrospective Research (Abstract #45)**  
G. Gu, Q. Xia, *Renji Hospital, Shanghai, China*



# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

Sunday, June 2

**3:42 PM Molecular Analysis of Rejection and Injury in Human Liver Transplant Biopsies: First Results of the INTERLIVER Study (Abstract #46)**  
P. F. Halloran and The INTERLIVER Study Group, University of Alberta, Edmonton AB, AB, Canada

## PTLD/Malignancies: All Topics

**Room: 311**

Chairs: O. Martinez, Stanford University Sch of Med, Stanford, CA and U. Allen, University of Toronto, Toronto, ON, Canada

**2:30 PM Risk Factors for 1-5 Year De Novo Cancers after Kidney Transplant (KTx) with First-Year Immunosuppression (IS) Data: An Analysis of the Choosing Immune Suppression by Efficacy and Morbidity (CISTEM) Study (Abstract #47)**  
V. Dharnidharka<sup>1</sup>, D. Axelrod<sup>2</sup>, Z. Zhang<sup>3</sup>, M. Schnitzler<sup>3</sup>, K. Lentine<sup>3</sup>, B. Kasiske<sup>4</sup>,  
<sup>1</sup>Washington Univ, St. Louis, MO, <sup>2</sup>Univ of Iowa, Iowa City, IA, <sup>3</sup>Saint Louis Univ, St. Louis, MO, <sup>4</sup>SRTR, Minneapolis, MN

**2:42 PM Lower Incidence of Posttransplant Malignancies under Vitamin D (Calcidiol) Treatment in Kidney Transplantation (Abstract #48)**  
I. Revuelta<sup>1</sup>, V. Tubita<sup>2</sup>, J. Ugalde<sup>1</sup>, D. Cucchiari<sup>1</sup>, F. Oppenheimer<sup>1</sup>, F. Diekmann<sup>1</sup>, J. Campistol<sup>1</sup>, J. Torregrosa<sup>1</sup>,  
<sup>1</sup>Department of Nephrology and Kidney Transplant, Hospital Clinic, Barcelona, Spain, <sup>2</sup>Experimental Laboratory of Nephrology and Kidney Transplant, IDIBAPS, Barcelona, Spain

**2:54 PM Lower Rates of Epstein-Barr Virus Viremia and Post-Transplant Lymphoproliferative Disease in Pediatric Solid Organ Transplant Recipients Who Received Valganciclovir Prophylaxis (Abstract #49)**  
E. A. Moulton<sup>1</sup>, M. Karandikar<sup>2</sup>, S. Bond<sup>3</sup>, S. Burchett<sup>2</sup>, T. Sharma<sup>2</sup>, F. M. Marty<sup>3</sup>,  
<sup>1</sup>Baylor College of Medicine, Houston, TX, <sup>2</sup>Boston Children's Hospital, Boston, MA, <sup>3</sup>Brigham and Women's Hospital, Boston, MA

**3:06 PM Regulation of Host microRNA Expression by Natural Variants of Epstein Barr Virus (EBV) Latent Membrane Protein 1 (LMP1) (Abstract #50)**  
O. Hatton<sup>1</sup>, A. Harris-Arnold<sup>2</sup>, A. Hui<sup>2</sup>, E. Maloney<sup>2</sup>, S. M. Krams<sup>2</sup>, O. M. Martinez<sup>2</sup>,  
<sup>1</sup>Molecular Biology, Colorado College, Colorado Springs, CO, <sup>2</sup>Program in Immunology and Department of Surgery, Stanford University, Stanford, CA

**3:18 PM Mass Cytometry-Based Characterization of Adaptive Immunity in Transplant Recipients with Self-Limiting or Chronic EBV Viremia (Abstract #51)**  
V. H. Ferreira<sup>1</sup>, C. J. Guidos<sup>2</sup>, A. Humar<sup>1</sup>, D. Kumar<sup>1</sup>,  
<sup>1</sup>UHN, Toronto, ON, Canada, <sup>2</sup>SickKids Research Inst, Toronto, ON, Canada

**3:30 PM Immune Cell Types and Host Gene Signatures Associated with Epstein-Barr Virus (EBV) Post-Transplant Lymphoproliferative Disorder (PTLD) (Abstract #52)**  
J. Toh<sup>1</sup>, F. Vallania<sup>1</sup>, W. A. Haynes<sup>1</sup>, G. Bhagat<sup>2</sup>, F. E. Craig<sup>3</sup>, S. H. Swerdlow<sup>4</sup>, T. Tousseyn<sup>5</sup>, S. M. Krams<sup>1</sup>, P. Khatri<sup>1</sup>, O. M. Martinez<sup>1</sup>,  
<sup>1</sup>Stanford University School of Medicine, Stanford, CA, <sup>2</sup>Columbia University Medical Center, New York, NY, <sup>3</sup>Mayo Clinic College of Medicine, Phoenix, AZ, <sup>4</sup>University of Pittsburgh School of Medicine, Pittsburgh, PA, <sup>5</sup>Katholieke Universiteit Leuven, Leuven, Belgium

**3:42 PM Ex-Vivo Perfusion Mediated Delivery of Rituximab to Clear Latent Epstein-Barr Virus (Abstract #53)**  
T. Ku, M. Cypel, R. V. Ribeiro, V. H. Ferreira, D. Kumar, A. Humar, UHN, Toronto, ON, Canada

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

## Biomarkers, Immune Monitoring and Outcomes I

**Room: 306**

*Chairs: T. Muthukumar, NY.*

**2:30 PM An 8-Gene Expression Assay in Peripheral Blood for Diagnosis of Antibody-Mediated Rejection after Kidney Transplantation (Abstract #54)**

E. Van Loon<sup>1</sup>, S. Gazut<sup>2</sup>, S. Yazdani<sup>1</sup>, E. Lerut<sup>1</sup>, H. de Loor<sup>1</sup>, M. Coemans<sup>1</sup>, L. Noël<sup>3</sup>, L. Thorrez<sup>1</sup>, L. Van Lommel<sup>1</sup>, F. Schuit<sup>1</sup>, D. Lambrechts<sup>1</sup>, T. Van Brussel<sup>1</sup>, B. Sprangers<sup>1</sup>, D. Kuypers<sup>1</sup>, M. Essig<sup>4</sup>, W. Gwinner<sup>5</sup>, D. Anglicheau<sup>6</sup>, P. Marquet<sup>7</sup>, M. Naesens<sup>1</sup>, <sup>1</sup>*Catholic University Leuven, Leuven, Belgium*, <sup>2</sup>*CEA, Gif-sur-Yvette, France*, <sup>3</sup>*Necker-Enfants Malades Institute, Paris, France*, <sup>4</sup>*CHU Limoges, Limoges, France*, <sup>5</sup>*Hannover Medical School, Hannover, Germany*, <sup>6</sup>*Paris Descartes, Sorbonne Paris Cité University, Paris, France*, <sup>7</sup>*RTRS Centaure, Necker Hospital, Paris, France*

**2:42 PM NK Cells Are Associated with Alloimmune Failure in Transplanted Children (Abstract #55)**

E. T. Chambers<sup>1</sup>, O. Martinez<sup>2</sup>, M. Robien<sup>3</sup>, C. Chan<sup>1</sup>, R. Ettenger<sup>4</sup>, P. Grimm<sup>5</sup>, H. Lee<sup>1</sup>, E. Reed<sup>4</sup>, L. Stempora<sup>6</sup>, M. Sarwal<sup>7</sup>, B. Warshaw<sup>8</sup>, C. Zhao<sup>1</sup>, A. D. Kirk<sup>6</sup>, <sup>1</sup>*Pediatrics, Duke University, Durham, NC*, <sup>2</sup>*Surgery, Stanford, Palo Alto, CA*, <sup>3</sup>*NIH, Bethesda, MD*, <sup>4</sup>*Pediatrics, UCLA, Los Angeles, CA*, <sup>5</sup>*Pediatrics, Stanford, Stanford, CA*, <sup>6</sup>*Surgery, Duke University, Durham, NC*, <sup>7</sup>*Pediatrics, UCSF, San Francisco, CA*, <sup>8</sup>*Pediatrics, Emory University, Atlanta, GA*

**2:54 PM Circulating T Follicular Helper Proliferation And Memory B Cell Activation Correlate With Donor Specific Allo-antibody Occurrence And Antibody-mediated Rejection After Kidney Transplantation (Abstract #56)**

K. Louis<sup>1</sup>, C. Macedo<sup>1</sup>, M. Marrari<sup>1</sup>, B. Ramaswami<sup>1</sup>, M. Lucas<sup>1</sup>, B. Elinoff<sup>1</sup>, M. Yamada<sup>1</sup>, X. Gu<sup>1</sup>, G. Chalasani<sup>1</sup>, A. Zeevi<sup>1</sup>, P. Randhawa<sup>1</sup>, C. Lefaucheur<sup>2</sup>, D. Metes<sup>1</sup>, <sup>1</sup>*Surgery, University of Pittsburgh, Pittsburgh, PA*, <sup>2</sup>*Inserm Unité mixte de recherche 1160, Paris, France*

**3:06 PM Impact of Cytomegalovirus on the Immune System of Healthy Humans (Abstract #57)**

W. Zhang, J. Robertson, G. Karadkhele, B. Johnson, C. Larsen, *Emory Transplant Center, Emory University, Atlanta, GA*

**3:18 PM A Molecular Analysis of Graft Survival in the INTERHEART Study (Abstract #58)**

P. Halloran<sup>1</sup>, J. Reeve and the INTERHEART investigators<sup>2</sup>, <sup>1</sup>*University of Alberta, Edmonton AB, AB, Canada*, <sup>2</sup>*ATAGC, University of Alberta, Edmonton AB, AB, Canada*

**3:30 PM One Study: A Consortium Model of Clinical Trials Optimized for Comparing New Immune Therapies via Centralized Immune Monitoring (Abstract #59)**

B. Sawitzki<sup>1</sup>, S. Schlickeiser<sup>1</sup>, M. Streitz<sup>1</sup>, K. Jürchott<sup>1</sup>, J. Hutchinson<sup>2</sup>, E. Geissler<sup>2</sup>, P. Investigators<sup>3</sup>, <sup>1</sup>*Charite Universitätsmedizin, Berlin, Germany*, <sup>2</sup>*University of Regensburg, Regensburg, Germany*, <sup>3</sup>*ONE Study Consortium, EU, Germany*

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

Sunday, June 2

**3:42 PM Viability Testing and Transplantation of Marginal Donor Livers (VITTAL) Trial: Metabolomics of Ex Vivo Normothermally Machine Perfused Livers Discloses Molecular Signatures Predictive of Graft Viability and Post Transplant Outcomes (Abstract #60)**  
J. Attard<sup>1</sup>, W. Dunn<sup>2</sup>, L. Wallace<sup>1</sup>, R. Laing<sup>1</sup>, Y. Boteon<sup>1</sup>, H. Mergental<sup>3</sup>, D. Mirza<sup>3</sup>, T. Perera<sup>3</sup>, S. Afford<sup>1</sup>,  
<sup>1</sup>CLGR, University of Birmingham and NIHR Biomedical Research Centre, Birmingham, United Kingdom, <sup>2</sup>Phenome Centre Birmingham, University of Birmingham, Birmingham, United Kingdom, <sup>3</sup>Liver Unit, Queen Elizabeth University Hospital, Birmingham, United Kingdom

## Tissue Engineering & Technology

**Room: 309**

Chairs: B. Ekser, Indiana University - Transplant Section, Indianapolis, IN and J. Wertheim; Northwestern University, Chicago, IL.

**2:30 PM Endothelial Cell Replacement - A Closer Step to Personalized, Tissue-Engineered Transplants (Abstract #61)**  
S. Cohen, S. Partouche, M. Gurevich, V. Mezhybovsky, V. Tennak, S. Eisner, E. Neshor, E. Mor, Rabin Medical Center, Petah-Tiqva, Israel

**2:42 PM MHC Molecule-Ablated Human Endothelial Cells Form Alloimmune-Evasive Microvessels (Abstract #62)**  
J. Merola<sup>1</sup>, M. Reschke<sup>2</sup>, L. Qin<sup>1</sup>, S. Spindler<sup>1</sup>, R. W. Pierce<sup>3</sup>, T. D. Manes<sup>4</sup>, G. Li<sup>1</sup>, L. Bracaglia<sup>2</sup>, N. Kirkiles-Smith<sup>4</sup>, T. Baltazar<sup>4</sup>, W. Saltzman<sup>2</sup>, G. T. Tietjen<sup>1</sup>, G. Tellides<sup>1</sup>, J. S. Pober<sup>4</sup>, <sup>1</sup>Surgery, Yale School of Medicine, New Haven, CT, <sup>2</sup>Biomedical Engineering, Yale School of Engineering and Applied Science, New Haven, CT, <sup>3</sup>Pediatrics, Yale School of Medicine, New Haven, CT, <sup>4</sup>Immunobiology, Yale School of Medicine, New Haven, CT

**2:54 PM Microparticle Delivery to Lymph Nodes Induces Specific Suppression to Prolong Islet Survival (Abstract #63)**  
Y. Xiong<sup>1</sup>, L. Tostanoski<sup>2</sup>, C. Jewell<sup>3</sup>, J. Bromberg<sup>1</sup>, <sup>1</sup>Surgery, U. Maryland, Baltimore, MD, <sup>2</sup>U. Maryland, Baltimore, MD, <sup>3</sup>U. Maryland, College Park, MD

**3:06 PM Hepatic Stellate Cells and Liver Derived Endothelial Cells Improve Scaffold-Free 3D-Bioprinted Liver Model (Abstract #64)**  
A. M. Chen<sup>1</sup>, W. Zhang<sup>1</sup>, C. J. Koehler<sup>1</sup>, K. Saglam<sup>1</sup>, A. Isidan<sup>1</sup>, J. R. Walsh<sup>1</sup>, R. A. Naqvi<sup>1</sup>, E. Gramelspacher<sup>1</sup>, L. J. Smith<sup>2</sup>, P. Li<sup>1</sup>, B. Ekser<sup>1</sup>, <sup>1</sup>Transplant Division, Department of Surgery, Indiana University, Indianapolis, IN, <sup>2</sup>3D-Bioprinting Core, Indiana University School of Medicine, Indianapolis, IN

**3:18 PM Evaluating Liver Regeneration during Normothermic Machine Perfusion in Hepatectomized Rat Liver Model (Abstract #65)**  
M. Aburawi<sup>1</sup>, S. Mert<sup>1</sup>, E. Hafiz<sup>2</sup>, P. Mahboub<sup>1</sup>, H. Yeh<sup>1</sup>, K. Uygun<sup>1</sup>, J. Markmann<sup>1</sup>, <sup>1</sup>Surgery, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Pathology and Electron Microscopy, Theodor Bilharz Research Institute, Cairo, Egypt

**3:30 PM Development and Characterization of Human-Derived Xenograft Model for Hepatocellular Carcinoma (Abstract #66)**  
M. Nazzal<sup>1</sup>, R. Steele<sup>2</sup>, R. Ray<sup>3</sup>, N. Phillips<sup>2</sup>, J. Long<sup>4</sup>, R. Ray<sup>2</sup>, <sup>1</sup>Surgery, Saint Louis University, Saint Louis, MO, <sup>2</sup>Pathology, Saint Louis University, Saint Louis, MO, <sup>3</sup>Internal Medicine, Saint Louis University, Saint Louis, MO, <sup>4</sup>Comparative Medicine, Saint Louis University, Saint Louis, MO

**3:42 PM Kidney Regeneration with Biomimetic Vascular Scaffolds Based on Vascular Corrosion Casts (Abstract #67)**  
S. Min<sup>1</sup>, H. Mo<sup>1</sup>, A. Han<sup>1</sup>, J. Ha<sup>1</sup>, J. Yoo<sup>2</sup>, <sup>1</sup>Seoul National University Hospital, Seoul, Korea, Republic of, <sup>2</sup>Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

## Endothelial Cell Biology

**Room: 310**

*Chairs: J. Pober, Yale Univ Sch of Medicine, New Haven, CT and D. Briscoe, Boston Children's Hospital, Boston, MA*

**2:30 PM Shroom3 Regulates Glomerular Hypertrophy after Uninephrectomy via mTOR (Abstract #68)**

K. Banu, F. Garzon, C. Wei, Z. Yi, W. Zhang, C. He, B. Murphy, M. C. Menon, Mount Sinai School of Medicine, New York, NY

**2:42 PM ZFYVE21 is a Novel Complement-Induced Rab5 Effector Protein Mediating Cardiac Allograft Vasculopathy (Abstract #69)**

D. Jane-wit<sup>1</sup>, C. Fang<sup>1</sup>, L. Liu<sup>1</sup>, L. Qin<sup>1</sup>, G. Guangxin Li<sup>1</sup>, P. Nigrovic<sup>2</sup>, G. Tellides<sup>3</sup>, J. Pober<sup>4</sup>, <sup>1</sup>Dept of Cardiology, Yale University School of Medicine, New Haven, CT, <sup>2</sup>Dept of Rheumatology, Immunology, and Allergy, Harvard University, Boston, MA, <sup>3</sup>Dept of Surgery, Yale University School of Medicine, New Haven, CT, <sup>4</sup>Dept of Immunobiology, Yale University School of Medicine, New Haven, CT

**2:54 PM Novel Activation Responses by Endothelial Cells within the Pro-Tolerogenic Intragraft Microenvironment (Abstract #70)**

J. Wedel<sup>1</sup>, K. Liu<sup>1</sup>, P. T. Sage<sup>2</sup>, C. V. Carman<sup>3</sup>, P. Bobrowicz<sup>4</sup>, S. Kong<sup>5</sup>, B. McLaughlin<sup>4</sup>, D. M. Briscoe<sup>1</sup>, <sup>1</sup>Transplant Research Program, Boston Children's Hospital, Boston, MA, <sup>2</sup>Transplant Research Center, Brigham and Woman Hospital, Boston, MA, <sup>3</sup>Harvard T.H. Chan School of Public Health, Boston, MA, <sup>4</sup>Compass Therapeutics, Cambridge, MA, <sup>5</sup>Computational Health Informatics Program, Boston Children's Hospital, Boston, MA

**3:06 PM Apoptotic Exosome-Like Vesicles Induce Endothelial Cell Plasticity and Accelerate Allograft Vascular Remodeling (Abstract #71)**

F. Migneault<sup>1</sup>, M. Dieudé<sup>1</sup>, J. Turgeon<sup>1</sup>, A. Karakeussian Rimbaud<sup>1</sup>, D. Beillevaire<sup>1</sup>, M. Hardy<sup>2</sup>, A. Brodeur<sup>1</sup>, N. Thibodeau<sup>1</sup>, C. Perreault<sup>2</sup>, M. Hébert<sup>1</sup>, <sup>1</sup>CRCHUM, Montreal, QC, Canada, <sup>2</sup>IRIC, Montreal, QC, Canada

**3:18 PM Cytomegalovirus (CMV) Infection Induces an Angiogenic Response through Hepatic Stellate Cells (HSCs) and Leads to Early Post-Transplant Liver Fibrosis (LF) and Poor Graft Survival (Abstract #72)**

B. H. Ozdemir<sup>1</sup>, G. Ozgun<sup>1</sup>, E. H. Ayvazoglu Soy<sup>2</sup>, N. Haberal<sup>1</sup>, G. Moray<sup>2</sup>, M. Haberal<sup>2</sup>, <sup>1</sup>Pathology, Baskent University, Ankara, Turkey, <sup>2</sup>Transplantation, Baskent University, Ankara, Turkey

**3:30 PM Ligation Of Hla Class II Molecules Disrupts Endothelial Barrier Through Src-dependent Ve-cadherin Destabilization (Abstract #73)**

F. Li<sup>1</sup>, R. A. Sosa<sup>1</sup>, N. M. Valenzuela<sup>1</sup>, E. Rozengurt<sup>2</sup>, E. F. Reed<sup>1</sup>, <sup>1</sup>Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA, <sup>2</sup>Digestive Diseases Research Center, University of California, Los Angeles, Los Angeles, CA

**3:42 PM Sphingosine 1-Phosphate Receptor 2 Regulates Migration through Endothelial Cell VCAM and Adherens Junctions (Abstract #74)**

Y. Xiong<sup>1</sup>, W. Piao<sup>1</sup>, C. Brinkman<sup>1</sup>, L. Li<sup>1</sup>, J. Kulinski<sup>2</sup>, A. Olivera<sup>2</sup>, A. Cartier<sup>3</sup>, T. Hla<sup>3</sup>, K. Hippen<sup>4</sup>, B. Blazar<sup>4</sup>, S. Schwab<sup>5</sup>, <sup>1</sup>Surgery, UMB, Baltimore, MD, <sup>2</sup>NIH, Bethesda, MD, <sup>3</sup>Boston Children's hospital, Boston, MA, <sup>4</sup>U. Minnesota, Minneapolis, MN, <sup>5</sup>NYU, NY, NY



# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

Sunday, June 2

## Ischemia Reperfusion & Organ Rehabilitation I

**Room: 313**

*Chairs: P. Martin, Univ Mass Memorial Medical Center, Worcester, MA and S. Tullius, Brigham & Women's Hospital, Boston, MA*

- 2:30 PM Prevention of Graft Ischemia-Reperfusion Injury in Ischemia-Free Liver Transplantation (Abstract #75)**  
*Z. Guo, X. He, Q. Zhao, S. Huang, Z. Zhang, L. Wang, W. Ju, G. Chen, Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China*
- 2:42 PM CD4 T Cell-Derived NGAL Mediates Experimental Acute Kidney Injury (Abstract #76)**  
*S. Lee, S. Noel, J. Kurzhagen, M. Sadasivam, A. Hamad, H. Rabb, Johns Hopkins, Baltimore, MD*
- 2:54 PM Sirna Uptake During Ex Vivo Hypothermic And Normothermic Liver Machine Perfusion: Beginning Of A New Era Of Organ Preservation (Abstract #77)**  
*A. Gillooly<sup>1</sup>, C. Moore<sup>1</sup>, J. Perry<sup>1</sup>, I. Bruggenwirth<sup>2</sup>, M. Thijssen<sup>2</sup>, X. Wang<sup>1</sup>, X. E<sup>1</sup>, P. Mandrekar<sup>1</sup>, T. Kowalik<sup>1</sup>, R. Porte<sup>2</sup>, H. Leuvenink<sup>2</sup>, R. Abdi<sup>3</sup>, A. Bozorgzadeh<sup>1</sup>, P. N. Martins<sup>1</sup>, <sup>1</sup>University of Massachusetts Medical School, Worcester, MA, <sup>2</sup>University of Groningen, Groningen, Netherlands, <sup>3</sup>Brigham and Women's Hospital, Boston, MA*
- 3:06 PM Senescent Cell Clearance with Senolytic Drugs Improves Cardiac Allograft Survival by Targeting mt-DNA Mediated Immune Responses (Abstract #78)**  
*J. Iske<sup>1</sup>, M. Koichiro<sup>1</sup>, M. Seyda<sup>1</sup>, T. Heinbokel<sup>1</sup>, Y. Nian<sup>1</sup>, R. Maenosono<sup>1</sup>, H. Azuma<sup>1</sup>, C. Falk<sup>2</sup>, T. Tchokonia<sup>3</sup>, J. Kirkland<sup>3</sup>, A. Elkhali<sup>1</sup>, S. Tullius<sup>1</sup>, <sup>1</sup>Transplant Surgery, Brigham and Women's Hospital, Boston, MA, <sup>2</sup>Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany, <sup>3</sup>Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN*
- 3:18 PM Minimizing Kidney Ischemia Reperfusion Injury by Transferring Exogenous Mitochondria (Abstract #79)**  
*A. Bajwa<sup>1</sup>, V. Bontha<sup>1</sup>, J. Eason<sup>2</sup>, D. Maluf<sup>3</sup>, V. Mas<sup>4</sup>, <sup>1</sup>UT, Memphis, TN, <sup>2</sup>Director of Transplant Institute. UTHSC, Memphis, TN, <sup>3</sup>UTHSC, Memphis, TN, <sup>4</sup>Director of Transplant Research Institute. UTHSC, Memphis, TN*
- 3:30 PM Anti CD45RB Antibody Therapy Attenuates Renal Ischemia Reperfusion Injury by Inducing Regulatory B Cells (Abstract #80)**  
*S. Lee<sup>1</sup>, S. Park<sup>1</sup>, J. Hwang<sup>1</sup>, J. Ryu<sup>2</sup>, T. Koo<sup>2</sup>, C. Ahn<sup>2</sup>, J. Yang<sup>3</sup>, <sup>1</sup>Biomedical Research Institute, Transplantation Center, Seoul National University Hospital, Seoul, Korea, Republic of, <sup>2</sup>Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of, <sup>3</sup>Department of surgery, Seoul National University Hospital, Seoul, Korea, Republic of*
- 3:42 PM PD-1+CD3+CD4-CD8- (Double Negative T-cells) Are Early Responders during Kidney Ischemia Reperfusion Injury and Regulated by Non-Classical MHC Molecules (Abstract #81)**  
*M. Sadasivam, S. Noel, S. Lee, J. Gong, A. Hamad, H. Rabb, Johns Hopkins University and School of Medicine, Baltimore, MD*

**AMERICAN TRANSPLANT CONGRESS**  
**Program, Sunday, June 2, 2019**

---

**Tolerance: Clinical Studies**

**Room: 208**

*Chairs: J. Scandling, Stanford Univ Medical Ctr, Palo Alto, CA and J. Leventhal, Northwestern University, Chicago, IL.*

**2:30 PM Impact of Immunosuppressive Drug Withdrawal on Persistent Mixed Chimerism in Recipients of HLA Haplo-Identical Kidney and Hematopoietic Cell Transplants (Abstract #82)**

S. Busque, J. Scandling, R. Lowsky, J. Shizuru, E. Meyer, K. Jensen, A. Shori, R. Hoppe, E. Engleman, S. Strober, *Stanford University School of Medicine, Stanford, CA*

**2:42 PM Persistent Mixed Chimerism, Immune Reconstitution, and Tolerance in Recipients of HLA Matched Kidney and Hematopoietic Cell Transplants (Abstract #83)**

S. Busque, J. Scandling, R. Lowsky, J. Shizuru, E. Meyer, K. Jensen, A. Shori, R. Hoppe, E. Engleman, T. Pham, S. Strober, *Stanford University School of Medicine, Stanford, CA*

**2:54 PM Use of Low Dose Interleukin-2 to Expand Regulatory T-cells and Facilitate the Complete Discontinuation of Immunosuppression in Human Liver Transplantation (Abstract #84)**

T. Lim<sup>1</sup>, P. Ruiz<sup>2</sup>, A. Kurt<sup>2</sup>, E. Kodela<sup>2</sup>, M. Martinez-Llordella<sup>2</sup>, T. Tree<sup>3</sup>, A. Sanchez-Fueyo<sup>1</sup>, <sup>1</sup>*Institute of Liver Studies, King's College Hospital, London, United Kingdom*, <sup>2</sup>*Department of Liver Sciences, King's College London, London, United Kingdom*, <sup>3</sup>*Department of Immunobiology, King's College London, London, United Kingdom*

**3:06 PM Tolerance Induction with Hematopoietic Stem Cells in Kidney Transplantations (Abstract #85)**

K. Lee, J. Park, Y. Chung, S. Kim, *Department of Surgery, Samsung Medical Center, Seoul, Korea, Republic of*

**3:18 PM Results of Litmus (nct 02541916): The Liver Immune Tolerance Bio Marker Utilization Study (Abstract #86)**

A. Chruscinski<sup>1</sup>, V. Rojas-Luengas<sup>1</sup>, S. Moshkelgosha<sup>1</sup>, J. Luo<sup>2</sup>, H. Yowanto<sup>2</sup>, Z. Galvin<sup>1</sup>, L. Lilly<sup>1</sup>, R. Smith<sup>1</sup>, E. Renner<sup>1</sup>, J. Zhang<sup>1</sup>, D. Grant<sup>1</sup>, O. Adeyi<sup>1</sup>, H. Atkins<sup>3</sup>, P. Juni<sup>4</sup>, N. Selzner<sup>1</sup>, S. Juvet<sup>1</sup>, G. Levy<sup>1</sup>, <sup>1</sup>*Multi-Organ Transplantation, University Health Network, Toronto, ON, Canada*, <sup>2</sup>*Sciex, Brea, CA*, <sup>3</sup>*Ottawa Hospital Research Institute, Ottawa, ON, Canada*, <sup>4</sup>*University of Toronto, Toronto, ON, Canada*

**3:30 PM Preliminary Mechanistic Studies of Regulatory Dendritic Cell (DCreg) Cell Infusion in Living Donor Liver Transplant Recipients (Abstract #87)**

A. Thomson, C. Macedo, A. Zahorchak, H. Dai, A. Humar, F. G. Lakkis, M. Styn, D. Metes, *Starzl Transplantation Institute, Pittsburgh, PA*

**3:42 PM An Open-Label Proof-of-Principle Phase 2A Study to Evaluate Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance (ASCOTT) (Abstract #88)**

A. Chruscinski<sup>1</sup>, H. Atkins<sup>2</sup>, A. Clement<sup>2</sup>, D. Grant<sup>1</sup>, C. Bredsen<sup>2</sup>, E. Renner<sup>1</sup>, J. Zhang<sup>1</sup>, M. Epstein<sup>1</sup>, L. Lilly<sup>1</sup>, N. Selzner<sup>1</sup>, O. Adeyi<sup>1</sup>, R. Smith<sup>1</sup>, S. Moshkelgosha<sup>1</sup>, A. Humar<sup>1</sup>, S. Juvet<sup>1</sup>, G. Levy<sup>1</sup>, <sup>1</sup>*Multi-Organ Transplantation, University Health Network, Toronto, ON, Canada*, <sup>2</sup>*Ottawa Hospital Research Institute, Ottawa, ON, Canada*

**AMERICAN TRANSPLANT CONGRESS**  
Program, Sunday, June 2, 2019

---

**Medley of Heart Transplantation Topics**

**Room: 206**

*Chairs: B. Lampert, Bexley, OH and H. Copeland;  
University of Mississippi Medical Center, Jackson,  
MS*

**2:30 PM Incidence and Risk of Allograft Rejection after Cardiac Transplantation in Left Ventricular Assist Device Patients (Abstract #89)**

*R. C. Patel<sup>1</sup>, L. B. Cooper<sup>2</sup>, S. D. Barnett<sup>2</sup>, R. T. Cole<sup>2</sup>, M. A. Psocka<sup>2</sup>, A. Cochrane<sup>2</sup>, S. Sinha<sup>2</sup>, L. J. Bogar<sup>2</sup>, S. S. Desai<sup>2</sup>, P. Shah<sup>2</sup>, <sup>1</sup>Virginia Commonwealth University School of Medicine, Inova Fairfax Hospital, Falls Church, VA, <sup>2</sup>Department of Heart Failure and Transplant, Inova Heart and Vascular Institute, Falls Church, VA*

**2:42 PM Low Frequency Of Canonical Human Leukocyte Antigen Alloimmunization In Heart Transplantation Candidates With Ventricular Assist Devices (Abstract #90)**

*G. K. Mahowald<sup>1</sup>, S. L. Saidman<sup>1</sup>, G. Lewis<sup>2</sup>, V. Pattanayak<sup>1</sup>, <sup>1</sup>Pathology, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Cardiology, Massachusetts General Hospital, Boston, MA*

**2:54 PM Does the Type of Pre-Heart Transplant Desensitization Therapy Affect 5-Year Post-Transplant Outcomes? (Abstract #91)**

*J. Patel, E. Kransdorf, R. Levine, S. Dimbil, L. Czer, J. A. Kobashigawa, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*

**3:06 PM Upregulation of Endothelial HLA Class II as a Marker of Antibody Mediated Rejection in Heart Allograft Biopsies (Abstract #92)**

*Q. Cai, Y. Butt, A. Hendricks, J. Torrealba, Pathology, UTSW Medical Ctr, Dallas, TX*

**3:18 PM Identification and Determinants of Cardiac Allograft Vasculopathy Trajectories after Heart Transplantation (Abstract #93)**

*G. Bonnet<sup>1</sup>, G. Coutance<sup>1</sup>, M. Racape<sup>1</sup>, M. Raynaud<sup>1</sup>, J. Van keer<sup>2</sup>, M. Bories<sup>1</sup>, S. Varnous<sup>3</sup>, P. Rouvier<sup>3</sup>, R. Guillemain<sup>4</sup>, L. Lecuyer<sup>4</sup>, P. Bruneval<sup>4</sup>, J. Duong-Van-Huyen<sup>1</sup>, J. Taupin<sup>5</sup>, M. Naesens<sup>2</sup>, C. Lefaucheur<sup>1</sup>, X. Jouven<sup>1</sup>, A. Loupy<sup>1</sup>, <sup>1</sup>Paris Transplant Group, Paris, France, <sup>2</sup>KU Leuven, Leuven, France, <sup>3</sup>Pitie Salpetriere Hospital, Paris, France, <sup>4</sup>Georges Pompidou Hospital, Paris, France, <sup>5</sup>Saint Louis Hospital, Paris, France*

**3:30 PM More Than Meets the Eye: The Use of Serial Intravascular Ultrasound for Assessment of Cardiac Allograft Vasculopathy after Heart Transplantation (Abstract #94)**

*Y. Moayed<sup>1</sup>, C. Fan<sup>2</sup>, M. Tremblay-Gravel<sup>1</sup>, R. J. Miller<sup>1</sup>, M. Kawana<sup>1</sup>, J. Parizo<sup>1</sup>, G. Oro<sup>1</sup>, R. Wainwright<sup>1</sup>, H. I. Luikart<sup>1</sup>, N. D'Emilio<sup>1</sup>, J. Gordon<sup>1</sup>, R. Kameda<sup>1</sup>, M. Ikutomi<sup>1</sup>, C. Manlhiot<sup>1</sup>, W. F. Fearon<sup>1</sup>, H. J. Ross<sup>1</sup>, K. K. Khush<sup>1</sup>, J. J. Teuteberg<sup>1</sup>, <sup>1</sup>Stanford University, Palo Alto, CA, <sup>2</sup>University of Toronto, Toronto, ON, Canada*

**Abstract Presenter Unable to Attend – Evaluation of Cytomegalovirus-Specific T Cell Response Can Improve Risk Stratification of CMV Infection in Heart Transplant Recipients (Abstract #95)**

*E. Garcia-Romero<sup>1</sup>, U. Lopez-Cardoza<sup>1</sup>, C. Diez-Lopez<sup>1</sup>, J. Roca-Elias<sup>1</sup>, I. Tatjer<sup>1</sup>, A. Cequier-Fillat<sup>2</sup>, N. Sabe<sup>3</sup>, N. Manito-Lorite<sup>1</sup>, O. Bestard<sup>4</sup>, J. Gonzalez-Costello<sup>1</sup>, <sup>1</sup>Advanced Heart Failure and Heart Transplantation Unit, Hospital Universitari de Bellvitge, Barcelona, Spain, <sup>2</sup>Cardiology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, <sup>3</sup>Infectious Diseases Department, Hospital Universitari de Bellvitge, Barcelona, Spain, <sup>4</sup>Nephrology Department, Hospital Universitari de Bellvitge, Barcelona, Spain*

Sunday, June 2

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

## Non-Organ Specific: Organ Preservation/ Ischemia Reperfusion Injury

**Room: 209**

*Chairs: D. Maluf, Director of Liver Transplantation, Memphis, TN and M. Levine, University of Pennsylvania, Philadelphia, PA*

### 2:30 PM **Multi-Omics Approach to Accurately Assess Early Graft Injury in Liver Transplantation (Abstract #96)**

D. Maluf<sup>1</sup>, V. Sai Bontha<sup>1</sup>, A. Bajwa<sup>1</sup>, R. Helmick<sup>1</sup>, P. J. Horton<sup>1</sup>, C. Eymard<sup>1</sup>, J. Eason<sup>2</sup>, V. Mas<sup>3</sup>, <sup>1</sup>UTHSC, Memphis, TN, <sup>2</sup>UTHSC. Director of Transplant Institute, Memphis, TN, <sup>3</sup>UTHSC Director Transplant Research Institute, Memphis, TN

### 2:42 PM **Improved Transplant Outcomes in Ischemia-Free Liver Transplantation: A Report of the First 30 Cases (Abstract #97)**

X. He, Z. Guo, W. Ju, Q. Zhao, S. Huang, J. Yang, L. Wang, Y. Tang, Z. Zhang, Z. Zhu, L. Yang, Y. Zhu, F. Gong, C. Cai, W. Huang, G. Chen, M. Chen, F. Ji, M. Han, A. Hu, L. Wu, Y. Ma, D. Wang, J. Huang, X. Li, *Organ Transplant Center, the First Affiliated Hospital of SYSU, Guangzhou, China*

### 2:54 PM **Histologic Ischemia Reperfusion Injury in Liver Transplantation: A Large Single Center Experience (Abstract #98)**

F. M. Kaldas, T. Ito, S. Younan, J. Aziz, M. Lu, V. G. Agopian, J. DiNorcia III, H. Yersiz, D. G. Farmer, R. W. Busuttil, *Department of Surgery, The Dumont-UCLA Transplant Center, Los Angeles, CA*

### 3:06 PM **Normothermic Regional Perfusion of Kidneys: A Single Non-Retrieval Centre Experience (Abstract #99)**

R. Pearson, C. Geddes, M. Clancy, J. Asher, *Renal Transplant, Queen Elizabeth University Hospital, Glasgow, Glasgow, United Kingdom*

### 3:18 PM **Hepatocyte SIRT1 Modulates ATF4/CHOP and Mitigates Liver Transplant Ischemia-Reperfusion Injury: From Bench-to-Bedside (Abstract #100)**

H. Hirao<sup>1</sup>, S. Kageyama<sup>1</sup>, K. Kadono<sup>1</sup>, K. Nakamura<sup>1</sup>, T. Ito<sup>1</sup>, K. J. Dery<sup>1</sup>, D. Oncel<sup>1</sup>, X. Li<sup>2</sup>, B. Ke<sup>1</sup>, F. M. Kaldas<sup>1</sup>, R. W. Busuttil<sup>1</sup>, J. W. Kupiec-Weglinski<sup>1</sup>, <sup>1</sup>Surgery, Dumont-UCLA Transplant Center, UCLA, Los Angeles, CA, <sup>2</sup>National Institute of Environmental Health Sciences, Research Triangle Park, NC

### 3:30 PM **Brief Normothermic Machine Perfusion is Superior to Cold Storage Alone - A Paired Discarded Human Kidney Analysis (Abstract #101)**

A. Hameed<sup>1</sup>, E. Patrick<sup>2</sup>, D. B. Lu<sup>1</sup>, C. P'ng<sup>1</sup>, M. Hu<sup>2</sup>, Y. Chew<sup>2</sup>, R. De Roo<sup>1</sup>, L. Yuen<sup>1</sup>, W. Hawthorne<sup>1</sup>, N. Rogers<sup>1</sup>, H. Pleass<sup>1</sup>, <sup>1</sup>Westmead Hospital, Sydney, Australia, <sup>2</sup>Westmead Institute for Medical Research, Sydney, Australia

### 3:42 PM **Impact of Preoperative Rifaximin Use on Reducing Graft Injury in Liver Transplantation: A Propensity Matched Analysis (Abstract #102)**

T. Ito, K. Nakamura, S. Kageyama, H. Hirao, K. Kadono, J. Aziz, J. DiNorcia, V. G. Agopian, H. Yersiz, D. G. Farmer, R. W. Busuttil, J. Kupiec-Weglinski, F. M. Kaldas, *Department of Surgery, The Dumont-UCLA Transplant Center, Los Angeles, CA*

## Student Program

2:30 pm – 5:30 pm

### **The Science, The Art, and The Allure of Transplantation**

**Room 210**

*Moderators: Dorry Segev, MD, PhD, Johns Hopkins University, Baltimore, MD, USA. Ronald Gill, PhD, University of Colorado, Denver, CO, USA.*

2:30 pm **Transplantation: The Big Picture**  
Anthony Jevnikar, BSc, MSc., London Health Sciences Centre and Western University, London, ON, Canada.



# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

- 2:45 pm** **Life on the Death Panels: Transplant Making its Own Policy**  
*Richard Formica, MD, Yale University, New Haven, CT, USA.*
- 3:00 pm** **Perspectives of a Transplant Surgeon and Award-Winning Author**  
*Josh Mezrich, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.*
- 3:15 pm** **Liver Transplantation: Big Operation, Big Impact**  
*Wendy Grant, MD, University of Nebraska, FACS, Omaha, NE, USA.*
- 3:30 pm** **Kidney Transplantation: Minimally Invasive, Maximally Effective**  
*Lloyd Ratner, MD, Columbia University, New York, NY, USA.*
- 3:45 pm** **Outcomes Research in Transplantation: Data All Around Us**  
*Jackie Garonzik-Wang, Johns Hopkins Medicine, Baltimore, MD, USA.*
- 4:00 pm** **Basic Science TResearch in Transplantation: The Quest to Understand the Immune System**  
*Howard Gebel, PhD, Emory University, Atlanta, GA, USA.*
- 4:15 pm** **Transplant ID: Now With Treatable Viruses!**  
*Emily Blumberg, MD, FAST, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.*
- 4:30 pm** **Pharmacy: Better Living Through Chemistry**  
*Lisa Potter, PharmD, University of Chicago, Chicago, IL, USA.*
- 4:45 pm** **Q&A**

## Coffee Break in Exhibit Hall

---

**4:00 pm – 4:30 pm**  
*Hall C/D*

## Concurrent Oral Abstract Sessions

---

**4:30 pm – 6:00 pm**

### Kidney Immunosuppression: Novel Regimens and Drug Minimization I

#### *Veterans Auditorium*

*Chairs: F. Shihab, University of Utah Sch of Med, Salt Lake City, UT and R. Shapiro, Mount Sinai Medical Center, New York, NY*

- 4:30 PM** **Antirejection Efficacy in De Novo Renal Transplant Recipients Receiving Everolimus with a Reduced-Exposure Calcineurin Inhibitor-Based Regimen: 24-Month Results from the TRANSFORM Study (Abstract #105)**  
*H. Tedesco Silva<sup>1</sup>, F. Citterio<sup>1</sup>, M. Henry<sup>1</sup>, T. R. Srinivas<sup>1</sup>, Y. Watarai<sup>1</sup>, S. Steinberg<sup>1</sup>, N. Basic-Jukic<sup>1</sup>, V. D. Garcia<sup>1</sup>, E. Mor<sup>1</sup>, V. R. Peddi<sup>1</sup>, P. Narvekar<sup>2</sup>, M. P. Hernandez Gutierrez<sup>2</sup>, P. Bernhardt<sup>2</sup>, J. Pascual<sup>1</sup>, <sup>1</sup>TRANSFORM Study Group, Basel, Switzerland, <sup>2</sup>Novartis Pharma AG, Basel, Switzerland*
- 4:42 PM** **Efficacy and Safety Outcomes with De Novo Use of Everolimus-Based Regimen in Renal Transplant Recipients with Delayed Graft Function from the TRANSFORM Study (Abstract #103)**  
*S. Chadban<sup>1</sup>, F. Oppenheimer<sup>1</sup>, F. Citterio<sup>1</sup>, O. Witzke<sup>1</sup>, V. D. Garcia<sup>1</sup>, A. Gutierrez-Dalmau<sup>1</sup>, P. Narvekar<sup>2</sup>, M. P. Hernandez Gutierrez<sup>2</sup>, P. Bernhardt<sup>2</sup>, A. Wiseman<sup>1</sup>, <sup>1</sup>TRANSFORM Study Group, Basel, Switzerland, <sup>2</sup>Novartis Pharma AG, Basel, Switzerland*
- 4:54 PM** **The Use of mTOR Inhibitors Prevents Acute Cellular Rejection in Kidney Transplantation on Belatacept Therapy (Abstract #104)**  
*J. Shoji, J. C. Leung, Q. Tang, J. P. Roberts, F. Vincenti, University of California San Francisco, San Francisco, CA*

Sunday, June 2

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

**5:06 PM Early Steroid Withdrawal in African American Deceased Donor Renal Transplant Recipients with Alemtuzumab Induction: Is Graft Loss on the Horizon? (Abstract #106)**  
R. Lynn, B. Ravichandran, T. Sparkes, A. Haririan, J. Bromberg, J. Casale, *University of Maryland Medical Center, Baltimore, MD*

**5:18 PM Early Outcomes Comparing Two Steroid-Avoidance Protocols in Pediatric Renal Transplantation (Abstract #107)**  
D. Puliyananda<sup>1</sup>, H. Pizzo<sup>1</sup>, N. Rodig<sup>2</sup>, M. Somers<sup>2</sup>, <sup>1</sup>*Cedars-Sinai Med Ctr, Los Angeles, CA*, <sup>2</sup>*Pediatric Nephrology, Boston Childrens Hospital, Boston, MA*

**5:30 PM Impact of Steroid-Free Protocol on Incidence of Posttransplantation Diabetes Mellitus: A Prospective, Randomized, Multicenter, Open-Label, Controlled Trial in Renal Transplant Recipients (Abstract #108)**  
J. Ekberg<sup>1</sup>, S. Baid-Agrawal<sup>1</sup>, B. Jespersen<sup>2</sup>, R. Källén<sup>3</sup>, E. Rafael<sup>3</sup>, K. Skov<sup>2</sup>, P. Lindnér<sup>1</sup>, <sup>1</sup>*Institute of Clinical Sciences, Transplant Institute, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden*, <sup>2</sup>*Department of Nephrology, Aarhus University Hospital, Aarhus, Denmark*, <sup>3</sup>*Department of Transplantation, Skane University Hospital, Malmoe, Sweden*

**5:42 PM What's in a High Dose? An Analysis of Tacrolimus Pharmacokinetic Parameters in Rapid Metabolizers (Abstract #109)**  
P. West-Thielke<sup>1</sup>, A. Maldonado<sup>2</sup>, S. J. Patel<sup>3</sup>, D. R. Stevens<sup>3</sup>, U. Meier-Kriesche<sup>3</sup>, D. Brennan<sup>4</sup>, <sup>1</sup>*University of Illinois, Chicago, Chicago, IL*, <sup>2</sup>*Vidant Medical Center, Greenville, NC*, <sup>3</sup>*Veloxis Pharmaceuticals Inc., Cary, NC*, <sup>4</sup>*Johns Hopkins University School of Medicine, Baltimore, MD*

## Kidney Acute Antibody Mediated Rejection

### Ballroom B

*Chairs: V. Kumar, University of Alabama at Birmingham, Birmingham, AL and Y. Qazi*

**4:30 PM Eculizumab Deposition in Renal Transplants (Abstract #110)**  
D. WANG<sup>1</sup>, S. H. Nasr<sup>1</sup>, A. B. Farris<sup>2</sup>, C. A. Schinstock<sup>3</sup>, M. P. Alexander<sup>1</sup>, L. D. Cornell<sup>1</sup>, <sup>1</sup>*Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN*, <sup>2</sup>*Pathology & Laboratory Medicine, Emory University, Atlanta, GA*, <sup>3</sup>*Division of Nephrology & Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN*

**4:42 PM Prevention of Ischemia Reperfusion Injury (IRI) & ABMR in HLA Sensitized Patients Treated with C1 Esterase Inhibitor (C1INH): Long-Term Follow Up (Abstract #111)**  
A. A. Vo, E. Huang, N. Ammerman, J. Choi, I. Kim, A. Peng, R. Najjar, S. Sethi, K. Lim, S. C. Jordan, *Cedars Sinai Medical Ctr, Los Angeles, CA*

**4:54 PM The Role of Neutrophil Extracellular Traps in Kidney Acute Antibody-Mediated Rejection (Abstract #112)**  
R. Villca-Gonzales<sup>1</sup>, J. Torres-Ruiz<sup>2</sup>, D. Gomez-Martin<sup>2</sup>, L. Morales-Buenrostro<sup>1</sup>, J. Alberu<sup>3</sup>, <sup>1</sup>*Nephrology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran, Mexico, Mexico*, <sup>2</sup>*Immunology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran, Mexico, Mexico*, <sup>3</sup>*Transplantation, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran, Mexico, Mexico*

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

**5:06 PM De Novo Donor Specific Antibody and Panel Reactivity Antibody Are Critical Risk Factors for Antibody Mediated Rejection of Kidney Allograft after Simultaneous Liver-Kidney Transplantation (a Single Center Study Using Surveillance Renal Biopsies) (Abstract #113)**

Y. Sun<sup>1</sup>, A. Zhang<sup>2</sup>, Z. Zaky<sup>2</sup>, <sup>1</sup>Avalon Medical University, Willemstad, Netherlands Antilles, <sup>2</sup>Cleveland Clinic, Cleveland, OH

**5:18 PM Prognostic Value of C3d Fixing Preformed Donor-Specific Antibody in Crossmatch-Positive Living Kidney Transplantation (Abstract #114)**

K. Miyake<sup>1</sup>, M. Okumi<sup>1</sup>, Y. Kakuta<sup>1</sup>, K. Unagami<sup>2</sup>, M. Furusawa<sup>1</sup>, H. Ishida<sup>2</sup>, K. Tanabe<sup>1</sup>, <sup>1</sup>Urology, Tokyo Women's Medical University, Sinjuku, Japan, <sup>2</sup>Organ Transplant Medicine, Tokyo Women's Medical University, Sinjuku, Japan

**5:30 PM CD19+ Cell Behavior in the 12 Months Following a Single Dose of Rituximab in Patients with Humoral Rejection: Clinical and Histological Outcomes (Abstract #115)**

L. Marino, I. A. Martínez-Juárez, J. R. Marino-Sánchez, J. I. Santander-Velez, F. Zamora, H. Juarez, R. Vazquez, L. Llorente, G. Lima, A. Cohen-Bucay, L. E. Morales-Buenrostro, *Nephrology, INCMNSZ, Mexico City, Mexico*

**5:42 PM Kinetics of Pretransplant DSA, Post-Transplant Histology, and Graft Failure after Kidney Transplantation (Abstract #116)**

A. Senev<sup>1</sup>, E. Lerut<sup>2</sup>, V. Van Sandt<sup>3</sup>, J. Callemeyn<sup>1</sup>, M. Coemans<sup>1</sup>, B. Sprangers<sup>2</sup>, D. Kuypers<sup>2</sup>, M. Emonds<sup>1</sup>, M. Naesens<sup>2</sup>, <sup>1</sup>Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium, <sup>2</sup>University Hospitals Leuven, Leuven, Belgium, <sup>3</sup>Histocompatibility and Immunogenetics Laboratory, Belgian Red Cross-Flanders, Mechelen, Belgium

**Kidney: Cardiovascular and Metabolic I**

## Ballroom C

*Chairs: A. Kukla, Mayo Clinic, Rochester, MN and A. Mehrotra, Lourdes Medical Associates Transplant Nephrology, Camden, NJ*

**4:30 PM Efficacy and Safety with Empagliflozin in Renal Transplant Recipients with Post-Transplant Diabetes Mellitus (Abstract #117)**

K. E. Kvitne<sup>1</sup>, T. S. Halden<sup>2</sup>, A. Åsberg<sup>2</sup>, K. Midtvedt<sup>2</sup>, A. Hartmann<sup>2</sup>, T. Jenssen<sup>2</sup>, <sup>1</sup>Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway, <sup>2</sup>Department of Transplantation Medicine, Section of Nephrology, Oslo University Hospital, Rikshospitalet, Oslo, Norway

**4:42 PM Belatacept Based Simultaneous Calcineurin Inhibitor Avoidance/ Early Corticosteroid Withdrawal is Associated with Low New Onset Diabetes Risk (Abstract #118)**

A. R. Shields<sup>1</sup>, P. West-Thielke<sup>2</sup>, E. S. Woodle<sup>1</sup>, D. B. Kaufman<sup>3</sup>, J. Lipscomb<sup>4</sup>, J. P. Leone<sup>5</sup>, A. Wiseman<sup>6</sup>, E. King<sup>4</sup>, A. J. Matas<sup>7</sup>, R. R. Alloway for the BEST Study Group<sup>4</sup>, <sup>1</sup>Transplant Surgery, U of Cincinnati, Cincinnati, OH, <sup>2</sup>UIC, Chicago, IL, <sup>3</sup>Transplant Surgery, U of Wisconsin, Madison, WI, <sup>4</sup>U of Cincinnati, Cincinnati, OH, <sup>5</sup>Tampa General, Tampa, FL, <sup>6</sup>U of Colorado, Denver, CO, <sup>7</sup>U Minnesota, Minneapolis, MN

Sunday, June 2

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

**4:54 PM Lifestyle Intervention in Renal Transplant Recipients: A Multicenter, Randomized Clinical Trial (Abstract #119)**

E. Corpeleijn<sup>1</sup>, G. Klaassen<sup>2</sup>, D. M. Zelle<sup>2</sup>, D. Dijkema<sup>3</sup>, I. van Vliet<sup>2</sup>, F. J. Bemelman<sup>4</sup>, G. J. Navis<sup>2</sup>, S. J. Bakker<sup>2</sup>,  
<sup>1</sup>Department of Epidemiology, University Medical Center Groningen, Groningen, Netherlands, <sup>2</sup>Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, Groningen, Netherlands, <sup>3</sup>Department of Dietetics, University Medical Center Groningen, Groningen, Netherlands, <sup>4</sup>Department of Nephrology, Amsterdam Medical Center, Amsterdam, Netherlands

**5:06 PM Long-Term Outcomes in Patients with Obesity and Renal Disease after Sleeve Gastrectomy (Abstract #120)**

A. Kassam, A. Mirza, Y. Kim, E. S. Woodle, S. A. Shah, M. C. Cuffy, R. C. Quillin III, L. Sage Silski, A. Govil, M. Cardi, T. S. Diwan, Department of Surgery, University of Cincinnati, Cincinnati, OH

**5:18 PM Recurrent Diabetic Nephropathy Despite Intensive Glycemic Control: An Observational Cohort Study (Abstract #121)**

M. Coemans, E. Van Loon, E. Lerut, D. Kuypers, B. Sprangers, P. Gillard, C. Mathieu, G. Verbeke, M. Naesens, KU Leuven, Leuven, Belgium

**5:30 PM The Evolution of Body Mass Index after Kidney Transplantation in Recipients with a Previous Laparoscopic Sleeve Gastrectomy (Abstract #122)**

G. Chan, F. Briere, Universite de Montreal, Hopital Maisonneuve-Rosemont, Montreal, QC, Canada

**5:42 PM Comparison of Two Glucagon-Like-Peptide-1 Analogs (GLP -1) Dulaglutide vs Liraglutide for the Management of Diabetes in Solid Organ Transplant (SOT) (Abstract #123)**

P. Singh, M. Taufeeq, T. E. Pesavento, K. Washburn, D. Walsh, S. Meng, Ohio State University, Columbus, OH

**Kidney Living Donor: Quality and Selection**

**Ballroom A**

Chairs: S. Westphal, University of Nebraska Medical Center, Omaha, NE and C. Thomas, University of Iowa, Iowa City, IA

**4:30 PM Preemptive Kidney Transplantation: Is There a Role for ABO Incompatible Transplantation? (Abstract #124)**

M. N. Mustian<sup>1</sup>, B. A. Shelton<sup>1</sup>, P. A. MacLennan<sup>1</sup>, R. D. Reed<sup>1</sup>, G. McGwin<sup>1</sup>, B. J. Orandi<sup>1</sup>, D. Sawinski<sup>2</sup>, V. Kumar<sup>1</sup>, J. E. Locke<sup>1</sup>, <sup>1</sup>University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>University of Pennsylvania, Philadelphia, PA

**4:42 PM Recipient Outcomes Following Transplantation Of Allografts From Older Live Kidney Donors With Hypertension (Abstract #125)**

F. Al Ammary<sup>1</sup>, S. Yu<sup>2</sup>, A. D. Muzaale<sup>3</sup>, D. C. Brennan<sup>4</sup>, A. C. Wiseman<sup>5</sup>, D. L. Segev<sup>3</sup>, A. B. Massie<sup>3</sup>, <sup>1</sup>Johns Hopkins Medicine, Greenbelt, MD, <sup>2</sup>Johns Hopkins Medicine, Baltimore, MD, <sup>3</sup>Surgery, Johns Hopkins Medicine, Baltimore, MD, <sup>4</sup>Medicine, Johns Hopkins Medicine, Baltimore, MD, <sup>5</sup>Medicine, University of Colorado, Aurora, CO

**4:54 PM External Validation of the Living Kidney Donor Profile Index (LKDPI) in the Canadian Kidney Transplant Recipient Population (Abstract #126)**

M. Shantier<sup>1</sup>, Y. Li<sup>1</sup>, M. Ashwin<sup>1</sup>, O. Famure<sup>1</sup>, S. K. Singh<sup>2</sup>, <sup>1</sup>Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, <sup>2</sup>Department of Medicine, University of Toronto, Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada



# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

**5:06 PM Risk Factors for Recurrence and Predictors of Response in Kidney Transplant Recipients with Primary FSGS (Abstract #127)**  
A. Uffing<sup>1</sup>, T. TANGO-consortium<sup>2</sup>, P. Cravedi<sup>3</sup>, L. V. Riella<sup>1</sup>, <sup>1</sup>Renal Division, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, <sup>2</sup>NA, Boston, MA, <sup>3</sup>Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

**5:18 PM Potential Living Kidney Donors' Interest in Kidney Paired and Non-Directed Donation (Abstract #128)**  
D. R. Helfer<sup>1</sup>, A. D. Love<sup>1</sup>, J. M. Konel<sup>1</sup>, J. Stanton<sup>2</sup>, M. G. Bowring<sup>1</sup>, K. Kumar<sup>1</sup>, S. R. Weeks<sup>1</sup>, M. L. Henderson<sup>1</sup>, D. L. Segev<sup>1</sup>, A. M. Cameron<sup>1</sup>, J. M. Garonzik Wang<sup>1</sup>, <sup>1</sup>Johns Hopkins University, Baltimore, MD, <sup>2</sup>East Carolina University, Greenville, NC

**5:30 PM Apolipoprotein L1 Genotyping in Potential African American Living Kidney Donors (Abstract #129)**  
P. Gudsoorkar, M. Anand, T. Kaur, S. Shah, S. Bumb, A. Govil, B. G. Abu Jawdeh, *U.Cincinnati, Cincinnati, OH*

**5:42 PM Living Donor Conversion Rates as a Quality Measure for Kidney Program Efficiency for Both New Referrals and Existing Listed Candidates (Abstract #130)**  
E. Woodle<sup>1</sup>, C. Siemers<sup>2</sup>, B. Woodle<sup>3</sup>, C. King<sup>2</sup>, R. Alloway<sup>1</sup>, S. Tremblay<sup>1</sup>, <sup>1</sup>U of Cincinnati, Cincinnati, OH, <sup>2</sup>UC Health, Cincinnati, OH, <sup>3</sup>U of Arkansas, Little Rock, AR

## Kidney: Pediatrics I

**Room: 304**

*Chairs: A. Gallo, Stanford University Medical Center, Palo Alto, CA and W. Andrews, Children's Mercy Hospital, Kansas City, MO*

**4:30 PM Utilization of Donor Kidneys with Acute Kidney Injury in Pediatric Transplantation (Abstract #131)**  
C. S. Hwang<sup>1</sup>, B. Tanriover<sup>2</sup>, S. Levea<sup>2</sup>, D. Desai<sup>1</sup>, V. Ariyamuthu<sup>2</sup>, P. Vagefi<sup>1</sup>, M. MacConmara<sup>1</sup>, <sup>1</sup>Surgery, UT Southwestern, Dallas, TX, <sup>2</sup>Medicine, UT Southwestern, Dallas, TX

**4:42 PM Have Graft Outcomes Improved for Pediatric Transplant Recipients Since the Implementation the Kidney Allocation System (Abstract #132)**  
C. S. Bell<sup>1</sup>, S. Hebert<sup>2</sup>, A. De Golovine<sup>3</sup>, R. Swinford<sup>1</sup>, <sup>1</sup>Division of Pediatric Nephrology & Hypertension, McGovern Medical School at UTHealth - Houston, Houston, TX, <sup>2</sup>Division of Nephrology, Department of Internal Medicine, Houston Methodist Hospital, Houston, TX, <sup>3</sup>Renal Diseases & Hypertension, McGovern Medical School at UTHealth - Houston, Houston, TX

**4:54 PM Undernutrition is Associated with Impaired T Cell Protective Immunity in Pediatric Kidney Transplantation (Abstract #133)**  
E. T. Chambers<sup>1</sup>, C. Chan<sup>1</sup>, R. Ettenger<sup>2</sup>, P. Grimm<sup>3</sup>, E. Reed<sup>2</sup>, M. Sarwal<sup>4</sup>, L. Stempora<sup>5</sup>, B. Warshaw<sup>6</sup>, C. Zhao<sup>1</sup>, O. Martinez<sup>7</sup>, A. Kirk<sup>5</sup>, <sup>1</sup>Pediatrics, Duke University, Durham, NC, <sup>2</sup>Pediatrics, UCLA, Los Angeles, CA, <sup>3</sup>Pediatrics, Stanford, Palo Alto, CA, <sup>4</sup>Pediatrics, UCSF, San Francisco, CA, <sup>5</sup>Surgery, Duke University, Durham, NC, <sup>6</sup>Pediatrics, Emory University, Atlanta, GA, <sup>7</sup>Surgery, Stanford, Palo Alto, CA

Sunday, June 2

**AMERICAN TRANSPLANT CONGRESS**  
**Program, Sunday, June 2, 2019**

---

- 5:06 PM Differences in Wait Time, Graft Quality and Outcome for Pediatric Kidney Recipients in the Post-Kidney Allocation System Era (Abstract #134)**  
P. Singer, K. Eng, L. Castellanos Reyes, C. Sethna, L. Teperman, E. Grodstein, Northwell Health, Manhasset, NY
- 5:18 PM United Kingdom National Outcomes of Transplants from Paediatric Donors: 10 Years Experience (Abstract #136)**  
M. A. Khurram, N. Karydis, C. Callaghan, I. Loukopoulos, T. Kasimatis, P. Chandak, F. Calder, N. Mamode, N. Kessararis, *Transplantation, Guy's and St Thomas NHS trust, London, United Kingdom*
- 5:30 PM Effect of Everolimus with Reduced-Exposure Tacrolimus and Early Steroid Elimination in Pediatric Kidney Transplant Recipients: 36-Month Outcomes from the CRADLE Study (Abstract #135)**  
H. Tedesco Silva<sup>1</sup>, R. Ettenger<sup>1</sup>, A. Bjerre<sup>1</sup>, M. Christian<sup>1</sup>, L. Dello Strologo<sup>1</sup>, S. D. Marks<sup>1</sup>, L. Pape<sup>1</sup>, P. Lopez<sup>2</sup>, M. Cousin<sup>2</sup>, P. Pandey<sup>2</sup>, B. Rauer<sup>2</sup>, M. Meier<sup>2</sup>, B. Tönshoff<sup>1</sup>, <sup>1</sup>*A2314 Study Group, Basel, Switzerland*, <sup>2</sup>*Novartis Pharma AG, Basel, Switzerland*
- 5:42 PM Emergence of Anti-HLA Antibodies after Catch-Up Vaccinations in Pediatric Kidney Transplant Candidates (Abstract #137)**  
H. Sweiss<sup>1</sup>, J. Lyons<sup>1</sup>, D. Ranch<sup>2</sup>, K. Hitchman<sup>2</sup>, E. Kincaide<sup>1</sup>, B. Crowther<sup>1</sup>, <sup>1</sup>*University Health System, The University of Texas at Austin, College of Pharmacy, Pharmacotherapy Division, Austin, TX, The University of Texas Health Science Center at San Antonio, San Antonio, TX*, <sup>2</sup>*University Health System, The University of Texas Health Science Center at San Antonio, San Antonio, TX*
- Liver: MELD, Allocation and Donor Issues (DCD/ECD) I**  
**Room: 312**  
*Chairs: P. Abt, Hospital of the University of Pennsylvania, Philadelphia, PA and K. Chavin, Medical University of South Carolina, Cleveland, OH*
- 4:30 PM Transplant Center Practices Are the Primary Drivers of United States Donation after Circulatory Death Liver Transplantation (Abstract #138)**  
L. Beal<sup>1</sup>, D. T. Nguyen<sup>2</sup>, T. Menser<sup>3</sup>, S. Zajac<sup>1</sup>, E. A. Graviss<sup>2</sup>, M. J. Hobeika<sup>1</sup>, <sup>1</sup>*Department of Surgery, Houston Methodist Hospital, Houston, TX*, <sup>2</sup>*Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston, TX*, <sup>3</sup>*Center for Outcomes Research, Houston Methodist Research Institute, Houston, TX*
- 4:42 PM Variations in DCD Procurement Procedures across Opos and Their Effects on Liver Transplant Outcomes (Abstract #139)**  
A. P. Choubey<sup>1</sup>, G. Mitro<sup>1</sup>, E. J. Siskind<sup>2</sup>, A. C. Ortiz<sup>3</sup>, M. Nayebpour<sup>4</sup>, N. Koizumi<sup>4</sup>, P. Wiederhold<sup>5</sup>, J. Ortiz<sup>1</sup>, <sup>1</sup>*The University of Toledo, Toledo, OH*, <sup>2</sup>*Inova Fairfax Hospital, Fairfax, VA*, <sup>3</sup>*University of California, Los Angeles (UCLA), Los Angeles, CA*, <sup>4</sup>*George Mason University, Fairfax, VA*, <sup>5</sup>*Life Connection Of Ohio, Maumee, OH*
- 4:54 PM Utilization of DCD Donors >50 Years Old for Liver Transplantation (Abstract #140)**  
T. Chaly, K. Hoidal, C. Cashman, J. Brink, A. Mehrotra, W. Van der Werf, *Arizona Transplant Associates, PC, Phoenix, AZ*
- 5:06 PM Ready for Prime Time: Intentional Allocation of Hepatitis C Positive Livers into Hepatitis C Negative Recipients (Abstract #141)**  
P. N. Martins<sup>1</sup>, B. Movahedi<sup>1</sup>, D. Devuni<sup>2</sup>, P. Mahboub<sup>1</sup>, A. Bozorgzadeh<sup>1</sup>, <sup>1</sup>*Surgery, Division of Transplantation, University of Massachusetts, Worcester, MA*, <sup>2</sup>*Medicine, Division of Hepatology, University of Massachusetts, Worcester, MA*



# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

**5:18 PM A Priori Identification of Hard-to-Place Livers (Abstract #142)**  
A. Wey<sup>1</sup>, N. Hadley<sup>1</sup>, J. Rosendale<sup>2</sup>, R. Hunter<sup>2</sup>, J. Prinz<sup>2</sup>, K. Audette<sup>1</sup>, N. Salkowski<sup>1</sup>, D. Zaun<sup>1</sup>, J. Snyder<sup>3</sup>, <sup>1</sup>SRTR, Minneapolis, MN, <sup>2</sup>OPTN, Richmond, VA, <sup>3</sup>SRTR, Minneapolis, MN

**5:30 PM Continuous Distribution: LSAM Simulation Study (Abstract #143)**  
T. Weaver<sup>1</sup>, N. Salkowski<sup>1</sup>, J. Snyder<sup>1</sup>, D. Schladt<sup>1</sup>, J. Pyke<sup>1</sup>, A. Herreid<sup>1</sup>, B. Thompson<sup>1</sup>, W. Kim<sup>2</sup>, J. Lake<sup>3</sup>, A. Israni<sup>1</sup>, <sup>1</sup>SRTR, Minneapolis, MN, <sup>2</sup>Stanford Univ, Stanford, CA, <sup>3</sup>Univ of Minnesota, Minneapolis, MN

**5:42 PM DOME: A New Strategy for Prioritizing Hepatocellular Carcinoma Patients on the Liver Transplant Waitlist (Abstract #144)**  
C. Rickert<sup>1</sup>, M. Akan<sup>2</sup>, Z. Leung<sup>3</sup>, J. F. Markmann<sup>1</sup>, S. Tayur<sup>2</sup>, H. Zhao<sup>3</sup>, H. Yeh<sup>1</sup>, <sup>1</sup>Massachusetts General Hospital, Boston, MA, <sup>2</sup>Tepper School of Business, Carnegie Mellon University, Pittsburgh, PA, <sup>3</sup>City University of Hong Kong, Hong Kong, China

## Liver Transplant Oncology

**Room: 311**

Chairs: V. Agopian, UCLA Medical Center, Los Angeles, CA and C. Enestvedt, Oregon Health and Science University, Portland, OR

**4:30 PM Adjuvant Immunotherapeutic Approach For Liver Transplant Recipients With Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells (Abstract #145)**  
M. Ohira<sup>1</sup>, R. Hotta<sup>1</sup>, Y. Imaoka<sup>1</sup>, K. Sato<sup>1</sup>, Y. Tanaka<sup>1</sup>, A. G. Tzakis<sup>2</sup>, S. Nishida<sup>3</sup>, H. Ohdan<sup>1</sup>, <sup>1</sup>Hiroshima University, Hiroshima, Japan, <sup>2</sup>Cleveland Clinic Florida, Weston, FL, <sup>3</sup>New York Medical College, Valhalla, NY

**4:42 PM Prospective Multi-Regional Study of Down-Staging of Hepatocellular Carcinoma to within Milan Criteria before Liver Transplantation (Abstract #146)**  
N. Mehta<sup>1</sup>, J. Guy<sup>2</sup>, C. Frenette<sup>3</sup>, P. Tabrizian<sup>4</sup>, M. Hoteit<sup>5</sup>, R. Dhanasekaran<sup>6</sup>, J. Dodge<sup>1</sup>, M. L. Holzner<sup>4</sup>, L. Frankul<sup>3</sup>, S. Florman<sup>4</sup>, N. Parikh<sup>7</sup>, F. Yao<sup>1</sup>, <sup>1</sup>UCSF, San Francisco, CA, <sup>2</sup>CPMC, San Francisco, CA, <sup>3</sup>Scripps Hospital, La Jolla, CA, <sup>4</sup>Mt Sinai, New York, NY, <sup>5</sup>U. Pennsylvania, Philadelphia, PA, <sup>6</sup>Stanford, Palo Alto, CA, <sup>7</sup>U. Michigan, Ann Arbor, MI

**4:54 PM Sustained Biologic Response To Neoadjuvant Therapy Predicts Excellent Liver Transplant Outcomes For Locally Advanced Intrahepatic Cholangiocarcinoma (Abstract #147)**  
K. E. Lunsford<sup>1</sup>, M. Javle<sup>2</sup>, K. Heyne<sup>3</sup>, R. A. Ali<sup>2</sup>, C. M. Mobley<sup>1</sup>, A. Saharia<sup>1</sup>, D. W. Victor<sup>1</sup>, M. J. Hobeika<sup>1</sup>, A. Kasab<sup>2</sup>, R. S. McFadden<sup>1</sup>, T. A. Aloia<sup>2</sup>, X. C. Li<sup>1</sup>, H. P. Monsour<sup>1</sup>, A. O. Gaber<sup>1</sup>, A. O. Gaber<sup>1</sup>, J. Vauthey<sup>2</sup>, R. M. Ghobrial<sup>1</sup>, <sup>1</sup>J.C. Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, TX, <sup>2</sup>The University of Texas MD Anderson Cancer Center, Houston, TX, <sup>3</sup>Department of Oncology, Houston Methodist Hospital, Houston, TX

**5:06 PM Outcomes of Liver Transplantation for Mixed Hepatocellular-Cholangiocarcinoma (Abstract #148)**  
M. Najjar<sup>1</sup>, K. Bruestle<sup>1</sup>, P. Jiang<sup>1</sup>, S. Robbins-Juarez<sup>1</sup>, R. Hwang<sup>1</sup>, A. Mathur<sup>1</sup>, E. C. Verna<sup>1</sup>, A. Griesemer<sup>1</sup>, B. Samstein<sup>1</sup>, T. Kato<sup>1</sup>, Y. M. Saenger<sup>1</sup>, K. J. Halazun<sup>2</sup>, J. C. Emond<sup>1</sup>, <sup>1</sup>Columbia University Medical Center, New York, NY, <sup>2</sup>Weill Cornell Medicine, New York, NY

**5:18 PM Predicting HCC Recurrence Following Liver Transplant - A Machine Learning Approach (Abstract #149)**  
L. F. Lau<sup>1</sup>, W. Nelson<sup>2</sup>, A. Gorgen<sup>1</sup>, L. Erdman<sup>2</sup>, P. Abreu<sup>1</sup>, A. Goldenberg<sup>2</sup>, G. Sapisochin<sup>1</sup>, <sup>1</sup>Department of Surgery, University of Toronto, Toronto, ON, Canada, <sup>2</sup>The Center for Computational Medicine, The Hospital for Sick Children, Toronto, ON, Canada

Sunday, June 2

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

**5:30 PM** **Decreased Cancer Susceptibility in Tolerant Liver Transplant Recipients: Another Benefit of Tolerance? (Abstract #150)**  
M. P. Bhat<sup>1</sup>, E. Pasini<sup>1</sup>, C. Baciu<sup>1</sup>, S. M. Kurian<sup>2</sup>, J. Levitsky<sup>3</sup>, <sup>1</sup>*Multi-Organ Transplant, UHN, Toronto, ON, Canada*, <sup>2</sup>*Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA*, <sup>3</sup>*Division of Gastroenterology & Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL*

**5:42 PM** **Spindle and Kinetochore Associated Complex Subunit 3 Promotes Tumor Growth by Regulating CDK2/p53 Phosphorylation in Hepatocellular Carcinoma (Abstract #151)**  
Y. Hou<sup>1</sup>, Z. Wang<sup>2</sup>, L. Wu<sup>3</sup>, <sup>1</sup>*Organ Transplant Center, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China*, <sup>2</sup>*The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China*, <sup>3</sup>*Organ transplant center, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China*

## Lymphocyte Biology - Basic

### Room: 306

*Chairs: A. Wells, The Children's Hospital of Philadelphia, Philadelphia, PA and C. A. Huang, Surgery, University of Colorado, Denver, Aurora, CO*

**4:30 PM** **Targeting Cell Metabolism for Efficient Large-Scale Expansion of Functional Regulatory T Cells (Abstract #152)**  
R. Gedaly-Eidelman, F. Marti, L. Turcios, E. Chacon, D. Valvi, *University of Kentucky, Lexington, KY*

**4:42 PM** **How and Why Dyrk1a is Required for Optimal Foxp3+ Treg Functions (Abstract #153)**  
W. W. Hancock, N. Zhou, R. Han, L. Wang, *Children's Hospital of Philadelphia, Philadelphia, PA*

**4:54 PM** **Role of MHC Class II in B Cell and Regulatory T Cell Development (Abstract #154)**  
S. K. Germana, Z. Wang, C. A. Huang, L. Kojima, C. G. Rickert, J. F. Markmann, C. LeGuern, *Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA*

**5:06 PM** **TORC1 Inhibition In Vitro and in a Humanized Mouse Model Protects Activated Human Regulatory T Cells from Self-Inflicted Damage via Granzyme B (Abstract #155)**  
B. S. Al Dulaijan, S. K. Eskandari, S. Cai, J. Y. Choi, H. Allos, I. Sulkaj, A. Bano, E. Al-Hussein, J. Azzi, *Transplantation Research Center, BWH/Harvard Medical School, Boston, MA*

**5:18 PM** **Undernutrition and Leptin Deficiency Modulates T Cell Immunity in Transplantation (Abstract #156)**  
E. David<sup>1</sup>, M. Zhu<sup>2</sup>, B. Bennett<sup>2</sup>, D. Cheng<sup>1</sup>, A. Nichols<sup>1</sup>, W. Parker<sup>2</sup>, P. Schroder<sup>2</sup>, N. McIver<sup>1</sup>, A. Kirk<sup>2</sup>, E. Chambers<sup>1</sup>, <sup>1</sup>*Pediatrics, Duke University, Durham, NC*, <sup>2</sup>*Surgery, Duke University, Durham, NC*

**5:30 PM** **Erythropoietin Ameliorates Parent to F1 Murine Graft versus Host Disease by Inhibiting TFH (Abstract #157)**  
A. Angeletti<sup>1</sup>, C. Donadei<sup>1</sup>, A. Cumpelik<sup>1</sup>, C. Cantarelli<sup>1</sup>, C. Guglielmo<sup>1</sup>, G. La Manna<sup>2</sup>, P. Heeger<sup>1</sup>, P. Cravedi<sup>1</sup>, <sup>1</sup>*Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY*, <sup>2</sup>*Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale (DIMES), Policlinico Sant'Orsola-Malpighi, Bologna, Italy*

**5:42 PM** **The miR17-92 Cluster Promotes Costimulation Resistant Effector Memory T Cell-Mediated Alloresponses (Abstract #158)**  
H. Xu<sup>1</sup>, Q. Guo<sup>1</sup>, M. Song<sup>1</sup>, A. Miler<sup>1</sup>, Q. Li<sup>2</sup>, A. Kirk<sup>1</sup>, <sup>1</sup>*Surgery, Duke University, Durham, NC*, <sup>2</sup>*Immunology, Duke University, Durham, NC*

**AMERICAN TRANSPLANT CONGRESS**  
Program, Sunday, June 2, 2019

---

**Histocompatibility and Immunogenetics**

**Room: 309**

*Chairs: P. Jindra, Houston, TX and R. Mannon, University of Alabama, Birmingham, Birmingham, AL*

**4:30 PM Mismatched Epitope and De Novo DSA Development: An Analysis of the Benefit and Benefit-EXT Renal Transplant Cohorts (Abstract #159)**

*V. Jucaud<sup>1</sup>, V. Burnett<sup>1</sup>, H. Gebel<sup>2</sup>, R. Bray<sup>2</sup>, M. Polinsky<sup>3</sup>, M. Everly<sup>1</sup>, <sup>1</sup>Terasaki Research Institute, Los Angeles, CA, <sup>2</sup>Emory University, Atlanta, GA, <sup>3</sup>Bristol-Myers Squibb, Princeton, NJ*

**4:42 PM Successful Kidney Transplantation of Highly Sensitized Candidates across Positive Cross Match and Strong Donor-Specific HLA-DP Antibodies without Desensitization (Abstract #160)**

*R. Rajalingam<sup>1</sup>, D. D. Gae<sup>2</sup>, Z. G. Laszik<sup>3</sup>, M. M. Tavakol<sup>4</sup>, A. B. Webber<sup>5</sup>, K. Cunniffe<sup>2</sup>, G. da Gente<sup>2</sup>, R. Hirose<sup>4</sup>, G. Roll<sup>4</sup>, C. E. Freise<sup>4</sup>, J. P. Roberts<sup>4</sup>, <sup>1</sup>Immunogenetics and Transplantation Laboratory (ITL), San Francisco, CA, <sup>2</sup>Department of Surgery, Immunogenetics and Transplantation Laboratory (ITL), San Francisco, CA, <sup>3</sup>Department of Pathology, University of California San Francisco, San Francisco, CA, <sup>4</sup>Department of Surgery, University of California San Francisco, San Francisco, CA, <sup>5</sup>Department of Medicine, University of California San Francisco, San Francisco, CA*

**4:54 PM Solving Target Recognition and Activation Mediated by Non-HLA Agonistic Antibodies Targeting ETAR (Abstract #161)**

*A. Philippe<sup>1</sup>, R. Catar<sup>1</sup>, P. Scheerer<sup>2</sup>, M. Szczepek<sup>2</sup>, D. Dragan<sup>1</sup>, <sup>1</sup>Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany, <sup>2</sup>Institute of Medical Physics and Biophysics, Charité Universitätsmedizin Berlin, Berlin, Germany*

**5:06 PM Inhibition of mTORC2 Causes Hyper Phosphorylation of ERK Induced by Co-Ligation of HLA-I and II Antibody (Abstract #162)**

*Y. Jin<sup>1</sup>, J. Sinnet-Smith<sup>2</sup>, E. Rozengurt<sup>2</sup>, E. F. Reed<sup>1</sup>, <sup>1</sup>Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA, <sup>2</sup>Medicine, University of California Los Angeles, Los Angeles, CA*

**5:18 PM Computational Assessment of T-cell and B-cell Allorecognition to Predict Donor HLA Immunogenicity (Abstract #163)**

*H. C. Copley<sup>1</sup>, M. Elango<sup>1</sup>, V. Kosmoliaptsis<sup>2</sup>, <sup>1</sup>Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospital, Cambridge, United Kingdom, <sup>2</sup>University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospital & NIHR Blood and Transplant Research Unit in Organ Donation and Transplantation at the University of Cambridge, Cambridge, UK., Cambridge, United Kingdom*

**5:30 PM Physiochemical Hla Properties Identify Low Immunogenic Donor/recipient Pairs Predicting Long-term Kidney Graft Survivals (Abstract #164)**

*D. Bekbolsynov<sup>1</sup>, B. Mierzejewska<sup>2</sup>, C. Ho<sup>1</sup>, M. Rees<sup>2</sup>, S. Stepkowski<sup>2</sup>, <sup>1</sup>Gift of Life Michigan, Ann Arbor, MI, <sup>2</sup>University of Toledo, Toledo, OH*

**5:42 PM Can Imputation of HLA Allele Level Typing Be Used Clinically in a Multiethnic Population? (Abstract #165)**

*R. M. Engen<sup>1</sup>, A. M. Jedraszko<sup>1</sup>, A. Tambur<sup>2</sup>, <sup>1</sup>Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL, <sup>2</sup>Northwestern University, Chicago, IL*

Sunday, June 2

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

## B-cell / Antibody /Autoimmunity

**Room: 310**

*Chairs: A. Chong, University of Chicago, Chicago, IL and G. Raimondi, Johns Hopkins School of Medicine, Baltimore, MD*

- 4:30 PM The Effects of Anti-BAFF Monoclonal Antibody in the HLA-A2 Sensitized Mouse Model (Abstract #166)**  
J. Min<sup>1</sup>, H. Lee<sup>2</sup>, B. Kim<sup>3</sup>, K. Park<sup>4</sup>, K. Doh<sup>3</sup>, T. Kim<sup>5</sup>, H. Yoon<sup>6</sup>, C. Yang<sup>7</sup>, E. Oh<sup>2</sup>, B. Chung<sup>7</sup>, <sup>1</sup>*Division of Nephrology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon-si, Korea, Republic of,* <sup>2</sup>*Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of,* <sup>3</sup>*Convergent Research Consortium for Immunologic Disease, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of,* <sup>4</sup>*Department of Molecular & Cell Biology, Graduate School, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of,* <sup>5</sup>*Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of,* <sup>6</sup>*Division of Nephrology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea, Republic of,* <sup>7</sup>*Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of*
- 4:42 PM Igratimod Inhibits the Donor Specific Antibodies Production and Attenuates the Antibody Mediated Rejection in Rat Kidney Transplantation (Abstract #167)**  
Z. Wang, M. Zheng, H. Chen, S. Li, Z. Han, J. Tao, X. Ju, R. Tan, M. Gu, No.300 Guangzhou Road of Nanjing, Nanjing, China

- 4:54 PM Decay Accelerating Factor (DAF) Regulates Germinal Center B-cell and Alloantibody Formation (Abstract #168)**  
A. Cumpelik<sup>1</sup>, G. Varano<sup>2</sup>, D. Heja<sup>1</sup>, D. Homann<sup>3</sup>, S. Lira<sup>4</sup>, D. Dominguez-Sola<sup>2</sup>, P. S. Heeger<sup>1</sup>, <sup>1</sup>*Nephrology, Mount Sinai School of Medicine, New York, NY,* <sup>2</sup>*Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY,* <sup>3</sup>*Medicine, Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, New York, NY,* <sup>4</sup>*Clinical Immunology, Mount Sinai School of Medicine, New York, NY*
- 5:06 PM Autoantibody Production Significantly Decreased with APRIL/BLyS Blockade in Murine Chronic Rejection Kidney Transplant Model (Abstract #169)**  
N. Bath, X. Ding, B. Verhoven, S. Reese, N. Wilson, A. Sukhwal, R. Redfield III, *University of Wisconsin, Madison, WI*
- 5:18 PM B Cell-Specific IRE1a Deficiency Protects Renal Allografts from Rejection via Inhibition of Donor-Specific Antibodies and Induction of B Regulatory Cells (Abstract #170)**  
L. Qiu<sup>1</sup>, J. Wang<sup>1</sup>, X. Yeap<sup>1</sup>, D. Fang<sup>2</sup>, Z. J. Zhang<sup>1</sup>, <sup>1</sup>*Comprehensive Transplant Center, Department of Surgery, Northwestern University, Chicago, IL,* <sup>2</sup>*Department of Pathology, Northwestern University, Chicago, IL*
- 5:30 PM Antibody-Suppressor CD8+ T Cells Require CXCR5 (Abstract #171)**  
J. Zimmerer<sup>1</sup>, B. A. Ringwald<sup>1</sup>, C. L. Avila<sup>1</sup>, S. M. Elzein<sup>1</sup>, R. T. Warren<sup>1</sup>, M. Abdel-Rasoul<sup>2</sup>, G. L. Bumgardner<sup>1</sup>, <sup>1</sup>*Surgery, The Ohio State University Wexner Medical Center, Columbus, OH,* <sup>2</sup>*Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH*



# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

**5:42 PM Anti-Donor M H C Class II Alloantibody Induce Glomerular Injury in Mouse Renal Allografts Subjected to Prolonged Cold Ischemia (Abstract #172)**

*V. Gorbacheva*, R. Fan, A. Beavers, R. Fairchild, W. Baldwin, A. Valujskikh, *Inflammation and Immunity, Cleveland Clinic, Cleveland, OH*

## Vaccines and Viruses

### Room: 313

*Chairs: S. Pouch, Decatur, GA and R. Miller, Duke University, Durham, NC*

**4:30 PM Evaluation of Influenza Virus Antibody Response in Naturally Infected and Vaccinated Transplant Recipients by Protein Microarray (Abstract #173)**

*C. Hirzel*, A. Chruscinski, V. H. Ferreira, A. G. L'Huillier, A. Humar, D. Kumar, *University Health Network, Toronto, ON, Canada*

**4:42 PM A Comparison of Cell-Mediated Immune Responses among Organ Transplant Recipients Receiving High-Dose vs Standard-Dose Influenza Vaccine (Abstract #174)**

*A. G. L'Huillier*, V. H. Ferreira, Y. Natori, T. Ku, C. Hirzel, M. Ierullo, A. Humar, D. Kumar, *University Health Network, Toronto, ON, Canada*

**4:54 PM Vaccination Rates and Relation to Health Beliefs in Inner-City Kidney Transplant Recipients (KTRs) (Abstract #175)**

Y. Akivis, J. Leong, I. Rosenstein, A. Myrie, M. Moy, *M. Markell*, *SUNY Downstate Medical Center, Brooklyn, NY*

**5:06 PM Burden of Respiratory Syncytial Disease among Hospitalized Immunocompromised Adults (Abstract #176)**

H. Nam, *M. Ison*, *Northwestern University Comprehensive Transplant Center, Chicago, IL*

**5:18 PM A Single-Center Experience with a 6-Month Regimen of Pneumocystis jiroveci Pneumonia Prophylaxis in HIV-Positive Kidney Transplant Recipients (Abstract #177)**

*C. Mejia*<sup>1</sup>, G. Malat<sup>2</sup>, D. H. Lee<sup>3</sup>, S. Epstein<sup>1</sup>, M. Harhay<sup>3</sup>, L. Levin Mizrahi<sup>3</sup>, K. Ranganna<sup>3</sup>, <sup>1</sup>*Drexel University, Philadelphia, PA*, <sup>2</sup>*Hahnemann University Hospital, Philadelphia, PA*, <sup>3</sup>*Medicine, Drexel University, Philadelphia, PA*

**5:30 PM The Spread of HIV Donation throughout a DSA (Abstract #178)**

*A. Friedman*, E. Marquez, J. A. Lewis, K. Delli Carpini, *LiveOnNY, New York, NY*

**5:42 PM Liver Transplant Candidate Attitudes towards Organs from Increased Risk Donors: A Single Center Survey (Abstract #179)**

*S. S. Humar*, J. Liu, N. Pinzon, D. Kumar, M. Bhat, L. Lilly, N. Selzner, *University Health Network, Toronto, ON, Canada*

## Psychosocial and Treatment Adherence

### Room: 208

*Chairs: A. Maldonado, Vidant Medical Center - Transplant Services, Greenville, NC and S. Jowsey-Gregoire, Mayo Clinic Transplant Center, Mayo Clinic, Rochester, MN*

**4:30 PM The Risk of Systematic Error in Liver Transplant Opioid Research (Abstract #180)**

*J. N. Fleming*, N. A. Pilch, S. Ball, P. K. Baliga, D. DuBay, D. J. Taber, *Medical University of South Carolina, Charleston, SC*

**4:42 PM African American Living Kidney Donors' Perceptions of APOL1 Genetic Testing and Its Impact on Ethnic Identity (Abstract #181)**

*E. J. Gordon*<sup>1</sup>, D. Amortegui<sup>1</sup>, C. Wicklund<sup>1</sup>, J. Friedewald<sup>1</sup>, R. Sharp<sup>2</sup>, <sup>1</sup>*Northwestern University, Chicago, IL*, <sup>2</sup>*Mayo Clinic, Rochester, MN*

Sunday, June 2

# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

---

- 4:54 PM Use of Latent Class Analysis to Identify Patient Symptom Burden Subgroups after Living Donor Kidney Transplant (Abstract #182)**  
J. Peipert, J. Caicedo-Ramirez, K. Ensor, J. Friedewald, M. Abecassis, D. Cella, D. Ladner, Z. Butt, *Northwestern University, Chicago, IL*
- 5:06 PM Patient-Reported Transplant-Related Symptoms in Kidney Transplant Recipients (Abstract #183)**  
J. L. Beaumont<sup>1</sup>, I. Purnajo<sup>1</sup>, M. Polinsky<sup>2</sup>, E. Alemao<sup>2</sup>, M. J. Everly<sup>1</sup>, <sup>1</sup>*Terasaki Research Institute, Los Angeles, CA*, <sup>2</sup>*Bristol Myers Squibb, Princeton, NJ*
- 5:18 PM Belatacept Treated Patients Experience Improved Health-Related Quality of Life and Lower Symptom Distress Compared to Cyclosporine Treated Patients: An Analysis of the Benefit and Benefit-EXT Cohorts (Abstract #184)**  
M. J. Everly<sup>1</sup>, I. Purnajo<sup>1</sup>, J. L. Beaumont<sup>1</sup>, M. Polinsky<sup>2</sup>, E. Alemao<sup>2</sup>, <sup>1</sup>*Terasaki Research Institute, Los Angeles, CA*, <sup>2</sup>*Bristol Myers Squibb, Princeton, NJ*
- 5:30 PM Technology Triggered Adherence Intervention - Preliminary Findings (Abstract #185)**  
T. E. Kaiser<sup>1</sup>, N. S. Ejaz<sup>1</sup>, S. Tremblay<sup>1</sup>, N. J. Parrish<sup>2</sup>, J. Benavides<sup>2</sup>, B. Rehe<sup>2</sup>, A. Govil<sup>1</sup>, E. S. Woodle<sup>1</sup>, R. R. Alloway<sup>1</sup>, <sup>1</sup>*University of Cincinnati, Cincinnati, OH*, <sup>2</sup>*UC Health, Cincinnati, OH*
- 5:42 PM Alcohol Recidivism In Liver Transplant Recipients With Alcoholic Liver Disease: Does Six-months Abstinence Rule Still Holds True? (Abstract #186)**  
S. K. Satapathy<sup>1</sup>, C. Thornburgh<sup>1</sup>, J. Yu<sup>2</sup>, J. Eason<sup>1</sup>, S. Kedia<sup>2</sup>, D. Maluf<sup>1</sup>, <sup>1</sup>*UTHSC, Memphis, TN*, <sup>2</sup>*University of Memphis, Memphis, TN*
- Setting the Table for Success after Lung Transplantation**  
*Room: 206*  
*Chairs: J. Edelman, Puget Sound VAMC, Seattle, WA and D. Dilling, Loyola University Medical Center, Maywood, IL*
- 4:30 PM Opioid and Benzodiazepine Use in Lung Transplant Candidates: A National Survey of Policies and Practices (Abstract #187)**  
H. Bruschwein<sup>1</sup>, V. Andersen<sup>1</sup>, H. Patel<sup>2</sup>, J. Fleming<sup>3</sup>, A. Shahane<sup>1</sup>, M. Weder<sup>1</sup>, <sup>1</sup>*University of Virginia, Charlottesville, VA*, <sup>2</sup>*University of North Carolina, Chapel Hill, NC*, <sup>3</sup>*Medical University of South Carolina, Charleston, SC*
- 4:42 PM The Burden of Recipient Driving Distance and Post Lung Transplant Outcomes: A National Cohort Study (Abstract #188)**  
W. Tsuang, S. Arrigain, R. Lopez, M. Snair, K. McCurry, M. Budev, J. Schold, *Cleveland Clinic, Cleveland, OH*
- 4:54 PM Lung Transplant Outcomes after CABG (Abstract #189)**  
S. Huddleston<sup>1</sup>, R. Aggarwal<sup>1</sup>, S. Jackson<sup>2</sup>, N. Lemke<sup>1</sup>, <sup>1</sup>*Surgery, University of Minnesota, Minneapolis, MN*, <sup>2</sup>*Surgery, Fairview Health Services, Minneapolis, MN*
- 5:06 PM Outcomes of Adult Lung Transplant Recipients of Donation after Circulatory Death Allografts in the US (Abstract #190)**  
W. S. Cherikh<sup>1</sup>, J. Stehlik<sup>2</sup>, A. Sadavarte<sup>1</sup>, D. Van Raemdonck<sup>3</sup>, <sup>1</sup>*United Network for Organ Sharing, Richmond, VA*, <sup>2</sup>*University of Utah School of Medicine, Salt Lake City, UT*, <sup>3</sup>*University Hospitals Leuven, Leuven, Belgium*



# AMERICAN TRANSPLANT CONGRESS

Program, Sunday, June 2, 2019

Sunday, June 2

**5:18 PM Center Variability in Organ Offer Acceptance and Waitlist Mortality in Lung Transplantation (Abstract #191)**

A. Y. Choi<sup>1</sup>, M. S. Mulvihill<sup>2</sup>, J. Weber<sup>3</sup>, H. Lee<sup>3</sup>, M. Cox<sup>2</sup>, B. Yerokun<sup>2</sup>, M. Kuchibhatla<sup>3</sup>, J. A. Klapper<sup>2</sup>, M. G. Hartwig<sup>2</sup>, <sup>1</sup>Duke University School of Medicine, Durham, NC, <sup>2</sup>Department of Surgery, Duke University Medical Center, Durham, NC, <sup>3</sup>Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC

**5:30 PM Assessment of Physical Frailty is Positively Correlated with LAS Score in Lung Transplant Candidates (Abstract #192)**

S. Jaladanki<sup>1</sup>, L. Shih<sup>1</sup>, O. Kwon<sup>2</sup>, N. Ventigan<sup>2</sup>, D. Nanayakkara<sup>2</sup>, S. Weigt<sup>3</sup>, J. Singer<sup>4</sup>, A. Ardehali<sup>1</sup>, R. Biniwale<sup>1</sup>, D. Goldwater<sup>5</sup>, J. Schaenman<sup>2</sup>, <sup>1</sup>Department of Cardiac Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, <sup>2</sup>Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, <sup>3</sup>Division of Pulmonary and Critical Care, David Geffen School of Medicine at UCLA, Los Angeles, CA, <sup>4</sup>Division of Pulmonary and Critical Care, UCSF School of Medicine, San Francisco, CA, <sup>5</sup>Division of Geriatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA

**5:42 PM The Impact of Removing DSA as a First Unit of Lung Allocation: Preliminary Results (Abstract #193)**

R. R. Lehman<sup>1</sup>, K. Uccellini<sup>2</sup>, M. Skeans<sup>3</sup>, M. Valapour<sup>3</sup>, E. D. Lease<sup>4</sup>, R. Daly<sup>5</sup>, K. M. Chan<sup>6</sup>, <sup>1</sup>Research, United Network for Organ Sharing, Richmond, VA, <sup>2</sup>Policy, United Network for Organ Sharing, Richmond, VA, <sup>3</sup>SRTR, Minneapolis, MN, <sup>4</sup>Univ of Washington, Seattle, WA, <sup>5</sup>Mayo Clinic, Rochester, MN, <sup>6</sup>Univ of Michigan, Ann Arbor, MI

## Pancreas and Islet: All Topics I

**Room: 209**

*Chairs: A. Singer, Mayo Clinic Arizona, Phoenix, AZ and M. Tan, Piedmont Hospital, Atlanta, GA*

**4:30 PM Outcomes for Robotic Pancreas Transplants in Obese Candidates (Abstract #194)**

M. Spaggiari, K. A. Tulla, O. T. Okoye, C. Di Bella, P. Di Cocco, J. A. Almario Alvarez, I. G. Tzvetanov, E. Benedetti, University of Illinois at Chicago, Chicago, IL

**4:42 PM Long-Term Survival after Kidney-Pancreas Transplantation: Lessons from World Largest Series of Long-Term Survivors (Abstract #195)**

S. Parajuli, F. Aziz, N. Garg, B. Muth, A. Djamali, R. Redfield, D. Kaufman, J. Odorico, D. Mandelbrot, H. Sollinger, University of Wisconsin, Madison, WI

**4:54 PM Circulating Donor Specific Antibody and Biopsy C4d Positivity in Pancreas Rejection Increase the Probability of Earlier Return to Insulin after Rejection (Abstract #196)**

S. M. Riad<sup>1</sup>, S. Jackson<sup>2</sup>, E. B. Finger<sup>3</sup>, R. Kandaswamy<sup>3</sup>, <sup>1</sup>Medicine, University of Minnesota, Minneapolis, MN, <sup>2</sup>Complex Care Analytics, Fairview Health Services, Minneapolis, MN, <sup>3</sup>Surgery, University of Minnesota, Minneapolis, MN

**5:06 PM Donor Insulin Therapy Predicts Better Graft Survival in Pancreas Transplantation (Abstract #197)**

I. Shapey, A. Summers, H. Khambalia, C. Fullwood, N. Hanley, T. Augustine, M. Rutter, D. van Dellen, University of Manchester, Manchester, United Kingdom

**5:18 PM Impact of Simultaneous Pancreas-Kidney Transplantation on Cardiovascular Risk in Type 1 Diabetic Patients (Abstract #198)**

E. Montagud-Marrahi, *Servei de Nefrologia i Trasplantament Renal, Hospital Clínic de Barcelona, Barcelona, Spain*

**AMERICAN TRANSPLANT CONGRESS**  
**Program, Sunday, June 2, 2019**

---

**5:30 PM Repeat-Pancreas Transplant after Pancreas Graft Failure in Simultaneous Pancreas and Kidney Transplants is Associated with Better Kidney Graft Survival (Abstract #199)**

*S. Parajuli, A. Arunachalam, K. Swanson, F. Aziz, N. Garg, R. Redfield, D. Kaufman, A. Djamali, J. Odorico, D. Mandelbrot, University of Wisconsin, Madison, WI*

**5:42 PM Belatacept Based CNI Free Immunosuppression in Pancreas Transplantation. Results at 4 Years (Abstract #200)**

*J. Chen, J. Fridell, M. Yaqub, T. Taber, D. Mlshler, O. Adebisi, M. Mujtaba, A. Sharfuddin, Indiana University School of Medicine, Indianapolis, IN*

**ASTS Town Hall & Reception**

---

5:45 pm – 7:45 pm

*Hall A*

**Poster Session B – Presenters in Attendance**

---

*Hall C/D*

Poster Viewing: 6:00 pm - 7:00 pm

Presenters in Attendance: 6:00 pm - 7:00 pm

Poster Session B can be found on pages 191-228.

# AMERICAN TRANSPLANT CONGRESS

## Day-at-a-Glance, Monday, June 3, 2019

---

**7:00 am – 8:15 am Sunrise Interactive**  
*(Continental Breakfast Included)*

Page 59 **How Does Kidney Paired Exchange (KPD) Become Standard of Care?**  
*Ballroom C*

Page 59 **The Kidney Allograft Recipient and Transplant Cardiovascular Care(Kardio-Care)**  
*Room 312*

Page 59 **U.S. Lung Allocation- Where are we Now?**  
*Room 313*

Page 60 **The Coming of Age- Childhood Conditions Affecting Post-Renal Transplant Outcomes into Adulthood**  
*Room 210*

Page 60 **Controversies in Intestinal Transplantation**  
*Room 206*

Page 60 **Battling Hepatocellular Carcinoma: Who Wins the Transplant Lottery?**  
*Room 309*

Page 60 **Fontan-Associated Liver Disease: Heart Alone or Heart Liver**  
*Room 310*

Page 61 **Challenges in Quality Improvement in Transplant Care: TOOLS, THREATS, and OPPORTUNITIES**  
*Ballroom A*

Page 61 **Updates in Primary Care- What Everyone Ought to Know About the Latest Trends in Patient Management**  
*Room 306*

Page 61 **Novel Pre-Market Therapies in Transplantation: Does FDA Endpoints Justify the Means?**  
*Room 311*

**7:00 am – 8:15 am Sunrise Didactic**  
*(Continental Breakfast Included)*

Page 62 **Top 10 Papers in Transplant Infectious Diseases**  
*Ballroom B*

Page 62 **Immunometabolism in Transplantation**  
*Room 302*

Page 62 **Gene Editing in Transplantation- A New Frontier**  
*Room 304*

**8:15 am – 8:30 am Break**

**8:30 am – 9:15 am Plenary II**

Page 62 *Veterans Auditorium*

**9:15 am – 9:45 am AST Presidential Address**

Page 63 *Veterans Auditorium*

**9:45 am – 10:15 am ASTS Presidential Address**

Page 63 *Veterans Auditorium*

**10:15 am – 10:45 am State-of-the-Art Speaker**

Page 63 **Thomas E. Starzl State-of-the-Art-Speaker Synthetic Organs**  
*George M. Church, PhD  
Wyss Institute at Harvard Medical School, Boston, MA, USA  
Veterans Auditorium*

**10:45 am – 11:15 am Coffee Break in the Exhibit Hall**  
*Hall C/D*

**11:15 am – 12:45 pm Midday Interactive**

Page 63 **To Transplant or Not to Transplant: Can the Virtual Crossmatch Answer this Question?**  
*Room 313*

Monday, June 3

**AMERICAN TRANSPLANT CONGRESS**  
**Day-at-a-Glance, Monday, June 3, 2019**

---

Page 64      **Results of the Consensus Conference on Frailty in Solid Organ Transplantation**  
*Ballroom C*

Page 64      **1000 LDLTS in the US: Pipedream or Near Future**  
*Room 306*

**11:15 am – 12:45 pm    Midday Didactic**

---

Page 64      **Normothermic Machine Perfusion of Livers: Are we Ready for Prime Time?**  
*Room 311*

Page 64      **A Multiparametric Approach to Deceased Kidney Donor Assessment**  
*Veterans Auditorium*

Page 65      **Opioid Stewardship in Solid Organ Transplant: It Takes a Multidisciplinary Approach**  
*Room 304*

Page 65      **CMV-Cutting Edge Approaches to Taming the Troll of Transplant**  
*Ballroom B*

Page 65      **Cutting Edge Medical and Surgical Options for Treating Diabetes: A Multidisciplinary Approach to New Therapies**  
*Room 310*

Page 66      **Vascular Flow Problems: An Achilles Heel in Pediatric Liver Transplantation**  
*Room 210*

Page 66      **From Policy to Postop: Opioid and Benzodiazepine Use Across the Transplant Process**  
*Room 208*

Page 66      **How Does Immunosuppression and Rejection Impact the Long-Term Survival of the Intestinal Transplant Recipient?**  
*Room 206*

Page 66      **Reproductive Health Issues in Transplant**  
*Room 309*

Page 67      **Liver Recipient Selection: Where Do You Draw the Line?**  
*Room 312*

Page 67      **Coinhibitory Pathways: From Bench to Bedside**  
*Ballroom A*

Page 67      **Lymphatics in Transplantation**  
*Room 302*

**12:45 pm – 1:00 pm    Break**

---

**1:00 pm – 2:15 pm    Sponsored Satellite Symposia**

---

Satellite Symposia are open to all registered Congress attendees. Satellite Symposia take place at the Sheraton Boston Hotel. Please check the ATC website, [www.atcmeeting.org](http://www.atcmeeting.org), or ATC mobile app (ATC19) for the full Satellite Symposia program listing.

Page 67      *Sheraton Boston Hotel*

**1:00 pm – 2:15 pm    Luncheon Workshops**

---

*(Additional Fees - Limited Ticketed Events)*

Page 68      **Two for the Price of One: The Explosion of Combined Heart-Kidneys and Lung-Kidneys**  
*Room 108*

Page 68      **Caring for the Caregiver in Transplantation: State of Affairs and Future Directions**  
*Room 109*

Page 68      **#SquadGoals: Expanding and Optimizing the Transplant Pharmacy Team**  
*Room 110*

# AMERICAN TRANSPLANT CONGRESS

## Day-at-a-Glance, Monday, June 3, 2019

---

Page 68      **Looking Under the Hood of High Impact Research: From Idea to AJT Publication**  
*Cafe, Across from Hall A Registration*

**2:15 pm – 2:30 pm      Break**

---

**2:30 pm – 4:00 pm      Concurrent Oral Abstract Sessions**

---

Page 69      **Kidney Complications: Late Graft Failure II**  
*Veterans Auditorium*

Page 70      **Kidney Deceased Donor Allocation II**  
*Ballroom B*

Page 70      **Kidney Donor Selection / Management Issues II**  
*Ballroom C*

Page 71      **Liver Transplant Complications and Retransplantation I**  
*Ballroom A*

Page 72      **Infectious Epidemiology**  
*Room 304*

Page 73      **Kidney Psychosocial I: Cognitive and Behavioral Factors**  
*Room 302*

Page 74      **Antigen Presentation and Allorecognition**  
*Room 311*

Page 75      **Biomarkers, Immune Monitoring and Outcomes II**  
*Room 306*

Page 76      **Immunosuppression Preclinical Studies**  
*Room 309*

Page 77      **Xenotransplantation**  
*Room 310*

Page 78      **Ischemia Reperfusion & Organ Rehabilitation II**  
*Room 313*

Page 79      **Quality Assurance Process Improvement & Regulatory Issues I**  
*Room 210*

Page 80      **Surgical Issues: All Organs**  
*Room 208*

Page 81      **Donor and Recipient Selection in Heart Transplantation**  
*Room 206*

Page 82      **Basic & Clinical Science - VCA**  
*Room 209*

**2:30 pm – 6:00 pm      Featured Multidisciplinary Transplant Professionals Symposium**

---

Page 83      **Expansion of the Multidisciplinary Team: From Waitlist to Transplant**  
*Room 312*

**4:00 pm – 4:30 pm      Coffee Break in the Exhibit Hall**  
*Hall C/D*

---

**4:30 pm – 6:00 pm      Concurrent Oral Abstract Sessions**

---

Page 83      **Kidney Immunosuppression: Novel Regimens and Drug Minimization II**  
*Veterans Auditorium*

Page 84      **Kidney Chronic Antibody Mediated Rejection**  
*Ballroom B*

Page 86      **Kidney: Cardiovascular and Metabolic II**  
*Ballroom C*

Page 87      **Breakthroughs in Cytomegalovirus**  
*Ballroom A*

Page 88      **Liver: MELD, Allocation and Donor Issues (DCD/ECD) II**  
*Room 302*

Monday, June 3

**AMERICAN TRANSPLANT CONGRESS**  
**Day-at-a-Glance, Monday, June 3, 2019**

---

<i>Page 89</i>	<b>Kidney: Pediatrics II</b> <i>Room 304</i>
<i>Page 90</i>	<b>Non-Organ Specific: Public Policy &amp; Allocation</b> <i>Room 311</i>
<i>Page 91</i>	<b>Biomarkers, Immune Monitoring and Outcomes III</b> <i>Room 306</i>
<i>Page 92</i>	<b>Islet and Cell Transplantation</b> <i>Room 309</i>
<i>Page 93</i>	<b>Tolerance / Immune Deviation</b> <i>Room 310</i>
<i>Page 94</i>	<b>Donor Management: All Organs Excluding Kidney</b> <i>Room 313</i>
<i>Page 95</i>	<b>Infections, Antibodies and Biomarkers in Lung Transplantation</b> <i>Room 206</i>
<i>Page 96</i>	<b>Non-Organ Specific: Pharmacogenomics / Pharmacokinetics</b> <i>Room 210</i>
<i>Page 96</i>	<b>Pancreas and Islet: All Topics II</b> <i>Room 209</i>

---

**4:30 pm – 6:00 pm      Young Investigator Oral  
Communication Session**

---

*Page 97                  Room 208*

---

**5:45 pm – 8:00 pm      AST Town Hall &  
Reception**

---

*Hall A*

---

**6:00 pm – 7:00 pm      Poster Session C**  
**Presenters in Attendance**  
*Hall C/D*

---



# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

## Sunrise Symposia: Interactive (Continental Breakfast Included)

7:00 am – 8:15 am

### How Does Kidney Paired Exchange (KPD) Become Standard of Care?

#### Ballroom C

Moderators: David Serur, MD, NYP-Weill Cornell, New York, NY, USA. Stuart Flechner, MD, FACS, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA.

7:00 am **The Elimination of Disincentives (and excuses) to Kidney Paired Donation (KPD)**

Nicole Turgeon, MD, Emory University, Atlanta, GA, USA.

7:20 am **How to Safely Transplant the Most Difficult Cases Through KPD**

Howard Gebel, PhD, Emory University, Atlanta, GA, USA.

7:40 am **The Value and Benefit of and to Compatible Pairs in KPD**

Didier Mandelbrot, MD, UW Health, Madison, WI, USA.

8:00 am **Panel Discussion**

### The Kidney Allograft Recipient and Transplant Cardiovascular Care (Kardio-Care)

#### Room 312

Moderators: John A. Kobashigawa, MD, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, USA. Janani Rangaswami, MD, FACP, Einstein Medical Center, Philadelphia, PA, USA.

7:00 am **Ischemic Heart Disease in the Kidney Allograft Recipient: State of the Art and Current Trials in 2019**

Sripal Bangalore, MD, NYU Langone Health, New York, NY, USA.

7:20 am **Heart failure and Pulmonary Hypertension in the Kidney Allograft Recipient**

Cyrus Kholdani, MD Beth Israel Deaconess Medical Center, Boston, MA, USA.

7:40 am **Evaluation and Management of Perioperative Risks in Kidney Transplant Candidates**

Jagbir Gill, MD, Centre for Health Evaluation & Outcome Sciences, West Vancouver, BC, Canada.

8:00 am **Panel Discussion**

### U.S. Lung Allocation-Where are we Now?

#### Room 313

Moderators: Christopher Wigfield, MD, Advocate Health Care, Elk Grove Village, IL., USA. Stuart Sweet, MD, PhD, Washington University, St. Louis, MO, USA.

7:00 am **How to Define Fair Distribution Schemes for U.S. Lung Allocation**  
Maryam Valapour, MD, MPP, Cleveland Clinic, Cleveland, OH, USA.

7:15 am **Impact of 2017 Elimination of DSA as the First Unit of Allocation**  
Kevin Chan, MD, University of Michigan, Ann Arbor, MI, USA.

7:30 am **Debate - Pro: Broader Geographic Sharing Increases Access to Transplant Without Adversely Impacting Transplant Outcomes**  
Joshua Mooney, MD, MS, Stanford University, Stanford, CA, USA.

7:40 am **Debate - Con: Broader Geographic Sharing Threatens Lung Post-Transplant Outcomes**  
Wayne Tsuang, MD, Cleveland Clinic, Cleveland, OH, USA.

7:50 am **Debate - Pro: Rebuttal**  
Joshua Mooney, MD, MS, Stanford University, Stanford, CA, USA.

7:55 am **Debate - Con: Rebuttal**  
Wayne Tsuang, MD, Cleveland Clinic, Cleveland, OH, USA.

8:00 am **Panel Discussion**

Monday, June 3

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

## The Coming of Age- Childhood Conditions Affecting Post-Renal Transplant Outcomes into Adulthood

### Room 210

Moderators: Julia M. Steinke, MD, MS, Helen DeVos Children's Hospital, Grand Rapids, MI, USA. Priya Verghese, MD, University of Minnesota, Minneapolis, MN, USA.

- 7:00 am **Cystinosis: No Longer Just a Pediatric Disease**  
Roshan P. George, MD, Emory University, Atlanta, GA, USA.
- 7:20 am **Atypical Hemolytic Uremic Syndrome - High Risks with Higher Rewards**  
Carla Nester, MD, University of Iowa, Iowa City, IA, USA.
- 7:40 am **CAKUT (Congenital Anomalies of the Kidney and the Urinary Tract): Beyond the Transplant**  
Scott McEwen, MD, PhD, University of Minnesota, Minneapolis, MN, USA.
- 8:00 am **Panel Discussion**

## Controversies in Intestinal Transplantation

### Room 206

Moderators: Douglas Farmer, MD, UCLA Health, Los Angeles, CA, USA. Shunji Nagai, MD, PhD, Henry Ford Hospital, Detroit, MI, USA.

- 7:00 am **The Patient with Extensive Porto-Mesenteric Thrombosis - Is This Always an Indication for a Multi-Visceral Transplant?**  
Kishore Iyer, MBBS, FRCS, Mount Sinai Hospital, New York, NY, USA.
- 7:20 am **Should Patients with Chronic Rejection Be Re-Transplanted and if Not, Can We Treat Them Medically?**  
Rodrigo Vianna, MD, PhD, Miami Transplant Institute, Miami, FL, USA.
- 7:40 am **The Patient with Recurrent Desmoid Turns and Unresectable Tumors- To Transplant or Not to Transplant?**  
Richard Mangus, MD, Indiana University School of Medicine, Indianapolis, IN, USA.
- 8:00 am **Panel Discussion**

## Battling Hepatocellular Carcinoma: Who Wins the Transplant Lottery?

### Room 309

Moderators: Angeles Baquerizo, MD, Scripps Health, La Jolla, CA, USA. Amit Singal, MD, MS, UT Southwestern Medical Center, Dallas, TX, USA.

- 7:00 am **Pre and Post Transplant Risk for Estimation of Recurrence, (Including Utility of Biomarkers)**  
Pratima Sharma, MD, MS, University of Michigan Health, Ann Arbor, MI, USA.
- 7:20 am **Surveillance and Prevention of HCC Recurrence Post Transplant in the High Risk Patients**  
Neil Mehta, MD, UCSF Health, San Francisco, CA, USA.
- 7:40 am **Management of Post Transplant Patients with Recurrence (mTOR and Adjuvant Therapy and Resection)**  
Anjana Pillai, MD, University of Chicago Medicine, Chicago, IL, USA.
- 8:00 am **Panel Discussion**

## Fontan-Associated Liver Disease: Heart Alone or Heart Liver

### Room 310

Moderators: Lisa VanWagner, MD MSc FAST FAHA, Northwestern Medicine, Chicago, IL, USA. Ram Subramanian, MD, MBA, Emory University, Atlanta, GA, USA.

- 7:00 am **The Liver after a Fontan Procedure**  
Elizabeth B. Rand, MD, The University of Pennsylvania, Philadelphia, PA, USA.
- 7:20 am **Debate - Pro: Combined Heart and Liver**  
Kim Olthoff, MD, University of Pennsylvania, Philadelphia, PA, USA.
- 7:35 am **Debate - Con: Heart Alone**  
John Lake, MD, University of Minnesota, Minneapolis, MN, USA.
- 7:50 am **Rebuttal: Pro**  
Kim Olthoff, MD, University of Pennsylvania, Philadelphia, PA, USA.
- 8:00 am **Rebuttal: Con**  
John Lake, MD, University of Minnesota, Minneapolis, MN, USA.
- 8:10 am **Audience Discussion**

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

## **Challenges in Quality Improvement in Transplant Care: TOOLS, THREATS, and OPPORTUNITIES**

### **Ballroom A**

Moderators: Stuart M. Greenstein, MD, Montefiore Medical Center, Bronx, NY, USA. Anil Paramesh, MD, Tulane University School of Medicine, New Orleans, LA, USA.

**7:00 am Making Friends with Your OPO: Initiatives to Increase Deceased Donor Transplant Through Standardizes, Mutually Agreeable Processes**

*Richard Hasz, MFS, CPTC, Gift of Life Donor Program, Philadelphia, PA, USA.*

**7:20 am Celebrate Your Program's Success and Learn from Others': Tools to Track Performance and Improve Quality Including TransQIP**

*Riyo Ryutaro, MD, UCSF Health, San Francisco, CA, USA.*

**7:40 am Navigating the Regulatory Waters Between the CMS and OPTN Icebergs**

*Diane Milman, JD, Powers Law, Washington, DC, USA.*

**8:00 am Panel Discussion**

## **Updates in Primary Care-What Everyone Ought to Know About the Latest Trends in Patient Management**

### **Room 306**

Moderators: Bethany Brady, PharmD, Indiana University Health System, Indianapolis, IN, USA. Danielle Krieger, NP, UCSF Health, San Francisco, CA, USA.

**7:00 am Novel Anti-Diabetic Agents and Their Role in Therapy After Transplantation**  
*Hazel Domingo, PA-C, University of Maryland Medical Center, Baltimore, MD, USA.*

**7:15 am Key Steak Holders - Bones and All it Takes to Keep Them Healthy After Transplant**  
*Ignatius Tang, PharmD, MD, University of Illinois at Chicago, Chicago, IL, USA.*

**7:30 am Lipid Management Challenges and Strategies in Transplant Recipients**  
*Douglas Jennings, PharmD, FCCP, Columbia University Medical Center, New York, NY, USA.*

**7:45 am Updates in Hypertension Management**  
*Erika Meredith, PharmD, Emory University Hospital, Atlanta, GA, USA.*

**8:00 am Panel Discussion**

## **Novel Pre-Market Therapies in Transplantation: Does FDA Endpoints Justify the Means?**

### **Room 311**

Moderators: Roslyn B. Mannon, MD, University of Alabama, Birmingham, AL, USA. Kenneth Newell, MD, PhD, Emory University, Atlanta, GA, USA.

**7:00 am Long and Short Acting Therapies: Aspects of drug development other than graft survival that also are important: Safety, Patient Reported Outcomes and Compliance**  
*Mark Stegall, MD, Mayo Clinic, Rochester, MN, USA.*

**7:20 am The Transplant Therapeutics Consortium: The Public Private Partnership Approach to Developing Novel Drug Development Tools**  
*Stephen Karpen, PharmD, Critical Path Institute, Tucson, AZ, USA.*

**7:40 am Regulatory Approach to Developing Biomarkers and Surrogate Endpoints in Transplantation: How to Predict Long Term Outcomes from 1-Year Post Transplant Measures**  
*Ulf Meier Kriesche, MD, FAST, Veloxis, Cary, NC, USA.*

**8:00 am Panel Discussion**

Monday, June 3

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

## Sunrise Symposia: Didactic (Continental Breakfast Included)

7:00 am – 8:15 am

### Top 10 Papers in Transplant Infectious Diseases

#### **Ballroom B**

Moderators: Lara Danziger-Isakov, MD, MPH, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. Jonathan Hand, MD, Ochsner Medical Center, New Orleans, LA, USA.

**7:00 am Top 10 Bacterial Papers**

Robin K. Avery, MD, Johns Hopkins, Baltimore, MD, USA.

**7:20 am Audience Discussion**

**7:25 am Top 10 Fungal Papers**

Barbara D. Alexander, MD, Duke University, Durham, NC, USA.

**7:45 am Audience Discussion**

**7:50 am Top 10 Viral Papers**

Joanna Schaefer, MD, PhD, UCLA Health, Los Angeles, CA, USA.

**8:10 am Audience Discussion**

### Immunometabolism in Transplantation

#### **Room 302**

Moderators: William Burlingham, PhD, University of Wisconsin, Madison, WI, USA. Paolo Cravedi, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

**7:00 am ATP in Transplantation**

Paolo Fiorina, MD, PhD, Boston Children's Hospital, Boston, MA, USA.

**7:20 am Audience Discussion**

**7:25 am T Cell Metabolism**

Ulf Beier, MD, FAAP, Penn Perelman School of Medicine, Philadelphia, PA, USA.

**7:45 am Audience Discussion**

**7:50 am T Cell Mitochondrial Effects**

Will Bailis, PhD, Children's Hospital of Pennsylvania, Philadelphia, PA, USA.

**8:10 am Audience Discussion**

### Gene Editing in Transplantation- A New Frontier

#### **Room 304**

Moderators: Martina McGrath, MD, BCh, Brigham and Women's Hospital, Boston, MA, USA. Megan Sykes, MD, Columbia University, New York, NY, USA.

**7:00 am CRISPR/CAS9 - How I Do It**

Omar Abudayyeh, MD, PhD, Broad Institute, Cambridge, MA, USA.

**7:20 am Audience Discussion**

**7:25 am Gene Editing in Xenotransplantation**

Alfred J. Tector, III, MD, PhD, University of Alabama at Birmingham, Birmingham, AL, USA.

**7:45 am Audience Discussion**

**7:50 am Using Genome Editing to Make Designer Stem Cells**

Chad Cowan, PhD, Harvard University, Cambridge, MA, USA.

**8:10 am Audience Discussion**

### Break

8:15 am - 8:30 am

### Plenary Session II

8:30 AM - 9:15 AM

#### **Veterans Auditorium**

Moderators: Lloyd Ratner, MD, MPH, President Elect, ASTS, New York, NY and Emily Blumberg, MD, FAST, President Elect, AST, Philadelphia, PA.

**8:30 AM Exogenous Erythropoietin Administration Promotes Murine Cardiac Allograft Survival via a Myeloid Cell-Dependent Mechanism (Abstract #201)**

J. Horwitz, P. Cravedi, P. Heeger, Icahn School of Medicine at Mount Sinai, NY, NY

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

**8:45 AM** **Fifteen Year Outcomes in the Astellas Double Blind Randomized Controlled Trial (RCT) Comparing Early Corticosteroid Withdrawal (CSWD) and Long-Term Corticosteroid Therapy Continuation (CCS) in Kidney Transplantation (Abstract #202)**  
E. Woodle<sup>1</sup>, S. Clark<sup>2</sup>, D. Stewart<sup>3</sup>, M. First<sup>4</sup>, R. Alloway<sup>5</sup>, J. Gill<sup>6</sup>, .. Split Rock Group<sup>7</sup>, <sup>1</sup>Transplant Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, <sup>2</sup>Providence Health Care, Vancouver, BC, Canada, <sup>3</sup>UNOS, Richmond, VA, <sup>4</sup>Transplant Genomics Inc. and Comprehensive Transplant Center, Northwestern University, Evanston, IL, <sup>5</sup>University of Cincinnati College of Medicine, Cincinnati, OH, <sup>6</sup>University of British Columbia, Vancouver, BC, Canada, <sup>7</sup>Yale University, New Haven, CT

**9:00 AM** **Butyrate-Producing Gut Bacteria and Future Development of Viral Infections in Kidney Transplant Recipients (Abstract #203)**  
J. Lee<sup>1</sup>, J. Huang<sup>1</sup>, M. Magruder<sup>1</sup>, L. Zhang<sup>1</sup>, M. Lubetzky<sup>1</sup>, D. Dadhania<sup>1</sup>, E. Edusei<sup>1</sup>, E. Pamer<sup>2</sup>, M. Suthanthiran<sup>1</sup>, <sup>1</sup>Weill Cornell Medicine, New York, NY, <sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, NY

## **AST Presidential Address**

---

### **Veterans Auditorium**

**9:15 am – 9:45 am**

*Dianne B. McKay, MD, FAST  
The Scripps Research Institute  
La Jolla, CA, USA*

## **ASTS Presidential Address**

---

### **Veterans Auditorium**

**9:45 am – 10:15 am**

*Dixon B. Kaufman, MD, PhD  
University of Wisconsin  
Madison, WI, USA*

### **Thomas A. Starzl State-of-the-Art Speaker**

---

### **Veterans Auditorium**

**10:15 am – 10:45 am**

#### **Synthetic Organs**

*George M. Church, PhD,  
Wyss Institute at Harvard Medical School  
Boston, MA, USA*

### **Coffee Break in Exhibit Hall**

---

**10:45 am – 11:15 am**

*Hall C/D*

### **Midday Symposia: Interactive**

---

**11:15 am – 12:45 pm**

#### **To Transplant or Not to Transplant: Can the Virtual Crossmatch Answer this Question?**

#### **Room 313**

*Moderators: Peter Jindra, PhD, D(ABHI), Baylor College of Medicine, Houston, TX, USA. Elaine Reed, Ph.D., D(ABHI), UCLA, Los Angeles, CA, USA.*

**11:15 am** **Proceeding Without a Physical XM for High Risk Patients**

*Howard Gebel, PhD, Emory University Hospital, Atlanta, GA, USA.*

**11:35 am** **How we do Virtual Crossmatching for Thoracic Transplantation**

*Michelle Hickey, PhD, D(ABHI), UCLA Immunogenetics, Los Angeles, CA, USA.*

**11:55 am** **Optimizing Unacceptable Antigen Listing for Highly Sensitized Renal Transplant Candidates**

*Anat Tambur, DMD PhD, Northwestern University, Chicago, IL, USA.*

**12:15 pm** **How to Avoid Breaking the Chains**

*Michael Cecka, PhD, UCLA Immunogenetics Center, Los Angeles, CA, USA.*

**12:35 pm** **Panel Discussion**

Monday, June 3



# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

## Results of the Consensus Conference on Frailty in Solid Organ Transplantation

### **Ballroom C**

Moderators: John A. Kobashigawa, MD, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, USA. Joanna Schaeffer, MD, PhD, UCLA Health, Los Angeles, CA, USA.

**11:15 am Frailty in Liver Transplantation**

Jennifer Lai, MD, MBA, UCSF, San Francisco, CA, USA.

**11:35 am Frailty in Heart Transplantation**

Palak Shah, MD, MS, Inova Heart and Vascular Institute, Falls Church, VA, USA.

**11:55 am Frailty in Kidney Transplantation**

Darshana Dadhania, MD, MS, Weill Cornell Medicine, New York, NY, USA.

**12:15 pm Frailty in Lung Transplantation**

Cassie Kennedy, MD, Mayo Clinic, Rochester, MN, USA.

**12:35 pm Panel Discussion**

## 1000 LDLTS in the US: Pipedream or Near Future

### **Room 306**

Moderators: Jean Emond, MD, Columbia University, New York, NY, USA. Swaytha Ganesh, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

**11:15 am Non-Directed Donation in LDLT**

Cristiano Quintini, MD, Cleveland Clinic, Cleveland, OH, USA.

**11:35 am Time to Change Paradigm for Liver Transplant**

Abhinav Humar, MD, University of Pittsburgh, Pittsburgh, PA.

**11:55 am LDLT Lessons from Overseas: Where it Works and Where it Doesn't**

Deniz Balci, MD, Ankara University, Ankara, Turkey.

**12:15 pm Will UNOS Policy Changes Bring Back LDLT?**

Benjamin Samstein, MD, Weill Cornell Medicine, Brooklyn, NY, USA.

**12:35 pm Panel Discussion**

## Midday Symposia: Didactic

11:15 am – 12:45 pm

### Normothermic Machine Perfusion of Livers: Are we Ready for Prime Time?

#### **Room 311**

Moderators: David Foley, MD, University of Wisconsin, Madison, WI, USA. David Classen, MD, UNOS, Richmond, VA, USA.

**11:15 am Perfusion Emerges from the Niche as a Standard of Practice**

Peter Friend, MA, MB, University of Oxford, Oxford, England.

**11:35 am Audience Discussion**

**11:45 am Barriers and Challenges to Implementation of Liver NMP Program at Your Transplant Center**

Andrew Barbas, MD, Duke University, Durham, NC, USA.

**12:05 pm Audience Discussion**

**12:15 pm Perfusion and Beyond: Optimizing Marginal Livers for Transplantation Future Approaches**

Korkut Uygun, PhD, Massachusetts General Hospital, Boston, USA.

**12:35 pm Audience Discussion**

### A Multiparametric Approach to Deceased Kidney Donor Assessment

#### **Veterans Auditorium**

Moderators: Richard N. Formica, MD, Yale School of Medicine, New Haven, CT, USA. Ron Shapiro, MD, Recantation/Miller Transplantation Institute, Mt. Sinai, New York, NY, USA.

**11:15 am Clinical Assessment of the Deceased Kidney Donor: Beyond KDPI**

Stuart M. Greenstein, MD, Montefiore Medical Center, Bronx, NY, USA.

**11:35 am Audience Discussion**

**11:45 am Histologic Assessment of Donor Kidney Biopsies: Are They Helpful or do They Merely Increase the Discard Rate?**

Parmjeet Randhawa, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.



# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

- 12:05 pm Audience Discussion
- 12:15 pm **Molecular Assessment of Preimplantation Biopsies**  
*Enver Akalin, MD, FAST, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.*

12:35 pm Audience Discussion

**Opioid Stewardship in Solid Organ Transplant: It Takes a Multidisciplinary Approach**

**Room 304**

Moderators: Elizabeth Cohen, PharmD, BCPS, Yale New Haven Hospital, New Haven, CT, USA. James N. Fleming, PharmD, Medical University of South Carolina, Charleston, SC, USA.

- 11:15 am **Identifying Patients with a Problem: Pretransplant Screening and Management for Opioid Addiction**  
*Georgene Smith, MHS, MS, The Hospital of the University of Pennsylvania, Philadelphia, PA, USA.*

11:35 am Audience Discussion

- 11:45 am **Opioid-minimizing Medication Regimens for Transplant Donors and Recipients**  
*Maya Campara, PharmD, University of Illinois at Chicago, Chicago, IL, USA.*

12:05 pm Audience Discussion

- 12:15 pm **Designing and Implementing a Large Surgical Opioid Stewardship Program**  
*Michael Engelsbe, MD, University of Michigan, Ann Arbor, MI, USA.*

12:35 pm Audience Discussion

**CMV: Cutting Edge Approaches to Taming the Troll of Transplant**

**Ballroom B**

Moderators: Judith Anesi, MD, University of Pennsylvania, Philadelphia, PA, USA. Ajit Lamaye, MD, UW Medicine, Seattle, WA, USA.

- 11:15 am **Diagnostics – Where Do We Go Next? Is a Universal Threshold Attainable or Should We Move to Individualized Medicine Approach?**  
*Raymund Razonable, MD, Mayo Clinic, Rochester, MN, USA.*

11:35 am Audience Discussion

- 11:45 am **CMV, Guidelines & Personalized Medicine: Immunodiagnostics, Immunosuppression, and Best Prevention**  
*Camille Kotton, MD, Massachusetts General Hospital, Boston, MA, USA.*

12:05 pm Audience Discussion

- 12:15 pm **Novel Therapies: Medications, Vaccines, and Management of Resistant Virus**  
*Atul Humar, MD, MSc, UHN Research, Toronto, Ontario.*

12:35 pm Audience Discussion

**Cutting EDGE Medical and Surgical Options for Treating Diabetes: A Multidisciplinary Approach to New Therapies**

**Room 310**

Moderators: Dixon Kaufman, MD, PhD, University of Wisconsin, Madison, WI, USA. Ronald Parsons, MD, Emory Transplant Center, Atlanta, GA, USA.

- 11:15 am **What is The New Treatment for Endocrinologist?**  
*Giulio Romeo, MD, Joslin Diabetes Center, Boston, MA, USA.*

11:35 am Audience Discussion

- 11:45 am **Is Pancreatic Transplant Surgery a Cure for All Diabetics?**  
*Matthew Cooper, MD, Medstar Georgetown Transplant Institute, Washington, DC, USA.*

12:05 pm Audience Discussion

- 12:15 pm **Nephrologists Central Role in Decision Making and Care**  
*Martha Pavlakis, MD, Beth Israel Deaconess Medical Center, Boston, MA, USA.*

12:35 pm Audience Discussion

Monday, June 3

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

## **Vascular Flow Problems: An Achilles Heel in Pediatric Liver Transplantation**

### **Room 210**

Moderators: John Goss, MD, Baylor College of Medicine, Houston, TX, USA. Patrick J. Healey, MD, Seattle Children's Hospital, Seattle, WA, USA.

- 11:15 am Options for Management of Insufficient Portal Flow in Pediatric Liver Transplant**  
*Carlos O. Esquivel, MD, PhD, Stanford Abdominal Transplantation, Stanford, CA, USA.*
- 11:35 am Audience Discussion**
- 11:45 am How I Do the Hepatic Artery Anastomosis: Microscope Versus Loops**  
*Mark Cattral, MD, F.R.C.S.C., University of Toronto, Toronto, Ontario.*
- 12:05 pm Audience Discussion**
- 12:15 pm Choosing the Type and Graft Size for Small Liver Recipients**  
*Dominique Jan, MD, Montefiore Medical Center, Bronx, NY, USA.*
- 12:35 pm Audience Discussion**

## **From Policy to Postop: Opioid and Benzodiazepine Use Across the Transplant Process**

### **Room 208**

Moderators: Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA, USA. Kristin Kronsoble, PhD, Tampa General Hospital, Tampa, FL, USA.

- 11:15 am Opioid and Benzodiazepine Use in Lung Transplant Candidates: A National Survey of Policies and Practices**  
*Heather Brus Schwein, PsyD, University of Virginia, Charlottesville, VA, USA.*
- 11:35 am Audience Discussion**
- 11:45 am The Percs of Transplant: Non-Prescription Drug Use Among Transplant Recipients**  
*Krista Lentine, MD, PhD, Saint Louis University, Saint Louis, MO, USA.*
- 12:05 pm Audience Discussion**

- 12:15 pm Marijuana Post Transplant**  
*Akhil Shenoy, MD, MPH, Columbia University Medical Center, New York, NY, USA.*

### **12:35 pm Audience Discussion**

## **How Does Immunosuppression and Rejection Impact the Long-Term Survival of the Intestinal Transplant Recipient?**

### **Room 206**

Moderators: Thomas Fishbein, MD, MedStar, Washington, DC, USA. Simon Horslem, MB, ChB, Seattle Children's Hospital, Seattle, WA, USA.

- 11:15 am Importance of Intestinal and Liver Histopathology in the Patient with Short Gut Syndrome and the Intestinal Transplant Recipient: ACR, AMR, Chronic Rejection and Other Complications**  
*Maria Isabel Fiel, MD, Mount Sinai, New York, NY, USA.*
- 11:35 am Audience Discussion**
- 11:45 am How Do We Prevent Rejection and Does AMR in the Intestinal Transplant Patient Exist? - DSA Monitoring, Protocol Intestinal Biopsies, Pre-Transplant Desensitization**  
*Debra Sudan, MD, Duke University Hospital, Durham, NC, USA.*
- 12:05 pm Audience Discussion**
- 12:15 pm Complications of Immunosuppression: PTL, GVHD, Cancer and Infections**  
*Alan Langnas, DO, University of Nebraska, Omaha, NB, USA.*
- 12:35 pm Audience Discussion**

## **Reproductive Health Issues in Transplant**

### **Room 309**

Moderators: Christina Klein, MD, Piedmont, Atlanta, GA, USA.

*Deirdre Sawinski, MD, University of Pennsylvania, Philadelphia, PA, USA.*

- 11:15 am Care of the Transgender Transplant Recipient**  
*Loreta Matheo, MD, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.*
- 11:35 am Audience Discussion**

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

**11:45 am** **Hormonal Management Across the Lifespan: Contraception, Conception and Menopause**

*Christina Doligalski, PharmD, BCPS, University of North Carolina Health System, Chapel Hill, NC, USA.*

**12:05 pm** **Audience Discussion**

**12:15 pm** **Long Term Health in Women After Transplant: Bone Health and Reproductive Malignancies**

*Michelle Josephson, MD, University of Chicago Medicine, Chicago, IL, USA.*

**12:35 pm** **Audience Discussion**

## **Liver Recipient Selection: Where Do You Draw the Line?**

### **Room 312**

*Moderators: Francois Durand, Professor, Hospital Beaujon, Clichy, University Paris Diderot, France. Goran Klintmalm, MD, PhD, Baylor University Medical Center, Dallas, TX, USA.*

**11:15 am** **Recipient with MELD > 40**

*Mitra Nadim, MD, FASN, University of Southern California, Los Angeles, CA, USA.*

**11:35 am** **Audience Discussion**

**11:45 am** **How Old is Too Old for a Combined Liver/Kidney Transplantation?**

*John Fung, MD, PhD, University of Chicago Medicine, Chicago, IL, USA.*

**12:05 pm** **Audience Discussion**

**12:15 pm** **Lessons Learnt from the Liver Eaters**

*Thomas D. Schiano, MD, The Mount Sinai Medical Center, New York, NY, USA.*

**12:35 pm** **Audience Discussion**

## **Coinhibitory Pathways: From Bench to Bedside**

### **Ballroom A**

*Moderators: David Matthews, MD, PhD, Emory University, Atlanta, GA, USA. Anil Chandraker, MD, Brigham and Women's Hospital, Boston, MA, USA.*

**11:15 am** **Bench: Coinhibitory Pathways in Transplantation**

*Peter Sage, PhD, Brigham and Women's Hospital, Boston, MA, USA.*

**11:35 am** **Audience Discussion**

**11:45 am** **Translational: Preclinical Models of Coinhibitory Blockade**

*Leonardo V. Riella, MD, PhD, Brigham and Women's Hospital, Boston, MA, USA.*

**12:05 pm** **Audience Discussion**

**12:15 pm** **Clinical: Bringing Coinhibitory Modulation to the Clinic**

*Haydn Kissick, PhD, Emory University, Atlanta, GA, USA.*

**12:35 pm** **Audience Discussion**

## **Lymphatics in Transplantation**

### **Room 302**

*Moderators: Mandy Ford, PhD, Emory University, Atlanta, GA, USA. Jonathan Bromberg, MD, PhD, University of Maryland School of Medicine, Baltimore, MD, USA.*

**11:15 am** **Lymphatics in Chronic Rejection**

*Wilson Wong, BSc MBBS, King's College London, London, England.*

**11:35 am** **Audience Discussion**

**11:45 am** **Lymphatics and Immunometabolism**

*Brian Wong, PhD, Washington University School of Medicine, St. Louis, MO, USA.*

**12:05 pm** **Audience Discussion**

**12:15 pm** **Lymph Node Scarring in Transplantation**

*Reza Abdi, MD, Brigham and Women's Hospital, Boston, MA, USA.*

**12:35 pm** **Audience Discussion**

## **Break**

**12:45 pm – 1:00 pm**

## **Sponsored Satellite Symposia**

**1:00 pm – 2:15 pm**

Satellite Symposia are open to all registered Congress attendees. Satellite Symposia take place at the Sheraton Boston Hotel. Please check the ATC website, [www.atcmeeting.org](http://www.atcmeeting.org), or ATC mobile app (ATC19) for the full Satellite Symposia program listing.

Monday, June 3

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

## **Luncheon Workshops (Additional Fees - Limited Ticketed Events)**

**1:00 pm – 2:15 pm**

### **Two for the Price of One: The Explosion of Combined Heart-Kidneys and Lung-Kidneys**

#### **Room 108**

*Moderators: Felicitas Killer, MD, The University of Mississippi Medical Center, Jackson, MS, USA.*

*Deborah Levine, MD, University of Texas Health Center San Antonio, San Antonio, TX, USA.*

### **Caring for the Caregiver in Transplantation: State of Affairs and Future Directions**

#### **Room 109**

*Moderators: Heather Bruschwein, PsyD, University of Virginia, Charlottesville, Va, USA. Michelle Jesse, PhD, Henry Ford Health System, Detroit, MI, USA.*

### **#SquadGoals: Expanding and Optimizing the Transplant Pharmacy Team**

#### **Room 110**

*Moderators: Katie Cunningham, PharmD, BCPS, Northwestern Memorial Hospital, Chicago, IL, USA. Ashley Feist, PharmD, BCPS, UC San Diego Health, San Diego, CA, USA. Bharath Ravichandran, PharmD, BCPS, University of Maryland Medical Center, Baltimore, MD, USA.*

### **Looking Under the Hood of High Impact Research: From Idea to AJT Publication**

#### **Cafe, Across from Hall A Registration**

**1:00 pm** **Intro: How to Get Published and Pitfalls**  
*Allan Kirk, MD, PhD, Duke University School of Medicine, Durham, NC, USA.*

**1:10 pm** **Intro: Sex-Based Disparities in Delisting for Being “Too Sick” for Liver Transplantation**  
*Deepika Devuni, MD, UMass Memorial Health Care, Worcester, MA, USA.*

**1:15 pm** **Sex-Based Disparities in Delisting for Being “Too Sick” for Liver Transplantation**  
*Giuseppe Cullaro, MD, University of California San Francisco, CA, USA.*  
**1:30 pm** *Audience Discussion*

**1:30 pm** **Audience Discussion**

**1:35 pm** **Intro: Risk of ESRD in Prior Living Kidney Donors**  
*Silvi Shah, MD, MS, University of Cincinnati, Cincinnati, OH, USA.*

**1:40 pm** **Risk of ESRD in Prior Living Kidney Donors**  
*Jennifer Wainright, PhD, UNOS, Richmond, VA, USA.*

**1:55 pm** **Audience Discussion**

**2:00 pm** **Intro: Pediatric Heart Transplantation Across a Positive Crossmatch: First Year Results from the CTOTC-04 Multi-Institutional Study**  
*Kevin Daly, MD, Boston Children’s Hospital, Boston, MA, USA.*

**2:05 pm** **Pediatric Heart Transplantation Across a Positive Crossmatch: First Year Results from the CTOTC-04 Multi-Institutional Study**  
*Steven Webber, M.B.Ch.B., MRCP, Vanderbilt University School of Medicine, Nashville, TN, USA*

**2:20 pm** **Audience Discussion**

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

## Break

2:15 pm-2:30 pm

## Concurrent Oral Abstract Sessions

2:30 pm – 4:00 pm

### Kidney Complications: Late Graft Failure II

#### Veterans Auditorium

Chairs: D. Dadhania, Weill Cornell Medicine - NYPH, New York, NY and E. Khankin, BIDMC/HMS, Boston, MA

#### 2:30 PM Epitop Matching Predicts Immunization in Kidney Transplant Recipients with Allograft Failure Leading to Worse Outcomes (Abstract #204)

F. Halleck<sup>1</sup>, M. Merkel<sup>1</sup>, P. Bach<sup>2</sup>, D. Schmidt<sup>1</sup>, M. Niemann<sup>3</sup>, N. Lachmann<sup>4</sup>, K. Budde<sup>1</sup>, <sup>1</sup>Nephrology, Charite, Berlin, Germany, <sup>2</sup>Institute of Biometry and Clinical Epidemiology, Charite, Berlin, Germany, <sup>3</sup>PIRCHE AG, Berlin, Germany, <sup>4</sup>Institute for Transfusion Medicine, H&I Laboratory, Charite, Berlin, Germany

#### 2:42 PM C4d Positivity in Renal Biopsies Following A2 to B Kidney Transplantation: Not All A B O Incompatibilities Are Equal (Abstract #205)

S. Radomski<sup>1</sup>, G. Vranic<sup>2</sup>, B. Thomas<sup>2</sup>, P. Abrams<sup>2</sup>, M. Cooper<sup>2</sup>, A. Gilbert<sup>2</sup>, <sup>1</sup>Georgetown University School of Medicine, Washington, DC, <sup>2</sup>Medstar Georgetown Transplant Institute, Washington, DC

#### 2:54 PM Donor Derived Cell Free DNA Initiates De-Novo Donor Specific Antibody (DSA) Responses (Abstract #207)

S. Jordan<sup>1</sup>, D. Sawinski<sup>2</sup>, S. Dholakia<sup>3</sup>, <sup>1</sup>Cedars-Sinai, Los Angeles, CA, <sup>2</sup>Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>3</sup>CareDx, Brisbane, CA

#### 3:06 PM Humoral Immune Responses to Kidney Associated Non-HLA Antigens is Not Associated with Progression to Chronic Immune Injury in Kidney Transplant Recipients (Abstract #208)

S. Sukumaran Nair<sup>1</sup>, R. Ravichandran<sup>2</sup>, R. Heilman<sup>1</sup>, A. Jaramillo<sup>1</sup>, D. Ramon<sup>1</sup>, M. Buras<sup>1</sup>, B. Kaplan<sup>1</sup>, T. Mohanakumar<sup>2</sup>, <sup>1</sup>Mayo Clinic, Phoenix, AZ, <sup>2</sup>St. Joseph's Hospital, Phoenix, AZ

#### 3:18 PM Angiotensin II Type 1 Receptor Antibodies Improve Risk Stratification for Kidney Allograft Outcomes at the Time of Transplantation (Abstract #209)

C. Lefaucheur<sup>1</sup>, D. Viglietti<sup>1</sup>, Y. Bouatou<sup>1</sup>, A. Philippe<sup>2</sup>, D. Pievani<sup>1</sup>, O. Aubert<sup>1</sup>, D. Glotz<sup>1</sup>, C. Legendre<sup>1</sup>, A. Loupy<sup>1</sup>, D. Dragun<sup>2</sup>, <sup>1</sup>Paris Translational Research Center for Organ Transplantation, Paris, France, <sup>2</sup>Medical Faculty of the Charité Berlin, Berlin, Germany

#### 3:30 PM Circulating Mirnas Regulate Gene Expression In Kidney Tissue During Transplant Glomerulopathy (Abstract #210)

C. Kuscu<sup>1</sup>, V. Sai Bontha<sup>1</sup>, C. Kuscu<sup>1</sup>, D. Maluf<sup>1</sup>, A. Bajwa<sup>1</sup>, J. Eason<sup>1</sup>, V. Mas<sup>1</sup>, E. Akalin<sup>2</sup>, <sup>1</sup>UTHSC, Memphis, TN, <sup>2</sup>Albert Einstein College of Medicine, NYC, NY

#### 3:42 PM The Use of dd-cfDNA as a Predictive Tool for Outcome Decreased Kidney Function (Abstract #206)

T. Alhamad<sup>1</sup>, E. Poggio<sup>2</sup>, D. Hiller<sup>3</sup>, S. Dholakia<sup>3</sup>, P. Sood<sup>4</sup>, <sup>1</sup>Washington University School of Medicine, St. Louis, MO, <sup>2</sup>Cleveland Clinic, Cleveland, OH, <sup>3</sup>CareDx, Brisbane, CA, <sup>4</sup>University of Pittsburgh Medical Center, Pittsburgh, PA

Monday, June 3



# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

## Kidney Deceased Donor Allocation II

### Ballroom B

Chairs: O. Ekwenna, Riverside Medical Center-Rush Health System, Toledo, OH and R. Parsons, Emory University School of Medicine, Atlanta, GA

**2:30 PM Regional Differences in Transplantation for Expected Post-Transplant Survival Top 20% Candidates (Abstract #211)**  
S. Husain, K. King, D. Tsapepas, G. Dube, D. Cohen, L. E. Ratner, S. Mohan, Columbia University Medical Center, New York, NY

**2:42 PM Measuring and Monitoring Disparities in Access to Kidney Transplantation Associated with Being Listed for a Multi-Organ Transplant (MOT) (Abstract #212)**  
D. E. Stewart, C. A. Custer, A. M. Robinson, A. R. Wilk, UNOS, Richmond, VA

**2:54 PM The Immigrant Bonus: Non US Deceased Donor Kidney Transplant Recipients Have Superior Outcomes versus US Citizen Recipients. A Retrospective Study of 30,092 Subjects Using the Organ Procurement and Transplant Network (OPTN) from 1992-2015 (Abstract #213)**  
T. Butler<sup>1</sup>, A. Rana<sup>2</sup>, S. Fink<sup>1</sup>, <sup>1</sup>Transplant Surgery, Crozer Prospect Medical Center-Drexel University, Upland, PA, <sup>2</sup>Transplant Surgery, Baylor College of Medicine, Houston, TX

**3:06 PM Dialysis Facility Profit Status and Referral for Kidney Transplantation (Abstract #214)**  
E. R. Walker<sup>1</sup>, L. J. McPherson<sup>1</sup>, J. C. Gander<sup>2</sup>, S. Pastan<sup>1</sup>, R. E. Patzer<sup>1</sup>, <sup>1</sup>Emory University School of Medicine, Atlanta, GA, <sup>2</sup>Kaiser Permanente Georgia, Atlanta, GA

**3:18 PM Factors Related to International Travel for Transplantation among US-Listed Kidney Transplant Candidates (Abstract #215)**

B. Koons<sup>1</sup>, M. L. Henderson<sup>2</sup>, A. G. Thomas<sup>3</sup>, T. Kear<sup>4</sup>, H. Moriarty<sup>4</sup>, <sup>1</sup>School of Nursing, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Department of Surgery in the Division of Transplantation, Johns Hopkins University, Baltimore, MD, <sup>3</sup>Department of Epidemiology, University of North Carolina, Chapel Hill, NC, <sup>4</sup>M. Louise Fitzpatrick College of Nursing, Villanova University, Villanova, PA

**3:30 PM Racial/Ethnic and Socio-Economic Disparities: Single versus Multi-Organ Transplant Recipients (Abstract #216)**  
C. A. Custer<sup>1</sup>, K. Ladin<sup>2</sup>, J. Entwistle<sup>3</sup>, E. J. Gordon<sup>4</sup>, <sup>1</sup>United Network for Organ Sharing, Richmond, VA, <sup>2</sup>Tufts University, Medford, MA, <sup>3</sup>Thomas Jefferson University, Washington, DC, <sup>4</sup>Northwestern University, Chicago, IL

**3:42 PM Hard-to-Place Kidney Offers: Through the Lens of the United Network for Organ Sharing Organ Center (Abstract #217)**  
S. M. Noreen, R. S. Brown, M. Lane, B. Wolford, C. A. Humphries, United Network for Organ Sharing, Richmond, VA

## Kidney Donor Selection / Management Issues II

### Ballroom C

Chairs: M. Hobeika, Houston Methodist, Houston, TX and H. Gritsch, University of California Los Angeles (Urology), Los Angeles, CA

**2:30 PM The Degree of Glomerulosclerosis in Procurement Renal Biopsy and its Implications in Predicting Graft Outcomes in Marginal Donor Kidneys (Abstract #218)**  
W. Cheungpasitporn<sup>1</sup>, W. Chon<sup>2</sup>, E. Island<sup>2</sup>, L. Cummings<sup>2</sup>, J. Forster<sup>2</sup>, N. Leeaphorn<sup>2</sup>, <sup>1</sup>University of Mississippi Medical Center, Jackson, MS, <sup>2</sup>Saint Luke's Health System, Kansas City, MO

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

- 2:42 PM Kidney Transplant Outcomes and Organ Acceptance Practice Patterns: Nationwide Analyses of the US and France (Abstract #219)**  
O. Aubert<sup>1</sup>, P. P. Reese<sup>2</sup>, Y. Bouatou<sup>1</sup>, M. Raynaud<sup>1</sup>, C. Legendre<sup>1</sup>, D. Glotz<sup>1</sup>, C. Lefaucheur<sup>1</sup>, C. Jacquelinet<sup>3</sup>, A. Loupy<sup>1</sup>, <sup>1</sup>Paris Translational Center for Organ Transplantation, Paris, France, <sup>2</sup>Department of Medicine, Renal-Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Agence de la Biomédecine, Paris, France
- 2:54 PM Impact Of Cold And Warm Ischemia Time On Outcomes For Kidneys Donated After Cardiac Death (Abstract #221)**  
C. Brennan<sup>1</sup>, P. R. Sandoval<sup>2</sup>, S. A. Husain<sup>2</sup>, D. Tsapepas<sup>1</sup>, S. Mohan<sup>2</sup>, L. E. Ratner<sup>2</sup>, <sup>1</sup>New York Presbyterian, New York, NY, <sup>2</sup>Columbia University Medical Center, New York, NY
- 3:06 PM Increase in Deceased Donor Acceptance Rate After Implementing Uniform Acceptance Criteria (Abstract #222)**  
C. Klein, T. Ommert, J. Hundley, J. Lizcano, A. Ray, R. Cross, K. Payne, *Piedmont Transplant Institute, Atlanta, GA*
- 3:18 PM Machine Perfusion Allows Use of High KDPI and Prolonged Cold Ischemia Time in Deceased Donors: A Single Center Effort to Decrease Discard Rates (Abstract #223)**  
M. Ortigosa-Goggins, J. Gaynor, A. Mattiazzi, J. Figueiro, G. Burke, G. Ciancio, G. Guerra, *Miami Transplant Institute, University of Miami, Miami, FL*
- 3:30 PM Kidney Donor Outcomes ≥ 50 Years Post Donation (Abstract #224)**  
D. Keys, S. Jackson, A. Matas, *University of Minnesota, Minneapolis, MN*

- 3:42 PM An International Comparison of Kidney Utilization in the United States and United Kingdom: What Can Be Learned? (Abstract #220)**  
D. Stewart<sup>1</sup>, G. Vece<sup>1</sup>, M. Ibrahim<sup>2</sup>, C. Callaghan<sup>2</sup>, <sup>1</sup>UNOS, Richmond, VA, <sup>2</sup>NHS, London, United Kingdom

## Liver Transplant Complications and Retransplantation I

### Ballroom A

Chairs: A. Humar, *Thomas E Starzl Transplant Inst, Pittsburgh, PA* and T. Schiano, *The Mount Sinai Medical Ctr, New York, NY*

- 2:30 PM Predictors and Outcomes of Acute Graft-versus-Host Disease after Liver Transplant (Abstract #225)**  
A. Caines<sup>1</sup>, S. Nagai<sup>2</sup>, R. Salgia<sup>1</sup>, <sup>1</sup>Gastroenterology and Hepatology, Henry Ford Health System, Detroit, MI, <sup>2</sup>Transplant Surgery, Henry Ford Health System, Detroit, MI
- 2:42 PM Renoportal Anastomosis in Liver Transplantation: Results from a Propensity Score-Based Outcome Analysis (Abstract #226)**  
G. D'Amico, S. Armanyous, L. Lomaglio, T. Diago Uso, K. Hashimoto, B. Eghtesad, M. Fujiki, F. Aucejo, K. Sasaki, H. Matsushima, C. Lindenmeyer, C. Miller, C. Quintini, *Cleveland Clinic, Cleveland, OH*
- 2:54 PM The Impact of Portal Flow after Reperfusion on Graft Outcomes after Deceased Donor Liver Transplantation (Abstract #227)**  
H. Matsushima, K. Sasaki, M. Fujiki, T. Diago Uso, B. Eghtesad, F. Aucejo, C. Kwon, C. Miller, C. Quintini, K. Hashimoto, *General Surgery, Digestive Disease & Surgery Institute, Cleveland Clinic, Cleveland Clinic, Cleveland, OH*

Monday, June 3

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

**3:06 PM The Impact of Sleeve Gastrectomy Following Liver Transplant in Patients with Non-Alcoholic Steatosis: A Five-Year Experience (Abstract #228)**

M. C. Morris<sup>1</sup>, A. D. Jung<sup>1</sup>, Y. Kim<sup>1</sup>, V. K. Dhar<sup>1</sup>, S. Shah<sup>1</sup>, D. Schauer<sup>2</sup>, E. Smith<sup>2</sup>, T. Diwan<sup>1</sup>, <sup>1</sup>*Surgery, University of Cincinnati, Cincinnati, OH*, <sup>2</sup>*Medicine, University of Cincinnati, Cincinnati, OH*

**3:18 PM Proximal Splenic Artery Embolization For Refractory Ascites And Hydrothorax After Liver Transplant: A Single Center Analysis Of Factors Associated With Success (Abstract #229)**

L. Lomaglio, G. D'Amico, S. Armanyous, T. Diago Uso, K. Hashimoto, B. Egtesad, M. Fujiki, F. Aucejo, K. Sasaki, C. Kwon, C. Coppa, M. Bayona Molano, C. Lindenmeyer, C. Miller, C. Quintini, *Cleveland Clinic, Cleveland, OH*

**3:30 PM The Impact of Extra-Anatomical Hepatic Artery Reconstruction during Living Donor Transplantation on Biliary Complications and Graft and Patient Survival (Abstract #230)**

Y. Chung, J. Kim, S. Kim, J. Rhu, S. Lee, K. Lee, S. Lee, G. Choi, J. Park, S. Kim, J. Joh, S. Lee, *Transplantation, Samsung Medical Center, Seoul, Korea, Republic of*

**3:42 PM The Comparative Safety and Efficacy of Direct Acting Oral Anticoagulants Relative to Warfarin Following Liver Transplantation (Abstract #231)**

A. Santeusano, A. Weinberg, T. Schiano, *Mount Sinai Hospital, New York, NY*

## Infectious Epidemiology

**Room: 304**

*Chairs: E. Blodget, USC Keck School of Medicine, Los Angeles, CA and R. Miller, Duke University, Durham, NC*

**2:30 PM Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Solid Organ Transplant Recipients at an Academic Medical Center (Abstract #232)**

J. S. Kerr, N. Law, S. Aslam, *Center for Transplantation, University of California, San Diego Health System, La Jolla, CA*

**2:42 PM Routine Molecular Clostridioides difficile Screening and Overtreatment in Solid Organ Transplant Recipients (Abstract #233)**

M. E. Newman<sup>1</sup>, C. Oehler<sup>1</sup>, M. Enriquez<sup>1</sup>, E. Landon<sup>1</sup>, C. T. Nguyen<sup>2</sup>, N. N. Pettit<sup>2</sup>, J. P. Ridgway<sup>1</sup>, J. Pisano<sup>1</sup>, <sup>1</sup>*Section of Infectious Disease, University of Chicago Medicine, Chicago, IL*, <sup>2</sup>*Department of Pharmacy, University of Chicago Medicine, Chicago, IL*

**2:54 PM Contemporary US Prevalence and Outcomes of Pneumocystis jirovecii Pneumonia and Toxoplasmosis in Pediatric Solid Organ and Hematopoietic Cell Transplantation Recipients (Abstract #234)**

M. I. Ardura<sup>1</sup>, J. Stanek<sup>2</sup>, B. Hanisch<sup>3</sup>, B. Hanisch<sup>4</sup>, K. Spratt<sup>5</sup>, H. Rangarajan<sup>6</sup>, <sup>1</sup>*Pediatrics, Infectious Diseases & Host Defense, Nationwide Children's Hospital & The Ohio State University, Columbus, OH*, <sup>2</sup>*Pediatrics, Biostatistics, Nationwide Children's Hospital, Columbus, OH*, <sup>3</sup>*Pediatrics, Infectious Diseases, Children's National Health System, Washington, DC*, <sup>4</sup>*Pediatrics, Infectious Diseases, Children's National Health System & The George Washington University, Washington, DC, DC*, <sup>5</sup>*Pediatrics, Pharmacy, Medical University of South Carolina, Charleston, SC*, <sup>6</sup>*Pediatrics, Hematology/Oncology/HCT, Nationwide Children's Hospital & The Ohio State University, Columbus, OH*

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

**3:06 PM Infectious Complications of Eculizumab Use in Abdominal Organ Transplant Recipients (Abstract #235)**

A. M. Nolan<sup>1</sup>, E. J. Fraser<sup>2</sup>, H. K. Grewal<sup>3</sup>, J. G. Timpone<sup>3</sup>, <sup>1</sup>Department of Pharmacy, Medstar Georgetown University Hospital, Washington, DC, <sup>2</sup>Georgetown University School of Medicine, Washington, DC, <sup>3</sup>Division of Infectious Diseases and Travel Medicine, Medstar Georgetown University Hospital, Washington, DC

**3:18 PM Spontaneous Bacterial Peritonitis Prophylaxis Increases the Risk of Multi-Drug Resistant Cultures and Infections in Liver Transplant Patients (Abstract #236)**

R. Rosenblatt, A. Schluger, M. Pereira, E. Verna, Columbia University Medical Center, New York, NY

**3:30 PM Predictors of Multidrug-Resistant Organisms among Solid Organ Transplant Donors (Abstract #237)**

J. A. Anesi<sup>1</sup>, E. A. Blumberg<sup>1</sup>, J. H. Han<sup>1</sup>, D. H. Lee<sup>2</sup>, H. Clauss<sup>3</sup>, A. Climaco<sup>4</sup>, R. Hasz<sup>5</sup>, E. Molnar<sup>3</sup>, D. Alimenti<sup>1</sup>, S. West<sup>5</sup>, W. Bilker<sup>1</sup>, P. Tolomeo<sup>1</sup>, E. Lautenbach<sup>1</sup>, <sup>1</sup>University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Drexel University College of Medicine, Philadelphia, PA, <sup>3</sup>Temple University, Philadelphia, PA, <sup>4</sup>Albert Einstein Medical Center, Philadelphia, PA, <sup>5</sup>Gift of Life Donor Program, Philadelphia, PA

**3:42 PM The Outcomes after an Infection in Older Liver Transplant Recipients is Comparable to Younger Adults (Abstract #238)**

J. Garcia-Diaz<sup>1</sup>, M. Kerkelis<sup>2</sup>, T. Shah<sup>3</sup>, M. Tucker<sup>4</sup>, M. Gastanaduy<sup>5</sup>, J. Woo<sup>1</sup>, M. Ponder<sup>1</sup>, M. Malinis<sup>6</sup>, M. Malinis<sup>6</sup>, <sup>1</sup>Infectious Diseases, Ochsner Medical Center, New Orleans, LA, <sup>2</sup>University of Queensland/Ochsner Clinical School, New Orleans, LA, <sup>3</sup>Internal Medicine, St. Joseph Hospital, Denver, CO, <sup>4</sup>Internal Medicine, Yale School of Medicine, New Haven, CT, <sup>5</sup>Center for Outcomes and Health Services Research, Ochsner Medical Center, New Orleans, LA, <sup>6</sup>Infectious Diseases, Yale School of Medicine, New Haven, CT

**Kidney Psychosocial I: Cognitive and Behavioral Factors**

**Room: 302**

Chairs: M. Chisholm-Burns and University of TN College of Pharm, Memphis, TN

**2:30 PM Patient-Reported Outcomes in a Prospective Multicenter Trial of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression Regimens in Kidney Transplantation (Abstract #239)**

J. M. Rohan<sup>1</sup>, J. P. Leone<sup>2</sup>, E. S. Woodle<sup>3</sup>, D. Kaufman<sup>4</sup>, A. R. Shields<sup>3</sup>, A. Wiseman<sup>5</sup>, A. J. Matas<sup>6</sup>, P. West-Thielke<sup>7</sup>, E. King<sup>3</sup>, R. R. Alloway<sup>3</sup>, <sup>1</sup>Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Tampa General Hospital, Tampa, FL, <sup>3</sup>University of Cincinnati College of Medicine, Cincinnati, OH, <sup>4</sup>University of Wisconsin – Madison, Madison, WI, <sup>5</sup>University of Colorado - Denver, Denver, CO, <sup>6</sup>University of Minnesota Medical Center, Minneapolis, MN, <sup>7</sup>University of Illinois – Chicago, Chicago, IL

**2:42 PM Cognitive Function & Risk Of Adverse Outcomes In Kidney Transplant Candidates (Abstract #240)**

N. Chu<sup>1</sup>, Z. Shi<sup>1</sup>, H. Ying<sup>1</sup>, C. Haugen<sup>1</sup>, S. Norman<sup>2</sup>, D. Segev<sup>1</sup>, M. McAdams-DeMarco<sup>1</sup>, <sup>1</sup>JHU, Baltimore, MD, <sup>2</sup>Michigan Medical Center, Ann Arbor, MI

Monday, June 3



# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

**2:54 PM Evaluation of Medication Burden in Kidney Transplant Recipients at Time of Index Hospitalization (Abstract #241)**

J. Hardcopf<sup>1</sup>, H. Meadows<sup>1</sup>, T. Harrison<sup>1</sup>, H. Corbo<sup>1</sup>, B. O'brien<sup>1</sup>, J. N. Fleming<sup>1</sup>, C. Perez<sup>1</sup>, N. Patel<sup>1</sup>, N. Pilch<sup>1</sup>, P. K. Baliga<sup>2</sup>, D. DuBay<sup>2</sup>, D. Taber<sup>1</sup>, <sup>1</sup>Department of Pharmacy Services, Medical University of South Carolina, Charleston, SC, <sup>2</sup>Division of Transplant Surgery, Department of Surgery, Medical University of South Carolina, Charleston, SC

**3:06 PM Your Path to Transplant Education Increases Patients' Transplant Knowledge, Attitudes, Informed Decision-Making, and Pursuit: An Randomized Controlled Trial (Abstract #242)**

A. D. Waterman<sup>1</sup>, Y. Cui<sup>2</sup>, J. D. Peipert<sup>3</sup>, J. L. Beaumont<sup>2</sup>, C. S. Anderson<sup>1</sup>, A. L. Paiva<sup>4</sup>, M. L. Robbins<sup>4</sup>, <sup>1</sup>Division of Nephrology, University of California, Los Angeles, Los Angeles, CA, <sup>2</sup>Terasaki Research Institute, Los Angeles, CA, <sup>3</sup>Department of Medical Social Sciences, Northwestern University, Chicago, IL, <sup>4</sup>Department of Psychology, University of Rhode Island, Kingston, RI

**3:18 PM "Getting Life Back" - Kidney Transplantation in the Elderly Patient (Abstract #243)**

V. Tsarpali<sup>1</sup>, K. Lønning<sup>2</sup>, K. Midtvedt<sup>2</sup>, T. Bernklev<sup>3</sup>, N. von der Lippe<sup>4</sup>, M. H. Andersen<sup>2</sup>, K. Haldal<sup>1</sup>, <sup>1</sup>Clinic of Internal Medicine, Telemark Hospital Trust, Skien, Norway, <sup>2</sup>Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway, <sup>3</sup>Vestfold Hospital Trust, Tønsberg, Norway, <sup>4</sup>Oslo University Hospital, Oslo, Norway

**3:30 PM The Effect of Kidney Transplantation on Neurocognitive Function: A Prospective Study (Abstract #244)**

B. P. Concepcion, J. C. Jackson, A. Kiehl, R. Adu-Boahene, E. Collar, M. Reed, M. Sika, J. Van, R. C. Forbes, Vanderbilt University Medical Center, Nashville, TN

**3:42 PM Non-adherence With Diet And Dialysis Prescription: Predictors Of Non-adherence Post-transplant? (Abstract #245)**

A. Padiyar<sup>1</sup>, A. Agrawal<sup>1</sup>, D. Hricik<sup>1</sup>, P. Bate<sup>2</sup>, J. Rockwell<sup>2</sup>, A. Eliason<sup>2</sup>, N. Sarabu<sup>1</sup>, A. Jittirat<sup>1</sup>, K. Yadav<sup>2</sup>, E. Sanchez<sup>2</sup>, M. Debroy<sup>2</sup>, V. Humphreville<sup>2</sup>, J. Rabets<sup>2</sup>, A. Palanisamy<sup>2</sup>, K. Chavin<sup>2</sup>, <sup>1</sup>Medicine, Nephrology, University Hospitals Cleveland Medical Center, Cleveland, OH, <sup>2</sup>Transplant Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH

## Antigen Presentation and Allorecognition

**Room: 311**

Chairs: A. Gelman, Washington University of Medicine, Saint Louis, MO and D. Kreisel, Washington University St Louis, St. Louis, MO

**2:30 PM Tolerogenic Nanoparticles Targeting the Aryl Hydrocarbon Receptor (Abstract #246)**

K. Janek<sup>1</sup>, J. Fechner<sup>1</sup>, S. Gong<sup>2</sup>, Y. Wang<sup>2</sup>, J. Mezrich<sup>1</sup>, <sup>1</sup>Department of Surgery, Division of Transplantation, University of Wisconsin Hospital and Clinics, Madison, WI, <sup>2</sup>Department of Biomedical Engineering, University of Wisconsin Madison, Madison, WI

**2:42 PM mTORC2 Restricts mTORC1 Metabolic Function in Dendritic Cells to Limit Their Allostimulatory Activity (Abstract #247)**

H. Dai<sup>1</sup>, A. Watson<sup>1</sup>, A. Menk<sup>2</sup>, D. Stolz<sup>3</sup>, G. Delgoffe<sup>2</sup>, A. Thomson<sup>1</sup>, <sup>1</sup>Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Tumor Microenvironment Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA, <sup>3</sup>Department of Cell Biology, University of Pittsburgh, Pittsburgh, PA



# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

**2:54 PM Myeloid AXL Promotes Cardiac Allograft Vasculopathy (Abstract #248)**  
K. E. Ginton<sup>1</sup>, X. Yeap<sup>1</sup>, Z. J. Zhang<sup>2</sup>, X. Luo<sup>3</sup>, E. B. Thorp<sup>1</sup>, <sup>1</sup>Pathology, FCVRR, Northwestern University - Feinberg School of Medicine, Chicago, IL, <sup>2</sup>Surgery, Northwestern University - Feinberg School of Medicine, Chicago, IL, <sup>3</sup>Duke Transplant Center, Duke University School of Medicine, Durham, NC

**3:06 PM FTY720 Regulates Mitochondria Biogenesis in Dendritic Cells to Prevent Kidney Ischemic Reperfusion Injury (Abstract #249)**  
A. Bajwa<sup>1</sup>, V. Bontha<sup>1</sup>, C. Kuscu<sup>1</sup>, L. Gallon<sup>2</sup>, C. Kuscu<sup>1</sup>, J. Eason<sup>3</sup>, D. Maluf<sup>1</sup>, V. Mas<sup>4</sup>, <sup>1</sup>UTHSC, Memphis, TN, <sup>2</sup>Northwestern University, Chicago, IL, <sup>3</sup>Director Transplant Institute, Memphis, TN, <sup>4</sup>Director Transplant Reserach Institute, Memphis, TN

**3:18 PM Dendritic Cells Transduced with Autoimmune Regulator Exhibit Immature Properties and Prolong Heart Allograft Survival (Abstract #250)**  
Y. Zhang, Z. Zhu, M. Chen, S. Huang, C. Sun, W. Ju, Z. Guo, X. He, *Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China*

**3:30 PM Tertiary Lymphoid Organs in Renal Chronic Allograft Rejection (Abstract #251)**  
K. Abou-Daya, D. Zhao, A. Williams, M. Oberbarnscheidt, *Starzl Transplantation Institute, Pittsburgh, PA*

**3:42 PM Prolongation of Allograft Survival via Donor MHC Chimerism Induced by Exosomes (Abstract #252)**  
B. Gonzalez Nolasco<sup>1</sup>, M. Wang<sup>1</sup>, W. Orent<sup>1</sup>, A. Prunevieuille<sup>1</sup>, J. O<sup>1</sup>, K. Ahrens<sup>1</sup>, J. C. Madsen<sup>2</sup>, G. Benichou<sup>1</sup>, <sup>1</sup>Department of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Department of Surgery, Center for Transplantation Sciences, Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA

## Biomarkers, Immune Monitoring and Outcomes II

**Room: 306**

*Chairs: E. Akalin, Albert Einstein College of Medicine, Montefiore Medical Ctr, Bronx, NY and M. McGrath, MA*

**2:30 PM Microscopic Hepatic Steatosis Prior to Liver Transplantation Influences Clinical Outcomes (Abstract #257)**  
K. Nakamura, H. Hirao, T. Ito, S. Kageyama, K. Kadono, K. J. Dery, J. Aziz, B. Ke, F. M. Kaldas, R. W. Busuttil, J. W. Kupiec-Weglinski, *Surgery, Liver Transplant, UCLA, Los Angeles, CA*

**2:42 PM Super-resolution Evaluation Of The Glomerular Basement Membrane Changes In The Course Of Transplant Glomerulopathy (Abstract #253)**  
D. Hammad, J. H. Miner, T. Alhamad, H. Suleiman, *Washinton University in St. Louis, St. Louis, MO*

**2:54 PM The Frequency of Tissue-Resident Donor T and NK Cells in Peripheral Blood after Lung Transplantation is Modulated by Normothermic Ex Vivo Lung Perfusion (Abstract #254)**  
C. S. Falk<sup>1</sup>, B. Wiegmann<sup>2</sup>, A. Hitz<sup>1</sup>, R. Bellmas-Sanz<sup>1</sup>, K. Bläsing<sup>1</sup>, F. Ius<sup>2</sup>, C. Kühn<sup>2</sup>, M. Avsar<sup>2</sup>, I. Tudorache<sup>2</sup>, J. Kühne<sup>1</sup>, F. Wandrer<sup>1</sup>, A. Haverich<sup>2</sup>, G. Warnecke<sup>2</sup>, <sup>1</sup>Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany, <sup>2</sup>Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany

**3:06 PM Assessment of Serum Tim3 and Gal9 Levels in Predicting the Risk of Infection after Kidney Transplantation (Abstract #255)**  
Y. Shi<sup>1</sup>, y. li<sup>2</sup>, Y. Li<sup>2</sup>, L. Yan<sup>2</sup>, J. Tang<sup>2</sup>, X. Wu<sup>2</sup>, Y. Bai<sup>2</sup>, Y. An<sup>2</sup>, B. Dai<sup>2</sup>, C. Yang<sup>2</sup>, L. Wang<sup>2</sup>, <sup>1</sup>Department of Nephrology, West China Hospital, Chengdu, China, <sup>2</sup>Department of Laboratory Medicine, West China Hospital, Chengdu, China

Monday, June 3

**AMERICAN TRANSPLANT CONGRESS**  
**Program, Monday, June 3, 2019**

---

**3:18 PM Targeted Proteomic Analysis Detects Acute T Cell-Mediated Kidney Allograft Rejection in Belatacept-Treated Patients (Abstract #256)**

M. van der Zwan, D. A. Hesselink, M. C. Clahsen-van Groningen, C. C. Baan, *Erasmus MC, Rotterdam, Netherlands*

**3:30 PM Elevated Podocyte-specific Urinary Extracellular Vesicles In Patients With Fsgs Recurrence After Kidney Transplantation (Abstract #258)**

H. Lau, A. Shimomura, E. Tantisattamo, U. G. Reddy, D. Dafoe, H. Ichii, *University of California Irvine, Orange, CA*

**3:42 PM CyTOF and RNAseq Analyses Unravel Early Phenotypic and Transcriptional Changes in Antibody-Secreting and Memory B Cells >1 Year Prior to Antibody-Mediated Rejection (Abstract #259)**

C. Fischman<sup>1</sup>, M. Fribourg<sup>1</sup>, J. Ansari<sup>2</sup>, L. Gallon<sup>2</sup>, F. Ginevri<sup>3</sup>, P. Comoli<sup>4</sup>, M. Cioni<sup>3</sup>, A. Nocera<sup>3</sup>, M. Bruschi<sup>3</sup>, C. Cantarelli<sup>1</sup>, L. Perin<sup>5</sup>, P. Cravedi<sup>1</sup>, <sup>1</sup>*Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY*, <sup>2</sup>*Department of Medicine, Northwestern University, Chicago, IL*, <sup>3</sup>*Department of Medicine, IRCCS Istituto G. Gaslini, Genoa, Italy*, <sup>4</sup>*Department of Medicine, IRCCS San Matteo Hospital, Pavia, Italy*, <sup>5</sup>*Department of Urology, Children's Hospital Los Angeles, Los Angeles, CA*

**Immunosuppression Preclinical Studies**

**Room: 309**

*Chairs: S. Cai, Renal Division, Brigham and Women's Hospital, Boston, MA and A. Siedlecki, Brigham and Women's Hospital, Boston, MA*

**2:30 PM Granulocyte - Colony Stimulating Factor (G-CSF) and Granulocyte - Macrophage Colony Stimulating Factor (GM-CSF) Administration Augments the Incidence of Peripheral Blood Suppressive Regulatory T Cells in Nonhuman Primates (Abstract #260)**

K. Sasaki, Y. Wang, L. Lu, J. Hughs, A. W. Thomson, M. B. Ezzelarab, *Department of Surgery, Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA*

**2:42 PM Mitochondrial Dysfunction and Metabolic Reprogramming: Critical Features of Cyclosporine A Nephrotoxicity (Abstract #261)**

A. A. Zmijewska, G. Benavides, V. Darley-Usmar, J. W. Zmijewski, R. B. Mannon, *University of Alabama at Birmingham, Birmingham, AL*

**2:54 PM Impact Of Selective Cd28 Blockade On Protective Immunity To A Murine Epstein-Barr Virus Homolog (Abstract #262)**

R. L. Crepeau, J. A. Elengickal, M. L. Ford, *Surgery, Emory University, ATLANTA, GA*

**3:06 PM Interruption of Notch Signaling via Blockade of Delta-Like Ligands 1 and 4 Prevents Co-Stimulation Blockade Resistant Allograft Rejection (Abstract #263)**

A. Matar, Y. Dong, B. Lovasik, D. Mathews, A. Ghosh, C. Breeden, A. Stephenson, W. Kitchens, A. Adams, *Surgery and Transplantation, Emory University, Atlanta, GA*

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

**3:18 PM Dual Targeting Desensitization with Carfilzomib Plus Lulizumab Significantly Prolongs Kidney Transplant Survival in Allosensitized Nonhuman Primates (Abstract #264)**  
P. M. Schroder, R. Schmitz, Z. Fitch, B. Ezekian, J. Yoon, A. Choi, A. Barbas, F. Leopardi, B. Collins, J. Kwun, S. J. Knechtle, *Department of Surgery, Duke University Medical Center, Durham, NC*

**3:30 PM Graft Perfusion with Alvespimycin, an HSP90 Inhibitor, Suppresses IL-2 and IL-12p40 Production in Graft-Infiltrating Cells, Leading to Prolongation of Graft Survival in Murine Heart Transplantation (Abstract #265)**  
T. Tanaka, T. Maehana, N. Masumori, *Department of Urology, Sapporo Medical University, Sapporo, Japan*

**3:42 PM Utilizing Changing Patterns of T-cell Metabolism in Aging for Effective Immunosuppression (Abstract #266)**  
Y. Nian, T. Heinbokel, K. Minami, R. Maenosono, J. Iske, A. El Khal, S. G. Tullius, *Transplant Surgery Research Lab, Brigham and Women's Hospital, Boston, MA*

## Xenotransplantation

**Room: 310**

*Chairs: M. Sykes, CCTI, New York, NY and R. N. Pierson*

**2:30 PM CD46 Transgene Modification and Thrombosis in Neonatal Porcine Islet Xenotransplantation (Abstract #267)**  
M. Song, K. Samy, Q. Gao, R. P. Davis, F. Leopard, Z. Fitch, C. Bennett, G. R. Devi, B. H. Collins, A. D. Kirk, *Surgery, Duke University, Durham, NC*

**2:42 PM Progress Using Genetically Engineered Pigs for Lung Xenotransplantation (Abstract #268)**

L. Burdorf<sup>1</sup>, C. Laird<sup>2</sup>, S. Sendil<sup>2</sup>, T. Zhang<sup>2</sup>, D. Parsell<sup>2</sup>, I. Tatarov<sup>2</sup>, B. Cerel<sup>1</sup>, Z. Abady<sup>1</sup>, S. Pratts<sup>1</sup>, C. J. Phelps<sup>3</sup>, D. L. Ayares<sup>3</sup>, A. M. Azimzadeh<sup>1</sup>, R. N. Pierson III<sup>1</sup>, <sup>1</sup>*Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Charlestown, MA*, <sup>2</sup>*Surgery, University of MD, Baltimore, MD*, <sup>3</sup>*Revivacor, Blacksburg, VA*

**2:54 PM Anti- CD154 / CD40 Costimulation Blockade is Superior to Tacrolimus in Prolonging Survival in Pig-to-Nonhuman Primate Renal Xenotransplantation (Abstract #269)**

B. P. Lovasik<sup>1</sup>, A. J. Matar<sup>1</sup>, C. Breeden<sup>1</sup>, J. Jenkins<sup>2</sup>, J. Tector<sup>3</sup>, S. C. Kim<sup>1</sup>, A. B. Adams<sup>1</sup>, <sup>1</sup>*Emory Transplant Center, Emory University, Atlanta, GA*, <sup>2</sup>*Yerkes National Primate Center, Emory University, Atlanta, GA*, <sup>3</sup>*University of Alabama at Birmingham, Birmingham, AL*

**3:06 PM The Role of CD47/SIRP $\alpha$  and CD47/TSP-1 Pathways in Pig-to-Baboon Kidney Transplantation Using hCD47 Transgenic Kidneys (Abstract #270)**

K. Takeuchi<sup>1</sup>, Y. Ariyoshi<sup>1</sup>, T. Pomposelli<sup>1</sup>, L. Boyd<sup>1</sup>, D. Ekanayake-Alper<sup>1</sup>, S. Arn<sup>1</sup>, R. Hawley<sup>1</sup>, D. Ayares<sup>2</sup>, M. Lorber<sup>3</sup>, M. Sykes<sup>1</sup>, D. Sachs<sup>1</sup>, R. Johnson<sup>4</sup>, K. Yamada<sup>1</sup>, <sup>1</sup>*CCTI/Surgery, Columbia University Medical Center, New York, NY*, <sup>2</sup>*Revivacor Inc., Blacksburg, VA*, <sup>3</sup>*Lung BioTechnology PBC, Silver Spring, MD*, <sup>4</sup>*Division of Renal Diseases and Hypertension, University of Colorado, Aurora, CO*

Monday, June 3

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

**3:18 PM Newly-Revealed Antibody Targets Lead to the Early Loss of Triple Knockout Pig Kidneys in a Pig to Baboon Model (Abstract #271)**

Y. Ariyoshi<sup>1</sup>, K. Takeuchi<sup>1</sup>, T. Pomposelli<sup>1</sup>, D. K. Ekanayake-Alper<sup>1</sup>, C. Schuetz<sup>1</sup>, H. Sahara<sup>1</sup>, L. Boyd<sup>1</sup>, E. Estime<sup>1</sup>, S. Arn<sup>1</sup>, D. Ayares<sup>2</sup>, M. Lorber<sup>3</sup>, M. Sykes<sup>1</sup>, D. Sachs<sup>1</sup>, K. Yamada<sup>1</sup>, <sup>1</sup>CCTI/Surgery, Columbia University Medical Center, New York, NY, <sup>2</sup>Revivicor Inc., Blacksburg, VA, <sup>3</sup>Lung BioTechnology PBC, Silver Spring, MD

**3:30 PM Kidney Xenotransplantation from Genetically Engineered Pigs to Baboons with FDA-Approved Immunosuppressive Therapy (Abstract #272)**

T. Yamamoto<sup>1</sup>, H. Hara<sup>1</sup>, J. Foote<sup>1</sup>, E. C. Klein<sup>2</sup>, H. J. Schuurman<sup>3</sup>, L. Wang<sup>1</sup>, Q. Li<sup>1</sup>, H. Zhou<sup>1</sup>, J. Li<sup>1</sup>, J. A. Tector<sup>1</sup>, Z. Zhang<sup>2</sup>, M. Ezzelarab<sup>2</sup>, R. Lovingood<sup>1</sup>, D. Ayares<sup>4</sup>, D. E. Eckhoff<sup>1</sup>, D. K. Cooper<sup>1</sup>, H. Iwase<sup>1</sup>, <sup>1</sup>University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>University of Pittsburgh, Pittsburgh, PA, <sup>3</sup>Schubiomed Consultancy, Utrecht, Netherlands, <sup>4</sup>Revivicor, Blacksburg, VA

**3:42 PM Utilizing Ides To Eliminate Residual Antibodies Targeting Xenografts (Abstract #273)**

C. Rickert, K. Lee, N. Tanimine, J. Lei, A. Cuenca, N. Feeney, K. Deng, H. Yeh, J. F. Markmann, *Massachusetts General Hospital, Boston, MA*

## Ischemia Reperfusion & Organ Rehabilitation II

**Room: 313**

*Chairs: H. Rabb, Johns Hopkins Univ Sch Med, Baltimore, MD*

**2:30 PM CEACAM1 - p38 Signaling Axis Alleviates Peri-Transplant Liver Injury: From Mouse-to-Human (Abstract #274)**

H. Hirao<sup>1</sup>, K. Nakamura<sup>1</sup>, S. Kageyama<sup>1</sup>, T. Ito<sup>1</sup>, K. Kadono<sup>1</sup>, M. Kujawski<sup>2</sup>, K. J. Dery<sup>1</sup>, R. A. Sosa<sup>1</sup>, E. F. Reed<sup>1</sup>, F. M. Kaldas<sup>1</sup>, R. W. Busuttil<sup>1</sup>, J. W. Kupiec-Weglinski<sup>1</sup>, <sup>1</sup>UCLA, Los Angeles, CA, <sup>2</sup>City of Hope, Duarte, CA

**2:42 PM Histone Deacetylase-2 Knockout in Renal Tubular Cells is Protective in Renal Ischemia-Reperfusion Injury (Abstract #275)**

P. T. Hernandez<sup>1</sup>, S. J. Concors<sup>1</sup>, L. Krumeich<sup>1</sup>, D. D. Aufhauser<sup>1</sup>, Z. Wang<sup>1</sup>, D. D. Murken<sup>1</sup>, G. Ge<sup>1</sup>, W. Hancock<sup>2</sup>, M. Levine<sup>3</sup>, <sup>1</sup>General Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Pathology, Children's Hospital of Philadelphia, Philadelphia, PA, <sup>3</sup>Transplant Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA

**2:54 PM Glycogen Synthase Kinase 3alpha Serine 21 Phosphorylation Inhibits Hepatocyte Autophagy to Facilitate Liver Ischemia Reperfusion Injury (Abstract #276)**

M. Ni<sup>1</sup>, H. Zhou<sup>2</sup>, R. Busuttil<sup>1</sup>, J. Kupiec-Weglinski<sup>1</sup>, X. Wang<sup>2</sup>, Y. Zhai<sup>1</sup>, <sup>1</sup>Surgery, Dumont-UCLA Transplant Center, Los Angeles, CA, <sup>2</sup>Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

**3:06 PM An Immediate and Persistent Post-Reperfusion Metabolic Collapse Precedes Delayed Graft Function (DGF) (Abstract #277)**

J. Lindeman, *Surgery, Leiden University Medical Center, Leiden, Netherlands*

**3:18 PM Defatting Steatotic Rat Livers during Ex Situ Normothermic Perfusion Improves Lactate Clearance and Bile Quality (Abstract #279)**

S. Raigani<sup>1</sup>, C. Carroll<sup>2</sup>, S. Cronin<sup>2</sup>, C. Pendexter<sup>2</sup>, I. Rosales<sup>3</sup>, M. Yarmush<sup>1</sup>, K. Uygun<sup>1</sup>, H. Yeh<sup>1</sup>, <sup>1</sup>Transplant Surgery, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Center for Engineering in Medicine, Shriners Childrens Hospital, Boston, MA, <sup>3</sup>Pathology, Massachusetts General Hospital, Boston, MA

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

**3:30 PM Apoptosis during Cold Ischemia and Rewarming Involves a Caspase Independent Pathway (Abstract #280)**  
S. Jain<sup>1</sup>, R. Plenter<sup>2</sup>, T. Nydam<sup>2</sup>, A. Jani<sup>1</sup>,  
<sup>1</sup>Renal Division, University of Colorado, Aurora, CO, <sup>2</sup>Transplant Microsurgery Program, University of Colorado, Aurora, CO

**3:42 PM Recipient Antibiotics Pretreatment Protects Liver Transplants from Ischemia-Reperfusion Injury via Prostaglandin E2: From Bench-to Bedside (Abstract #278)**  
K. Nakamura, S. Kageyama, T. Ito, H. Hirao, K. Kadono, K. J. Dery, J. Aziz, B. Ke, F. M. Kaldas, R. W. Busuttill, J. W. Kupiec-Weglinski, *Surgery, Dumont-UCLA Transplant Center, UCLA, Los Angeles, CA*

## Quality Assurance Process Improvement & Regulatory Issues I

### Room: 210

Chairs: J. Schold, Cleveland Clinic Foundation, Cleveland, OH and B. Kasiske, Hennepin County Medical Center, Minneapolis, MN

**2:30 PM Is Kidney Transplantation Actually a Cost-Effective Alternative Also for Older Patients? (Abstract #281)**  
K. Heldal<sup>1</sup>, K. Lønning<sup>2</sup>, V. Tsarpali<sup>1</sup>, K. Midtvedt<sup>2</sup>, <sup>1</sup>Clinic of Internal Medicine, Telemark Hospital Trust, Skien, Norway, <sup>2</sup>Oslo University Hospital, Oslo, Norway

**2:42 PM Diminishing Scientific Registry of Transplant Recipients Risk-Adjusted Mortality: Reaction to Flagging, Artifact of Modeling, or Both? (Abstract #282)**  
J. A. Gregg<sup>1</sup>, K. L. Womer<sup>1</sup>, A. Santos<sup>1</sup>, S. J. Moore<sup>2</sup>, K. A. Andreoni<sup>3</sup>, <sup>1</sup>Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, FL, <sup>2</sup>Shands Transplant Center, University of Florida, UF Health Shands, Gainesville, FL, <sup>3</sup>Department of Surgery, University of Florida, Gainesville, FL

**2:54 PM The Collaborative Improvement and Innovation Network (COIIN): Impact on Deceased Donor Transplant Rates and Offer Acceptance Practices (Abstract #283)**  
A. Wey<sup>1</sup>, S. Gustafson<sup>1</sup>, B. Carrico<sup>2</sup>, J. Foutz<sup>2</sup>, K. Sisaithong<sup>3</sup>, M. McBride<sup>2</sup>, D. Klassen<sup>2</sup>, D. Klassen<sup>2</sup>, N. Salkowski<sup>1</sup>, B. Kasiske<sup>1</sup>, A. Israni<sup>1</sup>, J. Snyder<sup>1</sup>, <sup>1</sup>SRTR, Minneapolis, MN, <sup>2</sup>OPTN, Richmond, VA, <sup>3</sup>OPTN, Minneapolis, MN

**3:06 PM OPO Aggressiveness Index: A Novel OPO Performance Metric That Incentivizes Pursuit of Marginal Deceased Donor Candidates (Abstract #284)**  
L. Liyanage, Y. Yu, K. Jackson, J. Garonzik-Wang, D. Segev, A. Massie, Johns Hopkins, Baltimore, MD

**3:18 PM Association of Pretransplant and Posttransplant 5-Tier Ratings with Candidate Mortality after Listing (Abstract #285)**  
A. Wey, S. Gustafson, N. Salkowski, B. Kasiske, M. Skeans, C. Schaffhausen, A. Israni, J. Snyder, SRTR, Minneapolis, MN

**3:30 PM Increased Access to Transplantation for Medicaid Patients Following Medicaid Expansion (Abstract #286)**  
A. Massie, M. Henderson, T. Hwee, D. Segev, Johns Hopkins, Baltimore, MD

**3:42 PM Simulated Tier Variability (Abstract #287)**  
N. Salkowski, A. Wey, J. Snyder, SRTR, Minneapolis, MN

Monday, June 3



# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

## Surgical Issues: All Organs

**Room: 208**

*Chairs: S. Alexopoulos, Surgery, Vanderbilt University Medical Center, Nashville, TN and P. Kim, Baylor University Medical Center, Vancouver, BC, Canada*

- 2:30 PM External Validation of the DCD-N Score and a Linear Prediction Model to Identify Potential Candidates for Donation after Circulatory Death: A Nation-Wide Cohort Study (Abstract #288)**  
*M. F. Nijhoff<sup>1</sup>, R. A. Pol<sup>1</sup>, M. Volbeda<sup>1</sup>, A. M. Kotsopoulos<sup>2</sup>, J. P. Sonneveld<sup>3</sup>, J. van Dongen<sup>4</sup>, W. F. Abdo<sup>5</sup>, V. Silderhuis<sup>6</sup>, C. Moers<sup>1</sup>, <sup>1</sup>Surgery – Organ Donation and Transplantation, University Medical Center Groningen, Groningen, Netherlands, <sup>2</sup>Department of Intensive Care Unit (ICU), Elisabeth Twee Steden Hospital, Tilburg, Netherlands, <sup>3</sup>Department of ICU, Isala, Zwolle, Netherlands, <sup>4</sup>Department of ICU, Catharina hospital, Eindhoven, Netherlands, <sup>5</sup>Department of ICU, Radboud University Medical Center, Nijmegen, Netherlands, <sup>6</sup>Department of ICU, Medisch Spectrum Twente, Enschede, Netherlands*
- 2:42 PM Comparison of Minimal Incision Kidney Transplantation with Conventional Incision Kidney Transplantation: Interim Report of a Randomized Controlled Trial (Abstract #289)**  
*T. Lin, T. Song, Y. Jiang, Y. Fan, X. Wang, Z. Huang, J. Liu, Z. Wang, Organ Transplantation Center, Urology Department, Urology Research Institute, WestChina Hospital, Sichuan University, Chengdu, China*

- 2:54 PM Surgeon Readiness For Entry Into Practice: A Survey Of Abdominal Transplant Surgeons In The United States (Abstract #290)**  
*M. Abouljoud<sup>1</sup>, R. Hirose<sup>2</sup>, S. Nagai<sup>1</sup>, C. Gordon<sup>3</sup>, D. Farmer<sup>4</sup>, <sup>1</sup>Henry Ford Transplant Institute, Detroit, MI, <sup>2</sup>Transplant Surgery, University of California San Francisco, San Francisco, CA, <sup>3</sup>American Society of Transplant Surgeons, Arlington, VA, <sup>4</sup>Transplant Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA*
- 3:06 PM National Trends in Bariatric Surgical Practice for Patients with End-Stage Renal Disease (Abstract #291)**  
*K. H. Sheetz<sup>1</sup>, K. J. Woodside<sup>1</sup>, V. B. Shahinian<sup>2</sup>, J. B. Dimick<sup>1</sup>, S. A. Waits<sup>1</sup>, <sup>1</sup>Department of Surgery, University of Michigan Hospitals and Health System, Ann Arbor, MI, <sup>2</sup>Department of Internal Medicine, University of Michigan Hospitals and Health System, Ann Arbor, MI*
- 3:18 PM TDCA/Valine Reverse Obesity and Ameliorate Alloimmune Responses through a Decreased Hypothalamic Expression of MCH (Abstract #292)**  
*A. ElKhal<sup>1</sup>, M. Markus Quante<sup>1</sup>, T. Heinbokel<sup>1</sup>, Y. Nian<sup>1</sup>, K. Minami<sup>1</sup>, R. Maenosono<sup>1</sup>, J. Iske<sup>1</sup>, B. Desai<sup>2</sup>, A. Banks<sup>2</sup>, E. Maratos-Flier<sup>2</sup>, A. ElKhal<sup>1</sup>, S. G. Tullius<sup>1</sup>, <sup>1</sup>Brigham and Women's Hospital, Boston, AL, <sup>2</sup>Beth Israel Deaconess Medical Center, Boston, AL*
- 3:30 PM Post-operative Opioid Requirements In Living Kidney And Liver Donors (Abstract #293)**  
*H. J. Braun, D. Adelman, T. Grace, M. E. Pulcrano, C. U. Niemann, N. L. Ascher, University of California, San Francisco, San Francisco, CA*

**AMERICAN TRANSPLANT CONGRESS**  
Program, Monday, June 3, 2019

---

**3:42 PM Effectiveness Of Percutaneous Embolization As Treatment Compared To Nephrectomy For Renal Graft Intolerance Syndrome In Late Graft Failure Patients (Abstract #294)**  
S. Kwon, J. Go, S. Park, S. Yoon, J. Kim, I. Moon, *Department of Vascular and Transplant Surgery, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of*

**Donor and Recipient Selection in Heart Transplantation**

**Room: 206**

*Chairs: P. Shah, Inova Heart and Vascular Institute, Falls Church, VA and S. Hall, Baylor Univ Medical Center, Dallas, TX*

**2:30 PM A Comprehensive and Updated Analysis of Combined Heart-Kidney Transplants Utilizing the United Network for Organ Sharing Database (Abstract #295)**  
V. M. Lim<sup>1</sup>, N. Khurmi<sup>1</sup>, W. R. Hewitt, Jr.<sup>2</sup>, A. K. Mathur<sup>2</sup>, O. E. Pajaro<sup>3</sup>, D. E. Jaroszewski<sup>3</sup>, B. D. Gaitan<sup>1</sup>,  
<sup>1</sup>Anesthesiology, Mayo Clinic Arizona, Phoenix, AZ, <sup>2</sup>Transplantation Surgery, Mayo Clinic Arizona, Phoenix, AZ, <sup>3</sup>Cardiovascular and Thoracic Surgery, Mayo Clinic Arizona, Phoenix, AZ

**2:42 PM What Are You Smoking? The Impact of Donor Drug Use on Long Term Survival Post-Transplant (Abstract #296)**  
D. A. Baran<sup>1</sup>, A. Long<sup>1</sup>, J. T. Lansinger<sup>2</sup>, H. Copeland<sup>3</sup>, J. M. Herre<sup>1</sup>, W. Old<sup>1</sup>, G. Zeevi<sup>1</sup>, C. Barreiro<sup>1</sup>, C. Kemp<sup>1</sup>, B. H. Smith<sup>1</sup>, K. Stelling<sup>1</sup>, A. Ingemi<sup>1</sup>, P. Bourassa<sup>1</sup>, J. Philpott<sup>1</sup>, <sup>1</sup>Sentara Heart Hospital, Norfolk, VA, <sup>2</sup>Eastern Virginia Medical School, Norfolk, VA, <sup>3</sup>Division of Cardiothoracic Surgery, University of Mississippi Medical Center, Jackson, MS

**2:54 PM Donors and Drugs: How Often Do They Mix? Utilization of Donors Based on Toxicology Findings (Abstract #297)**  
J. T. Lansinger<sup>1</sup>, A. Long<sup>1</sup>, C. Barreiro<sup>2</sup>, J. M. Herre<sup>2</sup>, H. Copeland<sup>3</sup>, W. Old<sup>2</sup>, G. Zeevi<sup>2</sup>, C. D. Kemp<sup>2</sup>, J. M. Philpott<sup>2</sup>, K. Stelling<sup>2</sup>, A. Ingemi<sup>2</sup>, B. H. Smith<sup>2</sup>, P. Bourassa<sup>2</sup>, D. A. Baran<sup>2</sup>, <sup>1</sup>Eastern Virginia Medical School, Norfolk, VA, <sup>2</sup>Sentara Heart Hospital, Norfolk, VA, <sup>3</sup>Division of Cardiothoracic Surgery, University of Mississippi Medical Center, Jackson, MS

**3:06 PM Preliminary Results from a Multicenter National Trial of Antiviral-Facilitated Transplantation of Hepatitis C Hearts to Expand the Donor Pool (Abstract #298)**  
K. Martits-Chalangari, A. K. Doss, M. Clark, J. Felius, S. A. Hall, R. L. Gottlieb, *Baylor University Medical Center, Dallas, TX*

**3:18 PM How Do We Choose? Predicting Utilization Of Cardiac Donors And The Effect Of Era (Abstract #299)**  
D. A. Baran<sup>1</sup>, J. T. Lansinger<sup>2</sup>, A. Long<sup>2</sup>, J. Philpott<sup>3</sup>, H. Copeland<sup>4</sup>, W. Old<sup>3</sup>, G. Zeevi<sup>3</sup>, C. Barreiro<sup>3</sup>, C. Kemp<sup>3</sup>, B. H. Smith<sup>3</sup>, K. Stelling<sup>3</sup>, A. Ingemi<sup>3</sup>, P. Bourassa<sup>3</sup>, J. M. Herre<sup>3</sup>, <sup>1</sup>Sentara Heart Hospital, Virginia Beach, VA, <sup>2</sup>Eastern Virginia Medical School, Norfolk, VA, <sup>3</sup>Sentara Heart Hospital, Norfolk, VA, <sup>4</sup>University of Mississippi Medical Center, Jackson, MS

**3:30 PM Geographic Disparities in Heart Transplant Rates (Abstract #300)**  
M. Kosztowski, S. Yu, A. Kilic, A. Massie, S. Zhou, D. Segev, S. Gentry, *JHU, Baltimore, MD*

**3:42 PM The National Landscape of Heart Transplant Candidates with HIV (Abstract #301)**  
A. A. Shaffer<sup>1</sup>, A. G. Thomas<sup>2</sup>, D. L. Segev<sup>1</sup>, <sup>1</sup>Surgery & Epidemiology, Johns Hopkins University, Baltimore, MD, <sup>2</sup>Epidemiology, University of North Carolina, Chapel Hill, NC

Monday, June 3

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

## Basic & Clinical Science - VCA

**Room: 209**

*Chairs: D. Granger, St John Hospital & Med Ctr, Detroit, MI and V. Gorantla, Surgery, Wake Forest Institute for Regenerative Medicine, Winston Salem, NC*

**2:30 PM Facial Composite Tissue Allotransplantation: First Canadian Experience (Abstract #302)**

*S. Collette<sup>1</sup>, A. Govshievich<sup>2</sup>, S. F. Dufresne<sup>1</sup>, D. Désy<sup>1</sup>, H. St-Jacques<sup>1</sup>, D. Borsuk<sup>1</sup>, <sup>1</sup>Hopital Maisonneuve-Rosemont, Montreal, QC, Canada, <sup>2</sup>University of Montreal, Montreal, QC, Canada*

**2:42 PM Adipose Stem Cells Promote Composite Tissue Engraftment (Abstract #303)**

*N. Shockcor<sup>1</sup>, B. Buckingham<sup>1</sup>, W. Hassanein<sup>1</sup>, D. Parsell<sup>1</sup>, U. Dhru<sup>1</sup>, B. Akinsiku<sup>2</sup>, E. Elster<sup>2</sup>, T. Davis<sup>2</sup>, J. Gimble<sup>3</sup>, A. Nam<sup>1</sup>, S. Bartlett<sup>1</sup>, R. Barth<sup>1</sup>, <sup>1</sup>Surgery, University of Maryland, Baltimore, MD, <sup>2</sup>Uniformed Services University of the Health Sciences, Bethesda, MD, <sup>3</sup>LaCell LLC, New Orleans, LA*

**2:54 PM Renal Failure as a Complication of Vascularized Composite Allotransplantation (Abstract #304)**

*R. N. Barth<sup>1</sup>, J. T. Shores<sup>2</sup>, G. Brandacher<sup>2</sup>, M. H. Levine<sup>3</sup>, A. Weissenbacher<sup>4</sup>, A. J. Nam<sup>1</sup>, N. Shockcor<sup>1</sup>, E. D. Rodriguez<sup>5</sup>, S. Schneeberger<sup>4</sup>, W. Lee<sup>2</sup>, S. T. Bartlett<sup>1</sup>, L. Levin<sup>3</sup>, <sup>1</sup>University of Maryland School of Medicine, Baltimore, MD, <sup>2</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>3</sup>University of Pennsylvania School of Medicine, Philadelphia, PA, <sup>4</sup>Medical University Innsbruck, Innsbruck, Austria, <sup>5</sup>New York University School of Medicine, New York, NY*

**3:06 PM Expansion of Regulatory T and B Cells in Swine Rendered Tolerant of Allogeneic Vascularized Composite Allografts via Mixed Chimerism (Abstract #305)**

*G. Saviane<sup>1</sup>, A. Lellouch<sup>1</sup>, A. Andrews<sup>1</sup>, L. Lantieri<sup>2</sup>, M. Randolph<sup>1</sup>, G. Benichou<sup>1</sup>, C. Cetrulo Jr<sup>1</sup>, <sup>1</sup>Center for Transplantation Sciences, Division of Plastic Surgery, Boston, MA, USA, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, <sup>2</sup>European Georges Pompidou Hospital, University of Paris, Department of Plastic Surgery, Paris, France*

**3:18 PM Uterus Transplantation: A Single Center's Experience of Peri and Postoperative Complications (Abstract #306)**

*L. Johannesson, G. Testa, Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX*

**3:30 PM Patterns of Rejection in Murine, Porcine, and Human Vascularized Composite Allografts Based on Clinical, Histologic, and Immunohistochemical Analysis (Abstract #307)**

*M. J. Grzelak, J. W. Etra, F. A. Chang, G. J. Furtmüller, A. R. Ahmadi, F. Nägele, Y. Guo, K. Kambarashvili, A. Jain, S. A. Beck, C. F. Brayton, I. B. Sander, W. A. Lee, G. Brandacher, Plastic and Reconstructive Surgery, Johns Hopkins School of Medicine, Baltimore, MD*

**3:42 PM The Evolving Clinical Presentation of Acute Rejection in Face Transplantation (Abstract #308)**

*V. Haug, B. Kollar, D. Obed, H. Kiwanuka, M. Turk, L. Wo, S. Tasigiorgos, M. Kueckelhaus, L. Riella, B. Pomahac, Plastic and Reconstructive Surgery, Brigham and Women's Hospital, Boston, MA*

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

## Featured Multidisciplinary Transplant Professionals Symposium

2:30 pm – 5:45 pm

### Expansion of the Multidisciplinary Team: From Waitlist to Transplant

#### Room 312

Moderators: Nicole McCormick, DNP, MBA, University of Colorado, Denver, CO, USA. Jim Thielke, PharmD, HHIO, Chicago, IL, USA.

- 2:30 pm Optimizing Vaccinations Pre-Transplant**  
*Kristine Schonder, PharmD, University of Pittsburgh, Pittsburgh, PA, USA.*
- 2:50 pm Audience Discussion**
- 2:55 pm Waitlist Management: The Role of the Advanced Practice Provider**  
*Kimberly L. Hoffman, DNP, ACNP-BC, University of Cincinnati, Cincinnati, OH, USA.*
- 3:15 pm Audience Discussion**
- 3:20 pm Beyond the Basics: Expanding the APP Role on Inpatient Services**  
*Katherine Klingenberg, PA-C, University of Colorado School of Medicine, Aurora, CO, USA.*
- 3:40 pm Audience Discussion**
- 3:45 pm The Evolution of the APP in Transplant**  
*Ashley Seawright, D.N.P., The University of Mississippi Medical Center, Jackson, MS, USA.*
- 4:05 pm Audience Discussion**
- 4:10 pm Coffee Break**
- 4:30 pm 7 on, 7 off: Creative Transplant Pharmacist Coverage Solutions**  
*Timothy Horwedel, PharmD, BCPS, Barnes-Jewish Hospital, St. Louis, MO, USA.*
- 4:50 pm Audience Discussion**
- 4:55 pm Banker's Hours No More: Weekend and Holiday Transplant Pharmacist Solutions**  
*Jennifer Geyston, PharmD, BCPS, University of Virginia Health System, Charlottesville, VA, USA.*

5:15 pm Audience Discussion

**5:20 pm It Takes a Village: Multidisciplinary Transitions of Care Strategies**  
*Nicole Alvey, PharmD, Rush University Medical Center, Chicago, IL, USA.*

5:40 pm Audience Discussion

## Coffee Break in Exhibit Hall

4:00 pm – 4:30 pm

Hall C/D

## Concurrent Oral Abstract Sessions

4:30 pm – 6:00 pm

### Kidney Immunosuppression: Novel Regimens and Drug Minimization II

#### Veterans Auditorium

Chairs: J. Helderma, Vanderbilt Univ Medical Ctr, Nashville, TN and F. Shihab, University of Utah Sch of Med, Salt Lake City, UT

**4:30 PM A Prospective Randomized Multicenter Trial (BEST Trial) of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression: Final Two Year Results (Abstract #309)**

*D. B. Kaufman<sup>1</sup>, A. R. Shields<sup>2</sup>, J. P. Leone<sup>3</sup>, A. Wiseman<sup>4</sup>, A. J. Matas<sup>5</sup>, P. West-Thielke<sup>6</sup>, J. Lipscomb<sup>2</sup>, E. King<sup>2</sup>, R. R. Alloway<sup>7</sup>, E. S. Woodle for the BEST Study Group<sup>2</sup>, <sup>1</sup>University of Wisconsin, Madison, WI, <sup>2</sup>University of Cincinnati, Cincinnati, OH, <sup>3</sup>Tampa General, Tampa, FL, <sup>4</sup>University of Colorado School of Medicine, Denver, CO, <sup>5</sup>University of Minnesota, Minneapolis, MN, <sup>6</sup>University of Illinois, Chicago, Chicago, IL, <sup>7</sup>University of Cincinnati, Cincinnati, WI*

Monday, June 3



# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

**4:42 PM Conversion from Calcineurin Inhibitors to Belatacept in Kidney Recipients with Donor-Specific Anti-HLA Antibodies and Calcineurin Inhibitor Nephrotoxicity Decreases the Pathogenicity of Donor-Specific Anti-HLA Antibodies (Abstract #310)**  
K. Louis<sup>1</sup>, D. Viglietti<sup>1</sup>, D. Pievani<sup>1</sup>, O. Aubert<sup>1</sup>, D. Glotz<sup>1</sup>, C. Legendre<sup>1</sup>, A. Zeevi<sup>2</sup>, A. Loupy<sup>1</sup>, C. Lefaucheur<sup>1</sup>, <sup>1</sup>Paris Translational Research Center for Organ Transplantation, Paris, France, <sup>2</sup>University of Pittsburgh Medical Center, Pittsburgh, PA

**Abstract Presenter Unable to Attend – Predictors of Graft Function Improvement after Conversion from Calcineurin Inhibitors to Belatacept in Kidney Recipients with Calcineurin Inhibitor Nephrotoxicity (Abstract #311)**

D. Viglietti, D. Pievani, K. Louis, D. Glotz, C. Legendre, A. Loupy, C. Lefaucheur, Paris Translational Research Center for Organ Transplantation, Paris, France

**4:54 PM Belatacept Monotherapy in Kidney Transplant Recipients with Failed Allografts Reduces Humoral Sensitization in a Single Center Randomized Controlled Trial (Abstract #312)**  
I. R. Badell, R. Elbein, R. A. Bray, H. M. Gebel, A. B. Adams, C. P. Larsen, Emory University School of Medicine, Atlanta, GA

**5:06 PM Four-Year Follow Up of Kidney Transplantation Using Alemtuzumab Induction and Belatacept/Sirolimus Maintenance Therapy (Abstract #313)**  
A. Kirk<sup>1</sup>, H. Xu<sup>1</sup>, A. Ghali<sup>2</sup>, A. Mehta<sup>2</sup>, A. Guasch<sup>2</sup>, <sup>1</sup>Surgery, Duke University, Durham, NC, <sup>2</sup>Transplant Center, Emory University, Atlanta, GA

**5:18 PM Comparative Analysis of Belatacept and Mycophenolate Monotherapy-Based Regimens for HLA Identical Living Donor Kidney Transplantation (Abstract #314)**  
M. Yamada, K. Meganathan, A. Shields, P. Brailey, S. Tremblay, A. Govil, R. R. Alloway, S. Shah, E. S. Woodle, B. G. Abu Jawdeh, Univ. of Cincinnati, Cincinnati, OH

**5:30 PM Impact of Belatacept Conversion on Renal Function, Histology and Gene Expression in Kidney Transplant Patients with Interstitial Fibrosis and Tubular Atrophy (Abstract #315)**  
G. Gupta<sup>1</sup>, D. Kumar<sup>1</sup>, M. Raynaud<sup>2</sup>, A. Loupy<sup>2</sup>, J. Chang<sup>3</sup>, J. Reeve<sup>3</sup>, P. Sanghi<sup>1</sup>, I. Yakubu<sup>1</sup>, L. Kamal<sup>1</sup>, M. Levy<sup>1</sup>, C. Bhati<sup>1</sup>, P. Kimball<sup>1</sup>, A. King<sup>1</sup>, H. Massey<sup>1</sup>, P. Halloran<sup>3</sup>, <sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Paris Transplant Group, Paris, France, <sup>3</sup>Alberta Transplant Genomics Applied Centre, Edmonton, AB, Canada

## Kidney Chronic Antibody Mediated Rejection

### Ballroom B

Chairs: C. Schinstock, Mayo Clinic, Rochester, MN and J. Locke, University of Alabama at Birmingham, Birmingham, AL

**4:30 PM Clazakizumab as an Agent to Reduce Donor Specific HLA Antibodies and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation (Abstract #316)**  
S. C. Jordan<sup>1</sup>, N. Ammerman<sup>1</sup>, M. Toyoda<sup>2</sup>, E. Huang<sup>1</sup>, C. C. Nast<sup>3</sup>, A. Peng<sup>1</sup>, S. Sethi<sup>1</sup>, R. Najjar<sup>1</sup>, I. Kim<sup>1</sup>, K. Lim<sup>1</sup>, J. Choi<sup>1</sup>, A. Vo<sup>1</sup>, <sup>1</sup>Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA, <sup>2</sup>Transplant Immunology Lab, Cedars-Sinai Medical Ctr, Los Angeles, CA, <sup>3</sup>Department of Pathology, Cedars-Sinai Medical Ctr, Los Angeles, CA



# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

**4:42 PM Clazakizumab (CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for Chronic Antibody-Mediated Rejection (cABMR) (Abstract #317)**  
B. Shin, S. Ge, A. Petrosyan, N. F. Ammerman, A. A. Vo, S. C. Jordan, M. Toyoda, Cedars-Sinai Medical Center, Los Angeles, CA

**4:54 PM Using Ensembles of Machine Learning Classifiers to Maximize the Accuracy and Stability of Molecular Biopsy Interpretation (Abstract #318)**  
J. Reeve<sup>1</sup>, K. S. Madill-Thomsen<sup>2</sup>, P. F. Halloran<sup>3</sup>, and the INTERCOMEX Study Group<sup>3</sup>, <sup>1</sup>University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton AB, AB, Canada, <sup>3</sup>University of Alberta, Edmonton AB, AB, Canada

**5:06 PM Impact of Belatacept Conversion on Renal Function, Histology and Gene Expression in Kidney Transplant Patients with Chronic Active Antibody-Mediated Rejection (Abstract #320)**  
D. Kumar<sup>1</sup>, M. Raynaud<sup>2</sup>, P. Halloran<sup>3</sup>, A. Loupy<sup>2</sup>, J. Chang<sup>3</sup>, J. Reeve<sup>3</sup>, I. Yakubu<sup>1</sup>, S. Bobba<sup>1</sup>, L. Kamal<sup>1</sup>, M. Levy<sup>1</sup>, C. Bhati<sup>1</sup>, P. Kimball<sup>1</sup>, A. King<sup>1</sup>, G. Gupta<sup>1</sup>, <sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Paris Transplant Group, Paris, France, <sup>3</sup>Alberta Transplant Genomics Applied Centre, Edmonton, AB, Canada

**5:18 PM Comparing Antibody-Mediated Rejection with or without Detectable DSA: Similar Pathology and Similar Poor Prognosis (Abstract #321)**  
G. Einecke<sup>1</sup>, J. Reeve<sup>2</sup>, P. F. Halloran<sup>3</sup>, <sup>1</sup>Dpt. of Nephrology, Hannover Medical School, Hannover, Germany, <sup>2</sup>Dpt. of Laboratory Medicine and Pathology and Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada, <sup>3</sup>Dpt. of Nephrology and Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada

**5:30 PM Long Term Outcomes Using Tocilizumab For The Treatment Of Chronic Antibody Mediated Rejection (Abstract #322)**  
J. Choi<sup>1</sup>, E. Huang<sup>1</sup>, O. Aubert<sup>2</sup>, A. Vo<sup>1</sup>, A. Peng<sup>1</sup>, R. Najjar<sup>1</sup>, S. Sethi<sup>1</sup>, N. Ammerman<sup>1</sup>, K. Lim<sup>1</sup>, D. Puliya<sup>1</sup>, A. Loupy<sup>2</sup>, S. Jordan<sup>1</sup>, <sup>1</sup>Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, <sup>2</sup>Paris Translational Center for Organ Transplantation, Paris, France

**Abstract Presenter Unable to Attend – Allograft Gene Expression Assessment Predicts Graft Loss in Kidney Recipients with Chronic Antibody-Mediated Rejection (Abstract #319)**  
D. Viglietti<sup>1</sup>, B. Adam<sup>2</sup>, Z. Kikic<sup>3</sup>, D. Cejka<sup>4</sup>, D. Pievani<sup>1</sup>, O. Aubert<sup>1</sup>, D. Glotz<sup>1</sup>, C. Legendre<sup>1</sup>, A. Loupy<sup>1</sup>, C. Lefaucheur<sup>1</sup>, M. Mengel<sup>2</sup>, <sup>1</sup>Paris Translational Research Center for Organ Transplantation, Paris, France, <sup>2</sup>University of Alberta, Edmonton, AB, Canada, <sup>3</sup>Universitätsklinik für Innere Medizin III, Vienna, Austria, <sup>4</sup>Hospital Elisabethinen, Linz, Austria

Monday, June 3

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

## Kidney: Cardiovascular and Metabolic II

### Ballroom C

Chairs: S. M. Riad, University of Minnesota, Eden Prairie, MN and D. Keys, Roseville, MN

**4:30 PM 6-Minute Walk Testing in Patients on the Kidney Transplant Waitlist (Abstract #323)**

X. S. Cheng<sup>1</sup>, J. Lee<sup>2</sup>, K. V. Discipulo<sup>1</sup>, J. Myers<sup>3</sup>, J. C. Tan<sup>1</sup>, <sup>1</sup>Nephrology, Stanford University, Palo Alto, CA, <sup>2</sup>Kidney Transplant, Stanford Hospital, Palo Alto, CA, <sup>3</sup>Cardiology, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA

**4:42 PM The More You Wait, the More You Lose: Prostatectomy and Kidney Transplant Waiting Time in End Stage Renal Disease (Abstract #324)**

N. Sarabu<sup>1</sup>, N. Schiltz<sup>2</sup>, K. D. Chavin<sup>1</sup>, D. E. Hricik<sup>1</sup>, <sup>1</sup>University Hospitals of Cleveland, Cleveland, OH, <sup>2</sup>Case Western Reserve University, Cleveland, OH

**4:54 PM Comparison of Pregnancy Outcomes by Conception Age in Female Kidney Transplant Recipients (Abstract #325)**

S. Rao<sup>1</sup>, L. A. Coscia<sup>2</sup>, D. Kliniewski<sup>2</sup>, S. Constantinescu<sup>3</sup>, M. J. Moritz<sup>4</sup>, <sup>1</sup>Medicine, University of Virginia Health System, Charlottesville, VA, <sup>2</sup>Gift of Life Institute, Transplant Pregnancy Registry International, Philadelphia, PA, <sup>3</sup>Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, <sup>4</sup>Surgery, Lehigh Valley Health Network, Allentown, PA

**5:06 PM Cardiovascular Mortality in Transplant Patients; A Population-Based Cohort Study 1988-2013 in Australia and New Zealand (Abstract #326)**

M. Wyld<sup>1</sup>, N. De La Mata<sup>2</sup>, P. Masson<sup>3</sup>, E. O'Lone<sup>2</sup>, A. Webster<sup>2</sup>, <sup>1</sup>Renal Department, Royal Prince Alfred Hospital, Camperdown, Australia, <sup>2</sup>School of Public Health, University of Sydney, Sydney, Australia, <sup>3</sup>Renal Department, Royal Free London NHS Foundation Trust, London, United Kingdom

**5:18 PM Extremes of Body Mass Index is Associated with Inferior Renal Allograft Outcomes in Type 2 Diabetic Deceased Donor Renal Transplant Recipients (Abstract #327)**

A. Brar, A. Gruessner, F. Tedla, R. Gruessner, J. Renz, N. Sumrani, D. John, M. O. Salifu, SUNY Downstate Medical Center, Brooklyn, NY

**5:30 PM Lower Extremity Impairment and Frailty among Adults with Diabetes Awaiting Kidney Transplantation (Abstract #328)**

E. Lorenz, A. Kukla, C. Kennedy, R. McCoy, L. Hickson, Mayo Clinic, Rochester, MN

**5:42 PM AKI and Long-Term Risk for Cardiovascular Events in Patients after Kidney Transplantation (Abstract #329)**

R. Rahamimov<sup>1</sup>, M. Molcho<sup>2</sup>, I. Vahav<sup>2</sup>, E. Mor<sup>3</sup>, T. Y. van Dijk<sup>4</sup>, B. Rozen-Zvi<sup>1</sup>, <sup>1</sup>Department of Nephrology, Rabin Medical Center, Petach Tikva, Israel, <sup>2</sup>Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, <sup>3</sup>Department of Transplantation, Rabin Medical Center, Petach Tikva, Israel, <sup>4</sup>Department of Emergency Medicine, Rabin Medical Center, Petach Tikva, Israel

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

## Breakthroughs in Cytomegalovirus

### Ballroom A

Chairs: A. Humar, Toronto General Hospital, Toronto, ON, Canada and M. Morris, Miami Beach, FL

- 4:30 PM A CMV Vaccine Based on Non-Replicating Lymphocytic Choriomeningitis Virus Vectors Expressing gB and pp65 is Safe and Immunogenic in Healthy Volunteers and Entering a Phase 2 Trial in Kidney Transplant Recipients (Abstract #330)**  
C. N. Kotton<sup>1</sup>, M. Schwendinger<sup>2</sup>, G. Thiry<sup>3</sup>, B. De Vos<sup>4</sup>, F. De Boever<sup>5</sup>, G. Leroux-Roels<sup>6</sup>, A. Lilja<sup>7</sup>, <sup>1</sup>Infectious Diseases Division, Boston, MA, <sup>2</sup>Hookipa Biotech AG, Vienna, Austria, <sup>3</sup>Hookipa Biotech GmbH, Vienna, Austria, <sup>4</sup>Bejamad sprl/bvba, Beersel, Belgium, <sup>5</sup>Centrum voor vaccinologie (CEVAC), Gdent, Belgium, <sup>6</sup>Centrum voor vaccinologie (CEVAC), Gent, Belgium, <sup>7</sup>Hookipa Biotech GmbH, Vienna, Austria
- 4:42 PM Donor Graft CMV Serostatus Influences the Development of Arterial and Venous Vascular Events in Seronegative Recipients after Organ Transplantation (Abstract #331)**  
S. Belga, C. MacDonald, D. Chiang, D. Kabbani, S. Shojai, J. G. Abraldes, C. Cervera, University of Alberta, Edmonton, AB, Canada
- 4:54 PM More Advanced Heart Failure Prior To Transplant May Influence The Cytomegalovirus Specific T Cell Response In Cytomegalovirus Positive Recipients. (Abstract #332)**  
U. López Cardoza, E. García, C. Díez, J. Roca, N. Sabé, N. Manito, I. Tatjer, A. Cequier, O. Bestard, J. González, Bellvitge University Hospital, L' Hospitalet de Llobregat, Spain

- 5:06 PM Letermovir For The Treatment And Secondary Prophylaxis Of Drug Resistant CMV In Solid Organ Transplant Recipients (Abstract #333)**  
M. R. Pereira<sup>1</sup>, J. G. Aaron<sup>1</sup>, C. J. Kubin<sup>2</sup>, <sup>1</sup>Medicine - Infectious Diseases, Columbia University Medical Center, New York, NY, <sup>2</sup>Medicine - Infectious Diseases, NewYork Presbyterian Hospital, New York, NY
- 5:18 PM Risk Stratification of Cytomegalovirus Seropositive Kidney Transplant Recipients for CMV Infection (Abstract #334)**  
M. M. Azar<sup>1</sup>, A. Baghban<sup>1</sup>, K. Belfield<sup>1</sup>, R. Assi<sup>2</sup>, M. Malinis<sup>1</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>University of Pennsylvania, Philadelphia, PA
- 5:30 PM Using a Commercially Available Assay That Measures Cytomegalovirus-Specific CD4+ and CD8+ T-cell Immunity to Predict Clinically Significant Cytomegalovirus Events in Solid Organ Transplant Recipients (Abstract #335)**  
R. Rogers<sup>1</sup>, K. Saharia<sup>2</sup>, A. Chandorkar<sup>2</sup>, Z. Weiss<sup>3</sup>, D. Farmakiotis<sup>1</sup>, <sup>1</sup>Infectious Diseases, Brown University, Providence, RI, <sup>2</sup>Infectious Diseases, University of Maryland, Baltimore, MD, <sup>3</sup>Internal Medicine, Brown University, Providence, RI
- 5:42 PM Preemptive Therapy is Cost Effective When Compared to Prophylaxis in Cytomegalovirus Donor Positive - Recipient Negative Liver Transplant Recipients (Abstract #336)**  
M. M. Wagener<sup>1</sup>, D. J. Winston<sup>2</sup>, R. R. Razonable<sup>3</sup>, G. M. Lyon III<sup>4</sup>, F. P. Silveira<sup>5</sup>, A. P. Limaye<sup>6</sup>, N. Singh<sup>1</sup>, <sup>1</sup>ID, U Pittsburgh and VAPHS, Pittsburgh, PA, <sup>2</sup>ID, UCLA, Los Angeles, CA, <sup>3</sup>ID, Mayo Clinic, Rochester, MN, <sup>4</sup>ID, Emory, Atlanta, GA, <sup>5</sup>ID, U Pittsburgh, Pittsburgh, PA, <sup>6</sup>ID, U Washington, Seattle, WA

Monday, June 3

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

## Liver: MELD, Allocation and Donor Issues (DCD/ECD) II

**Room: 302**

*Chairs: C. Quintini, Cleveland Clinic, Cleveland, OH and J. Magliocca, Emory University, Atlanta, GA*

- 4:30 PM Not for the Faint of Heart: The Impact of Post-Reperfusion Syndrome during Liver Transplantation Using Livers with Significant Macrosteatosis (Abstract #337)**  
K. P. Croome, D. Lee, S. Croome, R. Chadha, D. Livingston, P. Abader, A. P. Keaveny, C. Taner, *Mayo Clinic, Jacksonville, FL*
- 4:42 PM Reduction in Waitlist Time Using HCV Positive Liver Grafts in HCV Negative Recipients (Abstract #338)**  
E. M. Bugeaud, N. Bzowej, J. Hand, J. Scheuermann, H. Bohorquez, C. Brown, D. Bruce, I. Carmody, A. Cohen, S. Joshi, N. Latt, J. Seal, D. Sonnier, G. Therapondos, G. Tyson, N. Girgrah, G. Loss, *Ochsner Health System, New Orleans, LA*
- 4:54 PM Digital Imaging Software vs. the “Eyeball” Method in Quantifying Steatosis in a Liver Biopsy (Abstract #339)**  
J. Long<sup>1</sup>, J. Motter<sup>1</sup>, S. Besharati<sup>1</sup>, S. Jerman<sup>2</sup>, R. Anders<sup>1</sup>, A. Ortiz<sup>2</sup>, D. Bowman<sup>2</sup>, T. Dunn<sup>3</sup>, D. Lee<sup>4</sup>, A. Massie<sup>1</sup>, R. Barth<sup>5</sup>, B. Philosophe<sup>1</sup>, <sup>1</sup>*Johns Hopkins, Baltimore, MD*, <sup>2</sup>*Indica Labs, Corrales, NM*, <sup>3</sup>*UPenn, Philadelphia, PA*, <sup>4</sup>*Mayo Clinic, Jacksonville, FL*, <sup>5</sup>*University of MD, Baltimore, MD*
- 5:06 PM A Comparison of the BAR, DRM, DRI, sRRI, ET-DRI, D-MELD and SOFT Score to Predict Outcome after Liver Transplantation in the SRTR Database (Abstract #340)**  
J. D. de Boer<sup>1</sup>, H. Putter<sup>2</sup>, J. J. Blok<sup>1</sup>, I. P. Alwayn<sup>1</sup>, B. Van Hoek<sup>3</sup>, A. E. Braat<sup>1</sup>, <sup>1</sup>*Transplant Center, Leiden University Medical Center, Leiden, Netherlands*, <sup>2</sup>*Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands*, <sup>3</sup>*Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, Netherlands*
- 5:18 PM Nothing Lasts Forever, So Of The Donor Risk Index For Liver Transplant (Abstract #341)**  
K. Okubo, K. Sasaki, A. Moro, J. McBey, M. Fujiki, T. Diago Uso, B. Eghtesad, D. Kwon, C. Miller, C. Quintini, K. Hashimoto, F. Aucejo, *Cleveland Clinic, Cleveland, OH*
- 5:30 PM Expanding the Donor Pool with Extended Criteria DCD Livers (Abstract #342)**  
P. Mihaylov<sup>1</sup>, B. Ekser<sup>2</sup>, R. Mangus<sup>2</sup>, J. Fridell<sup>2</sup>, D. Soma<sup>2</sup>, C. Kubal<sup>2</sup>, <sup>1</sup>*Indiana Univ School of Medicine, Pavia Univ School of Medicine, Indianapolis, IN*, <sup>2</sup>*Indiana Univ School of Medicine, Indianapolis, IN*

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

**5:42 PM HOPE in Action: A Multicenter Prospective Study of HIV to HIV Liver Transplantation (Abstract #343)**  
C. Durand<sup>1</sup>, S. Florman<sup>2</sup>, M. Bowring<sup>3</sup>, D. Brown<sup>1</sup>, B. Haydel<sup>2</sup>, J. Hamilton<sup>1</sup>, P. Stock<sup>4</sup>, J. Price<sup>5</sup>, T. Pruett<sup>6</sup>, V. Kirchner<sup>7</sup>, D. Wojciechowksi<sup>8</sup>, N. Turgeon<sup>9</sup>, C. Wolfe<sup>10</sup>, V. Stosor<sup>11</sup>, J. Charette<sup>11</sup>, A. Cameron<sup>3</sup>, S. Ottmann<sup>3</sup>, S. Huprikar<sup>12</sup>, D. Segev<sup>3</sup>, <sup>1</sup>Medicine, Johns Hopkins University, Baltimore, MD, <sup>2</sup>Surgery, Mount Sinai, New York, NY, <sup>3</sup>Surgery, Johns Hopkins University, Baltimore, MD, <sup>4</sup>Surgery, University of California San Francisco, San Francisco, CA, <sup>5</sup>Medicine, University of California San Francisco, San Francisco, CA, <sup>6</sup>Surgery, University of Minnesota, Minneapolis, MN, <sup>7</sup>Medicine, University of Minnesota, Minneapolis, MN, <sup>8</sup>Medicine, Mass General Hospital, Boston, MA, <sup>9</sup>Surgery, Emory University, Atlanta, GA, <sup>10</sup>Medicine, Duke University, Durham, NC, <sup>11</sup>Medicine, Northwestern University, Chicago, IL, <sup>12</sup>Medicine, Mount Sinai, New York, NY

## Kidney: Pediatrics II

**Room: 304**

Chairs: A. Moudgil, Children's National Med. Ctr., Washington, DC and B. Chavers, Division of Nephrology, Minneapolis, MN

**4:30 PM Increase in 48 Month Cumulative Acute Rejection Rates in the Most Recent Cohort: The 2018 Transplant Report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) (Abstract #344)**  
V. Dharnidharka<sup>1</sup>, C. Cramer<sup>2</sup>, A. Chua<sup>3</sup>, A. Moudgil<sup>4</sup>, K. Martz<sup>5</sup>, T. Blydt-Hansen<sup>6</sup>, J. Smith<sup>7</sup>, A. Neu, on Behalf of The NAPRTCS Investigators<sup>8</sup>, <sup>1</sup>Washington University in St. Louis, Saint Louis, MO, <sup>2</sup>Mayo Clinic, Rochester, MN, <sup>3</sup>Duke University, Durham, NC, <sup>4</sup>Children's National Medical Center, Washington, DC, <sup>5</sup>Emmes Corporation, Rockville, MD, <sup>6</sup>BC Children's Hospital, Vancouver, BC, <sup>7</sup>Seattle Children's Hospital, Seattle, WA, <sup>8</sup>Johns Hopkins University, Baltimore, MD

**4:42 PM Epstein Barr Virus (EBV)-Specific T Cells as a Diagnostic Marker for the Individual EBV-Specific Immune Response after Pediatric Kidney Transplantation (Abstract #345)**  
T. Ahlenstiel-Grunow, L. Pape, *Pediatric Nephrology, Hannover Medical School, Hannover, Germany*

**4:54 PM Standardizing Blood Pressure Measurement across 17 Pediatric Transplant Centers: The Improving Renal Outcomes Collaborative (Abstract #346)**  
M. E. Seifert<sup>1</sup>, R. Garro<sup>2</sup>, R. P. George<sup>2</sup>, G. Barletta<sup>3</sup>, C. W. Belsha<sup>4</sup>, A. Chaudhuri<sup>5</sup>, J. W. Goebel<sup>6</sup>, L. Wickman<sup>7</sup>, D. Matossian<sup>8</sup>, J. Misurac<sup>9</sup>, C. Nailescu<sup>10</sup>, C. R. Nguyen<sup>11</sup>, M. Pearl<sup>12</sup>, A. Pollack<sup>13</sup>, C. S. Pruetter<sup>14</sup>, P. Singer<sup>15</sup>, P. S. Verghese<sup>16</sup>, B. A. Warady<sup>17</sup>, D. S. Dahale<sup>18</sup>, D. K. Hooper<sup>18</sup>, <sup>1</sup>University of Alabama, Birmingham, AL, <sup>2</sup>Emory University, Atlanta, GA, <sup>3</sup>Phoenix Children's Hospital, Phoenix, AZ, <sup>4</sup>Saint Louis University, St. Louis, MO, <sup>5</sup>Stanford University, Stanford, CA, <sup>6</sup>Children's Hospital Colorado, Aurora, CO, <sup>7</sup>Michigan Medicine, Ann Arbor, MI, <sup>8</sup>Lurie Children's Hospital, Chicago, IL, <sup>9</sup>University of Iowa, Iowa City, IA, <sup>10</sup>Riley Hospital For Children, Indianapolis, IN, <sup>11</sup>Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, <sup>12</sup>UCLA Mattel Children's Hospital, Los Angeles, CA, <sup>13</sup>Seattle Children's Hospital, Seattle, WA, <sup>14</sup>Johns Hopkins University, Baltimore, MD, <sup>15</sup>Cohen Children's Medical Center, New Hyde Park, NY, <sup>16</sup>University of Minnesota, Minneapolis, MN, <sup>17</sup>Children's Mercy Kansas City, Kansas City, MO, <sup>18</sup>Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Monday, June 3



# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

**5:06 PM Elevated Donor Derived Cell Free DNA (dd-cfDNA) Levels in the Presence of Donor Specific Antibodies (DSA) Are a Strong Predictor of Antibody Mediated Rejection (ABMR) in Pediatric Renal Transplant Recipients (Abstract #347)**  
D. Puliyananda<sup>1</sup>, R. D. Swinford<sup>2</sup>, H. Pizzo<sup>1</sup>, J. Garrison<sup>1</sup>, I. Kim<sup>1</sup>, A. M. De Golovine<sup>2</sup>, S. Jordan<sup>1</sup>, <sup>1</sup>*Pediatric Nephrology, Cedars-Sinai Med Ctr, Los Angeles, CA*, <sup>2</sup>*Pediatric Nephrology, UTHealth, Houston, TX*

**5:18 PM Tocilizumab for Refractory Antibody-Mediated Rejection in Pediatric Kidney Transplantation (Abstract #348)**  
A. Dokras, C. Butler, Q. Zhang, E. Reed, R. Ettenger, P. Weng, M. Pearl, *University of California, Los Angeles, Los Angeles, CA*

**5:30 PM Antithymocyte Globulin is Associated with Mature T Cell Phenotypes and Decreased Risk of Non-EBV Infections in Transplanted Children (Abstract #349)**  
B. I. Shaw<sup>1</sup>, L. Stempora<sup>1</sup>, C. Chan<sup>1</sup>, R. B. Ettenger<sup>2</sup>, P. C. Grimm<sup>3</sup>, H. Lee<sup>1</sup>, E. F. Reed<sup>2</sup>, M. M. Sarwal<sup>4</sup>, B. L. Warshaw<sup>5</sup>, C. Zhao<sup>1</sup>, O. M. Martinez<sup>3</sup>, A. D. Kirk<sup>1</sup>, E. T. Chambers<sup>1</sup>, <sup>1</sup>*Pediatrics/Surgery, Duke University, Durham, NC*, <sup>2</sup>*Pediatrics, University of California, Los Angeles, Los Angeles, CA*, <sup>3</sup>*Pediatrics/Surgery, Stanford University, Palo Alto, CA*, <sup>4</sup>*Pediatrics/Surgery, University of California, San Francisco, San Francisco, CA*, <sup>5</sup>*Pediatrics, Emory University, Atlanta, GA*

**5:42 PM Successful Use of Hizentra to Address BK Viremia in Pediatric Transplant Population (Abstract #350)**  
K. Gruenkemeyer, E. Wood, A. Beck, C. Belsha, *Pediatric Nephrology, Saint Louis University, Saint Louis, MO*

## Non-Organ Specific: Public Policy & Allocation

**Room: 311**

*Chairs: R. Lynch, Decatur, GA and K. Andreoni; University of Florida, Gainesville, FL*

**4:30 PM Capitalizing On Donor Density To Increase Organ Pool - An Analysis Of Urban And Rural Organ Donors (Abstract #351)**  
S. Bakhtiyar, S. Ahmed, J. A. Goss, A. Rana, *Baylor College of Medicine, Houston, TX*

**4:42 PM Association between Medicaid Expansion under the Affordable Care Act and Preemptive Kidney Transplantation of Low-Income Medicaid Beneficiaries (Abstract #352)**  
M. N. Harhay<sup>1</sup>, R. McKenna<sup>2</sup>, <sup>1</sup>*Medicine, Drexel University College of Medicine, Philadelphia, PA*, <sup>2</sup>*Health Management and Policy, Drexel University Dornsife School of Public Health, Philadelphia, PA*

**4:54 PM Creating Geographic Catchment Areas for Solid Organ Transplant Centers (Abstract #353)**  
K. Ross<sup>1</sup>, R. Patzer<sup>2</sup>, D. Axelrod<sup>3</sup>, <sup>1</sup>*Emory University, Emory Transplant Center, Georgetown, TX*, <sup>2</sup>*Emory University, Emory Transplant Center, Georgetown, GA*, <sup>3</sup>*Dept of Surgery, University of Iowa, Iowa City, IA*

**5:06 PM Changes in the Fate of KDPI < 35% Kidneys before and after Implementation of the New Kidney Allocation System (Abstract #354)**  
K. Eng, E. Grodstein, L. Castellanos Reyes, L. Teperman, C. Sethna, P. Singer, *Northwell Health, Manhasset, NY*

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

**5:18 PM Wide Geographic Variability in the Proportion of Donors with Cardiac Death - Lost Opportunities for Organ Donation? (Abstract #356)**  
E. M. Sonnenberg<sup>1</sup>, D. S. Goldberg<sup>2</sup>, J. Y. Hsu<sup>3</sup>, P. P. Reese<sup>2</sup>, P. L. Abt<sup>1</sup>, <sup>1</sup>Department of Surgery, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Department of Medicine, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA

**5:30 PM A 15-year Experience With Kidney Transplant In Undocumented Immigrants: Outcomes And An Argument For Transplantation (Abstract #357)**  
M. G. Janeway<sup>1</sup>, A. Foster<sup>2</sup>, S. De Geus<sup>1</sup>, K. Curreri<sup>1</sup>, T. Dechert<sup>1</sup>, M. Nuhn<sup>1</sup>, M. Nuhn<sup>1</sup>, <sup>1</sup>Surgery, Boston Medical Center, Boston, MA, <sup>2</sup>Boston University School of Medicine, Boston, MA

**5:42 PM Geographic Trends in Drug Intoxicated Deceased Donor Recovery and Utilization (Abstract #355)**  
R. Urban, D. Klassen, J. Rosendale, United Network for Organ Sharing, Richmond, VA

## Biomarkers, Immune Monitoring and Outcomes III

### Room: 306

Chairs: N. Goes, Swedish Medical Center, Seattle, WA and D. Levine, San Antonio, TX

**4:30 PM High Numbers of Differentiated CD8+CD28- T Cells Are Associated with a Substantially Lowered Risk for Late Rejection and Graft Loss after Kidney Transplantation (Abstract #358)**  
M. G. Betjes, A. Langerak, M. Klepper, N. Litjens, Nephrology & Transplantation, Erasmus MC, Rotterdam, Netherlands

**4:42 PM Biomarker Candidate Discovery for Kidney Allograft Monitoring via Urinary Exosome Proteome Analysis (Abstract #359)**  
J. Kim<sup>1</sup>, Y. Wee<sup>1</sup>, M. Choi<sup>1</sup>, H. Jung<sup>1</sup>, J. Choi<sup>1</sup>, H. Kwon<sup>1</sup>, J. Jung<sup>1</sup>, Y. Ko<sup>1</sup>, D. Kim<sup>1</sup>, K. Kim<sup>2</sup>, Y. Cho<sup>3</sup>, H. Go<sup>3</sup>, Y. Kim<sup>1</sup>, D. Han<sup>1</sup>, S. Shin<sup>1</sup>, <sup>1</sup>Department of Surgery, Asan Medical Center, Seoul, Korea, Republic of, <sup>2</sup>Department of Convergence Medicine, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea, Republic of, <sup>3</sup>Department of Pathology, Asan Medical Center, Seoul, Korea, Republic of

**4:54 PM microRNA-375 Provides an Objective Measure of Pancreas Quality in Organ Donors (Abstract #360)**  
I. Shapey<sup>1</sup>, A. Summers<sup>1</sup>, J. O'Sullivan<sup>1</sup>, P. Yiannoullou<sup>1</sup>, J. Casey<sup>2</sup>, S. Forbes<sup>2</sup>, M. Rosenthal<sup>3</sup>, P. Johnson<sup>4</sup>, P. Choudhary<sup>1</sup>, J. Bushnell<sup>5</sup>, J. Shaw<sup>6</sup>, N. Hanley<sup>1</sup>, T. Augustine<sup>1</sup>, M. Rutter<sup>1</sup>, D. van Dellen<sup>1</sup>, <sup>1</sup>University of Manchester, Manchester, United Kingdom, <sup>2</sup>University of Edinburgh, Edinburgh, United Kingdom, <sup>3</sup>Royal Free Hospital, London, United Kingdom, <sup>4</sup>University of Oxford, Oxford, United Kingdom, <sup>5</sup>Southmead Hospital, Bristol, United Kingdom, <sup>6</sup>University of Newcastle, Newcastle, United Kingdom

**5:06 PM A Metagene Signature of Lymphocytic Bronchitis Following Lung Transplantation (Abstract #361)**  
J. R. Greenland<sup>1</sup>, P. Wang<sup>2</sup>, J. J. Brotman<sup>2</sup>, R. Ahuja<sup>1</sup>, T. A. Chong<sup>2</sup>, M. Kleinhenz<sup>2</sup>, L. E. Leard<sup>2</sup>, J. A. Golden<sup>2</sup>, S. R. Hays<sup>2</sup>, J. P. Singer<sup>2</sup>, J. Kukreja<sup>3</sup>, N. Y. Greenland<sup>4</sup>, Z. Lasik<sup>4</sup>, P. Blanc<sup>1</sup>, <sup>1</sup>Medicine, VA Health Care System, San Francisco, CA, <sup>2</sup>Medicine, University of California, San Francisco, CA, <sup>3</sup>Surgery, University of California, San Francisco, CA, <sup>4</sup>Pathology, University of California, San Francisco, CA

Monday, June 3

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

**5:18 PM** **Advanced Immunological T-cell Ageing Defined by a Very Low Thymic Function Identifies Patients with a Substantial Increased Risk for Long-Term Mortality after Kidney Transplantation (Abstract #362)**  
*M. G. Betjes, A. Langerak, M. Klepper, N. Litjens, Nephrology & Transplantation, Erasmus MC, Rotterdam, Netherlands*

**5:30 PM** **Characterizing the Dominant Phenotype in Kidney Transplant Biopsies: Improving the Prediction of Risk by a Global View of Rejection, Injury, and Atrophy-Fibrosis (Abstract #363)**  
*P. F. Halloran and The INTERCOMEX Investigators<sup>1</sup>, J. Reeve<sup>2</sup>, <sup>1</sup>University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada*

**5:42 PM** **Gut Dysbiosis Predominates Post-Transplant Diarrhea in Kidney Transplant Recipients: A Validation Study (Abstract #364)**  
*L. Zhang, J. Lee, M. Magruder, E. Edusei, D. Dadhania, M. Lubetzky, S. Albakry, B. Botticelli, E. Pamer, M. Suthanthiran, Weill Cornell Medicine, New York, NY*

## Islet and Cell Transplantation

**Room: 309**

*Chairs: J. Markmann, Massachusetts General Hospital, Boston, MA and M. Koulmanda, Beth Israel Deaconess Medical Center, Boston, MA*

**4:30 PM** **The Protective Effects of siRNA Conjugated Nanoparticles in Pancreatic Islet Cells after Transplant (Abstract #365)**  
*T. Pomposelli, P. Wang, Y. Ariyoshi, K. Takeuchi, C. Schuetz, A. Moore, K. Yamada, Columbia Center for Translational Immunology, Columbia University, New York, NY*

**4:42 PM** **Islet Xenotransplantation: A Quest for Clinically Available Immunosuppression Regimens (Abstract #366)**  
*Z. W. Fitch<sup>1</sup>, Q. Gao<sup>1</sup>, R. P. Davis<sup>1</sup>, M. S. Mulvihill<sup>1</sup>, M. Song<sup>1</sup>, F. Leopardi<sup>1</sup>, M. Ribeiro<sup>1</sup>, T. How<sup>1</sup>, K. Reimann<sup>2</sup>, G. R. Devi<sup>1</sup>, B. H. Collins<sup>1</sup>, A. D. Kirk<sup>1</sup>, <sup>1</sup>Surgery, Duke University, Durham, NC, <sup>2</sup>University of Massachusetts, Worcester, MA*

**4:54 PM** **Preservation of Pancreatic Islets with Stem Cell Derived CD34+ Vascular Endothelial Progenitor Cells (Abstract #367)**  
*C. Ward<sup>1</sup>, L. Vo<sup>2</sup>, E. De Klerk<sup>2</sup>, G. Faleo<sup>2</sup>, Y. Kelly<sup>1</sup>, J. Bluestone<sup>2</sup>, M. Hebrok<sup>2</sup>, P. Stock<sup>1</sup>, Q. Tang<sup>1</sup>, <sup>1</sup>Surgery, UCSF, San Francisco, CA, <sup>2</sup>Diabetes Center, UCSF, San Francisco, CA*

**5:06 PM** **Resolution of Hyperglycemia Following Islet Allograft Transplantation in Non-Immunosuppressed Mice (Abstract #368)**  
*J. Ge<sup>1</sup>, K. Lee<sup>1</sup>, C. Yang<sup>1</sup>, R. White<sup>2</sup>, I. Rosales<sup>2</sup>, P. Russell<sup>1</sup>, C. Rickert<sup>1</sup>, J. Markmann<sup>1</sup>, J. Madsen<sup>1</sup>, R. Colvin<sup>2</sup>, A. Alessandrini<sup>1</sup>, <sup>1</sup>Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Pathology, Massachusetts General Hospital, Boston, MA*

**5:18 PM** **Toll Like Receptor 2 Mobilizes Regulatory T Cell Lymphatic Migration by Stimulating Lymphotoxin Expression (Abstract #369)**  
*W. Piao<sup>1</sup>, Y. Xiong<sup>2</sup>, L. Li<sup>3</sup>, V. Saxena<sup>3</sup>, C. Paluskievicz<sup>3</sup>, J. Bromberg<sup>4</sup>, <sup>1</sup>Microbiology and Immunology, U. Maryland, Baltimore, baltimore, MD, <sup>2</sup>Surgery, U. Maryland, Baltimore, baltimore, MD, <sup>3</sup>Surgery, U. Maryland, Baltimore, Baltimore, MD, <sup>4</sup>Surgery and Microbiology and Immunology, U. Maryland, Baltimore, Baltimore, MD*

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

**5:30 PM Allogenic Islets Cure Diabetes Following Transplantation in Omental Pouch in a Non-Human Primate Model (Abstract #370)**

J. Lei<sup>1</sup>, H. Deng<sup>1</sup>, K. Lee<sup>1</sup>, C. Peters<sup>1</sup>, G. Rickert<sup>1</sup>, R. Ivy<sup>1</sup>, M. Coronel<sup>2</sup>, E. Yolcu<sup>3</sup>, H. Shirwan<sup>4</sup>, A. García<sup>5</sup>, J. Markmann<sup>1</sup>, <sup>1</sup>*Surgery, Massachusetts General Hospital, Boston, MA*, <sup>2</sup>*Surgery, Georgia Institute of Technology, Atlanta, GA*, <sup>3</sup>*Institute for Cellular Therapeutics, University of Louisville School of Medicine, Louisville, KY*, <sup>4</sup>*Department of Microbiology and Immunology, University of Louisville School of Medicine, Louisville, KY*, <sup>5</sup>*School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA*

**5:42 PM Role of NF-κB in Release of Isletokines via Exosomes in Response to Islet Stress (Abstract #371)**

P. Saravanan<sup>1</sup>, M. Kanak<sup>1</sup>, J. Kalivarathan<sup>1</sup>, M. Lawrence<sup>2</sup>, M. Levy<sup>1</sup>, B. Naziruddin<sup>3</sup>, <sup>1</sup>*Department of Surgery, Virginia Commonwealth University, VCU Health, Richmond, VA*, <sup>2</sup>*Islet Cell Lab, Baylor Scott and White Research Institute, Dallas, TX*, <sup>3</sup>*Simmons Transplant Institute, Baylor Scott and White Medical Center, Dallas, TX*

## Tolerance / Immune Deviation

**Room: 310**

*Chairs: U. Beier, Children's Hospital of Philadelphia, Philadelphia, PA and R. Fairchild, Cleveland Clinic Foundation, Cleveland, OH*

**4:30 PM B Cell IL-4 Signaling Induces the IL-10 Secreting TIM-1+ Bregs and Suppresses T Cell Inflammatory Cytokines (Abstract #372)**

Z. Song, K. Mohib, D. M. Rothstein, *Surgery, Starzl Transplantation Institute, Pittsburgh, PA*

**4:42 PM High Fibre Diet Prevents Transplant-Associated Dysbiosis and Prevents Kidney Allograft Rejection (Abstract #373)**

J. J. Singer<sup>1</sup>, H. Wu<sup>1</sup>, T. Kwan<sup>1</sup>, Y. Loh<sup>1</sup>, C. Wang<sup>1</sup>, J. Tan<sup>2</sup>, L. Macia<sup>2</sup>, S. Alexander<sup>3</sup>, S. Chadban<sup>1</sup>, <sup>1</sup>*Kidney Node Laboratory, Charles Perkins Centre, The University of Sydney, Sydney, Australia*, <sup>2</sup>*Nutritional Immunometabolism Lab, Charles Perkins Centre, The University of Sydney, Sydney, Australia*, <sup>3</sup>*The Children's Hospital Westmead, Sydney, Australia*

**4:54 PM Treg And Bone Marrow Infusion Promotes Survival Of Donor Kidney Grafted Months After Disappearance Of Mixed Chimerism (Abstract #374)**

K. Bruestle, P. Alonso-Guallart, E. Lopes, G. Pierre, N. Llore, H. Sakai, S. Kofman, D. Ekanayake-Alper, M. Sykes, A. Griesemer, *Columbia Center for Translational Immunology, Columbia University, New York City, NY*

**5:06 PM Murine Cmv Infection Impairs Transplantation Tolerance: A Critical Role Of Intra-graft Anergic Cd4 T Cells (Abstract #375)**

A. Dangi<sup>1</sup>, E. B. Thorp<sup>2</sup>, X. Luo<sup>1</sup>, <sup>1</sup>*Medicine, Duke University, Durham, NC*, <sup>2</sup>*Pathology, Northwestern University, Chicago, IL*

**5:18 PM Tolerance Induction by Myeloid Progenitor Cells Modulates T and B Cell Responses (Abstract #376)**

J. Domen, Y. Li, *Allergy, Asthma and Immunology, Children's Mercy Hospital, Kansas City, MO*

**5:30 PM Implication of Melanocortin Receptors in Alloimmunity (Abstract #377)**

M. Uehara, B. S. Al Dulaijan, J. Azzi, R. Abdi, *Transplantation Research Center, Renal, Brigham and Women's Hospital, Boston, MA*

Monday, June 3



# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

**5:42 PM A Kidney Transplant Recipient with Severe Acute GvHD Promptly Rescued by Donor HLA-Targeted Serotherapy (Abstract #378)**

J. Zuber<sup>1</sup>, O. Boyer<sup>1</sup>, B. Neven<sup>1</sup>, R. Berthaud<sup>1</sup>, M. Ould Rabah<sup>1</sup>, I. Jollet<sup>2</sup>, V. Renac<sup>2</sup>, F. Pirenne<sup>2</sup>, S. Gross<sup>2</sup>, R. Djoudi<sup>2</sup>, P. Tiberghien<sup>2</sup>, J. Taupin<sup>3</sup>, S. Blanche<sup>1</sup>, R. Salomon<sup>1</sup>, <sup>1</sup>Paris Descartes University, Paris, France, <sup>2</sup>Etablissement Français du Sang, Paris, France, <sup>3</sup>Department of Immunology and Histocompatibility, St Louis Hospital, Paris, France

## Donor Management: All Organs Excluding Kidney

### Room: 313

Chairs: S. Shah, University of Cincinnati, Cincinnati, OH and S. Pelletier, University of Virginia Health System, Charlottesville, VA

**4:30 PM Incidence of Autoresuscitation in Donation after Cardiac Death Donors (Abstract #379)**

C. W. Koo<sup>1</sup>, R. A. Helmick<sup>1</sup>, K. Van Frank<sup>2</sup>, K. Gilley<sup>2</sup>, J. D. Eason<sup>1</sup>, <sup>1</sup>UTHSC / Methodist University Hospital Transplant Institute, Memphis, TN, <sup>2</sup>Mid South Transplant Foundation, Memphis, TN

**4:42 PM Occult Liver Graft Fibrosis Prior to Transplantation Influences Clinical Outcomes (Abstract #380)**

H. Hira<sup>o</sup>, T. Ito, K. Kadono, S. Kageyama, K. Nakamura, K. J. Dery, B. Ke, F. M. Kaldas, R. W. Busuttil, J. W. Kupiec-Weglinski, *Surgery, Dumont-UCLA Transplant Center, UCLA, Los Angeles, CA*

**4:54 PM Risk Factors to Define an Extended Criteria Donor Heart Do Not Appear to Have Cumulative Adverse Effects after Heart Transplantation (Abstract #381)**

M. Olymbios, S. Dimbil, R. J. Levine, F. Esmailian, J. Patel, J. A. Kobashigawa, *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*

**5:06 PM Discard Patterns in Donors with Non Alcoholic Fatty Liver Disease (Abstract #382)**

M. MacConmara<sup>1</sup>, A. Mufti<sup>2</sup>, S. Hanish<sup>1</sup>, P. Vagefi<sup>1</sup>, S. Tujius<sup>2</sup>, C. Hwang<sup>1</sup>, <sup>1</sup>Surgery (Division of Surgical Transplantation), UT Southwestern Medical Center, Dallas, TX, <sup>2</sup>Medicine (Transplant Hepatology), UT Southwestern Medical Center, Dallas, TX

**5:18 PM Intra-abdominal Hypertension And Abdominal Compartment Syndrome: An Organ Procurement Organization'S Experience (Abstract #383)**

J. Stefek<sup>1</sup>, L. E. Markham<sup>1</sup>, M. Ott<sup>1</sup>, S. S. Johnson<sup>2</sup>, J. C. Olson<sup>3</sup>, H. Sangha<sup>4</sup>, D. G. Vasquez<sup>5</sup>, S. P. Whitt<sup>6</sup>, H. E. Wilkins<sup>1</sup>, P. A. Webster<sup>1</sup>, M. Iliakova<sup>7</sup>, M. Moncure<sup>7</sup>, <sup>1</sup>Midwest Transplant Network, Westwood, KS, <sup>2</sup>Via Christi St Francis, Wichita, KS, <sup>3</sup>University of Kansas Medical Center, Kansas City, KS, <sup>4</sup>Lake Regional Health System, Osage Beach, MO, <sup>5</sup>Wesley Medical Center, Wichita, KS, <sup>6</sup>University of Missouri Health Care, Columbia, MO, <sup>7</sup>University of Missouri - Kansas City, Kansas City, MO

**5:30 PM Organ Donation is an Indication for Renal Replacement Therapy (RRT) (Abstract #384)**

A. L. Friedman, E. Marquez, J. A. Lewis, *LiveOnNY, New York, NY*

**5:42 PM Organ Donation Survey among Health Care Professionals in Argentina (Abstract #385)**

V. R. Ruiz<sup>1</sup>, A. D. Midley<sup>1</sup>, P. E. Rodriguez<sup>2</sup>, S. Bauque<sup>2</sup>, V. Morozovsky<sup>1</sup>, A. G. Da Iozzo<sup>3</sup>, <sup>1</sup>Respiratory Care, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, <sup>2</sup>Organ Procurement, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, <sup>3</sup>Lung Trasplant Surgery, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina



# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

## Infections, Antibodies and Biomarkers in Lung Transplantation

**Room: 206**

Chairs: M. Sala, Northwestern University, Chicago, IL and D. Dilling, Loyola University Medical Center, Maywood, IL

- 4:30 PM Transplanting Thoracic Organs From Hcv Donors To Uninfected Patients: Evaluation Of Lung Allografts (Abstract #386)**  
Y. Lo<sup>1</sup>, R. F. Padera<sup>1</sup>, H. R. Mallidi<sup>2</sup>, H. J. Goldberg<sup>3</sup>, S. K. Singh<sup>2</sup>, A. Coppolino, III<sup>4</sup>, L. R. Baden<sup>5</sup>, A. E. Woolley<sup>5</sup>, <sup>1</sup>Pathology, Brigham and Womens Hospital, Boston, MA, <sup>2</sup>Cardiac and Thoracic Surgery, Brigham and Womens Hospital, Boston, MA, <sup>3</sup>Pulmonary, Brigham and Womens Hospital, Boston, MA, <sup>4</sup>Thoracic Surgery, Brigham and Womens Hospital, Boston, MA, <sup>5</sup>Infectious Diseases, Brigham and Womens Hospital, Boston, MA
- 4:42 PM Success in Lung Transplantation Outcomes after Receiving a Standardized Desensitization Therapy (Abstract #387)**  
S. Ganesh<sup>1</sup>, C. L. Prohaska<sup>2</sup>, C. Mares<sup>2</sup>, M. J. Everly<sup>3</sup>, <sup>1</sup>Medicine, Keck Medical Center at the University of Southern California, Los Angeles, CA, <sup>2</sup>BioMatrix, Weston, FL, <sup>3</sup>Terasaki Research Institute, Los Angeles, CA
- 4:54 PM Circulating Exosomes Isolated from Human Lung Transplant Recipients with Respiratory Viral Infections Contain Nucleic Acids Specific to Virus and Can Lead to Activation of Stress Proteins (Abstract #388)**  
S. Bansal, R. Bremner, M. Smith, T. Mohanakumar, Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ

- 5:06 PM Bronchoalveolar Lavage Biomarkers Predict Lung Transplant Survival (Abstract #389)**  
A. Zarinsefat<sup>1</sup>, J. Y. Yang<sup>2</sup>, R. Sarwal<sup>1</sup>, J. Liberto<sup>1</sup>, D. Watson<sup>3</sup>, S. Verleden<sup>4</sup>, M. Sarwal<sup>1</sup>, <sup>1</sup>UC San Francisco, San Francisco, CA, <sup>2</sup>Johns Hopkin, Baltimore, MD, <sup>3</sup>Kit Bio, Los Altos, CA, <sup>4</sup>KU Leuven, Leuven, Belgium
- 5:18 PM Not All Donor-Specific Antibodies Are Equal: Predictors of Risk of Chronic Lung Allograft Dysfunction (Abstract #390)**  
C. J. Iasella<sup>1</sup>, C. R. Ensor<sup>2</sup>, M. Marrari<sup>3</sup>, M. Mangiola<sup>3</sup>, C. A. Moore<sup>1</sup>, M. R. Morrell<sup>4</sup>, J. Pilewski<sup>4</sup>, J. F. McDyer<sup>4</sup>, A. Zeevi<sup>3</sup>, <sup>1</sup>Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Florida Hospital Transplant Institute, AdventHealth Orlando, Orlando, FL, <sup>3</sup>Pathology, University of Pittsburgh, Pittsburgh, PA, <sup>4</sup>Medicine, University of Pittsburgh, Pittsburgh, PA
- 5:30 PM Decline in Club Cell Secretory Protein Results in Immune Responses to Lung Self-Antigens (K $\alpha$ 1 Tubulin and Collagen V) and Development of Chronic Rejection Following Human Lung Transplantation (Abstract #391)**  
Y. Itabashi<sup>1</sup>, R. Ravichandran<sup>1</sup>, M. Sharma<sup>1</sup>, R. Hachem<sup>2</sup>, R. Bremner<sup>1</sup>, M. Smith<sup>1</sup>, T. Mohanakumar<sup>1</sup>, <sup>1</sup>Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, <sup>2</sup>Washington University School of Medicine, St. Louis, MO
- 5:42 PM Association between Respiratory Virus Infections and the Development of De Novo HLA Donor-Specific Antibodies in Lung Transplant Recipients (Abstract #392)**  
M. I. Ali, J. Hata, J. Mallea, M. Elrefaei, Mayo Clinic, Jacksonville, FL

Monday, June 3

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

## Non-Organ Specific: Pharmacogenomics / Pharmacokinetics

**Room: 210**

*Chairs: R. Alloway, Univ of Cincinnati Coll of Med, Cincinnati, OH and P. Jacobson, Univ of MN, College of Pharmacy, Minneapolis, MN*

**4:30 PM Not All Poor Metabolizers Are Clinically Equal: Evaluating Weight-Based Tacrolimus Outcomes in CYP3A Loss of Function Variants (Abstract #393)**

A. Q. Maldonado, W. Irish, T. E. Asempa, J. Gooden, M. L. Davis, C. Haisch, H. Jones, D. Leeser, L. Rebellato, *Vidant Medical Center - Transplant Services, Greenville, NC*

**4:42 PM Impact of Liver Recipient Genotype on Tacrolimus (Abstract #394)**

S. Tremblay<sup>1</sup>, T. Fukuda<sup>2</sup>, T. Mizuno<sup>2</sup>, A. A. Vinks<sup>2</sup>, E. Woodle<sup>1</sup>, J. Klawitter<sup>3</sup>, J. Klawitter<sup>3</sup>, U. Christians<sup>3</sup>, R. R. Alloway<sup>1</sup>, <sup>1</sup>*University of Cincinnati, Cincinnati, OH*, <sup>2</sup>*Cincinnati Children's Hospital and Medical Center, Cincinnati, OH*, <sup>3</sup>*C42 Clinical Research and Development, Aurora, CO*

**4:54 PM Tacrolimus Pharmacokinetics in Young, Middle Age and Older Renal Transplant Recipients- Impact of CYP3A5\*3\*6\*7 Metabolic Composite (Abstract #395)**

K. Tornatore<sup>1</sup>, K. Attwood<sup>2</sup>, D. Brazeau<sup>3</sup>, R. Venuto<sup>4</sup>, <sup>1</sup>*University at Buffalo; School of Pharmacy, Buffalo, NY*, <sup>2</sup>*Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY*, <sup>3</sup>*Marshall University; School of Medicine, Huntington, WV*, <sup>4</sup>*University at Buffalo; School of Medicine, Buffalo, NY*

**5:06 PM A Clinical Pharmacogenetic Model to Predict the Efficacy of Sirolimus during the Early Administration in Renal Transplant Recipients (Abstract #396)**

Z. Wang, S. Fei, Z. Han, J. Tao, R. Tan, M. Gu, *No.300 Guangzhou Road of Nanjing, Nanjing, China*

**5:18 PM Polymorphisms in Mycophenolate Mofetil Glucuronidation Gene Are Associated with Leukopenia and Decreased CLAD-Free Survival (Abstract #397)**

A. Barnes, D. R. Calabrese, E. Henricksen, R. Florez, K. Dewey, P. Wang, J. Teraoka, K. Lien, S. Hays, J. P. Singer, J. Golden, J. Kukreja, J. R. Greenland, *UCSF Medical Center, San Francisco, CA*

**5:30 PM Association of Tacrolimus-Level Variance with De Novo DSA within the First 2 Years after Renal Transplantation (Abstract #398)**

M. J. Everly<sup>1</sup>, I. Purnajo<sup>1</sup>, K. P. Briley<sup>2</sup>, J. L. Beaumont<sup>1</sup>, P. Bolin<sup>2</sup>, S. A. Kendrick<sup>3</sup>, H. Jones<sup>3</sup>, K. McLawhorn<sup>3</sup>, A. Q. Maldonado<sup>4</sup>, D. Leeser<sup>2</sup>, C. E. Haisch<sup>2</sup>, L. M. Rebellato<sup>2</sup>, <sup>1</sup>*Terasaki Research Institute, Los Angeles, CA*, <sup>2</sup>*East Carolina University, Greenville, NC*, <sup>3</sup>*Eastern Nephrology Associates, Greenville, NC*, <sup>4</sup>*Vidant Medical Center, Greenville, NC*

**5:42 PM Intravenous Immunoglobulin Significantly Reduces Bioavailability of Concomitantly Administered Anti-C5 Monoclonal Antibodies (Abstract #399)**

S. C. Jordan<sup>1</sup>, K. Kucher<sup>2</sup>, M. Bagger<sup>2</sup>, H. Hockey<sup>3</sup>, K. Wagner<sup>4</sup>, N. Ammerman<sup>1</sup>, J. Choi<sup>1</sup>, A. Vo<sup>1</sup>, <sup>1</sup>*Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA*, <sup>2</sup>*Novartis Institutes for BioMedical Research, Basel, Switzerland*, <sup>3</sup>*Biometrics Matters Ltd, Hamilton, New Zealand*, <sup>4</sup>*Novartis Institutes for BioMedical Research, Cambridge, MA*

## Pancreas and Islet: All Topics II

**Room: 209**

*Chairs: S. Yi, Houston Methodist Hospital, Houston, TX and M. Cooper*

**4:30 PM Preserved Heart Rate Variability and Endothelial Function One Year after Pancreas Transplantation (Abstract #400)**

E. Nordheim, T. Halden, K. Birkeland, A. Åsberg, T. Jenssen, *Department of Transplantation Medicine, Oslo University Hospital, OSLO, Norway*

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

**4:42 PM Policy Changes in Facilitated Pancreas Allocation Support Pancreas Utilization (Abstract #401)**

R. Urban<sup>1</sup>, J. S. Odorico<sup>2</sup>, S. V. Niederhaus<sup>3</sup>, R. Carrico<sup>1</sup>, A. Fox<sup>1</sup>,  
<sup>1</sup>United Network for Organ Sharing, Richmond, VA, <sup>2</sup>Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, <sup>3</sup>Department of Surgery, University of Maryland Medical Center, Baltimore, MD

**4:54 PM Pancreas Transplant Alone Using Donation After Cardiac Death Donors Has Similar Outcomes As Donation After Brain Death Donors (Abstract #402)**

K. Espinoza<sup>1</sup>, D. Wall<sup>1</sup>, K. L. Lentine<sup>2</sup>, J. R. Wellen<sup>1</sup>, D. Hammad<sup>1</sup>, D. C. Brennan<sup>3</sup>, T. Alhamad<sup>1</sup>, <sup>1</sup>Washington University in St. Louis, St. Louis, MO, <sup>2</sup>Saint Louis University, St. Louis, MO, <sup>3</sup>Johns Hopkins University, St. Louis, MO

**5:06 PM Pancreata From Donors With Renal Insufficiency: Viable For Transplant? (Abstract #403)**

X. Luo<sup>1</sup>, J. Garonzik Wang<sup>2</sup>, M. B. Doyle<sup>1</sup>, A. Khan<sup>1</sup>, T. Alhamad<sup>3</sup>, W. C. Chapman<sup>1</sup>, A. Massie<sup>2</sup>, D. Segev<sup>2</sup>, J. R. Wellen<sup>1</sup>,  
<sup>1</sup>Section of Abdominal Transplant Surgery, Washington University School of Medicine, St. Louis, MO, <sup>2</sup>Department of Surgery, Johns Hopkins University, Baltimore, MD, <sup>3</sup>Division of Nephrology, Washington University School of Medicine, St. Louis, MO

**5:18 PM Outcomes after Simultaneous Kidney Pancreas versus Pancreas after Kidney Transplantation (Abstract #404)**

S. Parajuli, A. Arunachalam, K. Swanson, F. Aziz, N. Garg, R. Redfield, D. Kaufman, A. Djamali, J. Odorico, D. Mandelbrot, University of Wisconsin, Madison, WI

**5:30 PM Simultaneous Pancreas and Kidney Transplant Outcomes after Induction Therapy with Thymoglobulin Compared with Alemtuzumab (Abstract #405)**

B. Masters<sup>1</sup>, F. Bartlett<sup>2</sup>, C. Drachenberg<sup>3</sup>, S. Bartlett<sup>3</sup>, R. Barth<sup>3</sup>, J. Scalea<sup>3</sup>, A. Haririan<sup>3</sup>, <sup>1</sup>University of Maryland Medical Center, Baltimore, MD, <sup>2</sup>Barnes-Jewish Hospital, St. Louis, MO, <sup>3</sup>University of Maryland, School of Medicine, Baltimore, MD

**5:42 PM Portal-endocrine And Gastric-exocrine Drainage Technique In Pancreatic Transplantation (Abstract #406)**

G. Zibari, B. Samant, R. McMillan, N. Singh, H. Shokouh-Amiri, Willis-Knighton Regional Transplant Center, Shreveport, LA

**Young Investigator Oral Communication Session**

---

**4:30 PM - 6:00 PM**

**Room: 208**

Moderators: Silvi Shah, MD, MS, University of Cincinnati, Cincinnati, OH, USA. Deepika Devuni, MD, University of Massachusetts Medical School and UMass Memorial Healthcare, Worcester, MA, USA.

**4:30 PM Validation Of The Optimized Prediction Of Mortality (Opom) Machine Learning Model For Non-hepatocellular Carcinoma Candidates Awaiting Liver Transplant (Abstract #C288)**

L. Lau<sup>1</sup>, X. Xie<sup>2</sup>, F. Jia<sup>2</sup>, P. D. Greig<sup>1</sup>, T. C. Chan<sup>2</sup>, <sup>1</sup>Multi-Organ Transplant, Department of Surgery, University of Toronto, Toronto, ON, Canada, <sup>2</sup>Mechanical and Industrial Engineering, University of Toronto, Toronto, ON, Canada

Monday, June 3

# AMERICAN TRANSPLANT CONGRESS

Program, Monday, June 3, 2019

---

**4:50 PM Recipient Myeloid Notch1 Disruption Shifts Neutrophil towards Anti-Inflammatory Phenotype and Protects Liver Grafts from Ischemia-Reperfusion Injury (Abstract #C23)**  
*S. Kageyama*<sup>1</sup>, H. Hirao<sup>1</sup>, K. Kadono<sup>1</sup>, K. Nakamura<sup>1</sup>, K. J. Dery<sup>1</sup>, T. Ito<sup>2</sup>, D. Oncel<sup>1</sup>, J. Aziz<sup>1</sup>, B. Ke<sup>1</sup>, F. M. Kaldas<sup>2</sup>, R. W. Busuttil<sup>2</sup>, J. W. Kupiec-Weglinski<sup>1</sup>,  
<sup>1</sup>Dumont-UCLA Transplant Center, UCLA, Los Angeles, CA, <sup>2</sup>Surgery, Ronald Reagan UCLA Medical Center, UCLA, Los Angeles, CA

**5:00 PM Blockade of C3aR1 Signaling Suppresses Alloreactive CD8<sup>+</sup> T Cell Immunity and Prolongs Murine Cardiac Allograft Survival (Abstract #C36)**  
*J. Horwitz*, D. Mathern, P. Heeger, *Icahn School of Medicine at Mount Sinai, NY, NY*

**5:10 PM De Novo Complement-Activating Donor Specific Antibodies in Pediatric Renal Transplant Recipients Are Highly Responsive to Therapy (Abstract #D100)**  
*V. Sigurjonsdottir*, A. Chaudhuri, P. Grimm, *Pediatric Nephrology, Stanford, Los Altos, CA*

**5:20 PM FK506 Influence Glucose Metabolism by Short Chain Fatty Acid (Abstract #C50)**  
*W. Jiao*<sup>1</sup>, Z. Zhang<sup>1</sup>, L. Liu<sup>2</sup>, X. Hu<sup>1</sup>,  
<sup>1</sup>Urology, Capital Medical University Beijing Chaoyang Hospital, Beijing, China, <sup>2</sup>GI Division, West China Hospital, Beijing, China

**5:30 PM Poor Outcomes in Kidney Transplant Candidates & Recipients with History of Falls (Abstract #B246)**  
*N. Chu*<sup>1</sup>, H. Ying<sup>1</sup>, Z. Shi<sup>1</sup>, C. Haugen<sup>1</sup>, S. Norman<sup>2</sup>, D. Segev<sup>1</sup>, M. McAdams-DeMarco<sup>1</sup>, <sup>1</sup>Johns Hopkins, Baltimore, MD, <sup>2</sup>Michigan Medical Center, Ann Arbor, MI

**5:40 PM Delayed Kidney Transplantation in Combined Liver Kidney Transplantation: A Validation Analysis by the UNOS Registry (Abstract #A278)**  
*L. Chau*, M. Safwan, M. Rizzari, K. Collins, A. Yoshida, M. Abouljoud, D. Moonka, S. Nagai, *Transplant Surgery, Henry Ford Hospital, Detroit, MI*

---

## AST Town Hall & Reception

**5:45 pm -8:00 pm**

*Hall A*

---

## Poster Session C – Presenters in Attendance

*Hall C/D*

**Poster Viewing: 6:00 pm - 7:00 pm**

**Presenters in Attendance: 6:00 pm - 7:00 pm**

**Poster Session C can be found on pages 229-266.**

# AMERICAN TRANSPLANT CONGRESS

## Day-at-a-Glance, Tuesday, June 4, 2019

---

**7:00 am – 8:15 am Sunrise Interactive**  
(Continental Breakfast Provided)

Page 103 **The Enemy of Good is Better: Marginal Cardiac Donors Avoid Waste and Maximize Lives Saved**  
Room 310

Page 103 **ApoL1 Genotyping in Living Kidney Donors**  
Ballroom A

Page 103 **New Insights into Fungal Infections in Thoracic, Liver, and Kidney Transplant Recipients**  
Ballroom B

Page 103 **Organ Vigilance Around the World: Different Strokes for Different Folks**  
Room 304

Page 104 **What Do I Do Now: Challenging Cases in Post Renal Transplant Care**  
Ballroom C

Page 104 **Pancreas Transplant Program Management in the Era of Declining Numbers**  
Room 311

Page 104 **Assessing and Testing Mental Health Disorders in Transplant Recipients**  
Room 306

Page 104 **Optimizing Pregnancy Success After Transplant**  
Room 208

Page 105 **Challenges of Transplanting and Managing Alcoholic Hepatitis**  
Room 312

Page 105 **Joint AST-IPTA Symposium: “It’s Friday Night of a Long Weekend and the Pediatric Transplant ID Specialist’s Beeper Goes Off...”**  
Room 210

Page 105 **Brainstorming on Liver Allocation in Vulnerable Populations: Women and Children First?**  
Room 309

**7:00 am – 8:15 am Sunrise Didactic**  
(Continental Breakfast Provided)

Page 106 **TCR/BCR Sequencing and Tracking**  
Room 302

**8:15 am – 8:30 am Break**

**8:30 am – 9:15 am Plenary III**

Page 106 *Veterans Auditorium*

**9:15 am – 9:45 am State-of-the-Art Speaker**

Page 106 **Paul I. Terasaki State-of-the-Art Speaker Using Human Pluripotent Stem Cells to Make Tissue for Transplantation**  
*Douglas Melton, PhD*  
*Harvard Department of Stem Cell and Regenerative Biology*  
*Cambridge, MA, USA*  
*Veterans Auditorium*

**10:00 am – 10:15 am Break**

**10:00 am – 10:45 am Controversies in Transplantation-Basic**

Page 107 **Gene Editing in Transplantation**  
Ballroom B

**10:00 am – 10:45 am Controversies in Transplantation-Clinical**

Page 107 **Controversies in Clinical Transplantation**  
*Veterans Auditorium*

Tuesday, June 4



**AMERICAN TRANSPLANT CONGRESS**  
**Day-at-a-Glance, Tuesday, June 4, 2019**

---

**10:45 am – 11:15 am Coffee Break in Exhibit Hall**

*Hall C/D*

*Page 110*

**Hacking Organs During Preservation: Organ Repair and Regeneration Ex Vivo**  
*Room 309*

**11:15 am – 12:45 pm Midday Interactive**

*Page 108*

**Report of the UNOS Transplant System Performance Improvement Summit Workgroup**  
*Room 206*

*Page 110*

**An Ounce of Prevention Is Worth a Pound of Cure: Vaccination After Solid Organ Transplantation**  
*Ballroom B*

*Page 108*

**Simultaneous Liver and Kidney Transplant (SLKT): Two Years of the Policy Change**  
*Ballroom C*

*Page 110*

**Defining the Risks of VCA**  
*Room 209*

*Page 108*

**Are Protocol Biopsies Important in the Long Term Management of the Pediatric Liver Transplant Recipient?**  
*Room 208*

*Page 111*

**Technical Issues in Liver Transplantation**  
*Room 311*

*Page 111*

**Diagnosis of AMR- What is the Data to Support the Banff Criteria?**  
*Veterans Auditorium*

*Page 109*

**Wellness in the Workplace: Combating Burnout and Improving Experience Amongst Transplant Providers**  
*Ballroom A*

*Page 111*

**Islet Cell Transplantation: Time to Stop Talking About the Future and Implement Today!**  
*Room 310*

*Page 109*

**Organ Directed Therapy- From Regulation to Intervention**  
*Room 306*

*Page 111*

**The Science of Cellular Intervention**  
*Room 304*

**11:15 am – 12:45 pm Midday Didactic**

*Page 109*

**C4 Article: Challenges and Solutions for Appropriate and Timely Medication Access in Transplantation**  
*Room 210*

*Page 112*

**Xenotransplantation - Are We There Yet?**  
*Room 313*

**12:45 pm – 1:00 pm Break**

*Page 109*

**Macrophages in Tissue Injury and Repair**  
*Room 302*

**1:00 pm – 2:15 pm Sponsored Satellite Symposia**

*Page 110*

**What's the "Real" Story: Artificial Kidney, Artificial Heart (and Lung)**  
*Room 312*

Satellite Symposia are open to all registered Congress attendees. Satellite Symposia take place at the Sheraton Boston Hotel. Please check the ATC website, [www.atcmeeting.org](http://www.atcmeeting.org), or ATC mobile app (ATC19) for the full Satellite Symposia program listing.

*Page 112*

*Sheraton Boston Hotel*

**AMERICAN TRANSPLANT CONGRESS**  
**Day-at-a-Glance, Tuesday, June 4, 2019**

---

**1:00 pm – 2:15 pm Luncheon Workshops**  
*(Additional Fees - Limited Ticketed Events)*

- Page 113*      **Creating a Multidisciplinary Team for Successful Pediatric and Young Adult Transition of Care**  
*Room 108*
- Page 113*      **Addressing Sexuality and Fertility in the Transplant Recipient**  
*Room 109*
- Page 113*      **Understanding the Legal, Ethical and Financial Impact of Drug Testing for Transplant Populations**  
*Room 110*

*Page 119*      **Liver: Living Donors and Partial Grafts**  
*Room 312*

- Page 120*      **Novel Insights in Kidney Infections**  
*Room 311*
- Page 121*      **Biomarkers, Immune Monitoring and Outcomes IV**  
*Room 306*
- Page 122*      **Non-Organ Specific: Economics & Ethics**  
*Room 309*
- Page 123*      **Innate Immunity; Chemokines, Cytokines, Complement**  
*Room 310*
- Page 124*      **Acute Rejection: Basic**  
*Room 313*

**2:15 pm – 2:30 pm Break**

---

**2:30 pm – 4:00 pm Concurrent Oral Abstract Sessions**

---

- Page 113*      **Kidney Complications: Late Graft Failure III**  
*Veterans Auditorium*
- Page 114*      **Kidney Deceased Donor Allocation III**  
*Ballroom B*
- Page 115*      **Kidney: Acute Cellular Rejection**  
*Ballroom C*
- Page 116*      **Liver Transplant Complications and Retransplantation II**  
*Ballroom A*
- Page 117*      **Kidney Psychosocial II: Substances and Access & Barriers**  
*Room 302*
- Page 118*      **Kidney Living Donor: Long Term Outcomes**  
*Room 304*

- Page 124*      **Liver: Pediatrics**  
*Room 210*
- Page 125*      **Non-Organ Specific: Disparities and Access to Healthcare I**  
*Room 208*
- Page 126*      **Kidney Paired Exchange**  
*Room 206*
- Page 127*      **Small Bowel**  
*Room 209*

**4:00 pm – 4:30 pm Coffee Break in the Exhibit Hall**  
*Hall C/D*

---

**4:30 pm – 6:00 pm Concurrent Oral Abstract Sessions**

---

- Page 129*      **Kidney Immunosuppression: Novel Regimens and Drug Minimization III**  
*Veterans Auditorium*
- Page 130*      **Kidney: Polyoma**  
*Ballroom B*

**Tuesday, June 4**

**AMERICAN TRANSPLANT CONGRESS**  
**Day-at-a-Glance, Tuesday, June 4, 2019**

---

- Page 131*      **Kidney: Cardiovascular and  
Metabolic III**  
*Ballroom C*
- Page 131*      **Kidney Living Donor: Selection**  
*Ballroom A*
- Page 132*      **Liver - Kidney Issues in Liver  
Transplantation**  
*Room 302*
- Page 133*      **Kidney Immunosuppression:  
Induction Therapy**  
*Room 304*
- Page 134*      **Liver: Recipient Selection**  
*Room 312*
- Page 135*      **Lymphocyte Biology: Signaling,  
Co-Stimulation, Regulation**  
*Room 311*
- Page 136*      **Biomarkers, Immune Monitoring  
and Outcomes V**  
*Room 306*
- Page 137*      **Non-Organ Specific: Viral  
Hepatitis**  
*Room 309*
- Page 138*      **Stem Cell, Cellular Therapies and  
Regenerative Medicine**  
*Room 310*
- Page 139*      **Ischemia Reperfusion & Organ  
Rehabilitation III**  
*Room 313*
- Page 140*      **Quality Assurance Process  
Improvement & Regulatory  
Issues II**  
*Room 210*
- Page 141*      **Non-Organ Specific: Disparities  
and Access to Healthcare II**  
*Room 208*
- Page 142*      **Late Breaking Oral Abstract**  
*Room 206*

---

**6:00 pm – 7:00 pm      Poster Session D**  
**Presenters in Attendance**  
*Hall C/D*

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

## Sunrise Symposia: Interactive (Continental Breakfast Provided)

7:00 am – 8:15 am

### **The Enemy of Good is Better: Marginal Cardiac Donors Avoid Waste and Maximize Lives Saved**

#### **Room 310**

Moderators: Robert L. Gottlieb, MD, PhD, Baylor University Medical Center, Dallas, TX, USA. Jane Wilcox, MD, Northwestern Medicine, Chicago, IL, USA.

- 7:00 am **Until Death Do Us Part: The Art and Science of Matchmaking Marginal Donor and Recipient Pairs**  
*David Baran, MD, Sentara Heart Hospital, Norfolk, VA, USA.*
- 7:20 am **I'll take it! How a Large Center Decides to Accept the Hearts That the Smaller Center Declined for Organ Quality**  
*Michelle M. Kittleson, MD, PhD, Cedars-Sinai, Los Angeles, CA, USA.*
- 7:40 am **Going to the Ends of the Earth for a Heart: The UK Experience with Heart Transplantation from DCD Donors**  
*Stephen Large, Papworth Everard, England.*
- 8:00 am **Panel Discussion**

### **ApoLI Genotyping in Living Kidney Donors**

#### **Ballroom A**

Moderators: Vineeta Kumar, MD, University of Alabama at Birmingham, Birmingham, AL, USA. Deirdre Sawinski, MD, University of Pennsylvania, Philadelphia, PA, USA.

- 7:00 am **The NIH APOLLO Study: Assessing APOL1 in Transplant Outcomes**  
*Barry I. Freedman, MD, Wake Forrester School of Medicine, Winston-Salem, NC, USA.*
- 7:20 am **The Time Has Come - Test Everyone**  
*Mona Doshi, MD, University of Michigan Medicine, Ann Arbor, MI, USA.*
- 7:40 am **We Need More Data - Do Not Test**  
*Jayne E. Locke, MD, MPH, University of Alabama at Birmingham, Birmingham, AL, USA.*

8:00 am **Panel Discussion**

### **New Insights into Fungal Infections in Thoracic, liver, and Kidney Transplant Recipients**

#### **Ballroom B**

Moderators: Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada. Sophia Koo, MD, Brigham and Women's Hospital; Harvard Medical School, Boston, MA, USA.

- 7:00 am **Who, What, When, Where & Why? Antifungals in Practice**  
*Tracy Sparkes, PharmD, BCPS, University of Maryland Medical Center, Baltimore, MD, USA.*
- 7:15 am **Antifungal Drugs in Transplant Recipients: Drug-Drug Interactions, Dosing, and Inhaled, IV, and Oral Formulations**  
*Jennifer McDermott, PharmD, BCPS, Spectrum Health, Grand Rapids, MI, USA.*
- 7:30 am **New Diagnostics: Which are Worth Your Time and Money?**  
*Rachel Miller, MD, Duke University, Durham, NC, USA.*
- 7:45 am **Does This Patient Need Antifungal Prophylaxis?**  
*Fernanda Silveira, MD, University of Pittsburgh and UPMC, Pittsburgh, PA, USA.*

8:00 am **Panel Discussion**

### **Organ Vigilance Around the World: Different Strokes for Different Folks**

#### **Room 304**

Moderators: Michael Ison, MD, MS, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Cameron R. Wolfe, MBBS(Hons), MPH, Duke University Medical Center, Durham, NC, USA.

- 7:00 am **14 Years of DTAC: US perspective**  
*Marian Michaels, MD, MPH, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.*

Tuesday, June 4

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

**7:20 am Organ Vigilance: The Euro-transplant Experience**

*Serge Vogelaar, Manager Allocation, Eurotransplant International, Leiden, Netherlands.*

**7:40 am Project NOTIFY: What's it all about?**

*Ines Ushiro-Lumb, MD, MSc, NHS Blood and Transplant, London, England.*

**8:00 am Panel Discussion**

**What Do I Do Now? Challenging Cases in Post Renal Transplant Care**

**Ballroom C**

*Moderators: Michelle Lubetzsky, MD, Weill Cornell New York Presbyterian Hospital, New York, NY, USA. Parmjeet Randhawa, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.*

**7:00 am Provider-Perceived Common Immunosuppression Side Effects and Management in Kidney Transplant Recipients**

*Jennifer Trofe-Clark, PharmD, BCPS, University of Pennsylvania, Philadelphia, PA, USA.*

**7:20 am Treatment of Recurrent FSGS**

*Nada Alachkar, MD, Johns Hopkins University School of Medicine, Baltimore, MD, USA.*

**7:40 am Management Challenges in BK Virus Associated Nephropathy**

*Michelle Josephson, MD, University of Chicago Medicine, Chicago, IL, USA.*

**8:00 am Panel Discussion**

**Pancreases Transplant Program Management in the Era of Declining Numbers**

**Room 311**

*Moderators: John Friedewald, MD, FAST, Northwestern University, Chicago, IL, USA. Robert J. Stratta, MD, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.*

**7:00 am SPK Versus LD then PAK Versus Alternative Therapies**

*Jon Odorico, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.*

**7:20 am Maintaining Adequacy in a Low Volume Program**

*Ty B. Dunn, MD, MS, University of Pennsylvania, Philadelphia, PA, USA.*

**7:40 am Regulation and Stewardship for Pancreas Transplant Programs**

*Matthew Cooper, MD, Professor of Surgery, Medstar, Georgetown Transplant Institute Washington, DC, USA.*

**8:00 am Panel Discussion**

**Assessing and Treating Mental Health Disorders in Transplant Recipients**

**Room 306**

*Moderators: Wendy Balliet, PhD, Medical University of South Carolina, Charleston, SC, USA. Akhil Shenoy, MD, MPH, Columbia University Medical Center, New York, NY, USA.*

**7:00 am Personality Disorders and Transplantation**

*Mark W. Nickels, MD, University of Rochester Medical Center, Rochester, NY, USA.*

**7:20 am Adaptation to Illness for Transplant Candidates and Recipients**

*Alexandra Gee, PsyD, University of Cincinnati College of Medicine, Cincinnati, OH, USA.*

**7:40 am Psychiatric Medications and Transplantation**

*Kathy Coffman, MD, Cleveland Clinic, Cleveland, OH, USA.*

**8:00 am Panel Discussion**

**Optimizing Pregnancy Success After Transplant**

**Room 208**

*Moderators: Lisa Coscia RN, BSN, Transplant Pregnancy Registry International, Philadelphia, PA, USA. Sangeeta Borhade, MD, Northwestern Medicine; Feinberg School of Medicine, Chicago, IL, USA.*

**7:00 am Ethical Issues Surrounding Pregnancy Following SOT and VCA**

*Avivia Goldberg, MD, MA, University of Manitoba, Winnipeg, MB.*



# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

7:20 am **Ethical Issues Surrounding Pregnancy Following SOT and VCA**  
*Tam Khuu, PharmD, BCPS, UCLA, Los Angeles, CA, USA.*

7:40 am **Monitoring the Transplant During Pregnancy**  
*Jon A. Kobashigawa, MD, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, USA.*

8:00 am **Panel Discussion**

## **Challenges of Transplanting and Managing Alcoholic Hepatitis**

### **Room 312**

*Moderators: Norah Terrault, MD, Keck School of Medicine of USC, Los Angeles, CA, USA. Russ Weisner, MD, Mayo Clinic, Rochester, MN, USA.*

7:00 am **Psychosocial Evaluation and Management of Acute Alcoholic Hepatitis Needing Transplantation**  
*Andrew Cameron, MD, PhD, Johns Hopkins Hospital, Baltimore, MD, USA.*

7:20 am **Early and Late Outcome of Transplantation for Acute Alcoholic Hepatitis**  
*Gene Y. Im, MD, Icahn School of Medicine, Division of Liver Disease, RMTI, New York, NY, USA.*

7:40 am **Ramification of Transplanting Alcoholic Hepatitis on Allocation and Organ Donation**  
*Mike Abecassis, MD, MBA, Northwestern Medicine; Feinberg School of Medicine, Chicago, IL, USA.*

8:00 am **Panel Discussion**

## **Joint AST-IPTA Symposium: "It's Friday Night of Long Weekend and the Pediatric Transplant ID Specialist's Beeper Goes Off..."**

### **Room 210**

*Moderators: Michael Green, MD, MPH, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Timothy Pruett, MD, University of Minnesota, Minneapolis, MN, USA.*

7:00 am **'What Do You Mean You Have a Donor? She's infected!'**  
*Lara Danziger-Isakov, MD, MPH, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.*

7:20 am **Viral infections After a Solid Organ Transplantation (excluding EBV and CMV) Current State of Immunizations in Pediatric Transplantation**  
*Sharon Bazak, MD, University of Minnesota, Minneapolis, MN, USA.*

7:40 am **'But Dr. ID... None of my Transplant Patients Get Infections Anymore- What is the Point of Prophylaxis?'**  
*Upton Allen, MBBS, MSc, Sick Kids- The Hospital of Sick Children, Toronto, ON.*

8:00 am **Panel Discussion**

## **Brainstorming on Liver Allocation in Vulnerable Populations: Women and Children First?**

### **Room 309**

*Moderators: Thomas Fishbein, MD, MedStar Health, Washington, DC, USA. Richard Gilroy, MD, Intermountain Health, Murray, UT, USA.*

7:00 am **It's in the Heights: Eliminating Gender-Based Disparity in Liver Transplantation**  
*Jennifer Lai, MD, MBA, UCSF Health, San Francisco, CA, USA.*

7:20 am **Pediatric Prioritization: Moral Imperative on Behalf of Children and its Impact on Organ Donation and Public Opinion**  
*Evelyn Hsu, MD, Seattle Children's, Seattle, WA, USA.*

Tuesday, June 4

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

**7:40 am Splitting Up is Hard to Do: Split Liver Transplant and Other Approaches to Increasing Allograft Availability**  
*Bart Kane, MD, PhD, University of Kansas Medical Center, Kansas City, KS, USA.*

**8:00 am Panel Discussion**

## **Sunrise Symposia: Didactic (Continental Breakfast Provided)**

---

**7:00 am – 8:15 am**

### ***TCR/BCR Sequencing and Tracking***

#### **Room 302**

*Moderators: Xuonrong Luo, MD, PhD, Duke University, Durham, NC, USA. Roslyn Mannon, MD, University of Alabama-Birmingham, Birmingham, AL, USA.*

**7:00 am Alloreactive Cell Tracking**  
*Megan Sykes, MD, Columbia University, New York, NY, USA.*

**7:20 am Audience Discussion**

**7:25 am T Cell CMV Responses**  
*Jonathan Maltzman, MD, PhD, Stanford University, Palo Alto, CA, USA.*

**7:45 am Audience Discussion**

**7:50 am B Cell Antibodyomics in Transplantation**  
*Indira Guleria, PhD, Brigham and Women's Hospital, Boston, MA, USA.*

**8:00 am Audience Discussion**

## **Break**

---

**8:15 am - 8:30 am**

## **Plenary Session III**

---

**8:30 AM - 9:15 AM**

### **Veterans Auditorium**

*Chairs: Jean Emond, MD, Immediate Past President, ASTS, New York, NY and Ronald Gill, PhD, FAST, Past President, AST, Aurora, CO.*

**8:30 AM Pediatric Liver Replantation: Prognostic Scoring Tool (Abstract #407)**

*A. Kuhne, D. Vock, J. Back, K. Ramanathan, A. Matas, S. Chinnakotla, University of Minnesota Medical School, Minneapolis, MN*

**8:45 AM Lymphotoxin Beta Receptor in Lymphatic Endothelial Cells Regulates Treg Migration and Allograft Protection (Abstract #408)**

*V. Saxena, W. Piao, L. Li, C. M. Paluskievicz, Y. Xiong, T. Simon, J. S. Bromberg, U Maryland, Baltimore, MD*

**9:00 AM Actions Speak Louder Than Labs - The Impact of Dialysis Compliance on Posttransplant Outcomes (Abstract #409)**

*D. Sawinski<sup>1</sup>, H. Lindner<sup>2</sup>, J. Schults<sup>3</sup>, J. Locke<sup>4</sup>, P. Reese<sup>1</sup>, <sup>1</sup>Hospital of the U of Pennsylvania, Philadelphia, PA, <sup>2</sup>University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Children's Hospital of Pennsylvania, Philadelphia, PA, <sup>4</sup>University of Alabama at Birmingham, Birmingham, AL*

## **Paul I. Terasaki State-of-the-Art Speaker**

---

### **Veterans Auditorium**

**9:15 am – 9:45 am**

#### **Using Human Pluripotent Stem Cells to Make Tissue for Transplantation**

*Douglas Melton, PhD  
Harvard Department of Stem Cell and Regenerative Biology  
Cambridge, MA, USA*

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

## Break

9:45 am - 10:00 am

## Controversies in Transplantation: Basic - Gene Editing in Transplantation

10:00 am – 10:45 am

### Ballroom B

Moderators: Jay A. Fishman, MD, Massachusetts General Hospital- Harvard Medical School, Boston, MA, USA. Roslyn Mannon, MD, University of Alabama-Birmingham, Birmingham, AL, USA.

**10:00 am Debate - Pro: Gene Editing in Transplantation**

Alfred A. Tector III, MD, PhD, University of Alabama at Birmingham, Birmingham, AL, USA.

**10:10 am Debate - Con: Gene Editing in Transplantation**

Jay Fishman, MD, Massachusetts General Hospital - Harvard Medical School, Boston, MA, USA.

**10:20 am Rebuttal: Pro**

Alfred A. Tector III, MD, PhD, University of Alabama at Birmingham, Birmingham, AL, USA.

**10:25 am Rebuttal: Con**

Jay Fishman, MD, Massachusetts General Hospital - Harvard Medical School, Boston, MA, USA.

**10:30 am Panel Discussion**

**Panelists:**

Matthew Levine, MD, PhD, University of Pennsylvania, Philadelphia, PA, USA.

Roslyn Mannon, MD, University of Alabama-Birmingham, Birmingham, AL, USA.

Jonathan Bromberg, MD, PhD, University of Maryland School of Medicine, Baltimore, MD, USA.

Abarahm Shaked, MD, PhD, University of Pennsylvania, Philadelphia, PA, USA.

## Controversies in Transplantation-Clinical

10:00 am – 10:45 am

### Veterans Auditorium

Moderators: Richard Gilroy, MD, FRACP, Intermountain Healthcare, Murray, UT, USA. Robert Gaston, MD, CTI Clinical Trial & Consulting Services, Covington, KY, USA.

**10:00 am “Transplant Metrics Drive Quality Patient Care”**

Jon Snyder, PhD, CDRG, Minneapolis, MN, USA.

**10:15 am “Contemporary Use of Transplant Metrics have Perverse Effects on Innovation Organ Utilization and Access to Care”**

Jesse Schold, PhD, Cleveland Clinic, Cleveland, OH, USA.

**10:30 am Panel Discussion**

Shelley Hall, MD, Baylor Dallas, Dallas, TX, USA.

**10:30 am Panel Discussion**

John Gill, MD, MS, Providence Health Care, Vancouver, BC, Canada.

**10:30 am Panel Discussion**

David Goldberg, MD, MSCE, University of Pennsylvania, Philadelphia, PA, USA.

**10:30 am Panel Discussion**

Llyod Ratner, MD, Columbia University, New York, NY, USA.

## Coffee Break in Exhibit Hall

10:45 am – 11:15 am

Hall C/D

Tuesday, June 4

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

## Midday Symposia: Interactive

11:15 am – 12:45 pm

### Report of the UNOS Transplant System Performance Improvement Summit Workgroup

#### Room 206

Moderators: Diane Brockmeier, President and CEO, Mid-America Transplant Services, St. Louis, MO, USA. Matthew Cooper, MD, Medstar Georgetown Transplant Institute, Washington, DC, USA.

**11:15 am Leveraging Research and Technology for Improved Decision-Making- Catching Up to the 21st Century**  
*David Foley, MD, University of Wisconsin, Madison, WI, USA.*

**11:35 am Enhanced Performance Monitoring- A Better Look Inside and Out**  
*Jeffrey Orlowski, MS, LifeShare, Oklahoma City, OK, USA.*

**11:55 am Future Collaborative Improvement Projects and Engaging External Stakeholders- We're All In This Together!**  
*Susan Gunderson, MHA, LifeSource, Minneapolis, MN, USA.*

12:15 pm Panel Discussion

### Simultaneous Liver and Kidney Transplant (SLKT): Two Years of the Policy Change

#### Ballroom C

Moderators: Daniel (Gabriel) Danovitch, MD, FRCP, UCLA, Los Angeles, CA, USA. Pratima Sharma, MD, MS, University of Michigan Medicine, Ann Arbor, MI, USA.

**11:15 am Indications and Patient Selection for SLKT vs. Kidney after LT: Transplant Hepatologist Perspective**  
*James Trotter, MD, Baylor University, Dallas, TX, USA.*

**11:40 am Two Years after Policy Change Outcomes: Decision Making of SLKT vs. Kidney After LT: Transplant Nephrology Perspective**  
*Alexander Wiseman, MD, University of Colorado School of Medicine, Aurora, CO, USA.*

**12:05 pm Surgical Perspectives on Liver Kidney: Simultaneous vs.Short (Pump) vs. Long Delay (Safety Net)**  
*William Goggins, MD, Indiana University School of Medicine, Indianapolis, IN, USA.*

12:30 pm Panel Discussion

### Are Protocol Biopsies Important in the Long Term Management of the Pediatric Liver Transplant Recipient?

#### Room 208

Moderators: Estella Alonso, MD, Northwestern Medicine; Feinberg School of Medicine, Chicago, IL, USA. Michael Ishitani, MD, Mayo Clinic, Rochester, MD, USA.

**11:15 am Long Term Graft Survival in Pediatric Liver Transplant Patients**  
*Carlos O. Esquivel, Stanford Abdominal Transplantation, Stanford, CA, USA.*

**11:35 am Debate - Pro: Protocol Liver Biopsy Should be Done in All Pediatric Liver Transplant Recipients**  
*Udeme Ekong, MD, MPH, Yale University, New Haven, CT, USA.*

**11:55 am Debate - Con: Protocol Liver Biopsy Should be Done in All Pediatric Liver Transplant Recipients**  
*Simon Horslen, MB, ChB, Seattle Children's Hospital, Seattle, WA, USA.*

**12:15 pm Rebuttal: Pro**  
*Udeme Ekong, MD, MPH, Yale University, New Haven, CT, USA.*

**12:35 pm Rebuttal: Con**  
*Simon Horslen, MB, ChB, Seattle Children's Hospital, Seattle, WA, USA.*

12:35 pm Audience Discussion

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

## Wellness in the Workplace: Combating Burnout and Improving Experience Amongst Transplant Providers

### **Ballroom A**

Moderators: Teresa DeMarco, MD, UCSF Health, San Francisco, CA, USA. Anil Chandraker, MD, Brigham Health-Brigham and Women's Hospital, Boston, MA, USA.

#### **11:15 am The Importance of Work-Life Balance in Today's Society: The Novice's Perspective**

TrisAnn Rendulic, PharmD, BCPS, University of Kentucky HealthCare, Lexington, KY, USA.

#### **11:30 am Provider Burnout: Why is it Happening and What Effects Does It Have?**

Rupal Shah, MD, UCSF Health, San Francisco, CA, USA.

#### **11:50 am Provider Burnout: What Can We Do About It? Are the Solutions and How Can They Be Implemented?**

Elizabeth Pomfret, MD, PhD, University of Colorado Anschutz Medical Center, Aurora, CO, USA.

#### **12:10 pm Provider Burnout: How to Promote Provider Wellness Through Lessons Learned from Our Patients?**

Jennifer Guy, MD, Sutter Health, San Francisco, CA, USA.

#### **12:30 pm Panel Discussion**

## Organ Directed Therapy- From Regulation to Intervention

### **Room 306**

Moderators: Wayne Hancock, MD, PhD, University of Pennsylvania & Children's Hospital of Philadelphia, Philadelphia, PA, USA. Lorenzo Gallon, MD, Northwestern University, Chicago, IL, USA.

#### **11:15 am Regulatory Issues in Donor and Organ Interventional Studies**

Sandy Feng, MD, PhD, UCSF Health, San Francisco, CA, USA.

#### **11:40 am Whole Body Approaches to Intervention**

Stefan Tullius, MD, PhD, FACS, Brigham and Women's Hospital, Boston, MA, USA.

#### **12:05 pm Molecular Approaches to Organ Intervention**

Matthew Levine, MD, PhD, University of Pennsylvania, Philadelphia, PA, USA.

#### **12:30 pm Panel Discussion**

## Midday Symposia: Didactic

### **11:15 am – 12:45 pm**

#### **C4 Article: Challenges and Solutions for Appropriate and Timely Medication Access in Transplantation**

##### **Room 210**

Moderators: Lisa Potter, Angela Maldonado, Dave Taber, Barrett Crowther, Maya Campara, and Demetra Tsapepas.

### **11:15 am – 12:45 pm**

#### **Macrophages in Tissue Injury and Repair**

##### **Room 302**

Moderators: Jerzy W. Kupiec-Weglinski, MD, PhD, University of California Los Angeles, Los Angeles, CA, USA. Xian Li, MD, PhD, Houston Methodist Hospital, Houston, TX, USA.

#### **11:15 am Macrophages in Organ Ischemia-Reperfusion Injury**

Yuan Zhai, PhD, Surgery David Geffen School of Medicine-UCLA, Los Angeles, CA, USA.

#### **11:35 am Audience Discussion**

#### **11:45 am Macrophages in Transplantation Tolerance**

Jordi Ochando, PhD, Mount Sinani, New York, NY, USA.

#### **12:05 pm Audience Discussion**

#### **12:15 pm Macrophage Heterogenicity in Tissue Inflammation and Homeostasis**

Xian Li, MD, PhD, Houston Methodist Hospital, Houston, TX, USA.

#### **12:35 pm Audience Discussion**

Tuesday, June 4



# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

## What's the "Real" Story: Artificial Kidney, Artificial Heart (and Lung)

### Room 312

Moderators: Sean Pinney, MD, Mount Sinai, New York, NY, USA. Bryan Whitson, MD, PhD, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

**11:15 am Every Breath You Take - ECMO for Nephrologists**  
*Hannah Copeland, MD, University of Mississippi Medical Center, Jackson, MS, USA.*

**11:35 am Audience Discussion**

**11:45 am Be Still My Heart -Fundamentals of VAD Management for Nephrologists**  
*Palak Shah, MD, MD, Inova Hear and Vascular Institute, Falls Church, VA, USA.*

**12:05 pm Audience Discussion**

**12:15 pm Renal Replacement Therapy in Patients with Mechanical Support and Thoracic Transplants**  
*Dan Negoianu, MD, University of Pennsylvania, Philadelphia, PA, USA.*

**12:35 pm Audience Discussion**

## Hacking Organs During Preservation: Organ Repair and Regeneration Ex Vivo

### Room 309

Moderators: Jedd Lewis, JD, Organ Preservation Alliance, Berkeley, CA, USA. Giuseppe Orlando, MD, PhD, Wake Forest Baptist Health, Winston-Salem, NC, USA.

**11:15 am Implementing the Vision: The Organ Repair Center, Where Regenerative and Transplant Medicine Meet**  
*Shaf Keshavjee, MD, University Health Network, Toronto, Ontario.*

**11:35 am Audience Discussion**

**11:45 am Therapeutic Targets and Experimental Strategies to Optimize Normothermic Machine Perfusion of Livers**  
*Andrew Barbas, MD, Duke University, Durham, NC, USA.*

**12:05 pm Audience Discussion**

**12:15 pm Regenerative Liver Replacement: Resetting Terminal Liver Failure from Inside Out**

*Alejandro Soto-Gutierrez, MD, PhD, University of Pittsburgh, Pittsburgh, PA, USA.*

**12:35 pm Audience Discussion**

## An Ounce of Prevention is Worth a Pound of Cure: Vaccination After Solid Organ Transplantation

### Ballroom B

Moderators: Oriol Manuel, MD, CHUV, Lausanne, Suisse. Anoma Nellore, MD, University of Alabama Birmingham, Birmingham, AL, USA.

**11:15 am Pediatric Vaccination: Are We Ready to Give Live Viral Vaccines Post-Transplant?**

*Klara M. Posfay-Barbe, MD, MS, University Hospitals of Geneva & Geneva Medical School, Geneva, Switzerland.*

**11:35 am Audience Discussion**

**11:45 am Vaccines for Adult Transplant Recipients: New Data**  
*Deepali Kumar, MD, MSC, UHN Research, Toronto, Ontario.*

**12:05 pm Audience Discussion**

**12:15 pm 'B'-Sides Serology: Novel Measures of Vaccine Protection**  
*Anoma Nellore, MD, University of Alabama Birmingham, Birmingham, AL, USA.*

**12:35 pm Audience Discussion**

## Defining the Risks of VCA

### Room 209

Moderators: Rolf Barth, MD, University of Maryland, Baltimore, MD, USA. Andreas Tzakis, MD, Cleveland Clinic, Weston, FL, USA.

**11:15 am Complications of Immunosuppression in VCA**  
*Gerald Brandacher, MD, Johns Hopkins Medicine, Baltimore, MD, USA.*

**11:35 am Audience Discussion**

**11:45 am Surgical Complications in VCA**  
*Simon G. Talbot, MD, Brigham and Women's Hospital, Boston, MA, USA.*

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

12:05 pm Audience Discussion

12:15 pm **Risks of Mortality and End Stage Organ Damage in VCA Vijay**  
*Goranthla, MD, PhD, Wake Forest University Health Sciences, Winston Salem, NC, USA.*

12:35 pm Audience Discussion

## Technical Issues in Liver Transplantation

### **Room 311**

Moderators: Alan Langnas, DO, University of Nebraska, Omaha, NB, USA. John Goss, MD, Baylor College of Medicine, Houston, TX, USA.

11:15 am **Various Approaches to Portal Vein Thrombosis and Significant Venous Shunts**  
*Yuri Genyk, MD, University of Southern California, Los Angeles, CA, USA.*

11:35 am Audience Discussion

11:45 am **The Role of Venovenous Bypass and How to Manage Outflow Issues**  
*Vatche Agopian, MD, UCLA Health, Los Angeles, CA, USA.*

12:05 pm Audience Discussion

12:15 pm **What are the Risks and Benefits of Arterial Conduits - Results of the Conduit Study**  
*Henrik Petrowsky, MD, University Hospital Zurich, Zurich, Switzerland.*

12:35 pm Audience Discussion

## Diagnosis of AMR- What is the Data to Support the Banff Criteria?

### **Veterans Auditorium**

Moderators: Lorraine Racusen, MD, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Enver Akalin, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.

11:15 am **History and Evolution of Banff Criteria for AMR**  
*Mark Haas, MD, PhD, Cedars-Sinai Medical Center, Los Angeles, CA, USA.*

11:40 am **What is the Data to Support the Changes Made in the Banff 2017 Criteria?**  
*Alexandre Loupy, MD, PhD, Paris Transplant Group, Paris, France.*

12:05 pm **Who Should be Treated for AMR?**

*Peter Nickerson, MD, FRCPC, University of Manitoba, Winnipeg, MB, Canada.*

12:30 pm Panel Discussion

## Islet Cell Transplantation: Time to Stop Talking About the Future and Implement Today!

### **Room 310**

Moderators: Kenneth Brayman, MD, PhD, University of Virginia, Charlottesville, VA, USA. Peter Stock, MD, PhD, UCSF Health, San Francisco, CA, USA.

11:15 am **Islet Transplantation: Defining Outcomes and How to Optimize Immunosuppression**  
*Michael R. Rickels, MD, MS, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.*

11:35 am Audience Discussion

11:45 am **Cutting Edge Innovations in Islet Transplantation: What's New and What's Coming**  
*David A. Baidal, MD, Diabetes Research Institute, Hollywood, FL, USA.*

12:05 pm Audience Discussion

12:15 pm **How to Overcome Financial/Regulatory Hurdles for Islet Transplantation in the United States**  
*Kenneth Brayman, MD, PhD, University of Virginia, Charlottesville, VA, USA.*

12:35 pm Audience Discussion

## The Science of Cellular Intervention

### **Room 304**

Moderators: Reza Abdi, MD, Brigham and Women's Hospital, Boston, MA, USA. Robert Fairchild, PhD, Cleveland Clinic, Cleveland, OH, USA.

11:15 am **Dendritic Cell Intervention**  
*Angus Thompson, PhD, DSc, University of Pittsburgh, Pittsburgh, PA, USA.*

11:35 am Audience Discussion

11:45 am **Mesenchymal Stem Cell Intervention**  
*Marlies Reinders, MD, PhD, Leiden University, Leiden, Netherlands.*

12:05 pm Audience Discussion

Tuesday, June 4

# AMERICAN TRANSPLANT CONGRESS

## Program, Tuesday, June 4, 2019

---

**12:15 pm CAR Treg Development**  
*Qizhi Tang, PhD, University of California-San Francisco, San Francisco, CA, USA.*

**12:35 pm Audience Discussion**

### **Xenotransplantation - Are We There Yet?**

#### **Room 313**

*Moderators: Burcin Ekser, MD, PhD, Indiana University School of Medicine, Indianapolis, IN, USA.  
Ronald Gill, PhD, University of Colorado, Denver, CO, USA.*

**11:15 am Advances in Genetic Engineering for Xenotransplantation**  
*David Ayares, PhD, Revivicor Inc, Blacksburg, VA, USA.*

**11:30 am Progress in Xeno Islet Primate Work**  
*Andrew Adams, MD, PhD, Emory University, Atlanta, GA, USA.*

**11:45 am Process in Xeno Islet Primate Work and Clinical Trials**  
*Bernhard Hering, MD, University of Minnesota, Minneapolis, MN, USA.*

**12:00 pm We Can Handle the Infectious Concerns**  
*Jay Fishman, MD, Massachusetts General Hospital - Harvard Medical School, Boston, MA, USA.*

**12:15 pm Debate; Clinical Trial for a Xenotransplantation: Pro “We are Ready”**  
*Devin Eckhoff, MD, University of Alabama at Birmingham, Birmingham, AL, USA.*

**12:25 pm Debate; Clinical Trial for a Xenotransplantation: Con “I am Not Sure I Will Refer My Patient to You for This Clinical Trial”**  
*Robert Montgomery, MD, NYU Langone, Mineola, NY, USA.*

**12:35 pm Audience Discussion**

### **Break**

**12:45 pm - 1:00 pm**

### **Sponsored Satellite Symposia**

**1:00 pm – 2:15 pm**

Satellite Symposia are open to all registered Congress attendees. Satellite Symposia take place at the Sheraton Boston Hotel. Please check the ATC website, [www.atcmeeting.org](http://www.atcmeeting.org), or ATC mobile app (ATC19) for the full Satellite Symposia program listing.

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

## Luncheon Workshops (Additional Fees - Limited Ticketed Events)

1:00 pm – 2:15 pm

### Creating a Multidisciplinary Team for Successful Pediatric and Young Adult Transition of Care

#### Room 108

Moderators: Lorraine Bell, MDCM, FRCPC, Montreal Children's Hospital, Montreal, QC, Canada. Priya Verghese, MD, University of Minnesota, Minneapolis, MN, USA.

### Addressing Sexuality and Fertility in the Transplant Recipient

#### Room 109

Moderators: Lisa Coscia, RN, BSN, Transplant Pregnancy Registry International, Philadelphia, PA, USA. Serbian Constantinescu, MD, PhD, Lewis Katz School of Medicine-Temple University, Philadelphia, PA, USA.

### Understanding the Legal, Ethical and Financial Impact of Drug Testing for Transplant Populations

#### Room 110

Moderators: Sheila G. Jowsey-Gregorie, MD, Mayo Clinic, Rochester, MN, USA. Paul Zimbrea, MD, Yale University, New Haven, CT, USA.

## Break

2:15 pm-2:30 pm

## Concurrent Oral Abstract Sessions

2:30 pm – 4:00 pm

### Kidney Complications: Late Graft Failure III

#### Veterans Auditorium

Chairs: N. Goyal Tufts Medical Center, Boston, MA and N. Issa

#### 2:30 PM Galectin-3 and Long-Term Graft Failure in Renal Transplant Recipients: A Prospective Cohort Study (Abstract #410)

C. G. Sotomayor<sup>1</sup>, C. A. Keyzer<sup>1</sup>, J. L. Anderson<sup>1</sup>, R. O. Gans<sup>2</sup>, I. M. Nolte<sup>3</sup>, M. H. de Borst<sup>1</sup>, S. P. Berger<sup>1</sup>, G. J. Navis<sup>1</sup>,

R. A. de Boer<sup>4</sup>, S. J. Bakker<sup>1</sup>, <sup>1</sup>Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, Groningen, Netherlands, <sup>2</sup>Department of Internal Medicine, University Medical Center Groningen, Groningen, Netherlands, <sup>3</sup>Department of Epidemiology, University Medical Center Groningen, Groningen, Netherlands, <sup>4</sup>Department of Cardiology, University Medical Center Groningen, Groningen, Netherlands

#### 2:42 PM Impact of Functional Delayed Graft Function in the Modern Era of Kidney Transplantation (Abstract #411)

D. Cucchiari, A. Molina-Andujar, E. Montagud-Marrahi, J. Rovira, F. Diekmann, Renal Transplant Unit, Hospital Clínic, Barcelona, Spain

#### 2:54 PM The Economic Burden of Graft Failure in the United States (Abstract #412)

J. A. Sussell<sup>1</sup>, A. R. Silverstein<sup>1</sup>, P. Goutam<sup>1</sup>, D. Incerti<sup>1</sup>, R. Kee<sup>1</sup>, D. S. Batty, Jr.<sup>2</sup>, C. X. Chen<sup>2</sup>, J. Jansen<sup>1</sup>, B. L. Kasiske<sup>3</sup>, <sup>1</sup>Precision Health Economics, Oakland, CA, <sup>2</sup>Medeor Therapeutics, South San Francisco, CA, <sup>3</sup>Hennepin County Medical Center, Minneapolis, MN

#### 3:06 PM Association Of Kdpi And Dgf With Dcd Kidney Transplants Outcomes (Abstract #413)

M. Sampaio, B. Abdalla, S. Bunnapradist, David Geffen Sch of Med at UCLA, Los Angeles, CA

#### 3:18 PM Prophylactic Use of Eculizumab in Patients at High Risk of Post-Transplant aHUS Recurrence Improves Graft Outcomes (Abstract #414)

J. Zuber, S. Caillard, M. Frimat, N. Kamar, P. Gatault, F. Petitprez, M. Louis, V. Chatelet, A. Thierry, D. Bertrand, R. Gaisne, L. Couzi, L. Albano, N. Jourde-Chiche, M. Maignon, J. Bamoulid, C. Pouteil-Noble, M. Peraldi, C. Legendre, E. Rondeau, M. Le Quintrec, V. Frémeaux-Bacchi, On behalf of the French aHUS Group, France, France

Tuesday, June 4

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

**3:30 PM Keeping Patients Lifetime Perspective in Focus: Modest Rates and Wide Variation in Preemptive Re-Listing for Kidney Transplantation in the US (Abstract #415)**

J. Schold, J. Augustine, A. Huml, J. O'Toole, J. Sedor, E. Poggio, *Cleveland Clinic, Cleveland, OH*

**3:42 PM Outcomes Of Single And En-bloc Pediatric Kidneys According To Kdpi (Abstract #416)**

M. Sampaio, E. Lum, A. Gritsch, S. Bunnapradist, *David Geffen Sch of Med at UCLA, Los Angeles, CA*

## Kidney Deceased Donor Allocation III

### Ballroom B

*Chairs: K. Andreoni, University of Florida, Gainesville, FL and F. Wright, Texas Transplant Institute, San Antonio, TX*

**2:30 PM A Safe Anti-A2 Titer for a Successful A2 Incompatible Kidney Transplantation (Abstract #417)**

G. Nair, M. Ajaimy, J. Graham, L. Liriano-Ward, A. Campbell, C. Pynadath, Y. Azzi, O. Andacoglu, S. Greenstein, M. Kinkhabwala, J. Rocca, E. Akalin, *Montefiore Medical Center, Bronx, NY*

**2:42 PM Kidney Transplants Outcomes from Deceased Donors with Acute Kidney Injury (Abstract #418)**

C. Jung<sup>1</sup>, P. Sood<sup>2</sup>, R. Mehta<sup>2</sup>, D. Jorgensen<sup>2</sup>, M. Molinari<sup>2</sup>, S. Hariharan<sup>2</sup>, A. Ganoza<sup>2</sup>, D. Van Der Windt<sup>2</sup>, M. Wijkstrom<sup>2</sup>, C. Puttarajappa<sup>2</sup>, A. Tevar<sup>3</sup>, <sup>1</sup>*Korea Univ. Anam Hospital, Seoul, Korea, Republic of*, <sup>2</sup>*Univ. Pittsburgh Medical Center, Pittsburgh, PA*, <sup>3</sup>*Department of Surgery, Univ. Pittsburgh Medical Center, Pittsburgh, PA*

**2:54 PM The Effect Of Exclusive Virtual Crossmatch To Allocate Deceased Donor Kidney Transplant On Cold Ischemia Time And Acute Rejection (Abstract #419)**

E. Abuhelaiga<sup>1</sup>, M. Alkadi<sup>1</sup>, S. Thappy<sup>1</sup>, S. Saleh<sup>2</sup>, J. Mahmoud<sup>3</sup>, M. Jarman<sup>3</sup>, O. Fituri<sup>1</sup>, M. Elkhaliifa<sup>4</sup>, J. Wadström<sup>3</sup>, H. Al-Malki<sup>1</sup>, <sup>1</sup>*Medicine-Nephrology, Hamad Medical Corporation, Doha, Qatar*, <sup>2</sup>*Histocompatibility & Immunogenetics Laboratory,, Hamad Medical Corporation, Doha, Qatar*, <sup>3</sup>*Surgery-Transplant, Hamad Medical Corporation, Doha, Qatar*, <sup>4</sup>*Histocompatibility & Immunogenetics Laboratory, Hamad Medical Corporation, Doha, Qatar*

**3:06 PM Non-Immunologic Donor-Recipient Pairing, HLA Matching, and Graft Loss in Deceased Donor Kidney Transplantation (Abstract #420)**

A. Vinson<sup>1</sup>, B. Kiberd<sup>1</sup>, R. Davis<sup>2</sup>, K. Tennankore<sup>1</sup>, <sup>1</sup>*Dalhousie University, Halifax, NS, Canada*, <sup>2</sup>*Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA*

**3:18 PM Multi-Organ Transplant Results in Lower Patient and Graft Survival Than Kidney Alone Transplant (Abstract #421)**

C. A. Custer<sup>1</sup>, J. Entwistle<sup>2</sup>, K. Ladin<sup>3</sup>, L. Cartwright<sup>1</sup>, E. J. Gordon<sup>4</sup>, <sup>1</sup>*United Network for Organ Sharing, Richmond, VA*, <sup>2</sup>*Thomas Jefferson University, Washington, DC*, <sup>3</sup>*Tufts University, Medford, MA*, <sup>4</sup>*Northwestern University, Chicago, IL*

**3:30 PM Quantifying Donor Effects on Transplant Outcomes Using Kidney Pairs from Deceased Donors (Abstract #422)**

K. F. Kerr<sup>1</sup>, E. R. Morenz<sup>1</sup>, H. Thiessen Philbrook<sup>2</sup>, S. G. Coca<sup>3</sup>, F. P. Wilson<sup>4</sup>, P. P. Reese<sup>5</sup>, C. R. Parikh<sup>2</sup>, <sup>1</sup>*University of Washington, Seattle, WA*, <sup>2</sup>*Johns Hopkins University, Baltimore, MD*, <sup>3</sup>*Icahn School of Medicine at Mount Sinai, New York, NY*, <sup>4</sup>*Yale University, New Haven, CT*, <sup>5</sup>*University of Pennsylvania, Philadelphia, PA*



# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

**3:42 PM Unos Analysis Of Deceased Donor Renal Transplant (ddrtx) Outcomes In Sensitized Patients After Implementation Of The Kidney Allocation System (kas) (Abstract #423)**  
R. J. Crew, K. L. King, M. Fajardo, J. Hedvat, N. Lange, S. Husain, S. Mohan, L. E. Ratner, S. S. Patel, *Columbia University Irving Medical Center, New York, NY*

## Kidney: Acute Cellular Rejection

### Ballroom C

Chairs: M. Mengel, *University of Alberta, Edmonton, AB, Canada* and B. Adam, *Edmonton, AB, Canada*

**2:30 PM The Changing Face of T Cell-Mediated Rejection (Abstract #424)**  
A. Perkowska-Ptasinska and INTERCOMEX investigators<sup>1</sup>, P. F. Halloran<sup>2</sup>, *<sup>1</sup>Medical University of Warsaw, Warsaw, Poland, <sup>2</sup>Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada*

**2:42 PM Response to Treatment in Kidney Recipients with Acute T Cell-Mediated Rejection: Major Impact of Inflammation in Sclerotic Cortical Parenchyma (i-IF/TA) and Donor-Specific Antibodies (Abstract #425)**  
Y. Bouatou, D. Viglietti, D. Pievani, J. Duong Van Huyen, O. Aubert, D. Glotz, C. Legendre, A. Loupy, C. Lefaucheur, *Paris Translational Research Center for Organ Transplantation, Paris, France*

**2:54 PM IL-6R Blockade with Tocilizumab Increases Tregs and Decreases Early Graft Inflammation in Kidney Transplant Recipients: Results of a Randomized Controlled Trial (Abstract #426)**  
S. Chandran, J. Leung, Z. Laszik, Q. Tang, C. Hu, M. Joanes, F. Vincenti, *UCSF, San Francisco, CA*

**3:06 PM Predicted Indirectly Recognizable H L A Epitopes Are Associated with T-cell Mediated Rejection among Kidney Transplant Recipients with Preformed and De Novo Donor-Reactive T-cells (Abstract #427)**  
T. Schachtner<sup>1</sup>, M. Stein<sup>2</sup>, N. M. Otto<sup>3</sup>, P. M. Reinke<sup>2</sup>, *<sup>1</sup>Nephrology, University Hospital Zurich, Zurich, Switzerland, <sup>2</sup>Berlin-Brandenburg Center for Regenerative Therapies, Charite University Medicine Berlin, Berlin, Germany, <sup>3</sup>Berlin-Brandenburg Center for Regenerative Therapies, Charite University Medicine Berlin, Berlin, Germany*

**3:18 PM Urinary Injury Biomarkers in Deceased Donors and Acute Rejection Post Kidney Transplant (Abstract #428)**  
P. Reese<sup>1</sup>, I. Hall<sup>2</sup>, S. Mohan<sup>3</sup>, H. Theissen-Philbrook<sup>4</sup>, Y. Jia<sup>4</sup>, M. Doshi<sup>5</sup>, J. Bromberg<sup>6</sup>, S. Mansour<sup>7</sup>, M. Harhay<sup>8</sup>, F. Weng<sup>9</sup>, E. Akalin<sup>10</sup>, C. Parikh<sup>4</sup>, *<sup>1</sup>UPENN, Philadelphia, PA, <sup>2</sup>Univ of Utah, Salt Lake City, UT, <sup>3</sup>Columbia, NY, NY, <sup>4</sup>Johns Hopkins, Baltimore, MD, <sup>5</sup>Univ of Michigan, Ann Arbor, MI, <sup>6</sup>Univ of Maryland, Baltimore, MD, <sup>7</sup>Yale, New Haven, CT, <sup>8</sup>Drexel, Philadelphia, PA, <sup>9</sup>St. Barnabas, Philadelphia, PA, <sup>10</sup>Montefiore, NY, NY*

**3:30 PM Unique Gene Expression Signatures in Urine Distinguish T Cell Mediated Acute Rejection from BK Virus Nephropathy in Kidney Transplant Patients (Abstract #429)**  
K. S. Keslar<sup>1</sup>, W. Xu<sup>2</sup>, A. A. Zmijewska<sup>3</sup>, K. A. Newell<sup>4</sup>, J. J. Friedewald<sup>5</sup>, M. I. Abecassis<sup>5</sup>, P. S. Heeger<sup>6</sup>, J. S. Bromberg<sup>7</sup>, R. B. Mannon<sup>3</sup>, R. L. Fairchild<sup>1</sup>, *<sup>1</sup>Cleveland Clinic, Cleveland, OH, <sup>2</sup>Nanostring Technologies, Seattle, WA, <sup>3</sup>Univ. Alabama Birmingham, Birmingham, AL, <sup>4</sup>Emory Univ., Atlanta, GA, <sup>5</sup>Northwestern Univ., Chicago, IL, <sup>6</sup>Icahn School of Med., New York, NY, <sup>7</sup>Univ. Maryland, Baltimore, MD*

Tuesday, June 4

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

**3:42 PM Impact of Early Borderline Histological Changes on Subsequent Events in Renal Transplant Recipients (Abstract #430)**

R. Mehta, S. Tandukar, D. Jorgensen, I. Owoyemi, N. Shah, C. Puttarajappa, C. Wu, S. Hariharan, *University of Pittsburgh Medical Center, Pittsburgh, PA*

## Liver Transplant Complications and Retransplantation II

### Ballroom A

Chairs: S. Chinnakotla, *University of Minnesota Medical School, Minneapolis, MN* and T. Schiano, *The Mount Sinai Medical Ctr, New York, NY*

**2:30 PM Factors Associated with Cardiovascular Subclinical Target Organ Damage in Liver Transplant Recipients (Abstract #431)**

C. Kuepper<sup>1</sup>, N. Memaran<sup>1</sup>, B. Borchert<sup>1</sup>, A. von Wick<sup>1</sup>, E. Bauer<sup>1</sup>, E. Jäckel<sup>2</sup>, S. Ziegert<sup>2</sup>, B. M. Schmidt<sup>3</sup>, A. Melk<sup>1</sup>, <sup>1</sup>*Department of Pediatric Kidney, Liver, and Metabolic Diseases, Hannover Medical School, Hannover, Germany*, <sup>2</sup>*Department of Gastroenterology and Hepatology, Hannover Medical School, Hannover, Germany*, <sup>3</sup>*Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany*

**2:42 PM Global and Domain Specific Cognition in Liver Transplant Recipients (Abstract #432)**

D. Ko<sup>1</sup>, L. Bratzke<sup>2</sup>, <sup>1</sup>*School of Nursing, Vanderbilt University, Nashville, TN*, <sup>2</sup>*School of Nursing, University of Wisconsin-Madison, Madison, WI*

**2:54 PM Management of Anastomotic Biliary Strictures after Liver Transplant: Role of Covered Metal Stents (Abstract #433)**

A. Watson<sup>1</sup>, K. Haq<sup>1</sup>, K. Khorfan<sup>2</sup>, S. Singla<sup>1</sup>, A. Yoshida<sup>3</sup>, D. Moonka<sup>1</sup>, <sup>1</sup>*Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI*, <sup>2</sup>*Internal Medicine, Henry Ford Hospital, Detroit, MI*, <sup>3</sup>*Transplant Institute, Henry Ford Hospital, Detroit, MI*

**3:06 PM Post-Liver Transplant Atrial Fibrillation is Associated with Markedly Reduced Short- and Long-Term Patient Survival (Abstract #434)**

R. Rachwan<sup>1</sup>, I. Kutkut<sup>1</sup>, T. J. Hathaway<sup>2</sup>, L. R. Timsina<sup>2</sup>, M. S. Ghabril<sup>3</sup>, M. A. Lacerda<sup>3</sup>, C. A. Kubal<sup>2</sup>, P. D. Bourdillon<sup>4</sup>, R. S. Mangus<sup>2</sup>, <sup>1</sup>*Medicine, Indiana University School of Medicine, Indianapolis, IN*, <sup>2</sup>*Surgery, Indiana University School of Medicine, Indianapolis, IN*, <sup>3</sup>*Gastroenterology/Hepatology, Indiana University School of Medicine, Indianapolis, IN*, <sup>4</sup>*Cardiology, Indiana University School of Medicine, Indianapolis, IN*

**3:18 PM Presence of DSA Class 2 is Associated with Fibrosis Progression after OLT (Abstract #435)**

M. Sterneck<sup>1</sup>, B. Sultani<sup>2</sup>, M. Rodriguez Lago<sup>3</sup>, E. Grabhorn<sup>4</sup>, A. Briem-Richter<sup>4</sup>, U. Herden<sup>5</sup>, L. Fischer<sup>5</sup>, <sup>1</sup>*University Medical Center Hamburg Eppendorf, Hamburg, Germany*, <sup>2</sup>*University Transplant Center, University Medical Center Hamburg Eppendorf, Hamburg, Germany*, <sup>3</sup>*Department of Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany*, <sup>4</sup>*Department of Paediatric Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany*, <sup>5</sup>*Department of Visceral Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany*

**3:30 PM MELD Score and Anti-Angiotensin Receptor Antibody Predict Long-Term Survival of Liver Re-Transplant (Abstract #436)**

Q. Xu<sup>1</sup>, A. Skaro<sup>2</sup>, V. C. McAlister<sup>2</sup>, <sup>1</sup>*Pathology and Lab Medicine, London Health Science Center, London, ON, Canada*, <sup>2</sup>*Surgery, London Health Science Center, London, ON, Canada*

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

**3:42 PM Impact of Coronary Artery Disease on Long-Term Mortality after Liver Transplantation (Abstract #437)**  
S. S. Patel<sup>1</sup>, V. A. Rodriguez<sup>2</sup>, M. B. Siddiqui<sup>1</sup>, J. Laurenzano<sup>3</sup>, F. Lin<sup>3</sup>, J. Clinton<sup>3</sup>, M. Faridnia<sup>4</sup>, A. Chandrakumaran<sup>4</sup>, T. Reichman<sup>5</sup>, C. Bhati<sup>5</sup>, M. S. Siddiqui<sup>1</sup>, <sup>1</sup>Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Department of Bio-statistics, Virginia Commonwealth University, Richmond, VA, <sup>3</sup>Virginia Commonwealth University, Richmond, VA, <sup>4</sup>Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, <sup>5</sup>Department of Transplant Surgery, Virginia Commonwealth University, Richmond, VA

## Kidney Psychosocial II: Substances and Access & Barriers

**Room: 302**

Chairs: C. Nonterah, University of Richmond, Richmond, VA and R. Patzer, Atlanta, GA

**2:30 PM Impact of Race and Substance Use on Listing Decisions for Kidney Transplant (Abstract #438)**  
R. N. DeBlasio<sup>1</sup>, L. Myaskovsky<sup>2</sup>, K. Kendall<sup>1</sup>, A. DiMartini<sup>1</sup>, G. Switzer<sup>1</sup>, D. M. Posluszny<sup>1</sup>, C. Puttarajappa<sup>1</sup>, A. D. Tevar<sup>1</sup>, S. Hariharan<sup>1</sup>, R. Shapiro<sup>3</sup>, M. A. Dew<sup>1</sup>, <sup>1</sup>U Pittsburgh, Pittsburgh, PA, <sup>2</sup>U New Mexico, Albuquerque, NM, <sup>3</sup>Mt Sinai Recanati/Miller Transplantation Institute, New York, NY

**2:42 PM The Implementation and Impact of an Opioid Minimization Protocol in an Urban Renal Transplant Population (Abstract #439)**  
A. Lichvar, M. Campara, E. Benedetti, J. Benken, University of Illinois at Chicago, Chicago, IL

**2:54 PM Kidney Transplantation in the Lower-Income Bracket of South Korea; Widening Gap in Accessibility and Inferior Graft Outcome (Abstract #440)**  
G. Park<sup>1</sup>, S. Park<sup>1</sup>, J. Kim<sup>1</sup>, M. Yu<sup>1</sup>, Y. Kim<sup>1</sup>, K. Kim<sup>1</sup>, M. Park<sup>2</sup>, Y. Kim<sup>1</sup>, H. Lee<sup>1</sup>, <sup>1</sup>Seoul National University Hospital, Seoul, Korea, Republic of, <sup>2</sup>Severance Hospital, Seoul, Korea, Republic of

**3:06 PM Higher Level of Social Support is Associated with Higher Likelihood of Pursuit of Living Donor Kidney Transplant (LDKT) (Abstract #441)**  
T. Ahmed<sup>1</sup>, S. Dano<sup>1</sup>, Z. Zhou<sup>1</sup>, I. Unarain<sup>1</sup>, M. Saqib<sup>1</sup>, V. Li<sup>1</sup>, Y. Khoo<sup>1</sup>, M. Novak<sup>2</sup>, I. Mucsi<sup>1</sup>, <sup>1</sup>Multi-Organ Transplant Program and Division of Nephrology, University Health Network, Toronto, ON, Canada, <sup>2</sup>Centre for Mental Health, University Health Network, Toronto, ON, Canada

**3:18 PM The Risk of Systematic Error in Kidney Transplant Opioid Research (Abstract #442)**  
J. N. Fleming, N. A. Pilch, S. Ball, P. K. Baliga, V. Rohan, D. J. Taber, Medical University of South Carolina, Charleston, SC

**3:30 PM Access To The Kidney Transplant Waitlist For Patients With Hiv And End-stage Renal Disease (Abstract #443)**  
A. A. Shaffer<sup>1</sup>, H. Ying<sup>2</sup>, N. Chu<sup>1</sup>, A. G. Thomas<sup>3</sup>, C. Haugen<sup>2</sup>, S. Norman<sup>4</sup>, D. L. Segev<sup>1</sup>, M. A. McAdams-DeMarco<sup>1</sup>, <sup>1</sup>Surgery & Epidemiology, Johns Hopkins University, Baltimore, MD, <sup>2</sup>Surgery, Johns Hopkins University, Baltimore, MD, <sup>3</sup>Epidemiology, University of North Carolina, Chapel Hill, NC, <sup>4</sup>Surgery, University of Michigan, Ann Arbor, MI

Tuesday, June 4

**AMERICAN TRANSPLANT CONGRESS**  
Program, Tuesday, June 4, 2019

---

**3:42 PM Earlier Transplant Education as CKD Progresses? CKD 3-5 Patients and Providers Weigh In (Abstract #444)**  
A. D. Waterman<sup>1</sup>, O. N. Ranasinghe<sup>1</sup>, A. F. Lipsey<sup>2</sup>, C. S. Anderson<sup>1</sup>, A. Alem<sup>3</sup>, C. Bozzolo<sup>4</sup>, B. Dub<sup>3</sup>, S. L. Henry<sup>3</sup>, B. Mittman<sup>3</sup>, <sup>1</sup>*Division of Nephrology, UCLA School of Medicine, Los Angeles, CA*, <sup>2</sup>*Terasaki Research Institute, Los Angeles, CA*, <sup>3</sup>*Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA*, <sup>4</sup>*Insight Policy Research, Arlington, VA*

**Kidney Living Donor: Long Term Outcomes**

**Room: 304**

*Chairs: G. Danovitch, David Geffen School of Medicine @ UCLA, Los Angeles, CA*

**2:30 PM Maternal and Pregnancy Outcomes after Living Donor Nephrectomy in a Multistate Cohort (Abstract #445)**  
G. S. Lee<sup>1</sup>, R. X. Wang<sup>2</sup>, D. O. Walls<sup>3</sup>, P. P. Reese<sup>4</sup>, D. S. Goldberg<sup>4</sup>, P. L. Abt<sup>1</sup>, <sup>1</sup>*Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA*, <sup>2</sup>*Sidney Kimmel Medical College, Philadelphia, PA*, <sup>3</sup>*Surgery, Rutgers Robert Wood Johnson, New Brunswick, NJ*, <sup>4</sup>*Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA*

**2:42 PM Center-Level Variation in HLA-Incompatible Living Donor Kidney Transplantation Outcomes (Abstract #446)**  
K. Jackson<sup>1</sup>, J. Long<sup>1</sup>, K. Covarrubias<sup>1</sup>, J. Motter<sup>1</sup>, M. Bowring<sup>1</sup>, J. Chen<sup>1</sup>, M. Waldram<sup>1</sup>, B. Orandi<sup>2</sup>, N. Desai<sup>1</sup>, A. Massie<sup>1</sup>, D. Segev<sup>1</sup>, J. Garonzik-Wang<sup>1</sup>, <sup>1</sup>*Johns Hopkins University, Baltimore, MD*, <sup>2</sup>*University of Alabama School of Medicine, Birmingham, AL*

**2:54 PM Living Kidney Donors Who Lose Weight in Order to Be Able to Donate, Gain More Weight after Donation (Abstract #447)**  
S. R. Punjala, L. Silas, R. Gokmen, N. Karydis, *Department of Nephrology, Renal Transplant and Urology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom*

**3:06 PM Racial Variation in ESRD Diagnosis Patterns among Prior Living Kidney Donors on the OPTN Kidney Waiting List (Abstract #448)**  
J. Wainright<sup>1</sup>, A. Robinson<sup>1</sup>, A. Wilk<sup>1</sup>, D. Klassen<sup>2</sup>, W. Cherikh<sup>1</sup>, C. Custer<sup>1</sup>, R. Brown<sup>3</sup>, D. Stewart<sup>1</sup>, <sup>1</sup>*Research, UNOS, Richmond, VA*, <sup>2</sup>*Office of the Chief Medical Officer, UNOS, Richmond, VA*, <sup>3</sup>*Organ Center, UNOS, Richmond, VA*

**3:18 PM Sub-Optimal Renal Recovery and Progressive Chronic Kidney Disease after Living Kidney Donation (Abstract #449)**  
Y. Kim<sup>1</sup>, C. Jeong<sup>2</sup>, H. Kim<sup>2</sup>, J. Ha<sup>3</sup>, C. Ahn<sup>1</sup>, Y. Kim<sup>1</sup>, H. Lee<sup>1</sup>, <sup>1</sup>*Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of*, <sup>2</sup>*Department of Urology, Seoul National University Hospital, Seoul, Korea, Republic of*, <sup>3</sup>*Department of Surgery, Seoul National University Hospital, Seoul, Korea, Republic of*

**3:30 PM Changes in Kidney Function Following Live Donor Nephrectomy (Abstract #450)**  
N. N. Lam<sup>1</sup>, A. Lloyd<sup>1</sup>, K. L. Lentine<sup>2</sup>, R. R. Quinn<sup>3</sup>, B. R. Hemmelgarn<sup>3</sup>, S. Klarenbach<sup>1</sup>, A. X. Garg<sup>4</sup>, <sup>1</sup>*University of Alberta, Edmonton, AB, Canada*, <sup>2</sup>*Saint Louis University, St. Louis, LA*, <sup>3</sup>*University of Calgary, Calgary, AB, Canada*, <sup>4</sup>*Western University, London, ON, Canada*



# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

**3:42 PM Chronic Changes on Time Zero Living Donor Allograft Biopsy Do Not Portend Future Kidney Function (Abstract #451)**  
*A. Agarwal<sup>1</sup>, A. Sites<sup>2</sup>, K. L. Brayman<sup>1</sup>, A. Doyle<sup>3</sup>, J. Oberholzer<sup>1</sup>, A. Nishio-Lucar<sup>3</sup>, <sup>1</sup>Surgery, University of Virginia, Charlottesville, VA, <sup>2</sup>Transplant, University of Virginia, Charlottesville, VA, <sup>3</sup>Medicine, University of Virginia, Charlottesville, VA*

## Liver: Living Donors and Partial Grafts

### Room: 312

*Chairs: K. Conzen, University of Colorado, Aurora, CO and M. Cattral, Toronto General Hospital, University of Toronto, Toronto, ON, Canada*

**2:30 PM 5,000 Living Donor Liver Transplantations (Abstract #452)**  
*G. Song, S. Lee, S. Hwang, K. Kim, C. Ahn, D. Moon, T. Ha, D. Jung, G. Park, Y. Yoon, J. Kwon, H. Cho, Y. Jung, S. Kang, I. Jeong, J. Choi, Division of LT and HBB Surgery, Department of Surgery, Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea, Republic of*

**2:42 PM Pure Laparoscopic Donor Hepatectomy Based On Korean Multicenter Experience (Abstract #453)**  
*K. Suh<sup>1</sup>, S. Hong<sup>1</sup>, G. Choi<sup>2</sup>, K. Lee<sup>1</sup>, C. D. Kwon<sup>2</sup>, K. Kim<sup>3</sup>, S. Lee<sup>4</sup>, Y. Han<sup>5</sup>, J. Cho<sup>6</sup>, H. Han<sup>7</sup>, <sup>1</sup>Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of, <sup>2</sup>Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, <sup>3</sup>Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of, <sup>4</sup>Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of, <sup>5</sup>Surgery, Daegu Catholic University School of Medicine, Daegu, Korea, Republic of, <sup>6</sup>Surgery, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of, <sup>7</sup>Surgery, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of*

**2:54 PM Difficult Outflow Reconstruction Using Eptfe Vascular Grafts In Ldl: Technical Innovations And Outcomes. (Abstract #454)**  
*A. Thorat<sup>1</sup>, L. Jeng<sup>2</sup>, P. Li<sup>2</sup>, S. Hsu<sup>2</sup>, H. Yang<sup>2</sup>, C. Yeh<sup>2</sup>, T. Chen<sup>2</sup>, K. Poon<sup>2</sup>, <sup>1</sup>China Medical University Hospital, Taichung, Taiwan, <sup>2</sup>Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan*

**3:06 PM Donor Safety for Minimal Invasive Hepatectomy in Liver Transplantation: The Korean Organ Transplantation Registry (Abstract #455)**  
*H. Yu, J. Yang, S. Ahn, Chonbuk National University Hospital, Jeonju, Korea, Republic of*

**3:18 PM A Novel Program of Directed Domino and Split Liver Donations Increases Liver Transplants (Abstract #456)**  
*T. Fishbein, C. Matsumoto, N. Yazigi, R. Satoskar, S. Kaufman, K. Khan, K. Alexander, J. Hawksworth, M. Summer, Medstar Georgetown Transplant Institute, Georgetown University Hospital, Washington, DC*

**3:30 PM Primary Indications and Waitlist Status for Pediatric Living Donor Liver Transplants (Abstract #457)**  
*K. Goli<sup>1</sup>, K. Hosek<sup>2</sup>, A. Rana<sup>3</sup>, J. Goss<sup>3</sup>, T. Miloh<sup>3</sup>, <sup>1</sup>Rice University, Houston, TX, <sup>2</sup>Texas Children's Hospital, Houston, TX, <sup>3</sup>Abdominal Transplant, Baylor College of Medicine/Texas Children's Hospital, Houston, TX*

**3:42 PM Adult Living Donor vs. Deceased Donor Liver Transplant (LDLT vs. DDLT) at a Single US Center- Time to Change Our Paradigm for Liver Transplant (Abstract #458)**  
*A. Humar, D. Jorgensen, S. Ganesh, A. Tevar, M. Molinari, C. Hughes, Thomas E Starzl Transplant Inst, Pittsburgh, PA*

Tuesday, June 4



# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

## Novel Insights in Kidney Infections

**Room: 311**

*Chairs: N. Theodoropoulos, University of Massachusetts Medical School, Worcester, MA and G. Haidar, University of Pittsburgh Medical Center, Pittsburgh, PA*

### 2:30 PM Quantifying Differential Infection Risks in HLA- and/or ABO- Incompatible Kidney Transplant Recipients (Abstract #459)

R. Avery<sup>1</sup>, R. Montgomery<sup>2</sup>, J. Motter<sup>1</sup>, A. Massie<sup>1</sup>, E. Kraus<sup>1</sup>, K. Marr<sup>1</sup>, B. Lonze<sup>2</sup>, N. Alachkar<sup>1</sup>, K. Jackson<sup>1</sup>, M. Holechek<sup>1</sup>, D. Ostrander<sup>1</sup>, N. Desai<sup>1</sup>, M. Waldram<sup>1</sup>, S. Shoham<sup>1</sup>, S. Mehta<sup>1</sup>, J. Hiller<sup>1</sup>, J. Langlee<sup>1</sup>, S. Young<sup>1</sup>, D. Segev<sup>1</sup>, J. Garonzik Wang<sup>1</sup>, <sup>1</sup>Johns Hopkins, Baltimore, MD, <sup>2</sup>New York University, New York, NY

### 2:42 PM Evolution of HHV6- and CMV-Specific T Cell Functional Responses and Immune Cell Populations after Kidney Transplant (Abstract #460)

A. Gil<sup>1</sup>, M. Co<sup>2</sup>, M. Calvo-Calle<sup>1</sup>, J. Cruz<sup>1</sup>, L. Stern<sup>1</sup>, L. Gibson<sup>2</sup>, <sup>1</sup>Pathology, University of Massachusetts Medical School, Worcester, MA, <sup>2</sup>Medicine, University of Massachusetts Medical School, Worcester, MA

### 2:54 PM Nationwide Survey of Human T Cell Leukemia Virus Type 1-Infected Kidney Transplant Recipients in Japan (Abstract #461)

J. Yamauchi<sup>1</sup>, Y. Yamano<sup>1</sup>, M. Matsuoka<sup>2</sup>, N. Ichimaru<sup>3</sup>, M. Nishikido<sup>4</sup>, Y. Shibagaki<sup>5</sup>, A. Sugitani<sup>6</sup>, N. Nakamura<sup>7</sup>, M. Mieno<sup>8</sup>, K. Yuzawa<sup>9</sup>, <sup>1</sup>Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, <sup>2</sup>Institute for Virus Research, Kyoto University, Kyoto, Japan, <sup>3</sup>Advanced Technology for Transplantation, Osaka University, Osaka, Japan, <sup>4</sup>Blood Purification Center, Nagasaki University, Nagasaki, Japan, <sup>5</sup>Department of Nephrology and Hypertention, St. Marianna University School of Medicine, Kawasaki, Japan, <sup>6</sup>NHO Yonago Medical Center, Yonago, Japan, <sup>7</sup>Fukuoka University, Fukuoka, Japan, <sup>8</sup>Center for Information, Jichi Medical University, Shimotsuke, Japan, <sup>9</sup>Department of Transplantation Surgery, National Hospital Organization Mito Medical Center, Ibaraki, Japan

### 3:06 PM Vaccine Response as a Predictor of Kidney Transplant Rejection and Serious Infection (Abstract #462)

A. Ta'eed, K. R. Polkinghorne, W. R. Mulley, Department of Nephrology, Monash Health, Clayton, Australia

### 3:18 PM Risk Factors for 1-5 Year Major Infection Events (MIE) after Kidney Transplant (KTx) Including First-Year Immunosuppression (IS) Data: An Analysis of the Choosing Immune Suppression in Renal Transplantation by Efficacy and Morbidity (CISTEM) Study (Abstract #463)

V. Dharnidharka<sup>1</sup>, D. Axelrod<sup>2</sup>, Z. Zhang<sup>3</sup>, M. Schnitzler<sup>3</sup>, K. Lentine<sup>3</sup>, B. Kasiske<sup>4</sup>, <sup>1</sup>Washington Univ, St. Louis, MO, <sup>2</sup>Univ of Iowa, Iowa City, IA, <sup>3</sup>Saint Louis Univ, St. Louis, MO, <sup>4</sup>SRTR, Minneapolis, MN

**AMERICAN TRANSPLANT CONGRESS**  
Program, Tuesday, June 4, 2019

---

**3:30 PM**    **The Impact of Antibiotic Therapy on Clinical Outcomes in Kidney Transplant Recipients with Asymptomatic Bacteriuria (Abstract #464)**

J. Gabriel<sup>1</sup>, S. Shaikh<sup>2</sup>, J. Park<sup>1</sup>, S. Tischer<sup>1</sup>, D. Kaul<sup>1</sup>, T. Patel<sup>1</sup>, <sup>1</sup>*Michigan Medicine, Ann Arbor, MI*, <sup>2</sup>*MedStar Georgetown University Hospital, Washington, DC*

**3:42 PM**    **Infectious Complications in Tocilizumab-Treated Kidney Transplant Recipients (Abstract #465)**

S. Sethi, A. Peng, R. Najjar, A. Vo, S. Jordan, E. Huang, *Cedars Sinai Medical Center, Los Angeles, CA*

**Biomarkers, Immune Monitoring and Outcomes IV**

**Room: 306**

*Chairs: A. Haririan, Univ of Maryland Schl of Med, Baltimore, MD and C. Legendre, Hopital Necker, Paris, France*

**2:30 PM**    **Predicting Transplant Rejection by a Composite Urinary Injury Score (Abstract #466)**

J. Y. Yang, R. Sarwal, T. K. Sigdel, M. M. Sarwal, *Department of Surgery, UCSF, San Francisco, CA*

**2:42 PM**    **A Novel Genomic Approach for Acute Rejection across All Age Groups in Kidney Transplantation (Abstract #467)**

B. I. Shaw, D. K. Cheng, Q. Cheng, C. R. Acharya, A. D. Kirk, E. T. Chambers, *Pediatrics/Surgery, Duke University, Durham, NC*

**2:54 PM**    **Differences in CMV-Specific CD4 T Cell Population in De Novo Kidney Transplant Recipients Treated with Everolimus-Based Regimen Compared to a Standard Tacrolimus-MPA Regimen: Results from ATHENA (Abstract #468)**

I. A. Hauser<sup>1</sup>, S. Marx<sup>1</sup>, C. Sommerer<sup>1</sup>, B. Suwelack<sup>1</sup>, D. Dragun<sup>1</sup>, O. Witzke<sup>1</sup>, F. Lehner<sup>1</sup>, I. Kroeger<sup>2</sup>, M. Junge<sup>2</sup>, F. Thaiss<sup>1</sup>, B. Nashan<sup>1</sup>, M. Sester<sup>1</sup>, <sup>1</sup>*ATHENA, CMV Substudy Group, Germany*, <sup>2</sup>*Novartis, Pharma GmbH, Germany*

**3:06 PM**    **Identification Of Pre-transplant Biomarkers Of Recipient Immune Dysfunction That Predict Recipient Risk Of Death Following Liver Transplant: The Immune Frailty Index (Abstract #469)**

K. E. Lunsford<sup>1</sup>, N. Aware<sup>1</sup>, K. Cleveland<sup>1</sup>, C. J. Manner<sup>1</sup>, D. T. Nguyen<sup>2</sup>, E. A. Graviss<sup>2</sup>, J. V. Thomas<sup>1</sup>, H. Vyas<sup>1</sup>, L. W. Moore<sup>1</sup>, S. A. Dorman<sup>1</sup>, A. Saharia<sup>1</sup>, C. M. Mobley<sup>1</sup>, M. J. Hobeika<sup>1</sup>, X. C. Li<sup>1</sup>, R. M. Ghobrial<sup>1</sup>, <sup>1</sup>*Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Houston, TX*, <sup>2</sup>*Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX*

**3:18 PM**    **Correlation of Donor-Derived Cell-Free DNA with Histology and Molecular Diagnoses of Kidney Transplant Biopsies (Abstract #470)**

I. Moinuddin<sup>1</sup>, D. Kumar<sup>1</sup>, P. Halloran<sup>2</sup>, L. Kamal<sup>1</sup>, A. King<sup>1</sup>, P. Kimball<sup>1</sup>, M. Levy<sup>1</sup>, C. Bhati<sup>1</sup>, D. Massey<sup>1</sup>, G. Gupta<sup>1</sup>, <sup>1</sup>*VCU Medical Center, Richmond, VA*, <sup>2</sup>*Alberta Transplant Genomics Applied Centre, Edmonton, AB, Canada*

Tuesday, June 4

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

**3:30 PM Integrated Analysis of Messenger RNA and Micro RNA Profiles in Fatty Liver Donors: Molecular Networks during Ischemia Reperfusion Injury (Abstract #471)**

D. Maluf<sup>1</sup>, A. Bajwa<sup>1</sup>, S. K. Satapathy<sup>2</sup>, V. Sai Bontha<sup>1</sup>, A. Kadimella<sup>1</sup>, J. Eason<sup>3</sup>, V. Mas<sup>4</sup>, <sup>1</sup>UTHSC, Memphis, TN, <sup>2</sup>UTHSC, Memphis, TN, <sup>3</sup>Director of Transplant Institute - UTHSC, Memphis, TN, <sup>4</sup>Director of Transplant Research Institute, Memphis, TN

**3:42 PM Proteomics Reveals Compartment-Specific Alterations in the Extracellular Matrix of Kidney Allografts with Antibody-Mediated Rejection (Abstract #472)**

S. Clotet Freixas<sup>1</sup>, C. McEvoy<sup>1</sup>, I. Batruch<sup>2</sup>, M. Kotlyar<sup>3</sup>, C. Pastrello<sup>3</sup>, J. Van<sup>1</sup>, A. Bozovic<sup>1</sup>, V. Kulasingam<sup>1</sup>, P. Chen<sup>4</sup>, I. Jurisica<sup>3</sup>, A. Chruscinski<sup>1</sup>, R. John<sup>1</sup>, A. Konvalinka<sup>1</sup>, <sup>1</sup>University Health Network, Toronto, ON, Canada, <sup>2</sup>Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada, <sup>3</sup>Krembil Research Institute, Toronto, ON, Canada, <sup>4</sup>Institute of Medical Science, University of Toronto, Toronto, ON, Canada

## Non-Organ Specific: Economics & Ethics

### Room: 309

Chairs: P. Reese, University of Penn, Philadelphia, PA and J. Wellen, Saint Louis, MO

**2:30 PM Economic Impact of Donor Hepatitis C Kidney Transplantation: A Medicare Cost Analysis (Abstract #473)**

K. Lentine<sup>1</sup>, M. Schnitzler<sup>2</sup>, T. Alhamad<sup>3</sup>, H. Xiao<sup>2</sup>, H. Randall<sup>2</sup>, J. Wellen<sup>2</sup>, B. Kasiske<sup>4</sup>, G. Hess<sup>5</sup>, D. Axelrod<sup>6</sup>, <sup>1</sup>Saint Louis University Medical Center, St. Louis, MO, <sup>2</sup>Saint Louis Univ, St. Louis, MO, <sup>3</sup>Washington Univ, St. Louis, MO, <sup>4</sup>SRTR, Minneapolis, MN, <sup>5</sup>Univ of Pennsylvania, Philadelphia, PA, <sup>6</sup>Univ of Iowa, Iowa City, IA

**2:42 PM Improving Access to Lung Transplant through Donor Strategy: A Decision Analysis (Abstract #474)**

W. Tsuang, B. Udeh, Cleveland Clinic, Cleveland, OH

**2:54 PM Incorporating Tangible Benefits into the Risk-Benefit Analysis of Living Organ Donation Decisions (Abstract #475)**

M. Robin<sup>1</sup>, S. Rasmussen<sup>2</sup>, A. Saha<sup>2</sup>, A. Eno<sup>2</sup>, M. Waldram<sup>2</sup>, D. Segev<sup>2</sup>, M. Henderson<sup>2</sup>, <sup>1</sup>University of Maryland, Baltimore, MD, <sup>2</sup>Johns Hopkins University, Baltimore, MD

**3:06 PM The Increasing Financial Challenge of Liver Transplantation (Abstract #476)**

D. Axelrod<sup>1</sup>, S. Hohmann<sup>2</sup>, K. Lentine<sup>3</sup>, H. Xiao<sup>3</sup>, B. Kasiske<sup>4</sup>, J. Snyder<sup>4</sup>, M. Ostrander<sup>5</sup>, M. Schnitzler<sup>3</sup>, <sup>1</sup>Univ of Iowa, Iowa City, IA, <sup>2</sup>Vizient Inc, Chicago, IL, <sup>3</sup>Saint Louis Univ, St. Louis, MO, <sup>4</sup>SRTR, Minneapolis, MN, <sup>5</sup>Visient, Inc., Minneapolis, IA

**3:18 PM The Clinical & Economic Impact Of Allosensitization In Liver Alone And Simultaneous Liver Kidney Transplantation (Abstract #477)**

M. Askar<sup>1</sup>, G. Saracino<sup>1</sup>, A. Elsabbagh<sup>2</sup>, J. Fung<sup>3</sup>, T. Srinivas<sup>4</sup>, S. Flechner<sup>5</sup>, J. Trotter<sup>1</sup>, G. Testa<sup>1</sup>, B. Kaplan<sup>6</sup>, G. Klintmalm<sup>1</sup>, J. Schold<sup>5</sup>, S. Asrani<sup>1</sup>, <sup>1</sup>Transplant Center, Baylor Scott & White, Dallas, TX, <sup>2</sup>St. Vincent Health, Indianapolis, IN, <sup>3</sup>University of Chicago Medicine, Chicago, IL, <sup>4</sup>Intermountain Healthcare, Salt Lake City, UT, <sup>5</sup>Cleveland Clinic, Cleveland, OH, <sup>6</sup>Transplant Center, Baylor Scott & White, Temple, TX

**3:30 PM The Impact of Transplant Hospital Organ Procurement on Medicare Cost Report Reimbursement (Abstract #478)**

E. Y. Zavala<sup>1</sup>, J. Rogers<sup>2</sup>, <sup>1</sup>Transplant Center, Vanderbilt University Medical Center, Nashville, TN, <sup>2</sup>Transplant Management Group, San Diego, CA

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

**3:42 PM Patient Perspectives of Informed Consent for Deceased Donor Organ Intervention Research (Abstract #479)**  
E. Gordon<sup>1</sup>, B. Knopf<sup>1</sup>, A. Mussell<sup>2</sup>, C. Phillips<sup>2</sup>, R. Veatch<sup>3</sup>, P. Abt<sup>2</sup>, P. Reese<sup>2</sup>,  
<sup>1</sup>Northwestern University, Chicago, IL,  
<sup>2</sup>University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Georgetown University, Washington DC, DC

## Innate Immunity; Chemokines, Cytokines, Complement

### Room: 310

Chairs: A. Kroemer, Georgetown University Hospital, Washington, DC and X. Luo, Duke University School of Medicine, Durham, NC

**2:30 PM Laminin  $\alpha$ 5 Deficiency in Lymph Node Stromal Cells Promotes Treg Migration and Allograft Survival (Abstract #480)**  
L. Li, M. Shirkey, W. Piao, Y. Xiong, V. Saxena, T. Zhang, T. Simon, N. Toney, C. Paluskiewicz, J. S. Bromberg, Surgery, U. Maryland, Baltimore, Baltimore, MD

**2:42 PM Regulating T Cell Responses by Forced Transgenic Expression of Decay-Accelerating Factor (Abstract #481)**  
D. Heja<sup>1</sup>, Z. He<sup>1</sup>, S. A. Lira<sup>1</sup>, F. Lin<sup>2</sup>, D. Homann<sup>1</sup>, P. S. Heeger<sup>1</sup>, <sup>1</sup>Icahn School of Medicine at Mount Sinai, New York, NY, <sup>2</sup>Cleveland Clinic, Cleveland, OH

**2:54 PM Absence of Protective Innate Lymphoid Cell Type 3 (ILC3) and Persistence of Proinflammatory Innate Lymphoid Cell Subsets Immediately Post-Transplant Plays a Appreciable Role in Early Intestinal Barrier Dysfunction (Abstract #482)**  
J. Kang, L. Belyayev, K. Loh, P. Cha, S. Moturi, K. Khan, J. Hawksworth, C. Matsumoto, M. Zasloff, T. Fishbein, A. Kroemer, Georgetown University, Washington, DC

**3:06 PM Local IL-33 Regulates Heart Transplant Infiltrating Myeloid Cells Metabolism and Differentiation to Protect against Chronic Rejection (Abstract #483)**  
Z. Zhang<sup>1</sup>, Q. Liu<sup>1</sup>, T. Li<sup>1</sup>, G. S. Hussey<sup>2</sup>, M. Velayutham<sup>1</sup>, J. L. Dziki<sup>2</sup>, L. R. Mathews<sup>1</sup>, Y. C. Lee<sup>2</sup>, G. K. Dwyer<sup>1</sup>, H. Dai<sup>1</sup>, A. S. Roessing<sup>1</sup>, S. Shiva<sup>3</sup>, M. H. Oberbarnscheidt<sup>1</sup>, S. F. Badylak<sup>2</sup>, H. R. Turnquist<sup>1</sup>, <sup>1</sup>Department of Surgery, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, <sup>2</sup>Department of Bioengineering, McGowan Institute for Regenerative Medicine, Pittsburgh, PA, <sup>3</sup>Department of Pharmacology and Chemical Biology, Vascular Medicine Institute, Pittsburgh, PA

**3:18 PM Complement Blockade in Kidney Recipients Prevents Delayed Graft Function and Antibody-Mediated Rejection in Non-Human Primates (Abstract #484)**  
M. Eerhart<sup>1</sup>, J. Reyes<sup>1</sup>, C. Blanton<sup>1</sup>, J. Danobeitia<sup>1</sup>, P. Chlebeck<sup>1</sup>, L. Zitur<sup>1</sup>, J. Coonen<sup>1</sup>, S. Capuano<sup>1</sup>, A. D'Alessandro<sup>1</sup>, J. Torrealba<sup>2</sup>, W. Zhong<sup>1</sup>, Y. Yankol<sup>1</sup>, L. Fernandez<sup>1</sup>, <sup>1</sup>University of Wisconsin, Madison, WI, <sup>2</sup>UT Southwestern, Dallas, TX

**3:30 PM A Potential Role for IgE-Mediated Immune Response in the Pathogenesis of Chronic Antibody-Mediated Rejection (Abstract #485)**  
F. Rascio<sup>1</sup>, P. Pontrelli<sup>2</sup>, G. S. Netti<sup>3</sup>, E. Manno<sup>1</sup>, B. Infante<sup>1</sup>, S. Simone<sup>2</sup>, G. Castellano<sup>2</sup>, M. Seveso<sup>4</sup>, E. Cozzi<sup>4</sup>, L. Gesualdo<sup>2</sup>, G. Stallone<sup>1</sup>, G. Grandaliano<sup>1</sup>, <sup>1</sup>Department of Medical and Surgical Sciences, Nephrology Dialysis and Transplantation Unit, University of Foggia, Foggia, Italy, <sup>2</sup>Department of Emergency, and Organ Transplantation, Nephrology, Dialysis and Transplantation Unit, University of Bari, Bari, Italy, <sup>3</sup>Dept. of Medical and Surgical Sciences, Clinical Pathology Unit, University of Foggia, Foggia, Italy, <sup>4</sup>Department of Cardiac, Thoracic and Vascular Sciences, Transplant Immunology Unit, University of Padua, Padova, Italy

Tuesday, June 4

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

**3:42 PM SIRP $\alpha$  Typing as a Potential Tool for Risk Stratification in Kidney Transplantation (Abstract #486)**  
A. Casillas-Abundis, A. Tambur, D. F. Pinelli, R. Hod-Dvorai, C. Garcia-Sanchez, *Transplant Immunology Laboratory, Northwestern University, Chicago, IL*

## Acute Rejection: Basic

**Room: 313**

*Chairs: T. Borges and N. Chun, New York, NY*

**2:30 PM Urinary Cell mRNA Sequencing Profiles of Kidney Allograft Recipients Mirror Intra-graft Events and Demonstrate Enrichment for Immune Cells (Abstract #487)**  
M. Lubetzky<sup>1</sup>, A. Verma<sup>2</sup>, H. Yang<sup>1</sup>, T. Muthukumar<sup>1</sup>, S. Salvatore<sup>1</sup>, J. Lee<sup>1</sup>, D. Dadhania<sup>1</sup>, S. Seshan<sup>1</sup>, F. Mueller<sup>1</sup>, O. Elemento<sup>2</sup>, M. Suthanthiran<sup>1</sup>, <sup>1</sup>*Division of Nephrology, Weill Cornell, New York, NY*, <sup>2</sup>*Institute for Computational Biomedicine, Weill Cornell, New York, NY*

**2:42 PM Extracellular Vesicles (EV) Mediate Antibody-Independent Tubular Senescence via Cyclin-Dependent Kinase Inhibitors p21/p16 in Antibody-Mediated Rejection (AMR) (Abstract #488)**  
C. Divella<sup>1</sup>, A. Stasi<sup>1</sup>, R. Franzin<sup>1</sup>, F. Sallustio<sup>2</sup>, C. Curci<sup>1</sup>, G. Merlotti<sup>3</sup>, M. Quaglia<sup>3</sup>, L. Gesualdo<sup>1</sup>, V. Cantaluppi<sup>1</sup>, G. Castellano<sup>1</sup>, <sup>1</sup>*Emergency and Organ Transplantation, University of Bari, Bari, Italy*, <sup>2</sup>*Emergency and Organ Transplantation / Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy*, <sup>3</sup>*Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy*

**2:54 PM Plasmacytoid Dendritic Cell-Mediated Graft Prolongation Requires microRNA-181 and Semaphorin 4a (Abstract #489)**  
J. Harden, X. Qi, A. Lau, S. Krams, *Stanford Univ School of Med, Stanford, CA*

**3:06 PM Platelets Augment Granzyme K Production By Macrophages In Antibody-mediated Rejection (Abstract #490)**  
J. Dhar, K. Keslar, R. Fan, N. Dvorina, W. Baldwin, *Cleveland Clinic Main Campus, Lerner Research Institute, Cleveland, OH*

**3:18 PM Tissue Resident Memory T Cells in Murine Renal Transplantation (Abstract #491)**  
K. Abou-Daya, D. Zhao, R. Tieu, A. Williams, M. Oberbarnscheidt, F. Lakkis, *Starzl Transplantation Institute, Pittsburgh, PA*

**3:30 PM p40 Homodimer Indirectly Induce Proliferation of Endogenous Donor-Reactive Memory CD8 T Cells within High-Risk Allografts via IL-15 Signaling (Abstract #492)**  
H. Tsuda, A. Valujskikh, R. Fairchild, *Inflammation and Immunity, Cleveland Clinic, Cleveland, OH*

**3:42 PM Rejection Of Optic And Sciatic Transplants (Abstract #493)**  
M. Yonar<sup>1</sup>, M. Uehara<sup>1</sup>, V. Kasinath<sup>1</sup>, F. Bei<sup>2</sup>, R. Abdi<sup>1</sup>, <sup>1</sup>*Renal, Brigham and Women's Hospital, Boston, MA*, <sup>2</sup>*Neurosurgery, Brigham and Women's Hospital, Boston, MA*

## Liver: Pediatrics

**Room: 210**

*Chairs: B. Sayed, Toronto, ON, Canada*

**2:30 PM Use of Marginal Liver Donors in Pediatric Transplantation: Diverse Profiles of Use in Major Transplant Centers (Abstract #494)**  
C. S. Hwang<sup>1</sup>, A. Aqul<sup>2</sup>, A. Mufti<sup>3</sup>, S. Hanish<sup>1</sup>, D. Desai<sup>1</sup>, P. Vagefi<sup>1</sup>, M. MacConmara<sup>1</sup>, <sup>1</sup>*Surgery, UT Southwestern, Dallas, TX*, <sup>2</sup>*Pediatrics, UT Southwestern, Dallas, TX*, <sup>3</sup>*Medicine, UT Southwestern, Dallas, TX*



**AMERICAN TRANSPLANT CONGRESS**  
Program, Tuesday, June 4, 2019

---

**2:42 PM Disparities in Pediatric Liver Transplant Waitlist Access (Abstract #495)**  
S. C. Kim<sup>1</sup>, K. Ross<sup>1</sup>, E. Hsu<sup>2</sup>, R. Patzer<sup>1</sup>, R. J. Lynch<sup>1</sup>, <sup>1</sup>Emory University, Atlanta, GA, <sup>2</sup>University of Washington, Seattle, WA

**2:54 PM No Gains In Long-term Survival Of Pediatric Patients After Liver Transplantation - A Three Decade Analysis (Abstract #496)**  
S. Bakhtiyar, A. Rana, S. Ahmed, H. Naseem, M. Kueht, N. T. Galvan, R. T. Cotton, C. A. O'Mahony, J. A. Goss, Baylor College of Medicine, Houston, TX

**3:06 PM Factors Associated with Subclinical Cardiovascular Damage after Pediatric Liver Transplantation: A Longitudinal Observational Study (Abstract #497)**  
N. Memaran<sup>1</sup>, I. Goldschmidt<sup>1</sup>, B. Borchert<sup>1</sup>, R. I. Sugianto<sup>1</sup>, H. Wilke<sup>1</sup>, R. Blöte<sup>1</sup>, U. Baumann<sup>1</sup>, E. Bauer<sup>1</sup>, A. von Wick<sup>1</sup>, N. Junge<sup>1</sup>, C. Leiskau<sup>1</sup>, E. D. Pfister<sup>1</sup>, N. Richter<sup>2</sup>, B. M. Schmidt<sup>3</sup>, A. Melk<sup>1</sup>, <sup>1</sup>Department of Pediatric Kidney, Liver, and Metabolic Diseases, Hannover Medical School, Hannover, Germany, <sup>2</sup>Department of General, Visceral and Transplantation Surgery, Hannover Medical School, Hannover, Germany, <sup>3</sup>Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany

**3:18 PM Assessment of the Global Practice of Pediatric Living Donor Liver Transplantation: Comparison of U.S. and International Programs (Abstract #498)**  
J. Emamaullee<sup>1</sup>, M. Kim<sup>1</sup>, C. Conrad<sup>1</sup>, C. Lane<sup>1</sup>, P. Singh<sup>1</sup>, C. Niemann<sup>2</sup>, L. Sher<sup>1</sup>, Y. Genyk<sup>1</sup>, <sup>1</sup>University of Southern California, Los Angeles, CA, <sup>2</sup>University of California-San Francisco, San Francisco, CA

**3:30 PM Renal Recovery and Prognostic Factors in Children Following Liver Transplantation (Abstract #499)**  
R. Büscher, N. Gantenberg, A. Büscher, E. Lainka, P. Hoyer, Department of Pediatrics II, University Hospital Essen, Essen, Germany

**3:42 PM Clinical Implications of Serum Mac-2 Binding Protein in Regular Follow Up after Pediatric Living Donor Liver Transplantation (Abstract #500)**  
T. Ueno<sup>1</sup>, T. Kodama<sup>1</sup>, Y. Noguchi<sup>1</sup>, M. Nomura<sup>1</sup>, R. Saka<sup>1</sup>, Y. Takama<sup>1</sup>, Y. Tazuke<sup>1</sup>, K. Bessho<sup>2</sup>, H. Okuyama<sup>1</sup>, <sup>1</sup>Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Japan, <sup>2</sup>Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan

**Non-Organ Specific: Disparities and Access to Healthcare I**

**Room: 208**  
Chairs: J. Rodrigue, Beth Israel Deaconess Medical Center, Boston, MA and K. Dhanireddy, Tampa General Hospital, Tampa, FL

**2:30 PM Using Transplant Referral Regions to Measure Access to Kidney Transplant (Abstract #501)**  
K. Ross<sup>1</sup>, D. Axelrod<sup>2</sup>, R. Patzer<sup>1</sup>, <sup>1</sup>Emory University, Emory Transplant Center, Atlanta, GA, <sup>2</sup>Dept of Surgery, University of Iowa, Iowa City, IA

**2:42 PM Center-Level Probability of Kidney Transplant Varies Considerably for Waitlisted Patients (Abstract #502)**  
K. L. King<sup>1</sup>, S. A. Husain<sup>1</sup>, P. Reese<sup>2</sup>, J. Schold<sup>3</sup>, S. Pastan<sup>4</sup>, S. Mohan<sup>1</sup>, <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Cleveland Clinic, Cleveland, OH, <sup>4</sup>Emory University, Atlanta, GA

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

**2:54 PM A Randomized, Controlled, Trial of Interventions to Promote Walking after Abdominal Organ Transplantation: The LIFT Study (Abstract #503)**

M. Serper<sup>1</sup>, I. Barankay<sup>2</sup>, S. Chadha<sup>1</sup>, J. Shults<sup>3</sup>, P. Reese<sup>1</sup>, <sup>1</sup>University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, <sup>2</sup>Wharton School, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA

**3:06 PM Trends and Geographic Variation in the Recovery of Organs from Drug-Overdose Deaths with Donor Potential (Abstract #504)**

V. Garcia, D. Stewart, J. Rosendale, Research, UNOS, Richmond, VA

**3:18 PM Reduction In Early Readmission In Kidney Recipients - Outcomes At One Year With Standardized Intensive Follow Up (Abstract #505)**

A. Crane, M. Eltemamy, R. Fatica, E. Poggio, C. Modlin, A. Wee, V. Krishnamurthi, *Glickman Urological and Kidney Institute CCF, Cleveland, OH*

**3:30 PM Variation in Racial Disparities in Liver Transplant Outcomes by Hospital Quality (Abstract #506)**

K. Ross, R. Patzer, R. Lynch, *Emory University, Emory Transplant Center, Atlanta, GA*

**3:42 PM Multicenter Cohort Study of Frailty and Access to Kidney Transplantation (Abstract #507)**

C. Haugen<sup>1</sup>, N. Chu<sup>1</sup>, H. Ying<sup>1</sup>, N. Desai<sup>1</sup>, S. Norman<sup>2</sup>, J. Garonzik-Wang<sup>1</sup>, A. Bingaman<sup>3</sup>, D. Segev<sup>1</sup>, M. McAdams-DeMarco<sup>1</sup>, <sup>1</sup>JHU, Baltimore, MD, <sup>2</sup>Michigan, Ann Arbor, MI, <sup>3</sup>Methodist, San Antonio, TX

## Kidney Paired Exchange

**Room: 206**

*Chairs: D. Mandelbrot, UW Health, Madison, WI and C. Marsh, Scripps Clinic, La Jolla, CA*

**2:30 PM The End of Non-Directed Living Kidney Donation: The National Kidney Registry's Family Voucher Program (Abstract #508)**

M. Cooper<sup>1</sup>, D. Leaser<sup>2</sup>, S. Flechner<sup>3</sup>, J. Verbese<sup>1</sup>, M. Ronin<sup>4</sup>, G. Hil<sup>4</sup>, A. Waterman<sup>5</sup>, J. Veale<sup>5</sup>, <sup>1</sup>Georgetown Transplant Institute, Washington, DC, <sup>2</sup>East Carolina University, Greenville, NC, <sup>3</sup>Cleveland Clinic, Cleveland, OH, <sup>4</sup>National Kidney Registry, New York, NY, <sup>5</sup>UCLA, Los Angeles, CA

**2:42 PM Global Kidney Exchange (Abstract #509)**

D. N. Bozek<sup>1</sup>, O. Ekwenna<sup>1</sup>, S. Paloyo<sup>2</sup>, T. Dunn<sup>3</sup>, K. Krawiec<sup>4</sup>, S. Rees<sup>5</sup>, A. Roth<sup>6</sup>, M. Zimmerman<sup>7</sup>, J. Punch<sup>8</sup>, R. Forbes<sup>9</sup>, C. Marsh<sup>10</sup>, C. Kuhr<sup>11</sup>, J. Rogers<sup>12</sup>, M. Tan<sup>13</sup>, L. Basagoitia<sup>14</sup>, R. Correa-Rotter<sup>15</sup>, J. Ortiz<sup>1</sup>, P. Sindhwani<sup>1</sup>, M. A. Rees<sup>1</sup>, <sup>1</sup>University of Toledo Medical Center, Toledo, OH, <sup>2</sup>University of the Philippines – Philippine General Hospital; St. Luke's Medical Center, Manila, Philippines, <sup>3</sup>University of Minnesota, Minneapolis, MN, <sup>4</sup>Duke University, Durham, NC, <sup>5</sup>Alliance for Paired Donation, Perrysburg, OH, <sup>6</sup>Stanford University, Stanford, CA, <sup>7</sup>Froedert Hospital-Medical College of Wisconsin, Milwaukee, WI, <sup>8</sup>University of Michigan, Ann Arbor, MI, <sup>9</sup>Vanderbilt University Medical Center, Nashville, TN, <sup>10</sup>Scripps Green Hospital, San Diego, CA, <sup>11</sup>Virginia Mason Medical Center, Seattle, WA, <sup>12</sup>Wake Forest Baptist Medical Center, Winston-Salem, NC, <sup>13</sup>Piedmont Hospital, Atlanta, GA, <sup>14</sup>ProRenal, Mexico, <sup>15</sup>INNSZ, Mexico City, Mexico

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

**2:54 PM Compatible Pairs in Paired Kidney Exchange - Are There Winners and Losers? (Abstract #510)**  
V. Chipman<sup>1</sup>, B. Lee<sup>1</sup>, M. Cooper<sup>2</sup>, M. C. Cuffy<sup>3</sup>, M. Ronin<sup>4</sup>, G. Hil<sup>4</sup>, S. Flechner<sup>5</sup>, A. Thomas<sup>6</sup>, D. A. Mandelbrot<sup>7</sup>, A. D. Waterman<sup>8</sup>, C. E. Freise<sup>1</sup>, G. R. Roll<sup>1</sup>,  
<sup>1</sup>UCSF, San Francisco, CA, <sup>2</sup>Georgetown Univ, Washington, DC, <sup>3</sup>UC Hospital, Cincinnati, OH, <sup>4</sup>NKR, Babylon, NY, <sup>5</sup>Cleveland Clinic, Cleveland, OH, <sup>6</sup>Johns Hopkins, Baltimore, MD, <sup>7</sup>Univ of Wisconsin, Madison, WI, <sup>8</sup>UCLA and Terasaki Research Institute, Los Angeles, CA

**3:06 PM Are We Underestimating The Number Of Paired Kidney Exchange Transplants In The United States? Relationship Insights From The National Kidney Registry (Abstract #511)**  
A. Thomas<sup>1</sup>, A. Shaffer<sup>2</sup>, D. Segev<sup>2</sup>,  
<sup>1</sup>Epidemiology, UNC Chapel Hill, Chapel Hill, NC, <sup>2</sup>Johns Hopkins University, Baltimore, MD

**3:18 PM Transplant Nephrologist (Abstract #512)**  
K. A. AlMeshari<sup>1</sup>, D. Broering<sup>2</sup>, I. Alahmadi<sup>3</sup>, S. Raza<sup>3</sup>, T. Ali<sup>3</sup>, F. Alzayer<sup>4</sup>, A. Algharabli<sup>4</sup>, <sup>1</sup>King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, <sup>2</sup>Organ Transplant Center, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, <sup>3</sup>Kidney & Pancreas Transplantation Department, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, <sup>4</sup>Department of Pathology & Laboratory Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

**3:30 PM Kidney Paired Donation Transplant Outcomes: Experiences from the First Ten Years of the National Kidney Registry (Abstract #513)**  
D. B. Leeser<sup>1</sup>, A. G. Thomas<sup>2</sup>, A. A. Shaffer<sup>2</sup>, J. Veale<sup>3</sup>, A. B. Massie<sup>2</sup>, M. Cooper<sup>4</sup>, S. Kapur<sup>5</sup>, S. Kapur<sup>5</sup>, S. Kapur<sup>5</sup>, N. Turgeon<sup>6</sup>, D. Segev<sup>2</sup>, A. Waterman<sup>3</sup>, S. Flechner<sup>7</sup>, <sup>1</sup>East Carolina Univ Sch of Med, Greenville, NC, <sup>2</sup>Johns Hopkins, Baltimore, MD, <sup>3</sup>UCLA, Los Angeles, CA, <sup>4</sup>Georgetown, Washington, DC, <sup>5</sup>Weill Cornell Medical School, New York, NY, <sup>6</sup>Emory, Atlanta, GA, <sup>7</sup>Cleveland Clinic, Cleveland, OH

**3:42 PM Social Loafing: Distribution of Kidneys with Multiple Renal Arteries in a National Paired Kidney Exchange Program (Abstract #514)**  
G. R. Roll<sup>1</sup>, W. Irish<sup>2</sup>, M. Cooper<sup>3</sup>, M. Ronin<sup>4</sup>, G. Hil<sup>4</sup>, A. D. Waterman<sup>5</sup>, D. B. Leeser<sup>2</sup>, <sup>1</sup>UCSF, San Francisco, CA, <sup>2</sup>ECU, Greenville, NC, <sup>3</sup>Georgetown Univ, Washington, DC, <sup>4</sup>NKR, Babylon, NY, <sup>5</sup>UCLA and Terasaki Research Institute, Los Angeles, CA

## Small Bowel

### Room: 209

Chairs: C. Matsumoto, Georgetown Transplant Institute, Washington, DC and J. Moon, Mount Sinai Medical Center, New York, NY

**2:30 PM Successful Weaning Of Parenteral Nutrition After Serial Transverse Enteroplasty: The Largest Series Of Adult Short Gut Syndrome Patients (Abstract #515)**  
M. Fujiki, S. Armanyous, K. Abu-Elmagd, Cleveland Clinic Foundation, Cleveland, OH

Tuesday, June 4

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

**2:42 PM The Role of the T Regulatory Cell Compartment in Intestinal Transplant Patients: Helpful or Unhinged? (Abstract #516)**

L. Belyayev<sup>1</sup>, M. Sadat<sup>2</sup>, K. Loh<sup>3</sup>, S. Moturi<sup>2</sup>, K. Khan<sup>2</sup>, J. Hawksworth<sup>2</sup>, C. Matsumoto<sup>2</sup>, T. M. Fishbein<sup>2</sup>, A. Kroemer<sup>2</sup>, <sup>1</sup>*Surgery, Walter Reed National Military Medical Center, Bethesda, MD*, <sup>2</sup>*Transplant, MedStar Georgetown Transplant Institute, Washington D.C., DC*, <sup>3</sup>*Pediatrics, Children's National Medical Center, Washington D.C., DC*

**2:54 PM An International Multicentre Validation Study of the Toronto Listing Criteria for Pediatric Intestinal Transplant (Abstract #517)**

A. J. Roberts<sup>1</sup>, P. W. Wales<sup>2</sup>, S. V. Beath<sup>3</sup>, H. M. Evans<sup>1</sup>, J. Hind<sup>4</sup>, T. Wong<sup>5</sup>, D. Mercer<sup>6</sup>, J. Yap<sup>7</sup>, C. Belza<sup>8</sup>, D. Grant<sup>9</sup>, Y. Avitzur<sup>10</sup>, <sup>1</sup>*Department of Paediatric Gastroenterology, Starship Child Health - Auckland District Health Board, Auckland, New Zealand*, <sup>2</sup>*Division of General & Thoracic Surgery, Hospital for Sick Children, University of Toronto,, Group for Improvement of Intestinal Function and Treatment (GIFT), Transplant Centre, Toronto, ON, Canada*, <sup>3</sup>*The Liver Unit, Birmingham Children's Hospital, Birmingham, United Kingdom*, <sup>4</sup>*Paediatric Liver, GI & Nutrition Centre, King's College Hospital, London, United Kingdom*, <sup>5</sup>*The Liver Unit, Birmingham Children's Hospital, Birmingham, United Kingdom*, <sup>6</sup>*Children's Hospital and Medical Centre, Omaha, NE*, <sup>7</sup>*Department of Pediatrics, University of Alberta, Edmonton, AB, Canada*, <sup>8</sup>*Group for Improvement of Intestinal Function and Treatment (GIFT), Transplant Centre, Toronto, ON, Canada*, <sup>9</sup>*Department of Surgery, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada*, <sup>10</sup>*Division of Gastroenterology, Hepatology & Nutrition, Group for Improvement of Intestinal Function and Treatment (GIFT), Transplant Centre, Toronto, ON, Canada*

**3:06 PM Surgical Management Of Five Hundred Patients With Chronic Gut Failure At A Single Center: Autologous Reconstruction Versus Transplantation (Abstract #518)**

S. Armanyous, Y. Fouda, M. Fujiki, N. Parekh, M. Osman, R. Girlanda, K. Hashimoto, G. Costa, K. Abu-Elmagd, *Cleveland Clinic, Cleveland, OH*

**3:18 PM A National Survey of Immunosuppression Strategies in Intestinal Transplantation (Abstract #519)**

M. Segovia<sup>1</sup>, T. Beduschi<sup>2</sup>, J. Boike<sup>3</sup>, D. Farmer<sup>4</sup>, S. Horslen<sup>5</sup>, K. Iyer<sup>6</sup>, S. Jafri<sup>7</sup>, A. Langnas<sup>8</sup>, C. Matsumoto<sup>9</sup>, A. Mavis<sup>1</sup>, G. Mazariegos<sup>10</sup>, S. Nagai<sup>7</sup>, J. O'Leary<sup>11</sup>, Y. Patel<sup>1</sup>, D. Sudan<sup>1</sup>, N. Sulejmani<sup>7</sup>, B. Summers<sup>7</sup>, T. Schiano<sup>6</sup>, <sup>1</sup>*Duke, Durham, NC*, <sup>2</sup>*Univ Miami, Miami, FL*, <sup>3</sup>*NWU, Chicago, IL*, <sup>4</sup>*UCLA, Los Angeles, CA*, <sup>5</sup>*Seattle Child, Seattle, WA*, <sup>6</sup>*Mt Sinai, NY, NY*, <sup>7</sup>*Henry Ford, Detroit, MI*, <sup>8</sup>*UNMC, Omaha, NE*, <sup>9</sup>*Georgetown, Washington, DC*, <sup>10</sup>*UPMC, Pittsburgh, PA*, <sup>11</sup>*Dallas VAMC, Dallas, TX*

**3:30 PM First Report and Mechanistic Analysis of Operational Tolerance after Intestinal Transplant (Abstract #520)**

J. Weiner<sup>1</sup>, S. Moturi<sup>1</sup>, C. Ashokkumar<sup>2</sup>, K. Khan<sup>1</sup>, S. Kaufman<sup>1</sup>, R. Sindi<sup>2</sup>, C. Matsumoto<sup>1</sup>, T. Fishbein<sup>1</sup>, A. Kroemer<sup>1</sup>, <sup>1</sup>*MedStar Georgetown Transplant Institute, Washington, DC*, <sup>2</sup>*University of Pittsburgh, Pittsburgh, PA*

**3:42 PM Visceral Arterial Embolization - An Important Tool For Managing Blood Loss In Multivisceral Transplant Candidates With Portomesenteric Thrombosis (Abstract #521)**

D. P. Borle, J. A. Shah, R. Kadiyala Venkata, D. Vikraman, B. Collins, S. Knechtle, A. Rege, A. Barbas, C. Kim, T. Smith, P. Sohocki, D. L. Sudan, *Duke University Medical Center, Durham, NC*

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

## Coffee Break in the Exhibit Hall

4:00 pm – 4:30 pm

## Concurrent Oral Abstract Sessions

4:30 pm – 6:00 pm

### Kidney Immunosuppression: Novel Regimens and Drug Minimization III

#### *Veterans Auditorium*

*Chairs: D. Brennan, Johns Hopkins Medical Institute, Baltimore, MD and S. Kuten, Houston, TX*

#### 4:30 PM **Increasing Time-in-Therapeutic Range of Tacrolimus is Associated with Superior Outcomes in Living Kidney Transplants (Abstract #524)**

T. Lin, T. Song, S. Yin, Y. Jiang, Z. Huang, X. Wang, J. Liu, Z. Wang, *Organ Transplantation Center, Urology Department, Urology Research Institute, WestChina Hospital, Sichuan University, Chengdu, China*

#### 4:42 PM **Ten Year Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients (Abstract #522)**

J. Leventhal<sup>1</sup>, J. Galvin<sup>1</sup>, L. Gallon<sup>1</sup>, D. Stare<sup>1</sup>, K. Ravindra<sup>2</sup>, M. Horwitz<sup>2</sup>, M. Abecassis<sup>1</sup>, S. Ildstad<sup>3</sup>, <sup>1</sup>*Northwestern U, Chicago, IL*, <sup>2</sup>*Duke U, Durham, NC*, <sup>3</sup>*U Louisville, Louisville, KY*

#### 4:54 PM **Improving Medication Adherence and Outcomes in Adult Kidney Transplant Patients Using SystemCHANGEM: Results of the Medication Adherence Given Individual Change (MAGIC) Randomized Clinical Trial (Abstract #523)**

M. R. Wakefield<sup>1</sup>, C. M. Ashbaugh<sup>2</sup>, L. Remy<sup>3</sup>, D. Aholt<sup>3</sup>, C. Miller<sup>3</sup>, S. Ye<sup>3</sup>, D. K. Hathaway<sup>4</sup>, D. Clark<sup>4</sup>, V. S. Staggs<sup>5</sup>, K. Goggin<sup>6</sup>, R. J. Ellis<sup>7</sup>, C. L. Russell<sup>3</sup>, <sup>1</sup>*Surgery/Urology, University of Missouri School of Medicine, Columbia, MO*, <sup>2</sup>*Transplant, University of Missouri Health Care, Columbia, MO*, <sup>3</sup>*School of Nursing and Health Studies, University of Missouri-Kansas City, Kansas City, MO*, <sup>4</sup>*College of Nursing, University of Tennessee HSC, Memphis, TN*, <sup>5</sup>*Health Services and Outcomes Research, Children's Mercy Kansas City, Kansas City, MO*, <sup>6</sup>*Health Services and Outcomes Research, Children's Mercy Kansas City and Schools of Medicine and Pharmacy, University of Missouri-Kansas City, Kansas City, MO*, <sup>7</sup>*School of Nursing, Indiana University, Indianapolis, IN*

#### 5:06 PM **Tacrolimus Concentrations Can Be Reliably Measured in Capillary Microsamples (Abstract #525)**

M. T. Gustavsen, N. Vethe, M. Lauritsen, A. Andersen, A. Åsberg, S. Bergan, K. Midtvedt, *Oslo University Hospital, Rikshospitalet, Oslo, Norway*

#### 5:18 PM **Patient Centered AUC-Monitoring of Tacrolimus Using Capillary Microsampling (Abstract #526)**

M. T. Gustavsen, K. Midtvedt, N. Vethe, S. Bergan, A. Åsberg, *Oslo University Hospital, Rikshospitalet, Oslo, Norway*

Tuesday, June 4



# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

**5:30 PM LCP-Tacrolimus (LCPT; Envarsus XR) Dosing Considerations in De Novo Kidney Transplant Recipients (Abstract #527)**

D. Cibrik<sup>1</sup>, P. West-Thielke<sup>2</sup>, S. J. Patel<sup>3</sup>, D. R. Stevens<sup>4</sup>, U. Meier-Kriesche<sup>4</sup>,  
<sup>1</sup>University of Kansas Medical Center, Kansas City, KS, <sup>2</sup>University of Illinois Hospital and Health Sciences System, Chicago, Chicago, IL, <sup>3</sup>Veloxis Pharmaceuticals, Cary, NC, <sup>4</sup>Veloxis Pharmaceuticals Inc., Cary, NC

**5:42 PM Impact of Once-Daily Tacrolimus on Trough Concentration Variability in Stable Adolescent and Young Adult Renal Transplant Recipients (Abstract #528)**

M. Moss, J. Goebel, A. Lofton, E. Steinberg, M. Bock, *Children's Hospital Colorado, Aurora, CO*

## Kidney: Polyoma

### Ballroom B

*Chairs: H. Hirsch, University of Basel / Department Biomedicine, Basel, Switzerland and C. Tan, Beth Israel Deaconess Medical Center, Boston, MA*

**4:30 PM Epidemiology and Outcomes of BKV Nephropathy Management by Screening Policy in a Real-Life Setting (Abstract #529)**

V. D. GARCIA<sup>1</sup>, F. V. Raupp<sup>1</sup>, G. MEINERZ<sup>1</sup>, K. Piegas<sup>2</sup>, E. KEITEL<sup>1</sup>,  
<sup>1</sup>Nephrology and Kidney and Pancreas Transplant Department, ISCMPA, Porto Alegre, Brazil, <sup>2</sup>Pathology Department, ISCMPA, Porto Alegre, Brazil

**4:42 PM Impact Of Subclinical Bk Virus-associated Nephropathy In High-risk Recipients (Abstract #530)**

M. E. Seifert, E. P. Kasik, M. Bernard, G. Agarwal, H. Fatima, R. Gaston, B. Julian, C. Kew, V. Kumar, S. Mehta, S. Ong, F. Rosenblum, G. Towns, R. B. Mannon, *University of Alabama, Birmingham, AL*

**4:54 PM Deceased-Donor Acute Kidney Injury Associates with Less BK Viremia in Kidney Transplant Recipients (Abstract #531)**

I. E. Hall, P. P. Reese, S. G. Mansour, S. Mohan, M. D. Doshi, Y. Jia, H. R. Thiessen-Philbrook, E. Akalin, M. N. Harhay, T. Muthukumar, B. Schröppel, P. Singh, F. L. Weng, J. S. Bromberg, C. R. Parikh, *For the DDS Consortium, Baltimore, MD*

**5:06 PM Donor-Derived Cell-Free DNA in Urine Identifies BKVN with Graft Injury in BK Viruria Kidney Transplant Recipients (Abstract #532)**

G. Huang<sup>1</sup>, X. Chen<sup>1</sup>, S. Yang<sup>2</sup>, W. Chen<sup>2</sup>, P. Chen<sup>3</sup>, X. Hou<sup>4</sup>, T. Jiang<sup>5</sup>, H. Liu<sup>5</sup>, X. Li<sup>5</sup>, C. Wang<sup>1</sup>, <sup>1</sup>Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, <sup>2</sup>Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, <sup>3</sup>Department of clinical laboratory, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, <sup>4</sup>Guangzhou KingMed Center for Clinical Laboratory Co.,Ltd., Guangzhou, China, <sup>5</sup>Research and Development, AlloDx Biotech Co.Ltd., Suzhou, China

**5:18 PM The Complexity of T Cell-Mediated Rejection Scenarios: Identifying BK in Biopsies with TCMR (Abstract #533)**

P. F. Halloran and The INTERCOMEX Investigators<sup>1</sup>, G. Gupta<sup>2</sup>, J. Reeve<sup>3</sup>,  
<sup>1</sup>University of Alberta, Edmonton AB, AB, Canada, <sup>2</sup>Virginia Commonwealth University, Richmond, VA, <sup>3</sup>Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada

**5:30 PM Predictors of Response to Intravenous Immunoglobulin for Treatment of Polyoma Nephropathy (Abstract #534)**

S. Sethi, A. Vo, A. Peng, R. Najjar, K. Lim, S. Jordan, E. Huang, *Cedars Sinai Medical Center, Los Angeles, CA*

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

**5:42 PM Increasing Net Immunosuppression after BK Viremia (Abstract #535)**  
L. Cotiguala, A. Masood, J. Park, A. Naik,  
*University of Michigan, Ann Arbor, MI*

## **Kidney: Cardiovascular and Metabolic III**

### **Ballroom C**

*Chairs: B. Fischbach, Fort Worth, TX and V. Humphreville, University Hospitals Cleveland Medical Center/Case Western Reserve University School of Medicine, Cleveland, OH*

**4:30 PM Vo2peak Superior to Current Established Measure of Post Kidney Transplant Survival Score (EPTS Score) (Abstract #536)**  
H. Chakker<sup>1</sup>, R. Butterfield<sup>1</sup>, M. Buras<sup>1</sup>, B. Kaplan<sup>2</sup>, <sup>1</sup>Mayo Clinic Hospital, Phoenix, AZ, <sup>2</sup>Baylor Scott and White, Dallas, TX

**4:42 PM Can Cardiac Risk Predictor Models Be Trusted in Kidney Transplant Recipients? (Abstract #537)**  
K. L. Hoffman<sup>1</sup>, R. R. Alloway<sup>1</sup>, A. Shields<sup>2</sup>, E. Woodle<sup>2</sup>, A. Govil<sup>1</sup>, <sup>1</sup>Nephrology & Transplant Medicine, University of Cincinnati, Cincinnati, OH, <sup>2</sup>Transplant Surgery, University of Cincinnati, Cincinnati, OH

**4:54 PM Positron Emission Tomography (PET-CT) Global Coronary Flow Reserve (CFR) Stratifies Cardiovascular Risk among Renal Transplant (RTx) Candidates (Abstract #538)**  
M. Minder, S. Mason, J. Ethington, R. McCubrey, D. Min, N. Sekaran, J. Orford, D. Morris, S. Anand, T. Srinivas, *Intermountain Healthcare, Murray, UT*

**5:06 PM Aorto-Iliac Calcification is a Risk Factor for Inferior Patient and Graft Survival in Kidney Transplant Recipients; A Systematic Review and Meta-Analysis (Abstract #539)**  
A. A. Rijkse, J. L. van Dam, H. J. Kimenai, J. N. IJzermans, R. C. Minnee, *HPB/Transplant surgery, Erasmus Medical Center, Rotterdam, Netherlands*

**5:18 PM The Benefit of Kidney Transplantation over the Waitlist Depends on the Patient's Comorbidities (Abstract #540)**  
A. Andrade Izquierdo<sup>1</sup>, J. V. Reusing Jr<sup>1</sup>, V. Onusic<sup>1</sup>, F. Agena<sup>1</sup>, F. C. Lemos<sup>1</sup>, F. de Paula<sup>1</sup>, F. Gerab<sup>2</sup>, E. David-Neto<sup>1</sup>, <sup>1</sup>Renal Transplantation Service, Hospital das Clínicas - University of São Paulo School of Medicine, Sao Paulo, Brazil, <sup>2</sup>Department of Mathematics, FEI University, Sao Paulo, Brazil

**5:30 PM Pre-Transplant Cardiac Work Up Does Not Predict Post-Transplant Cardiac Events at One Year among Kidney and Pancreas Transplant Recipients (Abstract #541)**  
S. M. Riad<sup>1</sup>, S. Konety<sup>1</sup>, S. Jackson<sup>2</sup>, N. Raj<sup>1</sup>, V. Vakil<sup>1</sup>, D. Keys<sup>1</sup>, E. Finger<sup>3</sup>, R. Spong<sup>1</sup>, <sup>1</sup>Medicine, University of Minnesota, Minneapolis, MN, <sup>2</sup>Complex Care Analytics, Fairview Health Services, Minneapolis, MN, <sup>3</sup>Surgery, University of Minnesota, Minneapolis, MN

**5:42 PM Protocol Cardiac Catheterization in Renal Transplant Candidates (Abstract #542)**  
D. B. Leaser<sup>1</sup>, C. B. Stone<sup>2</sup>, A. Maldonado<sup>2</sup>, D. L. Morris<sup>3</sup>, K. L. McLawhorn<sup>2</sup>, H. B. Jones<sup>2</sup>, <sup>1</sup>Surgery, East Carolina Univ Sch of Med, Greenville, NC, <sup>2</sup>Transplantation, Vidant Medical Center, Greenville, NC, <sup>3</sup>Cardiology, East Carolina Univ Sch of Med, Greenville, NC

## **Kidney Living Donor: Selection**

### **Ballroom A**

*Chairs: D. Serur, Englewood, NJ and E. Poggio, Cleveland Clinic, Cleveland, OH*

**4:30 PM Opening the Doors of Hope: HIV-Positive Living Kidney Donation (Abstract #543)**  
S. Rusch, L. Fieldman, M. Hemmersbach-Miller, C. R. Wolfe, *Duke University Medical Center, Durham, NC*

Tuesday, June 4

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

**4:42 PM Care of International Living Kidney Donor Candidates in the U.S.: A Survey of Contemporary Experience, Practice & Challenges (Abstract #544)**

K. Lentine<sup>1</sup>, M. Henderson<sup>2</sup>, S. Rasmussen<sup>2</sup>, E. Shukhman<sup>3</sup>, J. Hunt<sup>4</sup>, F. Al Ammary<sup>2</sup>, V. Kumar<sup>5</sup>, D. Lapointe-Rudow<sup>4</sup>, H. Schaefer<sup>6</sup>, M. Cooper<sup>7</sup>, R. Hays<sup>8</sup>, M. Dunbar-Forrest<sup>9</sup>, A. Nishio-Lucar<sup>10</sup>, D. Mandelbrot<sup>8</sup>, <sup>1</sup>*Saint Louis Univ, Saint Louis, MO*, <sup>2</sup>*Johns Hopkins, Baltimore, MD*, <sup>3</sup>*Cedars Sinai, Los Angeles, CA*, <sup>4</sup>*Mount Sinai, New York, NY*, <sup>5</sup>*Univ Alabama, Birmingham, AL*, <sup>6</sup>*Vanderbilt, Nashville, TN*, <sup>7</sup>*Georgetown, Washington, DC*, <sup>8</sup>*Univ Wisconsin, Madison, WI*, <sup>9</sup>*UCLA, Los Angeles, CA*, <sup>10</sup>*Univ Virginia, Charlottesville, VA*

**4:54 PM Assessing Pressure to Donate among Potential Living Kidney Donors (Abstract #545)**

D. R. Helfer<sup>1</sup>, J. Stanton<sup>2</sup>, E. A. King<sup>1</sup>, A. K. Eno<sup>1</sup>, J. M. Ruck<sup>1</sup>, A. A. Shaffer<sup>1</sup>, A. G. Thomas<sup>1</sup>, M. M. Waldram<sup>1</sup>, A. M. Cameron<sup>1</sup>, J. Kahn<sup>1</sup>, L. Erby<sup>1</sup>, M. L. Henderson<sup>1</sup>, D. L. Segev<sup>1</sup>, J. M. Garonzik Wang<sup>1</sup>, <sup>1</sup>*Johns Hopkins University, Baltimore, MD*, <sup>2</sup>*East Carolina University, Greenville, NC*

**5:06 PM Kidney Evaluation in Living Kidney Donors: Survey of US Transplant Centers 2018 (Abstract #546)**

N. Garg<sup>1</sup>, K. L. Lentine<sup>2</sup>, L. Inker<sup>3</sup>, A. X. Garg<sup>4</sup>, J. Rodrigue<sup>5</sup>, D. Segev<sup>6</sup>, D. A. Mandelbrot<sup>1</sup>, <sup>1</sup>*UW Madison, Madison, WI*, <sup>2</sup>*SLU, St. Louis, MO*, <sup>3</sup>*Tufts, Boston, MA*, <sup>4</sup>*Western University, London, ON, Canada*, <sup>5</sup>*BIDMC, Boston, MA*, <sup>6</sup>*JHU, Baltimore, MD*

**5:18 PM Estimated Glomerular Filtration Rate at Donor Screening to Predict Measured Glomerular Filtration Rate after Living Kidney Donation (Abstract #547)**

J. van der Weijden, M. van Londen, M. Y. Said, S. J. Bakker, S. P. Berger, G. Navis, M. H. de Borst, *Nephrology, University Medical Center Groningen, Groningen, Netherlands*

**5:30 PM The Model For Predicting eGFR At A Year After Donation In Living Related Kidney Transplant Donors (Abstract #548)**

K. Shinoda, K. Sakurabayashi, T. Mizutani, Y. Takahashi, Y. Hyodo, Y. Itabashi, M. Muramatsu, T. Kawamura, S. Shishido, K. Sakai, *Nephrology, Toho University Faculty of Medicine, Tokyo, Japan*

**5:42 PM Metabolic and Cardiovascular Evaluation in Living Kidney Donors: Survey of US Transplant Centers 2018 (Abstract #549)**

N. Garg<sup>1</sup>, K. L. Lentine<sup>2</sup>, L. Inker<sup>3</sup>, A. X. Garg<sup>4</sup>, J. Rodrigue<sup>5</sup>, D. Segev<sup>6</sup>, D. A. Mandelbrot<sup>1</sup>, <sup>1</sup>*UW Madison, Madison, WI*, <sup>2</sup>*SLU, St. Louis, MO*, <sup>3</sup>*Tufts, Boston, MA*, <sup>4</sup>*Western University, London, ON, Canada*, <sup>5</sup>*BIDMC, Boston, MA*, <sup>6</sup>*JHU, Baltimore, MD*

## Liver - Kidney Issues in Liver Transplantation

**Room: 302**

*Chairs: R. Fontana, University of Michigan, Ann Arbor, MI and S. Fayek, Inova Fairfax Hospital, Falls Church, VA*

**4:30 PM A Randomized Controlled Clinical Trial of Thymoglobulin® and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection after Liver Transplantation: A Multicenter Study (Abstract #550)**

L. Coromina<sup>1</sup>, S. Shah<sup>2</sup>, B. Xervos<sup>3</sup>, M. Zimmerman<sup>4</sup>, K. Sasaki<sup>1</sup>, T. Diago<sup>1</sup>, K. Hashimoto<sup>1</sup>, F. Aucejo<sup>1</sup>, m. Fujiki<sup>1</sup>, H. Block-Beach<sup>1</sup>, A. Patterson<sup>2</sup>, C. Miller<sup>1</sup>, C. Quintini<sup>1</sup>, B. Eghtesad<sup>1</sup>, <sup>1</sup>*The Cleveland Clinic, Cleveland, OH*, <sup>2</sup>*University of Cincinnati, Cincinnati, OH*, <sup>3</sup>*The Cleveland Clinic, Weston, FL*, <sup>4</sup>*Medical College of Wisconsin, Milwaukee, WI*

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

**4:42 PM** Recipients with Model for End-Stage Liver Disease Sodium Score Driven by Renal Dysfunction Have Increased Post-Transplant Mortality (Abstract #551)

T. Bittermann, D. Goldberg,  
*Gastroenterology, University of Pennsylvania, Philadelphia, PA*

**4:54 PM** Early Impact of the New United Network for Organ Sharing Simultaneous Liver-Kidney Transplantation Allocation Policy: Improved Standardization but Similar Utilization (Abstract #552)

G. Cullaro<sup>1</sup>, E. C. Verna<sup>2</sup>, J. C. Lai<sup>1</sup>,  
<sup>1</sup>UCSF, San Francisco, CA, <sup>2</sup>Columbia University, New York, NY

**5:06 PM** Hephaistos Study Outcome on Renal Function after 12 Month Everolimus Plus Reduced Tacrolimus in De Novo Liver Transplant Recipients versus Standard Tacrolimus (Abstract #553)

F. Braun<sup>1</sup>, P. Schemmer<sup>1</sup>, H. Schlitt<sup>1</sup>,  
A. Pascher<sup>1</sup>, C. Klein<sup>1</sup>, U. Neumann<sup>1</sup>, I. Kroeger<sup>2</sup>, P. Wimmer<sup>2</sup>, B. Nashan<sup>1</sup>, <sup>1</sup>Study Group, Hephaistos, Germany, <sup>2</sup>Novartis Pharma GmbH, Nuernberg, Germany

**5:18 PM** Chronic Kidney Disease among Liver Transplant Candidates: A Rising Burden and Its Impact on Post-Liver Transplant Outcomes (Abstract #554)

G. Cullaro<sup>1</sup>, E. C. Verna<sup>2</sup>, B. P. Lee<sup>1</sup>,  
J. C. Lai<sup>1</sup>, <sup>1</sup>UCSF, San Francisco, CA, <sup>2</sup>Columbia University, New York, NY

**5:30 PM** The Use of Native Kidney Biopsy to Predict Renal Dysfunction Following Liver Transplantation (Abstract #555)

D. O. Walls<sup>1</sup>, L. Muraveika<sup>1</sup>, M. B. Palmer<sup>2</sup>, D. L. Sawinski<sup>3</sup>, B. J. Keating<sup>1</sup>,  
P. L. Abt<sup>1</sup>, <sup>1</sup>Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Pathology, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

**5:42 PM** Donation after Cardiac Simultaneous Liver-Kidney: An Updated Perspective (Abstract #556)

R. Nunez, P. Morgan, A. Mathur, K. S. Reddy, A. Moss, B. Aqel, C. Jadlowiec,  
*Mayo Clinic AZ, Phoenix, AZ*

## Kidney Immunosuppression: Induction Therapy

**Room: 304**

*Chairs: H. Wadei, Mayo Clinic, Jacksonville, FL and J. Rogers, Wake Forest Baptist Medical Center, Winston Salem, NC*

**4:30 PM** Effect of Induction Therapy on Outcomes of De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from the TRANSFORM Study (Abstract #557)

R. Oberbauer<sup>1</sup>, F. Vincenti<sup>1</sup>, O. Viklicky<sup>1</sup>,  
U. Huynh-Do<sup>1</sup>, D. Kim<sup>1</sup>, J. M. Cruzado<sup>1</sup>,  
Y. Qazi<sup>1</sup>, M. S. Kim<sup>1</sup>, P. Narvekar<sup>2</sup>, M. P. Hernandez Gutierrez<sup>2</sup>, P. Bernhardt<sup>2</sup>, D. Kuypers<sup>1</sup>, <sup>1</sup>TRANSFORM Study Group, Basel, Switzerland, <sup>2</sup>Novartis Pharma AG, Basel, Switzerland

**4:42 PM** Effect of ATG on Monocytic Myeloid-Derived Suppressor Cells and Its Associated Mechanisms in Kidney Transplantation Recipients (Abstract #558)

Y. Jiang, X. Zhang, *Beijing Chao-yang Hospital, Beijing, China*

**4:54 PM** To Each Their Own: Center-Level Variation in Tailoring Induction Immunosuppression to Kidney Transplant Recipients (Abstract #559)

S. Bae, A. Massie, J. Garonzik Wang, M. McAdams DeMarco, J. Coresh, D. Segev,  
*Johns Hopkins University, Baltimore, MD*

Tuesday, June 4



# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

**5:06 PM Association Of Lymphocyte-depleting Antibody And Steroids Induction With The Risk And Outcomes Of Post-transplant Diabetes: Analysis Of Deceased-donor Kidney Transplants (Abstract #560)**

A. Santos<sup>1</sup>, J. Gregg<sup>2</sup>, U. L. Akanit<sup>3</sup>, K. Alquadan<sup>1</sup>, H. Bejjanki<sup>1</sup>, K. L. Womer<sup>1</sup>,  
<sup>1</sup>Div. of Nephrology, Hypertension & Renal Transplantation, University of Florida, Gainesville, FL, <sup>2</sup>University of Florida, Gainesville, FL, <sup>3</sup>Ubon Ratchathani University, Ubonratchathani, Thailand

**5:18 PM Basiliximab versus T-cell Depleting Induction Therapy in Elderly Kidney Transplant Recipients (Abstract #561)**

G. Vranic, H. Shah, B. Thomas, B. Javaid, J. Moore, M. Cooper, A. Gilbert, MedStar Georgetown Transplant Institute, Washington, DC

**5:30 PM Age-Related Effects on Thymic Output and Homeostatic T Cell Expansion Following Depletional Induction (Abstract #562)**

H. Xu, H. Lee, A. Kirk, Surgery, Duke University, Durham, NC

**5:42 PM Is Alemtuzumab Induction Safe In Septuagenarians Undergoing Deceased Donor Kidney Transplantation? (Abstract #563)**

D. Harriman, V. Gurrum, C. Jay, J. Rogers, A. Farney, G. Orlando, A. Reeves-Daniel, A. Mena-Gutierrez, R. Stratta, Wake Forest Baptist Medical Center, Winston-Salem, NC

## Liver: Recipient Selection

**Room: 312**

*Chairs: G. E. Loss, Ochsner Health System, New Orleans, LA and R. Wiesner, Mayo Clinic, Rochester, MN*

**4:30 PM Patterns and Predictors of Alcohol Use after Early Liver Transplant for Alcoholic Hepatitis (Abstract #564)**

B. P. Lee<sup>1</sup>, M. Rinella<sup>2</sup>, G. Im<sup>3</sup>, J. Rice<sup>4</sup>, O. Fix<sup>5</sup>, G. Therapondos<sup>6</sup>, H. Han<sup>7</sup>, D. Victor<sup>8</sup>, E. Weinberg<sup>9</sup>, C. Hsu<sup>10</sup>, M. Voigt<sup>11</sup>, H. Maddur<sup>2</sup>, S. Eswaran<sup>12</sup>, D. Foley<sup>4</sup>, R. Ghobrial<sup>8</sup>, L. Dinges<sup>5</sup>, J. Dodge<sup>1</sup>, N. Mehta<sup>1</sup>, M. Lucey<sup>4</sup>, N. Terrault<sup>1</sup>, <sup>1</sup>UCSF, SF, CA, <sup>2</sup>NW, Chicago, IL, <sup>3</sup>MtSinai, NYC, NY, <sup>4</sup>Wisconsin, Madison, WI, <sup>5</sup>Swedish, Seattle, WA, <sup>6</sup>Ochsner, Jefferson, LA, <sup>7</sup>USC, LA, CA, <sup>8</sup>Houston, Houston, TX, <sup>9</sup>Penn, Philadelphia, PA, <sup>10</sup>Georgetown, DC, WA, <sup>11</sup>Iowa, Iowa City, IA, <sup>12</sup>Rush, Chicago, IL

**4:42 PM Frailty and BMI in Liver Transplant Candidates: 9-Center Functional Assessment in Liver Transplantation Study (Abstract #565)**

C. Haugen<sup>1</sup>, M. McAdams-DeMarco<sup>1</sup>, D. Segev<sup>1</sup>, E. Verna<sup>2</sup>, R. Rahimi<sup>3</sup>, M. Kappus<sup>4</sup>, M. Volk<sup>5</sup>, M. Dunn<sup>6</sup>, A. Duarte Rojo<sup>6</sup>, D. Granger<sup>7</sup>, J. O'Leary<sup>8</sup>, D. Ladner<sup>7</sup>, J. Lai<sup>9</sup>, <sup>1</sup>JHU, Baltimore, MD, <sup>2</sup>Columbia, NYC, NY, <sup>3</sup>Baylor, Dallas, TX, <sup>4</sup>Duke, Durham, NC, <sup>5</sup>Loma Linda, Loma Linda, CA, <sup>6</sup>Pitt, Pittsburgh, PA, <sup>7</sup>Northwestern, Chicago, IL, <sup>8</sup>DVA, Dallas, TX, <sup>9</sup>UCSF, San Francisco, CA

**4:54 PM Impact of Recipient Age in Combined Liver-Kidney Transplantation (CLKT): Caution is Needed for Elderly Patients ≥ 70 Years (Abstract #566)**

B. Ekser<sup>1</sup>, W. C. Goggins<sup>1</sup>, R. S. Mangus<sup>1</sup>, P. Mihaylov<sup>1</sup>, J. A. Fridell<sup>1</sup>, M. A. Lacerda<sup>2</sup>, M. S. Ghabril<sup>2</sup>, J. A. Powelson<sup>1</sup>, C. A. Kubal<sup>1</sup>, <sup>1</sup>Transplant Division, Department of Surgery, Indiana University, Indianapolis, IN, <sup>2</sup>Gastroenterology, Indiana University, Indianapolis, IN



# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

**5:06 PM Elevated Visceral Adiposity is Associated with Post-Liver Transplant Mortality and Poorly Correlates with BMI in a Prospective Cohort Study (Abstract #567)**  
R. Sharma, R. Rosenblatt, R. Knotts, J. Pisa, E. Verna, *Division of Liver Diseases and Transplantation, Columbia University Medical Center, New York, NY*

**5:18 PM Halt-hcc At The Time Of Listing Is Superior To Other Allocation Metrics At Predicting Waitlist Dropout; An Srtr Analysis (Abstract #568)**  
J. C. McVey<sup>1</sup>, K. Sasaki<sup>1</sup>, D. J. Firl<sup>2</sup>, C. M. Miller<sup>1</sup>, K. Hashimoto<sup>1</sup>, C. Quintini<sup>1</sup>, F. N. Aucejo<sup>1</sup>, <sup>1</sup>*Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH*, <sup>2</sup>*Department of General Surgery, Duke University, Durham, NC*

**5:30 PM Favorable Waitlist Outcomes in Patients with Alcoholic Liver Disease in the MELD-Na Era (Abstract #569)**  
M. Safwan, K. Collins, D. Moonka, S. Jafri, M. Rizzari, A. Yoshida, M. Abouljoud, S. Nagai, *Henry Ford Health System, Detroit, MI*

**5:42 PM TIPS Effectively Treats Refractory Hepatic Hydrothorax: A Multi-Center U.S. Retrospective Study of 1,260 Patients (Abstract #570)**  
M. German<sup>1</sup>, A. Lee<sup>1</sup>, A. Hristov<sup>1</sup>, A. Said<sup>1</sup>, J. Boike<sup>2</sup>, J. Ge<sup>3</sup>, N. Jest<sup>4</sup>, G. Morelli<sup>4</sup>, K. Koll<sup>3</sup>, J. Lai<sup>3</sup>, A. Desai<sup>5</sup>, S. Junna<sup>6</sup>, B. Pokhrel<sup>6</sup>, T. Couri<sup>7</sup>, S. Paul<sup>7</sup>, C. Frenette<sup>8</sup>, N. Christian-Miller<sup>8</sup>, E. Verna<sup>9</sup>, U. Rahim<sup>10</sup>, A. Goel<sup>10</sup>, A. Das<sup>2</sup>, S. Pine<sup>2</sup>, D. Gregory<sup>2</sup>, L. VanWagner<sup>2</sup>, E. Spengler<sup>1</sup>, <sup>1</sup>*University of Wisconsin, Madison, WI*, <sup>2</sup>*Northwestern University, Chicago, IL*, <sup>3</sup>*University of California, San Francisco, San Francisco, CA*, <sup>4</sup>*University of Florida, Gainesville, FL*, <sup>5</sup>*University of Indiana, Indianapolis, IN*, <sup>6</sup>*University of Arizona, Tucson, AZ*, <sup>7</sup>*University of Chicago, Chicago, IL*, <sup>8</sup>*Scripps Clinic, San Diego, CA*, <sup>9</sup>*Columbia University, New York, NY*, <sup>10</sup>*Stanford University, Palo Alto, CA*

## Lymphocyte Biology: Signaling, Co-Stimulation, Regulation

**Room: 311**

*Chairs: W. W. Hancock, Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA and R. Abdi, Brigham & Womens Hosp, Boston, MA*

**4:30 PM Single Nucleotide Polymorphisms in NFACT1 rs2290154 Associated with the Risk of T Cell-Mediated Rejection of Recipients Following Kidney Transplantation (Abstract #571)**  
Z. Wang, S. Fei, H. Chen, L. Sun, Z. Han, J. Tao, X. Ju, R. Tan, M. Gu, *No.300 Guangzhou Road of Nanjing, Nanjing, China*

**4:42 PM Selective CD28 Blockade-Mediated Inhibition of T Follicular Helper Cell and DSA Responses is CTLA-4 Dependent (Abstract #572)**  
G. M. La Muraglia II, M. L. Ford, I. R. Badell, *Emory Transplant Center, Atlanta, GA*

**4:54 PM Type-1 Interferons Impair the Key Immunoregulatory Activity of IL-10 in the Promotion of Transplant Tolerance (Abstract #573)**  
M. Iglesias Lozano, M. Chicco, D. Bibicheff, G. Brandacher, G. Raimondi, *Plastic Surgery, Johns Hopkins University, Baltimore, MD*

**5:06 PM FcγRIIB is a Novel CD8+ Effector T Cell Intrinsic Regulatory Pathway That Correlates with Freedom from Rejection in Renal Transplant Patients (Abstract #574)**  
A. B. Morris<sup>1</sup>, D. F. Pinelli<sup>1</sup>, D. Liu<sup>1</sup>, J. M. Boss<sup>2</sup>, C. D. Scharer<sup>2</sup>, M. Fribourg<sup>3</sup>, P. Cravedi<sup>3</sup>, P. S. Heeger<sup>3</sup>, M. L. Ford<sup>1</sup>, <sup>1</sup>*Surgery, Emory University, Atlanta, GA*, <sup>2</sup>*Micro & Immuno, Emory University, Atlanta, GA*, <sup>3</sup>*Center for Translational Transplant Research, Icahn SOM at Mount Sinai, New York, NY*

Tuesday, June 4

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

**5:18 PM Lymphotoxin Signaling Regulates T Cell Lymphatic Trafficking (Abstract #575)**

W. Piao<sup>1</sup>, L. Li<sup>2</sup>, V. Saxena<sup>2</sup>, Y. Xiong<sup>2</sup>, M. WillsonShirkey<sup>2</sup>, C. Paluskievicz<sup>2</sup>, J. Bromberg<sup>3</sup>, <sup>1</sup>*Microbiology and Immunology, U. Maryland, Baltimore, Baltimore, MD*, <sup>2</sup>*Surgery, U. Maryland, Baltimore, Baltimore, MD*, <sup>3</sup>*Microbiology and Immunology, U. Maryland, Baltimore, Baltimore, MD*

**5:30 PM Memory T Follicular Helper Cell Alloresponse is Memory B Cell Independent and Inhibited by CD28 Costimulation Blockade (Abstract #576)**

S. Zeng, G. M. La Muraglia II, M. L. Ford, I. R. Badell, *Emory University School of Medicine, Atlanta, GA*

**5:42 PM Circulating Donor T and NK Cells in Lung Transplantation Recipients Are Derived from the Donor Lung Parenchyma and Represent Tissue-Resident Memory Cells (Abstract #577)**

J. F. Kuehne<sup>1</sup>, R. Ballmàs Sanz<sup>1</sup>, A. Hitz<sup>1</sup>, B. Wiegmann<sup>2</sup>, K. A. Bläsing<sup>1</sup>, F. Ius<sup>2</sup>, A. Knoefel<sup>2</sup>, I. Tudorache<sup>2</sup>, M. Avsar<sup>2</sup>, D. Jonigk<sup>3</sup>, A. Haverich<sup>2</sup>, G. Warnecke<sup>2</sup>, C. Falk<sup>1</sup>, <sup>1</sup>*Institute of Transplant Immunology, Hannover Medical School (MHH), Hannover, Germany*, <sup>2</sup>*Department for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School (MHH), Hannover, Germany*, <sup>3</sup>*Institute of Pathology, Hannover Medical School (MHH), Hannover, Germany*

**Biomarkers, Immune Monitoring and Outcomes V**

**Room: 306**

*Chairs: B. Keating, Philadelphia, PA and M. M. Sarwal, AL*

**4:30 PM Pre-Transplant Transcriptomic Signature in Peripheral Blood Predicts Early Acute Rejection after Kidney Transplant (Abstract #578)**

W. Zhang<sup>1</sup>, Z. Yi<sup>1</sup>, C. Wei<sup>1</sup>, K. Keung<sup>2</sup>, Z. Sun<sup>1</sup>, C. Xi<sup>1</sup>, C. Woytovich<sup>1</sup>, S. Farouk<sup>1</sup>, L. Gallon<sup>3</sup>, M. Menon<sup>1</sup>, C. Magee<sup>4</sup>, N. Najafian<sup>4</sup>, M. Samaniego<sup>5</sup>, A. Djamali<sup>6</sup>, S. Alexander<sup>2</sup>, I. Rosales<sup>7</sup>, R. Smith<sup>7</sup>, P. O'Connell<sup>2</sup>, R. Colvin<sup>7</sup>, P. Cravedi<sup>1</sup>, B. Murphy<sup>1</sup>, <sup>1</sup>*Icahn School of Medicine at Mount Sinai, New York, NY*, <sup>2</sup>*The University of Sydney, Sydney, Australia*, <sup>3</sup>*Northwestern University Feinberg School of Medicine, Chicago, IL*, <sup>4</sup>*Brigham and Women's Hospital, Boston, MA*, <sup>5</sup>*Henry Ford Hospital, Detroit, MI*, <sup>6</sup>*University of Wisconsin, Madison, WI*, <sup>7</sup>*Massachusetts General Hospital, Boston, MA*

**4:42 PM Promotion of Chimerism by Lymphohematopoietic Graft-versus-Host Responses in Patients Receiving Intestinal Transplantation (Abstract #579)**

J. Fu<sup>1</sup>, J. Zuber<sup>1</sup>, B. Shonts<sup>1</sup>, A. Obradovic<sup>1</sup>, K. Frangaj<sup>1</sup>, E. E. Waffarn<sup>1</sup>, S. Lau<sup>1</sup>, T. M. Savage<sup>1</sup>, S. Yang<sup>1</sup>, K. Rogers<sup>1</sup>, P. Satwani<sup>2</sup>, S. Ho<sup>1</sup>, Y. Shen<sup>3</sup>, A. Griesemer<sup>4</sup>, M. Martinez<sup>2</sup>, T. Kato<sup>4</sup>, M. Sykes<sup>1</sup>, <sup>1</sup>*Columbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, NY*, <sup>2</sup>*Department of Pediatrics, Columbia University, New York, NY*, <sup>3</sup>*Department of Systems Biology, Columbia University, New York, NY*, <sup>4</sup>*Department of Surgery, Columbia University, New York, NY*

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

**4:54 PM** **Monitoring Circulating T Follicular Helper Cells Polarization, Activation and Function Distinguishes Asymptomatic Donor-Specific Anti-HLA Antibody Positive Kidney Transplant Recipients from Those Undergoing Antibody-Mediated Rejection (Abstract #580)**

*C. Macedo*<sup>1</sup>, *K. Louis*<sup>1</sup>, *P. Fadakar*<sup>2</sup>, *M. Yamada*<sup>2</sup>, *B. Elinoff*<sup>1</sup>, *K. Hadi*<sup>1</sup>, *P. Randhawa*<sup>1</sup>, *D. Metes*<sup>1</sup>, <sup>1</sup>*Starzl Transplantation Institute, Pittsburgh, PA*, <sup>2</sup>*Children's Hospital of Pittsburgh, Pittsburgh, PA*

**5:06 PM** **Significantly High FOXP3 mRNA in the Renal Allograft as a Mechanism of Tolerance Induced by Transient Mixed Chimerism in Non-Human Primates (Abstract #581)**

*M. Matsunami*<sup>1</sup>, *I. Rosales*<sup>1</sup>, *T. Oura*<sup>1</sup>, *B. Adam*<sup>2</sup>, *M. Mengel*<sup>2</sup>, *R. Smith*<sup>1</sup>, *A. Cosimi*<sup>1</sup>, *R. Colvin*<sup>1</sup>, *T. Kawai*<sup>1</sup>, <sup>1</sup>*Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA*, <sup>2</sup>*Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada*

**5:18 PM** **A Single Measurement of Torque Teno Virus Helps to Predict Mortality in Renal Transplant Patients (Abstract #582)**

*E. Gore*<sup>1</sup>, *C. van Leer*<sup>1</sup>, *A. de Joode*<sup>2</sup>, *I. Nolte*<sup>3</sup>, *J. Westra*<sup>4</sup>, *A. Gomes Neto*<sup>2</sup>, *H. G. Niesters*<sup>1</sup>, *S. J. Bakker*<sup>2</sup>, <sup>1</sup>*Department of Medical Microbiology, University Medical Centre Groningen, Groningen, Netherlands*, <sup>2</sup>*Department of Nephrology, University Medical Centre Groningen, Groningen, Netherlands*, <sup>3</sup>*Department of Epidemiology, University Medical Centre Groningen, Groningen, Netherlands*, <sup>4</sup>*Department of Immunology, University Medical Centre Groningen, Groningen, Netherlands*

**5:30 PM** **Early CXCR5+PD1+ICOS+ Circulating Follicular T Helpers Are Associated with De Novo Donor-Specific Anti-HLA Antibodies after Renal Transplantation (Abstract #583)**

*R. Danger*<sup>1</sup>, *M. Chesneau*<sup>1</sup>, *F. Delbos*<sup>2</sup>, *S. Lebot*<sup>1</sup>, *C. Kerleau*<sup>1</sup>, *A. Chenouard*<sup>1</sup>, *A. Cesbron*<sup>2</sup>, *M. Giral*<sup>3</sup>, *S. Brouard*<sup>3</sup>, <sup>1</sup>*CRTI- INSERM UMR 1064- ITUN-Labex IGO -Université de Nantes -CHU Nantes, Nantes, France*, <sup>2</sup>*Laboratoire Histocompatibilité et Immunogénétique - Etablissement Français du sang, Nantes, France*, <sup>3</sup>*Centre d'Investigation Clinique en Biothérapie, Centre de ressources biologiques, Fondation Centaure, CRTI-INSERM UMR 1064- ITUN- Labex IGO -Université de Nantes -CHU Nantes, Nantes, France*

**5:42 PM** **Outcomes and Clinical Utility of the kSORT Assay in the Prism Prospective Clinical Trial of Highly Sensitized Kidney Transplant Recipients (Abstract #584)**

*A. Schroeder*, *P. Towfighi*, *C. Hu*, *S. Hsieh*, *J. Liberto*, *I. Damm*, *T. Sigdel*, *P. Millar*, *M. Sarwal*, *F. Vincenti*, *Department of Surgery, UCSF, San Francisco, CA*

## Non-Organ Specific: Viral Hepatitis

**Room: 309**

*Chairs: E. Verna, NY and D. Sawinski, Hospital of the U of Pennsylvania, Philadelphia, PA*

**4:30 PM** **Consideration for Offering Hepatitis C Antibody Positive Donor Grafts to All Patients Listed for Transplant (Abstract #585)**

*L. Smith*, *Vanderbilt Transplant Center, Nashville, TN*

Tuesday, June 4

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

**4:42 PM Optimal Timing of Hepatitis C Treatment among HIV/HCV Co-Infected End-Stage Renal Disease Patients: Pre vs. Post-Transplant (Abstract #586)**  
B. Shelton<sup>1</sup>, G. Berdahl<sup>1</sup>, D. Sawinski<sup>2</sup>, B. Linas<sup>3</sup>, P. Reese<sup>2</sup>, M. Mustian<sup>1</sup>, R. Reed<sup>1</sup>, P. MacLennan<sup>1</sup>, J. Locke<sup>1</sup>, <sup>1</sup>University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, <sup>3</sup>Boston University School of Medicine, Boston, MA

**4:54 PM Hepatitis C Treatment and Transplant Outcomes in Liver Transplant Recipients with Hepatitis C Positive Donors (Abstract #587)**  
I. Booth, J. Clark, J. C. LaMattina, A. Haririan, R. N. Barth, B. Ravichandran, University of Maryland Medical Center, Baltimore, MD

**5:06 PM Hepatitis C Positive Donor to Negative Recipient Kidney Transplantation: A Single Center Real World Experience (Abstract #588)**  
N. Jandovitz, V. Nair, E. Grodstein, E. Molmenti, A. Fahmy, M. Bhaskaran, L. Teperman, North Shore University Hospital, Manhasset, NY

**5:18 PM Rapid Growth of HCV-Infected Donors for HCV-Uninfected Kidney and Liver Transplant Recipients in the United States (Abstract #589)**  
M. Bowring, A. Shaffer, A. Massie, N. Desai, M. Sulkowski, A. Cameron, J. Garonzik-Wang, D. Segev, Johns Hopkins University, Baltimore, MD

**5:30 PM Renal Outcomes from Expander-1: Pilot Study of HCV+ Donor Kidneys for HCV- Kidney Recipients (Abstract #590)**  
S. Thaduri<sup>1</sup>, C. Durand<sup>1</sup>, N. Desai<sup>2</sup>, D. Segev<sup>2</sup>, N. Bair<sup>1</sup>, D. Brown<sup>1</sup>, F. F. Naqvi<sup>1</sup>, <sup>1</sup>Medicine, -Johns Hopkins University, -Baltimore, MD, <sup>2</sup>Surgery, -Johns Hopkins University, -Baltimore, MD

**5:42 PM Results from the LIVE-C Free Trial (Abstract #591)**  
J. N. Fleming<sup>1</sup>, D. DuBay<sup>1</sup>, N. L. Jonassaint<sup>2</sup>, R. S. Satoskar<sup>3</sup>, K. D. Chavin<sup>4</sup>, <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>3</sup>Medstar Georgetown Medical Center, Washington, DC, <sup>4</sup>University Hospital, Cleveland, OH

## Stem Cell, Cellular Therapies and Regenerative Medicine

**Room: 310**  
Chairs: E. Yolcu, Louisville, Louisville, KY and C. Blosser, WA

**4:30 PM Human Urine-Derived Stem Cells Protect against Renal Ischemia Reperfusion Injury via Releasing Exosomal miR-146a-5p Which Targets IRAK1 in a Rat Model (Abstract #592)**  
X. Li, Z. Bi, Q. Su, H. Huang, L. Liu, C. Wang, Organ Transplant Center, Sun Yat-sen University, Guangzhou, China

**4:42 PM Lineage Tracing Identifies C-Kit Cells as a Population of Kidney-Specific Stem Cells during Development and in Acute and Chronic Kidney Diseases (Abstract #593)**  
E. B. Rangel<sup>1</sup>, E. Higuti-Sousa<sup>1</sup>, G. Goss<sup>2</sup>, B. Goldstein<sup>2</sup>, B. Seidler<sup>3</sup>, D. Saur<sup>3</sup>, S. A Gomes<sup>4</sup>, J. M. Hare<sup>2</sup>, <sup>1</sup>Albert Einstein Hospital, São Paulo, Brazil, <sup>2</sup>University of Miami, Miami, FL, <sup>3</sup>Medizinische Klinik, Technische Universität München, Munich, Germany, <sup>4</sup>University of São Paulo, São Paulo, Brazil



# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

**4:54 PM Differences of Gut Microbiota Composition between Donor and Recipient May Predict 1-Year Graft Function (Abstract #594)**  
J. Kim<sup>1</sup>, H. Cho<sup>2</sup>, J. Park<sup>3</sup>, J. Jeong<sup>1</sup>, M. Kwak<sup>4</sup>, B. Kim<sup>4</sup>, D. Kim<sup>1</sup>, J. Lee<sup>5</sup>, B. Kim<sup>6</sup>, Y. Kim<sup>1</sup>, H. Lee<sup>1</sup>, <sup>1</sup>Seoul National University Hospital, Seoul, Korea, Republic of, <sup>2</sup>Chungbuk National University Hospital, Cheongju, Korea, Republic of, <sup>3</sup>Kangwon National University Hospital, Seoul, Korea, Republic of, <sup>4</sup>Chunlab Inc., Seoul, Korea, Republic of, <sup>5</sup>Seoul National University Boramae Hospital, Seoul, Korea, Republic of, <sup>6</sup>Hallym University, Chuncheon, Korea, Republic of

**5:06 PM Engineering Regulatory T Cells With TCR-Signaling-Responsive Interleukin 2 Nanoparticles Provides In Situ Suppression Of Alloimmunity (Abstract #595)**  
S. K. Eskandari<sup>1</sup>, M. B. Melo<sup>2</sup>, I. Sulkaj<sup>1</sup>, N. Li<sup>2</sup>, S. Cai<sup>1</sup>, H. Allos<sup>1</sup>, J. Y. Choi<sup>1</sup>, D. J. Irvine<sup>2</sup>, J. R. Azzi<sup>1</sup>, <sup>1</sup>Harvard Medical School, Brigham and Women's Hospital, Boston, MA, <sup>2</sup>David H. Koch Institute for Integrative Cancer Research, Cambridge, MA

**5:18 PM Differentiation and Characterization of Human Endodermal Precursors for Liver Cell Therapies (Abstract #596)**  
W. S. Fagg<sup>1</sup>, N. Liu<sup>1</sup>, M. Shoja<sup>1</sup>, I. Patrikeev<sup>2</sup>, M. Motamedi<sup>2</sup>, J. Fair<sup>1</sup>, <sup>1</sup>Surgery, University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX

**5:30 PM Immunosuppression Increases Regenerative Potential of Adult Rat Cardiac Progenitor Cells in Allogeneic Rat Myocardial Infarction Model (Abstract #597)**  
M. Gunasekaran, R. Mishra, S. Sharma, P. Saha, M. Y. Arfat, C. Ambastha, D. Morales, F. Xuebin, G. J. Bittle, D. Li, S. Kaushal, Department of Surgery, University of Maryland, Baltimore 21201, MD

**5:42 PM MDSCs Prolong Allogeneic Cardiac Graft Survival by Regulating Interferon Type 1 Signaling (Abstract #598)**  
S. Cai<sup>1</sup>, P. T. Sage<sup>1</sup>, T. J. Borges<sup>1</sup>, T. Ichimura<sup>1</sup>, S. K. Eskandari<sup>1</sup>, J. Y. Choi<sup>1</sup>, I. Salkuj<sup>1</sup>, B. S. Al Dulaijan<sup>1</sup>, H. Allos<sup>1</sup>, J. Miao<sup>2</sup>, L. V. Riella<sup>1</sup>, A. K. Chandraker<sup>1</sup>, J. R. Azzi<sup>1</sup>, <sup>1</sup>Brigham and Women's Hospital, Harvard Medical School, Boston, MA, <sup>2</sup>Boston Children's Hospital, Harvard Medical School, Boston, MA

## Ischemia Reperfusion & Organ Rehabilitation III

**Room: 313**

**Chairs:** H. Yeh, Massachusetts General Hospital, Boston, MA and A. Jani

**4:30 PM Total Parenteral Nutrition in Ex Vivo Lung Perfusion: Addressing Metabolism Improves Both Inflammation and Overall Graft Performance (Abstract #599)**  
M. T. Buchko, S. Hatami, C. J. Stewart, S. Himmat, D. H. Freed, J. Nagendran, Department of Surgery, Division of Cardiac Surgery, University of Alberta, Edmonton, AB, Canada

**4:42 PM Normothermic Ex-Vivo Kidney Perfusion Preservation Consistently Improves Extreme Marginal Graft Function Compared to Hypothermic Machine Perfusion (Abstract #600)**  
P. Urbanellis<sup>1</sup>, M. Hamar<sup>1</sup>, I. Linares<sup>1</sup>, D. Kollmann<sup>1</sup>, S. Ganesh<sup>1</sup>, F. Oquendo<sup>1</sup>, M. Sharma<sup>1</sup>, R. John<sup>1</sup>, A. Ghanekar<sup>1</sup>, I. Mucsi<sup>1</sup>, D. Bagli<sup>2</sup>, A. Konvalinka<sup>1</sup>, L. Robinson<sup>3</sup>, M. Selzner<sup>1</sup>, <sup>1</sup>Multi-Organ Transplantation Program, University Health Network, Toronto, ON, Canada, <sup>2</sup>Division of Urology, The Hospital for Sick Children, Toronto, ON, Canada, <sup>3</sup>Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada

Tuesday, June 4



# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

---

**4:54 PM** **Donation After Circulatory Death Kidneys With Prolonged Delayed Graft Function Present Widespread Metabolic And Translational Deficiencies At Time Of Retrieval (Abstract #601)**  
M. L. Lo Faro<sup>1</sup>, K. Rozenberg<sup>1</sup>, H. Huang<sup>1</sup>, S. Maslau<sup>1</sup>, H. Leuvenink<sup>2</sup>, E. Sharples<sup>3</sup>, R. Ploeg<sup>1</sup>, <sup>1</sup>*Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom*, <sup>2</sup>*University Medical Centre Groningen, Groningen, Netherlands*, <sup>3</sup>*Oxford Transplant Centre, Oxford, United Kingdom*

**5:06 PM** **Ex Vivo Normothermic Perfusion Of Discarded Human Kidneys Reveals Cold-storage-induced Renal Fibrinogen And Provides A Platform For Therapeutic Repair (Abstract #603)**  
J. DiRito<sup>1</sup>, S. A. Hosgood<sup>2</sup>, M. Reschke<sup>3</sup>, M. L. Nicholson<sup>2</sup>, G. T. Tietjen<sup>4</sup>, <sup>1</sup>*Surgery, Yale University & University of Cambridge, New Haven, CT*, <sup>2</sup>*Surgery, University of Cambridge, Cambridge, United Kingdom*, <sup>3</sup>*Biomedical Engineering, Yale University, New Haven, CT*, <sup>4</sup>*Surgery - Transplantation, Yale University, New Haven, CT*

**5:18 PM** **Organ Resilience Contributes to Different Impact of Delayed Graft Function (DGF) on Graft Survival in Kidneys Donated by Brain Death (DBD) and Circulatory Death Donors (DCD) (Abstract #604)**  
M. J. de Kok, A. F. Schaapherder, L. G. Wijermars, D. K. de Vries, J. L. Lindeman, *Transplantation Center, LUMC, Leiden, Netherlands*

**5:30 PM** **Effects of Static Subnormothermic Preservation of Extended Warm Ischemic Porcine Kidneys Assessed by Ex-Vivo Machine Perfusion and Renal Transplant Model (Abstract #605)**  
H. Sahara, Y. Ariyoshi, M. Sekijima, T. Iwanaga, A. Shimizu, K. Yamada, *Center for Advanced Biomedical Science and Swine Research, Kagoshima University, Kagoshima, Japan*

**5:42 PM** **miR-20a Inhibits Autophagy by Targeting AKT and BIM in Renal Reperfusion Injury (Abstract #602)**  
T. Lin, T. Song, Y. Jiang, J. Liu, Z. Wang, L. Li, Z. Huang, Y. Fan, X. Wang, *Organ Transplantation Center, Urology Department, Urology Research Institute, WestChina Hospital, Sichuan University, Chengdu, China*

## Quality Assurance Process Improvement & Regulatory Issues II

**Room: 210**

*Chairs: K. Lentine, Saint Louis University Medical Center, Saint Louis, MO and R. Hasz, Gift of Life Donor Program, Philadelphia, PA*

**4:30 PM** **Opioid Minimization in Kidney Transplant: Achievable Quicker Than You Think (Abstract #606)**  
J. N. Fleming, N. Patel, H. Gonzales, N. A. Pilch, S. Parks, C. Perez, P. K. Baliga, S. N. Nadig, D. J. Taber, V. Rohan, *Medical University of South Carolina, Charleston, SC*

**4:42 PM** **Role of Procurement and Reperfusion Biopsy in Kidney Transplant in Evaluating and Predicting Outcomes of Deceased Donor Kidneys (Abstract #607)**  
S. Faiz, A. Pai, A. De Golovine, A. Edwards, W. Glass, A. Tchakarov, *UT Houston, Houston, TX*

**4:54 PM** **Improving Living Donor Follow Up (Abstract #608)**  
L. Aronoff, V. Nair, C. Flores, M. Bhaskaran, E. Molmenti, A. Fahmy, M. Zhou, E. Grodstein, D. Campbell, C. Literello, L. Teperman, *Renal Transplant, Northwell Health, Manhasset, NY*

**5:06 PM** **Using Liver Transplant (LT) Data And Analytics to Improve Program Clinical and Financial Performance (Abstract #609)**  
A. Bonham<sup>1</sup>, Z. Tulu<sup>2</sup>, W. Concepcion<sup>1</sup>, A. Gallo<sup>1</sup>, M. Melcher<sup>1</sup>, P. Kwo<sup>1</sup>, A. Ahmed<sup>1</sup>, C. Esquivel<sup>1</sup>, <sup>1</sup>*Stanford University Medical School, Palo Alto, CA*, <sup>2</sup>*Stanford Health Care, Palo Alto, CA*

# AMERICAN TRANSPLANT CONGRESS

Program, Tuesday, June 4, 2019

**5:18 PM Using an Electronic Medical Record Tool to Document Transplant Option Discussions among Patients with EGFR  $\leq$  20 mL/min/1.73m<sup>2</sup> (Abstract #610)**

A. Yishak<sup>1</sup>, R. R. Brentari<sup>2</sup>, R. M. Love La Londe<sup>3</sup>, E. Clark<sup>4</sup>, E. Clark<sup>4</sup>, J. Sun<sup>5</sup>, S. Vupputuri<sup>6</sup>, <sup>1</sup>Nephrology, MAPMG, Mc Lean, VA, <sup>2</sup>KP National Transplant Service, Oakland, CA, <sup>3</sup>KP National Transplant Services, Oakland, CA, <sup>4</sup>KP National Transplant Services, silver spring, MD, <sup>5</sup>KP, Rockville, MD, <sup>6</sup>MAPRI, MAPMG, Rockville, MD

**5:30 PM Development of a Pharmacy Collaborative Practice Agreement to Improve Efficiency and Management of Prescribing in a Renal Transplant Clinic (Abstract #611)**

R. Chelewski<sup>1</sup>, K. Johnson<sup>1</sup>, A. Zuckerman<sup>2</sup>, J. DeClercq<sup>3</sup>, L. Choi<sup>3</sup>, M. Peter<sup>2</sup>, A. J. Langone<sup>4</sup>, <sup>1</sup>Vanderbilt Specialty Pharmacy Services, Vanderbilt Univ Medical Ctr, Nashville, TN, <sup>2</sup>Department of Pharmacy, Vanderbilt Univ Medical Ctr, Nashville, TN, <sup>3</sup>Department of Biostatistics, Vanderbilt Univ Medical Ctr, Nashville, TN, <sup>4</sup>Division of Nephrology, Vanderbilt Univ Medical Ctr, Nashville, TN

**5:42 PM Improving the Organ Donation Process: Updated (Abstract #612)**

J. Yeh, M. P. Jarrett, L. Teperman, Northwell Health, New Hyde Park, NY

**Non-Organ Specific: Disparities and Access to Healthcare II**

**Room: 208**

*Chairs: S. Mohan, Columbia University Medical Center, New York, NY and J. Rodrigue, Beth Israel Deaconess Medical Center, Boston, MA*

**4:30 PM Dialysis Facility Provider Transplant Knowledge after a Randomized Multilevel Intervention to Increase Kidney Transplant Referral and Evaluation in the Southeast (Abstract #613)**

K. Maroney<sup>1</sup>, R. Hamoda<sup>1</sup>, L. McPherson<sup>1</sup>, A. Cruz<sup>2</sup>, S. Pastan<sup>1</sup>, L. Plantinga<sup>1</sup>, S. Paul<sup>1</sup>, M. Ellis<sup>3</sup>, D. DuBay<sup>4</sup>, A. Reeves-Daniel<sup>5</sup>, R. Detwiler<sup>6</sup>, E. Hartmann<sup>7</sup>, H. Jones<sup>8</sup>, B. Thrasher<sup>9</sup>, C. Zayas<sup>10</sup>, L. Mulloy<sup>10</sup>, S. Wright<sup>11</sup>, R. Patzer<sup>1</sup>, <sup>1</sup>Emory University, Atlanta, GA, <sup>2</sup>IPRO Network of the South Atlantic, Raleigh, NC, <sup>3</sup>Duke University, Durham, NC, <sup>4</sup>Medical University of South Carolina, Charleston, SC, <sup>5</sup>Wake Forest Health Transplant Center, Winston-Salem, NC, <sup>6</sup>UNC Center for Transplantation, Chapel Hill, NC, <sup>7</sup>Piedmont Transplant Institute, Atlanta, GA, <sup>8</sup>Vidant Medical Center Transplant Services, Greenville, NC, <sup>9</sup>Carolinas Transplant Center, Charlotte, NC, <sup>10</sup>Augusta University, Augusta, GA, <sup>11</sup>IPRO Network of the South Atlantic, Morrisville, NC

**4:42 PM Racial and Ethnic Disparities in Access to Living Donor Kidney Transplantation in the US: Have We Made Any Progress among Pediatric Candidates over the Last Twenty Years? (Abstract #614)**

T. Purnell<sup>1</sup>, S. Bae<sup>1</sup>, X. Luo<sup>1</sup>, A. Chen<sup>1</sup>, D. Crews<sup>1</sup>, L. Cooper<sup>1</sup>, O. N. Bignall II<sup>2</sup>, K. Covarrubias<sup>1</sup>, D. Segev<sup>1</sup>, <sup>1</sup>Johns Hopkins School of Medicine, Baltimore, MD, <sup>2</sup>Nationwide Children's Hospital, Columbus, OH

Tuesday, June 4

**AMERICAN TRANSPLANT CONGRESS**  
Program, Tuesday, June 4, 2019

---

**4:54 PM Gender Disparity In Access To Liver Transplant Larger In White Than Black Patients (Abstract #615)**

K. Guo, J. Peipert, M. Abecassis, L. Zhao, D. Ladner, *Northwestern University, Chicago, IL*

**5:06 PM Women Who Undergo Liver Transplant Have Increased Health Care Utilization in the Peri-Transplant Period Compared with Men (Abstract #616)**

J. B. Rubin, G. Cullaro, J. Ge, J. C. Lai, *Department of Medicine, Division of Gastroenterology & Hepatology, University of California-San Francisco, San Francisco, CA*

**5:18 PM Association between a Chronic Kidney Disease Treatment Education Class and Receipt of a Kidney Transplantation in the Southeastern U.S. Population (Abstract #617)**

J. C. Gander<sup>1</sup>, L. Cromwell<sup>1</sup>, A. S. Wilk<sup>2</sup>, R. E. Patzer<sup>2</sup>, M. Sesay<sup>1</sup>, D. Walker-Williams<sup>1</sup>, T. Davis<sup>1</sup>, J. P. Austin<sup>1</sup>, N. Mukerji<sup>1</sup>, <sup>1</sup>*Kaiser Permanente, Atlanta, GA*, <sup>2</sup>*Emory University, Atlanta, GA*

**5:30 PM Racial and Income-Based Disparities in Access to Kidney Transplantation in the Context of a Nationally-Financed Health System in Brazil (Abstract #618)**

A. Saha<sup>1</sup>, G. Ferreira<sup>2</sup>, Y. Yu<sup>1</sup>, M. Waldram<sup>1</sup>, V. Colares<sup>2</sup>, J. Bastos<sup>2</sup>, M. Henderson<sup>1</sup>, D. Segev<sup>1</sup>, A. Massie<sup>1</sup>, <sup>1</sup>*Surgery, Johns Hopkins School of Medicine, Baltimore, MD*, <sup>2</sup>*Santa Casa de Misericordia de Juiz de Fora, Juiz de Fora, Brazil*

**5:42 PM Racial Disparity in Pre-Kidney Transplant Work-Up (Abstract #619)**

J. Buggs<sup>1</sup>, H. Mohamed<sup>2</sup>, C. Myer<sup>3</sup>, S. Lloyd<sup>4</sup>, E. Rogers<sup>1</sup>, H. Pearson<sup>1</sup>, J. Clement<sup>1</sup>, D. Zunick<sup>1</sup>, A. Kumar<sup>2</sup>, V. Bowers<sup>1</sup>, <sup>1</sup>*Tampa General Hospital, Tampa, FL*, <sup>2</sup>*University of South Florida, Tampa, FL*, <sup>3</sup>*University of Tampa, Tampa, FL*, <sup>4</sup>*University of Florida, Gainesville, FL*

**Late Breaking Oral Abstract**

*Room: 206*

**4:30 PM Concentric Circles, One Year in: Concentrated Organ Discard and Waitlist Deaths in High Traffic Areas (Abstract #626)**

R. J. Lynch<sup>1</sup>, S. Karp<sup>2</sup>, W. Chapman<sup>3</sup>, <sup>1</sup>*Emory, Atlanta, GA*, <sup>2</sup>*Vanderbilt, Nashville, TN*, <sup>3</sup>*Washington University St. Louis, St. Louis, MO*

**4:42 PM Ultra-Short Duration Direct Acting Anti-Viral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kidney Transplant Recipients (Abstract #627)**

G. Gupta, I. Yakubu, C. Bhati, A. Ferreira-Gonzalez, D. Kumar, I. Moinuddin, L. Kamal, A. King, M. Levy, A. Sharma, A. Cotterell, T. Reichman, A. Khan, P. Kimball, R. Stiltner, M. Baldecchi, N. Brigle, T. Gehr, R. Sterling, *Virginia Commonwealth University, Richmond, VA*

**4:54 PM Treg Suppressor Function within Allografts is Required for Tolerance (Abstract #628)**

J. Ossart, A. Pena, H. Dai, L. Bauer, A. Williams, G. Camirand, *Surgery, University of Pittsburgh, Pittsburgh, PA*

**5:06 PM Treatment Modality Affects Outcomes of Recurrent Hepatocellular Carcinoma Following Liver Transplantation: A US Multicenter Analysis of 2786 Patients (Abstract #629)**

P. Tabrizian<sup>1</sup>, K. J. Halazun<sup>2</sup>, M. L. Holzner<sup>1</sup>, N. Mehta<sup>3</sup>, F. Y. Yao<sup>3</sup>, J. Roberts<sup>3</sup>, J. C. Emond<sup>4</sup>, B. Samstein<sup>2</sup>, R. S. Brown<sup>4</sup>, S. Florman<sup>1</sup>, M. E. Schwartz<sup>1</sup>, M. M. Doyle<sup>5</sup>, W. C. Chapman<sup>5</sup>, M. Najjar<sup>4</sup>, R. W. Busuttill<sup>6</sup>, V. G. Agopian<sup>6</sup>, <sup>1</sup>*Transplant, Mount Sinai Medical Center, New York, NY*, <sup>2</sup>*Transplant, Weill Cornell Medicine, New York, NY*, <sup>3</sup>*Transplant, University of California San Francisco, San Francisco, CA*, <sup>4</sup>*Transplant, Columbia University Medical Center, New York, NY*, <sup>5</sup>*Transplant, Washington University School of Medicine, St Louis, MO*, <sup>6</sup>*Transplant, David Geffen School of Medicine at UCLA, Los Angeles, CA*

**AMERICAN TRANSPLANT CONGRESS**  
Program, Tuesday, June 4, 2019

---

**5:18 PM**    **After 10 Years: The Results of HLA Mismatched Combined Kidney and Bone Marrow Transplantation for Renal Allograft Tolerance (Abstract #630)**  
T. Kawai<sup>1</sup>, D. H. Sachs<sup>1</sup>, T. Spitzer<sup>1</sup>, N. Tolckoff-Rubin<sup>1</sup>, R. B. Colvin<sup>1</sup>, N. Elias<sup>1</sup>, M. Sykes<sup>2</sup>, A. Cosimi<sup>1</sup>, <sup>1</sup>Massachusetts General Hospital, Boston, MA, <sup>2</sup>Columbia University, NYC, NY

**5:30 PM**    **Donate HCV Trial: Transplanting Thoracic Organs from Hepatitis C Donors to Uninfected Patients (Abstract #631)**  
A. E. Woolley<sup>1</sup>, S. K. Singh<sup>2</sup>, H. J. Goldberg<sup>3</sup>, M. M. Givertz<sup>4</sup>, M. R. Mehra<sup>4</sup>, A. Coppolino, III<sup>5</sup>, V. Cheng<sup>1</sup>, J. Fanikos<sup>6</sup>, D. P. Harrington<sup>7</sup>, H. R. Mallidi<sup>2</sup>, L. R. Baden<sup>1</sup>, <sup>1</sup>Infectious Diseases, Brigham and Womens Hospital, Boston, MA, <sup>2</sup>Cardiac and Thoracic Surgery, Brigham and Womens Hospital, Boston, MA, <sup>3</sup>Pulmonary, Brigham and Womens Hospital, Boston, MA, <sup>4</sup>Cardiology, Brigham and Womens Hospital, Boston, MA, <sup>5</sup>Thoracic Surgery, Brigham and Womens Hospital, Boston, MA, <sup>6</sup>Pharmacy, Brigham and Womens Hospital, Boston, MA, <sup>7</sup>Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

**5:42 PM**    **CNI-Free Therapy with Iscalimab (anti-CD40 mAb) Preserves Allograft Histology Compared to Standard of Care after Kidney Transplantation (Abstract #632)**  
E. Farkash<sup>1</sup>, A. Naik<sup>1</sup>, H. Tedesco-Silva<sup>2</sup>, B. Nashan<sup>3</sup>, O. Witzke<sup>4</sup>, M. van den Hoogen<sup>5</sup>, S. Berger<sup>6</sup>, D. M. Cibrik<sup>7</sup>, S. Mulgaonkar<sup>8</sup>, D. B. Leese<sup>9</sup>, R. Alloway<sup>10</sup>, A. Patel<sup>11</sup>, J. Pratchke<sup>12</sup>, C. Sommerer<sup>13</sup>, A. Wiseman<sup>14</sup>, A. Van Zuilen<sup>15</sup>, U. Laessing<sup>16</sup>, J. Rush<sup>16</sup>, B. Haraldsson<sup>16</sup>, <sup>1</sup>Univ of Michigan, Ann Arbor, MI, <sup>2</sup>Hospital do Rim, São Paulo, Brazil, <sup>3</sup>Univ. Hamburg, Hamburg, Germany, <sup>4</sup>Univ Essen, Essen, Germany, <sup>5</sup>Erasmus MC, Rotterdam, Netherlands, <sup>6</sup>UMC Groningen, Gröningen, Netherlands, <sup>7</sup>Univ of Kansas, Kansas City, KS, <sup>8</sup>Saint Barnabas MC, Livingston, NJ, <sup>9</sup>East Carolina Univ, Greenville, NC, <sup>10</sup>Univ of Cincinnati, Cincinnati, OH, <sup>11</sup>Henry Ford Hosp, Detroit, MI, <sup>12</sup>Charité Univ, Berlin, Germany, <sup>13</sup>Univ Heidelberg, Heidelberg, Germany, <sup>14</sup>Univ of Colorado SM, Denver, CO, <sup>15</sup>Univ MC, Utrecht, Netherlands, <sup>16</sup>Novartis, Basel, Switzerland

**Poster Session D – Presenters in Attendance**

---

*Hall C/D*

Poster Viewing: 6:00 pm - 7:00 pm  
Presenters in Attendance: 6:00 pm - 7:00 pm

Poster Session D can be found on pages 267-309.

**AMERICAN TRANSPLANT CONGRESS**  
**Day-at-a-Glance, Wednesday, June 5, 2019**

---

**7:00 am – 8:15 am Sunrise Interactive**  
*(Continental Breakfast Included)*

Page 145 **Optimizing Spend: Cost Saving Strategies in Transplantation**  
*Room 302*

Page 145 **HCV-Viremic Recipients: The New Standard of Care?**  
*Ballroom B*

Page 145 **Controversies in Live Kidney Donor Selection and Care**  
*Ballroom C*

Page 145 **Pros and Cons of Presumed Consent: Is Opt-In a Cop-Out?**  
*Room 306*

Page 146 **Unlocking Concepts of VCA vs. Solid Organ Transplant**  
*Room 310*

Page 146 **The Changing Face of Cholangiocarcinoma in 2019**  
*Room 311*

Page 146 **Marginal Liver Organs: Have We Pushed the Limit?**  
*Room 312*

Page 146 **The “OMICS” of Thoracic Organ Transplantation**  
*Room 304*

**7:00 am – 8:15 am Sunrise Didactic**  
*(Continental Breakfast Included)*

Page 147 **T Cells Driving the Alloantibody Response**  
*Ballroom A*

**8:15 am – 8:30 am Break**

---

**8:30 am – 10:00 am Plenary IV**

---

Page 147 *Veterans Auditorium*

**10:00 am – 10:15 am Coffee Break**  
*Foyer C/D*

---

**10:15 am – 11:30 am ATC’s People’s Choice Award Session**

---

Page 148 *Veterans Auditorium*



# AMERICAN TRANSPLANT CONGRESS

Program, Wednesday, June 5, 2019

---

## Sunrise Symposia: Interactive (Continental Breakfast Included)

7:00 am – 8:15 am

### Optimizing Spend: Cost Saving Strategies in Transplantation

#### Room 302

Moderators: Jamie Benken, PharmD, BCPS, University of Illinois at Chicago, Chicago, IL, USA.  
Dave Taber, PharmD, MS, Medical University of South Carolina, Charleston, SC, USA.

- 7:00 am **Thinking Strategically: How to Approach Cost Savings**  
*Nicole Pilch, PharmD, MSCR, Medical University of South Carolina, Charleston, SC, USA.*
- 7:15 am **Delaying Valganciclovir: A Smart Move or Playing with Fire?**  
*Shree Patel, PharmD, BCPS, College of Pharmacy-Chicago Rockford, Chicago, IL, USA.*
- 7:30 am **Cost Saving Strategies for Transplant Programs**  
*Gwen McNatt, MS, CNN, Northwestern Memorial Hospital, Chicago, IL, USA.*
- 7:45 am **Getting the Underfunded Patient Out the Door**  
*Angela Maldonado, PharmD, CPP, Vidant Medical Center, Greenville, NC, USA.*
- 8:00 am **Panel Discussion**

### HCV-Viremic Recipients: The New Standard of Care?

#### Ballroom B

Moderators: David Goldberg, MD, MSCE, University of Pennsylvania, Philadelphia, PA, USA. Elizabeth Verna, MD, MS, Columbia University, New York, NY, USA.

- 7:00 am **HCV-Viremic Donors in Liver Recipients: When and How to Treat**  
*Robert S. Brown Jr., MD, MPH, Weill Cornell Medical College, New York, NY, USA.*

- 7:20 am **HCV-Viremic Donors in Kidney Recipients: Impact on Wait Times and Post-Transplant Kidney Function**  
*Peter Reese, MD, MSCE, University of Pennsylvania, Philadelphia, PA, USA.*
- 7:40 am **HCV-Viremic Donors in Heart and Lung Recipients: Novel Strategies and Post-Transplant Outcomes**  
*Marcelo Cypel, MD, MSc, University of Toronto, Toronto, Ontario.*

8:00 am **Panel Discussion**

### Controversies in Live Kidney Donor Selection and Care

#### Ballroom C

Moderators: Todd Pesavento, MD, The Ohio State University, Columbus, OH, USA. Arthur J. Matas, MD, University of Minnesota, Minneapolis, MN, USA.

- 7:00 am **Outcomes of Living Kidney Donation Among African American Donors and How One Could Use Transplant Models in Counseling**  
*Krista Lentine, MD, PhD, Saint Louis University, St. Louis, MO, USA.*
- 7:20 am **Elevated Blood Pressure: Is It Ever Acceptable to Approve the Donor?**  
*Hassan Ibrahim, MD, MS, Houston Methodist Hospital, Houston, TX, USA.*
- 7:40 am **Discrepancies in Kidney Size/Volume: How Do You Decide?**  
*Stuart M. Flechner, MD, FACS, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA.*
- 8:00 am **Panel Discussion**

### Pros and Cons of Presumed Consent: Is Opt-in a Cop-Out?

#### Room 306

Moderators: Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA. Linda Ohler, MSN, FAAN, New York University Langone Health, New York, NY, USA.

- 7:00 am **Debate - Pro: Presumed Consent: Is Opt-in a Cop-Out**  
*Amy Friedman, MD, LiveOnNY, New York, NY, USA.*

Wednesday, June 5

# AMERICAN TRANSPLANT CONGRESS

Program, Wednesday, June 5, 2019

---

**7:20 am Debate - Con: Presumed Consent: Is Opt-in a Cop-Out**  
*Charlie Miller, MD, Cleveland Clinic, Cleveland, OH, USA.*

**7:40 am Pro: Rebuttal**  
*Amy Friedman, MD, LiveOnNY, New York, NY, USA.*

**7:50 am Con: Rebuttal**  
*Charlie Miller, MD, Cleveland Clinic, Cleveland, OH, USA.*

**8:00 am Panel Discussion**

## **Unlocking Concepts of VCA vs. Solid Organ Transplant**

### **Room 310**

*Moderators: Hatem Amer, MD, Mayo Clinic, Rochester, MN, USA. Andreas Tzakis, MD, Cleveland Clinic, Weston, FL, USA.*

**7:00 am VCA vs. SOT: Innate - Adaptive Immune Interface**  
*Jerzy W. Kupiec-Weglinski, MD, University of California-Los Angeles, Los Angeles, CA, USA.*

**7:20 am Nerve Regeneration and Autoimmunity**  
*Rolf Barth, MD, University of Maryland, Baltimore, MD, USA.*

**7:40 am How Qualitative Research Informs Clinical Decision Making in VCA**  
*Sheila G. Jowsey-Gregorie, MD, Mayo Clinic, Rochester, MN, USA.*

**8:00 am Panel Discussion**

## **The Changing Face of Cholangiocarcinoma in 2019**

### **Room 311**

*Moderators: Keri Lunsford, MD, PhD, Houston Methodist Hospital, Houston, TX, USA. Anjana Pillai, MD, University of Chicago Medicine, Chicago, IL, USA.*

**7:00 am Liver Transplantation for Hilar Cholangiocarcinoma- Have we Mastered This?**  
*Wendy Grant, MD, University of Nebraska Medical Center, Omaha, NB, USA.*

**7:20 am Liver Transplantation for Intrahepatic Cholangiocarcinoma – Can It Work?**  
*Mark Ghobrial, MD, PhD, Houston Methodist Hospital, Houston, TX, USA.*

**7:40 am The Promise of New Systemic Therapy for Cholangiocarcinoma and its Implications on Liver Transplantation**  
*Rachna T. Shroff, MD, MS, University of Arizona Cancer Center, Tucson, AZ, USA.*

**8:00 am Panel Discussion**

## **Marginal Liver Organs: Have we Pushed the Limit?**

### **Room 312**

*Moderators: Walid Ayoub, MD, FAASLD, Cedars Sinai Medical Center, Los Angeles, CA, USA. George Loss JR., MD, FACS, Ochsner, New Orleans, LA, USA.*

**7:00 am Should I Transplant this Liver? (Surgeon Perspective)**  
*Karim Halazun, MD, New York Presbyterian, New York, NY, USA.*

**7:20 am Should My Patient Consider this Offer? (Hepatologist Perspective)**  
*David Douglas, MD, FAST, Mayo Clinic, Phoenix, AZ, USA.*

**7:40 am What Does the Patient Under About this Liver? (Medical Ethicist Perspective on Informed Consent in Marginal Organ Transplantation)**  
*Elisa J. Gordon, PhD, MPH, Northwestern University, Chicago, IL, USA.*

**8:00 am Panel Discussion**

## **The “OMICS” of Thoracic Organ Transplantation**

### **Room 304**

*Moderators: Sundaram Hariharan, MD, Starzl Transplant Institute, Pittsburgh, PA, USA. Howard J. Eisen, MD, Pennsylvania State College of Medicine, Hershey, PA, USA.*

**7:00 am Intra-graft Genomics and Allograft Rejection (INTERHEART and INTERLUNG)**  
*Brendan Keating, D.Phil., University of Pennsylvania, Philadelphia, PA, USA.*

# AMERICAN TRANSPLANT CONGRESS

Program, Wednesday, June 5, 2019

---

**7:20 am Epigenetics, microRNA, Transcriptome**  
*Thalachallour Mohanakumar, PhD,  
Norton Thoracic Institute, St. Joseph's  
Hospital & Medical Center, Phoenix, AZ,  
USA.*

**7:40 am Exosomes and Proteomics**  
*Prashanth Vallabhajosyula, MD,  
MS, Hospital of the University of  
Pennsylvania, Philadelphia, PA, USA.*

**8:00 am Panel Discussion**

## Sunrise Symposia: Didactic (Continental Breakfast Included)

---

**7:00 am – 8:15 am**

### T Cells Driving the Alloantibody Response

#### **Ballroom A**

*Moderators: Paolo Cravedi, MD, PhD, Icahn School  
of Medicine at Mount Sinai, New York, NY, USA.  
Melissa Yeung, MD, Harvard Medical School,  
Boston, MA, USA.*

**7:00 am T Follicular Cells in Alloimmunity**  
*Gavin Pettigrew, Dr, University of  
Cambridge, Cambridge, England.*

**7:20 am Audience Discussion**

**7:25 am Follicular Regulatory T Cells**  
*Peter Sage, PhD, Harvard University,  
Boston, MA, USA.*

**7:45 am Audience Discussion**

**7:50 am Human Circulating T Follicular Helper  
Cells**  
*Diana Metes, MD, Starzl Transplant  
Institute; University of Pittsburgh,  
Pittsburgh, PA, USA.*

## Break

**8:15 am - 8:30 am**

---

## Plenary Session IV

---

**8:30 AM - 10:00 AM**

### **Veterans Auditorium**

*Chairs: Devin Eckhoff, MD, ATC Program Chair,  
ASTS, Birmingham, AL and Ronald Gill, PhD, FAST,  
ATC Program Chair, AST, Aurora, CO.*

**8:30 AM Three-Year Outcomes of Highly-  
Sensitized Kidney Transplant  
Recipients Desensitized with Imlifidase  
(IdeS) (Abstract #620)**

*E. Huang<sup>1</sup>, J. Choi<sup>1</sup>, A. Vo<sup>1</sup>, A. Peng<sup>1</sup>,  
R. Najjar<sup>1</sup>, S. Sethi<sup>1</sup>, C. Kjellman<sup>2</sup>, L.  
Winstedt<sup>2</sup>, N. Ammerman<sup>1</sup>, S. C. Jordan<sup>1</sup>,  
<sup>1</sup>Cedars Sinai Medical Center, Los  
Angeles, CA, <sup>2</sup>Hansa Medical, Lund,  
Sweden*

**8:45 AM Central Role of Graft Resident Memory  
T Cells in Pathogenesis of GVHD after  
Bowel Transplantation (Abstract #621)**

*J. Weiner, N. Svetlicky, J. Schmidt, S.  
Moturi, O. Aguirre, J. Kang, M. Sadat,  
K. Khan, J. Hawksworth, C. Matsumoto,  
T. Fishbein, A. Kroemer, MedStar  
Georgetown Transplant Institute,  
Washington, DC*

**9:00 AM ABO Incompatibility in Kidney  
Transplantation Can Increase a Safety  
Margin of Epitope Mismatch Levels  
against De Novo DSA Production  
(Abstract #622)**

*T. Kobayashi<sup>1</sup>, K. Iwasaki<sup>1</sup>, M. Okada<sup>2</sup>,  
K. Horimi<sup>1</sup>, Y. Matsuoka<sup>1</sup>, A. Takeda<sup>2</sup>,  
N. Goto<sup>2</sup>, S. Narumi<sup>2</sup>, Y. Watarai<sup>2</sup>, <sup>1</sup>Aichi  
Medical University School of Medicine,  
Nagakute, Japan, <sup>2</sup>Nagoya Daini Red  
Cross Hospital, Nagoya, Japan*

Wednesday, June 5

**AMERICAN TRANSPLANT CONGRESS**  
**Program, Wednesday, June 5, 2019**

---

**9:15 AM Alloreactive B Cells in Transplant Tolerant Recipients Cannot Differentiate into Antibody-Secreting Cells but Can Suppress Donor-Specific IgG Production By Naïve B Cells (Abstract #623)**

S. H. Khiew<sup>1</sup>, J. Chen<sup>1</sup>, D. Jain<sup>1</sup>, Q. Wang<sup>1</sup>, D. Yin<sup>1</sup>, M. Alegre<sup>2</sup>, A. S. Chong<sup>1</sup>,  
*<sup>1</sup>Department of Surgery, Section of Transplant, University of Chicago, Chicago, IL, <sup>2</sup>Department of Medicine, University of Chicago, Chicago, IL*

**9:30 AM Long Term Renal Function Following Islet Transplantation in the Clinical Islet Transplantation Consortium (Abstract #624)**

L. G. Hunsicker<sup>1</sup>, T. L. Eggerman<sup>2</sup>, M. R. Rickels<sup>3</sup>, t. Clinical Islet Transplantation (CIT) Consortium<sup>4</sup>, *<sup>1</sup>Internal Medicine, U. Iowa, Iowa City, IA, <sup>2</sup>NIDDK/NIH, Bethesda, MD, <sup>3</sup>Internal Medicine, U. Pennsylvania, Philadelphia, PA, <sup>4</sup>Internal Medicine, University of Iowa, Iowa City, IA*

**9:45 AM Intact Lymphatics Are Essential for Costimulation Blockade-Induced Lung Allograft Survival (Abstract #625)**

L. Wang<sup>1</sup>, H. Reed<sup>2</sup>, R. Han<sup>1</sup>, M. Kahn<sup>2</sup>, W. W. Hancock<sup>1</sup>, *<sup>1</sup>Children's Hospital of Philadelphia, Philadelphia, PA, <sup>2</sup>University of Pennsylvania, Philadelphia, PA*

**Coffee Break**

**10:00 am – 10:15 am**

*Foyers of Hall C&D*

**People's Choice Awards**

**10:15 am – 11:30 am**

***Veterans Auditorium***

ATC's People's Choice Awards allow attendees to have the opportunity to engage in providing feedback on plenary abstracts and have a new way to view and learn about content.

At the end of each daily Plenary Session, attendees will vote on which Plenary Abstract is the MOST impactful to the Transplant Community. A daily winner will be selected. The daily winner will then present in the final session, ATC's People's Choice Award Session.

## Poster Session A: Acute Rejection

Poster Viewing: 5:30 pm - 7:30 pm  
Presenters in Attendance: 5:30 pm - 7:30 pm  
Hall C & D

A# indicates the board location where the poster will be displayed.

† Those posters identified as an ATC Poster of Distinction by this symbol have received review scores that place them in the top 10% of their category. The Planning Committee encourages you to make them a priority when you visit the poster session.

- A1**      **Molecular Microscope Proves i-IFTA Lack of Specificity**  
A. Perkowska-Ptasinska<sup>1</sup>, M. Ciszek<sup>2</sup>, D. Deborska-Materkowska<sup>1</sup>, A. Debska-Slizien<sup>3</sup>, P. F. Halloran<sup>4</sup>, M. Myslak<sup>5</sup>,  
<sup>1</sup>Warsaw Medical Univeristy, Warsaw, Poland, <sup>2</sup>Department of Immunology, Transplantology and Internal Diseases, Warsaw Medical Univeristy, Warsaw, Poland, <sup>3</sup>Gdansk Medical University, Gdansk, Poland, <sup>4</sup>ATAGC, University of Alberta, Edmonton AB, AB, Canada, <sup>5</sup>Pomeranian Medical University, Szczecin, Poland
- A2**      **T Cell Repertoire of Tissue Infiltrating T-cells at Time of Rejection**  
R. Reindl-Schwaighofer<sup>1</sup>, J. Vetter<sup>2</sup>, J. Weinberger<sup>3</sup>, S. Schaller<sup>2</sup>, A. Heinzl<sup>1</sup>, G. Gualdoni<sup>1</sup>, C. Aschauer<sup>1</sup>, K. Jelencsics<sup>1</sup>, K. Hu<sup>1</sup>, S. Winkler<sup>2</sup>, R. Oberbauer<sup>1</sup>,  
<sup>1</sup>Nephrology, Medical University of Vienna, Vienna, Austria, <sup>2</sup>University of Applied Sciences Upper Austria, Hagenberg, Austria, <sup>3</sup>Austrian Red Cross, Vienna, Austria
- A3**      **RNA Sequencing Guided Identification of Shared mRNAs in Human Kidney Allograft Recipients with Acute T Cell Mediated Rejection or Active Antibody Mediated Rejection**  
B. Dooley<sup>1</sup>, A. Verma<sup>2</sup>, R. Ding<sup>1</sup>, C. Li<sup>1</sup>, C. Snopkowski<sup>1</sup>, H. Yang<sup>1</sup>, B. Botticelli<sup>1</sup>, S. Albakry<sup>1</sup>, E. Edusei<sup>1</sup>, T. Muthukumar<sup>1</sup>, M. Lubetzky<sup>1</sup>, D. Dadhanian<sup>1</sup>, J. Lee<sup>1</sup>, O. Elemento<sup>2</sup>, M. Suthanthiran<sup>1</sup>,  
<sup>1</sup>Transplantation Medicine, Weill Cornell Medical College, New York, NY, <sup>2</sup>Institute for Computational Biomedicine, Weill Cornell Medical College, New York, NY

- A4**      **Single Cell Analysis of Kidney Allograft Rejection**  
C. M. Castro-Rojas<sup>1</sup>, K. M. Roskin<sup>2</sup>, C. G. Moore<sup>2</sup>, B. Abu Jawdeh<sup>3</sup>, N. Salomonis<sup>2</sup>, R. R. Alloway<sup>4</sup>, E. Woodle<sup>4</sup>, D. A. Hildeman<sup>1</sup>, <sup>1</sup>Immunobiology, Cincinnati Children's Hospital, Cincinnati, OH, <sup>2</sup>Biomedical Informatics, Cincinnati Children's Hospital, Cincinnati, OH, <sup>3</sup>Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, <sup>4</sup>Transplantation, University of Cincinnati College of Medicine, Cincinnati, OH
- A5**      **Integrative Analysis of Immune Repertoire and Gene Expression from RNA-seq in Kidney Organ Transplants**  
S. Pineda<sup>1</sup>, A. Ravoor<sup>2</sup>, O. Bestard<sup>3</sup>, M. Sarwal<sup>1</sup>, M. Sirota<sup>2</sup>, <sup>1</sup>Department of Surgery, UCSF, San Francisco, CA, <sup>2</sup>BCHSI, UCSF, San Francisco, CA, <sup>3</sup>Department of Surgery, Bellvitge University Hospital, Barcelona, Spain
- A6**      **Analysis of Immune Cell Proportions in Kidney Transplant Biopsies of Acute Cellular Rejection and Antibody Mediated Rejection Compared with Non-Rejecters**  
C. R. Dorr<sup>1</sup>, A. Muthusamy<sup>1</sup>, D. P. Schladt<sup>1</sup>, W. Guan<sup>2</sup>, B. Wu<sup>2</sup>, J. S. Maltzman<sup>3</sup>, W. S. Oetting<sup>2</sup>, P. A. Jacobson<sup>2</sup>, A. K. Israni<sup>1</sup>, <sup>1</sup>Hennepin Healthcare Research Institute, Minneapolis, MN, <sup>2</sup>University of Minnesota, Minneapolis, MN, <sup>3</sup>Stanford University, Palo Alto, CA
- A7**      **Immunomics of Renal Allograft Acute T-Cell Mediated Rejection Biopsies of Tacrolimus- and Belatacept- Treated Patients**  
M. van der Zwan<sup>1</sup>, C. C. Baan<sup>1</sup>, R. C. Colvin<sup>2</sup>, R. N. Smith<sup>2</sup>, R. A. White<sup>2</sup>, D. N. Ndishabandi<sup>2</sup>, A. L. Nigg<sup>1</sup>, T. P. van den Bosch<sup>1</sup>, G. N. de Graav<sup>1</sup>, M. C. Clahsen-van Groningen<sup>1</sup>, D. A. Hesselink<sup>1</sup>,  
<sup>1</sup>Internal Medicine, Division Nephrology and Transplantation, Erasmus MC, Rotterdam, Netherlands, <sup>2</sup>Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA



- A8**      **Quantitative Proteome Profiling in T Cell-Mediated Rejection**  
L. Song<sup>1</sup>, G. Zeng<sup>2</sup>, P. Liu<sup>3</sup>, F. Fang<sup>4</sup>, H. Liu<sup>4</sup>, X. Xie<sup>1</sup>, P. Randhawa<sup>2</sup>, K. Xiao<sup>4</sup>, <sup>1</sup>*Department of Urological Organ Transplantation, The Second Xiangya Hospital, Central-South University, Changsha, China*, <sup>2</sup>*Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA*, <sup>3</sup>*Department of Biostatistics, Graduate School of Public Health, and Departments of Pharmacology and P, University of Pittsburgh Medical Center, Pittsburgh, PA*, <sup>4</sup>*Department of Pharmacology and Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA*
- A9 †**      **Single Cell RNA-seq Analysis of Antibody-Mediated Rejection Reveals Endothelial - Pericyte NOTCH Signaling**  
A. F. Malone, A. Chadha, H. Wu, S. Ramakrishnan, E. Donnelly, B. D. Humphreys, *Washington University School of Medicine, Saint Louis, MO*
- A10 †**      **Multiplexed Droplet Single-Cell RNA-Sequencing for Cellular Profiling of Transplant Rejection**  
A. Schroeder, T. Sigdel, I. Damm, S. Sur, G. Hartoularos, J. Ye, M. Sarwal, *Department of Surgery, UCSF, San Francisco, CA*
- A11**      **Effect of Chronic Kidney Disease on Allo-Immune Response in Mice**  
P. D. Winterberg<sup>1</sup>, H. Li<sup>1</sup>, M. E. Wagener<sup>2</sup>, M. L. Ford<sup>2</sup>, <sup>1</sup>*Pediatrics, Emory University School of Medicine, Atlanta, GA*, <sup>2</sup>*Surgery, Emory University School of Medicine, Atlanta, GA*
- A12**      **Dual Treatment of CD40 Silencing or Mesenchymal Stem Cells Infusion with Sub-Therapeutic Doses of Cyclosporine Effectively Prevents Acute Rejection in an Allogenic Model of Renal Transplantation**  
J. Guiteras<sup>1</sup>, L. De Ramon<sup>1</sup>, N. Bolaños<sup>1</sup>, M. Franquesa<sup>2</sup>, M. Gomà<sup>3</sup>, J. Cruzado<sup>4</sup>, N. Lloberas<sup>1</sup>, J. Grinyó<sup>4</sup>, J. Torras<sup>4</sup>, <sup>1</sup>*IDIBELL, Hospitalet de Llobregat, Spain*, <sup>2</sup>*IGTP, Badalona, Spain*, <sup>3</sup>*Bellvitge Hospital, Hospitalet de Llobregat, Spain*, <sup>4</sup>*Bellvitge Hospital / IDIBELL, Hospitalet de Llobregat, Spain*
- A13 †**      **Differential Impact of Donor and Recipient Age on Post-Lung Transplantation Outcomes**  
K. Patel<sup>1</sup>, C. Li<sup>1</sup>, C. Wallace<sup>1</sup>, J. Kilkenny<sup>1</sup>, D. P. Allen<sup>1</sup>, S. Nadig<sup>1</sup>, M. Goddard<sup>2</sup>, C. Krieg<sup>1</sup>, C. Atkinson<sup>1</sup>, <sup>1</sup>*Surgery, Medical University of South Carolina, Charleston, SC*, <sup>2</sup>*Pathology, Royal Papworth Hospital NHS Trust, C, SC*
- A14**      **Exosomes Isolated from Human Lung Transplant Recipients Diagnosed with Bronchiolitis obliterans Syndrome are Unique in Their Ability to Induce IL-6 via Rab27A Signaling Pathway**  
M. Rahman, M. Sharma, S. Angara, M. Smith, R. Bremner, T. Mohanakumar, *Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*
- A15**      **A Novel Ex Vivo Normothermic Perfusion Model of Human Antibody Mediated Rejection**  
P. Chandak<sup>1</sup>, B. L. Phillips<sup>1</sup>, R. Uwechue<sup>1</sup>, C. J. Callaghan<sup>1</sup>, O. Shaw<sup>2</sup>, T. Maggs<sup>3</sup>, L. Woodford<sup>3</sup>, D. Veniard<sup>3</sup>, R. Perera<sup>4</sup>, K. Parmar<sup>3</sup>, B. Hunt<sup>5</sup>, D. Bennett<sup>6</sup>, N. Kessar<sup>1</sup>, A. Dorling<sup>7</sup>, N. Mamode<sup>1</sup>, <sup>1</sup>*Transplantation, Guy's and St Thomas Hospitals NHS Trust and King's College London, London, United Kingdom*, <sup>2</sup>*Transplantation and CTL Laboratory, Guy's and St Thomas Hospitals NHS Trust and King's College London, London, United Kingdom*, <sup>3</sup>*Haematology and Thrombosis, Guy's and St Thomas Hospitals NHS Trust, London, United Kingdom*, <sup>4</sup>*Histopathology, Guy's and St Thomas Hospitals NHS Trust, London, United Kingdom*, <sup>5</sup>*Haematology and Thrombosis, Guy's and St Thomas Hospitals NHS Trust and King's College London, London, United Kingdom*, <sup>6</sup>*Interface Physics, University of Bristol, London, United Kingdom*, <sup>7</sup>*Inflammation, Thrombosis and Repair and Transplantation, Guy's and St Thomas Hospitals NHS Trust and King's College London, London, United Kingdom*

- A16 Depletional Induction Therapy in Non-Human Primates - Preclinical Modeling of Polyclonal Depletion with Rhesus-Specific ATG**  
R. Schmitz<sup>1</sup>, M. S. Mulvihill<sup>1</sup>, P. M. Schroder<sup>1</sup>, Z. Fitch<sup>1</sup>, F. Leopardi<sup>1</sup>, D. Magnani<sup>2</sup>, J. Kwun<sup>1</sup>, S. J. Knechtle<sup>1</sup>, A. D. Kirk<sup>1</sup>, <sup>1</sup>*Surgery, Duke University Medical Center, Durham, NC*, <sup>2</sup>*University of Massachusetts Medical School, Boston, MA*
- A17 Inhibition of Autophagy Prolongs Recipients Survival through Accelerating CD8+ T Cell Apoptosis in a Rat Liver Transplantation Model**  
X. Chen<sup>1</sup>, Q. Yang<sup>1</sup>, X. Li<sup>2</sup>, Y. Deng<sup>1</sup>, G. Chen<sup>1</sup>, G. Wang<sup>1</sup>, <sup>1</sup>*Department of Hepatic Surgery, Liver Transplantation, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China*, <sup>2</sup>*Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China*
- A18 † BTLA Suppressed Acute Rejection by Regulating T Cell Receptor Downstream Signal Pathways and Cytokine Production in Renal Transplant and Contributed to Prolongation of Allograft Survival**  
J. Zhang, Z. Wang, S. Fei, H. Chen, L. Sun, Z. Han, J. Tao, X. Ju, R. Tan, M. Gu, *No.300 Guangzhou Road of Nanjing, Nanjing, China*
- A19 Expression of Prostaglandin E2 Receptors Track with Rejection in Porcine Kidney Transplants**  
A. Harner<sup>1</sup>, Y. Wang<sup>2</sup>, X. Fang<sup>2</sup>, R. Lassiter<sup>1</sup>, T. D. Merchen<sup>1</sup>, S. Ho<sup>3</sup>, S. Nahman Jr<sup>2</sup>, <sup>1</sup>*Surgery, Augusta University, Augusta, GA*, <sup>2</sup>*Nephrology, Augusta University, Augusta, GA*, <sup>3</sup>*Gift of Life Michigan, Ann Arbor, MI*
- A20 Timing and Donor-Specific Antibodies, but Not C4d Deposition, Determine Leukocyte Infiltration in Renal Allograft Biopsies with the Histological Picture of Antibody-Mediated Rejection**  
J. Callemeyn<sup>1</sup>, A. Senev<sup>1</sup>, E. Lerut<sup>2</sup>, M. Coemans<sup>1</sup>, D. Kuypers<sup>1</sup>, W. Gwinner<sup>3</sup>, M. Essig<sup>4</sup>, D. Anglicheau<sup>5</sup>, P. Marquet<sup>6</sup>, M. Naesens<sup>1</sup>, <sup>1</sup>*Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium*, <sup>2</sup>*Department of Pathology, University Hospitals Leuven, Leuven, Belgium*, <sup>3</sup>*Department of Nephrology, Hannover Medical School, Hannover, Germany*, <sup>4</sup>*Department of Nephrology, Dialysis and Transplantation, University of Limoges, Limoges, France*, <sup>5</sup>*Necker-Enfants Malades Institute, French National Institute of Health and Medical Research U1151, Paris, France*, <sup>6</sup>*U850 INSERM, University of Limoges, Limoges, France*
- A21 Conceptual Extension of SNP Based Abundance Profiling to Infer Donor Derived Cell-Free DNA Fraction as an Indication of Organ Rejection**  
R. Sinha, K. Mickey, J. Grantham, M. Wissel, M. Altrich, S. Kleiboeker, *R&D, Viracor-Eurofins, Lee's Summit, MO*
- A22 Replication of Diagnostic Biomarkers Using Orthogonal State-of-the-Art Technologies**  
M. Cassidy, B. Dooley, A. Verma, H. Yang, T. Muthukumar, R. Ding, C. Li, C. Snopkowski, B. Botticelli, S. Albakry, E. Edusei, M. Lubetzky, D. Dadhanian, J. Lee, O. Elemento, M. Suthanthiran, *WCM, New York, NY*
- A23 Recipient Monocytes Activated by Endobronchial Toll-Like Receptor 2 Agonist Prevent Tolerance Induction after Lung Transplantation**  
S. Tanaka<sup>1</sup>, J. M. Gauthier<sup>1</sup>, Y. Terada<sup>1</sup>, T. Takahashi<sup>1</sup>, W. Li<sup>1</sup>, R. Higashikubo<sup>1</sup>, A. Y. Tong<sup>1</sup>, V. Puri<sup>1</sup>, A. S. Krupnick<sup>2</sup>, A. E. Gelman<sup>1</sup>, D. Kreisel<sup>1</sup>, <sup>1</sup>*Department of Surgery, Washington University in St. Louis, St. Louis, MO*, <sup>2</sup>*Department of Surgery, The University of Virginia, Charlottesville, VA*

- A24 Donor-derived Cell-free Dna In Donor Specific Antibody Positive Kidney Transplant Recipients**  
D. Cheng<sup>1</sup>, X. Li<sup>2</sup>, T. Jiang<sup>2</sup>, H. Liu<sup>2</sup>, Y. Zhou<sup>3</sup>, H. Shi<sup>3</sup>, <sup>1</sup>*National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China*, <sup>2</sup>*Research and Development, AlloDx Biotech Co.Ltd., Suzhou, China*, <sup>3</sup>*Precise Medicine Center, Biology and Science School, JiangSu University, Zhenjiang, China*
- A25 Promoting Mitochondrial Fusion Alters the Interaction between Endothelial Cells and T Cells in Models of Transplantation**  
D. T. Tran, C. Atkinson, S. N. Nadig, *Medical University of South Carolina, Charleston, SC*
- A26 Gut Microbiome And Acute Rejection After Kidney Transplantation**  
H. Cho<sup>1</sup>, Y. Yang<sup>1</sup>, J. Kim<sup>2</sup>, J. Moon<sup>2</sup>, J. Jeong<sup>2</sup>, J. Park<sup>3</sup>, M. Kwak<sup>4</sup>, B. Kim<sup>4</sup>, D. Kim<sup>2</sup>, J. Lee<sup>5</sup>, B. Kim<sup>6</sup>, Y. Kim<sup>2</sup>, H. Lee<sup>2</sup>, <sup>1</sup>*Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea, Republic of*, <sup>2</sup>*Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of*, <sup>3</sup>*Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea, Republic of*, <sup>4</sup>*ChunLab Inc., Seoul, Korea, Republic of*, <sup>5</sup>*Internal Medicine, Seoul National University, Boramae Hospital, Seoul, Korea, Republic of*, <sup>6</sup>*Hallym University, Chuncheon, Korea, Republic of*
- Poster Session A: Antigen Presentation / Allorecognition / Dendritic Cells**
- A27 Clonal Composition And Single-cell Characterization Of T-cell Infiltrates In Cardiac Allograft Vasculopathy**  
M. V. Habal<sup>1</sup>, A. Myung<sup>2</sup>, H. Yan<sup>2</sup>, S. Rao<sup>2</sup>, S. Lin<sup>2</sup>, S. See<sup>2</sup>, P. Roy<sup>2</sup>, R. Shihab<sup>2</sup>, C. Marboe<sup>3</sup>, S. Restaino<sup>1</sup>, A. Han<sup>2</sup>, M. Givertz<sup>4</sup>, J. C. Madsen<sup>5</sup>, L. Addonizio<sup>1</sup>, M. Farr<sup>1</sup>, E. Zorn<sup>2</sup>, <sup>1</sup>*Cardiology, Columbia University Medical Center, New York, NY*, <sup>2</sup>*Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY*, <sup>3</sup>*Pathology, Columbia University Medical Center, New York, NY*, <sup>4</sup>*Cardiology, Brigham and Women's Hospital, Boston, MA*, <sup>5</sup>*Surgery, Massachusetts General Hospital, Boston, MA*
- A28 In Vitro Model to Study the Effect of Irradiation Preconditioning on Alloimmune Responses: Development of Potential Predictive Markers**  
K. Shimozawa, K. Janec, L. Contreras-Ruiz, E. C. Guinan, *Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA*
- A29 The Impact of Biological Behavior of Allograft Infiltrating Lymphocytes during Early Phase**  
Y. Ganchiku, R. Goto, R. Igarashi, R. Kanazawa, K. Shibuya, Y. Fukasaku, N. Kawamura, M. Zaistu, M. Watanabe, M. Fukai, A. Taketomi, *Gastroenterological Surgery I, Hokkaido University, Sapporo, Japan*
- A30 † IgG Glycosylation Causes Podocyte Injury in Transplant Glomerulopathy through Calcium Calmodulin Kinase IV**  
R. Bhargava, K. Maeda, M. Pavlakis, G. Tsokos, *Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA*

**Poster Session A: B-cell / Antibody / Autoimmunity**

**A31 † Natural Anti-a Antibody Production In Mice Is Cd4 T Cell-independent**  
I. Adam<sup>1</sup>, B. Motyka<sup>2</sup>, L. West<sup>3</sup>, <sup>1</sup>Medical Microbiology & Immunology, University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Pediatrics, University of Alberta, Edmonton, AB, Canada, <sup>3</sup>Pediatrics, Surgery, Immunology, Lab Medicine & Canadian Donation and Transplant Research Program, University of Alberta, Edmonton, AB, Canada

**A32 † Effects of Standard Drug Immunosuppression on Peripheral Transitional B Cells and Gene Expression in Non-Human Primates**  
A. Bean<sup>1</sup>, J. Paster<sup>1</sup>, K. Pruner<sup>1</sup>, J. O<sup>1</sup>, W. Sommer<sup>2</sup>, K. Robinson<sup>3</sup>, I. Hanekamp<sup>1</sup>, G. Benichou<sup>1</sup>, J. Madsen<sup>1</sup>, <sup>1</sup>Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Klinik für Herz Thorax Transplantation, Medizinische Hochschule Hannover, Hannover, Germany, <sup>3</sup>Beth Israel Deaconess Medical Center, Boston, MA

**A33 APRIL-/-/BLyS-/- Deplete Antibody Secreting Cells and Alloantibody Production in Sensitized Antibody Mediated Rejection Model**  
N. Bath, B. Verhoven, N. Wilson, R. Redfield III, University of Wisconsin, Madison, WI

**A34 Differential Expression of B Cell Activating Factor in Experimental Models of Acute and Chronic Active Antibody-Mediated Rejection**  
S. Reese, N. Wilson, L. Ptak, R. Redfield, A. Djamali, S. E. Panzer, University of Wisconsin Madison, Madison, WI

**A35 Comparison of Isolated Transplant Glomerulopathy with Chronic Antibody-Mediated Rejection in Regards to Endothelial-to-Mesenchymal Transition and Graft Survival**  
B. H. Ozdemir<sup>1</sup>, F. N. Ozdemir<sup>2</sup>, G. Moray<sup>3</sup>, M. Haberal<sup>3</sup>, <sup>1</sup>Pathology, Baskent University, Ankara, Turkey, <sup>2</sup>Nephrology, Baskent University, Ankara, Turkey, <sup>3</sup>Transplantation, Baskent University, Ankara, Turkey

**A36 IL-1 $\beta$  and IL-6 Facilitate T Cell Reconstitution in Heart Allograft Recipients Treated with Anti-Thymocyte Globulin**  
S. Hasgur, R. Fan, A. Valujskikh, *Inflammation and Immunity, Cleveland Clinic, Cleveland, OH*

**A37 Identification of Antibodies Reactive to Vimentin in a Rat Kidney Transplant Model of Chronic Antibody-Mediated Rejection**  
S. Reese, N. Wilson, L. Ptak, J. Sullivan, W. Burlingham, A. Djamali, S. E. Panzer, University of Wisconsin Madison, Madison, WI

**A38 † Treg Plasticity is Induced by ENV,HERV1\_I and UPR Activation in De Novo Autoimmune Hepatitis**  
J. Yao<sup>1</sup>, A. Ling<sup>1</sup>, A. Arterbery<sup>1</sup>, Y. Avitzur<sup>2</sup>, S. Lobritto<sup>3</sup>, M. Martinez<sup>3</sup>, U. Ekong<sup>1</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>University of Toronto, Toronto, ON, Canada, <sup>3</sup>Columbia University, New York, NY

**A39 † Interleukin-27 is Required for Donor Specific Antibody Production in Response to Heart Allograft Transplantation**  
M. Nicosia, S. Miyairi, R. Fan, A. Beavers, V. Gorbacheva, A. Valujskikh, *Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH*

**A40 Natural Antibodies and Left Ventricular Assist Device Complications**  
S. B. See<sup>1</sup>, A. Pinsino<sup>2</sup>, R. Shihab<sup>1</sup>, N. Kunimune<sup>1</sup>, D. Onat<sup>2</sup>, E. Hittesdorf<sup>3</sup>, A. R. Garan<sup>2</sup>, V. K. Topkara<sup>2</sup>, Y. Naka<sup>4</sup>, H. Takayama<sup>4</sup>, K. Takeda<sup>4</sup>, P. Colombo<sup>2</sup>, M. Yuzefpolskaya<sup>2</sup>, G. Wagener<sup>3</sup>, E. Zorn<sup>1</sup>, <sup>1</sup>Columbia Center for Translational Immunology, Columbia University, New York, NY, <sup>2</sup>Division of Cardiology, Columbia University, New York, NY, <sup>3</sup>Department of Anesthesiology, Columbia University, New York, NY, <sup>4</sup>Department of Surgery, Columbia University, New York, NY



- A41 Non-HLA Antibodies against Structural and Non-Structural Target in C4d Negative Antibody Mediated Rejections after Renal Transplantation**  
S. Kanangat<sup>1</sup>, I. Kurbegovic-Skaljic<sup>2</sup>, D. Cimbalkuk<sup>2</sup>, M. Oppermann<sup>2</sup>, S. Jensik<sup>3</sup>, E. Hollinger<sup>3</sup>, O. Olaitan<sup>4</sup>, R. DeCresce<sup>2</sup>, <sup>1</sup>Tumor Immunology, NIH/NCI Bethesda MD, USA, Bethesda, MD, <sup>2</sup>Pathology, Rush University Medical Center, Chicago, IL, <sup>3</sup>Surgery, Rush University Medical Center, Chicago, IL, <sup>4</sup>Tumor Immunology, Rush University Medical Center, Chicago, IL
- A42 Igratimod Attenuates the Production of Donor Specific Antibody by Inducing CD19+Tim-1+ Regulatory B Cells and Imbalance of Th17 Treg**  
Z. Wang, S. Fei, H. Chen, Z. Han, L. Sun, J. Tao, X. Ju, M. Zheng, R. Tan, M. Gu, No.300 Guangzhou Road of Nanjing, Nanjing, China
- A43 JAK Inhibitor as a Novel Conditioning Approach to Establish Mixed Chimerism and Prevent Type 1 Diabetes Nonmyeloablatively**  
H. Xu<sup>1</sup>, A. Merchak<sup>1</sup>, J. Xu<sup>2</sup>, Y. Huang<sup>1</sup>, S. T. Ildstad<sup>1</sup>, <sup>1</sup>University of Louisville, Institute for Cellular Therapeutics, Louisville, KY, <sup>2</sup>DuPont Manual High School, Louisville, KY
- A44 Development of Non-Human Leukocyte Antigen Antibodies in Cardiac Antibody-Mediated Rejection**  
S. B. See<sup>1</sup>, B. S. Mantell<sup>2</sup>, K. J. Clerkin<sup>3</sup>, B. Ray<sup>4</sup>, E. R. Vasilescu<sup>5</sup>, C. Marboe<sup>5</sup>, Y. Naka<sup>6</sup>, S. Restaino<sup>1</sup>, P. C. Colombo<sup>3</sup>, L. J. Addonizio<sup>2</sup>, M. A. Farr<sup>3</sup>, E. Zorn<sup>1</sup>, <sup>1</sup>Columbia Center for Translational Immunology, Columbia University, New York, NY, <sup>2</sup>Department of Pediatrics, Columbia University, New York, NY, <sup>3</sup>Division of Cardiology, Columbia University, New York, NY, <sup>4</sup>Immucor, Georgia, GA, <sup>5</sup>Department of Pathology and Cell Biology, Columbia University, New York, NY, <sup>6</sup>Department of Surgery, Columbia University, New York, NY
- A45 B Cell Immunophenotypes in Transplantation**  
M. Cascalho<sup>1</sup>, M. de Mattos-Barbosa<sup>2</sup>, E. A. Farkash<sup>3</sup>, J. L. Platt<sup>2</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>Surgery, University of Michigan, Ann Arbor, MI, <sup>3</sup>Pathology, University of Michigan, Ann Arbor, MI
- A46 Kidney Allograft Recipient Absence of Myeloperoxidase Decreases Donor-Specific Antibody Titers and Attenuates Antibody-Mediated Allograft Rejection**  
S. Miyairi, N. Dvorina, A. Valujuskikh, W. M. Baldwin 3rd, R. L. Fairchild, Immunology, Cleveland Clinic Lerner Institute, Cleveland, OH
- A47 TACI Polymorphisms Associated with Increased Alloimmunity and Allograft Rejection**  
M. Garcia de Mattos-Barbosa<sup>1</sup>, E. A. Farkash<sup>2</sup>, J. L. Platt<sup>1</sup>, M. Cascalho<sup>1</sup>, <sup>1</sup>Transplant Surgery, University of Michigan, Ann Arbor, MI, <sup>2</sup>Pathology, University of Michigan, Ann Arbor, MI
- A48 Increasing Expression of B-cell Maturation Antigen during the Development of Recall Antibody Responses: A Prospective Pharmaceutical Target for B-cell Suppression?**  
G. Wu, I. Kim, N. Chai, A. Klein, S. Jordan, Cedars-Sinai Med Ctr, Los Angeles, CA
- A49 CD19+Tim-1+ Regulatory B Cells Mediate the Balance of Th17 Treg to Decrease the Level of Donor-Specific Antibodies in Mice Secondary Skin Transplantation Model**  
Z. Wang, S. Fei, H. Chen, L. Sun, Z. Han, J. Tao, X. Ju, R. Tan, M. Gu, No.300 Guangzhou Road of Nanjing, Nanjing, China
- A50 AMD3100 and Low-Dose FK506 Prevent De Novo Donor Specific Antibody Formation and Rejection in a Sensitized Kidney Transplantation Model**  
A. R. Ahmadi, L. Qi, R. N. Wesson, A. M. Cameron, Z. Sun, Johns Hopkins University School of Medicine, Baltimore, MD



**A51 BCMA Expression by Alloreactive B Cells Increases during De Novo Alloantibody Responses**

N. Chai, G. Wu, I. Kim, A. Klein, S. Jordan, *Comprehensive Transplant Center, Cedars-Sinai Med Ctr, Los Angeles, CA*

**A52 † In Vitro Model for Detection of HLA Antibodies from Long Lived Plasma Cells**

M. Merzkani<sup>1</sup>, N. Moore<sup>1</sup>, X. Benavides<sup>1</sup>, B. Smith<sup>1</sup>, W. Park<sup>1</sup>, A. Bentall<sup>1</sup>, K. Medina<sup>2</sup>, M. Gandhi<sup>3</sup>, M. Stegall<sup>1</sup>, <sup>1</sup>*Transplant, Mayo Clinic, Rochester, MN*, <sup>2</sup>*Immunology, Mayo Clinic, Rochester, MN*, <sup>3</sup>*Transfusion Medicine, Mayo Clinic, Rochester, MN*

**Poster Session A: Basic & Clinical Science – VCA**

**A53 Psychosocial Factors and Medication Adherence among Recipients of Vascularized Composite Allografts**

S. Rasmussen<sup>1</sup>, M. Henderson<sup>1</sup>, C. Cooney<sup>1</sup>, J. Shores<sup>1</sup>, W. Lee<sup>1</sup>, E. Goldman<sup>2</sup>, C. Kaufman<sup>2</sup>, D. Segev<sup>1</sup>, G. Brandacher<sup>1</sup>, <sup>1</sup>*Johns Hopkins University, Baltimore, MD*, <sup>2</sup>*Christine M Kleinert Institute, Louisville, KY*

**A54 A Novel Multi-Thermic, Antiseptic, and Anthropomorphic System for Ex-Vivo Face Perfusion**

J. W. Etra<sup>1</sup>, J. Brassil<sup>2</sup>, F. A. Chang<sup>1</sup>, S. A. Fidler<sup>1</sup>, D. S. Cooney<sup>1</sup>, G. Brandacher<sup>1</sup>, <sup>1</sup>*Johns Hopkins University School of Medicine, Baltimore, MD*, <sup>2</sup>*Functional Circulation LLC, Northbrook, IL*

**A55 Trends in Vascularized Composite Allograft Transplantation in the United States**

J. Wainright<sup>1</sup>, C. Wholley<sup>2</sup>, W. Cherikh<sup>1</sup>, D. Klassen<sup>3</sup>, <sup>1</sup>*Research, UNOS, Richmond, VA*, <sup>2</sup>*Policy and Community Relations, UNOS, Richmond, VA*, <sup>3</sup>*Office of Chief Medical Officer, UNOS, Richmond, VA*

**A56 Regulatory T Cells Combined with Costimulation Blockade Prevent Rejection of Vascularized Composite Allografts**

B. Oh<sup>1</sup>, G. Furtmüller<sup>1</sup>, M. Grzelak<sup>1</sup>, L. Vuong<sup>2</sup>, M. Iglesias<sup>1</sup>, M. Fryer<sup>3</sup>, D. Cooney<sup>1</sup>, R. Chen<sup>4</sup>, Y. Guo<sup>5</sup>, W. Lee<sup>1</sup>, G. Raimondi<sup>1</sup>, G. Brandacher<sup>1</sup>, <sup>1</sup>*Johns Hopkins University School of Medicine, Baltimore, MD*, <sup>2</sup>*Washington University in St. Louis School of Medicine, St. Louis, MO*, <sup>3</sup>*The University of Massachusetts Medical School, Worcester, MA*, <sup>4</sup>*Kaohsiung Medical University Hospital, Kaohsiung, Taiwan*, <sup>5</sup>*Kaohsiung Medical University Hospital, Kaohsiung, Taiwan*

**A57 Uterus Transplantation: Recipient Surgery**

L. Johannesson, A. Wall, J. Bayer, G. J. McKenna, G. Testa, *Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX*

**A58 Characterization of Innate Lymphoid Cells in Full Facial and Limb Transplant Recipients**

T. J. Borges<sup>1</sup>, J. T. O'Malley<sup>2</sup>, B. Kollar<sup>3</sup>, B. Pomahac<sup>3</sup>, S. G. Talbot<sup>3</sup>, L. V. Riella<sup>1</sup>, <sup>1</sup>*Schuster Transplantation Research Center, Brigham & Women's Hospital, Harvard Medical School, Boston, MA*, <sup>2</sup>*Department of Dermatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA*, <sup>3</sup>*Division of Plastic Surgery, Department of Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, MA*

**A59 Mechanical Irritation in Vascularized Tissue Allotransplantation Triggers Localized Skin Rejection**

F. Messner, A. Fischer, E. Runggaldier, S. Eiter, B. Zelger, B. Zelger, S. Sprung, D. Öfner, S. Schneeberger, T. Hautz, *Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria*

- A60 Efficacy of Photobiomodulatory Therapy Combined with Short-Term Immunosuppressants Prolonged Allograft Survival in a Rodent Hind-Limb Model**  
Y. KUO<sup>1</sup>, Y. Li<sup>1</sup>, C. Chen<sup>1</sup>, R. Chen<sup>1</sup>, G. Brandacher<sup>2</sup>, <sup>1</sup>*Division of Plastic Surgery, Department of Surgery,, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan,* <sup>2</sup>*Department of Plastic Surgery, VCA center, Johns Hopkins University, Baltimore, MD*
- A61 Beta2-Adrenergic Receptor Activation Prolongs Survival of Vascularized Composite Tissue Allotransplants in a Murine Model**  
M. Kim<sup>1</sup>, D. Fisher<sup>1</sup>, J. Loo<sup>1</sup>, P. Bogner<sup>2</sup>, U. Sharma<sup>3</sup>, J. Skitzki<sup>1</sup>, E. Repasky<sup>4</sup>, <sup>1</sup>*Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY,* <sup>2</sup>*Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY,* <sup>3</sup>*Cardiology, University at Buffalo, Buffalo, NY,* <sup>4</sup>*Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY*
- A62 Stem Cell and Granulocyte- Colony Stimulating Factor Therapies to Improve Functional Outcomes in Limb Transplantation**  
J. Weiss<sup>1</sup>, C. Phillips<sup>1</sup>, E. Malin<sup>1</sup>, V. Gorantla<sup>2</sup>, S. K. Salgar<sup>3</sup>, <sup>1</sup>*Surgery, Madigan Army Medical Center, Tacoma, WA,* <sup>2</sup>*Surgery, Wake Forest University, Salem, NC,* <sup>3</sup>*Clinical Investigation, Madigan Army Medical Center, Tacoma, WA*
- A63 Desensitization Using Costimulatory Blockade and Bortezomib Does Not Prevent DSA Formation and Rejection in Reconstructive Transplantation**  
F. Messner<sup>1</sup>, Y. Guo<sup>1</sup>, R. Chen<sup>2</sup>, Y. Kuo<sup>2</sup>, G. Brandacher<sup>1</sup>, B. Oh<sup>1</sup>, <sup>1</sup>*Department of Plastic and Reconstructive Surgery, Johns Hopkins UJohns Hopkins University School of Medicine, Baltimore, MD,* <sup>2</sup>*Division of Plastic Surgery, Kaohsiung Medical Univerity Hospital, Kaohsiung, Taiwan*
- A64 Deceased Donor Vascularized Abdominal Wall Allograft Procurement - Lessons Learned from Early Experiences**  
J. A. Shah, D. L. Sudan, D. Erdmann, K. V. Ravindra, *Abdominal Transplant Surgery, Duke University Medical Center, Durham, NC*
- A65 The Scope and Limitations of Current Public Education Materials on Vascular Composite Allotransplantation and Donation in the United States**  
M. Henderson<sup>1</sup>, S. Rasmussen<sup>1</sup>, J. Uriarte<sup>2</sup>, N. Anderson<sup>2</sup>, B. Doby<sup>1</sup>, C. Cooney<sup>1</sup>, G. Brandacher<sup>1</sup>, D. Segev<sup>1</sup>, E. Gordon<sup>2</sup>, <sup>1</sup>*Johns Hopkins University, Baltimore, MD,* <sup>2</sup>*Northwestern University, Chicago, IL*
- A66 The Innsbruck Handtransplant Program: Eighteen Years of Experience**  
F. Messner, T. Hautz, A. Weissenbacher, S. Schneeberger, *Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria*
- A67 † Comparison with Solid Organ Transplants Reveals Distinct Face Transplant Rejection Gene Signature That Reflects the Unique Immunobiology of Skin**  
T. Win, B. Dyring-Andersen, R. Lopdrup, J. Teague, N. Murakami, A. Chandraker, S. G. Tullius, B. Pomahac, L. V. Riella, R. A. Clark, *Brigham and Women's Hospital, Boston, MA*
- A68 † Long-Term Outcomes after Face Transplantation**  
B. Kollar, S. Tasigiorgos, M. Turk, E. Bueno, B. Perry, M. Alhefzi, H. Kiwanuka, M. Nizzi, N. Krezdorn, T. Win, M. I. Dorante, V. Haug, D. J. Annino, F. M. Marty, A. Chandraker, S. G. Tullius, L. V. Riella, B. Pomahac, *Brigham and Women's Hospital, Boston, MA*
- A69 Functional Characterization of Orthotopic Hind-Limb Transplants in Rats**  
F. Zheng, X. Zhang, L. Qiu, J. Wang, X. Yeap, K. M. Koss, J. Wertheim, Z. J. Zhang, *Comprehensive Transplant Center and Department of Surgery, Northwestern University, Chicago, IL*

- A70** **AMD3100 (Plerixafor) as a Single-Dose Stem Cell Mobilizing Agent in Vascularized Composite Tissue Allograft (VCA) Transplantation in a Canine DLA-Mismatch Model**  
B. Swearingen<sup>1</sup>, S. Graves<sup>2</sup>, R. Storb<sup>2</sup>, D. W. Mathes<sup>1</sup>, <sup>1</sup>University of Colorado School of Medicine, Aurora, CO, <sup>2</sup>Fred Hutchinson Cancer Research Center, Seattle, WA
- A71** **Clinical Response to Pathological Finding in Uterus Transplantation**  
L. Johannesson, G. Testa, Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX
- A72** **VCA Deceased Donor Solid Organ Yield**  
J. Wainright<sup>1</sup>, G. Vece<sup>1</sup>, C. Wholley<sup>2</sup>, J. Rosendale<sup>1</sup>, W. Cherikh<sup>1</sup>, C. Curran<sup>3</sup>, A. Robinson<sup>1</sup>, D. Di Battista<sup>4</sup>, D. Klassen<sup>5</sup>, <sup>1</sup>Research, UNOS, Richmond, VA, <sup>2</sup>Policy and Community Relations, UNOS, Richmond, VA, <sup>3</sup>New England Donor Services, Waltham, MA, <sup>4</sup>Professional Education, UNOS, Richmond, VA, <sup>5</sup>Office of Chief Medical Officer, UNOS, Richmond, VA
- A73** **Cryopreserved Human Iliac Arteries Allografts: Different Thawing Rates Affect on Their Structural Changes and Mechanical Properties**  
R. Novotny<sup>1</sup>, J. Chlupac<sup>1</sup>, R. Matejka<sup>2</sup>, T. Marada<sup>1</sup>, P. Mericka<sup>3</sup>, L. Sterba<sup>3</sup>, L. Janousek<sup>1</sup>, J. Fronek<sup>1</sup>, <sup>1</sup>Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, <sup>2</sup>Department of Biomedical Engineering, Faculty of Biomedical Engineering, Czech Technical University, Prague, Czech Republic, <sup>3</sup>Tissue Bank, Faculty Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- A74** **Heterozygous Gene Mutations In The Complement Factor I (cfi) Was Susceptibility Gene For The C3 Glomerulonephritis In Native Kidney And Renal Allograft**  
J. Wen, H. Song, X. Ni, M. Zhang, F. Xu, X. Zhu, Jinling Hospital, Nanjing University School of Medicine, National Clinical Research Center of Kidney Diseases, Nanjing, Jiangsu, China

- A75** **Immunosuppression after Organ Transplantation Does Not Enhance Patency of Cold-Stored Vein Allografts for Critical Limb Ischemia -Single Centre Experience**  
J. Chlupac, T. Marada, R. Novotny, K. Lipar, L. Janousek, J. Fronek, Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- A76 †** **Uterine Graft Procurement in a Living Donor**  
L. Johannesson, A. Wall, J. Bayer, G. J. McKenna, G. Testa, Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX

## Poster Session A: Endothelial Cell Biology

- A77** **Protection of the Donor Kidney Vascular Endothelium by Ex-Vivo Perfusion with a Pan-Caspase Inhibitor**  
R. Plenter<sup>1</sup>, S. Jain<sup>2</sup>, T. Nydam<sup>1</sup>, A. jani<sup>2</sup>, <sup>1</sup>Transplant Microsurgery Program, University of Colorado, Aurora, CO, <sup>2</sup>Renal Division, University of Colorado, Aurora, CO
- A78** **Achieving Robust Targeting of Antibody-Conjugated Nanoparticles Delivered during Ex Vivo Machine Perfusion of Human Kidneys**  
J. R. DiRito<sup>1</sup>, S. Hosgood<sup>1</sup>, M. L. Nicholson<sup>1</sup>, G. Tietjen<sup>2</sup>, <sup>1</sup>Surgery, University of Cambridge, Cambridge, United Kingdom, <sup>2</sup>Surgery, Yale School of Medicine, New Haven, CT
- A79** **Endothelial Cell Cytoskeleton Rearrangement (ECCSKR) and Endothelial to Mesenchymal Transition (EndoMT) in Liver Allografts Following Acute Rejection (AR): Its Significance on the Development of Liver Fibrosis (LF) and Graft Survival**  
B. H. Ozdemir<sup>1</sup>, G. Ozgun<sup>1</sup>, E. H. Ayvazoglu Soy<sup>2</sup>, N. Haberal<sup>1</sup>, G. Moray<sup>2</sup>, M. Haberal<sup>2</sup>, <sup>1</sup>Pathology, Baskent University, Ankara, Turkey, <sup>2</sup>Transplantation, Baskent University, Ankara, Turkey

**A80 Differential Regulation of Phosphokinases by Anti-HLA Class I and 11 Antibodies**

A. Babu<sup>1</sup>, B. Tran<sup>2</sup>, M. Hamdorf<sup>2</sup>, V. Jucaud<sup>2</sup>, S. Daga<sup>3</sup>, D. Mitchell<sup>4</sup>, M. Everly<sup>2</sup>, <sup>1</sup>Henry Ford Hospitals, Detroit, MI, <sup>2</sup>Terasaki Research Institute, Los Angeles, CA, <sup>3</sup>University of Warwick, Coventry, United Kingdom, <sup>4</sup>Medical Sciences, University of Warwick, Coventry, United Kingdom

**A81 Clazakizumab Acts on Endothelial Cells to Limit Antibody Mediated Damage**

J. Lion<sup>1</sup>, K. Poussin<sup>1</sup>, E. Chong<sup>2</sup>, D. Glotz<sup>3</sup>, N. A. Mooney<sup>1</sup>, <sup>1</sup>Alloimmunité-Autoimmunité-Transplantation, INSERM, Paris, France, <sup>2</sup>Vitaeris, Vancouver, BC, Canada, <sup>3</sup>Nephrology and Transplantation, Hôpital Saint Louis, Paris, France

**A82 Mitochondrial Permeability Regulates Heart Graft Ischemia - Reperfusion Injury and Rejection**

A. Qamar<sup>1</sup>, J. Jiang<sup>1</sup>, X. Huang<sup>2</sup>, P. McLeod<sup>2</sup>, A. M. Jevnikar<sup>2</sup>, Z. Zhang<sup>2</sup>, <sup>1</sup>Pathology and Laboratory Medicine, University of Western Ontario, London, ON, Canada, <sup>2</sup>London Health Sciences Centre, London, ON, Canada

**A83 † Treg-Lymphatic Crosstalk: Lymphotoxin Signals as Modulators of Immunity and Suppression**

W. Piao<sup>1</sup>, L. Li<sup>2</sup>, V. Saxena<sup>2</sup>, Y. Xiong<sup>2</sup>, C. Paluskiewicz<sup>2</sup>, J. Bromberg<sup>3</sup>, <sup>1</sup>Microbiology and Immunology, U. Maryland, Baltimore, baltimore, MD, <sup>2</sup>Surgery, U. Maryland, Baltimore, Baltimore, MD, <sup>3</sup>Surgery and Microbiology and Immunology, U. Maryland, Baltimore, Baltimore, MD

**Poster Session A: Ischemia Reperfusion & Organ Rehabilitation**

**A84 Optimizing a Protocol for Extended Ex-Vivo Extremity Perfusion**

C. J. Stewart<sup>1</sup>, M. T. Buchko<sup>2</sup>, X. Wang<sup>1</sup>, G. Brandacher<sup>3</sup>, A. Ladak<sup>4</sup>, D. H. Freed<sup>2</sup>, J. Nagendran<sup>2</sup>, <sup>1</sup>Surgery, University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Cardiac Surgery, University of Alberta, Edmonton, AB, Canada, <sup>3</sup>Plastic and Reconstruction Surgery, Johns Hopkins University, Baltimore, MD, <sup>4</sup>Plastic Surgery, University of Alberta, Edmonton, AB, Canada

**A85 Ischemic Preconditioning Attenuates Renal Ischemia-Reperfusion Injury through Activating the Nrf2/HO-1 Pathway Enhanced Autophagy**

H. Choi<sup>1</sup>, Y. Kim<sup>2</sup>, M. Kim<sup>2</sup>, K. Jun<sup>2</sup>, S. Kim<sup>2</sup>, S. Park<sup>3</sup>, J. Kim<sup>4</sup>, I. Moon<sup>5</sup>, J. Hwang<sup>6</sup>, <sup>1</sup>Clinical Research Center, Daejeon St. Mary's Hospital, Daejeon, Korea, Republic of, <sup>2</sup>Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, <sup>3</sup>Transplant Surgery, Seoul St. Mary's Hospital, Seoul, Korea, Republic of, <sup>4</sup>Transplant Surgery, Uijeongbu St. Mary's Hospital, Uijeongbu, Korea, Republic of, <sup>5</sup>Transplant Surgery, Yeouido St. Mary's Hospital, Seoul, Korea, Republic of, <sup>6</sup>Transplant Surgery, Daejeon St. Mary's Hospital, Daejeon, Korea, Republic of

**A86 NQO-1 Attenuates Renal Ischemia-Reperfusion Injury in Mice**

D. Choi<sup>1</sup>, J. Hwang<sup>2</sup>, J. Jeong<sup>3</sup>, K. Lee<sup>1</sup>, K. Na<sup>1</sup>, Y. Ham<sup>1</sup>, J. Jeon<sup>1</sup>, H. Kim<sup>1</sup>, Y. Chang<sup>1</sup>, <sup>1</sup>Nephrology, Chungnam National University, Daejeon, Korea, Republic of, <sup>2</sup>Laboratory Animal Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea, Republic of, <sup>3</sup>Medical Science, Chungnam National University, Daejeon, Korea, Republic of



- A87 Heart-Associated Cytokine and Endothelial Patterns Dominate the Ischemia/Reperfusion Response in Recipients of Combined Heart/Lung Transplantation in Comparison to Lung Transplantation**  
 F. Wandrer<sup>1</sup>, B. Wiegmann<sup>2</sup>, N. Ledwoch<sup>1</sup>, R. Bellmas Sanz<sup>1</sup>, F. Ius<sup>2</sup>, W. Sommer<sup>2</sup>, S. Rojas<sup>2</sup>, C. Kühn<sup>2</sup>, I. Tudorache<sup>2</sup>, M. Avsar<sup>2</sup>, A. Haverich<sup>2</sup>, G. Warnecke<sup>2</sup>, C. S. Falk<sup>1</sup>, <sup>1</sup>*Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany*, <sup>2</sup>*Department for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany*
- A88 Soluble C Type Lectin Receptor Protein Inhibition of Natural Killer Cell Mediated Tubular Epithelial Cell Death**  
 S. Balaji<sup>1</sup>, B. Fuhrmann<sup>2</sup>, D. Lian<sup>3</sup>, H. Diao<sup>3</sup>, S. Ma<sup>3</sup>, Z. Zhang<sup>3</sup>, A. M. Jevnikar<sup>3</sup>, <sup>1</sup>*Physiology, Western University, London, ON, Canada*, <sup>2</sup>*Microbiology and Immunology, Western University, London, ON, Canada*, <sup>3</sup>*London Health Sciences Centre, London, ON, Canada*
- A89 Sigma-1 Receptor Agonists Are Renoprotective in a Rat Model of Kidney Transplantation**  
 A. Hosszu<sup>1</sup>, Z. Antal<sup>2</sup>, L. Illesy<sup>2</sup>, L. Lenart<sup>1</sup>, D. B. Balogh<sup>1</sup>, L. Wagner<sup>3</sup>, A. Vannay<sup>4</sup>, A. J. Szabo<sup>2</sup>, A. Fekete<sup>1</sup>, <sup>1</sup>*"Lendulet" Diabetes Research Group, MTA-SE, Budapest, Hungary*, <sup>2</sup>*1st Department of Pediatrics, Semmelweis University, Budapest, Hungary*, <sup>3</sup>*Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary*, <sup>4</sup>*Pediatrics and Nephrology Research Group, MTA-SE, Budapest, Hungary*
- A90 Indocyanine Green Fluorescence Imaging during Normothermic Ex Vivo Liver Perfusion for the Assessment of Hepatocyte, Biliary, and Vascular Function**  
 T. Goto, I. Linares, S. Ganesh, L. Mazilescu, P. Urbanellis, N. Selzner, M. Selzner, *Multi-Organ Transplant Program, Department of Surgery, Toronto General Hospital, Toronto, ON, Canada*
- A91 Randomized Controlled Trial Of Spironolactone Effect In Kidney Transplant Recipients Of Living Donors**  
 N. A. Bobadilla<sup>1</sup>, L. E. Morales-Buenrostro<sup>1</sup>, J. A. Ortega-Trejo<sup>1</sup>, R. Perez-Villalva<sup>1</sup>, L. Marino<sup>1</sup>, Y. González-Bobadilla<sup>1</sup>, H. Juarez<sup>1</sup>, F. Zamora-Mejía<sup>1</sup>, N. Gonzalez<sup>1</sup>, R. Espinoza<sup>2</sup>, J. Barrera-Chimal<sup>3</sup>, <sup>1</sup>*Nephrology, INCMNSZ, Mexico City, Mexico*, <sup>2</sup>*Nephrology, Centro Médico Nacional Siglo XXI, Mexico City, Mexico*, <sup>3</sup>*Molecular Physiology Unit, Instituto de Investigaciones Biomédicas, UNAM, Mexico City, Mexico*
- A92 Alpha-1 Antitrypsin Reduces Liver Ischemia Reperfusion Injury during Ex-Vivo Normothermic Machine Perfusion**  
 D. Detelich<sup>1</sup>, R. de Vries<sup>1</sup>, C. Carroll<sup>1</sup>, M. Stein<sup>2</sup>, K. Uygun<sup>1</sup>, H. Yeh<sup>1</sup>, J. Markmann<sup>1</sup>, <sup>1</sup>*Massachusetts General Hospital, Boston, MA*, <sup>2</sup>*Kamada, Rehovot, Israel*
- A93 Reverse Signaling through CD137 Ligand Promotes Tissue Repair after Ischemia-Reperfusion Kidney Injury**  
 H. R. Cho<sup>1</sup>, S. Lee<sup>2</sup>, J. S. Lee<sup>3</sup>, S. J. Park<sup>1</sup>, B. Kwon<sup>2</sup>, <sup>1</sup>*Ulsan University Hospital, Ulsan, Korea, Republic of*, <sup>2</sup>*Biomedical Research Center, Ulsan University Hospital, Ulsan, Korea, Republic of*, <sup>3</sup>*Department of Internal Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of*
- A94 † Predominant Role of Microvascular over Tubular Injury as Driver of Progressive Renal Damage and Fibrosis Post Ischemia Reperfusion Injury**  
 S. Lan<sup>1</sup>, B. Yang<sup>1</sup>, M. Dieudé<sup>1</sup>, J. Sabo-Vatasescu<sup>2</sup>, A. Karakeussian-Rimbaud<sup>2</sup>, J. Turgeon<sup>2</sup>, S. Qi<sup>3</sup>, N. Patey<sup>4</sup>, M. Hébert<sup>1</sup>, <sup>1</sup>*Medicine Faculty, CRCHUM, University of Montreal, Montreal, QC, Canada*, <sup>2</sup>*CRCHUM, Montreal, QC, Canada*, <sup>3</sup>*Department of Surgery, CRCHUM, University of Montreal, Montreal, QC, Canada*, <sup>4</sup>*Department of Pathology and Cell Biology, CHU Saint-Justine, University of Montreal, Montreal, QC, Canada*



- A95 Hypothermic Protection Attenuates Kidney Injury in Renal Ischemia-Reperfusion Injury via Phosphorylation of ERK**  
D. Choi<sup>1</sup>, J. Jeong<sup>2</sup>, K. Lee<sup>1</sup>, K. Na<sup>1</sup>, Y. Chang<sup>3</sup>, Y. Ham<sup>1</sup>, J. Jeon<sup>1</sup>, H. Kim<sup>1</sup>,  
<sup>1</sup>*Nephrology, Chungnam National University, Daejeon, Korea, Republic of*,  
<sup>2</sup>*Medical Science, Chungnam National University, Daejeon, Korea, Republic of*,  
<sup>3</sup>*Nephrology, Catholic University of Korea, Daejeon, Korea, Republic of*
- A96 Perfluorocarbon (PFC) Solutions for Organ Preservation**  
N. Battula, T. Parsons, J. Zhu, C. Giordano, A. Esnakula, B. Spiess, M. Johnson, A. Zarrinpar, K. Andreoni,  
*University of Florida, Gainesville, FL*
- A97 Novel Molecular Mechanisms Associated with Normothermic Ex-Vivo Kidney Perfusion**  
C. McEvoy<sup>1</sup>, T. Tokar<sup>2</sup>, S. Reid<sup>3</sup>, P. Urbanellis<sup>3</sup>, M. Hamar<sup>1</sup>, M. Kathis<sup>1</sup>, I. Jurisica<sup>2</sup>, L. Robinson<sup>4</sup>, M. Selzner<sup>1</sup>, A. Konvalinka<sup>1</sup>,  
<sup>1</sup>*MOT Programme, University Health Network, Toronto, ON, Canada*,  
<sup>2</sup>*Krembil Research Institute, UHN, Toronto, ON, Canada*,  
<sup>3</sup>*Institute of Medical Science, University of Toronto, Toronto, ON, Canada*,  
<sup>4</sup>*Sick Kids Research Institute, Toronto, ON, Canada*
- A98 Flow Cytometric Analysis of Leukocyte Migration during Ex Vivo Lung Perfusion with CXCR4 Inhibition**  
J. Yerxa<sup>1</sup>, Q. Gao<sup>1</sup>, R. P. Davis<sup>2</sup>, M. Zhang<sup>1</sup>, U. Scheuermann<sup>1</sup>, W. Parker<sup>1</sup>, M. G. Hartwig<sup>2</sup>, A. Barbas<sup>1</sup>,  
<sup>1</sup>*General Surgery, Duke University, Durham, NC*,  
<sup>2</sup>*Thoracic Surgery, Duke University, Durham, NC*
- A99 Impact of Time-of-Day of Declamping on Kidney Transplant Outcome**  
D. Montaigne<sup>1</sup>, N. Al Hawajri<sup>2</sup>, M. Jacquelinet<sup>1</sup>, A. Coppin<sup>1</sup>, M. Frimat<sup>3</sup>, S. Bouyé<sup>3</sup>, G. Lebuffe<sup>3</sup>, F. Bayer<sup>2</sup>, M. Lassalle<sup>2</sup>, B. Staels<sup>1</sup>, M. Hazzan<sup>3</sup>, C. Jacquelinet<sup>4</sup>,  
<sup>1</sup>*University Hospital CHU Lille, Lille University and Inserm U1011, University Lille - EGID, Institut Pasteur de Lille, 59000, Lille, France*,  
<sup>2</sup>*Agence de la Biomedecine, 93212, Saint-Denis la Plaine, France*,  
<sup>3</sup>*University Hospital CHU Lille, University of Lille, 59000, Lille, France*,  
<sup>4</sup>*REIN Registry, Agence de la Biomedecine and Inserm U1018, 93212, Saint-Denis la Plaine, France*
- A100 Aquaporins May Be Involved in Renal Ischemia-Reperfusion Injury by Affecting the Pyroptosis of Renal Tubular Epithelial Cells**  
T. Lin, Y. Fan, Y. Jiang, J. Liu, Z. Wang, L. Li, T. Song, Z. Huang, X. Wang,  
*Organ Transplantation Center, Urology Department, Urology Research Institute, WestChina Hospital, Sichuan University, Chengdu, China*
- A101 Pharmacological Mobilization of Host Stem Cells Prevents Delayed Graft Function Following Kidney Transplantation in Rats**  
W. Wang, L. Qi, J. Huang, A. Ahmadi, A. Krishnan, R. Wesson, A. Cameron, Z. Sun,  
*Johns Hopkins University School of Medicine, Baltimore, MD*
- A102 Kidney-Intrinsic Innate Immunity and Endoplasmic Reticulum Stress Pathways are Key Determinants of Severity of Ischemia-Reperfusion Injury Following Transplantation**  
L. Qiu<sup>1</sup>, J. Wang<sup>1</sup>, X. Yeap<sup>1</sup>, C. Lin<sup>1</sup>, Y. S. Kanwar<sup>2</sup>, D. Fang<sup>2</sup>, M. M. Abecassis<sup>1</sup>, Z. J. Zhang<sup>1</sup>,  
<sup>1</sup>*Comprehensive Transplant Center, Department of Surgery, Northwestern University, Chicago, IL*,  
<sup>2</sup>*Department of Pathology, Northwestern University, Chicago, IL*

- A103** **Determining the Molecular Nature and Role of Cytoglobin in Chronic Allograft Nephropathy**  
D. Patel<sup>1</sup>, T. Divanyan<sup>1</sup>, E. Acosta<sup>1</sup>, K. Carnes<sup>2</sup>, D. Howard<sup>3</sup>, F. Jourd'heuil<sup>3</sup>, D. Jourd'heuil<sup>3</sup>, R. Lopez-Soler<sup>4</sup>, <sup>1</sup>*Albany Medical College, Albany, NY*, <sup>2</sup>*Urology, Albany Medical College, Albany, NY*, <sup>3</sup>*Molecular and Cellular Physiology, Albany Medical College, Albany, NY*, <sup>4</sup>*Surgery, Section of Transplantation, Albany Medical College, Albany, NY*
- A104 †** **Donor Renal Macrophages in Post-Transplant Ischemia/Reperfusion Injury (IRI): Role of IL-1R8 in Modulating Fate, Phenotype and Function**  
S. Aiello, P. Rodriguez, N. Azzollini, F. Casiraghi, M. Noris, G. Remuzzi, A. Benigni, *Mario Negri Institute, Ranica, Italy*
- A105 †** **Loss of FXR Exacerbates Liver Damage by Activating NLRP3 Inflammasome Induced Pyroptosis in Liver Ischemia Reperfusion Injury**  
Z. Zhu, Y. Zhang, Y. Tang, S. Huang, Q. Zhao, W. Ju, Z. Guo, X. He, *Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China*
- A106** **Inhibition of Cyclin-Dependent Kinase 2 Signaling Prevents Liver Ischemia and Reperfusion Injury**  
Z. Xue, J. Xu, C. Zhang, Y. Liu, R. Busuttil, J. Kupiec-Weglinski, H. Ji, *Dumont-UCLA Transplant Center, Los Angeles, CA*
- A107** **CD38 Inhibition: A Novel Target for Hepatic Ischemia Reperfusion Injury**  
C. Akateh<sup>1</sup>, B. F. Reader<sup>1</sup>, Y. Lee<sup>1</sup>, J. Kim<sup>1</sup>, K. Maynard<sup>1</sup>, K. W. Washburn<sup>1</sup>, J. L. Zweier<sup>2</sup>, B. A. Whitson<sup>1</sup>, S. M. Black<sup>1</sup>, <sup>1</sup>*Surgery, The Ohio State University Wexner Medical Center, Columbus, OH*, <sup>2</sup>*The Ohio State University Wexner Medical Center, Columbus, OH*
- A108** **Multi-omic Analysis Of Hepatic Ischemia/reperfusion Injury Identifies Novel Targets To Mitigate Hepatocellular Damage**  
S. Duarte<sup>1</sup>, V. Boominathan<sup>2</sup>, Z. Huo<sup>3</sup>, A. Kobayashi<sup>2</sup>, U. Kim<sup>2</sup>, Y. Lai<sup>2</sup>, A. Coito<sup>1</sup>, A. Zarrinpar<sup>2</sup>, <sup>1</sup>*Surgery, UCLA, Los Angeles, CA*, <sup>2</sup>*Surgery, University of Florida, Gainesville, FL*, <sup>3</sup>*Biostatistics, University of Florida, Gainesville, FL*
- A109** **Tubastatin-A, an HDAC6 Inhibitor, is Protective in Liver Ischemia Reperfusion Injury and Acetaminophen-Mediated Liver Injury**  
S. Concors<sup>1</sup>, D. Murken<sup>1</sup>, P. Hernandez<sup>1</sup>, D. Aufhauser<sup>1</sup>, Z. Wang<sup>1</sup>, G. Ge<sup>1</sup>, L. Krumeich<sup>1</sup>, T. Bhatti<sup>2</sup>, A. Kozikowski<sup>3</sup>, W. Hancock<sup>2</sup>, M. H. Levine<sup>1</sup>, <sup>1</sup>*Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA*, <sup>2</sup>*Children's Hospital of Philadelphia, Philadelphia, PA*, <sup>3</sup>*Starwise Therapeutics, Madison, WI*
- A110 †** **Distinct Delayed Classical Complement Pathway Activation Highlights Transition of Ischemic Acute Kidney Injury to Chronic Kidney Disease with Interstitial Fibrosis/Tubular Atrophy**  
S. Kumar, S. Jordan, *Comprehensive Transplant Center, Cedars Sinai Medical Ctr, Los Angeles, CA*
- A111** **Kupffer Cells Are Critical for Inflammation Resolution in Liver Ischemia Reperfusion Injury via TIM-4 Mediated Efferocytosis**  
M. Ni<sup>1</sup>, H. Wang<sup>1</sup>, D. Jin<sup>1</sup>, J. Zhang<sup>1</sup>, R. Busuttil<sup>1</sup>, J. Kupiec-Weglinski<sup>1</sup>, X. Wang<sup>2</sup>, Y. Zhai<sup>1</sup>, <sup>1</sup>*Dumont-UCLA Transplant Center, Los Angeles, CA*, <sup>2</sup>*The First Affiliated Hospital of Nanjing Medical University, Nanjing, China*
- A112** **Graft TIM4 Deficiency Protects Liver from Ischemia Reperfusion Injury: From Mouse to Human**  
S. Kageyama<sup>1</sup>, K. Kadono<sup>1</sup>, H. Hirao<sup>1</sup>, K. Nakamura<sup>1</sup>, T. Ito<sup>2</sup>, K. J. Dery<sup>1</sup>, D. Oncel<sup>1</sup>, B. Ke<sup>1</sup>, F. M. Kaldas<sup>2</sup>, R. W. Busuttil<sup>2</sup>, J. W. Kupiec-Weglinski<sup>1</sup>, <sup>1</sup>*Surgery, Dumont-UCLA Transplant Center, Los Angeles, CA*, <sup>2</sup>*Surgery, Ronald Reagan UCLA Medical Center, Los Angeles, CA*

- A113 Withaferin A as a Possible Therapy for Chronic Allograft Nephropathy**  
T. Divanyan<sup>1</sup>, D. Patel<sup>1</sup>, E. Acosta<sup>1</sup>, D. Howard<sup>2</sup>, F. Jour'd'heuil<sup>2</sup>, D. Jour'd'heuil<sup>2</sup>, R. Lopez-Soler<sup>3</sup>, <sup>1</sup>Albany Medical College, Albany, NY, <sup>2</sup>Molecular and Cellular Physiology, Albany Medical College, Albany, NY, <sup>3</sup>Surgery, Section of Transplantation, Albany Medical College, Albany, NY
- A114 Evaluation of New Baskent University Preservation Solution for Liver, Kidney and Intestine Graft during Cold Ischemia: Preliminary Experimental Animal Study**  
M. Haberal<sup>1</sup>, M. Kirnap<sup>1</sup>, R. Erdem<sup>2</sup>, H. Ozdemir<sup>3</sup>, M. Lux<sup>2</sup>, D. Bacanli<sup>4</sup>, <sup>1</sup>Transplantation, Baskent University, Ankara, Turkey, <sup>2</sup>Pharmacology, Baskent University, Ankara, Turkey, <sup>3</sup>Pathology, Baskent University, Ankara, Turkey, <sup>4</sup>Experimental Laboratory, Baskent University, Ankara, Turkey
- A115 † Normothermic Ex Situ Liver Perfusion with Different Clinical Perfusates and Their Effect on Pig Liver Transplant Outcomes in a Donation after Circulatory Death Model**  
I. Linares-Cervantes, D. Kollmann, T. Goto, J. Echeverri, M. Kathis, M. Hamar, P. Urbanellis, L. Mazilescu, R. Rosales, C. Bruguera, F. Oquendo, S. Ganesh, O. Adeyi, P. Yip, N. Selzner, M. Selzner, Toronto General Hospital, Toronto, ON, Canada
- A116 Recombinant Apoptosis Inhibitor of Macrophage Protein Ameliorates Transplant Ischemia-Reperfusion Injury**  
J. Y. Lee<sup>1</sup>, X. Zhang<sup>2</sup>, D. Lian<sup>3</sup>, A. R. Haig<sup>4</sup>, T. Miyazaki<sup>5</sup>, L. Gunaratnam<sup>6</sup>, <sup>1</sup>Department of Microbiology and Immunology, Western University, London, ON, Canada, <sup>2</sup>Matthew Mailing Centre for Translational Transplant Studies, London Health Sciences Centre, London, ON, Canada, <sup>3</sup>Matthew Mailing Centre for Translational Transplant Studies, London Health Sciences Centre, London, ON, Canada, <sup>4</sup>Department of Pathology, Western University, London, ON, Canada, <sup>5</sup>Center for Disease Biology and Integrative Medicine, University of Tokyo, Tokyo, Japan, <sup>6</sup>Department of Medicine, Western University, London, ON, Canada

## Poster Session A: Islet Cell and Cell Transplantation

- A117 Withaferin A Shifts Circulating Lymphocytes toward Protective T Cell Subsets and Prolongs Islet Allograft Survival in a Mouse Transplant Model**  
K. Kumano<sup>1</sup>, M. Kanak<sup>2</sup>, C. Darden<sup>3</sup>, S. Vasu<sup>1</sup>, Y. Liu<sup>4</sup>, M. C. Lawrence<sup>1</sup>, B. Naziruddin<sup>4</sup>, <sup>1</sup>Baylor Scott and White Research Institute, Dallas, TX, <sup>2</sup>Department of Surgery, Virginia Commonwealth University, Richmond, VA, <sup>3</sup>Institute of Biomedical Studies, Baylor University, Waco, TX, <sup>4</sup>Baylor Simmons Transplant Institute, Dallas, TX
- A118 Analysis of Islet Exosomal miRNAs Released Post-Transplant in Response to Inflammation**  
P. Saravanan<sup>1</sup>, M. Kanak<sup>1</sup>, G. Yoshimatsu<sup>2</sup>, C. Darden<sup>2</sup>, M. Lawrence<sup>2</sup>, M. Levy<sup>1</sup>, B. Naziruddin<sup>3</sup>, <sup>1</sup>Department of Surgery, Virginia Commonwealth University, VCU Health, Richmond, VA, <sup>2</sup>Islet Cell Lab, Baylor Scott and White Research Institute, Dallas, TX, <sup>3</sup>Simmons Transplant Institute, Baylor Scott and White Research Center, Dallas, TX
- A119 Assessment of Culture/Preservation Conditions on Survival and Function of Islets**  
Y. Shindo, M. F. Levy, M. A. Kanak, Surgery, Virginia Commonwealth University, Richmond, VA
- A120 Microfluidic Study Analyzing the Effect of Immediate-Release and Extended-Release Tacrolimus on Islet Function**  
P. West-Thielke<sup>1</sup>, J. Oberholzer<sup>2</sup>, Y. Wang<sup>3</sup>, <sup>1</sup>University of Illinois, Chicago, IL, <sup>2</sup>University of Virginia, Charlottesville, VA, <sup>3</sup>University of Virginia, Charlottesville, VA
- A121 Islet Stress Leads to Increased Release of Exosomes That Stimulate Immune Cell Response**  
S. Vasu<sup>1</sup>, C. Darden<sup>2</sup>, K. Kumano<sup>1</sup>, B. Naziruddin<sup>3</sup>, M. Lawrence<sup>3</sup>, <sup>1</sup>Baylor Scott and White Research Institute, Dallas, TX, <sup>2</sup>Institute of Biomedical Studies, Baylor University, Waco, TX, <sup>3</sup>Baylor University Medical Ctr, Dallas, TX

**A122**     **Pancreatic Extracellular Matrix Improves Human Islet Culture and Function In Vitro**  
Y. Shindo, R. Pouillot, B. M. Young, P. Link, R. L. Heise, M. F. Levy, M. A. Kanak, *Virginia Commonwealth University, Richmond, VA*

**A123 †**   **Improvement of the Outcome of Clinical Islet Transplantation Depending on the Era in Japan**  
Y. Akashi<sup>1</sup>, T. Kenmochi<sup>2</sup>, T. Ito<sup>3</sup>, K. Kurihara<sup>2</sup>, N. Aida<sup>2</sup>, A. Kawai<sup>2</sup>, M. Hayashi<sup>4</sup>, K. Kouketsu<sup>4</sup>, <sup>1</sup>*Faculty of Nursing, School of Health Sciences, Fujita Health University, Toyoake, Japan*, <sup>2</sup>*Department of Transplantation and Regenerative Medicine, Fujita Health University, Toyoake, Japan*, <sup>3</sup>*Department of Transplantation and Regenerative Medicine, Fujita Health University, Toyoake, Japan*, <sup>4</sup>*Transplant medical support office, Fujita Health University Hospital, Toyoake, Japan*

**A124**     **The Efficacy of Spheroidal Hepatocytes for Hepatocyte Transplantation**  
K. Shibuya, M. Watanabe, Y. Ganchiku, R. Kanazawa, Y. Koshizuka, M. Zaitso, R. Goto, A. Taketomi, *Department of Gastroenterological Surgery I Hokkaido University Graduate School, Sapporo, Japan*

**A125**     **Human Mesenchymal Stem Cells Inhibits Hypoxia-Induced Islets Apoptosis via Regulation of Autophagy**  
R. Pengfei, X. Yuzhi, *The Third Xiang Ya Hospital, Central South University, ChangSha, China*

**A126 †**   **Parathyroid CD34+ Cells Induce Neovascularization of Donor and Recipient Leading to Chimeric Vessel Formation and Improved Engraftment of Co-Transplanted Pancreatic Islets**  
Y. Kelly<sup>1</sup>, C. Ward<sup>1</sup>, Q. Duh<sup>1</sup>, W. Chang<sup>2</sup>, P. Stock<sup>1</sup>, Q. Tang<sup>1</sup>, <sup>1</sup>*UCSF, San Francisco, CA*, <sup>2</sup>*San Francisco Veterans Affairs, San Francisco, CA*

**A127 †**   **Exosomes Carry Stress and Damage Specific miRNAs during Peritransplant Period in TPIAT**  
P. Saravanan<sup>1</sup>, M. Kanak<sup>1</sup>, S. Vasu<sup>2</sup>, M. Lawrence<sup>2</sup>, M. Levy<sup>1</sup>, B. Naziruddin<sup>3</sup>, <sup>1</sup>*Department of Surgery, Virginia Commonwealth University, VCU Health, Richmond, VA*, <sup>2</sup>*Islet Cell Lab, Baylor Scott and White Research Institute, Dallas, TX*, <sup>3</sup>*Simmons Transplant Institute, Baylor Scott and White Medical Center, Dallas, TX*

**A128 †**   **Insulin Treatment in Pancreas Donors on the Intensive Care is a Marker of Beta Cell Death as Evidenced by microRNA Data**  
I. Shapey, A. Summers, J. O'Sullivan, P. Yiannoullou, N. Hanley, T. Augustine, M. Rutter, D. van Dellen, *University of Manchester, Manchester, United Kingdom*

## Poster Session A: Biomarkers, Immune Monitoring and Outcomes

**A129**     **Galectin-3 Levels Are Associated with the Incidence and Severity of Chronic GVHD One Year after Allogeneic Hematopoietic Cell Transplantation**  
N. Navarro-Alvarez<sup>1</sup>, A. R. Andrews<sup>1</sup>, Z. DeFilipp<sup>2</sup>, Y. A. Chen<sup>2</sup>, V. T. Ho<sup>3</sup>, J. Ritz<sup>3</sup>, T. R. Spitzer<sup>4</sup>, C. A. Huang<sup>5</sup>, <sup>1</sup>*Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA*, <sup>2</sup>*Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA*, <sup>3</sup>*Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA*, <sup>4</sup>*Hematology/Oncology, Massachusetts General Hospital, Boston, MA*, <sup>5</sup>*Plastic & Reconstructive Surgery and Transplant Surgery Divisions, University of Colorado, Denver, Aurora, CO*

**A130 †**   **A Prognostic Biomarker to Estimate the Likelihood of Developing De Novo Donor Specific Antibody in Kidney Transplant Recipients**  
S. Kawakita<sup>1</sup>, L. M. Rebellato<sup>2</sup>, K. P. Briley<sup>2</sup>, A. Q. Maldonado<sup>3</sup>, C. E. Haisch<sup>2</sup>, P. Bolin<sup>2</sup>, S. A. Kendrick<sup>4</sup>, H. Jones<sup>4</sup>, K. McLawhorn<sup>4</sup>, D. Leeser<sup>2</sup>, V. Jucaud<sup>1</sup>, V. Burnett<sup>1</sup>, M. J. Everly<sup>1</sup>, <sup>1</sup>*Terasaki Research Institute, Los Angeles, CA*, <sup>2</sup>*East Carolina University, Greenville, NC*, <sup>3</sup>*Vidant Medical Center, Greenville, NC*, <sup>4</sup>*Eastern Nephrology Associates, Greenville, NC*



- A131 Transcriptome Profiling Of Renal Transplant Biopsies With Acute Cellular Rejection From Patients On Calcineurin Inhibitor-based Or Cni-avoidance Immunosuppression**  
D. Dobi<sup>1</sup>, F. Vincenti<sup>2</sup>, Z. G. Laszik<sup>1</sup>,  
<sup>1</sup>Department of Pathology, University of California, San Francisco, San Francisco, CA, <sup>2</sup>Departments of Medicine and Surgery, University of California, San Francisco, San Francisco, CA
- A132 † Urinary Exosomal microRNA as a Non-Invasive Biomarker for the Diagnosis of Acute Rejection in Kidney Transplant Recipients**  
 J. Seo<sup>1</sup>, Y. Lee<sup>1</sup>, S. Jung<sup>1</sup>, Y. Kim<sup>1</sup>, J. Moon<sup>1</sup>, K. Jeong<sup>1</sup>, C. Kim<sup>2</sup>, J. Park<sup>3</sup>, B. Chung<sup>4</sup>, Y. Kim<sup>5</sup>, S. Lee<sup>1</sup>, <sup>1</sup>Nephrology, Kyung Hee University College of Medicine, Seoul, Korea, Republic of, <sup>2</sup>Nephrology, Kyungpook National University College of Medicine, Daegu, Korea, Republic of, <sup>3</sup>Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, <sup>4</sup>Nephrology, The St. Mary's Hospital of Catholic University of Korea, Seoul, Korea, Republic of, <sup>5</sup>Nephrology, Inje University College of Medicine, Busan, Korea, Republic of
- A133 External Validation of Donor-Derived Cell-Free DNA to Detect Rejection in Kidney Transplant Recipients**  
E. Huang, S. Sethi, A. Peng, R. Najjar, A. Vo, S. Jordan, Cedars Sinai Medical Center, Los Angeles, CA
- A134 IE-1 Specific T Cell Receptor Repertoire Diversity and Protection against CMV Reactivation**  
M. Lucia Perez<sup>1</sup>, F. Rubelt<sup>1</sup>, S. Busque<sup>1</sup>, C. O. Esquivel<sup>1</sup>, S. M. Krams<sup>1</sup>, O. Bestard<sup>2</sup>, O. M. Martinez<sup>1</sup>, <sup>1</sup>Surgery, Stanford University School of Medicine, Stanford, CA, <sup>2</sup>Nephrology, University of Barcelona, L'Hospitalet de Llobregat, Spain
- A135 B Cell Derived Exosomes Are Associated with Antibody Mediated Rejection in Kidney Transplant Recipients Desensitized for a Positive Cross-Match**  
D. Cucchiari<sup>1</sup>, V. Tubita<sup>2</sup>, M. J. Ramirez-Bajo<sup>2</sup>, J. Rovira<sup>2</sup>, F. E. Borràs<sup>3</sup>, L. Carreras-Planella<sup>3</sup>, A. Hertig<sup>4</sup>, F. Oppenheimer<sup>1</sup>, F. Diekmann<sup>1</sup>, I. Revuelta<sup>1</sup>, <sup>1</sup>Renal Transplant Unit, Hospital Clínic, Barcelona, Spain, <sup>2</sup>Laboratori Experimental de Nefrologia i Trasplantament, IDIBAPS, Barcelona, Spain, <sup>3</sup>REMAR-IVECAT group, IGTP, Badalona, Spain, <sup>4</sup>Department of Nephrology and Kidney Transplantation, Hôpital Tenon, Paris, France
- A136 Next Gen ABO Antibody Assessment: Development of a Bead-Based ABO Antibody Detection Assay**  
A. Halpin<sup>1</sup>, J. Pearcey<sup>2</sup>, B. Motyka<sup>2</sup>, S. Maier<sup>2</sup>, J. Zhou<sup>3</sup>, T. L. Lowary<sup>4</sup>, C. W. Cairo<sup>4</sup>, L. J. West<sup>1</sup>, <sup>1</sup>Dept of Pediatrics, Dept of Laboratory Medicine, GlycoNet, ATI, CDTRP, University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Dept of Pediatrics, ATI, GlycoNet, CDTRP, University of Alberta, Edmonton, AB, Canada, <sup>3</sup>Dept of Laboratory Medicine, University of Alberta, Edmonton, AB, Canada, <sup>4</sup>Dept of Chemistry, GlycoNet, CDTRP, University of Alberta, Edmonton, AB, Canada
- A137 Human Leukocyte Antigen Class I (HLA-I) Antibodies in Patients Undergoing Liver Transplantation: Implications for Platelet Transfusion Support**  
M. Wong<sup>1</sup>, R. Narra<sup>2</sup>, M. Selim<sup>1</sup>, M. A. Zimmerman<sup>1</sup>, A. Padmanabhan<sup>3</sup>, J. C. Hong<sup>1</sup>, <sup>1</sup>Div. of Transplant Surgery, Medical College of Wisconsin, Milwaukee, WI, <sup>2</sup>Div. of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, <sup>3</sup>Medical College of Wisconsin and BloodCenter of Wisconsin, Milwaukee, WI



- A138 † Predicting Post-Transplant Graft Function in Deceased Donor Kidney Transplant Recipients**  
K. Archer<sup>1</sup>, Y. Zhang<sup>1</sup>, V. Bontha<sup>2</sup>, J. Eason<sup>3</sup>, L. Gallon<sup>4</sup>, E. Akalin<sup>5</sup>, D. Maluf<sup>2</sup>, V. Mas<sup>2</sup>, <sup>1</sup>OSU, Columbus, OH, <sup>2</sup>UTHSC, Memphis, TN, <sup>3</sup>UTHSC Director of Transplant Institute, Memphis, TN, <sup>4</sup>NWU, Chicago, IL, <sup>5</sup>Albert Einstein College of Medicine, NYC, NY
- A139 † Evaluating Adherence to Immunosuppressive Drugs through Trackyourmed® an Innovative Qr Code-Scanner App in Renal Transplantation: Preliminary Results from i-COM Trial**  
E. Melilli<sup>1</sup>, M. Meneghini<sup>1</sup>, N. Montero<sup>1</sup>, A. Coloma<sup>1</sup>, I. Revuelta<sup>2</sup>, F. Moreso<sup>3</sup>, V. Torregrosa<sup>2</sup>, J. Grinyo<sup>1</sup>, O. Bestard<sup>1</sup>, <sup>1</sup>Renal Transplant Unit, Bellvitge University Hospital, L'Hospitalet de Llobregat, Spain, <sup>2</sup>Renal Transplant Unit, Hospital Clinic, Barcelona, Spain, <sup>3</sup>Renal Transplant Unit, Vall D'Hebron Hospital, Barcelona, Spain
- A140 Increase in Proinflammatory CD14++CD16+ Monocytes in Samples from Aspiration Cytology Compared with Peripheral Blood in Kidney Transplant Patients with Borderline Rejection**  
T. Vazquez-Sanchez<sup>1</sup>, A. Caballero-Gonzalez<sup>2</sup>, E. Sola<sup>1</sup>, P. Ruiz-Esteban<sup>1</sup>, E. Marques<sup>1</sup>, J. Alonso-Titos<sup>1</sup>, E. Palma<sup>1</sup>, C. Jironda<sup>1</sup>, M. Cabello<sup>1</sup>, V. Lopez<sup>1</sup>, P. Hidalgo<sup>1</sup>, M. Leon<sup>1</sup>, D. Hernandez<sup>1</sup>, <sup>1</sup>Nephrology, Hospital Regional Universitario de Málaga, Universidad de Málaga, IBIMA, REDinREN (RD16/0009/0006), Málaga, Spain, <sup>2</sup>Immunology, Hospital Regional Universitario de Málaga, Universidad de Málaga, IBIMA, REDinREN (RD16/0009/0006), Málaga, Spain
- A141 Clinical, Aging, Morphometric Measures & Adverse Outcomes in Kidney Transplant Recipients**  
A. Muzaale<sup>1</sup>, N. Chu<sup>1</sup>, H. Ying<sup>1</sup>, B. Ross<sup>2</sup>, D. Segev<sup>1</sup>, M. McAdams-Demarco<sup>1</sup>, <sup>1</sup>JHU, Baltimore, MD, <sup>2</sup>UM, Ann Habor, MI
- A142 Whole-Exome Sequencing Identifies PMS1 and DYRK1A Genes Contributing to Occurrence of Liver Cancer**  
Y. Zhao, B. Yang, D. Chen, L. Wei, Z. Chen, Tongji hospital, Huazhong university, Organ Transplantation, Wuhan, China
- A143 A Prognostic Model to Identify Deceased Donor Kidney Transplant Recipients at High Risk for Delayed Graft Function**  
S. Kawakita, J. L. Beaumont, M. J. Everly, Terasaki Research Institute, Los Angeles, CA
- A144 Use Of Perirenal Adipose Tissue As A Source Of Donor Cells Allowing Evaluation Of Endothelial Inflammation And Quality Of Expanded Criteria Kidneys**  
R. Boissier<sup>1</sup>, L. Lyonnet<sup>2</sup>, P. Francois<sup>3</sup>, M. Meunier<sup>4</sup>, B. Gondran-Tellier<sup>5</sup>, T. Legris<sup>6</sup>, J. Magalon<sup>5</sup>, C. Picard<sup>7</sup>, F. Dignat George<sup>5</sup>, E. Lechevallier<sup>8</sup>, G. Karsenty<sup>8</sup>, F. Sabatier<sup>9</sup>, P. Paul<sup>1</sup>, <sup>1</sup>INSERM 1263, Centre de recherche en cardiovasculaire et nutrition, INSERM, Aix Marseille Univ, Assistance Publique Hopitaux Marseille, Marseille, France, <sup>2</sup>Vascular Biology and Hematology department, Assistance publique Hopitaux Marseille (AP-HM), Marseille, France, <sup>3</sup>INSERM 1263, Centre de recherche en cardiovasculaire et nutrition, INSERM, Aix Marseille Univ., Marseille, France, <sup>4</sup>Nephrology Dialysis and Renal Transplantation Center, AP-HM, Marseille, France, <sup>5</sup>INSERM 1263, C2VN, INSERM, Aix Marseille Univ., Marseille, France, <sup>6</sup>Nephrology Dialysis and Renal Transplantation Center, AP-HM, Marseille, France, <sup>7</sup>Etablissement Français du Sang, Alpes Méditerranée, Marseille, France, <sup>8</sup>Urology and Transplantation Unit, AP-HM, Marseille, France, <sup>9</sup>INSERM 1263, Centre de recherche en cardiovasculaire et nutrition, INSERM, Aix Marseille Univ, Marseille, France

- A145**      **The Polish Troubled Kidney Transplant Biopsy Study: External Validation of the Molecular Microscope System**  
M. Myślak<sup>1</sup>, D. Deborska-Materkowska<sup>2</sup>, M. Ciszek<sup>2</sup>, J. Mazurkiewicz<sup>1</sup>, A. Debska-Slizien<sup>3</sup>, P. F. Halloran<sup>4</sup>, A. Perkowska-Ptasińska<sup>5</sup>, <sup>1</sup>*Pomeranian Medical University, Szczecin, Poland*, <sup>2</sup>*Warsaw Medical University, Warsaw, Poland*, <sup>3</sup>*Gdansk Medical University, Gdansk, Poland*, <sup>4</sup>*Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton AB, AB, Canada*, <sup>5</sup>*Medical University of Warsaw, Warsaw, Poland*
- A146**      **High Urinary Neutrophil Gelatinase Lipocalins (NGAL) Levels in Kidney Perfusates as Predictor of a Better Renal Function**  
A. Angeletti, C. Donadei, V. De Pace, I. Capelli, V. Corradetti, C. Zannini, F. Alviano, L. Bonsi, G. Comai, M. Ravaioli, G. La Manna, *DIMES, S.Orsola-Malpighi Hospital, Bologna University, Bologna, Italy*
- A147**      **Assessment of the Relationship between Inflammation and Glomerular Filtration Rate**  
J. B. Ramirez-Gonzalez<sup>1</sup>, L. E. Morales-BuenRostro<sup>2</sup>, J. Furuzawa-Carballeda<sup>3</sup>, L. Garcia-Covarrubias<sup>4</sup>, R. L. Pacheco-Domínguez<sup>5</sup>, R. Durazo-Arvizu<sup>6</sup>, J. Alberu<sup>3</sup>, E. N. Cuevas-Medina<sup>7</sup>, M. López-Cervantes<sup>5</sup>, R. A. Osorio-Juárez<sup>5</sup>, <sup>1</sup>*Faculty of Medicine, Public Health Department, Universidad Nacional Autónoma de México, Mexico, Mexico*, <sup>2</sup>*Department of Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico*, <sup>3</sup>*Department of Transplantation, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico*, <sup>4</sup>*Department of Transplantation, Hospital General de México Doctor Eduardo Liceaga, Mexico, Mexico*, <sup>5</sup>*Faculty of Medicine, Department of Public Health, Universidad Nacional Autónoma de México, Mexico, Mexico*, <sup>6</sup>*Department of Public Health Sciences, Loyola University Chicago, Chicago, IL*, <sup>7</sup>*Department of Cardiology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico, Mexico*
- A148**      **Rapid Detection of Kidney Transplant Injury by Quantifying Donor-Derived Cell-Free Deoxyribonucleic Acid via Massively Multiplex Polymerase Chain Reaction**  
T. K. Sigdel<sup>1</sup>, F. Acosta<sup>2</sup>, S. Navarro<sup>2</sup>, B. Zimmermann<sup>2</sup>, Z. P. Demko<sup>2</sup>, S. Moshkevich<sup>2</sup>, P. R. Billings<sup>2</sup>, M. M. Sarwal<sup>1</sup>, <sup>1</sup>*University of California San Francisco, San Francisco, CA*, <sup>2</sup>*Natera Inc., San Carlos, CA*
- A149**      **Involvement of Genetic Variation and Related Gene Expression Changes on Acute Rejection in Renal Transplant Recipients**  
H. Hwang<sup>1</sup>, J. Seo<sup>1</sup>, J. Kim<sup>1</sup>, Y. Kim<sup>1</sup>, J. Moon<sup>1</sup>, K. Jeong<sup>1</sup>, C. Kim<sup>2</sup>, J. Park<sup>3</sup>, B. Chung<sup>4</sup>, Y. Kim<sup>5</sup>, S. Lee<sup>1</sup>, <sup>1</sup>*Division of Nephrology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Korea, Republic of*, <sup>2</sup>*Division of Nephrology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea, Republic of*, <sup>3</sup>*Department of Surgery, Samsung Medical Center, Seoul, Korea, Republic of*, <sup>4</sup>*Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea, Seoul, Korea, Republic of*, <sup>5</sup>*Division of Nephrology, Department of Internal Medicine, College of Medicine, Inje University, Pusan, Korea, Republic of*
- A150**      **Pre-Transplant Donor-Specific IFN-γ ELISPOT as a Predictor of Allograft Rejection: A Diagnostic Test Accuracy Meta-Analysis**  
S. Farouk<sup>1</sup>, I. Gandolfini<sup>2</sup>, N. Montero<sup>3</sup>, E. Crespo<sup>4</sup>, M. Jarque<sup>4</sup>, M. Meneghini<sup>4</sup>, U. Maggiore<sup>2</sup>, O. Bestard<sup>3</sup>, P. Cravedi<sup>1</sup>, <sup>1</sup>*Medicine, Division of Nephrology, Icahn School of Medicine at Mt. Sinai, New York, NY*, <sup>2</sup>*Centro Trapianti Rene-Pancreas, Azienda Ospedaliera-Universitaria di Parma, Parma, Italy*, <sup>3</sup>*Nephrology, Bellvitge University Hospital, Barcelona, Spain*, <sup>4</sup>*Experimental Nephrology Laboratory. IDIBELL, Barcelona, Spain*

- A151**     **Surveillance Biopsy Utilization Reported Higher In Transplant Centers Performing Over 100 Kidney Transplants Per Year.**  
D. M. Lee<sup>1</sup>, R. First<sup>1</sup>, S. Rose<sup>1</sup>, M. Abecassis<sup>2</sup>, <sup>1</sup>*Transplant Genomics Inc, Mansfield, MA*, <sup>2</sup>*Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL*
- A152**     **Post-Reperfusion Hepatic Beta-Catenin Activation Regulates Graft Damage, Inflammatory Responses and Transplant Outcomes**  
H. Hirao, K. Kadono, S. Kageyama, K. Nakamura, T. Ito, J. Aziz, K. J. Dery, F. M. Kaldas, R. W. Busuttil, J. W. Kupiec-Weglinski, *Dumont-UCLA Transplant Center, UCLA, Los Angeles, CA*
- A153**     **Elevated Urinary Injury Biomarkers in Deceased Donors Are Not Associated with Long-Term Kidney Transplant Outcomes**  
N. Koyawala, I. E. Hall, Y. Jia, S. G. Mansour, P. P. Reese, H. R. Thiessen-Philbrook, E. Akalin, J. S. Bromberg, M. D. Doshi, M. N. Harhay, S. Mohan, T. Muthukumar, B. Schroppel, P. Singh, F. L. Weng, C. R. Parikh, *DDS Consortium, Baltimore, MD*
- A154 †**    **Liquid Biopsy for Chronic Rejection after Kidney Transplantation. A Novel Non-Invasive Biomarker Involved in Inflammatory Amplifier**  
Y. Takada<sup>1</sup>, D. Kamimura<sup>2</sup>, H. Higuchi<sup>1</sup>, D. Iwami<sup>1</sup>, K. Hotta<sup>1</sup>, N. Iwahara<sup>1</sup>, N. Shinohara<sup>1</sup>, M. Murakami<sup>2</sup>, <sup>1</sup>*Renal and Genitourinary Surgery, Hokkaido University Hospital, Sapporo, Japan*, <sup>2</sup>*Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan*
- A155**     **Characterization of HLA Antibodies by C3d Assay and IgG Subclasses in Sensitized Kidney Transplant Patients**  
A. Casillas-Abundis, J. M. Arreola-Guerra, J. Alberu, M. I. Solis-G, L. Llorente, J. Granados, M. Vilatoba, R. Cruz-Martinez, L. Morales-Buenrostro, A. G. Contreras, *Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico*
- A156**     **Proteomics Reveals Molecular Window and Metabolism of Normothermally Perfused Human Kidneys**  
A. Weissenbacher<sup>1</sup>, H. Huang<sup>2</sup>, A. Thorne<sup>3</sup>, L. M. Lo Faro<sup>3</sup>, J. Hunter<sup>3</sup>, R. Ploeg<sup>3</sup>, C. C. Coussios<sup>4</sup>, P. J. Friend<sup>3</sup>, B. Kessler<sup>5</sup>, <sup>1</sup>*Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria*, <sup>2</sup>*Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford, United Kingdom*, <sup>3</sup>*Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom*, <sup>4</sup>*Oxford Institute of Biomedical Engineering, University of Oxford, Oxford, United Kingdom*, <sup>5</sup>*Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford, United Kingdom*
- A157**     **The Combination of 3-Month Estimated Glomerular Filtration Rate and Proteinuria is a Valuable Tool for Evaluating Long-Term Kidney Graft Survival**  
C. Mottola<sup>1</sup>, N. Girerd<sup>2</sup>, K. Duarte<sup>3</sup>, A. Aarnink<sup>4</sup>, M. Kessler<sup>5</sup>, L. Frimat<sup>6</sup>, S. Girerd<sup>6</sup>, <sup>1</sup>*Nephrology and Kidney Transplant Unit, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France*, <sup>2</sup>*Clinical Investigation Center 1433, INSERM U1116, INI-CRCT, F-CRIN, Lorraine University, Vandoeuvre-lès-Nancy, France*, <sup>3</sup>*Clinical Investigation Center 1433, INSERM 1116, INI-CRCT, F-CRIN, Lorraine University, Vandoeuvre-lès-Nancy, France*, <sup>4</sup>*Laboratoire d'Histocompatibilité, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France*, <sup>5</sup>*Nephrology and kidney transplant unit, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France*, <sup>6</sup>*Nephrology and kidney transplant unit, INI-CRCT, F-CRIN, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France*
- A158**     **Impact of IgG Subclass and C1q Binding Donor-Specific HLA Antibodies on Antibody Mediated Rejection in Kidney Transplant Recipients**  
H. Lee<sup>1</sup>, J. Ryu<sup>1</sup>, S. Yun<sup>1</sup>, T. Ban<sup>2</sup>, E. Ko<sup>2</sup>, C. Yang<sup>2</sup>, E. Oh<sup>1</sup>, <sup>1</sup>*Department of Laboratory Medicine, The Catholic University of Korea, Seoul, Korea, Republic of*, <sup>2</sup>*Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea, Republic of*

- A159 Subtyping Of Histologically Stable Kidney Transplants In Molecular Meta-analysis**  
D. Rychkov<sup>1</sup>, T. Sigdel<sup>2</sup>, J. Liberto<sup>2</sup>, M. Sarwal<sup>2</sup>, M. Sirota<sup>3</sup>, <sup>1</sup>ICHS, Department of Surgery, UCSF, San Francisco, CA, <sup>2</sup>Department of Surgery, UCSF, San Francisco, CA, <sup>3</sup>ICHS, UCSF, San Francisco, CA
- A160 Application of Small Molecule Fluorescent Probes in Early Activation Imaging of CD8+ T Lymphocytes**  
P. Rong, X. Zhou, Central South University, The Third Xiangya Hospital, Changsha, China
- A161 Urine Uromodulin Associates with Deceased Donor Acute Kidney Injury and Allograft Failure**  
S. G. Mansour<sup>1</sup>, I. Hall<sup>2</sup>, P. Reese<sup>3</sup>, T. Ashkar<sup>4</sup>, Y. Jia<sup>4</sup>, H. Thiessen-Philbrook<sup>4</sup>, M. Doshi<sup>5</sup>, C. R. Parikh<sup>4</sup>, <sup>1</sup>Yale, New Haven, CT, <sup>2</sup>University of Utah, Salt Lake City, UT, <sup>3</sup>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, <sup>4</sup>Johns Hopkins University, Baltimore, MD, <sup>5</sup>University of Michigan, Ann Arbor, MI
- A162 Cell Coding Transcriptomic Analysis Of Serial Blood And Biopsy Samples In A Large Cohort Of Kidney Transplant Recipients**  
W. Zhang<sup>1</sup>, Z. Yi<sup>1</sup>, Z. Sun<sup>1</sup>, K. Keung<sup>2</sup>, C. Wei<sup>1</sup>, C. Xi<sup>1</sup>, S. Farouk<sup>1</sup>, M. Menon<sup>1</sup>, P. Cravedi<sup>1</sup>, P. O'Connell<sup>2</sup>, B. Murphy<sup>1</sup>, <sup>1</sup>Icahn School of Medicine at Mount Sinai, New York, NY, <sup>2</sup>The University of Sydney, Sydney, Australia
- A163 Dynamic Characterization of Cells in the Perfusate from Cold Ischemic Liver Grafts**  
R. J. de Vries, C. Pendexter, S. E. Cronin, B. Marques, J. F. Markmann, S. L. Stott, H. Yeh, M. Toner, K. Uygun, S. N. Tessier, Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA
- A164 NK Cell Quantification by Paraffin Immunohistochemistry is Not Predictive of Graft Outcome in 1-Year Surveillance Biopsies**  
J. Barnes<sup>1</sup>, F. Suliman<sup>2</sup>, A. Shammout<sup>1</sup>, E. A. Farkash<sup>1</sup>, <sup>1</sup>Pathology, Michigan Medicine, Ann Arbor, MI, <sup>2</sup>Nephrology, Michigan Medicine, Ann Arbor, MI
- A165 Subclinical Rejection by Biopsy or Gene Expression Profile Predicts Long Term Kidney Function in Patients in the CTOT08 Trial**  
R. Heilman<sup>1</sup>, D. Taber<sup>2</sup>, K. Guo<sup>3</sup>, S. Brietigam<sup>3</sup>, J. Charette<sup>3</sup>, S. Kurian<sup>4</sup>, M. Abecassis<sup>3</sup>, J. Friedewald<sup>3</sup>, <sup>1</sup>Mayo Clinic AZ, Scottsdale, AZ, <sup>2</sup>MUSC, Charleston, SC, <sup>3</sup>Northwestern University, Chicago, IL, <sup>4</sup>Scripps, La Jolla, CA
- A166 Utility of AlloSure Monitoring in Simultaneous Kidney and Pancreas Recipients**  
J. A. Klein, A. Gupta, P. Budhiraja, D. Cibrik, Nephrology, University of Kansas Medical Center, Kansas City, KS
- A167 Symptom Burden after Living Donor Kidney Transplant Measured with the Functional Assessment of Cancer Therapy - Kidney Symptom Index is Associated with Worse Transplant Outcomes**  
J. Peipert, J. Caicedo-Ramirez, K. Ensor, J. Friedewald, M. Abecassis, D. Cella, D. Ladner, Z. Butt, Northwestern University, Chicago, IL
- A168 Transcriptional Changes in PBMC Associated with Development of Infection and Rejection in Older and Younger Kidney Transplant Recipients**  
J. Schaenman<sup>1</sup>, M. Rossetti<sup>2</sup>, E. Liang<sup>1</sup>, O. E. Beaird<sup>1</sup>, S. Bunnapradist<sup>3</sup>, E. F. Reed<sup>2</sup>, S. Cole<sup>4</sup>, <sup>1</sup>Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, <sup>2</sup>Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, <sup>3</sup>Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, CA, <sup>4</sup>Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA
- A169 Using Multidimensional Quality of Life Measurement to Better Understand the Benefit of Living Donor Kidney Transplant**  
J. Peipert, J. Caicedo-Ramirez, K. Ensor, J. Friedewald, M. Abecassis, D. Cella, Z. Butt, D. Ladner, Northwestern University, Chicago, IL



- A170**     **Evaluation of Delayed Renal Allograft Function after DCD with New Biomarkers in Donor Blood**  
*X. Zheng, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China*
- A171**     **Non-Invasive Monitoring of the Kidney Allograft**  
*S. Bontha<sup>1</sup>, G. Darville<sup>1</sup>, C. Kuscu<sup>1</sup>, C. Kuscu<sup>2</sup>, A. Bajwa<sup>1</sup>, J. Eason<sup>3</sup>, D. Maluf<sup>4</sup>, V. Mas<sup>5</sup>, <sup>1</sup>Surgery, UTHSC, Memphis, TN, <sup>2</sup>Surgery, UTHSC, Memphis, TN, <sup>3</sup>Surgery, Director of Transplant Institute - UTHSC, Memphis, TN, <sup>4</sup>UTHSC, Memphis, TN, <sup>5</sup>Surgery, Director of Transplant Research Institute, Memphis, TN*
- A172**     **Urinary Biomarkers- CXCL9 and CXCL10 for Non-Invasive, Early Diagnosis of Rejection in Pediatric Renal Transplantation**  
*R. P. George<sup>1</sup>, B. Hanberry<sup>2</sup>, I. Dave<sup>2</sup>, B. Lee<sup>2</sup>, R. Garro<sup>1</sup>, C. McCracken<sup>2</sup>, B. Warshaw<sup>1</sup>, <sup>1</sup>Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, <sup>2</sup>Pediatrics, Emory University, Atlanta, GA*
- A173**     **Absolute Quantification of Micro RNA and Messenger RNA Using a Customized Amplicon in Real Time Quantitative Polymerase Chain Reaction Assays**  
*C. Li, C. Snopkowski, M. Cassidy, B. Botticelli, S. Albakry, J. R. Lee, M. Lubetzky, D. Dadhania, H. Yang, R. Ding, T. Muthukumar, M. Suthanthiran, WCMC, New York, NY*
- A174 †**     **Novel Flow-Based Assay to Identify Allo-Specific T Cell Exhaustion**  
*N. Tanimine<sup>1</sup>, C. Rickert<sup>1</sup>, K. Lee<sup>1</sup>, K. Deng<sup>1</sup>, N. Feeney<sup>1</sup>, C. Leguern<sup>1</sup>, B. Burrell<sup>2</sup>, J. Markmann<sup>1</sup>, <sup>1</sup>Department of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Immune Tolerance Network, Bethesda, MD*
- A175 †**     **RNA Sequencing Identifies a Differential Role of Coding and Non-Coding Genes by Types of Rejection**  
*S. Pineda<sup>1</sup>, O. Bestard<sup>2</sup>, T. K. Sigdel<sup>1</sup>, M. Sirota<sup>3</sup>, M. Sarwal<sup>1</sup>, <sup>1</sup>Department of Surgery, UCSF, San Francisco, CA, <sup>2</sup>Department of Surgery, Bellvitge University Hospital, Barcelona, Spain, <sup>3</sup>BCHSI, UCSF, San Francisco, CA*
- A176**     **Hepatoblastoma Tumors Requiring Liver Transplantation Manifest Dysregulated Ciliary, Autophagy and Cell Cycling Pathways in Systems Biology Analysis**  
*T. Narayanan<sup>1</sup>, M. Ningappa<sup>2</sup>, B. W. Higgs<sup>2</sup>, S. Subramaniam<sup>3</sup>, R. Sindhia<sup>2</sup>, <sup>1</sup>Bioengineering, University of California, San Diego, CA, <sup>2</sup>Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, PA, <sup>3</sup>University of California, San Diego, CA*
- A177 †**     **Evidence to Support the Use of Kidney Allograft Function as a Clinical Trial Outcome Measure**  
*M. Kadatz, J. Gill, S. Clark, J. S. Gill, Nephrology, University of British Columbia, Vancouver, BC, Canada*
- A178 †**     **Utilizing Imagestream Technology to Determine Hepatocellular CD38 Localization**  
*Y. Lee, J. Kim, B. F. Reader, C. Akath, K. R. Maynard, K. W. Washburn, J. L. Zweier, B. A. Whitson, S. M. Black, Department of Cardiac Surgery, The Ohio State Univ. Medical Center, Columbus, OH*
- A179**     **Monitoring Inflammatory Cytokine Levels in Kidney Transplant Patients (KTx Pts) with Chronic Antibody Mediated Rejection (cABMR) Treated with Clazakizumab (CLZ, Humanized Anti-IL-6 Monoclonal Antibody)**  
*S. Ge<sup>1</sup>, A. Petrosyan<sup>1</sup>, M. Chu<sup>1</sup>, N. Ammerman<sup>2</sup>, A. Vo<sup>2</sup>, S. C. Jordan<sup>2</sup>, X. Zhang<sup>3</sup>, M. Toyoda<sup>1</sup>, <sup>1</sup>Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, <sup>2</sup>Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, <sup>3</sup>HLA Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA*



**A180** **Matrix Metalloproteinase-9 and Neutrophil Extracellular Traps in Human and Mouse Liver Ischemia and Reperfusion Injury**  
S. Duarte, A. Zarrinpar, R. W. Busuttil, A. J. Coito, *Dumont-UCLA Transplant Center, Los Angeles, CA*

**A181** **Predicting Allograft Outcomes of Renal Transplantation with Pretransplant Metrics**  
J. Tchervenkov<sup>1</sup>, M. Nguyen<sup>2</sup>, S. Negi<sup>1</sup>, S. Paraskevas<sup>1</sup>, <sup>1</sup>*RIMUHC, Montreal, QC, Canada*, <sup>2</sup>*SSM Health Saint Louis University Hospital, St. Louis, MO*

**A182** **Characterization of Intra-Exosomal Cargoes of Circulating Donor Heart Specific Exosomes in Murine Heart Transplantation Model**  
J. Harmon, V. Korutla, L. Korutla, R. Hu, S. Rostami, A. Habertheuer, P. Zielinski, A. Freas, C. Ram, A. Najj, M. Davis, P. Vallabhajosyula, *Department of Surgery, University of Pennsylvania, Philadelphia, PA*

**A183** **Donor-Derived Cell-Free DNA is Associated Specifically with Antibody Mediated Injury in Patients with Renal Allograft Dysfunction**  
B. Obrisca<sup>1</sup>, C. Blosser<sup>2</sup>, I. De Castro<sup>2</sup>, C. Johnson<sup>2</sup>, B. Sorohan<sup>1</sup>, L. Sibulesky<sup>2</sup>, R. Bakthavatsalam<sup>2</sup>, G. Ismail<sup>1</sup>, N. Leca<sup>2</sup>, <sup>1</sup>*Fundeni Clinical Institute, Bucharest, Romania*, <sup>2</sup>*University of Washington, Seattle, WA*

### **Poster Session A: Donor Management: All Organs Excluding Kidney**

---

**A184** **'Back-to-Base' Normothermic Clinical Liver Perfusion - Cold before NMP Does Not Compromise Protective Benefit**  
K. Dajani, M. Bral, D. Leon Izquierdo, D. Bigam, N. Kneteman, J. Shapiro, *University of Alberta Hospital, Edmonton, AB, Canada*

**A185 †** **Effectiveness Of The Vittal Viability Criteria During Ex Situ Normothermic Machine Perfusion To Discriminate Hepatobiliary Organ Injury And Investigation Of Biochemical Markers For Post-transplant Complications**  
Y. L. Boteon, R. Laing, J. Attard, L. Wallace, A. Smith, M. Perera, D. Mirza, H. Mergental, S. Afford, *Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom*

**A186** **HIV Resistance among HOPE Donor Referrals**  
B. Barnaba<sup>1</sup>, W. Werbel<sup>1</sup>, O. Kusemiju<sup>1</sup>, C. Kirby<sup>1</sup>, Y. Eby<sup>1</sup>, R. Fernandez<sup>1</sup>, J. Miller<sup>1</sup>, A. Redd<sup>2</sup>, D. Segev<sup>1</sup>, A. Tobian<sup>1</sup>, C. Durand<sup>1</sup>, <sup>1</sup>*Johns Hopkins University School of Medicine, Baltimore, MD*, <sup>2</sup>*National Institute of Allergy and Infectious Diseases, Bethesda, MD*

### **Poster Session A: Kidney Chronic Antibody Mediated Rejection**

---

**A187** **Validation of Gene Expression Signatures Associated with Antibody-Mediated Rejection (ABMR) in Renal Allograft Biopsies (Bx) of HLA-Sensitized Patients**  
H. Zhang<sup>1</sup>, C. C. Nast<sup>2</sup>, N. Ammerman<sup>3</sup>, A. A. Vo<sup>3</sup>, S. C. Jordan<sup>3</sup>, M. Toyoda<sup>1</sup>, <sup>1</sup>*Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA*, <sup>2</sup>*Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA*, <sup>3</sup>*Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA*

**A188 †** **Multiple Non-HLA Antibodies Are Significantly Increased in Chronic Active Antibody Mediated Rejection**  
K. Sablik<sup>1</sup>, E. Kamburova<sup>2</sup>, D. Roelen<sup>3</sup>, H. Otten<sup>2</sup>, M. Betjes<sup>1</sup>, <sup>1</sup>*Erasmus MC, Rotterdam, Netherlands*, <sup>2</sup>*University Medical Center Utrecht, Utrecht, Netherlands*, <sup>3</sup>*University Medical Center Leiden, Leiden, Netherlands*

- A189 Molecular Phenotype of Proliferative Arteriopathy in Kidney Grafts**  
A. Perkowska-Ptasinska<sup>1</sup>, M. Ciszek<sup>1</sup>, D. Deborska-Materkowska<sup>1</sup>, A. Debska-Slizien<sup>2</sup>, P. F. Halloran<sup>3</sup>, M. Myslak<sup>4</sup>,  
<sup>1</sup>Warsaw Medical University, Warsaw, Poland, <sup>2</sup>Gdansk Medical University, Gdansk, Poland, <sup>3</sup>University of Alberta, Edmonton AB, AB, Canada, <sup>4</sup>Pomeranian Medical University, Szczecin, Poland
- A190 Lack of Response to Tocilizumab in Kidney Transplants with Chronic Antibody-Mediated Rejection**  
D. Kumar<sup>1</sup>, F. Safavi<sup>1</sup>, R. Sandhu<sup>1</sup>, P. Halloran<sup>2</sup>, I. Yakubu<sup>1</sup>, M. Levy<sup>1</sup>, I. Moinuddin<sup>1</sup>, P. Kimball<sup>1</sup>, L. Kamal<sup>1</sup>, A. King<sup>1</sup>, H. Massey<sup>1</sup>, G. Gupta<sup>1</sup>, <sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Alberta Transplant Genomics Applied Centre, Edmonton, AB, Canada
- A191 Significance of Histopathologic Features for Predicting Progression in Patients with Transplant Glomerulopathy**  
X. Li, J. Chen, D. Cheng, R. Wang, W. Wang, M. Zhang, F. Xu, J. Wen, Z. Tang, National Clinical Research Center of Kidney Diseases, Nanjing, China
- A192 † Automated Histology Lesion Interpretation in Kidney Transplant Biopsies Shows That Pathologists Often Deviate from Banff Guidelines**  
K. S. Madill-Thomsen<sup>1</sup>, J. Reeve<sup>2</sup>, G. Bohmig<sup>3</sup>, F. A. Eskandary<sup>4</sup>, A. Perkowska-Ptasinska<sup>5</sup>, M. Myslak<sup>6</sup>, P. F. Halloran and the INTERCOMEX Study Group<sup>1</sup>,  
<sup>1</sup>University of Alberta, Edmonton AB, AB, Canada, <sup>2</sup>Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, <sup>3</sup>Medical University of Vienna, Vienna, Austria, <sup>4</sup>Medical University of Vienna, Edmonton AB, AB, Canada, <sup>5</sup>Medical University of Warsaw, Warsaw, Poland, <sup>6</sup>Pomeranian Medical University, Szczecin, Poland
- A193 Clazakizumab (CLZ, Anti-IL-6 Monoclonal Antibody) Treatment of Patients (Pts) with Chronic Antibody-Mediated Rejection (cABMR) Reduces Total Immunoglobulin (Ig) and Anti-HLA IgG Antibody Levels**  
B. Shin, N. F. Ammerman, A. A. Vo, X. Zhang, S. C. Jordan, M. Toyoda, Cedars-Sinai Medical Center, Los Angeles, CA
- A194 CD56+CD57+ Infiltrate is a Predominant Subset of Infiltrating Natural Killer Cell in Renal Transplant Biopsies with Antibody-Mediated Rejection**  
H. Jung<sup>1</sup>, Y. Wee<sup>2</sup>, J. Kim<sup>2</sup>, M. Choi<sup>2</sup>, J. Choi<sup>2</sup>, H. Kwon<sup>2</sup>, J. Jung<sup>2</sup>, S. Kim<sup>3</sup>, Y. Cho<sup>4</sup>, Y. Park<sup>4</sup>, H. Go<sup>4</sup>, M. Han<sup>5</sup>, Y. Kim<sup>2</sup>, D. Han<sup>2</sup>, S. Shin<sup>2</sup>, <sup>1</sup>Department of Biomedical Science, Asan Medical Institute of Convergence Science and Technology (AMIST), Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of, <sup>2</sup>Division of Kidney and Pancreas Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of, <sup>3</sup>Department of Convergence Medicine, Asan Institute for life sciences, Asan Medical Center, Seoul, Korea, Republic of, <sup>4</sup>Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of, <sup>5</sup>Department of Clinical Epidemiology, Asan Medical Center, Seoul, Korea, Republic of
- A195 Natural Killer Cells Express Significantly More CD16 during Chronic Active Antibody Mediated Rejection Which is Not Caused by a Single Nucleotide Polymorphism within the CD16 Gene**  
K. Sablik, N. Litjens, A. Peeters, M. Clahsen-van Groningen, M. Klepper, M. Betjes, Erasmus MC, Rotterdam, Netherlands

**A196** **Back Signaling of HLA Class I Molecules and NK Cell Receptor Ligands in Renal Epithelial Cells Contributes to the Rejection-Specific Microenvironment**  
E. Chichelnitskiy<sup>1</sup>, J. Egelkamp<sup>1</sup>, K. Daemen<sup>1</sup>, J. Keil<sup>1</sup>, C. Neudörfl<sup>1</sup>, J. Bräsen<sup>2</sup>, J. Schmitz<sup>2</sup>, H. Haller<sup>3</sup>, C. Blume<sup>4</sup>, C. Falk<sup>5</sup>, <sup>1</sup>*Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany*, <sup>2</sup>*Nephropathology Unit, Institute of Pathology, Hannover Medical School, Hannover, Germany*, <sup>3</sup>*Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany*, <sup>4</sup>*Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany*; *Institute of Technical Chemistry, Leibniz University, Hannover, Germany*, <sup>5</sup>*Institute of Transplant Immunology, Hannover Medical School; DZIF, German Center for Infection Research, TTU-IICH, Hannover/Braunschweig, Germany*

**A197** **Change in Estimated Glomerular Filtration Rate and Risk of Allograft Failure in Patients Diagnosed with Active Antibody-Mediated Rejection Following Kidney Transplantation**  
W. Irish<sup>1</sup>, P. Nickerson<sup>2</sup>, B. Astor<sup>3</sup>, E. Chong<sup>4</sup>, C. Wiebe<sup>2</sup>, F. Moreso<sup>5</sup>, D. Seron<sup>5</sup>, M. Crespo<sup>5</sup>, L. Gache<sup>6</sup>, A. Djamali<sup>3</sup>, <sup>1</sup>*East Carolina University, Greenville, NC*, <sup>2</sup>*University of Manitoba, Winnipeg, MB, Canada*, <sup>3</sup>*University of Wisconsin, Madison, WI*, <sup>4</sup>*Vitaeris, Inc, Vancouver, BC, Canada*, <sup>5</sup>*University Hospital Vall d'Hebron, Barcelona, Spain*, <sup>6</sup>*CTI Clinical Trial & Consulting, Covington, KY*

**A198** **Increased Number of Intra-graft FoxP3+ T Cells is Strongly Correlated with Decreased Graft Survival in Chronic Active Antibody Mediated Rejection**  
K. Sablik<sup>1</sup>, K. Jordanova<sup>2</sup>, M. Clahsen-van Groningen<sup>1</sup>, M. Betjes<sup>1</sup>, <sup>1</sup>*Erasmus MC, Rotterdam, Netherlands*, <sup>2</sup>*Amsterdam UMC, Amsterdam, Netherlands*

**A199** **The Impact of Calcineurin Inhibitors on De Novo DSA in Primary Kidney Transplantation**  
T. Hiramitsu, T. Tomosugi, K. Futamura, M. Okada, M. Tsujita, T. Ichimori, N. Goto, S. Narumi, Y. Watarai, *Nagoya Daini Red Cross Hospital, Nagoya Aichi, Japan*

## Poster Session A: Kidney Deceased Donor Allocation

**A200** **Impact of Extremely Prolonged Cold Ischemia Time in Combination with AKI on Kidney Transplantation Outcome - A Single Center Experience**  
N. Sharma, Z. Haddad, Y. Qazi, *USC, Los Angeles, CA*

**A201** **Kidney Grafts From Donors After Circulatory Death Provide Comparable Outcome To Donors After Brain Death Without Intracorporeal In Situ Cooling**  
H. Harada, M. Miura, A. Mitsuke, H. Higuchi, N. Fukuzawa, H. Tanaka, T. Hirano, T. Seki, *Sapporo City General Hospital, Sapporo, Hokkaido, Japan*

**A202** **Estimated Post Transplant Survival Allocation: Not Just Better Kidneys, but Faster Ones as Well**  
L. Ormiston<sup>1</sup>, G. Vranic<sup>2</sup>, J. Moore<sup>2</sup>, B. Thomas<sup>2</sup>, M. Cooper<sup>2</sup>, A. Gilbert<sup>2</sup>, <sup>1</sup>*Georgetown University School of Medicine, Washington, DC*, <sup>2</sup>*Medstar Georgetown Transplant Institute, Washington, DC*

**A203** **Predicting Kidney Discards with Donor Admission Text**  
A. Placona, C. Martinez, B. Carrico, *United Network for Organ Sharing, Richmond, VA*

**A204** **A2 To B Kidney Transplants Under Kidney Allocation System: A Prospective Study Of Anti A Titers And Correlation With Outcomes**  
H. Schaefer, I. Feurer, S. Rega, R. Forbes, D. Shaffer, *Vanderbilt University, Nashville, TN*

**A205** **Should Kidney Retransplants Be Performed From Either Extended Criteria Donor Or Donation After Cardio Circulatory Death Donors?**  
D. Harriman, V. Gurrarn, A. Farney, J. Rogers, G. Orlando, C. Jay, A. Reeves-Daniel, A. Mena-Gutierrez, M. Gautreaux, W. Doares, S. Kaczorski, R. Stratta, *Wake Forest Baptist Medical Center, Winston-Salem, NC*

- A206 The Impact of Eplet Mismatches on Kidney Transplant Outcome: A Single-Center Cohort Study**  
A. Senev<sup>1</sup>, M. Coemans<sup>1</sup>, V. Van Sandt<sup>2</sup>, B. Sprangers<sup>3</sup>, D. Kuypers<sup>3</sup>, M. Emonds<sup>2</sup>, M. Naesens<sup>3</sup>, <sup>1</sup>*Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium*, <sup>2</sup>*Histocompatibility and Immunogenetics Laboratory, Belgian Red Cross-Flanders, Mechelen, Belgium*, <sup>3</sup>*University Hospitals Leuven, Leuven, Belgium*
- A207 Investigating Deceased Donor Kidney Discard Trend - An Opportunity To Expand The Donor Pool**  
J. A. Shah<sup>1</sup>, D. P. Borle<sup>1</sup>, K. Koontz<sup>2</sup>, W. Irish<sup>1</sup>, K. V. Ravindra<sup>1</sup>, <sup>1</sup>*Abdominal Transplant Surgery, Duke University Medical Center, Durham, NC*, <sup>2</sup>*Carolina Donor Services, Durham, NC*
- A208 Single Center Deceased Donor Renal Transplant (DDRTx) Outcomes in Sensitized Patients after Implementation of the Kidney Allocation System (KAS)**  
S. S. Patel, K. L. King, J. Kamal, E. Vasilescu, A. Husain, S. Mohan, L. E. Ratner, R. Crew, *Columbia University Irving Medical Center, New York, NY*
- A209 Impact Of The Provision Of Transplant Information On Access To First And Repeat Kidney Transplantation**  
S. Clark, A. Abdalla, M. Kadatz, J. Gill, J. S. Gill, *Nephrology, University of British Columbia, Vancouver, BC, Canada*
- A210 Graft Survival of Fourth Time Renal Transplant Recipients Are Similar to Third Time Transplants: A SRTR Database Analysis**  
B. Petrun, R. Nygaard, M. Hill, C. Richardson, A. Israni, P. Stahler, *Hennepin County Medical Center, Minneapolis, MN*
- A211 Management of Inactive Candidates on the Kidney Transplant Waitlist: Results from a National Survey**  
J. Hiller, J. Chen, K. Covarrubias, K. Jackson, J. Long, S. DiBrito, D. Segev, J. Garonzik Wang, *Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD*
- A212 The Impact of KDPI on Post Transplant Kidney Function: Intercept versus Slope. A Single Center Study**  
M. Molinari<sup>1</sup>, D. Jorgensen<sup>2</sup>, R. Mehta<sup>3</sup>, P. Sood<sup>3</sup>, A. Ganoza<sup>2</sup>, C. Puttarajappa<sup>3</sup>, R. Lopez<sup>2</sup>, M. Wijkstrom<sup>2</sup>, A. Tevar<sup>2</sup>, S. Hariharan<sup>3</sup>, <sup>1</sup>*University of Pittsburgh Medical Centre, Pittsburgh, PA*, <sup>2</sup>*Surgery, University of Pittsburgh Medical Centre, Pittsburgh, PA*, <sup>3</sup>*Medicine, University of Pittsburgh Medical Centre, Pittsburgh, PA*
- A213 Donor And Recipient Age Matching Versus Mismatching In Expanded Criteria Donor Kidney Transplants: Does It Make A Difference?**  
D. Harriman, V. Gurram, A. Farney, J. Rogers, G. Orlando, C. Jay, A. Reeves-Daniel, A. Mena-Gutierrez, M. Gautreaux, W. Doares, S. Kaczorski, R. Stratta, *Wake Forest Baptist Medical Center, Winston-Salem, NC*
- A214 Unifying Interpretation of Molecular HLA Typing Data between the Solid Organ Allocation Match Run and Virtual Crossmatch**  
N. Kaur<sup>1</sup>, E. Kransdorf<sup>2</sup>, M. Pando<sup>3</sup>, L. Gragert<sup>1</sup>, <sup>1</sup>*Tulane University School of Medicine, New Orleans, LA*, <sup>2</sup>*Cedars-Sinai Heart Institute, Los Angeles, CA*, <sup>3</sup>*Baylor Scott & White, Temple, TX*
- A215 ilearnKAS: An Animated Video to Educate African Americans about Key Concepts of Kidney Allocation**  
J. Narvaez, B. Dolph, T. Feeley, L. Kayler, *University at Buffalo, Buffalo, NY*
- A216 Temporal Trends of First-Year Mortality on the Adult Kidney-Only Wait List in the United States**  
F. Tedla, A. Gruessner, I. Puri, A. Brar, N. Sumrani, D. John, J. Renz, R. Gruessner, M. Salifu, *SUNY Downstate Medical Center, Brooklyn, NY*



- A217 Oral Preconditioning of Donors after Brain Death with Calcineurin Inhibitors vs. Inhibitors of Mammalian Target for Rapamycin in Pig Kidney Transplantation**  
S. Abbasi Dezfouli<sup>1</sup>, M. Golriz<sup>1</sup>, O. Ghamarnejad<sup>1</sup>, E. Khajeh<sup>1</sup>, S. Mohammadi<sup>1</sup>, M. Nikdad<sup>1</sup>, A. Majlesara<sup>1</sup>, M. Sabagh<sup>1</sup>, P. Fathi<sup>1</sup>, S. Shafiei<sup>1</sup>, M. Kentar<sup>2</sup>, A. Younsi<sup>2</sup>, C. Eckert<sup>3</sup>, T. Poth<sup>3</sup>, A. Mehrabi<sup>1</sup>, A. Nickkholgh<sup>1</sup>, <sup>1</sup>*Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany*, <sup>2</sup>*Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany*, <sup>3</sup>*Department of Pathology, University of Heidelberg, Heidelberg, Germany*
- A218 Donor-Recipient Matching in Kidney Transplant: The Whole is Greater Than the Sum of the Parts**  
A. Vinson, K. Tennankore, B. Kiberd, *Dalhousie University, Halifax, NS, Canada*
- A219 Effect of Human Leukocytic Antigen Matching on Clinical Outcomes after Deceased Donor Renal Allograft Transplant: A Single Centre Experience**  
M. E. Gramlick<sup>1</sup>, M. K. Heer<sup>2</sup>, S. Yausis<sup>2</sup>, P. R. Trevillian<sup>2</sup>, <sup>1</sup>*Department of Surgery, John Hunter Hospital, Newcastle, Australia*, <sup>2</sup>*Newcastle Transplant Unit, John Hunter Hospital, Newcastle, Australia*
- A220 Should First and Second Transplant Candidates Be Treated Equally?**  
S. Clark, M. Kadatz, J. Gill, J. S. Gill, *Nephrology, University of British Columbia, Vancouver, BC, Canada*
- A221 Reevaluating Cut-Off Points for the Expansion of Deceased Donor Criteria for Kidney Transplantation in Japan**  
Y. NAKAGAWA<sup>1</sup>, M. Masahiro<sup>2</sup>, M. Tasaki<sup>2</sup>, K. Saito<sup>3</sup>, K. Takahashi<sup>4</sup>, <sup>1</sup>*Department of Urology,, Uonuma Kikan Hospital, Niigata, Japan*, <sup>2</sup>*Department of Regenerative and Transplant Medicine, Niigata University, Niigata, Japan*, <sup>3</sup>*Department of Urology,, Niigata University, Niigata, Japan*, <sup>4</sup>*Department of Urology,, Otsukadai Clinic, Tokyo, Japan*
- A222 † Renal Transplantation in Patients Older Than 60 Years with High Comorbidity. Is There a Survival Benefit? A Multicenter Study in Argentina**  
G. D. Fragale<sup>1</sup>, G. A. Laham<sup>2</sup>, L. Bisignano<sup>3</sup>, A. Antik<sup>3</sup>, P. M. Raffaele<sup>4</sup>, M. Fortunato<sup>4</sup>, H. Trimarchi<sup>5</sup>, V. Pomeranz<sup>5</sup>, R. Maldonado<sup>6</sup>, N. Matamala<sup>6</sup>, N. C. Imperiali<sup>7</sup>, M. C. Giordani<sup>7</sup>, M. F. Taylor<sup>8</sup>, J. M. Ciappa<sup>8</sup>, J. L. De La Fuente<sup>9</sup>, S. Naser<sup>10</sup>, G. Soler Pujol<sup>2</sup>, <sup>1</sup>*Nephrology, Hospital Universitario Austral, Derqui, Argentina*, <sup>2</sup>*Nephrology, CEMIC, Buenos Aires, Argentina*, <sup>3</sup>*INCUCAI, Buenos Aires, Argentina*, <sup>4</sup>*Fundacion Favaloro, Buenos Aires, Argentina*, <sup>5</sup>*Hospital Britanico de Buenos Aires, Buenos Aires, Argentina*, <sup>6</sup>*Clinica Velez Sarsfield, Cordoba, Argentina*, <sup>7</sup>*Hospital Italiano de Buenos Aires, Buenos Aires, Argentina*, <sup>8</sup>*Crai Sur, Buenos Aires, Argentina*, <sup>9</sup>*Hospital Privado Universitario de Cordoba, Cordoba, Argentina*, <sup>10</sup>*Hospital Privado Universitario de Cordoba, Buenos Aires, Argentina*
- A223 DR53, You Can't See Me: A Deceased Donor Tale of Ambiguous Typing**  
S. Dionne<sup>1</sup>, S. Shetty<sup>1</sup>, L. Santiago<sup>1</sup>, K. Klama<sup>2</sup>, <sup>1</sup>*VRL Eurofins, Centennial, CO*, <sup>2</sup>*VRL Eurofins, Philadelphia, PA*
- A224 † Risk of Delayed Graft Function after Deceased Donor Kidney Transplantation in the Current Era**  
I. Helanterä<sup>1</sup>, H. N. Ibrahim<sup>2</sup>, M. Lempien<sup>1</sup>, P. Finne<sup>3</sup>, <sup>1</sup>*Transplantation and Liver Surgery, Helsinki University Hospital, Helsinki, Finland*, <sup>2</sup>*Department of Medicine, Houston Methodist Hospital, Houston, TX*, <sup>3</sup>*Nephrology, Helsinki University Hospital, Helsinki, Finland*
- A225 † Estimated vs. Actual Graft Failure and Patient Survival after Kidney Transplantation**  
J. Buggs<sup>1</sup>, T. Thigpen<sup>2</sup>, E. Rogers<sup>1</sup>, A. Kumar<sup>3</sup>, V. Bowers<sup>1</sup>, <sup>1</sup>*Tampa General Hospital, Tampa, FL*, <sup>2</sup>*Wesleyan College, Macon, GA*, <sup>3</sup>*University of South Florida, Tampa, FL*
- A226 † Transplantation of the Highly Sensitized Renal Transplant Candidate in the Post-KAS Era: Who is Left Out?**  
C. Schinstock, B. Smith, A. Bentall, M. Stegall, *Mayo Clinic, Rochester, MN*



**Poster Session A: Kidney  
Immunosuppression: Novel Regimens  
and Drug Minimization**

- A227 † Efficacy of Belatacept Conversion Protocols**  
M. Yazdi, J. Kahwaji, S. Meguerditchian, R. Lee, *Kaiser Los Angeles Medical Center, Los Angeles, CA*
- A228 † Long-Term Efficacy and Safety of Everolimus Based Immunosuppression on De Novo Kidney Transplantation with 10 Years Follow-Up**  
Y. Watarai<sup>1</sup>, S. Narumi<sup>1</sup>, T. Tomosugi<sup>1</sup>, K. Futamura<sup>2</sup>, M. Okada<sup>1</sup>, M. Tsujita<sup>2</sup>, T. Hiramitsu<sup>1</sup>, T. Kobayashi<sup>3</sup>, N. Goto<sup>2</sup>, <sup>1</sup>*Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan*, <sup>2</sup>*Transplant Nephrology, Nagoya Daini Red Cross Hospital, Nagoya, Japan*, <sup>3</sup>*Kidney Transplantation, Aichi Medical University, Nagoya, Japan*
- A229 † Race-Sex Effects on Immune Response Potential during Tacrolimus Minimization Therapy in Stable Renal Allograft Recipients**  
K. Tornatore<sup>1</sup>, K. Attwood<sup>2</sup>, R. Venuto<sup>3</sup>, H. Minderman<sup>4</sup>, <sup>1</sup>*University at Buffalo; School of Pharmacy, Buffalo, NY*, <sup>2</sup>*Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY*, <sup>3</sup>*University at Buffalo; School of Medicine: Nephrology, Buffalo, NY*, <sup>4</sup>*Flow & Image Cytometry, Roswell Park Comprehensive Cancer Center, Buffalo, NY*
- A230 † Use of mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Breaking False Myths**  
D. Cucchiari<sup>1</sup>, A. Molina-Andujar<sup>1</sup>, E. Montagud-Marrahi<sup>1</sup>, F. J. Centellas-Pérez<sup>2</sup>, I. Revuelta<sup>1</sup>, F. Oppenheimer<sup>1</sup>, F. Diekmann<sup>1</sup>, <sup>1</sup>*Renal Transplant Unit, Hospital Clínic, Barcelona, Spain*, <sup>2</sup>*Complejo Hospitalario Universitario, Albacete, Spain*
- A231 † Tacrolimus Concentration/Dose Ratio is an Independent Predictor of Death-Censored Kidney Allograft Survival**  
T. Jouve<sup>1</sup>, J. Noble<sup>1</sup>, X. Fonrose<sup>2</sup>, B. Janbon<sup>1</sup>, G. Fiard<sup>3</sup>, P. Malvezzi<sup>1</sup>, L. Rostaing<sup>1</sup>, <sup>1</sup>*Nephrology, Dialysis, Aphereses and Transplantation Department, Grenoble University Hospital, Grenoble, France*, <sup>2</sup>*Pharmacology, Pharmacogenetics and Toxicology Laboratory, Grenoble University Hospital, Grenoble, France*, <sup>3</sup>*Urology and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France*
- A232 Eculizumab in Kidney Transplant Recipients with Atypical Hemolytic Uremic Syndrome - Single Center Experience**  
A. Bhalla, S. Alasfar, N. Alachkar, *Division of Transplant Nephrology, Johns Hopkins Hospital, Baltimore, MD*
- A233 CYP3A5 Genotype Had No Influence on Renal Function after Renal Transplantation**  
J. E. Kimpton, A. J. Hughes, I. MacPhee, *Renal Medicine and Transplantation, St George's University Hospitals NHS Foundation Trust, London, United Kingdom*
- A234 Impact of Induction Choice and Early Steroid Withdrawal on Outcomes in HLA Zero Mismatched Kidney Transplant Recipients**  
C. Votruba<sup>1</sup>, K. Holdener<sup>1</sup>, B. Astor<sup>2</sup>, F. Aziz<sup>2</sup>, D. Mandelbrot<sup>2</sup>, <sup>1</sup>*Pharmacy, University of Wisconsin Hospitals and Clinics, Madison, WI*, <sup>2</sup>*Nephrology, University of Wisconsin Hospitals and Clinics, Madison, WI*
- A235 Long Term Outcomes in Kidney Transplant Recipients Receiving Everolimus (EVR) or Mycophenolate (MPS) in Combination with Tacrolimus (TAC)**  
K. Ficher, C. Rosso Felipe, Y. Cardoso Dreige, K. Linhares, A. Ferreira Brígido, S. Stopa, L. Viana, M. Cristelli, P. Gessolo Lins, W. Aguiar, H. Proença, R. Marco, M. Gerbase de Lima, H. Tedesco Silva Junior, J. Medina Pestana, *Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil*

- A236 Implementation of a De Novo Belatacept Protocol**  
D. Wojciechowski<sup>1</sup>, M. Jacobs<sup>2</sup>, K. Safa<sup>1</sup>, H. Gilligan<sup>1</sup>, H. Eliot<sup>1</sup>, W. W. Williams, Jr<sup>1</sup>, <sup>1</sup>Massachusetts General Hospital, Boston, MA, <sup>2</sup>Wake Forest, Winston-Salem, NC
- A237 The Effect Of Tacrolimus Trough Variability On Kidney Transplant Outcomes**  
S. Heeney<sup>1</sup>, K. R. Szempruch<sup>1</sup>, R. Lee<sup>1</sup>, A. Mintz<sup>2</sup>, P. Serrano<sup>1</sup>, R. Detwiler<sup>1</sup>, C. Doligalski<sup>1</sup>, <sup>1</sup>University of North Carolina Medical Center, Chapel Hill, NC, <sup>2</sup>University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC
- A238 Dosing and Exposure over 2 Years with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac) in De Novo Kidney Transplantation**  
K. Budde<sup>1</sup>, S. Bunnapradist<sup>2</sup>, S. Patel<sup>3</sup>, D. Stevens<sup>3</sup>, U. Meier-Kriesche<sup>3</sup>, B. Suwelack<sup>4</sup>, <sup>1</sup>Charité University Medicine Berlin, Berlin, Germany, <sup>2</sup>UCLA Medical Center, Los Angeles, CA, <sup>3</sup>Veloxis Pharmaceuticals Inc, Cary, NC, <sup>4</sup>University Hospital of Münster, Münster, Germany
- A239 Time within Therapeutic Range: A Comparison of Three Tacrolimus Formulations within Ninety Days of Renal Transplant**  
S. Patel, K. Khalil, A. Lichvar, E. Benedetti, P. West-Thielke, *University of Illinois Hospital and Health Sciences System, Chicago, IL*
- A240 Early Conversion to Belatacept in High Risk Renal Transplant Recipients**  
A. Santeusanio, A. Bhansali, R. Shapiro, V. Delaney, S. Florman, G. De Boccardo, *Mount Sinai Hospital, New York, NY*
- A241 The Effect of a Novel Dosing Protocol for the De Novo Use of LCP Tacrolimus in Kidney Transplant Recipients Managed on a Steroid-Free Maintenance Immunosuppression Regimen**  
R. Wolff<sup>1</sup>, A. Nasstrom<sup>1</sup>, C. Borscheid<sup>1</sup>, C. Martin<sup>1</sup>, A. Temelie<sup>1</sup>, R. Spong<sup>2</sup>, D. Keys<sup>2</sup>, T. B. Dunn<sup>3</sup>, <sup>1</sup>School of Pharmacy, MHealth U of MN Medical Center-Fairview, Mpls, MN, <sup>2</sup>Medicine, MHealth U of MN Medical Center-Fairview, Mpls, MN, <sup>3</sup>Surgery, U of Pennsylvania, Phila, PA
- A242 Conversion from Tacrolimus Immediate Release to Tacrolimus Extended Release (Envarsus XR®): A Real World Cohort Highlighting Dosing Variability among Patients**  
K. D. Belfield<sup>1</sup>, D. Malhotra<sup>2</sup>, M. Waleed<sup>3</sup>, E. A. Cohen<sup>1</sup>, <sup>1</sup>Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, <sup>2</sup>Yale University School of Medicine, New Haven, CT, <sup>3</sup>University of Connecticut School of Pharmacy, Storrs, CT
- A243 Effect of Everolimus on IgM and IgG Memory B Cell Growth and Survival In Vitro and Applications for Effective Administration in Clinical Practice**  
Y. Matsuda, *Osaka University Graduate School of Medicine, Osaka, Japan*
- A244 Clinical Implications of Belatacept Conversion in a High-Risk, Urban Renal Transplant Population**  
B. Valdepenas, J. Benken, E. Benedetti, Z. Hajjiri, A. Lichvar, *University of Illinois at Chicago, Chicago, IL*
- A245 Clinical Impact of Race and Timing of Acute Rejection on Recipients of Kidney Transplant on Early Steroid Withdrawal Protocol**  
O. Adebisi, S. Yaqub, W. Goggins, D. Mishler, T. Taber, A. Sharfuddin, *Indiana University, Indianapolis, IN*
- A246 Dosing Requirements Of Astagraf XI In African American Kidney Transplant Recipients Converted From Twice-daily Tacrolimus (aaaktrs)**  
J. N. Fleming, M. A. Posadas-Salas, D. J. Taber, *Medical University of South Carolina, Charleston, SC*

- A247 Early Tacrolimus Trough Attainment in De Novo Kidney Transplant Recipients Treated with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac)**  
K. Budde<sup>1</sup>, S. Bunnapradist<sup>2</sup>, S. J. Patel<sup>3</sup>, D. R. Stevens<sup>3</sup>, U. Meier-Kriesche<sup>3</sup>, B. Suwelack<sup>4</sup>, <sup>1</sup>Charité University Medicine Berlin, Berlin, Germany, <sup>2</sup>UCLA Medical Center, Los Angeles, CA, <sup>3</sup>Veloxis Pharmaceuticals Inc., Cary, NC, <sup>4</sup>University Hospital of Münster, Münster, Germany
- A248 Everolimus/Low Tacrolimus Exposure versus Sodium Mycophenolate/ Standard Tacrolimus for the Elderly Kidney Transplant Recipient. A 4-y Follow-Up of the nEverOld Trial**  
E. David-Neto, F. Agena, F. J. Paula, N. Z. Galante, D. S. David, F. Ramos, A. K. Triboni, P. Romano, P. A. Ebner, V. Coelho, M. Altona, R. Falci, A. Piovesan, W. C. Nahas, *Renal Transplantation Service, Hospital das Clínicas - University of São Paulo School of Medicine, Sao Paulo, Brazil*
- A249 Evaluation of Envarsus XR in African American Kidney Transplant Recipients**  
L. R. Lineberger<sup>1</sup>, E. Hollinger<sup>2</sup>, N. Kenyon<sup>1</sup>, M. Brokohf<sup>1</sup>, N. Alvey<sup>1</sup>, <sup>1</sup>Pharmacy, Rush University Medical Center, Chicago, IL, <sup>2</sup>Rush University Medical Center, Chicago, IL
- A250 Abatacept as Rescue Immunosuppression after Calcineurin Inhibitor Treatment Failure in Renal Transplantation**  
I. R. Badell, P. Vasanth, A. B. Farris, J. M. Robertson, G. M. Karadkhele, C. P. Larsen, *Emory University School of Medicine, Atlanta, GA*
- A251 Combination of Extended-Release Tacrolimus Plus Everolimus Once Daily in De Novo Kidney Transplant Recipients: ER-Tac vs LCPT**  
G. Spagnoletti, M. P. Salerno, F. De Gennaro, J. Romagnoli, F. Citterio, *Surgery, Renal Transplant Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy*
- A252 A Retrospective Observational Analysis of Tacrolimus Metabolism Rate: No Evidence for Impact on Renal Function**  
A. J. Hughes, J. E. Kimpton, I. MacPhee, *Renal Medicine and Transplantation, St George's University Hospitals NHS Foundation Trust, London, United Kingdom*
- A253 Belatacept Conversion for Calcineurin Inhibitor-Associated Thrombotic Microangiopathy in Kidney Transplant Recipients**  
S. A. Muhsin, K. Safa, H. M. Gilligan, E. C. Heher, W. W. Williams, D. M. Wojciechowski, *Nephrology Division, MGH, Boston, MA*
- A254 Outcomes of ABO Incompatible Transplant on Steroid Free Immunosuppression**  
A. Wang, D. Mishler, T. Taber, M. Yaqub, A. Sharfuddin, W. Goggins, O. Adebisi, *Department of Medicine, Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN*
- A255 Belatacept Use in High Kidney Donor Profile Index Kidney Transplant Recipients**  
D. Britt<sup>1</sup>, A. Gharabagi<sup>1</sup>, K. Botkin<sup>1</sup>, T. Horwedel<sup>2</sup>, C. Carthon<sup>1</sup>, J. Hagopian<sup>1</sup>, <sup>1</sup>Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, <sup>2</sup>Veloxis Pharmaceuticals, Cary, NC
- A256 Conversion to Belatacept in Kidney Transplant Recipients with Systemic Lupus Erythematosus**  
I. Carrión Barberà, M. C. Fajardo, D. Tsapepas, J. Gartshteyn, A. Askanase, H. E. Fernandez, *Columbia University MC, New York, NY*

- A257** **Assessment of Proteinuria Reported as Adverse Events in De Novo Renal Transplant Recipients Receiving an Everolimus-Based Regimen: 24-Month Results from TRANSFORM**  
C. Legendre<sup>1</sup>, S. Berger<sup>1</sup>, F. Oppenheimer<sup>1</sup>, A. Wiseman<sup>1</sup>, S. Steinberg<sup>1</sup>, O. Viklicky<sup>1</sup>, G. Russ<sup>1</sup>, R. Danguilan<sup>1</sup>, N. Basic-Jukic<sup>1</sup>, E. Mor<sup>1</sup>, P. Narvekar<sup>2</sup>, M. P. Hernandez Gutierrez<sup>2</sup>, P. Bernhardt<sup>2</sup>, C. Sommerer<sup>1</sup>, <sup>1</sup>TRANSFORM Study Group, Basel, Switzerland, <sup>2</sup>Novartis Pharma AG, Basel, Switzerland
- A258** **Delayed Achievement of Therapeutic Tacrolimus Levels with De Novo Extended-Release Tacrolimus Tablets and the Incidence of Rejection in Kidney Transplant Patients**  
C. E. Carthon<sup>1</sup>, J. C. Hagopian<sup>1</sup>, S. E. January<sup>1</sup>, A. Gharabagi<sup>1</sup>, R. Delos Santos<sup>2</sup>, T. A. Horwedel<sup>3</sup>, <sup>1</sup>Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, <sup>2</sup>Nephrology, Washington University School of Medicine, Saint Louis, MO, <sup>3</sup>Veloxis Pharmaceuticals, Inc., Cary, NC
- A259** **A Naturalistic Study of De Novo Extended-Release Tacrolimus Tablets vs. Tacrolimus Immediate-Release Capsules in Kidney Transplant Recipients**  
T. A. Horwedel<sup>1</sup>, C. E. Carthon<sup>1</sup>, S. E. January<sup>1</sup>, A. Gharabagi<sup>1</sup>, R. Delos Santos<sup>2</sup>, J. C. Hagopian<sup>1</sup>, <sup>1</sup>Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, <sup>2</sup>Nephrology, Washington University School of Medicine, Saint Louis, MO
- A260** **Calcineurin Inhibitor Holiday for Management of Post Transplant Acute Kidney Injury**  
S. Sriperumbuduri, D. Lazarus, T. Fairhead, S. Hoar, J. Karpinski, G. Knoll, *Nephrology, The Ottawa hospital, Ottawa, ON, Canada*
- A261** **Adverse Effect Differences between Tacrolimus-IR and LCP-Tacrolimus**  
J. Hagopian<sup>1</sup>, C. Carthon<sup>1</sup>, S. January<sup>1</sup>, A. Gharabagi<sup>2</sup>, R. Delos Santos<sup>3</sup>, T. Horwedel<sup>4</sup>, <sup>1</sup>Barnes-Jewish Hospital, Saint Louis, MO, <sup>2</sup>St. Louis College of Pharmacy, Saint Louis, MO, <sup>3</sup>Washington University, Saint Louis, MO, <sup>4</sup>Veloxis Pharmaceuticals, Inc, Cary, NC
- A262** **Impact of Tacrolimus Formulation on Tacrolimus Level Coefficient of Variations**  
S. January<sup>1</sup>, T. Horwedel<sup>2</sup>, J. Hagopian<sup>1</sup>, C. Carthon<sup>1</sup>, A. Gharabagi<sup>3</sup>, R. Delos Santos<sup>4</sup>, <sup>1</sup>Barnes-Jewish Hospital, Saint Louis, MO, <sup>2</sup>Veloxis Pharmaceuticals, Inc., Cary, NC, <sup>3</sup>Saint Louis College of Pharmacy, Saint Louis, MO, <sup>4</sup>Washington University School of Medicine, Saint Louis, MO
- A263** **Relationship between Comorbidities and Infectious Disease in Kidney Transplant Recipients Receiving Rituximab**  
A. Molina-Andújar<sup>1</sup>, E. Hermida<sup>1</sup>, J. Rovira<sup>2</sup>, F. Cofan<sup>1</sup>, P. Ventura-Aguiar<sup>1</sup>, N. Esforzado<sup>1</sup>, V. Torregrosa<sup>1</sup>, D. Cucchiari<sup>1</sup>, E. de Souza<sup>1</sup>, I. Revuelta<sup>1</sup>, F. Oppenheimer<sup>1</sup>, F. Diekmann<sup>1</sup>, G. Piñeiro<sup>1</sup>, <sup>1</sup>Renal Transplant Unit, Hospital Clínic de Barcelona, Barcelona, Spain, <sup>2</sup>Laboratori Experimental de Nefrologia i Trasplantament, IDIBAPS, Barcelona, Spain
- A264** **De Novo Belatacept to Delay Tacrolimus Initiation in Renal Transplants with Delayed Graft Function**  
A. Dao, A. Reyad, L. Kautzman, M. Madhrira, I. Memon, O. Elmhishi, B. Sankarapandian, J. Johnson, S. Patel, S. Allam, *Medical City Fort Worth Transplant Institute, Fort Worth, TX*
- A265** **Outcomes in Kidney Transplant Recipients after Conversion from Tacrolimus to Belatacept-Based Regimens**  
H. Underwood, N. Lange, J. Hedvat, C. Brennan, D. Tsapepas, K. King, S. Husain, D. Salerno, S. Patel, S. Mohan, R. Crew, *Columbia University Irving Medical Center, New York, NY*



- A266** **Impacts of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation 5 Years Results**  
 Y. Watarai<sup>1</sup>, S. Narumi<sup>1</sup>, T. Tomosugi<sup>1</sup>, M. Okada<sup>1</sup>, K. Futamura<sup>2</sup>, M. Tsujita<sup>2</sup>, T. Hiramitsu<sup>1</sup>, T. Kobayashi<sup>3</sup>, N. Goto<sup>2</sup>,  
<sup>1</sup>Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan, <sup>2</sup>Transplant Nephrology, Nagoya Daini Red Cross Hospital, Nagoya, Japan, <sup>3</sup>Kidney Transplant Surgery, Aichi Medical University, Nagoya, Japan
- A267** **Risk Factors for Initial Sub- and Supra-Therapeutic Tacrolimus Trough Levels in Renal Transplant Recipients**  
 M. Kapugi, K. Cunningham, C. D'Agostino, C. Kane, A. Novak, J. Schulte, Northwestern Memorial Hospital, Chicago, IL
- A268** **Long-Term Survival Analysis of Kidney Transplant Recipients Receiving Mizoribine as a Maintenance Immunosuppressant**  
 J. Kim<sup>1</sup>, D. Lee<sup>1</sup>, J. Oh<sup>1</sup>, J. Lee<sup>1</sup>, H. Kim<sup>1</sup>, Y. Son<sup>2</sup>, <sup>1</sup>Nephrology, Bongseng hospital, Busan, Korea, Republic of, <sup>2</sup>Nephrology, Donga University hospital, Busan, Korea, Republic of
- A269** **Chloroquine's Effect on T cell Proliferation**  
 R. Muschalek<sup>1</sup>, P. Jindra<sup>2</sup>, R. Kerman<sup>2</sup>, M. Kueht<sup>2</sup>, W. Etheridge<sup>2</sup>, M. Cusick<sup>2</sup>,  
<sup>1</sup>Baylor College of Medicine, Houston, TX, <sup>2</sup>Department of Surgery, Baylor College of Medicine, Houston, TX
- A270** **Difference in DSA Formation between Tacrolimus-XR and Tacrolimus-IR**  
 J. Hagopian<sup>1</sup>, C. Carthon<sup>1</sup>, S. January<sup>1</sup>, A. Gharabagi<sup>2</sup>, R. Delos Santos<sup>3</sup>, T. Horwedel<sup>4</sup>, <sup>1</sup>Barnes-Jewish Hospital, Saint Louis, MO, <sup>2</sup>St. Louis College of Pharmacy, Saint Louis, MO, <sup>3</sup>Washington University, Saint Louis, MO, <sup>4</sup>Veloxis Pharmaceuticals, Inc., Cary, NC
- A271** **Impact of HLA-DR Matching on HLA-DQ Matching Status and the Development of Anti-HLA-DQ De Novo DSA under Calcineurin Inhibitor or Belatacept Immunosuppression**  
 V. Jucaud<sup>1</sup>, H. Gebel<sup>2</sup>, R. Bray<sup>2</sup>, M. Polinsky<sup>3</sup>, M. Everly<sup>1</sup>, <sup>1</sup>Terasaki Research Institute, Los Angeles, CA, <sup>2</sup>Emory University, Atlanta, GA, <sup>3</sup>Bristol-Myers Squibb, Princeton, NJ
- A272** **Sirolimus (SRL) versus Everolimus (EVR) versus Mycophenolate (MPA) in Kidney Transplant Recipients Receiving Anti-Thymocyte Globulin Induction (r-ATG), Tacrolimus (TAC), and Prednisone**  
 C. Rosso Felipe, L. Viana, M. Pontello Cristelli, J. Toniato, K. Ficher, S. Poletto, H. Proença, R. de Marco, M. Gerbase-Lima, A. Brigido, J. Medina Pestana, H. Tedesco-Silva, Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
- A273** **Comparison of Initial Sirolimus (SRL) and Everolimus (EVR) Exposure Patterns in Kidney Transplant Recipients**  
 C. Rosso Felipe, L. Viana, M. Pontello Cristelli, M. Nakamura, L. Ramagnoli, S. Braga, V. Lima, A. Carnevalle, D. Casarini, J. Medina Pestana, H. Tedesco Silva Junior, Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
- A274** **Early Rejection Outcomes with IL-2 vs. ATG Induction among Kidney Transplant Recipients Induction Differences with Early Steroid Withdrawal**  
 C. Burelli, A. Szczepanik, K. Yadav, E. Sanchez, M. Debroy, V. Humphreville, J. Rabets, A. Padiyar, N. Sarabu, A. Jittirat, A. Palanisamy, K. Chavin, University Hospitals Cleveland Medical Center, Cleveland, OH
- A275 †** **Optimizing Opportunity and Benefits of Steroid Avoidance in the New KAS Era**  
 S. Sultan, M. Aull, R. Friedlander, V. K. Sharma, D. Serur, A. Watkins, S. Kapur, D. Dadhania, New York Presbyterian / Weill Cornell, New York, NY



**A275.1 Long-Term Outcomes of Early Conversion to Sirolimus-Based Immunosuppression in Children with Living Donor Kidney Transplants**  
B. Stotter<sup>1</sup>, S. Lui<sup>1</sup>, E. Weller<sup>2</sup>, L. Ganapathi<sup>1</sup>, M. Ferguson<sup>1</sup>, A. Traum<sup>1</sup>, M. Somers<sup>1</sup>, N. Rodig<sup>1</sup>, <sup>1</sup>*Pediatrics, Boston Children's Hospital, Boston, MA*, <sup>2</sup>*Biostatistics and Research Design Center, Boston Children's Hospital, Boston, MA*

## Poster Session A: Liver - Kidney Issues in Liver Transplantation

---

**A276 Early Renal Allograft Failure after Simultaneous Liver-Kidney Transplantation: Evidence for Utilization of the Safety Net**  
G. Cullaro<sup>1</sup>, E. C. Verna<sup>2</sup>, B. J. Orandi<sup>3</sup>, J. C. Lai<sup>1</sup>, <sup>1</sup>*UCSF, San Francisco, CA*, <sup>2</sup>*Columbia University, New York, NY*, <sup>3</sup>*University of Alabama at Birmingham, Birmingham, AL*

**A277 † Outcomes for Liver Transplant Recipients on Renal Replacement Therapy: Who Cannot Wait for Safety Net**  
A. Pita<sup>1</sup>, N. Kaur<sup>1</sup>, M. Lo<sup>2</sup>, A. F. Sabour<sup>1</sup>, V. Tristan<sup>1</sup>, Y. Genyk<sup>1</sup>, M. K. Nadim<sup>3</sup>, L. Sher<sup>1</sup>, <sup>1</sup>*Department of Surgery, Keck Medical Center of USC, Los Angeles, CA*, <sup>2</sup>*Department of Preventive Medicine, Keck Medical Center of USC, Los Angeles, CA*, <sup>3</sup>*Department of Medicine, Keck Medical Center of USC, Los Angeles, CA*

**A278 † Delayed Kidney Transplantation in Combined Liver Kidney Transplantation: A Validation Analysis by the UNOS Registry**  
L. Chau, M. Safwan, M. Rizzari, K. Collins, A. Yoshida, M. Abouljoud, D. Moonka, S. Nagai, *Transplant Surgery, Henry Ford Hospital, Detroit, MI*

**A279 Urinary Biomarkers of Kidney Injury in Liver Transplant Recipients with Calcineurin Inhibitors Based Immunosuppression**  
D. Maluf<sup>1</sup>, V. Bontha<sup>1</sup>, A. Bajwa<sup>2</sup>, A. Abdelaal<sup>1</sup>, C. Koo<sup>1</sup>, J. D. Eason<sup>2</sup>, V. Mas<sup>2</sup>, <sup>1</sup>*UTHSC, Memphis, TN*, <sup>2</sup>*Transplant Institute, Memphis, TN*

**A280 De Novo Glomerulonephritis after Non Renal Abdominal Organ Transplantation**  
C. Farkas<sup>1</sup>, R. B. Ettenger<sup>1</sup>, J. Zuckerman<sup>2</sup>, R. S. Venick<sup>3</sup>, P. Weng<sup>1</sup>, <sup>1</sup>*Pediatric Nephrology, UCLA, Los Angeles, CA*, <sup>2</sup>*Pathology, UCLA, Los Angeles, CA*, <sup>3</sup>*Pediatric Gastroenterology, UCLA, Los Angeles, CA*

**A281 Long-Term Kidney Graft Evolution in Simultaneous Liver-Kidney Transplants with Immunological Risk**  
G. J. Piñeiro<sup>1</sup>, E. Montagud<sup>1</sup>, J. Ugalde<sup>1</sup>, R. Gelpi<sup>1</sup>, V. Torregrosa<sup>1</sup>, J. Rovira<sup>2</sup>, J. Colmenero<sup>3</sup>, F. Diekmann<sup>1</sup>, N. Esforzado<sup>1</sup>, <sup>1</sup>*Nephrology and Kidney Transplantation, Hospital Clinic of Barcelona, Barcelona, Spain*, <sup>2</sup>*Nephrology and Kidney Transplantation, Laboratori Experimental de Nefrologia i Trasplantament, IDIBAPS, Barcelona, Spain*, <sup>3</sup>*Liver Transplant Unit, Hospital Clínic of Barcelona, Barcelona, Spain*

**A282 Monitoring And Management Of Proteinuria Is Often Ignored In Patients Receiving mTOR Therapy Following Orthotopic Liver Transplantation**  
R. Kaur<sup>1</sup>, O. Sadiq<sup>2</sup>, M. Alimirah<sup>1</sup>, F. Kumssa<sup>1</sup>, A. Patel<sup>3</sup>, S. Jafri<sup>2</sup>, <sup>1</sup>*Internal Medicine, Henry Ford Hospital, Detroit, MI*, <sup>2</sup>*Gastroenterology, Henry Ford Hospital, Detroit, MI*, <sup>3</sup>*Nephrology, Henry Ford Hospital, Detroit, MI*

**A283 Poor Long-Term Outcome of Liver Transplant Recipients with Preexisting Renal Insufficiency**  
M. Sterneck<sup>1</sup>, M. Touma<sup>1</sup>, T. Horvatits<sup>2</sup>, S. Pischke<sup>2</sup>, U. Herden<sup>3</sup>, A. Lohse<sup>2</sup>, L. Fischer<sup>3</sup>, <sup>1</sup>*University Transplant Center, University Medical Center Hamburg Eppendorf, Hamburg, Germany*, <sup>2</sup>*Department of Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany*, <sup>3</sup>*Department of Visceral Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany*

- A284** **Intraoperative Portal Vein Flow Can Predict Early Acute Kidney Injury Following Allogeneic Liver Transplantation: A Retrospective Observational Study**  
J. Zhang<sup>1</sup>, A. Jiao<sup>2</sup>, Q. Liu<sup>1</sup>, C. Zhang<sup>1</sup>, N. Sun<sup>1</sup>, X. Li<sup>1</sup>, <sup>1</sup>Hepatobiliary Surgery Department and Unit of Organ Transplantation, The First Hospital of China Medical University, Shenyang, China, <sup>2</sup>Department of Hepato-Biliary-Pancreatic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China
- A285** **Renal Safety Of Entecavir And Tenofovir With Hepatitis B Immunoglobulin In Liver Transplant Patients**  
D. Kim<sup>1</sup>, J. Lee<sup>1</sup>, E. Kim<sup>1</sup>, S. Kim<sup>1</sup>, K. Ihn<sup>1</sup>, D. Joo<sup>1</sup>, K. Huh<sup>1</sup>, B. Kim<sup>2</sup>, M. Kim<sup>1</sup>, S. Kim<sup>1</sup>, Y. Kim<sup>1</sup>, J. Lee<sup>1</sup>, <sup>1</sup>Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of, <sup>2</sup>Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
- A286** **Sequential Liver Kidney Transplant Has Comparable Outcomes As Combined Liver Kidney Transplant Except For Ckd 5 In Patient With Cld With Ckd In Live Donor Program- Retrospective Analysis Of 2182 Cases**  
S. Verma, S. Naganathan, S. Gupta, Center for Liver and Biliary Sciences, Max Superspeciality hospital, New Delhi, India
- A287** **Combined Liver and Delayed Kidney Transplantation (CLKT) Enables Similar Patient Survival as Liver Transplantation Alone (LTA): Propensity Score-Based Comparison**  
B. Ekser<sup>1</sup>, C. A. Kubal<sup>1</sup>, R. S. Mangus<sup>1</sup>, P. Mihaylov<sup>1</sup>, J. A. Fridell<sup>1</sup>, L. R. Timsina<sup>1</sup>, M. Lacerda<sup>2</sup>, M. Ghabril<sup>2</sup>, J. A. Powelson<sup>1</sup>, W. C. Goggins<sup>1</sup>, <sup>1</sup>Transplant Division - Department of Surgery - Indiana University, Indianapolis, IN, <sup>2</sup>Gastroenterology, Indiana University, Indianapolis, IN
- A288** **Risk Stratification of Patients Undergoing Simultaneous Liver Transplantation and Cardiac Surgery**  
T. Diago Uso, G. D'Amico, S. Armanyous, L. Lomaglio, B. Eghtesad, M. Fujiki, F. Aucejo, K. Sasaki, N. K. Menon, M. Fares, M. Tong, K. Hashimoto, C. Miller, C. Quintini, Cleveland Clinic, Cleveland, OH
- A289** **Illustration of Renal Recovery in SLK with Utilization of Most Recent Allocation Criteria**  
B. Patel, R. Prashar, A. Babu, Henry Ford Hospital Detroit, Detroit, MI
- A290** **Pre-Liver Transplant Renal Dysfunction is an Independent Predictor of Post-Liver Transplant Return to the Operating Room**  
H. M. Wadei, M. L. Mai, C. Taner, A. P. Keaveny, S. Mao, P. Abader, P. Kroner, K. Croome, Department of Transplant, Mayo Clinic, Jacksonville, FL
- A291** **Staged Procedure In Simultaneous Liver And Kidney Transplant -the "Swedish" Experience**  
A. Gravetz, Transplant Surgery, Swedish Medical Center, Seattle, WA
- A292** **Outcomes of En Bloc Simultaneous Liver-Kidney Transplantation Compared to the Traditional Technique**  
A. R. Cortez, T. C. Lee, A. Kassam, M. C. Morris, L. K. Winer, L. Sage Silski, M. C. Cuffy, T. S. Diwan, R. C. Quillin, S. A. Shah, University of Cincinnati, Cincinnati, OH
- A293** **Incidence and Predictors of Post-Kidney Biopsy (KBx) Bleeding in Liver Transplant (LT) Candidates with Renal Dysfunction**  
H. M. Wadei<sup>1</sup>, P. Abader<sup>1</sup>, N. Aslam<sup>2</sup>, T. Jarmi<sup>1</sup>, A. P. Keaveny<sup>1</sup>, K. Croome<sup>1</sup>, D. D. Lee<sup>1</sup>, C. Taner<sup>1</sup>, <sup>1</sup>Department of Transplant, Mayo Clinic, Jacksonville, FL, <sup>2</sup>Department of Medicine, Division of Nephrology, Mayo Clinic, Jacksonville, FL

**A294 Early Achievement of Sustained Virological Response in Liver Transplant Recipients with Hepatitis C Reduces Risks of End Stage Renal Disease**

M. Yoshikawa<sup>1</sup>, T. Fukumoto<sup>2</sup>,  
<sup>1</sup>Nephrology, Kobe University Hospital, Kobe, Japan, <sup>2</sup>Hepato-Biliary-Pancreas Surgery, Kobe University Hospital, Kobe, Japan

**A295 Renal Failure after Liver Transplantation: Benefits from a Little Pinch of KALT**

R. Ruiz<sup>1</sup>, K. Holmes<sup>2</sup>, G. McKenna<sup>1</sup>, N. Onaca<sup>1</sup>, G. Testa<sup>1</sup>, H. Fernandez<sup>1</sup>, J. Bayer<sup>1</sup>, A. Wall<sup>1</sup>, E. Martinez<sup>1</sup>, E. Martinez<sup>1</sup>, A. Gupta<sup>1</sup>, R. Goldstein<sup>1</sup>, G. Klintmalm<sup>1</sup>, <sup>1</sup>Baylor All Saints Medical Center, Fort Worth, TX, <sup>2</sup>Medical City Fort Worth, Fort Worth, TX

**A296 Does Secondary Simultaneous Liver Kidney versus Liver Alone Make a Difference in Terms of Patient and Graft Survival**

C. Blanton, J. Reyes, M. Eerhart, P. Chlebeck, L. Fernandez, *University of Wisconsin, Madison, WI*

**A297 Outcomes of Inguinal and Incisional Hernias in Patients Undergoing Liver Transplant**

H. Aziz, V. Tristan, Y. Genyk, K. Etesami, *Transplant Surgery, USC, Los Angeles, CA*

**A298 Is Bariatric Surgery Feasible in the Setting of Liver and Kidney Transplants?**

L. M. Potter, A. Saharia, C. Mobley, K. Lunsford, M. Hobeika, N. Tariq, H. Podder, A. O. Gaber, R. M. Ghobrial, *Liver Transplant and Hepatobiliary Surgery, The Houston Methodist Hospital, Houston, TX*

## Poster Session A: Liver: Recipient Selection

---

**A299 † Extreme Hyponatremia as a Risk Factor for Early Mortality after Liver Transplantation in the Model for End-Stage Liver Disease-Sodium Period**

H. Mouzaihem, M. Safwan, L. C. Chau, D. Moonka, M. Abouljoud, S. Nagai, *Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI*

**A300 Trimming the Fat?: Optimizing Utilization of Liver Allografts with Macrosteatosis >30% in Recipients with MELD Scores <35**

J. A. Steggerda<sup>1</sup>, M. B. Bloom<sup>1</sup>, T. Todo<sup>2</sup>, T. V. Brennan<sup>2</sup>, N. N. Nissen<sup>2</sup>, A. S. Klein<sup>2</sup>, I. K. Kim<sup>2</sup>, <sup>1</sup>Surgery, Cedars-Sinai Medical Center, Los Angeles, Los Angeles, CA, <sup>2</sup>Transplant Surgery, Cedars-Sinai Medical Center, Los Angeles, Los Angeles, CA

**A301 † The Effect of Lifestyle Intervention on Physical Functionality, Progress of Liver Disease and Mortality in Decompensated Cirrhosis Patients in a Community Model**

S. Habib, F. Alsafar, *Liver Institute PLLC, Tucson, AZ*

**A302 † The Risks Are Not Always The Same; Peak Timing Of Risk In Liver Transplantation**

K. Sasaki, J. McVey, D. Firl, K. Okubo, M. Fujiki, T. Diago Uso, D. Kwon, B. Eghtesad, C. Quintini, C. Miller, F. Aucejo, K. Hasimoto, *Cleveland Clinic, Cleveland, OH*

**A303 Recipient Sex Interacts with Primary Diagnosis to Affect Liver Transplant Graft Survival**

D. Yoeli<sup>1</sup>, R. Choudhury<sup>1</sup>, H. Moore<sup>1</sup>, M. Simpson<sup>2</sup>, A. Sauaia<sup>1</sup>, E. Pomfret<sup>1</sup>, T. Nydam<sup>1</sup>, <sup>1</sup>Surgery, University of Colorado, Denver, CO, <sup>2</sup>Surgery, Lahey Clinic, Burlington, MA

**A304 Utility Of SIPAT Scoring System In Predicting Risk Of Recidivism In Patients With Alcoholic Liver Disease.**

A. Ur Rahman<sup>1</sup>, H. Singh<sup>1</sup>, M. Abusaif<sup>1</sup>, J. Shaw<sup>2</sup>, O. Knighton<sup>2</sup>, L. Clark<sup>2</sup>, T. Santos<sup>2</sup>, S. Ebaid<sup>2</sup>, D. Reino<sup>2</sup>, J. Vanatta<sup>2</sup>, A. Tzakis<sup>2</sup>, K. Alkhaloufi<sup>2</sup>, X. Zervos<sup>2</sup>, <sup>1</sup>Gastroenterology, Cleveland Clinic Florida, Weston, FL, <sup>2</sup>Transplant Institute, Cleveland Clinic Florida, Weston, FL

- A305**      **Comparable Outcomes of Deceased Donor Liver Transplant Outcomes in Recipients with Previous Abdominal Surgery (PAS) after Pre Listing Surgical Categorization. A Propensity-Score Matched Pair Analysis**  
H. Sharma, H. Bohorquez, D. Oganesyanyan, D. Bruce, E. Bugeaud, I. Carmody, A. Cohen, J. Seal, D. Sonnier, G. Loss, *Department of Transplant Surgery, Ochsner Medical Center, New Orleans, LA*
- A306**      **Higher Population Donor Service Areas Are Associated With Lower Meld At Death On Wait List And Higher Meld At Removal For “Too Sick”**  
Y. Hung, Y. Bababekov, C. Rickert, Y. Hsu, D. Chang, H. Yeh, *Massachusetts General Hospital, Boston, MA*
- A307**      **Statin Underutilization in Patients Listed for Liver Transplant**  
K. Mishra<sup>1</sup>, S. Naffouj<sup>1</sup>, S. Modi<sup>1</sup>, C. Dagher<sup>1</sup>, S. Gorgis<sup>1</sup>, D. Venkat<sup>2</sup>, <sup>1</sup>*Internal Medicine, Henry Ford Hospital, Detroit, MI*, <sup>2</sup>*Transplant Hepatology, Henry Ford Hospital, Detroit, MI*
- A308**      **Liver Transplant Centers Select Different Characteristics for Recipients and Deceased Donors: Implications for Patients When Choosing a Center**  
C. R. Schaffhausen<sup>1</sup>, M. J. Bruin<sup>2</sup>, S. Chu<sup>2</sup>, D. Schladt<sup>1</sup>, S. Chinnakotla<sup>3</sup>, J. R. Lake<sup>4</sup>, W. Kim<sup>5</sup>, S. W. Biggins<sup>6</sup>, J. J. Snyder<sup>7</sup>, B. L. Kasiske<sup>7</sup>, A. K. Israni<sup>1</sup>, <sup>1</sup>*Hennepin Healthcare Research Institute, Minneapolis, MN*, <sup>2</sup>*College of Design, University of Minnesota, Minneapolis, MN*, <sup>3</sup>*Department of Surgery, University of Minnesota, Minneapolis, MN*, <sup>4</sup>*Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, MN*, <sup>5</sup>*Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA*, <sup>6</sup>*Division of Gastroenterology, University of Washington, Seattle, WA*, <sup>7</sup>*Scientific Registry of Transplant Recipients, Minneapolis, MN*
- A309 †**    **Preoperative Risk Factor-based Cardiac Catheterization Is Associated With Low Cardiac Morbidity And Mortality In Liver Transplant Patients**  
R. Rachwan<sup>1</sup>, I. Kutkut<sup>1</sup>, P. D. Bourdillon<sup>2</sup>, L. R. Timsina<sup>3</sup>, M. Ghabril<sup>4</sup>, C. A. Kubal<sup>5</sup>, M. A. Lacerda<sup>6</sup>, R. S. Mangus<sup>5</sup>, <sup>1</sup>*Internal Medicine, Indiana University, Indianapolis, IN*, <sup>2</sup>*Internal Medicine, Indiana University, Division of Cardiology, Indianapolis, IN*, <sup>3</sup>*Department of Biostatistics, Indiana University, Indianapolis, IN*, <sup>4</sup>*Internal Medicine, Indiana University, Division of Hepatology, Indianapolis, IN*, <sup>5</sup>*Surgery, Transplant Division, Indiana University, Indianapolis, IN*, <sup>6</sup>*Internal Medicine, Division of Hepatology, Indiana University, Indianapolis, IN*
- A310**      **Outcomes of Side-to-Side Cavocavostomy versus Traditional Piggyback Implantation in Liver Transplantation**  
T. Lee, V. Dhar, M. Morris, L. Winer, A. Cortez, L. Sage Silski, M. Cuffy, T. Diwan, R. Quillin, III, S. Shah, *University of Cincinnati, Cincinnati, OH*
- A311**      **Functional Measures of Frailty and Not Sarcopenia Predict Mortality in a Prospective Cohort of Liver Transplant Candidates**  
R. Sharma, R. Rosenblatt, R. Knotts, J. Pisa, E. Verna, *Division of Liver Diseases and Transplantation, Columbia University Medical Center, New York, NY*
- A312**      **Feasibility of a Rapid Magnetic Resonance Protocol to Assess Body Composition Profiles in Adult Liver Transplant Candidates**  
S. Pine<sup>1</sup>, L. Adamski<sup>1</sup>, D. Gregory<sup>1</sup>, C. Padilla<sup>1</sup>, J. Gottstein<sup>2</sup>, A. Lemmer<sup>1</sup>, M. Forsgren<sup>3</sup>, M. Rinella<sup>1</sup>, L. B. VanWagner<sup>4</sup>, <sup>1</sup>*Medicine-GI & Hepatology, Northwestern University, Chicago, IL*, <sup>2</sup>*Northwestern University, Chicago, IL*, <sup>3</sup>*Center for Medical Image Science, Linköping University, Linköping, Sweden*, <sup>4</sup>*Medicine-GI & Hepatology and Preventive Medicine, Northwestern University, Chicago, IL*



- A313 † Liver Transplantation for Acute Liver Failure: A 16 Year Experience with 214 Patients in the Post-MELD Era**  
R. McMillan, T. Ito, A. Aziz, A. Amin, A. Murray, J. DiNorcia III, V. G. Agopian, H. Yersiz, D. G. Farmer, R. W. Busuttil, F. M. Kaldas, *Department of Surgery, The Dumont-UCLA Transplant Center, Los Angeles, CA*
- A314 † The Liver Frailty Index is Associated with Current and Subsequent Disability in Liver Transplant Candidates**  
J. C. Lai, J. L. Dodge, C. E. McCulloch, K. E. Covinsky, J. P. Singer, *University of California, San Francisco, San Francisco, CA*
- A315 † A Randomized Pilot Trial of Home-Based Physical Activity Plus Dietary Intervention to Improve Physical Function in Patients with Advanced Liver Disease**  
H. Chen<sup>1</sup>, A. A. Ferrando<sup>2</sup>, M. G. White<sup>2</sup>, M. Pauly<sup>2</sup>, T. Bartter<sup>2</sup>, M. A. Dunn<sup>1</sup>, W. R. Kim<sup>3</sup>, A. Duarte-Rojo<sup>1</sup>, <sup>1</sup>T.E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>2</sup>University of Arkansas for Medical Sciences, Little Rock, AR, <sup>3</sup>Stanford University, Palo Alto, CA
- A316 Evaluation of Liver Transplantation among Advanced Age Recipients in a Large Multicenter U.S. Cohort**  
A. Goel<sup>1</sup>, A. Kwong<sup>2</sup>, D. Devuni<sup>3</sup>, C. Wang<sup>2</sup>, J. Boike<sup>4</sup>, J. Jo<sup>4</sup>, L. VanWagner<sup>4</sup>, M. Serper<sup>5</sup>, L. Jones<sup>5</sup>, R. Sharma<sup>6</sup>, E. Verna<sup>6</sup>, J. Shor<sup>3</sup>, M. German<sup>7</sup>, A. Hristov<sup>7</sup>, A. Lee<sup>7</sup>, E. Spengler<sup>7</sup>, A. Koteish<sup>8</sup>, G. Sehmbey<sup>9</sup>, A. Seetharam<sup>9</sup>, N. John<sup>1</sup>, Y. Patel<sup>10</sup>, M. Kappus<sup>10</sup>, T. Couri<sup>11</sup>, R. Salgia<sup>12</sup>, Q. Nhu<sup>13</sup>, C. Frenette<sup>13</sup>, J. Lai<sup>2</sup>, <sup>1</sup>Stanford University, Palo Alto, CA, <sup>2</sup>University of California, San Francisco, CA, <sup>3</sup>University of Massachusetts, Worcester, MA, <sup>4</sup>Northwestern, Chicago, IL, <sup>5</sup>University of Pennsylvania, Philadelphia, PA, <sup>6</sup>Columbia University, New York, NY, <sup>7</sup>University of Wisconsin, Madison, WI, <sup>8</sup>Florida Hospital, Orlando, FL, <sup>9</sup>University of Arizona, Phoenix, AZ, <sup>10</sup>Duke University, Durham, NC, <sup>11</sup>University of Chicago, Chicago, IL, <sup>12</sup>Henry Ford Hospital, Detroit, MI, <sup>13</sup>Scripps, San Diego, CA
- A317 Dobutamine Stress Echocardiography is a Poor Predictor of Clinically Significant Coronary Artery Disease in Patients Undergoing Liver Transplant Evaluation**  
D. L. Hughes<sup>1</sup>, J. Rice<sup>1</sup>, J. R. Burton<sup>1</sup>, E. A. Pomfret<sup>2</sup>, J. J. Pomposelli<sup>2</sup>, A. V. Ambardekar<sup>3</sup>, S. M. Mandell<sup>4</sup>, M. S. Kriss<sup>1</sup>, <sup>1</sup>Division of Gastroenterology & Hepatology, University of Colorado School of Medicine (UCSOM), Aurora, CO, <sup>2</sup>Division of Transplant Surgery, UCSOM, Aurora, CO, <sup>3</sup>Division of Cardiology, UCSOM, Aurora, CO, <sup>4</sup>Department of Anesthesiology, UCSOM, Aurora, CO
- A318 Portal Vein Thrombosis Discovered at Liver Transplant: Barrier to Success**  
J. Seltman<sup>1</sup>, M. Kazimi<sup>2</sup>, J. Duque<sup>3</sup>, R. Cross<sup>2</sup>, A. Ray<sup>2</sup>, T. Ommert<sup>2</sup>, R. A. Rubin<sup>2</sup>, <sup>1</sup>Mercer University Medical School, Macon, GA, <sup>2</sup>Transplantation, Piedmont Transplant Institute, Atlanta, GA, <sup>3</sup>Piedmont Heart Institute, Atlanta, GA
- A319 Orthotopic Liver Transplantation in MPV17 Deficiency: A Case Series**  
E. A. Gerzina<sup>1</sup>, E. D. Witte<sup>1</sup>, M. L. Kueht<sup>2</sup>, R. W. Himes<sup>3</sup>, <sup>1</sup>Baylor College of Medicine, Houston, TX, <sup>2</sup>Department of Surgery, Division of Abdominal Transplant, Baylor College of Medicine, Houston, TX, <sup>3</sup>Pediatrics-Gastroenterology, Baylor College of Medicine, Houston, TX
- A320 Liver Transplant Outcomes in Patients with Atrial Fibrillation**  
D. Devuni<sup>1</sup>, P. Mahboub<sup>2</sup>, P. Martins<sup>2</sup>, C. Barry<sup>1</sup>, I. Zacharias<sup>1</sup>, B. Movahedi<sup>2</sup>, G. Barnard<sup>1</sup>, A. Bozorgzadeh<sup>2</sup>, <sup>1</sup>Division of Gastroenterology, University of Massachusetts Medical School, Worcester, MA, <sup>2</sup>Surgery, Division of Transplantation, University of Massachusetts Medical School, Worcester, MA



**Poster Session A: Transplant Infectious Diseases**

- A321**      **Use of a CMV Specific T Cell Immunity Assay in Late-Onset CMV Infection**  
O. Beaird<sup>1</sup>, M. Carlson<sup>1</sup>, P. Gaynor<sup>1</sup>, D. Nanayakkara<sup>1</sup>, B. Abdalla<sup>2</sup>, S. Bunnapradist<sup>2</sup>, J. Schaeffer<sup>1</sup>,  
<sup>1</sup>Department of Internal Medicine - Division Infectious Diseases, UCLA, Los Angeles, CA, <sup>2</sup>Department of Internal Medicine - Division Nephrology, UCLA, Los Angeles, CA
- A322**      **Comparison of Two Dosing Regimens of Valganciclovir for Cytomegalovirus Prophylaxis in High-Risk Liver Transplant Recipients**  
A. L. Bixby, L. Fitzgerald, L. Cotiguala, J. M. Park, D. Kaul, C. Sonnenday, S. Tischer, *Michigan Medicine, Ann Arbor, MI*
- A323**      **Letermovir for CMV Treatment in Solid Organ Transplant**  
O. Witkowski, M. Chunduru, A. Chung, A. Diez, *The Ohio State University Wexner Medical Center, Columbus, OH*
- A324**      **De-Novo Letermovir Resistant Mutations in Cytomegalovirus-Infected Tissues of Solid Organs Transplant Recipients**  
S. HAN, H. Cho, S. Min, Y. Hong, *Internal Medicine, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea, Republic of*
- A325**      **Experience With Letermovir Use For The Management Of Cytomegalovirus In Solid Organ Transplant Recipients**  
J. L. Orejas<sup>1</sup>, F. M. Marty<sup>1</sup>, A. M. McDonnell<sup>2</sup>, M. P. Cheng<sup>1</sup>, E. Arbona-Haddad<sup>1</sup>, S. P. Hammond<sup>1</sup>, S. Koo<sup>1</sup>,  
<sup>1</sup>Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, <sup>2</sup>Department of Pharmacy, Brigham and Women's Hospital, Boston, MA

- A326**      **Incidence of Cytomegalovirus in Moderate Risk Kidney Transplant Recipients Receiving Low Dose Valganciclovir**  
T. Fallah<sup>1</sup>, A. Logan<sup>2</sup>, L. Beltran Garcia<sup>3</sup>, L. Bowman<sup>2</sup>, <sup>1</sup>Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Tampa General Hospital, Tampa, FL, <sup>3</sup>Florida Kidney Physicians, Tampa General Hospital, Tampa, FL
- A327**      **Donor Derived Tuberculosis in Solid Organ Transplantation in the United States: 10 Years of UNOS Ad Hoc Disease Transmission Advisory Committee Experience**  
M. F. Malinis<sup>1</sup>, R. LaHoz<sup>1</sup>, G. Vece<sup>2</sup>, S. Tlusty<sup>2</sup>, S. Aslam<sup>1</sup>, R. Bag<sup>1</sup>, J. Bucio<sup>1</sup>, L. Danziger-Isakov<sup>1</sup>, D. F. Florescu<sup>1</sup>, M. Rana<sup>1</sup>, C. Wolfe<sup>1</sup>, M. G. Michaels<sup>1</sup>,  
<sup>1</sup>DTAC, Richmond, VA, <sup>2</sup>UNOS, Richmond, VA
- A328**      **Syphilis Transmission in Solid Organ Transplantation**  
M. Morrison, M. Hurtik, G. M. Lyon, S. Pouch, *Emory University Hospital, Atlanta, GA*
- A329**      **Preventing Donor Derived Cryptococcal Infections: Should We Screen Potential Organ Donors with a Serum Cryptococcal Antigen? A Cost Analysis**  
C. Santos<sup>1</sup>, E. Ritz<sup>1</sup>, Y. Rhee<sup>1</sup>, I. George<sup>2</sup>, J. Pulvirenti<sup>3</sup>, N. Moore<sup>1</sup>, E. Hollinger<sup>1</sup>, L. Proia<sup>1</sup>, <sup>1</sup>Rush University Medical Center, Chicago, IL, <sup>2</sup>Washington University, St. Louis, MO, <sup>3</sup>Mercy Hospital, Rockford, IL
- A330**      **Impact of Multidrug-Resistant Organisms among Donors on Organ Utilization**  
J. A. Anesi<sup>1</sup>, E. Lautenbach<sup>1</sup>, J. H. Han<sup>1</sup>, D. H. Lee<sup>2</sup>, H. Clauss<sup>3</sup>, A. Climaco<sup>4</sup>, R. Hasz<sup>5</sup>, E. Molnar<sup>3</sup>, D. Alimenti<sup>1</sup>, S. West<sup>5</sup>, W. B. Bilker<sup>1</sup>, P. Tolomeo<sup>1</sup>, E. A. Blumberg<sup>1</sup>, <sup>1</sup>University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Drexel University College of Medicine, Philadelphia, PA, <sup>3</sup>Temple University, Philadelphia, PA, <sup>4</sup>Albert Einstein Medical Center, Philadelphia, PA, <sup>5</sup>Gift of Life Donor Program, Philadelphia, PA

- A331 † Donor Derived Strongyloidiasis, a Preventable Event**  
R. M. La Hoz<sup>1</sup>, G. Vece<sup>2</sup>, L. Danziger-Isakov<sup>1</sup>, D. Florescu<sup>1</sup>, M. Malinis<sup>1</sup>, K. Lilly<sup>1</sup>, L. Strasfeld<sup>1</sup>, R. P. Wood<sup>1</sup>, S. Tlusty<sup>2</sup>, C. R. Wolfe<sup>1</sup>, M. G. Michaels<sup>1</sup>, <sup>1</sup>DTAC, Richmond, VA, <sup>2</sup>UNOS, Richmond, VA
- A332 Impact of Multidrug-Resistant Microbes of Donor Lower Respiratory Tract on Early Posttransplant Pneumonia in Bilateral Lung Transplant Recipients without Pretransplant Infection**  
S. HAN<sup>1</sup>, S. Kim<sup>2</sup>, M. Park<sup>3</sup>, J. Lee<sup>4</sup>, H. Paik<sup>4</sup>, <sup>1</sup>Internal Medicine, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea, Republic of, <sup>2</sup>Internal Medicine, Yonsei University Health System Yonsei University Health System, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea, Republic of, <sup>3</sup>Internal Medicine, Yonsei University Health System, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea, Republic of, <sup>4</sup>Chest Surgery, Yonsei University Health System, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea, Republic of
- A333 Transmission of Infections from Organ Donor to Recipient - German Data**  
K. Moench, A. Rahmel, A. P. Barreiros, German Foundation for Organtransplantation (DSO), Frankfurt, Germany
- A334 Breakthrough Invasive Fungal Infections in Solid Organ Transplant Patients Receiving Isavuconazole**  
M. Fung, C. Devoe, B. S. Schwartz, S. B. Doernberg, J. Babik, P. V. Chin-Hong, University of California, San Francisco, San Francisco, CA
- A335 Targeted Antifungal Prophylaxis in Liver Transplant Recipients: Two Year, Retrospective Cohort Analysis**  
N. Persun<sup>1</sup>, J. Doyon<sup>2</sup>, E. Blumberg<sup>2</sup>, S. Prenner<sup>2</sup>, V. Khungar<sup>2</sup>, P. Abt<sup>3</sup>, C. Sammons<sup>1</sup>, <sup>1</sup>Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA
- A336 † Evaluation of an Invasive Fungal Infection Prophylaxis Strategy after Liver Transplantation at a Large Academic Medical Center**  
M. Jorgenson<sup>1</sup>, J. Descourouez<sup>1</sup>, D. Felix<sup>1</sup>, N. Marka<sup>2</sup>, G. Levenson<sup>2</sup>, J. Smith<sup>2</sup>, L. Fernandez<sup>2</sup>, D. Foley<sup>2</sup>, <sup>1</sup>UW Health, Madison, WI, <sup>2</sup>University of Wisconsin School of Medicine and Public Health, Madison, WI
- A337 Profile of Invasive Fungal Disease after Kidney Transplantation in a Single Brazilian Center**  
S. C. Miranda, G. M. Pereira Junior, C. A. Felipe, A. S. Alvarenga, P. A. Macedo Souza, C. Ribeiro, S. C. Cantini, Nephrology, Santa Casa de Belo Horizonte, Belo Horizonte, Brazil
- A338 Is Exposure to Wildfires Associated with Invasive Fungal Infections?**  
J. S. Mulliken<sup>1</sup>, A. G. Rappold<sup>2</sup>, M. Fung<sup>1</sup>, J. M. Babik<sup>1</sup>, S. B. Doernberg<sup>1</sup>, <sup>1</sup>Division of Infectious Diseases, University of California San Francisco, San Francisco, CA, <sup>2</sup>National Health and Environmental Effects Research Laboratory, United States Environmental Protection Agency, Durham, NC
- A339 Target Itraconazole Trough Concentration for Prophylaxis in Lung Transplant**  
J. A. Morillas-Rodriguez<sup>1</sup>, H. Hassouna<sup>2</sup>, F. Marco-Canosa<sup>3</sup>, K. D. Brizendine<sup>1</sup>, <sup>1</sup>Infectious disease, Cleveland Clinic, Cleveland, OH, <sup>2</sup>Infectious disease, Spectrum health, Grand rapids, MI, <sup>3</sup>Cleveland Clinic, Cleveland, OH
- A340 Candida auris after Liver Transplant**  
N. M. Theodoropoulos, R. Ellison, J. S. Daly, A. Bozorgzadeh, D. A. Mack, L. Gibson, S. M. Levitz, University of Massachusetts Medical School, Worcester, MA

- A341 † CCR5-Mediated Recruitment of NK Cells to the Kidney is a Critical Step for Host Defense to Candida albicans Infection**  
H. R. Cho<sup>1</sup>, V. G. Tran<sup>2</sup>, N. N. Nguyen<sup>3</sup>, S. Lee<sup>4</sup>, S. W. Kang<sup>4</sup>, J. Kim<sup>4</sup>, H. J. Kim<sup>4</sup>, S. J. Park<sup>1</sup>, J. S. Lee<sup>5</sup>, B. Kwon<sup>6</sup>,  
<sup>1</sup>Department of Surgery, Ulsan University Hospital, Ulsan, Korea, Republic of, <sup>2</sup>School of Biological Sciences, University of Ulsan, Ulsan, Republic of Korea, Ulsan, Korea, Republic of, <sup>3</sup>School of Biological Sciences, University of Ulsan, Ulsan, Republic of Korea, Ulsan, Korea, Republic of, <sup>4</sup>Biomedical Research Center, Ulsan University Hospital, Ulsan, Korea, Republic of, <sup>5</sup>Division of Nephrology, Department of Internal Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of, <sup>6</sup>Biomedical Research Center, Ulsan University Hospital, School of Medicine, University of Ulsan, Ulsan, Korea, Republic of
- A342 Outbreak of Pneumocystis Pneumonia in a Transplant Center Linked to a Single Genotype of Pneumocystis jirovecii: Effects of Cytomegalovirus Infection and Allograft Rejection**  
S. Hosseini-Moghaddam<sup>1</sup>, S. Dufresne<sup>2</sup>, M. Shokoohi<sup>3</sup>, G. Singh<sup>1</sup>, E. HunterGutierrez<sup>1</sup>, P. Dufresne<sup>2</sup>, A. House<sup>1</sup>, P. Luke<sup>1</sup>, A. Nagpal<sup>1</sup>, P. Marotta<sup>1</sup>, A. Humar<sup>4</sup>, A. Jevnikar<sup>1</sup>, D. Kumar<sup>4</sup>,  
<sup>1</sup>Western University, LHSC, University Hospital, London, ON, Canada, <sup>2</sup>Maisonneuve-Rosemont Hospital, Université de Montréal, Montreal, QC, Canada, <sup>3</sup>Epidemiology and Biostatistics, Western University, London, ON, Canada, <sup>4</sup>University of Toronto, University Health Network, Toronto General Hospital, Toronto, ON, Canada
- A343 Evaluation of Pneumocystis jirovecii Pneumonia Prophylaxis among Kidney and Liver Transplant Recipients; Trimethoprim/Sulfamethoxazole vs Alternative Therapies**  
E. Aldag, C. Pagels, R. Pedersen, I. Nadeem, V. Gunabushanam, A. Sahajpal, T. J. Dilworth, Aurora St Luke's Medical Center, Milwaukee, WI
- A344 Pneumocystis Prophylaxis in Solid Organ Transplant Recipients at Two Large Transplant Centers from 2015-2016: Why Not Trimethoprim-Sulfamethoxazole?**  
J. M. Lum<sup>1</sup>, V. Athans<sup>2</sup>, I. Echenique<sup>3</sup>, C. E. Koval<sup>1</sup>, <sup>1</sup>Infectious Diseases, Cleveland Clinic Foundation, Cleveland, OH, <sup>2</sup>Infectious Diseases, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Infectious Diseases, Cleveland Clinic Florida, Weston, FL
- A345 Phylogenetic Analysis of the Epstein Barr Virus Nuclear Antigen-1 and Associated Correlates among Canadian Transplant Patients**  
M. Abdulnoor<sup>1</sup>, S. Isabel<sup>1</sup>, T. Paton<sup>1</sup>, N. Khodai-Booran<sup>1</sup>, T. Schechter<sup>1</sup>, P. Birk<sup>2</sup>, T. Blydt-Hansen<sup>3</sup>, B. Foster<sup>4</sup>, S. Mital<sup>1</sup>, V. Phan<sup>5</sup>, S. Urschel<sup>6</sup>, G. Casallo<sup>1</sup>, T. Papaz<sup>1</sup>, L. Hamiwka<sup>7</sup>, S. Min<sup>1</sup>, U. Allen<sup>1</sup>, <sup>1</sup>University of Toronto, Toronto, ON, Canada, <sup>2</sup>University of Manitoba, Winnipeg, MB, Canada, <sup>3</sup>University of British Columbia, Vancouver, BC, Canada, <sup>4</sup>McGill University, Montreal, QC, Canada, <sup>5</sup>University of Montreal, Montreal, QC, Canada, <sup>6</sup>University of Alberta, Edmonton, AB, Canada, <sup>7</sup>University of Calgary, Calgary, AB, Canada
- A346 Comparison of Proton Pump Inhibitors versus Histamine-2-Receptor Antagonists on Clostridium difficile Rates in Liver Transplant Recipients**  
S. Wiehe, K. Roach, A. Qamar, Lahey Hospital and Medical Center, Burlington, MA
- A347 † Predictors of Clostridium difficile Infection and Recurrence among 2,622 Solid Organ Transplant Recipients**  
A. Schluger, R. Rosenblatt, R. Knotts, E. Verna, M. Pereira, Columbia University, New York, NY

- A348 Burden of Respiratory Virus Infections in Solid-Organ Transplant Recipients: A Nationwide Multi-Season Cohort Study**  
M. Mombelli<sup>1</sup>, D. Neofytos<sup>2</sup>, J. Aubert<sup>1</sup>, C. Benden<sup>3</sup>, C. Berger<sup>3</sup>, K. Boggian<sup>4</sup>, A. Egli<sup>5</sup>, P. Gasche<sup>2</sup>, H. Hirsch<sup>5</sup>, C. Hirzel<sup>6</sup>, N. Mueller<sup>3</sup>, C. Van Delden<sup>2</sup>, O. Manuel<sup>1</sup>, <sup>1</sup>CHUV, Lausanne, Switzerland, <sup>2</sup>HUG, Geneva, Switzerland, <sup>3</sup>USZ, Zurich, Switzerland, <sup>4</sup>KSSG, St. Gallen, Switzerland, <sup>5</sup>USB, Basel, Switzerland, <sup>6</sup>ISB, Bern, Switzerland
- A349 Respiratory Viral Infections and Patient Outcomes in Solid Organ Transplant Recipients**  
M. Gonzalez<sup>1</sup>, A. Vostal<sup>1</sup>, N. Darling<sup>2</sup>, C. Papastamelos<sup>2</sup>, M. Natarajan<sup>3</sup>, P. Kumar<sup>3</sup>, J. Timpone<sup>3</sup>, <sup>1</sup>Internal Medicine, MedStar Georgetown University Medical Center, Washington, DC, <sup>2</sup>School of Medicine, Georgetown University, Washington, DC, <sup>3</sup>Infectious Disease, MedStar Georgetown University Medical Center, Washington, DC
- A350 The Impact of Pneumonia after Liver Transplant**  
N. M. Theodoropoulos, P. Mahboub, A. Bozorgzadeh, *University of Massachusetts Medical School, Worcester, MA*
- A351 Infectious Complications in Kidney Transplant Recipients Age 65 and Older**  
L. E. Liriano-Ward<sup>1</sup>, M. Barbachan e Silva<sup>2</sup>, Y. Azzi<sup>1</sup>, M. Ajaimy<sup>1</sup>, A. Cambell<sup>1</sup>, J. Graham<sup>1</sup>, J. Rocca<sup>1</sup>, C. Pynadath<sup>1</sup>, G. Nair<sup>1</sup>, O. Andacoglu<sup>1</sup>, S. Greenstein<sup>1</sup>, P. Ó Broin<sup>2</sup>, E. Akalin<sup>1</sup>, <sup>1</sup>Transplant, Einstein/Montefiore Medical Center, Bronx, NY, <sup>2</sup>School of Mathematics, Statistics & Applied Mathematics, National University of Ireland Galway, Galway, Ireland
- A352 Patterns Of Anti-retroviral Use Among U.s. Liver Transplant Candidates With Hiv**  
A. A. Shaffer<sup>1</sup>, A. G. Thomas<sup>2</sup>, D. L. Segev<sup>3</sup>, <sup>1</sup>Johns Hopkins University, Baltimore, MD, <sup>2</sup>Epidemiology, University of North Carolina, Chapel Hill, NC, <sup>3</sup>Surgery & Epidemiology, Johns Hopkins University, Baltimore, MD
- A353 Treatment of Pseudomonas Infection with Beta-Lactams Including Ceftolozane-Tazobactam in Solid Organ Transplant Recipients**  
M. Henry<sup>1</sup>, J. Puvvula<sup>2</sup>, J. John Schoen<sup>1</sup>, L. Puzniak<sup>3</sup>, J. Raddatz<sup>4</sup>, T. Van Schooneveld<sup>2</sup>, S. Bergman<sup>1</sup>, <sup>1</sup>Nebraska Medicine, Omaha, NE, <sup>2</sup>University of Nebraska Medical Center, Omaha, NE, <sup>3</sup>Merck & Co., Inc, Kenilworth, NJ, <sup>4</sup>Merck & Co., Inc, Kenilworth, NJ, NJ
- A354 Efficacy of Filgrastim in Solid Organ Transplant Recipients**  
M. Spinner<sup>1</sup>, K. Gaffney<sup>1</sup>, S. Gundling<sup>2</sup>, <sup>1</sup>Pharmacy, Cleveland Clinic, Cleveland, OH, <sup>2</sup>University of Pittsburgh School of Pharmacy, Pittsburgh, PA
- A355 A Nurse-Driven Influenza Vaccine Ordering Protocol Improves Vaccination Rates in Abdominal Organ Transplant Recipients**  
T. Ho<sup>1</sup>, C. D. Sifri<sup>2</sup>, J. D. Lewis<sup>3</sup>, <sup>1</sup>Department of Medicine, Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, <sup>3</sup>Division of Infectious Diseases, Medical University of South Carolina, Charleston, SC
- A356 Need For Protocol Driven Mmr/vzv Serologic Screening**  
A. Agarwal<sup>1</sup>, L. Brumble<sup>1</sup>, H. Wade<sup>2</sup>, C. Libertin<sup>1</sup>, <sup>1</sup>Department of Medicine, Division of Infectious Diseases, Mayo Clinic, Jacksonville, FL, <sup>2</sup>Department of Transplant, Mayo Clinic, Jacksonville, FL
- A357 Impact of a Short Duration, Narrow Spectrum Perioperative Antibiotic Prophylaxis Regimen on Multi-Drug Resistant Surgical Site Infections in Adult Orthotopic Liver Transplantation**  
M. John<sup>1</sup>, K. Maguigan<sup>1</sup>, D. Schain<sup>2</sup>, E. Thomas<sup>3</sup>, P. Efron<sup>4</sup>, J. Nelson<sup>5</sup>, <sup>1</sup>Pharmacy, UF Health Shands Hospital, Gainesville, FL, <sup>2</sup>Infectious Diseases, UF Health Shands Hospital, Gainesville, FL, <sup>3</sup>Transplant Surgery, University Health System, San Antonio, TX, <sup>4</sup>Surgery, UF Health Shands Hospital, Gainesville, FL, <sup>5</sup>Pharmacy, University Health System, San Antonio, TX



- A358 Daptomycin Perioperative Prophylaxis for Prevention of Vancomycin-Resistant Enterococcus Infection in VRE-Colonized Liver Transplant Recipients during the Early Post-Transplant Period**  
S. Sarwar, S. Gleeson, M. Malinis, M. M. Azar, *Section of Infectious Diseases, Department of Medicine, Yale School of Medicine, New Haven, CT*
- A359 Impact of Vancomycin-Resistant Enterococci Gut Colonization on Liver Transplant Outcomes**  
D. Chiang, T. C. Dingle, S. Belga, D. Kabbani, J. Walter, J. G. Abraldes, C. Cervera, *University of Alberta, Edmonton, AB, Canada*
- A360 Infectious Complications in 71 Heart Transplant Recipients at King Chulalongkorn Memorial Hospital, Thailand**  
N. Sangpornasuk<sup>1</sup>, J. Wanichwatphibun<sup>2</sup>, A. Ariyachaipanich<sup>3</sup>, P. Ongcharit<sup>4</sup>, K. Jutivorakool<sup>5</sup>, J. Vanichanan<sup>5</sup>, <sup>1</sup>*Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand,* <sup>2</sup>*Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand,* <sup>3</sup>*Excellent Center for Organ Transplantation, King Chulalongkorn Memorial Hospital, Bangkok, Thailand,* <sup>4</sup>*Cardiothoracic Surgery Unit, Department of Surgery, King Chulalongkorn Memorial Hospital, Bangkok, Thailand,* <sup>5</sup>*Division of Infectious Diseases, Department of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand*
- A361 Infective Complications after Renal Transplantation - A Single Centre Experience Comparing Alemtuzumab to Basiliximab Induction**  
R. Czajka, M. Welberry Smith, M. Gittus, E. Lindley, M. Vernon, *Renal Medicine, St James' University Hospital, Leeds, United Kingdom*
- A362 Cholecystitis in High-Acuity Patients Undergoing Liver Transplantation: A Five-Year Analysis of Incidence, Causes and Impact**  
D. S. Graham, T. Ito, M. M. Lu, J. DiNorcia, V. G. Agopian, H. Yersiz, D. G. Farmer, R. W. Busuttil, F. M. Kaldas, *Dumont-UCLA Liver Transplant Center, Department of Surgery, UCLA School of Medicine, Los Angeles, CA*
- A363 The Economic Impact of Surgical Site Infections in Liver Transplantation**  
Y. Natori<sup>1</sup>, D. Kumar<sup>2</sup>, A. Humar<sup>2</sup>, S. Husain<sup>2</sup>, C. Rotstein<sup>3</sup>, <sup>1</sup>*Miami Transplant Institute, University of Miami, Miami, FL,* <sup>2</sup>*Transplant Infectious Diseases, University of Toronto, Toronto, ON, Canada,* <sup>3</sup>*University of Toronto, Toronto, ON, Canada*
- A364 HTLV Screening among Solid Organ Transplant Candidates at a Large Transplant Center**  
J. Simkins<sup>1</sup>, J. A. Morillas-Rodriguez<sup>1</sup>, M. I. Morris<sup>1</sup>, L. M. Abbo<sup>1</sup>, J. F. Camargo<sup>1</sup>, S. Anjan<sup>1</sup>, W. Kupin<sup>1</sup>, P. Ruiz<sup>2</sup>, C. Fernandez-Bango<sup>2</sup>, J. C. Ramos<sup>1</sup>, <sup>1</sup>*Medicine, University of Miami, Miami, FL,* <sup>2</sup>*Surgery, University of Miami, Miami, FL*
- A365 Donor Derived Cell Free DNA (dd-cfDNA) May Aid in the Diagnosis of BK Virus Nephropathy**  
D. Brennan<sup>1</sup>, J. Bromberg<sup>2</sup>, J. Yee<sup>3</sup>, S. Dholakia<sup>3</sup>, M. Haas<sup>4</sup>, <sup>1</sup>*Johns Hopkins, Baltimore, MD,* <sup>2</sup>*University of Maryland School of Medicine, Baltimore, MD,* <sup>3</sup>*CareDx, Brisbane, CA,* <sup>4</sup>*Cedars-Sinai Medical Center, Los Angeles, CA*
- A366 Real-Life Food Safety Behavior and Incidence of Food-Borne Infections in Solid-Organ Transplant Recipients**  
M. Lindup, D. Golshayan, M. Pascual, O. Manuel, M. Mombelli, *CHUV, Lausanne, Switzerland*
- A367 † Perceptions and Attitude of Transplant Clinicians towards Antimicrobial Resistance and Stewardship in Transplant Recipients: A Survey of the American Society of Transplantation**  
M. So<sup>1</sup>, J. Hand<sup>2</sup>, M. Richmond<sup>1</sup>, A. Morris<sup>3</sup>, S. Husain<sup>1</sup>, <sup>1</sup>*University Health Network, Toronto, ON, Canada,* <sup>2</sup>*Ochsner Medical Center, New Orleans, LA,* <sup>3</sup>*Sinai Health System, Toronto, ON, Canada*



**A368**

**Vaccination And Allosensitization In  
Solid Organ Transplant Candidates**

L. Lourenco<sup>1</sup>, K. B. Bain<sup>2</sup>, L. Bowman<sup>3</sup>,  
D. C. Brennan<sup>4</sup>, G. A. Ewald<sup>5</sup>, R. R.  
Hachem<sup>6</sup>, <sup>1</sup>*Pharmacy, University  
of Chicago Medicine, Chicago, IL,*  
<sup>2</sup>*Pharmacy, Barnes-Jewish Hospital, St.  
Louis, MO,* <sup>3</sup>*Pharmacy, Tampa General  
Hospital, Tampa, FL,* <sup>4</sup>*Internal Medicine,  
The Johns Hopkins School of Medicine,  
Baltimore, MD,* <sup>5</sup>*Heart Failure and Heart  
Transplantation, Washington University  
School of Medicine, St. Louis, MO,*  
<sup>6</sup>*Pulmonary and Critical Care Medicine,  
Washington University School of  
Medicine, St. Louis, MO*

## Poster Session B: Ischemia Reperfusion & Organ Rehabilitation

Poster Viewing: 6:00 pm - 7:00 pm  
Presenters in Attendance: 6:00 pm - 7:00 pm  
Hall C & D

A# indicates the board location where the poster will be displayed.

† Those posters identified as an ATC Poster of Distinction by this symbol have received review scores that place them in the top 10% of their category. The Planning Committee encourages you to make them a priority when you visit the poster session.

- B1** **Erk-*elk1*-mir-711 Signalling In Cardiac Ischemia Reperfusion Injury In Heart Transplantation**  
H. Zheng, Y. Su, C. Zhu, V. Veramkovich, X. Zheng, *Pathology, University of Western Ontario, London, ON, Canada*
- B2** **Treprostinil Attenuates Renal Ischemia-Reperfusion Injury in Rat**  
M. Ding<sup>1</sup>, E. Tolbert<sup>2</sup>, M. Birkenbach<sup>3</sup>, C. Chung<sup>4</sup>, R. Gohh<sup>5</sup>, F. Akhlaghi<sup>1</sup>, N. Ghonem<sup>1</sup>, <sup>1</sup>*Biomedical and Pharmaceutical Sciences, URI, Kingston, RI*, <sup>2</sup>*Nephrology, Rhode Island Hospital, Providence, RI*, <sup>3</sup>*Pathology, Rhode Island Hospital, Providence, RI*, <sup>4</sup>*Surgery, Rhode Island Hospital, Providence, RI*, <sup>5</sup>*Organ Transplantation, Rhode Island Hospital, Brown University, KINGSTON, RI*
- B3** **Combined Ischemic and Rapamycin Preconditioning Alleviated Liver Ischemia and Reperfusion Injury by Restoring Autophagy in Old Mice**  
Z. Rao, X. Pan, W. Zhong, Z. Ding, H. Zhou, C. Liu, *The First Affiliated Hospital of Nanjing Medical University, Nanjing, China*
- B4** **Epithelial to Mesenchymal Transition: A Cellular Mediator of Ischemic Cholangiopathy after Liver Transplant**  
N. A. Wickramaratne<sup>1</sup>, R. Li<sup>2</sup>, R. C. Fyffe-Freil<sup>2</sup>, T. Tian<sup>2</sup>, M. J. Mangino<sup>2</sup>, <sup>1</sup>*VCUHealth, Richmond, VA*, <sup>2</sup>*Department of Surgery, VCUHealth, Richmond, VA*

- B5** **Long Term Cold Ischemia Time in Kidney Transplantation. The Role of Hypothermic Machine Perfusion**  
G. ADANI<sup>1</sup>, U. Baccarani<sup>1</sup>, P. Tulissi<sup>2</sup>, C. Vallone<sup>2</sup>, A. Risaliti<sup>1</sup>, <sup>1</sup>*General Surgery and Transplantation, Academic Hospital P. le S.M. della Misericordia, 33100 Udine, Italy, Udine, Italy*, <sup>2</sup>*Nephrology, Dialysis and Kidney Transplantation, Academic Hospital P. le S.M. della Misericordia, 33100 Udine, Italy, Udine, Italy*

- B6** **Effects of Omega-3 Fatty Acids on Outcome after Living Donor Right Hepatectomy**  
S. Lee, J. Kim, G. Choi, J. Joh, S. Lee, *Department of Surgery, Samsung Medical Center, Seoul, Korea, Republic of*

- B7** **Activation of Oxidative Stress-Adoptive Responses during Extended Ex Situ Heart Perfusion**  
S. Hatami, X. Qi, M. Buchko, C. W. White, S. Bozso, S. Himmat, J. Nagendran, D. H. Freed, *Department of Surgery, University of Alberta, Edmonton, AB, Canada*

- B8** **Fractalkine is Crucial in Ischemia Reperfusion Injury Related to Acute Rejection in an Allogeneic Heart Transplantation Model**  
T. Kanzawa<sup>1</sup>, D. Tokita<sup>1</sup>, T. Yamakawa<sup>1</sup>, H. Ishigooka<sup>1</sup>, H. Fukuda<sup>1</sup>, H. Katsumata<sup>1</sup>, S. Miyairi<sup>1</sup>, R. Ishii<sup>1</sup>, T. Hirai<sup>1</sup>, K. Saiga<sup>1</sup>, M. Okumi<sup>1</sup>, T. Imai<sup>2</sup>, K. Tanabe<sup>1</sup>, <sup>1</sup>*Urology, Tokyo Women's Medical University, Tokyo, Japan*, <sup>2</sup>*KAN Research Institute, Kobe, Japan*

- B9** **Phenotype and Course of Renal Tubular Cell Death during Cold Ischemia versus Cold Ischemia Followed by Transplant**  
S. Jain<sup>1</sup>, R. Plenter<sup>2</sup>, T. Nydam<sup>2</sup>, A. Jani<sup>1</sup>, <sup>1</sup>*Renal Division, University of Colorado, Aurora, CO*, <sup>2</sup>*Transplant Microsurgery Program, University of Colorado, Aurora, CO*

- B10**      **Hypothermic Machine Perfusion Protects Donation After Cardiac Death Liver Graft Through Gstm1-mediated Cytochrome P450 Exogenous Substance Metabolism Pathway**  
*W. Liang, S. Ye, Z. Zhong, Q. Hu, Y. Wang, Q. Ye, Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases, Wuhan, China*
- B11**      **Inhibition of TLR4 Mediated Programmed Necrosis Does Not Improve Graft Function and Histology in a Murine Kidney Transplant Model**  
*S. Jain<sup>1</sup>, R. Plenter<sup>2</sup>, T. Nydam<sup>2</sup>, A. Jani<sup>1</sup>, <sup>1</sup>Renal Division, University of Colorado, Aurora, CO, <sup>2</sup>Transplant Microsurgery Program, University of Colorado, Aurora, CO*
- B12**      **New Reactive Oxygen Species Scavenger Prevents Injury in Ischemia-Reperfusion Injury Model**  
*N. Bath, W. Fahl, R. Redfield III, University of Wisconsin, Madison, WI*
- B13**      **Quantitative Proteomics Analysis of Ischemia Reperfusion Injured Liver Tissue Provides Insight into Liver Allograft Quality Evaluation**  
*M. Chen, M. Han, W. Ju, Q. Zhao, D. Wang, Z. Guo, X. He, Transplant Center, Sun Yat-sen University, Guangzhou, China*
- B14**      **Damage-Associated Molecular Pattern Release and Toll-Like Receptor Activation during Cold Storage and Ex Vivo Reperfusion of Old Rat Livers**  
*U. Scheuermann, E. R. Seyferth, M. Zhu, M. Song, J. Yerxa, R. P. Davis, W. Parker, M. Hartwig, J. Kwun, J. Lee, A. S. Barbas, Department of Surgery, Duke University Medical Center, Durham, NC*
- B15 †**     **Normothermic Machine Perfusion of Human Kidneys without an Oxygen Carrier**  
*D. Detelich, C. Eymard, M. Aburawi, C. Carroll, K. Uygun, H. Yeh, J. F. Markmann, Massachusetts General Hospital, Boston, MA*
- B16**      **Role of Mitochondria, Metabolism and Inflammation: Pathways Influencing Short Term Outcomes Post-Renal Transplantation**  
*S. Bontha<sup>1</sup>, A. Bajwa<sup>1</sup>, G. Lorenzo<sup>2</sup>, J. Eason<sup>3</sup>, D. Maluf<sup>4</sup>, V. Mas<sup>5</sup>, <sup>1</sup>Surgery, UTHSC, Memphis, TN, <sup>2</sup>Northwestern University, Chicago, IL, <sup>3</sup>Director of Transplant Institute UTHSC, Memphis, TN, <sup>4</sup>UTHSC, Memphis, TN, <sup>5</sup>Director of Transplant Research Institute, Memphis, TN*
- B17**      **Stabilization of Cell Junctions Ameliorates the Effects of Brain Death Induced Acute Lung Injury Post-Transplantation**  
*D. P. Allen<sup>1</sup>, Z. Tu<sup>1</sup>, C. Wallace<sup>1</sup>, C. Li<sup>1</sup>, J. Kilkenny<sup>1</sup>, K. J. Patel<sup>1</sup>, D. Nord<sup>2</sup>, S. N. Nadig<sup>1</sup>, C. Atkinson<sup>2</sup>, <sup>1</sup>Surgery, Medical University of South Carolina, CHARLESTON, SC, <sup>2</sup>Microbiology & Immunology, Medical University of South Carolina, CHARLESTON, SC*
- B18**      **Microvascular Rarefaction and Long-Term Graft Dysfunction in Kidney Transplant Recipients with Delayed Graft Function**  
*A. Doreille, S. Larivière-Beaudoin, A. Karakeussian-Rimbaud, M. Hébert, M. Dieudé, N. Patey, H. Cardinal, <sup>1</sup>Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada*
- B19**      **Pgc1 $\alpha$  Protects against Graft Ischemic Injury and Reduces Alloimmunity**  
*T. J. Borges<sup>1</sup>, M. T. Tran<sup>2</sup>, S. Cai<sup>1</sup>, N. Murakami<sup>1</sup>, A. Uffing<sup>1</sup>, M. Uehara<sup>1</sup>, E. P. Rhee<sup>3</sup>, S. M. Parikh<sup>4</sup>, L. V. Riella<sup>1</sup>, <sup>1</sup>Schuster Transplantation Research Center, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, <sup>2</sup>Division of Nephrology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, <sup>3</sup>Nephrology Division, Massachusetts General Hospital, Boston, MA, <sup>4</sup>Division of Nephrology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA*

- B20** **CD47 Blockade Promotes Hepatic Macrophage Polarization toward M1 during Normothermic Machine Perfusion of Discarded Human Livers**  
M. Xu<sup>1</sup>, F. Zhou<sup>1</sup>, S. Garcia-Aroz<sup>1</sup>, B. Banan<sup>1</sup>, W. Yang<sup>2</sup>, G. Upadhyay<sup>1</sup>, K. Byrnes<sup>3</sup>, B. Wong<sup>1</sup>, P. Manning<sup>4</sup>, Y. Lin<sup>1</sup>, W. Chapman<sup>1</sup>, <sup>1</sup>Department of Surgery, Washington University School of Medicine, St. Louis, MO, <sup>2</sup>Department of Genetics, Washington University School of Medicine, St. Louis, MO, <sup>3</sup>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, <sup>4</sup>Arch Oncology, St. Louis, MO, USA, St. Louis, MO
- B21** **Impact of an Intra-Abdominal Cooling Device during Open Kidney Transplantation in Pigs**  
A. Longchamp<sup>1</sup>, R. P. Meier<sup>2</sup>, N. Colucci<sup>3</sup>, A. Balaphas<sup>3</sup>, L. Orci<sup>3</sup>, A. Nastasi<sup>3</sup>, G. Longchamp<sup>1</sup>, S. Moll<sup>4</sup>, A. Klauser<sup>5</sup>, F. Lazeyras<sup>5</sup>, M. Pascual<sup>6</sup>, J. Corpataux<sup>7</sup>, L. Bühler<sup>8</sup>, <sup>1</sup>Department of Vascular Surgery, CHUV, Lausanne, Switzerland, <sup>2</sup>Department of Surgery, University of California San Francisco, San Francisco, CA, <sup>3</sup>Department of Surgery, HUG, Geneva, Switzerland, <sup>4</sup>Department of Pathology, HUG, Geneva, Switzerland, <sup>5</sup>Department of Radiology, HUG, Geneva, Switzerland, <sup>6</sup>Department of Transplantation, CHUV, Lausanne, Switzerland, <sup>7</sup>Department of Vascular Surgery, CHUV, Lausanne, Switzerland, <sup>8</sup>Department of Surgery, CHUV, Lausanne, Switzerland
- B22** **Estrogen Mediated Protection in Renal Ischemia Reperfusion Injury (IRI) is Extrinsic to the Kidney**  
D. D. Aufhauser<sup>1</sup>, S. J. Concors<sup>1</sup>, P. T. Hernandez<sup>1</sup>, Z. Wang<sup>1</sup>, L. Krumeich<sup>1</sup>, D. R. Murken<sup>1</sup>, G. Ge<sup>1</sup>, W. W. Hancock<sup>2</sup>, M. H. Levine<sup>1</sup>, <sup>1</sup>Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Pathology, Children's Hospital of Philadelphia, Philadelphia, PA
- B23** **Metabolic Profiling of Steatotic Human Livers during Ex-Vivo Normothermic Machine Perfusion**  
S. Raigani<sup>1</sup>, N. Karimian<sup>2</sup>, V. Huang<sup>2</sup>, S. Geerts<sup>2</sup>, S. Nagpal<sup>2</sup>, K. Uygun<sup>1</sup>, M. Yarmush<sup>1</sup>, H. Yeh<sup>1</sup>, <sup>1</sup>Transplant Surgery, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Center for Engineering in Medicine, Shriners Childrens Hospital, Boston, MA
- B24** **Ceria-Zirconia Nanoparticles as an Enhanced Antioxidant Attenuates Apoptosis of Human Kidney Proximal Tubular Epithelial Cells in Hypoxia**  
S. Yoon<sup>1</sup>, K. Yoon<sup>2</sup>, S. Hong<sup>3</sup>, S. Yun<sup>1</sup>, W. Hwang<sup>1</sup>, J. Moon<sup>4</sup>, J. Lee<sup>1</sup>, H. Jeon<sup>1</sup>, <sup>1</sup>Nephrology, Konyang University Hospital, Daejeon, Korea, Republic of, <sup>2</sup>Hannam University, Daejeon, Korea, Republic of, <sup>3</sup>Chemistry, Hannam University, Daejeon, Korea, Republic of, <sup>4</sup>General Surgery, Konyang University Hospital, Daejeon, Korea, Republic of
- B25** **Histone Deacetylase-8 (HDAC8) Inhibition is Protective in a Murine Model of Renal Ischemia Reperfusion Injury (IRI)**  
P. T. Hernandez<sup>1</sup>, S. J. Concors<sup>1</sup>, D. D. Aufhauser<sup>1</sup>, L. Krumeich<sup>1</sup>, Z. Wang<sup>1</sup>, G. Ge<sup>1</sup>, A. Beeler<sup>2</sup>, M. Levine<sup>1</sup>, W. Hancock<sup>3</sup>, <sup>1</sup>Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Chemistry, Boston University, Boston, MA, <sup>3</sup>Children's Hospital of Philadelphia, Philadelphia, PA
- B26 †** **Transfer of Healthy Mitochondria in Established Ischemic Injury Reduces Progression to Interstitial Fibrosis and Tubular Atrophy**  
A. Bajwa<sup>1</sup>, V. Bontha<sup>1</sup>, D. Maluf<sup>1</sup>, J. Eason<sup>2</sup>, V. Mas<sup>3</sup>, <sup>1</sup>UTHSC, Memphis, TN, <sup>2</sup>Director of Transplant Institute, Memphis, TN, <sup>3</sup>Director of Transplant Research Institute, Memphis, TN
- B27 †** **Ischemia-Free Liver Transplantation Protects Bile Duct from Ischemia/Reperfusion Injury**  
J. Yang, S. Huang, Z. Zhang, Q. Zhao, W. Ju, Z. Zhu, Y. Tang, L. Wang, Y. Zhang, C. Sun, L. Wu, Z. Guo, X. He, Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

**B28**      **Cryopreservation Allows for Extended Graft Survival in a Rat Orthotopic Hind Limb Model**  
S. A. Fidler<sup>1</sup>, B. Oh<sup>1</sup>, F. Messner<sup>1</sup>, G. Furtmueller<sup>1</sup>, K. Helke<sup>2</sup>, E. Greene<sup>3</sup>, Z. Chen<sup>3</sup>, L. Campbell<sup>3</sup>, G. Brandacher<sup>1</sup>, K. Brockbank<sup>3</sup>, <sup>1</sup>*Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD*, <sup>2</sup>*Department Of Comparative Medicine, Medical University of South Carolina, Charleston, SC*, <sup>3</sup>*Tissue Testing Technologies LLC, Charleston, SC*

**B29 †**    **Sequestration of PLIN2 Regulates High-Fat Diet Induced Metabolic Syndrome and Nonalcoholic Fatty Liver Disease in a Mouse Model of Ischemia Reperfusion Injury**  
K. Loh<sup>1</sup>, X. Liu<sup>1</sup>, L. Belyayev<sup>1</sup>, C. Albanese<sup>2</sup>, W. Cui<sup>1</sup>, T. M. Fishbein<sup>1</sup>, K. M. Khan<sup>1</sup>, A. Kroemer<sup>1</sup>, <sup>1</sup>*Transplant, MedStar Georgetown Transplant Institute, Washington, DC*, <sup>2</sup>*Oncology, Georgetown University, Washington, DC*

**B30**      **The Impact of Thrombin / Protease-Activated Receptor-1 Pathway in Hepatic Ischemia-Reperfusion Injury in Mice**  
D. Noguchi, N. Kuriyama, T. Fujii, H. Kato, M. Kishiwada, S. Mizuno, M. Usui, H. Sakurai, S. Isaji, *Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan*

## Poster Session B: Biomarkers, Immune Monitoring and Outcomes

---

**B31**      **Predicting Risk of Cytomegalovirus with Viral-Antigen-Specific CD154+ T-cells after Liver or Intestine Transplantation**  
C. Ashokkumar, K. Soltys, M. Green, G. Mazariegos, G. Bond, K. Jones, A. Rzepoluch, M. Zaccagnini, P. Sethi, B. W. Higgs, R. Sindhi, *Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, PA*

**B32**      **Long-Term Exposure to Particulate Matter Air Pollution and the Risk of Graft Failure and Mortality in Kidney Transplant Recipients**  
Y. Kim<sup>1</sup>, S. Kwon<sup>1</sup>, J. Park<sup>2</sup>, J. Lee<sup>3</sup>, <sup>1</sup>*Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of*, <sup>2</sup>*Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Korea, Republic of*, <sup>3</sup>*Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea, Republic of*

**B33**      **A Robust and Portable Protocol for RNA Isolation from Urinary Cells for Noninvasive Monitoring of Kidney Allograft Recipients**  
B. Botticelli, S. Albakry, E. Edusei, H. Yang, M. Cassidy, C. Li, C. Snopkowski, M. Lubetzky, J. Lee, D. Dadhania, T. Muthukumar, M. Suthanthiran, *Weill Cornell, New York, NY*

**B34**      **The Molecular Profile of Kidney Allografts Unveil Specific Biomarkers for Subclinical Acute Rejection (SAR). Towards an Early Detection and a Targeted Treatment**  
S. N. Cox, S. Chiurlia, F. P. Schena, *Schena Foundation, Valenzano-Bari, Italy*

**B35**      **Donor Management in Donation after Brain Death: A Window of Opportunity - Are Pro-Inflammatory Mediators the Target and What is the Effect of Duration of Brain Death?**  
K. D. Bera<sup>1</sup>, J. Tabak<sup>2</sup>, M. L. Lo Faro<sup>1</sup>, R. J. Ploeg<sup>1</sup>, <sup>1</sup>*Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom*, <sup>2</sup>*University of Exeter, Exeter, United Kingdom*

**B36**      **miRNA Signatures as Prediction Tool for DSA Development and Rejection**  
M. Hamdorf<sup>1</sup>, L. M. Rebellato<sup>2</sup>, K. P. Briley<sup>2</sup>, M. J. Everly<sup>1</sup>, <sup>1</sup>*Terasaki Research Institute, Los Angeles, CA*, <sup>2</sup>*East Carolina University, Greenville, NC*



- B37 † Viability Testing and Transplantation of Marginal Donor Livers (VITTAL) Trial Outcomes: Proteomic Analysis of Perfusates from Livers Undergoing Normothermic Machine Liver Perfusion Reveals Biomarkers Predictive of Graft Viability and Post-Transplant Complications**  
S. Afford<sup>1</sup>, L. Wallace<sup>1</sup>, J. Attard<sup>1</sup>, Y. Boteon<sup>1</sup>, R. Laing<sup>1</sup>, J. Yu<sup>2</sup>, T. Perera<sup>3</sup>, D. Mirza<sup>4</sup>, H. Mergental<sup>5</sup>, <sup>1</sup>Centre for Liver and Gastroenterology Research, University of Birmingham, Birmingham, United Kingdom, <sup>2</sup>The School of Biosciences Proteomics Facility, University of Birmingham, Birmingham, United Kingdom, <sup>3</sup>Liver Unit, Queen Elizabeth University Hospital, Birmingham, United Kingdom, <sup>4</sup>Liver Unit, The Queen Elizabeth University Hospital, Birmingham, United Kingdom, <sup>5</sup>The Liver Unit, Queen Elizabeth University Hospital, Birmingham, United Kingdom
- B38 A Prognostic Drug Development Tool to Assess the Transplantability at the Time of Listing for Kidney Transplant Candidates**  
S. Kawakita<sup>1</sup>, L. Hidalgo-Semlek<sup>2</sup>, J. L. Beaumont<sup>1</sup>, J. Lee<sup>2</sup>, M. J. Everly<sup>1</sup>, <sup>1</sup>Terasaki Research Institute, Los Angeles, CA, <sup>2</sup>Hansa Medical AB, Lund, Sweden
- B39 Impact of a Novel Digital Medicine Program on Adherence and Utilization in Pediatric Transplant Patients**  
S. Sullivan<sup>1</sup>, K. N. Triplett<sup>1</sup>, C. Sacks<sup>2</sup>, M. Tran<sup>2</sup>, D. M. Desai<sup>3</sup>, <sup>1</sup>Solid Organ Transplant, Children's Medical Center, Dallas, Dallas, TX, <sup>2</sup>Proteus Digital Health, Redwood City, CA, <sup>3</sup>Transplant Surgery, University of Texas Southwestern Medical Center at Dallas, Dallas, TX
- B40 CMV-Specific Cell-Mediated Immunity Early after Transplantation Discriminates R+ Transplant Patients at Risk of CMV Infection among Different Solid Organ Transplants**  
M. Jarque<sup>1</sup>, A. Cachero<sup>2</sup>, E. Garcia-Romero<sup>3</sup>, L. Lladó<sup>2</sup>, C. Baliellas<sup>2</sup>, C. Diez<sup>3</sup>, E. Melilli<sup>4</sup>, J. Fabregat<sup>2</sup>, J. Gonzalez-Costello<sup>3</sup>, O. Bestard<sup>4</sup>, <sup>1</sup>Experimental Nephrology laboratory, IDIBELL, L'Hospitalet de Llobregat. Barcelona, Spain, <sup>2</sup>Liver Transplant Department, Bellvitge University Hospital, L'Hospitalet de Llobregat. Barcelona, Spain, <sup>3</sup>Heart Transplant Unit, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat. Barcelona, Spain, <sup>4</sup>Kidney Transplantation Unit, Bellvitge University Hospital- IDIBELL, L'Hospitalet de Llobregat. Barcelona, Spain
- B41 Urinary Podocin mRNA as Predictor of Renal Allograft Function Decline**  
A. Naik<sup>1</sup>, J. Aqeel<sup>1</sup>, D. Cibrik<sup>2</sup>, M. Samaniego<sup>3</sup>, L. Wickman<sup>1</sup>, S. Wang<sup>1</sup>, M. Chowdhury<sup>1</sup>, R. Wiggins<sup>1</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>University of Kansas, Kansas City, KS, <sup>3</sup>Henry Ford, Detroit, MI
- B42 † Characterization of Circulating T-cell Specific Exosomes during Acute Rejection in Murine Heart Transplantation Model**  
R. Hu<sup>1</sup>, V. Korutla<sup>1</sup>, L. Korutla<sup>1</sup>, S. Rostami<sup>1</sup>, A. Habertheuer<sup>1</sup>, S. Addya<sup>2</sup>, J. Harmon<sup>1</sup>, P. Zielinski<sup>1</sup>, S. Reddy<sup>1</sup>, A. Freas<sup>1</sup>, C. Ram<sup>1</sup>, A. Naji<sup>1</sup>, P. Vallabhajosyula<sup>1</sup>, <sup>1</sup>Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Thomas Jefferson University, Philadelphia, PA
- B43 The Negative Costimulatory Pd-1/pd-I1 Pathway Is Upregulated In Early Cell-mediated Rejection**  
T. Kurashige, R. Khedraki, K. Keslar, N. Dvorina, W. Baldwin, Cleveland Clinic Main Campus, Lerner Research Institute, Cleveland, OH

- B44**      **Dissecting The Role Of Donor Acute Kidney Injury On Molecular Responses Post-transplantation**  
 S. Bontha<sup>1</sup>, D. Maluf<sup>1</sup>, E. Akalin<sup>2</sup>, L. Gallon<sup>3</sup>, J. Eason<sup>4</sup>, V. Mas<sup>5</sup>, <sup>1</sup>UTHSC, Memphis, TN, <sup>2</sup>Albert Einstein Medical College, Bronx, NY, <sup>3</sup>Northwestern University, Chicago, IL, <sup>4</sup>Director of Transplantation, Memphis, TN, <sup>5</sup>Director of Transplant Research, Memphis, TN
- B45 †**      **Immunobiogram, a New IVD Immunoassay to Test the Sensitivity Profile of Kidney Transplant Recipients to Immunosuppressive Drugs: Further Results from BH-Pilot Study**  
 C. Jimenez<sup>1</sup>, J. M. Portoles<sup>2</sup>, D. Blázquez<sup>3</sup>, L. Arribas<sup>3</sup>, A. Ortega<sup>4</sup>, T. Diez<sup>5</sup>, I. Portero<sup>6</sup>, <sup>1</sup>Nephrology Department, La Paz Hospital, Madrid, Spain, <sup>2</sup>Nephrology Department, Puerta de Hierro Mahadahonda Hospital, Madrid, Spain, <sup>3</sup>Adamas Engineering Consulting, Madrid, Spain, <sup>4</sup>I+D, Biohope, Madrid, Spain, <sup>5</sup>Medical, Biohope, Madrid, Spain, <sup>6</sup>CEO, Biohope, Madrid, Spain
- B46**      **Increased Ratio of Circulating Tfh for Tfr Cells in Chronic Renal Allograft Dysfunction: A Pilot Study**  
 L. Yan, Y. Li, Y. Li, X. Wu, X. Wang, L. Wang, Y. Shi, J. Tang, West China Hospital OF Sichuan University, Chengdu, China
- B47**      **Urinary Extracellular Vesicles-Related Protein Biomarkers for the Non-Invasive Monitoring of Rejection in Kidney Transplanted Patients**  
 L. Carreras-Planella<sup>1</sup>, I. Bancu<sup>2</sup>, D. Cucchiari<sup>3</sup>, L. Cañas<sup>2</sup>, J. Juega<sup>2</sup>, M. Franquesa<sup>1</sup>, M. Perez-Mir<sup>2</sup>, I. Revuelta<sup>3</sup>, F. Diekman<sup>4</sup>, R. Lauzurica<sup>2</sup>, F. Borràs<sup>1</sup>, <sup>1</sup>REMAR-IVECAT Group, Institut Germans Trias i Pujol, Badalona, Spain, <sup>2</sup>Nephrology- Renal Transplant Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, <sup>3</sup>Dept. Nefrologia i Trasplantament Renal, Institut Clínic de Nefrologia i Urologia (ICNU), Hospital Clinic, Barcelona, Spain, <sup>4</sup>Dept. Nefrologia i Trasplantament Renal, Institut Clínic de Nefrologia i Urologia (ICNU), Hospital Clinic, Badalona, Spain
- B48**      **Broadly Profiling the Activation Status of Circulating Immune Cells in Chronic Active Antibody Mediated Rejection Reveals Increased CD38 and CD16 Expression on Monocytes and NK Cells**  
 K. Sablik, N. Litjens, M. Klepper, M. Betjes, Erasmus MC, Rotterdam, Netherlands
- B49**      **Development of De Novo DSA after Kidney Transplant Correlates with Low Quantity of Peripheral Blood “Antibody-Suppressor” CD8+ T Cells**  
 J. Zimmerer<sup>1</sup>, M. Basinger<sup>1</sup>, B. Ringwald<sup>1</sup>, R. Pelletier<sup>1</sup>, A. Rajab<sup>1</sup>, A. El-Hinnawi<sup>1</sup>, M. Abdel-Rousoul<sup>2</sup>, H. Parekh<sup>3</sup>, K. Washburn<sup>1</sup>, G. Bumgardner<sup>1</sup>, <sup>1</sup>Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, <sup>2</sup>Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH, <sup>3</sup>Clinical Histocompatibility Laboratory, The Ohio State University Wexner Medical Center, Columbus, OH
- B50**      **Post-Transplant Lymphopenia is Associated with Higher Risk of Graft Failure, Death and Viral Infections**  
 A. Dujardin<sup>1</sup>, M. Lorent<sup>2</sup>, C. Kerleau<sup>1</sup>, S. Brouard<sup>3</sup>, M. Giral<sup>1</sup>, <sup>1</sup>Nephrology, Nantes University Hospital, Nantes, France, <sup>2</sup>UMR\_S 1246, INSERM, Nantes, France, <sup>3</sup>CRTI UMR 1064, Inserm, Nantes, France
- B51**      **The Number of Donor-Specific IL-21 Producing Cells before and after Transplantation Predicts Kidney Graft Rejection**  
 N. M. van Besouw<sup>1</sup>, L. Yan<sup>1</sup>, R. de Kuiper<sup>1</sup>, M. Klepper<sup>1</sup>, D. Reijerkerk<sup>1</sup>, M. Dieterich<sup>1</sup>, D. L. Roelen<sup>2</sup>, F. H. Claas<sup>2</sup>, M. C. Claassen-van Groningen<sup>3</sup>, D. A. Hesselink<sup>1</sup>, C. C. Baan<sup>1</sup>, <sup>1</sup>Internal Medicine - Nephrology & Transplantation, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, <sup>2</sup>Immunohematology and Blood Transfusion, Leiden University Medical Centre, Leiden, Netherlands, <sup>3</sup>Pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands

- B52 Functional Dependence, Access to Kidney Transplantation and Waitlist Mortality**  
A. Muzaale<sup>1</sup>, N. Chu<sup>1</sup>, H. Ying<sup>1</sup>, S. Norman<sup>2</sup>, S. Sison<sup>1</sup>, D. Segev<sup>1</sup>, M. McAdams-Demarco<sup>1</sup>, <sup>1</sup>JHU, Baltimore, MD, <sup>2</sup>UM, Ann Arbor, MI
- B53 † ICOS+PD-1+ Circulating T Follicular Helper Cells Are a Biomarker of Humoral Alloreactivity and Predict Donor-Specific Antibody Generation Following Transplantation**  
G. M. La Muraglia II, M. E. Wagener, M. L. Ford, I. R. Badell, *Emory Transplant Center, Atlanta, GA*
- B54 Studying the Association of Melanocortin Receptor-4 Gene Polymorphism and Renal Transplant Rejection**  
E. Yilmaz<sup>1</sup>, R. Abdi<sup>1</sup>, B. J. Keating<sup>2</sup>, V. R. Mas<sup>3</sup>, <sup>1</sup>Renal Division, Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, <sup>2</sup>Surgery, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Director Transplant Research Institute, Department of Surgery, The University of Tennessee Health Science Center, Memphis, TN
- B55 Patient Reported Side Effects Associated with Reduced Quality of Life after Living Donor Kidney Transplant**  
J. Peipert, J. C. Caicedo-Ramirez, K. Ensor, J. Friedewald, M. Abecassis, D. Cella, D. Ladner, Z. Butt, *Northwestern University, Chicago, IL*
- B56 CNV Screening For End-stage Renal Disease**  
C. E. Fishman, B. Chang, A. Shaked, B. J. Keating, *Surgery, University of Pennsylvania, Philadelphia, PA*
- B57 The Value of SCS Perfusate Biomarkers for Predicting DGF of DCD Donor Kidneys**  
X. Li, W. Wang, X. Zhang, *Beijing Chaoyang Hospital, Capital Medical University, Beijing, China*
- B58 Use of TruGraf Serial Testing for Confirming Stability in Kidney Transplant Patients with Stable Renal Function**  
V. Peddi<sup>1</sup>, C. Schieve<sup>2</sup>, S. Rose<sup>2</sup>, M. First<sup>2</sup>, <sup>1</sup>California Pacific Med Ctr, San Francisco, CA, <sup>2</sup>Transplant Genomics Inc, Mansfield, MA
- B59 Metabolomic Study Of Sarcopenia In Patients Prior To Liver Transplantation**  
S. Ries<sup>1</sup>, N. J. Skill<sup>1</sup>, E. Campbell<sup>1</sup>, R. Daniel<sup>2</sup>, C. A. Kubal<sup>1</sup>, M. S. Richard<sup>1</sup>, M. A. Maluccio<sup>1</sup>, <sup>1</sup>Surgery, Indiana University, Indianapolis, IN, <sup>2</sup>University of Washington, Seattle, WA
- B60 Torque Teno Virus is a Prognostic Biomarker for Acute Biopsy-Proven Alloreactivity in Kidney Transplants**  
K. Doberer, *Dpt. of Internal Medicine III, Div. of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria*
- B61 † Pharmacological Enhancement of Bile Duct Preservation and Function during Ex-Situ Normothermic Machine Perfusion**  
Y. L. Boteon, J. Attard, A. P. Boteon, L. Wallace, G. Reynolds, D. Mirza, H. Mergental, R. Bhogal, S. Afford, *Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom*
- B62 † Contribution of CD38 to Methionine Choline Deficient (MCD) Diet-Induced Liver Injury in Rats**  
J. Kim, Y. Lee, B. F. Reader, C. Akateh, K. R. Maynard, K. W. Washburn, J. L. Zweier, B. A. Whitson, S. M. Black, *Department of Cardiac Surgery, The Ohio State Univ. Medical Center, Columbus, OH*
- B63 Comparison between Urine and Blood NGAL for Early Prediction of Delayed Graft Function in Adult Kidney Transplant Recipients: A Systematic Review and Meta-Analysis**  
Y. Li, Y. Li, L. Yan, H. Wang, X. Wu, J. Tang, L. Wang, Y. Shi, *Department of Laboratory Medicine, West China Hospital, Chengdu, China*

- B64 †** **HuR Dictates HO-1 Expression, Modulates Inflammation and Influences Recipient Outcomes in Liver Transplant Patients**  
 K. J. Dery, K. Nakamura, K. Kadono, H. Hirao, S. Kageyama, T. Ito, J. Aziz, B. Ke, F. M. Kaldas, R. W. Busuttil, J. W. Kupiec-Weglinski, *Dumont-UCLA Transplant Center, UCLA, Los Angeles, CA*
- B65** **Pre-Treatment Lymphocyte Status in HCC Patients Associates with DEB-TACE Response and Correlates with Increased Regulatory Immune Cells**  
 K. Nunez<sup>1</sup>, T. Sandow<sup>2</sup>, S. Robertson<sup>1</sup>, P. Thevenot<sup>1</sup>, A. Cohen<sup>1</sup>, <sup>1</sup>*Ochsner Health System, New Orleans, LA*, <sup>2</sup>*Interventional Radiology, Ochsner Health System, New Orleans, LA*
- B66** **Use of Anti-Vimentin Antibodies as a Possible Marker for Graft Dysfunction Following Renal Transplant, a Prospective Study**  
 E. Acosta<sup>1</sup>, T. Divanyan<sup>1</sup>, D. Patel<sup>1</sup>, F. Jourd'heuil<sup>2</sup>, D. Jourd'heuil<sup>2</sup>, R. Lopez-Soler<sup>3</sup>, <sup>1</sup>*Albany Medical College, Albany, NY*, <sup>2</sup>*Molecular and Cellular Physiology, Albany Medical College, Albany, NY*, <sup>3</sup>*Surgery, Section of Transplantation, Albany Medical College, Albany, NY*
- B67** **High Prevalence of Allergic Disorders but No Specific Immune Phenotype Pattern in Children Awaiting Transplantation**  
 T. B. Kim<sup>1</sup>, Y. Avitzur<sup>2</sup>, L. Ionescu<sup>1</sup>, U. Allen<sup>2</sup>, S. Mital<sup>2</sup>, B. Foster<sup>3</sup>, T. Blydt-Hansen<sup>4</sup>, L. Hamiwka<sup>5</sup>, P. Birk<sup>6</sup>, V. Phan<sup>7</sup>, S. Urschel<sup>1</sup>, <sup>1</sup>*University of Alberta, Edmonton, AB, Canada*, <sup>2</sup>*Hospital for Sick Children, Toronto, ON, Canada*, <sup>3</sup>*McGill University, Montreal, QC, Canada*, <sup>4</sup>*University of British Columbia, Vancouver, BC, Canada*, <sup>5</sup>*University of Calgary, Calgary, AB, Canada*, <sup>6</sup>*University of Manitoba, Winnipeg, MB, Canada*, <sup>7</sup>*Université de Montréal, Montreal, QC, Canada*
- B68** **Personality Traits of Liver Transplant Candidates - Unappreciated Challenges**  
 D. Ladner<sup>1</sup>, J. Lai<sup>2</sup>, A. N. Hall<sup>1</sup>, E. D. Bastarache<sup>1</sup>, A. Daud<sup>1</sup>, T. Bogg<sup>3</sup>, A. Lebsack<sup>1</sup>, T. Kalume<sup>1</sup>, D. Mroczek<sup>1</sup>, <sup>1</sup>*Northwestern University, Chicago, IL*, <sup>2</sup>*UCSF, San Francisco, CA*, <sup>3</sup>*Wayne State University, Chicago, IL*
- B69 †** **Donor-Recipient HLA Mismatched Peptides Calculated by PIRCHE Algorithm Associate with De Novo Donor-Specific Cellular and Humoral Alloreactivity and Predicts Inferior Graft Outcome**  
 M. Meneghini<sup>1</sup>, E. Crespo<sup>2</sup>, M. Niemann<sup>3</sup>, A. Torija<sup>2</sup>, E. Melilli<sup>4</sup>, M. Jarque<sup>2</sup>, N. Montero<sup>4</sup>, J. Cruzado<sup>1</sup>, J. Grinyo<sup>1</sup>, O. Bestard<sup>1</sup>, <sup>1</sup>*Kidney Transplantation Unit, Bellvitge University Hospital- IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain*, <sup>2</sup>*Experimental Nephrology Laboratory, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain*, <sup>3</sup>*PIRCHE AG, Berlin, Germany*, <sup>4</sup>*Kidney Transplantation Unit, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain*
- B70** **Global Analysis of Fc-gamma Receptors Binding Capacity of Human Leukocyte Antigen Donor Specific Antibody**  
 E. S. Woodle, A. Girnita, *University of Cincinnati Academic Health Center, Cincinnati, OH*
- B71** **Higher Post-Transplant CXCL13 Correlates with the Occurrence of Infection within 1 Year after Kidney Transplantation**  
 Y. Li<sup>1</sup>, Y. Li<sup>1</sup>, L. Yan<sup>1</sup>, L. Wang<sup>1</sup>, Y. Shi<sup>2</sup>, J. Tang<sup>1</sup>, <sup>1</sup>*Department of Laboratory Medicine/Research Centre of Clinical Laboratory Medicine, West China Hospital, Chengdu, China*, <sup>2</sup>*Department of Nephrology, West China Hospital, Chengdu, China*



- B72 Paradoxical Differential Post-transplant Rates Of Change Of Serum Proteins In Pediatric Liver Patients With Evidence For A Novel Sarcopenic-dependent Serum Protein Stimulating Factor**  
C. M. Schmidt<sup>1</sup>, J. Molleston<sup>2</sup>, G. S. Rao<sup>2</sup>, C. A. Kubal<sup>1</sup>, S. Atoa<sup>1</sup>, R. S. Mangus<sup>1</sup>,  
<sup>1</sup>*Surgery, Transplant Division, Indiana University, Indianapolis, IN*, <sup>2</sup>*Pediatrics, Division of GI and Hepatology, Indiana University, Indianapolis, IN*
- B73 Chemokine Ligand 14 is a Novel Therapeutic Target in Kidney Fibrosis**  
S. Lee<sup>1</sup>, Y. Kim<sup>1</sup>, J. Moon<sup>1</sup>, H. Lee<sup>1</sup>, S. Han<sup>1</sup>, J. Lee<sup>2</sup>, R. Cha<sup>3</sup>, D. Kim<sup>1</sup>, C. Lee<sup>4</sup>, K. Kim<sup>5</sup>, Y. Kim<sup>1</sup>, S. Yang<sup>6</sup>,  
<sup>1</sup>*Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of*, <sup>2</sup>*Internal Medicine, Boramae Medical Center, Seoul, Korea, Republic of*, <sup>3</sup>*Internal Medicine, National Medical Center, Seoul, Korea, Republic of*, <sup>4</sup>*Internal Medicine, Cheju Halla University Hospital, Jeju, Korea, Republic of*, <sup>5</sup>*Biomedical Science, Seoul National University, Seoul, Korea, Republic of*, <sup>6</sup>*Seoul National University College of Medicine, Seoul, Korea, Republic of*
- B74 Need of a New Formula to Estimate Creatinine Clearance in Immediate Post Kidney Transplant Period with Functioning Allograft**  
A. B. Jain<sup>1</sup>, U. Farooq<sup>2</sup>, A. Brooks<sup>1</sup>, T. Dohi<sup>1</sup>, F. Butt<sup>1</sup>, Z. Kadry<sup>1</sup>,  
<sup>1</sup>*Surgery (Transplant), Penn State Milton Hershey Medical Center, Hershey 17033, PA*, <sup>2</sup>*Medicine( Nephrology), Penn State Milton Hershey Medical Center, Hershey, PA*
- B75 Pre-Transplant Multidimensional Flow Cytometric Analysis of Kidney Transplant Recipients Reveals Novel Immune Signature of Allograft Rejection**  
P. Schroder<sup>1</sup>, J. S. Yi<sup>1</sup>, K. J. Weinhold<sup>1</sup>, C. Chan<sup>2</sup>, M. Joshi<sup>3</sup>, C. Walters<sup>3</sup>, J. Kwun<sup>1</sup>, S. J. Knechtle<sup>1</sup>,  
<sup>1</sup>*Department of Surgery, Duke University Medical Center, Durham, NC*, <sup>2</sup>*Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC*, <sup>3</sup>*Substrate Services Core and Research Support, Duke University Medical Center, Durham, NC*
- B76 Relationship between HLA-DPB1 Gene Expression in Pre-Implantation Kidney Biopsies, Rs9277534 Polymorphism, and Late Graft Function**  
K. L. Mine<sup>1</sup>, T. B. Mourão<sup>1</sup>, C. Felipe<sup>2</sup>, G. F. Rampim<sup>1</sup>, J. O. Medina-Pestana<sup>2</sup>, H. Tedesco-Silva<sup>2</sup>, M. Gerbase-DeLima<sup>1</sup>,  
<sup>1</sup>*Immunogenetics Institute, Associação Fundo de Incentivo a Pesquisa - AFIP, Sao Paulo, SP, Brazil*, <sup>2</sup>*Hospital do Rim, Sao Paulo, SP, Brazil*
- B77 Absence of Non Alcoholic Fatty Liver Disease in Allografts from Morbidly Obese Donors: A Marker for Success?**  
M. MacConmara, A. Mufti, S. Hanish, T. Kerr, P. Vagefi, C. Hwang,  
*Surgery (Division of Surgical Transplantation), UT Southwestern, Dallas, TX*
- B78 Normothermic Ex-Situ Liver Perfusion Parameters of Liver Viability in a Porcine Model of Liver Transplantation with Marginal Grafts**  
I. Linares-Cervantes<sup>1</sup>, J. Echeverri<sup>1</sup>, S. Cleland<sup>1</sup>, M. Kathis<sup>1</sup>, R. Rosales<sup>1</sup>, T. Goto<sup>1</sup>, D. Kollmann<sup>1</sup>, M. Hamar<sup>1</sup>, P. Urbanellis<sup>1</sup>, L. Mazilescu<sup>1</sup>, S. Ganesh<sup>1</sup>, O. Adeyi<sup>1</sup>, P. Yip<sup>1</sup>, B. Bojko<sup>2</sup>, P. Gorynzka<sup>2</sup>, K. Gorynski<sup>2</sup>, D. Grant<sup>1</sup>, N. Selzner<sup>1</sup>, M. Wasowicz<sup>1</sup>, M. Selzner<sup>1</sup>,  
<sup>1</sup>*Toronto General Hospital, Toronto, ON, Canada*, <sup>2</sup>*University of Nicolaus Copernicus, Torun, Poland*
- B79 Evaluation of Liver Function and Biomarkers Predicts Tumor Progression in Treatment-Naïve Hepatocellular Carinoma Patients**  
K. Nunez, T. Sandow, S. Robertson, P. Thevenot, A. Cohen,  
*Ochsner Health System, New Orleans, LA*



**B80 †** **Combined Pre-Transplant Anti-Donor T-Cell Sensitization with Single Nucleotid Polimorphisms (SNPs) for CYP3A4 Tacrolimus Metabolism Identifies Kidney Transplant Patients at High Risk of Allograft Rejection**  
E. Crespo<sup>1</sup>, A. Vidal<sup>1</sup>, A. Sefrin<sup>2</sup>, P. Fontova<sup>1</sup>, M. Stein<sup>2</sup>, H. Volk<sup>2</sup>, J. Grinyó<sup>3</sup>, P. Reinke<sup>2</sup>, N. Lloberas<sup>1</sup>, O. Bestard<sup>3</sup>,  
<sup>1</sup>Experimental Nephrology Laboratory, IDIBELL, L'Hospitalet de Llobregat. Barcelona, Spain, <sup>2</sup>Nephrology, Charité Campus Virchow-Klinikum, Berlin, Germany, <sup>3</sup>Kidney Transplant Unit, Bellvitge University Hospital- IDIBELL, L'Hospitalet de Llobregat. Barcelona, Spain

**B81** **Subclinical Antibody Mediation Rejection in Stable Kidney Recipients with De Novo Donor Specific Antibodies and Correlation with Donor Derived Cell Free DNA Testing**  
A. P. Bregman, E. J. Stites, J. Gralla, A. Wiseman, J. E. Cooper, *Kidney and Pancreas Transplant, University of Colorado-Denver, Aurora, CO*

**B82** **Nephrotoxicity Caused by Calcineurin Inhibitors is Mediated by BAX, NOL3 and XIAP Apoptotic Genes Dysregulation**  
G. Queipo<sup>1</sup>, M. Fonseca-Sanchez<sup>1</sup>, J. Sanchez<sup>1</sup>, L. Garcia<sup>1</sup>, M. Carmona<sup>2</sup>, E. Villanueva<sup>1</sup>, G. Melendez<sup>1</sup>, L. Morales-Buenrostro<sup>3</sup>, M. Alamilla<sup>1</sup>, <sup>1</sup>Hospital General de Mexico-Eduardo Liceaga Facultad de Medicina UNAM, Mexico City, Mexico, <sup>2</sup>Facultad de Medicina UNAM, Mexico City, Mexico, <sup>3</sup>Instituto Nacional de Ciencias Médicas Salvador Zubirán, Mexico City, Mexico

**B83** **Multi-Center Validation of TruGraf V2 - A Peripheral Blood Diagnostic for Subclinical Kidney Rejection**  
C. Marsh<sup>1</sup>, S. Kurian<sup>1</sup>, C. Schieve<sup>2</sup>, R. Heilman<sup>3</sup>, M. Stegall<sup>4</sup>, S. Rose<sup>2</sup>, J. Case<sup>1</sup>, J. Friedewald<sup>5</sup>, M. Abecassis<sup>5</sup>, R. First<sup>2</sup>,  
<sup>1</sup>Scripps Health, La Jolla, CA, <sup>2</sup>Transplant Genomics Inc., Mansfield, MA, <sup>3</sup>Mayo Clinic, Scottsdale, AZ, <sup>4</sup>Mayo Clinic, Rochester, MN, <sup>5</sup>Northwestern University, Chicago, IL

**B84** **First UK Experience of the Molecular Microscope (MMDX™) in the Kidney Transplant Clinic**  
C. Lawrence<sup>1</sup>, S. Thiru<sup>2</sup>, A. Manoj<sup>1</sup>, S. Fluck<sup>1</sup>, <sup>1</sup>Renal Medicine, The Lister Hospital, Stevenage, United Kingdom, <sup>2</sup>Histopathology, Addenbrookes Hospital, Cambridge, United Kingdom

## Poster Session B: Heart and VADs: All Topics

---

**B85** **Association between Recipient Sex and Risk of Heart Graft Failure**  
A. Chackowicz<sup>1</sup>, X. Zhang<sup>2</sup>, M. Dahhou<sup>2</sup>, R. Sapir-Pichhadze<sup>3</sup>, H. Cardinal<sup>4</sup>, B. Foster<sup>5</sup>, <sup>1</sup>Faculty of Medicine, McGill University, Montreal, QC, Canada, <sup>2</sup>Research Institute of the McGill University Health Centre, Montreal, QC, Canada, <sup>3</sup>Dept. of Medicine, McGill University, Montreal, QC, Canada, <sup>4</sup>Dept. of Medicine, Université de Montréal, Montreal, QC, Canada, <sup>5</sup>Dept. of Pediatrics, McGill University, Montreal, QC, Canada

**B86** **Role of Kidney Biopsy in Simultaneous Heart-Kidney Transplantation**  
P. B. Shah<sup>1</sup>, M. A. Josephson<sup>1</sup>, K. Henriksen<sup>2</sup>, A. Chang<sup>2</sup>, <sup>1</sup>Nephrology, University of Chicago Medicine, Chicago, IL, <sup>2</sup>Pathology, University of Chicago Medicine, Chicago, IL

**B87 †** **Pre-Transplant Ventricular Assist Device (VAD) Impacts Heart Transplant (HT) Survival**  
M. S. Gharibdousti<sup>1</sup>, M. T. Khasawneh<sup>2</sup>, A. L. Friedman<sup>3</sup>, <sup>1</sup>Research, LiveOnNY, Manhattan, NY, <sup>2</sup>Binghamton University, Binghamton, NY, <sup>3</sup>LiveOnNY, Manhattan, NY

**B88** **Prognostic Value Of Dobutamine Stress Echocardiography In Heart Transplantation Recipients**  
A. Singhvi, R. Araujo-Gutierrez, M. H. Park, A. Bhimaraj, B. H. Trachtenberg, I. Hussain, A. Guha, *Division of Cardiology/JC Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, TX*

- B89 Outcome Of Late Biopsy-negative Rejection After Heart Transplantation**  
M. Kittleson, J. Patel, E. Kransdorf, S. Dimbil, R. Levine, J. A. Kobashigawa, *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- B90 Could Intravenous Iron Strengthen The Chances Of Heart Transplantation For Patients With Left Ventricular Assist Devices?**  
A. Mardis<sup>1</sup>, C. Mardis<sup>2</sup>, J. Barham<sup>3</sup>, A. Poole<sup>3</sup>, S. Branham<sup>3</sup>, R. Napier<sup>4</sup>, J. Martin<sup>3</sup>, P. McCann<sup>4</sup>, <sup>1</sup>*Department of Pharmacy, Palmetto Health, Columbia, SC*, <sup>2</sup>*Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia, SC*, <sup>3</sup>*Cardiothoracic Surgery, Palmetto Health, Columbia, SC*, <sup>4</sup>*Cardiology, Palmetto Health, Columbia, SC*
- B91 Impact of HLA Mismatches and Cytomegalovirus Seropositivity on Outcomes Following Heart Transplantation**  
A. Singhvi, R. Araujo-Gutierrez, M. H. Park, A. Bhimaraj, B. H. Trachtenberg, I. Hussain, A. Guha, *Division of Cardiology/JC Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, TX*
- B92 † Rejection, Infectious, and Renal Outcomes with Perioperative Desensitization in Orthotopic Heart Transplant Recipients**  
M. Plazak, B. Reed, S. Hammad, S. Gale, V. Ton, D. Kaczorowski, T. Trobiano, B. Ravichandran, *University of Maryland Medical Center, Baltimore, MD*
- B93 Increasing Doses of Pain Medications Pre-Heart Transplant as a Risk Factor for Outcomes after Transplant**  
K. Shah, D. H. Chang, J. Patel, R. J. Levine, S. Dimbil, E. Passano, J. A. Kobashigawa, *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- B94 Prevalence of Donor Specific Antibody in Heart Transplant Recipients with Antibody-Mediated Rejection as Compared to Abnormal Intragraft mRNA Transcripts by Molecular Microscope System**  
K. Shah, R. J. Levine, S. Dimbil, S. Sana, P. F. Halloran, J. Patel, D. H. Chang, E. Kransdorf, M. Kittleson, J. A. Kobashigawa, *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- B95 Unfair Waiting Time Calculation? Impact of Accumulated Wait Time Restart with a Decrease in Status from 1A to 1B or 2 on Mortality of Heart Transplant Candidates**  
S. Yu, M. Kosztowski, M. Waldram, D. L. Segev, A. B. Massie, *Department of Surgery, Johns Hopkins, Baltimore, MD*
- B96 Amiodarone And Primary Graft Dysfunction In Heart Transplantation: Reality Or Myth?**  
M. Kittleson, J. Patel, D. H. Chang, E. Kransdorf, S. Dimbil, R. Levine, K. Yabuno, L. Czer, M. Hamilton, F. Esmailian, J. A. Kobashigawa, *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- B97 3-year Outcome Of Heart Transplantation In Patients With Amyloidosis**  
J. Patel, M. Kittleson, D. H. Chang, R. Levine, S. Dimbil, L. Czer, F. Esmailian, J. A. Kobashigawa, *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- B98 Reference Ranges Donor-Derived Cell-Free DNA in a Heart Transplant Population**  
A. Kao<sup>1</sup>, S. Dholakia<sup>2</sup>, M. Deng<sup>3</sup>, <sup>1</sup>*Saint Luke's, Kansas City, MO*, <sup>2</sup>*CareDx, Brisbane, CA*, <sup>3</sup>*University of Los Angeles, Los Angeles, CA*
- B99 † Influence Of HLA-DR Mismatches On Long Term Outcomes Following Heart Transplantation**  
A. Singhvi, R. Araujo-Gutierrez, M. H. Park, A. Bhimaraj, B. H. Trachtenberg, I. Hussain, A. Guha, *Division of Cardiology/JC Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, TX*

- B100 Donor, Recipient Indices and Frailty Predict Outcomes after Heart-Kidney Transplantation**  
C. Beifeld<sup>1</sup>, V. Dio Guardi<sup>1</sup>, K. Lau<sup>1</sup>, A. Di Carlo<sup>1</sup>, S. Karhadkar<sup>2</sup>, <sup>1</sup>*Surgery, Temple University Hospital, Philadelphia, PA*, <sup>2</sup>*Temple University Hospital, Philadelphia, PA*
- B101 Anemia and Hemolysis on Dapsone Despite Normal Glucose-6-Phosphate Dehydrogenase Activity in Heart Transplant Recipients**  
K. Lor, E. Kransdorf, J. Patel, M. Kittleson, D. Chang, J. A. Kobashigawa, *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- B102 Effect of DSA-Free Heart Allocation on Children**  
M. Skeans<sup>1</sup>, J. Pyke<sup>1</sup>, K. Audette<sup>1</sup>, R. White<sup>2</sup>, W. Mahle<sup>3</sup>, A. Savage<sup>4</sup>, J. Smith<sup>5</sup>, <sup>1</sup>*SRTR, Minneapolis, MN*, <sup>2</sup>*Children's Hosp, Philadelphia, PA*, <sup>3</sup>*Emory Univ., Atlanta, GA*, <sup>4</sup>*Med University of SC, Charleston, SC*, <sup>5</sup>*Seattle Children's Hosp, Seattle, WA*
- B103 Association Between Cumulative Pre-transplant Amiodarone Dose And Post-transplant Outcomes After Heart Transplantation**  
K. Lang<sup>1</sup>, M. Sullivan<sup>2</sup>, P. Simone<sup>1</sup>, S. Patel<sup>1</sup>, L. M. Lourenco<sup>1</sup>, <sup>1</sup>*Pharmacy, University of Chicago Medicine, Chicago, IL*, <sup>2</sup>*Pharmacy, Northwestern Medicine, Chicago, IL*
- B104 † Idarucizumab For The Reversal Of Dabigatran In Patients Undergoing Heart Transplantation**  
J. Van Keer<sup>1</sup>, T. Vanassche<sup>1</sup>, W. Droogne<sup>1</sup>, S. Rex<sup>2</sup>, F. Rega<sup>3</sup>, J. Van Cleemput<sup>1</sup>, P. Verhamme<sup>1</sup>, M. Naesens<sup>4</sup>, <sup>1</sup>*Cardiology, University Hospitals Leuven, Leuven, Belgium*, <sup>2</sup>*Anesthesiology, University Hospitals Leuven, Leuven, Belgium*, <sup>3</sup>*Cardiovascular Surgery, University Hospitals Leuven, Leuven, Belgium*, <sup>4</sup>*Nephrology, University Hospitals Leuven, Leuven, Belgium*
- B105 Outcome Of Left Main Stenting After Heart Transplantation**  
S. Dimbil, J. Patel, B. Azarbal, M. Kittleson, R. Levine, D. H. Chang, J. A. Kobashigawa, *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- B106 Immune Privilege May Predispose Patients after Orthotopic Heart Transplantation to Develop Recipient to Donor Atrial Connections Associated with Atrial Arrhythmias**  
B. Herweg<sup>1</sup>, M. Nellaiyappan<sup>1</sup>, T. Tran<sup>1</sup>, G. Mabry<sup>1</sup>, K. Weston<sup>1</sup>, H. J. Eisen<sup>2</sup>, M. Weston<sup>3</sup>, <sup>1</sup>*Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL*, <sup>2</sup>*Heart and Vascular Institute, Pennsylvania State University, Hershey, PA*, <sup>3</sup>*Tampa General Hospital, Tampa, FL*
- B107 Mycophenolic Acid Area under the Curve Monitoring via Limited Sampling Strategy in Pediatric Heart Transplant Recipients**  
S. Crow, S. H. Dahl, J. N. Johnson, *Mayo Clinic, Rochester, MN*
- B108 Exercise after Heart Transplantation: What is the Reality?**  
A. Velleca, K. Norland, N. Musto, N. Mikhail, H. Barone, G. Jamero, R. J. Levine, S. Dimbil, R. Sharoff, E. Passano, J. A. Kobashigawa, *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- B109 First Experience For Cold Storage Of Donor Hearts With Paragonix SherpaPak**  
L. Stastny<sup>1</sup>, M. Kofler<sup>1</sup>, D. Höfer<sup>1</sup>, G. Pölzl<sup>2</sup>, R. Breitkopf<sup>3</sup>, M. Grimm<sup>1</sup>, H. Antretter<sup>1</sup>, J. Dumfarth<sup>1</sup>, <sup>1</sup>*Cardiac Surgery, Medical University Innsbruck, Innsbruck, Austria*, <sup>2</sup>*Internal Medicine, Medical University Innsbruck, Innsbruck, Austria*, <sup>3</sup>*Intensive Care Unit, Medical University Innsbruck, Innsbruck, Austria*
- B110 Is Muscular Dystrophy A Contraindication To Heart Transplantation?**  
M. Kittleson, J. Patel, D. H. Chang, S. Dimbil, R. Levine, L. Czer, J. A. Kobashigawa, *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*

- B111**     **The Use Of First-year Intravascular Ultrasound In The Tacrolimus Era In Heart Transplantation**  
S. Dimbil<sup>1</sup>, M. Kittleson<sup>1</sup>, J. Patel<sup>1</sup>, D. Geft<sup>1</sup>, R. Cheng<sup>1</sup>, R. Levine<sup>1</sup>, T. Sato<sup>1</sup>, L. Czer<sup>1</sup>, R. Zabner<sup>2</sup>, P. Zakowski<sup>2</sup>, J. A. Kobashigawa<sup>1</sup>, B. Azarbal<sup>1</sup>, <sup>1</sup>*Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*, <sup>2</sup>*Cedars-Sinai Medical Center, Los Angeles, CA*
- B112**     **Gene Expression Profiling for Cardiac Transplant Recipients: Results from the Outcomes AlloMap® Registry**  
S. Hall<sup>1</sup>, G. Ewald<sup>2</sup>, P. Berman<sup>3</sup>, A. Kao<sup>4</sup>, T. Wolf-Doty<sup>5</sup>, J. Yee<sup>5</sup>, J. Kobashigawa<sup>6</sup>, <sup>1</sup>*Baylor University Medical Center, Dallas, TX*, <sup>2</sup>*Washington University, St. Louis, MO*, <sup>3</sup>*Tampa General Hospital, Tampa, FL*, <sup>4</sup>*Saint Luke's Mid America Heart Institute, Kansas City, MO*, <sup>5</sup>*CareDx, Brisbane, CA*, <sup>6</sup>*Cedars-Sinai Medical Center, Los Angeles, CA*
- B113**     **Slowed Progression of Maximal Intimal Thickening by Intravascular Ultrasound after Initiation of Sirolimus**  
A. Putschoggl<sup>1</sup>, K. Campbell<sup>1</sup>, M. Everitt<sup>1</sup>, S. Miyamoto<sup>1</sup>, B. Pietra<sup>2</sup>, S. Auerbach<sup>1</sup>, <sup>1</sup>*Children's Hospital Colorado, Aurora, CO*, <sup>2</sup>*University of Florida Health, Gainesville, FL*
- B114**     **Liver Allograft Provides Protection Against Cardiac Allograft Rejection In Combined Heart And Liver Transplantation**  
K. Zhao<sup>1</sup>, R. Wang<sup>2</sup>, M. Kamoun<sup>3</sup>, K. Olthoff<sup>1</sup>, M. Hoteit<sup>4</sup>, E. Rame<sup>5</sup>, M. Levine<sup>1</sup>, R. Mclean<sup>5</sup>, P. Abt<sup>1</sup>, <sup>1</sup>*Surgery, University of Pennsylvania, Philadelphia, PA*, <sup>2</sup>*Jefferson University, Philadelphia, PA*, <sup>3</sup>*Pathology, University of Pennsylvania, Philadelphia, PA*, <sup>4</sup>*Gastroenterology, University of Pennsylvania, Philadelphia, PA*, <sup>5</sup>*Cardiology, University of Pennsylvania, Philadelphia, PA*
- B115**     **Room for Improvement: Adherence to Vaccination Recommendations in a Heart Transplant Cohort**  
D. Jandhyala, J. D. Lewis, *Medical University of South Carolina, Charleston, SC*
- B116**     **Alteration of Myocardial Velocities and T1 Times in Patients with Acute Cellular Rejection during First Year Post Heart Transplant**  
R. Sarnari, A. Ruh, M. Abbasi, J. Blaisdell, R. Dolan, J. Wilcox, S. Khan, E. Vorovich, J. Rich, A. Anderson, C. Yancy, J. Carr, M. Markl, K. Ghafourian, *Northwestern University, Chicago, IL*
- B117**     **Cardioprotective Effects of Pre-Operative Cyclosporine in Patients Undergoing Heart Transplantation**  
Y. Hirase, M. Harris, M. Watson, H. Lee, C. Patel, *Duke University Hospital, Durham, NC*
- B118**     **Do Heart Transplant Patients Have Support Personnel Ready to Help Them If Necessary?**  
A. Velleca, K. Norland, M. Curry, N. Ransbottom, B. Kearney, R. Levine, S. Dimbil, R. Sharoff, E. Passano, J. A. Kobashigawa, *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- B119**     **Infectious Risk of Rejection Therapy Following Heart Transplantation; Can It Be Avoided?**  
M. Kittleson, J. Patel, S. Dimbil, R. J. Levine, G. Esmailian, A. Shen, T. Hage, J. A. Kobashigawa, *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- B120**     **Extracorporeal Photopheresis for Specific Immune Tolerance Responses in Heart Transplant Recipients**  
M. J. Barten<sup>1</sup>, K. Klaeske<sup>2</sup>, J. Wittke<sup>2</sup>, M. Borger<sup>2</sup>, J. Garbade<sup>2</sup>, S. Lehmann<sup>3</sup>, H. Reichenspurner<sup>1</sup>, M. Dieterlen<sup>2</sup>, <sup>1</sup>*Cardiovascular Surgery, University Heart Center, Hamburg, Germany*, <sup>2</sup>*Cardiac Surgery, University Heart Center Leipzig, Leipzig, Germany*, <sup>3</sup>*Cardiac Surgery, University Heart Center Leipzig, Leipzig, Germany*
- B121**     **Intravenous Methamphetamine Does Not Appear To Be A Contraindication For Heart Donation In Heart Transplantation**  
A. Velleca, J. Patel, M. Kittleson, R. Levine, S. Dimbil, S. Mersola, M. Hamilton, F. Esmailian, J. A. Kobashigawa, *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*



**B122** **Rabbit Anti-Thymocyte Globulin (rATG) Induction in Heart Transplant Recipients at High Risk for Rejection**  
B. Kitto<sup>1</sup>, B. Baetz<sup>1</sup>, S. Krim<sup>2</sup>, H. Patel<sup>2</sup>, S. Mandras<sup>2</sup>, S. Desai<sup>2</sup>, C. Eiswirth<sup>2</sup>, H. Ventura<sup>2</sup>, S. Thai<sup>1</sup>, <sup>1</sup>Pharmacy, Ochsner Medical Center, New Orleans, LA, <sup>2</sup>Heart Transplant, Ochsner Medical Center, New Orleans, LA

**B123** **Utility of Gallium-67 Single Photon Emission Computed Tomography in the Evaluation of Left Ventricular Assist Device Infections**  
F. Parkar<sup>1</sup>, A. Tlamsa<sup>2</sup>, J. Nistico<sup>2</sup>, V. A. Muggia<sup>2</sup>, G. Y. Minamoto<sup>2</sup>, U. Jorde<sup>3</sup>, D. J. Goldstein<sup>3</sup>, R. Moadel<sup>1</sup>, Y. A. Puius<sup>2</sup>, <sup>1</sup>Division of Nuclear Medicine, Montefiore Medical Center, Bronx, NY, <sup>2</sup>Division of Infectious Diseases, Montefiore Medical Center, Bronx, NY, <sup>3</sup>Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Bronx, NY

**B124** **Efficacy of Long-Acting Octreotide in Left Ventricular Assist Device Patients with Recurrent Gastrointestinal Bleeding**  
T. Wilson<sup>1</sup>, D. Baran<sup>2</sup>, J. Herre<sup>2</sup>, C. Cameron<sup>1</sup>, W. Old<sup>3</sup>, G. Zeevi<sup>2</sup>, C. Barreiro<sup>4</sup>, C. Kemp<sup>4</sup>, J. Philpott<sup>4</sup>, A. Ingemi<sup>5</sup>, <sup>1</sup>Pharmacy Department, Sentara Norfolk General Hospital, Norfolk, VA, <sup>2</sup>Advanced Heart Failure Department, Sentara Norfolk General Hospital, Norfolk, VA, <sup>3</sup>Bayview Cardiovascular Associates, Norfolk, VA, <sup>4</sup>Division of Cardiothoracic Surgery, Sentara Norfolk General Hospital, Norfolk, VA, <sup>5</sup>Department of Pharmacy, Sentara Norfolk General Hospital, Norfolk, VA

**B125** **What is the Post-Heart Transplant Risk of Infectious Complications from Pre-Transplant Desensitization Therapy?**  
E. Kransdorf, J. Patel, S. Dimbil, R. Levine, D. H. Chang, J. A. Kobashigawa, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA

## Poster Session B: Kidney Donor Selection / Management Issues

**B126 †** **HOPE Act Deceased Donors Referrals: Barriers to Donation**  
O. Kusemiju, C. Durand, B. Doby, M. Bowring, B. Barnaba, W. Werbel, D. Brown, A. Tobian, S. Seaman, D. Ostrander, D. Segev, Johns Hopkins University, Baltimore, MD

**B127** **No Plan is a Bad Plan! Results of the American Society of Transplantation (AST) Living Donor Community of Practice Mortality Workgroup Survey on Disaster Planning Following a Living Donor Death**  
M. L. Henderson<sup>1</sup>, S. E. Van Pilsum Rasmussen<sup>1</sup>, M. M. Waldram<sup>1</sup>, K. L. Lentine<sup>2</sup>, D. A. Mandelbrot<sup>3</sup>, R. L. Hays<sup>3</sup>, D. G. Maluf<sup>4</sup>, M. Cooper<sup>5</sup>, <sup>1</sup>Johns Hopkins, Baltimore, MD, <sup>2</sup>Saint Louis University, St Louis, MO, <sup>3</sup>University of Wisconsin, Madison, WI, <sup>4</sup>University of Tennessee, Memphis, TN, <sup>5</sup>Georgetown University, Washington, DC

**B128 †** **GFR Outcomes for Recipients and Donors with IgA, FSGS, Alports and Thin Basement Membrane Disease: A Comparison of Living Related to Unrelated Donors**  
D. Keys, S. Jackson, S. Riad, R. Spong, V. Vakil, A. Matas, P. Nachman, University of Minnesota, Minneapolis, MN

**B129 †** **Impact of Donor Acute Kidney Injury on GFR at 1 Year**  
R. Heilman, A. Kumar, A. Srinivasan, M. Smith, J. Huskey, H. Khamash, A. Mathur, C. Jadlowiec, A. Moss, K. S. Reddy, Mayo Clinic, Phoenix, AZ

**B130 †** **Trends in Utilization of Deceased Donor Kidneys Based on Donor Hep C Antibody and Nucleic Acid Status**  
V. Ariyamuthu<sup>1</sup>, R. M. LaHoz<sup>1</sup>, N. AbdulRahim<sup>1</sup>, S. Levea<sup>1</sup>, M. MacConmara<sup>2</sup>, C. Hwang<sup>2</sup>, B. Sandikci<sup>3</sup>, B. Tanriover<sup>1</sup>, <sup>1</sup>Internal Medicine, UT Southwestern Medical Center, Dallas, TX, <sup>2</sup>Surgery, UT Southwestern Medical Center, Dallas, TX, <sup>3</sup>University of Chicago Booth School of Business, Chicago, IL



- B131 Predictors of Glomerular Filtration Rate after Renal Transplantation**  
O. Andacoglu, Y. Dong, J. Liu, M. Parides, J. Rocca, J. Graham, M. Ajaimy, Y. Azzi, C. Pynadath, L. Liriano-Ward, M. Kinkhabwala, E. Akalin, S. Greenstein, *Montefiore Medical Center, Bronx, NY*
- B132 One Organ Procurement Organization's Uncontrolled Donation After Cardiocirculatory Death Program Increases The Donor Pool And Results In The Transplantation Of 254 Organs**  
R. D. Hasz, S. M. West, H. M. Nathan, *Gift of Life Donor Program, Philadelphia, PA*
- B133 Kidney Donor Profile Index Significantly Correlates With Reperfusion Biopsy Findings**  
A. Perez-Gutierrez<sup>1</sup>, P. Witkowski<sup>1</sup>, J. Fung<sup>1</sup>, D. N. Danz<sup>2</sup>, R. Cummings<sup>1</sup>, A. Chang<sup>3</sup>, <sup>1</sup>*Transplantation Institute, University of Chicago Medicine, Chicago, IL*, <sup>2</sup>*Economics, University of Pittsburgh, Pittsburgh, PA*, <sup>3</sup>*Pathology, University of Chicago Medicine, Chicago, IL*
- B134 † Intrinsic Organ Quality Assessment Using Integrative Short Outcome Prediction Composite Scores**  
K. Archer<sup>1</sup>, V. Bontha<sup>2</sup>, Y. Zhang<sup>1</sup>, J. Eason<sup>3</sup>, A. Bajwa<sup>2</sup>, L. Gallon<sup>4</sup>, E. Akalin<sup>5</sup>, D. Maluf<sup>2</sup>, V. Mas<sup>6</sup>, <sup>1</sup>*OSU, Columbus, OH*, <sup>2</sup>*UTHSC, Memphis, TN*, <sup>3</sup>*UTHSC Director of Transplant Institute, Memphis, TN*, <sup>4</sup>*NWU, Chicago, IL*, <sup>5</sup>*Albert Einstein College of Medicine, NYC, NY*, <sup>6</sup>*UTHSC Director of Transplant Research Institute, Memphis, TN*
- B135 Individualized Preconditioning for ABO-Incompatible Living Donor Kidney Transplantation: An Initial Report of 48 Cases from China**  
X. -. Wang, *Department of Urology/Institute of Urology, West China Hospital of Sichuan University, Chengdu, China*
- B136 Outcomes after Declining Increased Infectious Risk Kidney Offers for Pediatric Candidates in the United States**  
M. Bowring, K. Jackson, H. Wasik, A. Neu, J. Garonzik-Wang, C. Durand, N. Desai, A. Massie, D. Segev, *Johns Hopkins University, Baltimore, MD*
- B137 † Impact of Donor Acute Kidney Injury on the Outcome of Graft Delayed Graft Function**  
C. Jadowiec, A. Kumar, A. Srinivasan, A. Mathur, M. Smith, J. Huskey, A. Moss, H. Khamash, R. L. Heilman, K. S. Reddy, *Mayo Clinic, Phoenix, AZ*
- B138 Implementation of Novel Machine-Learning Techniques to Tailor DonorNet® Organ Offers to Center and Surgeon Preference**  
A. C. Perez-Ortiz, N. Elias, *Transplant Center, Massachusetts General Hospital, Boston, MA*
- B139 † Unsuccessful Resuscitative Thoracotomy Patients Are Potential Kidney Donors**  
K. Prins<sup>1</sup>, H. B. Moore<sup>1</sup>, A. Sauaia<sup>1</sup>, R. Choudhury<sup>1</sup>, R. C. McIntyre<sup>1</sup>, A. Cralley<sup>2</sup>, S. Urban<sup>1</sup>, E. E. Moore<sup>2</sup>, E. A. Pomfret<sup>1</sup>, T. L. Nydam<sup>1</sup>, <sup>1</sup>*University of Colorado Hospital, Aurora, CO*, <sup>2</sup>*Denver Health Medical Center, Denver, CO*
- B140 Organ-Procurement Organization and Donor Factor-Related Variation in Deceased Donor Kidney Biopsies and Discards: A National Practice Patterns Analysis**  
K. Lentine<sup>1</sup>, A. Naik<sup>2</sup>, M. Schnitzler<sup>1</sup>, H. Randall<sup>1</sup>, J. Wellen<sup>3</sup>, B. Kasiske<sup>4</sup>, G. Marklin<sup>5</sup>, D. Brockmeier<sup>5</sup>, M. Cooper<sup>6</sup>, H. Xiao<sup>1</sup>, Z. Zhang<sup>1</sup>, R. Gaston<sup>6</sup>, R. Rothweiler<sup>5</sup>, D. Axelrod<sup>7</sup>, <sup>1</sup>*Saint Louis Univ, St. Louis, MO*, <sup>2</sup>*Univ of Michigan, Ann Arbor, MI*, <sup>3</sup>*Washington Univ, St. Louis, MO*, <sup>4</sup>*SRTR, Minneapolis, MN*, <sup>5</sup>*Mid-America Transplant, St. Louis, MO*, <sup>6</sup>*Georgetown Univ, Washington, DC*, <sup>7</sup>*Univ of Iowa, Iowa City, IA*
- B141 Temporal Trends Following Uncontrolled Donation after Cardiac Death Kidney Transplantation: Implications for Normothermic Regional Perfusion?**  
R. A. Choudhury, K. Prins, D. Yoeli, H. B. Moore, T. L. Nydam, *Transplant Surgery, University of Colorado, Aurora, CO*
- B142 Transplant Outcomes of DCD Kidneys Recovered with vs. without Pre-Recovery Heparin Administration**  
J. Narvaez, L. Kayler, *Division of Transplantation, University at Buffalo, Buffalo, NY*

- B143**     **The Association of Kidney Transplant Center Volume with 3-Year Outcomes**  
E. M. Sonnenberg<sup>1</sup>, J. B. Cohen<sup>2</sup>, J. Y. Hsu<sup>3</sup>, V. S. Potluri<sup>2</sup>, M. H. Levine<sup>1</sup>, P. L. Abt<sup>1</sup>, P. P. Reese<sup>2</sup>, <sup>1</sup>*Surgery, University of Pennsylvania, Philadelphia, PA*, <sup>2</sup>*Renal Division, University of Pennsylvania, Philadelphia, PA*, <sup>3</sup>*Biostatistics, University of Pennsylvania, Philadelphia, PA*
- B144**     **Prospective Evaluation of Living Kidney Donor Anxiety: Concerns, Anxiety Mitigation, and Realized Negative Experiences**  
A. A. Krause, R. S. Mangus, M. French, V. Martine, J. Powelson, W. C. Goggins, *Medicine, Indiana University Health, Indianapolis, IN*
- B145**     **Racial Differences in Acute Kidney Injury Occurrence among Deceased Kidney Donors**  
M. Doshi<sup>1</sup>, I. Hall<sup>2</sup>, S. Mohan<sup>3</sup>, C. Liu<sup>4</sup>, H. Philbrook<sup>4</sup>, P. Reese<sup>5</sup>, S. Mansour<sup>6</sup>, F. Weng<sup>7</sup>, E. Akalin<sup>8</sup>, J. Bromberg<sup>9</sup>, M. Harhay<sup>10</sup>, T. Muthukumar<sup>11</sup>, B. Schroepfel<sup>12</sup>, P. Singh<sup>13</sup>, C. Parikh<sup>4</sup>, <sup>1</sup>*University of Michigan, Ann Arbor, MI*, <sup>2</sup>*University of Utah, Salt Lake City, UT*, <sup>3</sup>*Columbia, New York, NY*, <sup>4</sup>*Johns Hopkins, Baltimore, MD*, <sup>5</sup>*University of Pennsylvania, Philadelphia, PA*, <sup>6</sup>*Yale University, New Haven, CT*, <sup>7</sup>*St. Barnabas, Livingston, NJ*, <sup>8</sup>*Mount Sinai, New York, NY*, <sup>9</sup>*University of Maryland, Baltimore, MD*, <sup>10</sup>*Drexel, Philadelphia, PA*, <sup>11</sup>*Cornell, New York, NY*, <sup>12</sup>*University of Ulm, Ulm, Germany*, <sup>13</sup>*Jefferson, Philadelphia, PA*
- B146**     **Primary Nonfunction after Kidney Transplantation is Associated with Elevated Donor Urinary Biomarkers**  
S. Mohan, P. Reese, I. Hall, M. Doshi, Y. Jia, H. T. Philbrook, E. Akalin, J. Bromberg, M. Harhay, S. Mansour, T. Muthukumar, B. Schröppel, P. Singh, F. Weng, C. Parikh, *for the DDS Consortium, Baltimore, MD*
- B147**     **Effect of HLA Mismatch on Recurrence and Graft Loss in Living versus Deceased Kidney Transplant Recipients with IgA Nephropathy**  
T. Ishaque, F. A. Ammary, K. Jackson, D. L. Segev, A. B. Massie, *Johns Hopkins School of Medicine, Baltimore, MD*
- B148**     **Differential Effects Of Prolonged Cold Ischemia On Outcomes In Donation After Cardio Circulatory Death Versus Acute Kidney Injury Donor Kidney Transplants**  
D. Harriman, V. Gurrarn, J. Rogers, A. Farney, G. Orlando, C. Jay, A. Reeves-Daniel, A. Mena-Gutierrez, M. Gautreaux, W. Doares, S. Kaczorski, R. Stratta, *Wake Forest Baptist Medical Center, Winston-Salem, NC*
- B149**     **Renal Allograft Survival after Dual Kidney Transplantation is at Least as Favorable as Outcome after Expanded Criteria Donor Kidney Transplantation**  
A. Brar<sup>1</sup>, M. Sattar<sup>1</sup>, A. Gruessner<sup>1</sup>, R. M. Jindal<sup>2</sup>, R. Nee<sup>3</sup>, R. Gruessner<sup>1</sup>, M. Salifu<sup>1</sup>, <sup>1</sup>*SUNY Downstate Medical Center, Brooklyn, NY*, <sup>2</sup>*Department of Surgery,, USU-Walter Reed Uniformed Services University, Bethesda, MD*, <sup>3</sup>*USU-Walter Reed Uniformed Services University, Bethesda, MD*
- B150**     **Usefulness of the Assessment of CT-Based Donor Kidney Function Compared with Radionuclide Scintigraphy**  
K. Park, J. Yoon, H. Kim, C. Baek, S. Park, H. Kim, *Division of Nephrology, Department of Internal Medicine, Asan Medical Center, SEOUL, Korea, Republic of*
- B151**     **Pushing the Limits: A Large Multicentric Case-Control Study Evaluating the Impact of Kidney Transplants from Expanded Criteria Donors after Controlled Circulatory Death the Limits: A Large Multicentric Case-Control Study Evaluating the Impact of Kidney Transplants from Expanded Criteria Donors after Controlled Circulatory Death**  
N. Toapanta<sup>1</sup>, R. Alvarez<sup>2</sup>, G. Lluís<sup>3</sup>, C. Facundo<sup>3</sup>, F. Diekmann<sup>4</sup>, I. Revuelta<sup>4</sup>, M. Meneghini<sup>2</sup>, F. Moreso<sup>1</sup>, O. Bestard<sup>2</sup>, <sup>1</sup>*Kidney Transplantation Unit, Vall d'Hebron University Hospital, Barcelona, Spain*, <sup>2</sup>*Kidney Transplantation Unit, Bellvitge University Hospital- IDIBELL, L'Hospitalet de Llobregat. Barcelona, Spain*, <sup>3</sup>*Kidney Transplantation Unit, Puigvert University Hospital, Barcelona, Spain*, <sup>4</sup>*Kidney Transplantation Unit, Clinica University Hospital, Barcelona, Spain*

- B152**     **The Predictive Value Of Pre-transplant Biopsies For Short-term And Long-term Graft Function In Kidney Transplantation**  
H. Zhang<sup>1</sup>, L. Liu<sup>1</sup>, S. Yang<sup>2</sup>, W. Chen<sup>2</sup>, X. Chen<sup>1</sup>, Y. Li<sup>2</sup>, C. Wang<sup>1</sup>, <sup>1</sup>Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, <sup>2</sup>Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- B153**     **Can National Data Predict Which Older Kidney Donors Are More Likely to Yield Higher eGFR 1-Year Post-Transplant?**  
C. A. Custer<sup>1</sup>, R. J. Carrico<sup>1</sup>, T. L. Pruett<sup>2</sup>, <sup>1</sup>United Network for Organ Sharing, Richmond, VA, <sup>2</sup>University of Minnesota, Minneapolis, MN
- B154**     **Kidney Donor 70 Years Of Age Or Older - How Far Can We Go? A Registry Analysis**  
R. W. Gruessner, J. F. Renz, F. Tedla, A. Brar, S. Saggi, M. Salifu, A. C. Gruessner, SUNY Downstate Medical Center, Brooklyn, NY
- B155**     **Outcomes From Very Old Deceased Kidney Donors For Transplantation**  
E. Guillen<sup>1</sup>, P. Ventura-Aguiar<sup>1</sup>, A. Ruiz<sup>2</sup>, G. Piñeiro<sup>1</sup>, D. Cucchiari<sup>1</sup>, I. Revuelta<sup>1</sup>, V. Torregrosa<sup>1</sup>, F. Cofan<sup>1</sup>, E. De Sousa<sup>1</sup>, N. Esforzado<sup>1</sup>, M. Musquera<sup>3</sup>, L. Peri<sup>3</sup>, F. Oppenheimer<sup>1</sup>, F. Diekmann<sup>1</sup>, <sup>1</sup>Renal Transplant Unit, Nephrology and Kidney Transplantation Department, Hospital Clinic, Barcelona, Spain, <sup>2</sup>Organ Transplantation Coordination Department, Hospital Clinic, Barcelona, Spain, <sup>3</sup>Renal Transplant Unit, Urology Department, Hospital Clinic, Barcelona, Spain
- B156**     **Pediatric Kidneys: One for Two or Two for One?**  
D. Das, J. Harbell, A. Mathur, A. Singer, W. Hewitt, K. S. Reddy, A. Moss, R. Heilman, C. Jadlowiec, Mayo Clinic AZ, Phoenix, AZ
- B157**     **The Kidney Donor Profile Index (KDPI) Predicts the Risk of Graft Loss in Patients with a Kidney Transplant from Maastricht Type III Asystolic Donors**  
V. Lopez Jimenez, C. Casas, P. Ruiz-Esteban, M. Cabello, E. Sola, P. Hidalgo, J. Alonso, M. González-Molina, D. Hernandez, Nephrology, H.R.U Carlos Haya, Málaga, Spain
- B158**     **Impact of Cold Ischemia Time on DCD Kidney Transplant Outcomes**  
J. Narvaez, L. Kayler, Transplant Surgery Division, Dept of Surgery, University at Buffalo, Buffalo, NY
- B159**     **The Implications of Donor Proteinuria in Deceased Donor Kidney Transplantation**  
A. Vinson, T. Keough-Ryan, K. West, K. Tennankore, Dalhousie University, Halifax, NS, Canada
- B160**     **Impact of the Organ Procurement Organization Surgeon on Utilization of High KDPI Kidneys**  
C. S. Hwang<sup>1</sup>, J. Reese<sup>2</sup>, T. Anthony<sup>2</sup>, P. Vagefi<sup>1</sup>, B. Tanriover<sup>3</sup>, V. Ariyamuthu<sup>3</sup>, S. Levea<sup>3</sup>, M. MacConmara<sup>1</sup>, <sup>1</sup>Surgery, UT Southwestern Medical Center, Dallas, TX, <sup>2</sup>Southwest Transplant Alliance, Dallas, TX, <sup>3</sup>Medicine, UT Southwestern Medical Center, Dallas, TX
- B161**     **A Retrospective Analysis Evaluating Various Tissue Biopsy Scoring Systems in Predicting Recipient Outcomes Following Transplantation of Extended Criteria Donor Kidneys**  
A. Hijazi<sup>1</sup>, D. Nap<sup>1</sup>, M. Gabriel<sup>2</sup>, M. Moussa<sup>2</sup>, V. Ibrahim<sup>3</sup>, M. A. Levine<sup>4</sup>, M. Madruah<sup>4</sup>, P. Luke<sup>4</sup>, A. Sener<sup>4</sup>, <sup>1</sup>Schulich School of Medicine and Dentistry, London, ON, Canada, <sup>2</sup>Pathology, London Health Sciences Center, London, ON, Canada, <sup>3</sup>Western University, London, ON, Canada, <sup>4</sup>Urology, London Health Sciences Center, London, ON, Canada
- B162**     **Determinants of Allograft Injury during Procurement in Deceased Donors**  
E. Taber-Hight<sup>1</sup>, R. Cauwels<sup>2</sup>, E. Eidbo<sup>2</sup>, A. S. Paramesh<sup>3</sup>, R. Squires<sup>4</sup>, T. Taber<sup>1</sup>, <sup>1</sup>Nephrology, Indiana University, Indianapolis, IN, <sup>2</sup>AOPO, Vienna, VA, <sup>3</sup>Louisiana Organ Procurement Agency, New Orleans, LA, <sup>4</sup>University of Oklahoma, Oklahoma City, OK

- B163** **Clinical and Pathologic Differences between Young and Old Living Donors in Young Kidney Transplant Recipients**  
C. Baek, H. Kim, H. Lee, Y. Kim, S. Park, *Asan Medical Center, Seoul, Korea, Republic of*
- B164** **Aborted Live Donor Organ Recovery Procedures in the United States**  
M. Henderson, M. Waldram, A. Thomas, N. Desai, S. Ottman, J. Garonzik Wang, A. Massie, D. Segev, J. Bannon, F. Al Ammary, D. Brennan, *Johns Hopkins, Baltimore, MD*
- B165** **Kidney Transplants Following Donation after Circulatory Death and Donation after Brain Death Have Similar Early Outcomes**  
M. Hobeika<sup>1</sup>, D. Nguyen<sup>2</sup>, E. Graviss<sup>2</sup>, A. Gaber<sup>1</sup>, H. Podder<sup>1</sup>, S. Yi<sup>1</sup>, S. Kuten<sup>3</sup>, S. Patel<sup>3</sup>, R. Knight<sup>1</sup>, <sup>1</sup>J.C. Walter, Jr. *Transplant Center, Houston Methodist Hospital, Houston, TX, <sup>2</sup>Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist Research Institute, Houston, TX, <sup>3</sup>Pharmacy, Houston Methodist Hospital, Houston, TX*
- B166** **Can Financial Incentives Improve Patient Compliance with Optn Live Kidney Donor Follow-Up Policy? Results of a Randomized Controlled Trial**  
M. Henderson, M. Waldram, S. DiBrito, A. Thomas, F. Al Ammary, S. Ottman, A. Massie, J. Garonzik Wang, D. Segev, *Johns Hopkins, Baltimore, MD*
- B167** **Predicting Deceased Donor Kidney Transplant Outcomes: Comparing KDRI/KDPI with Machine Learning**  
E. Pahl, *HealthTech Solutions, Inc., Coralville, IA*
- B168** **Delayed Graft Function as a Survival Prognostic Factor in Elderly Recipients of Kidney Transplantation**  
G. J. Piñeiro, E. Guillen, P. Ventura, J. V. Torregrosa, R. Gelpi, I. Revuelta, F. Cofan, E. De Sousa, D. Cucchiari, J. Ugalde, F. Oppenheimer, F. Diekmann, N. Esforzado, *Nephrology and Kidney Transplantation, Hospital Clínic of Barcelona, Barcelona, Spain*
- B169** **Evaluation of Pretransplant Biopsy as a Influence Factor of Early Graft Function after Donated Kidney Transplantation**  
X. Qiuxiang, W. Zhendi, *Urology Surgery, Wuhan Union Hospital, Wuhan, China*
- B170** **Attitudes and Knowledge about Organ Donation in a Cohort of Medical Students: Association of Religion and Ethnicity**  
M. Markell, A. Cerrato, M. Salifu, *Nephrology/Medicine, SUNY Downstate Medical Center, Brooklyn, NY*
- B171** **Donor Source of Kidney Transplantation in New Zealand by Ethnicity: A Longitudinal Cohort Study**  
S. Donnellan<sup>1</sup>, N. Cross<sup>1</sup>, J. Williman<sup>2</sup>, S. C. Palmer<sup>3</sup>, <sup>1</sup>Nephrology, Canterbury District Health Board, Christchurch, New Zealand, <sup>2</sup>Biostatistics and Computational Biology Unit, University of Otago, Christchurch, New Zealand, <sup>3</sup>Medicine, University of Otago Christchurch, Christchurch, New Zealand
- B172** **A New Risk Stratification Scoring System for Deceased Donor Kidneys and Suitable Candidates for Marginal Kidneys in Korea**  
T. Koo<sup>1</sup>, J. Ryu<sup>1</sup>, S. Park<sup>2</sup>, S. Lee<sup>2</sup>, J. Hwang<sup>2</sup>, C. Ahn<sup>3</sup>, J. Yang<sup>1</sup>, <sup>1</sup>Transplantation Center, Seoul National University Hospital, Seoul, Korea, Republic of, <sup>2</sup>Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of, <sup>3</sup>Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of
- B173** **Outcomes of Renal Transplantation in Elderly Patients Older Than 60 Years of Age**  
R. Yemini<sup>1</sup>, E. Nesher<sup>2</sup>, R. Rahamimov<sup>3</sup>, S. Eizner<sup>2</sup>, V. Mazhybovsky<sup>2</sup>, V. Tennak<sup>2</sup>, M. Gurevich<sup>2</sup>, R. Ghinea<sup>2</sup>, E. Mor<sup>2</sup>, <sup>1</sup>Department of Surgery, Assuta Ashdod Medical Center, Ashdod, Israel, <sup>2</sup>Department of Transplant Surgery, Beilinson Medical Center, Petach-Tikva, Israel, <sup>3</sup>Department of Nephrology, Beilinson Medical Center, Petach-Tikva, Israel



**Poster Session B: Kidney  
Immunosuppression: Desensitization**

**B174 † 5-Year Post-Transplant Outcomes with Bortezomib-Based Desensitization in Renal Transplant Recipients**  
K. Zheng<sup>1</sup>, S. Tremblay<sup>1</sup>, A. R. Shields<sup>2</sup>, M. A. Cardi<sup>2</sup>, J. Kremer<sup>2</sup>, R. R. Alloway<sup>1</sup>, E. S. Woodle<sup>1</sup>, <sup>1</sup>*U of Cincinnati, Cincinnati, OH*, <sup>2</sup>*Christ Hospital, Cincinnati, OH*

**B175 † Reduction of Circulating DSA: Does It Affect Histology?**  
M. Gupta<sup>1</sup>, E. Edusei<sup>1</sup>, S. Tsai<sup>2</sup>, M. Magruder<sup>2</sup>, J. Lee<sup>1</sup>, J. Lee<sup>1</sup>, C. Hartono<sup>1</sup>, T. Muthukumar<sup>1</sup>, M. Everly<sup>3</sup>, D. Dadhanian<sup>1</sup>, <sup>1</sup>*Nephrology, New York Presbyterian Weill Cornell, New York, NY*, <sup>2</sup>*New York Presbyterian Weill Cornell, New York, NY*, <sup>3</sup>*Terasaki Research Institute, Los Angeles, CA*

**B176 Reduction of Pre-Existing Alloantibodies in Highly Sensitized Belatacept-Treated Kidney Recipients**  
R. F. Parsons<sup>1</sup>, S. Bumb<sup>2</sup>, H. Decker<sup>1</sup>, A. Zahid<sup>1</sup>, C. Sullivan<sup>1</sup>, T. Pearson<sup>1</sup>, C. Larsen<sup>1</sup>, M. Levine<sup>3</sup>, M. Kamoun<sup>3</sup>, R. A. Bray<sup>1</sup>, H. M. Gebel<sup>1</sup>, <sup>1</sup>*Emory University School of Medicine, Atlanta, GA*, <sup>2</sup>*University of Cincinnati, Cincinnati, OH*, <sup>3</sup>*University of Pennsylvania, Philadelphia, PA*

**B177 Successful Use of Nonantigen Specific Immunoabsorption In ABO-Incompatible Desensitization and Humoral Rejection Treatment in Kidney Transplantation**  
E. Montagud-Marrahi, *Servei de Nefrologia i Trasplantament Renal, Hospital Clínic de Barcelona, Barcelona, Spain*

**B178 Detection and Desensitization of Donor-Specific Antibody Reduces Risk of Early but Not Late Renal Transplant Failure in a Cohort of 1000 Cases**  
M. Tsai, C. Lee, C. Yang, C. Chen, *Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan*

**B179 Outcomes in Preformed Donor-Specific Human Leukocyte Antibody Positive Living Kidney Transplant Recipients Desensitized with Intravenous Immunoglobulin and Rituximab**  
Y. Kakuta<sup>1</sup>, M. Okumi<sup>1</sup>, T. Kanzawa<sup>1</sup>, K. Unagami<sup>2</sup>, H. Ishida<sup>2</sup>, K. Tanabe<sup>1</sup>, <sup>1</sup>*Urology, Tokyo Women's Medical University, Tokyo, Japan*, <sup>2</sup>*Organ Transplant Medicine, Tokyo Women's Medical University, Tokyo, Japan*

**B180 Hepatitis Flare in Hepatitis B Core Antibody Positive Kidney Recipients Treated with Rituximab**  
M. Raja<sup>1</sup>, Y. Natori<sup>1</sup>, C. Donato<sup>1</sup>, D. De Lima<sup>1</sup>, J. Rivollo<sup>2</sup>, A. Centeno<sup>2</sup>, Y. Ebisu<sup>1</sup>, L. Abbo<sup>1</sup>, J. Simkins<sup>1</sup>, S. Anjan<sup>1</sup>, J. Camargo<sup>1</sup>, M. I. Morris<sup>1</sup>, <sup>1</sup>*Internal Medicine, University of Miami Miller School of Medicine, Miami, FL*, <sup>2</sup>*Jackson Memorial Hospital, Miami, FL*

**B181 Desensitization Using Only Polyvalent Immunoglobulins (IVIg) for Kidney Transplantation with Living Donors (LD)**  
L. R. Ulisses, J. O. Paixão, P. S. Souza, G. Bezerra, H. Rodrigues, N. Panajatopoulos, F. J. De Paula, E. David-Neto, M. C. R. Castro, *Renal Transplant Service, Renal Transplant Service, Hospital das Clinicas and Laboratory of Immunology-LIM-19, Medical School of te University of São Paulo, São Paulo, Brazil, São Paulo, Brazil*

**B182 Costs Associated with A2 to B Kidney Transplantation: A Barrier to Its Utilization?**  
R. Forbes, B. Concepcion, D. Shaffer, *Vanderbilt University Medical Center, Nashville, TN*

**B183 Sequential Dosing of Rituximab and IVIg for Desensitization of Highly-HLA Sensitized (HS) Patients Awaiting HLAI Kidney Transplantation**  
A. A. Vo, E. Huang, S. Williamsons, C. Myers, A. Peng, R. Najjar, S. Sethi, K. Lim, N. Ammerman, S. C. Jordan, *Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA*



**B184**      **“Desens Light”**: Single Center Experience Using Rituximab for High Immunologic Risk Kidney Transplant Recipients with Historic DSA  
*A. Casillas-Abundis, A. Tambur, A. Shetty, C. D’Agostino, J. R. Leventhal, Comprehensive Transplant Center, Northwestern Memorial Hospital, Chicago, IL*

**B185**      **Efficacy Of Rituximab Monotherapy On Anti-human Leukocyte Antigen Antibodies In Highly Sensitized Living Donor Kidney Transplant Patients.**  
*D. J. Sindi<sup>1</sup>, A. Al Jedai<sup>2</sup>, H. Aleid<sup>3</sup>, J. Brockmann<sup>4</sup>, M. Al-Awwami<sup>5</sup>, D. Alissa<sup>2</sup>, E. De Vol<sup>6</sup>, H. Al Khabbaz<sup>7</sup>, L. Fajji<sup>8</sup>, <sup>1</sup>Clinical Pharmacy, King Faisal Specialist Hospital and Research Center (KFSH&RC), Riyadh, Saudi Arabia, <sup>2</sup>Clinical Pharmacy, KFSH&RC, Riyadh, Saudi Arabia, <sup>3</sup>Kidney and Pancreas transplantation, KFSH&RC, Riyadh, Saudi Arabia, <sup>4</sup>KFSH&RC, Riyadh, Saudi Arabia, <sup>5</sup>Clinical Director, Histocompatibility and Immunogenetics Laboratory, KFSH&RC, Riyadh, Saudi Arabia, <sup>6</sup>KFSH&RC, Riyadh, Saudi Arabia, <sup>7</sup>Riyadh Elm University, Riyadh, Saudi Arabia, <sup>8</sup>Clinical Transplant Coordinator, KFSH&RC, Riyadh, Saudi Arabia*

**B186**      **Overcoming Anti-HLA Sensitization in Kidney Transplantation**  
*R. C. Siqueira<sup>1</sup>, P. Malafrente<sup>2</sup>, J. C. Baptista-Silva<sup>2</sup>, E. F. Silva<sup>2</sup>, M. C. Camargo<sup>2</sup>, M. C. Ribeiro Castro<sup>2</sup>, <sup>1</sup>Nephrology Post-Graduation, University of Sao Paulo, São Paulo, Brazil, <sup>2</sup>Kidney Transplant Unit, Hospital Samaritano de São Paulo, São Paulo, Brazil*

**B187**      **Blood Group Incompatible Living Donor Kidney Transplantation in Patients with End-Stage Kidney Disease Due to Diabetes Kidney Disease**  
*J. Uchida<sup>1</sup>, A. Kosoku<sup>1</sup>, K. Kabei<sup>1</sup>, S. Nishide<sup>1</sup>, H. Shimada<sup>1</sup>, K. Maeda<sup>2</sup>, Y. Yoshikawa<sup>3</sup>, T. Iwai<sup>1</sup>, N. Kuwabara<sup>1</sup>, T. Naganuma<sup>1</sup>, N. Kumada<sup>4</sup>, Y. Takemoto<sup>1</sup>, T. Nakatani<sup>1</sup>, <sup>1</sup>Urology, Osaka City University Graduate School of Medicine, Osaka, Japan, <sup>2</sup>Nursing, Osaka City University Hospital, Osaka, Japan, <sup>3</sup>Osaka City University, Osaka, Japan, <sup>4</sup>Urology, Suita Municipal Hospital, Suita, Japan*

**B188**      **Desensitization Using Only IVIG: Is That an Option for Highly-Sensitized Patients Waiting for Kidneys from Cadaveric Donors?**  
*J. O. Paixão, L. R. Ulisses, P. S. Souza, G. Bezerra, F. Agena, H. P. Rodrigues, N. Panajotopoulos, F. J. Paula, E. David-Neto, M. R. Castro, Nefrologia, Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil*

## **Poster Session B: Kidney Immunosuppression: Induction Therapy**

**B189**      **Induction Therapy in Elderly Kidney Transplant Recipients with Low Immunological Risk**  
*C. Masset<sup>1</sup>, J. Boucquemont<sup>2</sup>, V. Garrigue<sup>3</sup>, M. Ladrière<sup>4</sup>, F. Buron<sup>5</sup>, E. Cassuto<sup>6</sup>, Y. Foucher<sup>2</sup>, J. Dantal<sup>1</sup>, <sup>1</sup>University Hospital of Nantes, Nantes, France, <sup>2</sup>University of Nantes, Nantes, France, <sup>3</sup>University Hospital of Montpellier, Montpellier, France, <sup>4</sup>University Hospital of Nancy, Nancy, France, <sup>5</sup>University Hospital of Lyon, Lyon, France, <sup>6</sup>University Hospital of Nice, Nice, France*

**B190**      **Safety and Efficacy of Alemtuzumab Compared to Rabbit Anti-Thymocyte Globulin as Induction for Secondary Transplant after a Primary Transplant with Alemtuzumab Induction**  
*J. L. Fose<sup>1</sup>, M. R. Jorgenson<sup>1</sup>, G. E. Levenson<sup>2</sup>, R. R. Redfield<sup>2</sup>, <sup>1</sup>Pharmacy, UW Health, Madison, WI, <sup>2</sup>University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI*

**B191**      **Alemtuzumab Induction in Living Donor Renal Transplantation**  
*O. Witkowsky, H. Winters, K. Washburn, G. Bumgardner, A. Rajab, A. El-Hinnawi, T. Pesavento, The Ohio State University Wexner Medical center, Columbus, OH*

**B192 †**      **Induction Type Does Not Influence Kidney Graft or Patient Survival in Recipients with a Previous Lung Transplant in the United States**  
*S. Riad<sup>1</sup>, U. Goswami<sup>2</sup>, S. Jackson<sup>3</sup>, M. Hertz<sup>2</sup>, <sup>1</sup>Medicine, University of Minnesota, Eden Prairie, MN, <sup>2</sup>Medicine, University of Minnesota, Minneapolis, MN, <sup>3</sup>Complex Care Analytics, Fairview Health Services, Minneapolis, MN*

- B193** **Kidney Transplantation in Older Recipients with HLA-DR Mismatch: Impact of Induction Type on Outcomes**  
K. K. Sureshkumar<sup>1</sup>, N. L. Thai<sup>2</sup>, B. Chopra<sup>1</sup>, <sup>1</sup>*Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, PA*, <sup>2</sup>*Abdominal Transplantation, Allegheny General Hospital, Pittsburgh, PA*
- B194** **Alemtuzumab versus Anti-Thymocyte Globulin Induction in the Setting of Immediate Post-Renal Transplant Acute Tubular Necrosis in an Urban, Minority Patient Population**  
K. Tejani, E. Benedetti, A. Lichvar, *University of Illinois at Chicago, Chicago, IL*
- B195** **Living Donor Renal Transplantation without Any Induction Immunosuppression in Spousal Donors - Single Center Experience**  
R. Bhat, F. Aziz, I. N. Abubecker, S. Narayanan, B. Hafeeqe, *Nephrology & Transplantation, Malabar Institute of Medical Sciences, Calicut, India*
- B196** **Induction with Thymoglobulin in DCD Kidneys. Dose Effect and Predictors of Outcome**  
A. Asderakis, T. Sabah, A. Jones, E. Ablorsu, L. Szabó, R. Chavez, *Cardiff Transplant Unit, University Hospital of Wales, Cardiff, United Kingdom*
- B197** **Thymoglobulin Versus Alemtuzumab Induction in High Immunologic Risk Kidney Transplants**  
J. Lockridge<sup>1</sup>, J. Pryor<sup>1</sup>, D. Norman<sup>1</sup>, A. Olyaei<sup>2</sup>, <sup>1</sup>*OHSU, Portland, OR*, <sup>2</sup>*Pharmacy, OHSU, Portland, OR*
- B198** **Combined Antithymocyte Globulin (ATG) and Rituximab (RTX) Induction in African American (AA) Kidney Transplant Recipients**  
S. J. Patel, S. Kuten, C. Pham, R. Knight, M. Hobeika, D. Nguyen, E. Graviss, S. Yi, T. Eagar, A. Gaber, *Methodist Hospital, Houston, TX*
- B199** **Safety Outcomes in Elderly Patients Who Receive Alemtuzumab Induction for Kidney Transplant**  
S. Anders, A. Freeman, A. Mohammed, L. Hutchinson, U. Kaszubski, M. Janusek, J. Garces, H. Bohorquez, *Ochsner Clinic Foundation, New Orleans, LA*
- B200** **Induction Type Does Not Influence Kidney Graft or Patient Survival in Recipients with a Previous Heart Transplant in the United States**  
S. M. Riad<sup>1</sup>, A. Tamas<sup>1</sup>, S. Jackson<sup>2</sup>, C. Martin<sup>1</sup>, <sup>1</sup>*Medicine, University of Minnesota, Minneapolis, MN*, <sup>2</sup>*Complex Care Analytics, Fairview Health Services, Minneapolis, MN*
- B201** **Outcomes of Reduced Thymoglobulin Induction Dosing in Elderly Kidney Transplant Recipients at a Steroid Sparing Center**  
E. C. Liu, J. H. Lee, R. Abramova, *Pharmacy, NewYork-Presbyterian, New York, NY*
- B202** **Low Dose Anti-Thymocyte Globulin is Enough to Prevent Acute Cellular Rejection in Kidney Transplant**  
P. W. Baron<sup>1</sup>, J. Weissman<sup>2</sup>, F. Fazeli<sup>3</sup>, C. Zuppan<sup>4</sup>, R. Villicana<sup>3</sup>, P. Wai<sup>1</sup>, L. Beeson<sup>5</sup>, M. De Vera<sup>1</sup>, <sup>1</sup>*Surgery/Transplantation Institute, Loma Linda University Health, Loma Linda, CA*, <sup>2</sup>*Pharmacy, Loma Linda University Health, Loma Linda, CA*, <sup>3</sup>*Transplantation Institute, Loma Linda University Health, Loma Linda, CA*, <sup>4</sup>*Pathology, Loma Linda University Health, Loma Linda, CA*, <sup>5</sup>*Center for Nutrition, Healthy Lifestyle and Disease Prevention/School of Public Health, Loma Linda University Health, Loma Linda, CA*
- B203** **Basiliximab vs. Low-Dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients: Prospective Randomized Study in Southeastern Mexico**  
G. Martinez-Mier, P. I. Moreno-Ley, L. F. Budar-Fernandez, M. T. Mendez-Lopez, D. A. Barrera-Amoros, M. De la Paz-Roman, L. A. Jimenez-López, E. G. Aguilar-Sandoval, C. A. Allende-Castellanos, *Organ Transplantation & Research, IMSS UMAE HE 14, Veracruz, Mexico*

- B204**      **Alemtuzumab versus Antithymocyte Globulin Induction Immunosuppression in Highly Sensitized Kidney Transplant Recipients**  
A. Brueckner<sup>1</sup>, E. Yanqui<sup>1</sup>, C. Truong<sup>1</sup>, R. Baliga<sup>2</sup>, L. Bowman<sup>1</sup>, <sup>1</sup>Tampa General Hospital, Tampa, FL, <sup>2</sup>Florida Kidney Physicians, Tampa, FL
- B205**      **Type of Induction Does Not Impact Patient or Kidney Allograft Survival in Simultaneous Liver and Kidney Transplant Recipients in the United States**  
S. Riad<sup>1</sup>, N. Lim<sup>2</sup>, S. Jackson<sup>3</sup>, J. Lake<sup>2</sup>, <sup>1</sup>University of Minnesota, Minneapolis, MN, <sup>2</sup>Medicine, University of Minnesota, Minneapolis, MN, <sup>3</sup>Complex Care Analytics, Fairview Health Services, Minneapolis, MN
- B206**      **Comparing the Rate of Opportunistic Infection after Renal Transplant between Alemtuzumab and Basiliximab for Induction Immunosuppression**  
J. A. Seaman<sup>1</sup>, S. G. Westphal<sup>2</sup>, F. Qiu<sup>3</sup>, D. Bremers<sup>4</sup>, D. Florescu<sup>5</sup>, <sup>1</sup>College of Medicine, University of Nebraska Medical Center, Omaha, NE, <sup>2</sup>Internal Medicine Division of Nephrology, University of Nebraska Medical Center, Omaha, NE, <sup>3</sup>Biostatistics, University of Nebraska Medical Center, Omaha, NE, <sup>4</sup>Donate Life, Nebraska Medicine, Omaha, NE, <sup>5</sup>Internal Medicine Division of Infectious Disease, University of Nebraska Medical Center, Omaha, NE
- B207**      **Evaluation of Induction Immunosuppression in Elderly Kidney Transplant Recipients**  
C. Pham, S. Kuten, A. Rogers, R. Knight, D. T. Nguyen, E. Graviss, A. Gaber, Houston Methodist Hospital, Houston, TX
- B208**      **Outcomes Of Dosing Weight Selection On Rabbit Anti-thymocyte Globulin Induction Immunosuppression In High-risk, Obese Renal Transplant Recipients**  
A. C. Cordry<sup>1</sup>, K. Trobaugh<sup>1</sup>, L. Ramsey<sup>2</sup>, A. L. Castellanos<sup>3</sup>, H. Fattah<sup>3</sup>, T. Rendulic<sup>1</sup>, <sup>1</sup>Pharmacy, University of Kentucky HealthCare, Lexington, KY, <sup>2</sup>University of Kentucky College of Pharmacy, Lexington, KY, <sup>3</sup>Nephrology, University of Kentucky HealthCare, Lexington, KY
- B209**      **Outcomes of Induction Therapy with Bortezomib and High-Dose Intravenous Immunoglobulin for Kidney Transplantation with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies**  
Y. Miyauchi, T. Noda, N. Miura, T. Kikugawa, T. Saika, Department of Urology, Ehime University, Toon, Japan
- B210 †**    **Panel Reactive Antibody Stratification as a Guide to Induction Selection in Deceased-Donor Kidney Transplantation: Impact of Clinical Practice on Outcomes**  
H. Ibrahim<sup>1</sup>, J. Gregg<sup>1</sup>, K. Alquadan<sup>1</sup>, U. Akanit<sup>2</sup>, K. L. Womer<sup>1</sup>, A. H. Santos<sup>1</sup>, <sup>1</sup>Medicine, University of Florida, Gainesville, FL, <sup>2</sup>Ubon Ratchathani University, Ubonratchathani, Thailand
- B211**      **Impact Of Rituximab And Maintenance Steroid In The Recurrence Of Focal Segmental Glomerulosclerosis**  
L. A. Mendez Castaner, Transplant, Miami Transplant Institute-University of Miami, Miami, FL
- 
- Poster Session B: Kidney Infections**
- B212**      **Impact of Protease Inhibitor-Based Anti-Retroviral Therapy on Tacrolimus Inpatient Variability in HIV+ Kidney Transplant Recipients**  
M. H. Cooper, I. E. Dunne, S. A. Kuten, A. E. Cantwell, E. A. Graviss, D. T. Nguyen, M. J. Hobeika, A. O. Gaber, Houston Methodist Hospital, Houston, TX

- B213** **A Cluster of Late Onset of Pneumocystis jirovecii Pneumonia (PJP) in Renal Transplant Patients: First Cluster Report from Saudi Arabia**  
Y. Aljishi, M. AlBugumi, A. Abadi, A. AlJanobi, M. Al Lawiam, N. Alzawad, M. Al Sardi, Z. AlMaa, H. Al-Ramadan, J. Kabanja, N. Rayyan, k. Beleed-Akkari, *King Fahad specialist hospital - Dammam, Dammam, Saudi Arabia*
- B214** **The Association Of Frailty With Risk Of Cytomegalovirus And BK Infection**  
J. Norman<sup>1</sup>, A. Gupta<sup>2</sup>, A. Naik<sup>3</sup>, D. Cibrik<sup>2</sup>, S. Norman<sup>3</sup>, <sup>1</sup>Internal Medicine, Univ of Michigan Medical Ctr, Ann Arbor, MI, <sup>2</sup>Internal Medicine/Nephrology, Kansas University Medical Center, Kansas City, KS, <sup>3</sup>Internal Medicine/Nephrology, Univ of Michigan Medical Ctr, Ann Arbor, MI
- B215** **Retrospective Evaluation of Dapsone Prophylaxis Complications in Kidney Transplant Recipients**  
S. Hamel<sup>1</sup>, V. Johnson<sup>2</sup>, D. Johnson<sup>2</sup>, E. Blumberg<sup>3</sup>, R. Bloom<sup>4</sup>, J. Trofe-Clark<sup>2</sup>, <sup>1</sup>Pharmacy, Vanderbilt Univ. Medical Center, Nashville, TN, <sup>2</sup>Pharmacy, Hospital of the Univ. of Pennsylvania, Philadelphia, PA, <sup>3</sup>Infectious Diseases, Univ. of Pennsylvania, Philadelphia, PA, <sup>4</sup>Renal, Univ. of Pennsylvania, Philadelphia, PA
- B216** **Evaluation of Rabbit Antithymocyte Globulin (rATG) Dosing and Incidence of Opportunistic Viral Infections in Kidney Transplant Recipients Using Tacrolimus (TAC), Mycophenolate (MPA) and Steroid Free Maintenance Immunosuppression**  
L. Von Stein, A. Leino, R. Amer, T. Pesavento, H. Winters, *The Ohio State University Wexner Medical Center, Columbus, OH*
- B217** **Approach to Leukopenia in Older Kidney Transplant Recipients**  
M. Shearer, M. Labonte, L. Erbe, R. Rodgriguez, A. Price, V. Rao, M. Casey, K. Soliman, D. Lazarus, D. Taber, M. Posadas Salas, *Dept of Medicine, Medical University of South Carolina, Charleston, SC*
- B218** **Multidisciplinary Transplant UTI Service; Challenging the Stalemate**  
J. J. Chong, A. Adiki, D. Ness, J. Olsburgh, R. H. Zakri, *Guy's Hospital, London, United Kingdom*
- B219** **Prevalence of Varicella Zoster Infection in Renal Transplant Recipients**  
P. T. Gaynor, D. Nanayakkara, O. E. Beaird, J. Schaeenman, S. Bunnapradist, *Infectious Diseases, UCLA, Los Angeles, CA*
- B220** **Low-Dose Valacyclovir Prophylaxis for Cytomegalovirus Infection in Renal Transplant Recipients with Intermediate Risk**  
A. Velioglu<sup>1</sup>, H. Arikan<sup>1</sup>, E. Asicioglu<sup>1</sup>, S. Alagoz<sup>2</sup>, N. Seyahi<sup>2</sup>, S. Tuglular<sup>1</sup>, C. Ozener<sup>1</sup>, <sup>1</sup>Nephrology, Marmara University School of Medicine, Istanbul, Turkey, <sup>2</sup>Nephrology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey
- B221** **Association of Induction Immunosuppression Agents with Incidence of Cytomegalovirus Infection Following Kidney Transplantation**  
S. A. Medani, B. C. Astor, A. Djamali, M. A. Mohamed, *Medicine- Nephrology, University of Wisconsin, Madison, WI*
- B222 †** **Epidemiology of Parvovirus B19 and Anemia among Kidney Transplant Recipients**  
N. Khoury<sup>1</sup>, C. Thongprayoon<sup>2</sup>, N. Leeaphorn<sup>3</sup>, J. Bruminhent<sup>4</sup>, W. Cheungpasitporn<sup>5</sup>, <sup>1</sup>Henry Ford Transplant Institute, Detroit, MI, <sup>2</sup>Mayo Clinic, Rochester, MN, <sup>3</sup>University of Missouri, Kansas City, MO, <sup>4</sup>Mahidol University, Bangkok, Thailand, <sup>5</sup>University of Mississippi, Jackson, MS
- B223** **Donor-Derived Carbapenem-Resistant Klebsiella Pneumoniae Infection after Renal Transplantation**  
B. Liu, M. Wang, F. Zeng, S. Chang, N. Gong, G. Chen, Z. Chen, *Institute of Transplantation, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China*



- B224**      **Evaluation of Infection and Renal Transplant Outcomes in the Hmong Population**  
M. Jorgenson<sup>1</sup>, J. Descourouez<sup>1</sup>, D. Yang<sup>2</sup>, G. Levenson<sup>2</sup>, J. Smith<sup>2</sup>, R. Redfield<sup>2</sup>, <sup>1</sup>*UW Health, Madison, WI*, <sup>2</sup>*University of Wisconsin School of Medicine and Public Health, Madison, WI*
- B225**      **Treatment of Latent Tuberculosis Infection with Short-Course Regimens in Potential Living Kidney Donors**  
J. Simkins, C. Donato-Santana, M. I. Morris, L. M. Abbo, J. F. Camargo, S. Anjan, Y. Natori, G. Guerra, *Medicine, University of Miami, Miami, FL*
- B226**      **Kidney Transplantation in Patients with Neurogenic Bladder**  
Z. Jurekovic, M. Knotek, *Clinical Hospital Merkur, 10000 Zagreb, Croatia*
- B227**      **Effect of Induction Therapy on Absolute CD4 Count and CD4 Percentage in HIV Positive Kidney Transplant Recipients**  
S. A. Kuten<sup>1</sup>, I. E. Dunne<sup>1</sup>, A. E. Cantwell<sup>1</sup>, M. J. Hobeika<sup>2</sup>, S. G. Yi<sup>2</sup>, W. Musick<sup>1</sup>, R. J. Knight<sup>2</sup>, A. O. Gaber<sup>2</sup>, <sup>1</sup>*Pharmacy, Houston Methodist Hospital, Houston, TX*, <sup>2</sup>*Surgery, Houston Methodist Hospital, Houston, TX*
- B228**      **Epidemiology and Risk Factors of Early Post-Transplant Clostridium difficile Infection in Renal Transplant Recipients**  
M. Jorgenson<sup>1</sup>, J. Descourouez<sup>1</sup>, D. Yang<sup>2</sup>, G. Levenson<sup>2</sup>, C. Saddler<sup>2</sup>, J. Smith<sup>2</sup>, R. Redfield<sup>2</sup>, <sup>1</sup>*UW Health, Madison, WI*, <sup>2</sup>*University of Wisconsin School of Medicine and Public Health, Madison, WI*
- B229**      **Risk Factors for Recurrent Urinary Tract Infections and Antimicrobial Resistant Organisms in Kidney Transplant Recipients**  
S. Greissman<sup>1</sup>, A. Mattiazzi<sup>2</sup>, J. Quinonez<sup>1</sup>, M. Grady<sup>1</sup>, R. Zukerman<sup>1</sup>, A. Wawrzyniak<sup>3</sup>, M. Morris<sup>4</sup>, S. Anjan<sup>4</sup>, J. Simkins<sup>4</sup>, J. Camargo<sup>4</sup>, L. Abbo<sup>5</sup>, <sup>1</sup>*University of Miami Miller School of Medicine, Miami, FL*, <sup>2</sup>*Department of Transplant Nephrology, University of Miami Miller School of Medicine, Miami, FL*, <sup>3</sup>*Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL*, <sup>4</sup>*Department of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL*, <sup>5</sup>*Department of Infection Control and Prevention and Antimicrobial Stewardship, University of Miami Miller School of Medicine, Miami, FL*
- B230 †**      **Real World Data Support International Consensus Guidelines on Management of CMV after Kidney Transplantation**  
A. Asberg, G. B. Kro, A. V. Reisæter, A. Hartmann, K. Midtvedt, *Oslo University Hospital - Rikshospitalet, Oslo, Norway*
- B231 †**      **Risk of Opportunistic Infection in Kidney Transplant Recipients with Cytomegalovirus Infection and Associated Outcomes**  
M. Jorgenson<sup>1</sup>, J. Descourouez<sup>1</sup>, B. Cardinale<sup>2</sup>, B. Lyu<sup>3</sup>, B. Astor<sup>3</sup>, N. Garg<sup>3</sup>, C. Saddler<sup>3</sup>, J. Smith<sup>3</sup>, D. Mandelbrot<sup>3</sup>, <sup>1</sup>*UW Health, Madison, WI*, <sup>2</sup>*University of Wisconsin-Madison School of Pharmacy, Madison, WI*, <sup>3</sup>*University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI*
- B232**      **Incidence of Viral Infections in Kidney Transplant Recipients with Alemtuzumab or Rabbit Antithymocyte Globulin Induction**  
A. Brueckner<sup>1</sup>, C. Truong<sup>1</sup>, E. Yanqui<sup>1</sup>, R. Baliga<sup>2</sup>, L. Bowman<sup>1</sup>, <sup>1</sup>*Tampa General Hospital, Tampa, FL*, <sup>2</sup>*Florida Kidney Physicians, Tampa, FL*



**B233 † Human Adenovirus-Specific T Cell Response in Kidney Transplant Recipients Diagnosed with Adenovirus Infection**  
J. Bruminhent<sup>1</sup>, N. Apiwattanakul<sup>2</sup>, S. Hongeng<sup>3</sup>, S. Kantachuvessiri<sup>4</sup>, S. P. Watcharananan<sup>1</sup>, <sup>1</sup>*Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand,* <sup>2</sup>*Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand,* <sup>3</sup>*Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand,* <sup>4</sup>*Division of Nephrology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand*

**B234 The Natural History and Time to Seroconversion of CMV in the Era of Post-Transplantation Chemoprophylaxis: A Single Center Study**  
S. Farran, T. Zangeneh, M. Al-Obaidi, *Division of Infectious Diseases, University of Arizona, Tucson, AZ*

**B235 Pneumocystis jirovecii Pneumonia among Kidney Transplant Recipients: The Forgotten Infection**  
L. Bowman<sup>1</sup>, R. Baliga<sup>2</sup>, K. Zeitler<sup>1</sup>, <sup>1</sup>*Tampa General Hospital, Tampa, FL,* <sup>2</sup>*Florida Kidney Physicians, Tampa, FL*

**B236 † Kidney Biopsies In Hiv-negative To Hiv-positive Kidney Transplants - An Institutional Experience**  
V. Walavalkar<sup>1</sup>, A. Zarinsefat<sup>2</sup>, A. Urisman<sup>1</sup>, D. Dobi<sup>1</sup>, J. Vasquez<sup>3</sup>, P. Stock<sup>2</sup>, Z. Laszik<sup>1</sup>, <sup>1</sup>*Pathology, UCSF Medical Center, San Francisco, CA,* <sup>2</sup>*Transplant Surgery, UCSF Medical Center, San Francisco, CA,* <sup>3</sup>*Medicine, UCSF Medical Center, San Francisco, CA*

**B237 Effect of Influenza Vaccine in Patients with Kidney Transplant during 2017/2018**  
K. Tsujimura<sup>1</sup>, M. Ota<sup>1</sup>, H. Ishida<sup>2</sup>, K. Tanabe<sup>2</sup>, <sup>1</sup>*Surgery, Tomishiro Central Hospital, Okinawa, Japan,* <sup>2</sup>*Urology, Tokyo Women's Medical University, Tokyo, Japan*

**B238 The Significance and Impact of Screening Preservation Fluid Cultures in Renal Transplant Recipients**  
A. Reticker, A. Lichvar, A. Gross, E. Benedetti, S. Patel, *University of Illinois Hospital and Health Sciences System, Chicago, IL*

**B239 Pharmacokinetics of Innovative versus Generic Valganciclovir in Kidney Transplant Recipients**  
I. Parra-Avila<sup>1</sup>, A. Cohen-Bucay<sup>1</sup>, J. Alberu<sup>2</sup>, G. Castañeda-Hernandez<sup>3</sup>, L. E. Morales-Buenrostro<sup>1</sup>, <sup>1</sup>*Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición, Ciudad de Mexico, Mexico,* <sup>2</sup>*Transplant, Instituto Nacional de Ciencias Médicas y Nutrición, Ciudad de Mexico, Mexico,* <sup>3</sup>*Pharmacology, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Ciudad de Mexico, Mexico*

**B240 No Indication of Increased CMV Infection in Kidney Transplant Recipients without Pharmacological Prophylaxis Receiving a Single 3mg/kg Dose of Rabbit Anti-Thymocyte Globulin (ATG) Instead of No-Induction**  
M. Ivani de Paula, M. Grace Bowring, A. A. Shaffer, J. Garonzik-Wang, A. Barros Bessa, C. Rosso Felipe, M. Pontello Cristelli, A. B. Massie, J. Medina Pestana, H. Silva Junior, D. L. Segev, *Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil*

**Poster Session B: Kidney Living Donor: Long Term Outcomes**

**B241 Preoperative Marginal Factors Do Not Affect the Medically Complex Living Donors for Kidney Transplantation**  
T. Hiramitsu, T. Tomosugi, K. Futamura, M. Okada, M. Tsujita, T. Ichimori, N. Goto, S. Narumi, Y. Watarai, *Nagoya Daini Red Cross Hospital, Nagoya Aichi, Japan*

- B242 Kidney Volumes in Healthy Donors - Does Size Really Matter?**  
F. R. Schwartz<sup>1</sup>, B. I. Shaw<sup>2</sup>, F. Vernuccio<sup>1</sup>, F. Rigioli<sup>1</sup>, F. Gonzalez<sup>1</sup>, R. Lerebours<sup>3</sup>, K. Ravindra<sup>2</sup>, D. Marin<sup>1</sup>,  
<sup>1</sup>Radiology, Duke University, Durham, NC, <sup>2</sup>General Surgery, Duke University, Durham, NC, <sup>3</sup>Biostatistics and Bioinformatics, Duke University, Durham, NC
- B243 Post-Donation Hypertension is Highly Associated with Estimated Nephron Number, Post-Donation Weight Gain, and Family History: A Prospective 5-Year Follow-Up after Living Kidney Donation**  
T. Schachtner<sup>1</sup>, N. M. Otto<sup>2</sup>, P. Reinke<sup>2</sup>,  
<sup>1</sup>University Hospital Zurich, Zurich, Switzerland, <sup>2</sup>Charite University Medicine Berlin, Zurich, Germany
- B244 Gender Disparity: Do Female Donors Suffer from Living Kidney Donation?**  
N. Ebeling<sup>1</sup>, B. Suwelack<sup>1</sup>, M. Burgmer<sup>2</sup>, a. the SoLKiD Study Group<sup>1</sup>, <sup>1</sup>MED D, Universitaetsklinikum Muenster, Muenster, Germany, <sup>2</sup>Psychosomatic medicine, Universitaetsklinikum Muenster, Muenster, Germany
- B245 Long-Term Outcomes and Safety of Living Kidney Transplantation from Older Donors**  
Y. Kakuta<sup>1</sup>, M. Okumi<sup>1</sup>, T. Kanzawa<sup>1</sup>, K. Unagami<sup>2</sup>, H. Ishida<sup>2</sup>, K. Tanabe<sup>1</sup>,  
<sup>1</sup>Urology, Tokyo Women's Medical University, Tokyo, Japan, <sup>2</sup>Organ Transplant Medicine, Tokyo Women's Medical University, Tokyo, Japan
- B246 † Poor Outcomes in Kidney Transplant Candidates & Recipients with History of Falls**  
N. Chu<sup>1</sup>, H. Ying<sup>1</sup>, Z. Shi<sup>1</sup>, C. Haugen<sup>1</sup>, S. Norman<sup>2</sup>, D. Segev<sup>1</sup>, M. McAdams-DeMarco<sup>1</sup>, <sup>1</sup>Johns Hopkins, Baltimore, MD, <sup>2</sup>Michigan Medical Center, Ann Arbor, MI
- B247 High HLA-DQ Epitope Mismatch Load and Low Tacrolimus Level Are Associated with Development of De Novo Donor Specific Antibody**  
D. Lee<sup>1</sup>, B. Kim<sup>2</sup>, J. Kim<sup>3</sup>, I. Kim<sup>4</sup>, M. Jeon<sup>5</sup>, J. Ahn<sup>1</sup>, S. Choi<sup>6</sup>, <sup>1</sup>Nephrology, Maryknoll Medical Center, Busan 48972, Korea, Republic of, <sup>2</sup>Laboratory Medicine, Maryknoll Medical Center, Busan 48972, Korea, Republic of, <sup>3</sup>Surgery, Maryknoll Medical Center, Busan 48972, Korea, Republic of, <sup>4</sup>Urology, Maryknoll Medical Center, Busan 48972, Korea, Republic of, <sup>5</sup>Pathology, Maryknoll Medical Center, Busan 48972, Korea, Republic of, <sup>6</sup>Transplantation Center, Coordinator : Nurse, Maryknoll Medical Center, Busan 48972, Korea, Republic of
- B248 Outcomes after Prolonged Therapeutic Plasma Exchange in Pediatric Kidney Transplant Patients with Early Recurrence of Focal Segmental Glomerular Sclerosis**  
D. K. O'Connor<sup>1</sup>, P. R. Srivaths<sup>2</sup>, K. Hosek<sup>3</sup>, E. Gerzina<sup>1</sup>, A. Huynh<sup>1</sup>, A. Thorsen<sup>1</sup>, E. Brewer<sup>2</sup>, T. Galvan<sup>1</sup>,  
<sup>1</sup>Division of Abdominal Transplantation, Baylor College of Medicine, Houston, TX, <sup>2</sup>Department of Pediatrics, Baylor College of Medicine, Houston, TX, <sup>3</sup>Texas Children's Hospital, Houston, TX
- B249 Long-Term Outcomes of Elderly Living Donors: A Nationwide Population-Based Study**  
H. Yoon<sup>1</sup>, Y. Kim<sup>2</sup>, S. Shin<sup>1</sup>, J. Ahn<sup>3</sup>, C. Yang<sup>1</sup>, B. Chung<sup>1</sup>, <sup>1</sup>-The Catholic University of Korea, -Seoul, Korea, Republic of, <sup>2</sup>Yonsei University Wonju College of Medicine, Wonju, Korea, Republic of, <sup>3</sup>Department of Information & Statistics, Yonsei University, Wonju, Korea, Republic of
- B250 Qualitative Recovery Outcomes of Living Kidney Donors**  
J. Huang<sup>1</sup>, M. Mahoney<sup>2</sup>, J. Buggs<sup>1</sup>, E. Rogers<sup>1</sup>, A. Kumar<sup>3</sup>, <sup>1</sup>Tampa General Hospital, Tampa, FL, <sup>2</sup>University of Florida, Gainesville, FL, <sup>3</sup>University of South Florida, Tampa, FL

**B251**      **Quality of Life in Tolerant Living Donor Kidney Transplants vs. Standard of Care**  
 D. Tollerud<sup>1</sup>, J. Leventhal<sup>2</sup>, J. Galvin<sup>2</sup>, J. Mathew<sup>2</sup>, L. Gallon<sup>2</sup>, D. Stare<sup>2</sup>, J. Miller<sup>2</sup>, M. Abecassis<sup>2</sup>, S. Ildstad<sup>3</sup>, <sup>1</sup>*Regenerex, Inc., Louisville, KY*, <sup>2</sup>*Northwestern U, Chicago, IL*, <sup>3</sup>*U of Louisville, Louisville, KY*

**B256**      **Unusual Suspects: Real Time Physiological Evaluation of Stressors during Laparoscopic Donor Nephrectomy**  
 C. A. Wilson<sup>1</sup>, S. Chahine<sup>1</sup>, S. Cristancho<sup>1</sup>, S. Aquil<sup>2</sup>, M. Mandurah<sup>2</sup>, M. A. Levine<sup>2</sup>, A. Sener<sup>2</sup>, <sup>1</sup>*Psychology and Center for Education Research & Innovation, Western University, London, ON, Canada*, <sup>2</sup>*Surgery, Western University, London, ON, Canada*

**Poster Session B: Kidney Living Donor: Quality and Selection**

**B252 †**      **Long-Term Influence of Arteriosclerosis in Kidney Grafts Proven by a Zero-Hour Biopsy**  
 Y. Kakuta<sup>1</sup>, M. Okumi<sup>1</sup>, T. Kanzawa<sup>1</sup>, K. Unagami<sup>2</sup>, H. Ishida<sup>1</sup>, K. Tanabe<sup>1</sup>, <sup>1</sup>*Urology, Tokyo Women's Medical University, Tokyo, Japan*, <sup>2</sup>*Organ Transplant Medicine, Tokyo Women's Medical University, Tokyo, Japan*

**B257**      **Hypertrophy Prediction Model for Contralateral Kidney after Living Donation**  
 K. Okumura<sup>1</sup>, K. Tanaka<sup>2</sup>, Y. Hidaka<sup>2</sup>, M. Toyoda<sup>3</sup>, S. Uekihara<sup>3</sup>, A. Inadome<sup>4</sup>, H. Yokomizo<sup>2</sup>, S. Yamanaga<sup>2</sup>, <sup>1</sup>*Department of Surgery, University of Pittsburgh, Pittsburgh, PA*, <sup>2</sup>*Department of Surgery, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan*, <sup>3</sup>*Department of Nephrology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan*, <sup>4</sup>*Department of Urology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan*

**B253 †**      **Enhanced Advocacy and Health Systems Training through Patient Navigation Increases Access to Living Donor Kidney Transplantation**  
 R. D. Reed<sup>1</sup>, V. Kumar<sup>1</sup>, B. Berry<sup>1</sup>, D. Hendricks<sup>1</sup>, A. Carter<sup>1</sup>, B. A. Shelton<sup>1</sup>, M. N. Mustian<sup>1</sup>, P. A. MacLennan<sup>1</sup>, H. Qu<sup>1</sup>, L. Hannon<sup>2</sup>, C. Yates<sup>2</sup>, M. J. Hanaway<sup>1</sup>, J. E. Locke<sup>1</sup>, <sup>1</sup>*University of Alabama at Birmingham, Birmingham, AL*, <sup>2</sup>*Tuskegee University, Tuskegee, AL*

**B258**      **Evolution Of Right Laparoscopic Nephrectomy, Report Of A Tertiary Care Center In Mexico**  
 L. Noriega- Salas, J. Cruz-Santiago, M. Quiñones-Gamero, J. Barcena, M. De Gante, G. Bernaldez-Gomez, *Transplant Department, Instituto Mexicano Del Seguro Social, Mexico City, Mexico*

**B254 †**      **Post-Transplant Functional Status Trajectory among Adult Kidney Transplant Recipients**  
 N. Chu, Z. Shi, H. Ying, C. Haugen, D. Segev, M. McAdams-DeMarco, *Johns Hopkins University, Baltimore, MD*

**B259**      **Two-Year, Single Center, Retrospective Review of Herbal Supplement Use in Living Kidney Donors**  
 N. Persun<sup>1</sup>, D. Johnson<sup>1</sup>, A. Leonberg-Yoo<sup>2</sup>, J. Bahrainwala<sup>2</sup>, P. P. Reese<sup>2</sup>, D. M. Collins<sup>3</sup>, M. Houston<sup>3</sup>, A. Najj<sup>4</sup>, J. Trofe-Clark<sup>1</sup>, <sup>1</sup>*Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA*, <sup>2</sup>*Renal Division, Perelman School of Medicine, Univ. of Pennsylvania, Philadelphia, PA*, <sup>3</sup>*Hospital of the University of Pennsylvania, Philadelphia, PA*, <sup>4</sup>*Surgery, Perelman School of Medicine, Univ. of Pennsylvania, Philadelphia, PA*

**B255**      **Facilitators and Barriers to the Implementation of Culturally Competent Care to Increase Living Kidney Donation in Transplant Centers**  
 E. J. Gordon, E. Romo, D. Amortegui, A. Rodas, N. Anderson, J. Uriarte, J. Caicedo, M. Shumate, *Northwestern University, Chicago, IL*

- B260**      **The Outcomes of Living Donor Kidney Transplantation in Donors or Recipients with Donors' Renal Arteriosclerotic Lesions on Preoperative Computed Tomography**  
Y. Miyauchi, T. Noda, N. Miura, T. Kikugawa, T. Saika, *Ehime University, Toon, Japan*
- B261**      **Renal Pathological Findings in Living Kidney Donor Candidates with Minimal Urinary Abnormalities**  
H. Ahmed<sup>1</sup>, C. Drachenberg<sup>2</sup>, R. Ugarte<sup>1</sup>, N. Costa<sup>1</sup>, C. Cangro<sup>1</sup>, R. N. Barth<sup>3</sup>, M. Weir<sup>1</sup>, A. Harirain<sup>1</sup>, <sup>1</sup>*Medicine-Nephrology, University of Maryland Medical Center, Baltimore, MD*, <sup>2</sup>*Pathology, University of Maryland Medical Center, Baltimore, MD*, <sup>3</sup>*Surgery, University of Maryland Medical Center, Baltimore, MD*
- B262**      **Use of Opioids and NSAIDs in Living Kidney Donors: Clinical Correlates and Early Outcomes**  
K. Lentine<sup>1</sup>, L. Vest<sup>1</sup>, Z. Zhang<sup>1</sup>, F. Koraihy<sup>1</sup>, M. Schnitzler<sup>1</sup>, A. Garg<sup>2</sup>, D. Axelrod<sup>3</sup>, B. Kasiske<sup>4</sup>, G. Hess<sup>5</sup>, A. Naik<sup>6</sup>, D. Segev<sup>7</sup>, M. Henderson<sup>7</sup>, A. Massie<sup>7</sup>, N. Lamm<sup>8</sup>, <sup>1</sup>*Saint Louis Univ, St. Louis, MO*, <sup>2</sup>*Western Univ, London, ON, Canada*, <sup>3</sup>*Univ of Iowa, Iowa City, IA*, <sup>4</sup>*SRTR, Minneapolis, MN*, <sup>5</sup>*Univ of Pennsylvania, Philadelphia, PA*, <sup>6</sup>*Univ of Michigan, Ann Arbor, MI*, <sup>7</sup>*Johns Hopkins, Baltimore, MD*, <sup>8</sup>*Univ Alberta, Edmonton, AB, Canada*
- B263**      **Innovations in Transplant Education: 360° Virtual Reality Videos of a Live Kidney Donation and Transplantation**  
V. A. Huurman<sup>1</sup>, A. D. Pieterse<sup>2</sup>, F. Luk<sup>2</sup>, M. E. Reinders<sup>2</sup>, <sup>1</sup>*Surgery, Leiden University Medical Center, Leiden, Netherlands*, <sup>2</sup>*Internal Medicine, Leiden University Medical Center, Leiden, Netherlands*
- B264**      **Changing Education Paradigms: Training Fellows for High Stake Procedures**  
T. Rice<sup>1</sup>, H. Lewis<sup>1</sup>, M. Cuffy<sup>1</sup>, L. Ratner<sup>2</sup>, T. Diwan<sup>1</sup>, <sup>1</sup>*Department of Surgery, University of Cincinnati Medical Center, Cincinnati, OH*, <sup>2</sup>*Department of Surgery, Columbia University, New York, NY*
- B265**      **Facilitators and Barriers to Implementing the Live Donor Champion Program**  
A. D. Love<sup>1</sup>, D. R. Helfer<sup>1</sup>, S. Rasmussen<sup>1</sup>, M. Johnson<sup>1</sup>, J. M. Konel<sup>1</sup>, J. R. Wellen<sup>2</sup>, S. M. Nazarian<sup>3</sup>, E. King<sup>1</sup>, D. L. Segev<sup>1</sup>, T. Hwee<sup>1</sup>, A. M. Cameron<sup>1</sup>, M. L. Henderson<sup>1</sup>, E. J. Gordon<sup>4</sup>, J. M. Garonzik Wang<sup>1</sup>, <sup>1</sup>*Surgery, Johns Hopkins University, Baltimore, MD*, <sup>2</sup>*Abdominal Transplant Surgery, Washington University School of Medicine, St. Louis, MO*, <sup>3</sup>*Surgery, Penn Transplant Institute, Philadelphia, PA*, <sup>4</sup>*Surgery, Northwestern Feinberg School of Medicine, Chicago, IL*
- B266**      **A Novel Trapezoidal Area Under Curve (AUC) Based Glomerular Filtration Rate (GFR) Measurement Using Non Radioactive Iohexol Plasma Clearance in Potential Kidney Donors**  
V. Ariyamuthu<sup>1</sup>, L. Anderson<sup>2</sup>, N. AbdulRahim<sup>1</sup>, S. Levea<sup>3</sup>, M. MacConmara<sup>4</sup>, C. Hwang<sup>4</sup>, K. Fankhauser<sup>5</sup>, I. Hashim<sup>5</sup>, B. Tanriover<sup>1</sup>, <sup>1</sup>*UT Southwestern Medical Center, Dallas, TX*, <sup>2</sup>*Internal Medicine/Nephrology, UT Southwestern Medical Center, Dallas, TX*, <sup>3</sup>*Internal Medicine, UT Southwestern Medical Center, Dallas, TX*, <sup>4</sup>*Surgery, UT Southwestern Medical Center, Dallas, TX*, <sup>5</sup>*Clinical Chemistry, UT Southwestern Medical Center, Dallas, TX*
- B267**      **Chylous Ascites Following Laparoscopic Live Donor Nephrectomy: A New Improved Treatment Paradigm**  
L. Dale<sup>1</sup>, R. Sandoval<sup>2</sup>, L. E. Ratner<sup>2</sup>, <sup>1</sup>*Columbia University Vagelos College of Physicians and Surgeons, New York, NY*, <sup>2</sup>*Surgery, Columbia University Medical Center, New York, NY*
- B268**      **Unhinged or Unselfish: A Deep Dive into Non-Directed Donors**  
J. Verbesey<sup>1</sup>, M. Williams<sup>2</sup>, S. Ghasemian<sup>1</sup>, A. Bacigalupo<sup>1</sup>, A. Gilbert<sup>1</sup>, G. Vranic<sup>1</sup>, B. Javaid<sup>1</sup>, M. Cooper<sup>1</sup>, A. Marsh<sup>2</sup>, <sup>1</sup>*MedStar Georgetown Transplant Institute, Washington, DC*, <sup>2</sup>*Georgetown University Hospital, Washington, DC*



- B269 Arterial Blood Pressure Circadian Rhythm in Renal Transplant Recipients**  
A. M. Arriaga, Y. J. Lopez, J. A. Cedillo, L. A. Marino, J. M. Mejia, I. Parra, A. Cohen, L. E. Morales, *Nephrology, National Institute of Medical Sciences and Nutrition Salvador Zubirán,, Mexico City, Mexico*
- B270 Better Education of Kidney Recipients and Improved Access for Donor Referrals May Lead to Higher Living Donation Rates: An Early Single Center Analysis**  
V. Humphreville, N. Sarabu, M. DebRoy, M. Schuster, E. Sanchez, A. Padiyar, A. Jittirat, K. Yadav, J. Rabets, A. Palanisamy, K. Chavin, *University Hospitals Cleveland Medical Center, Cleveland, OH*
- B271 Sex, Race, Social Networks, and Requests for Living Donation**  
A. Gillespie<sup>1</sup>, H. Gardiner<sup>2</sup>, E. L. Fink<sup>3</sup>, P. P. Reese<sup>4</sup>, C. Gadegbeku<sup>1</sup>, Z. Obradovic<sup>5</sup>, *<sup>1</sup>Nephrology, Hypertension, and Kidney Transplantation, Lewis Katz School of Medicine Temple University, Philadelphia, PA, <sup>2</sup>College of Public Health, Temple University, Philadelphia, PA, <sup>3</sup>Communication and Social Influence, Temple University Klein College of Media and Communication, Philadelphia, PA, <sup>4</sup>Renal-Electrolyte and Hypertension, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, <sup>5</sup>College of Computer and Information Sciences, Temple University, Philadelphia, PA*
- B272 Analgesia and Control of Pain Following Laparoscopic Donor Nephrectomy**  
J. Hedvat<sup>1</sup>, N. W. Lange<sup>1</sup>, P. Sandoval<sup>2</sup>, L. E. Ratner<sup>2</sup>, D. S. Tsapepas<sup>2</sup>, *<sup>1</sup>Pharmacy, NewYork-Presbyterian Hospital, New York, NY, <sup>2</sup>Surgery, Columbia University Irving Medical Center, New York, NY*
- B273 Mathematical Model of Post-Transplant Serum Creatinine**  
B. Jun Bae, O. Chang-Kwon, *Department of Transplant and Vascular Surgery, Ajou University Medical School, Suwon, Korea, Republic of*
- B274 Variation in Living Donor Kidney Transplantation and the Impact of Medicaid Expansion**  
T. A. Melanson<sup>1</sup>, S. Pastan<sup>2</sup>, R. Patzer<sup>1</sup>, *<sup>1</sup>Department of Surgery, Emory University, Atlanta, GA, <sup>2</sup>SOM: Medicine: Nephrology, Emory University, Atlanta, GA*
- B275 Standardized Pain Management Post Donor Nephrectomy Results in Decreased Length of Stay**  
N. Alvey<sup>1</sup>, B. Hohoff<sup>2</sup>, M. Brokhof<sup>1</sup>, N. Kenyon<sup>1</sup>, E. Hollinger<sup>3</sup>, *<sup>1</sup>Pharmacy, Rush University Medical Center, Chicago, IL, <sup>2</sup>Transplant, Rush University Medical Center, Chicago, IL, <sup>3</sup>Surgery, Rush University Medical Center, Chicago, IL*
- B276 Outcomes after Incompatible Living Donor Kidney Transplantation in Older Recipients**  
J. Long<sup>1</sup>, K. Jackson<sup>1</sup>, J. Motter<sup>1</sup>, S. Bae<sup>1</sup>, A. Massie<sup>1</sup>, M. Waldram<sup>1</sup>, K. Covarrubias<sup>1</sup>, J. Chen<sup>1</sup>, B. Orandi<sup>2</sup>, N. Desai<sup>1</sup>, D. Segev<sup>1</sup>, J. Garonzik-Wang<sup>1</sup>, *<sup>1</sup>Johns Hopkins School of Medicine, Baltimore, MD, <sup>2</sup>Surgery, University of Alabama at Birmingham, Birmingham, AL*
- B277 Robotic Donor Nephrectomy: Is It Safe Alternative?**  
D. Friedman, R. Shahbazov, I. Bandler, T. Malik, Z. Acun, K. Olivera-Wright, B. Gallay, O. Pankewycz, M. Laftavi, *Surgery, Upstate Medical University, Syracuse, NY*
- B278 Kidney Function Evaluation Among Living Donors In A Multiracial Population. The Results From A Brazilian Single-center Cohort Study.**  
L. R. Requião-Moura, P. R. Bicalho, A. Pacheco-Silva, *Hospital Israelita Albert Einstein, São Paulo, Brazil*
- B279 Using a Massive Open Online Course on Clinical Kidney, Pancreas and Islet Transplantation in Different Settings of Transplant Education**  
P. G. De Jong<sup>1</sup>, R. A. Hendriks<sup>1</sup>, F. Luk<sup>2</sup>, M. E. Reinders<sup>2</sup>, *<sup>1</sup>Center for Innovation in Medical Education, Leiden University Medical Center, Leiden, Netherlands, <sup>2</sup>Internal Medicine, Leiden University Medical Center, Leiden, Netherlands*



**Poster Session B: Kidney Living Donor: Selection**

---

- B280**      **Kidney Transplant Recipient Outcomes from Living Donors with Stones**  
S. Doshi, T. Taber, M. S. Yaqub, O. Adebisi, D. Mshler, C. Sundaram, J. Powelson, W. Goggins, A. Sharfuddin, *Indiana University School of Medicine, Indianapolis, IN*
- B281**      **Correlates of Surgical Difficulty and Post-Operative Complications in Living Donor Kidney Procurement**  
B. I. Shaw<sup>1</sup>, F. R. Schwartz<sup>2</sup>, F. Vernucci<sup>2</sup>, F. Rigioli<sup>2</sup>, F. Gonzalez<sup>2</sup>, R. Lerebours<sup>3</sup>, A. S. Rege<sup>1</sup>, D. Vikraman<sup>1</sup>, D. Marin<sup>2</sup>, K. V. Ravindra<sup>1</sup>, <sup>1</sup>*Surgery, Duke University, Durham, NC*, <sup>2</sup>*Radiology, Duke University, Durham, NC*, <sup>3</sup>*Biostatistics, Duke University, Durham, NC*
- B282**      **Renal Transplantation from a Living Donor with a Horseshoe Kidney**  
J. CHOI, J. Jung, J. Kim, H. Kwon, S. Shin, Y. Kim, D. Han, *Division of Kidney & Pancreas Transplantation, Department of Surgery, Asan Medical Center, Seoul, Korea, Republic of*
- B283**      **Complex Live Donor Anatomy Does Not Preclude Kidney Transplantation**  
P. Veitch, T. Brown, A. Courtney, J. McDaid, *Transplant Department, Belfast City Hospital, Belfast, United Kingdom*
- B284**      **An Interesting Case of Proteinuria in Living Kidney Donor**  
A. Yadav, W. Maley, P. Singh, *Thomas Jefferson University, Philadelphia, PA*
- B285**      **Surgical Outcome and Analysis of Risk of Complications in Kidney Donors Receiving Laparoscopic Live Donor Nephrectomy**  
C. Yang, C. Yeh, C. Lee, C. Chen, I. Lai, P. Lee, M. Tsai, *Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan*
- B286**      **Impact of Discards for Living Donor Kidney Transplantation in Center Transplant Program**  
H. Villafuerte<sup>1</sup>, E. De Sousa-Amorim<sup>2</sup>, L. Peri<sup>3</sup>, M. Musquera<sup>3</sup>, E. Palou<sup>4</sup>, M. Lozano<sup>5</sup>, J. Cid<sup>5</sup>, J. Martorell<sup>4</sup>, J. M. Campistol<sup>2</sup>, F. Oppenheimer<sup>2</sup>, F. Diekmann<sup>2</sup>, I. Revuelta<sup>2</sup>, <sup>1</sup>*Department of Nephrology, Hospital Clinic Lozano Blesa, Zaragoza, Spain*, <sup>2</sup>*Department of Nephrology and Kidney Transplant, Hospital Clinic, Barcelona, Spain*, <sup>3</sup>*Department of Urology, Hospital Clinic, Barcelona, Spain*, <sup>4</sup>*Department of Immunology, Hospital Clinic, Barcelona, Spain*, <sup>5</sup>*Department of Apheresis, Hospital Clinic, Barcelona, Spain*
- B287**      **Living Donor Kidney Transplantation. Overcoming Sex Disparity In Japan**  
M. Yoshikawa, *Nephrology, Kobe University Hospital, Kobe, Japan*
- B288**      **Individualized Preconditioning for ABO-Incompatible Living Donor Kidney Transplantation: An Initial Report of 48 Cases from China**  
X. Wang, J. Liu, *Department of Urology/Institute of Urology, West China Hospital of Sichuan University, Chengdu, China*
- B289**      **Is Living Donor Kidney Donor Profile Index Useful for Japanese?**  
K. Okumura<sup>1</sup>, K. Tanaka<sup>2</sup>, Y. Hidaka<sup>2</sup>, M. Toyoda<sup>3</sup>, S. Uekihara<sup>3</sup>, A. Inadome<sup>4</sup>, H. Yokomizo<sup>2</sup>, S. Yamanaga<sup>2</sup>, <sup>1</sup>*Department of Surgery, University of Pittsburgh, Pittsburgh, PA*, <sup>2</sup>*Department of Surgery, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan*, <sup>3</sup>*Department of Nephrology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan*, <sup>4</sup>*Department of Urology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan*

**B290**      **How Challenging Will Be My Living Donor? CT Scan and Clinical Evaluation Can Predict Technical Difficulty of Laparoscopic Donor Nephrectomy**

V. Bianchi<sup>1</sup>, G. Spagnoletti<sup>1</sup>, R. Iezzi<sup>2</sup>, F. E. Rossini<sup>1</sup>, A. Posa<sup>2</sup>, A. E. Rossini<sup>1</sup>, M. P. Salerno<sup>1</sup>, F. Citterio<sup>1</sup>, J. Romagnoli<sup>1</sup>,  
<sup>1</sup>Renal Transplant Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy, <sup>2</sup>Radiology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy

**B291**      **HbA1c as a Noninvasive Predictor of Chronic Histopathologic Changes in Living Donors for Kidney Transplantation**

K. Tanaka<sup>1</sup>, S. Nishida<sup>1</sup>, K. Kinoshita<sup>1</sup>, Y. Hidaka<sup>1</sup>, M. Toyoda<sup>2</sup>, A. Inadome<sup>3</sup>, A. Takeda<sup>4</sup>, H. Yokomizo<sup>5</sup>, S. Uekihara<sup>6</sup>, J. Shoji<sup>7</sup>, S. Yamanaga<sup>1</sup>, <sup>1</sup>Surgery, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, <sup>2</sup>general medicine, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, <sup>3</sup>Urology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, <sup>4</sup>Nephrology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan, <sup>5</sup>Surgery, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, <sup>6</sup>general medicine, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, <sup>7</sup>Nephrology, UCSF Connie Frank Transplant Center, San Francisco, CA

**B292 †**    **Comparison Of Estimating Glomerular Filtration Equations In Living Kidney Donor Candidates Prior To Donation**

S. Hebert<sup>1</sup>, J. Xu<sup>2</sup>, H. Ibrahim<sup>1</sup>,  
<sup>1</sup>Nephrology, Hypertension and Transplantation, Houston Methodist Hospital, Houston, TX, <sup>2</sup>Houston Methodist Research Institute, Houston, TX

**Poster Session B: Kidney Paired Exchange**

**B293 †**    **Mitigating Racial and Gender Disparities in Access to Living Donor Kidney Transplantation: Impact of the Nation's Longest Single-Center Kidney Chain**

M. N. Mustian, V. Kumar, K. Stegner, D. Mompoin-Williams, M. Hanaway, M. H. Deierhoi, C. Young, B. Orandi, D. Anderson, P. A. MacLennan, R. D. Reed, B. A. Shelton, D. Eckhoff, J. E. Locke, University of Alabama at Birmingham, Birmingham, AL

**B294**      **Causes of 30 Day Graft Loss among Shared Kidneys in the National Kidney Registry (NKR)**

J. Verbesey<sup>1</sup>, A. Thomas<sup>2</sup>, M. Ronin<sup>3</sup>, D. Segev<sup>4</sup>, A. Waterman<sup>5</sup>, S. Flechner<sup>6</sup>, M. Cooper<sup>1</sup>, <sup>1</sup>Georgetown University Hospital, Washington, DC, <sup>2</sup>University of North Carolina, Chapel Hill, NC, <sup>3</sup>National Kidney Registry, New York, NY, <sup>4</sup>Johns Hopkins University, Baltimore, MD, <sup>5</sup>UCLA, Los Angeles, CA, <sup>6</sup>Cleveland Clinic, Cleveland, OH

**B295**      **Inclusion of Compatible Pairs in the Australian Paired Kidney Exchange Program**

E. van Hardeveld<sup>1</sup>, S. McGinn<sup>2</sup>, L. Cantwell<sup>3</sup>, M. Kummrow<sup>3</sup>, P. Hughes<sup>1</sup>,  
<sup>1</sup>Nephrology, Royal Melbourne Hospital, Melbourne, Victoria, Australia, <sup>2</sup>Nephrology, Royal North Shore Hospital, Sydney, New South Wales, Australia, <sup>3</sup>Victorian Transplantation and Immunogenetics Service, Australian Red Cross Blood Service, Melbourne, Victoria, Australia

**B296**      **Desensitization Protocols vs Kidney Paired Donation to Overcome ABO Incompatibility and/or Donor Specific Antibodies in Living Donor Kidney Transplantation**

F. Vistoli, V. Perrone, L. Gozzini, E. Kauffmann, N. Napoli, S. Iacopi, C. Lombardo, G. Amorese, U. Boggi, Pancreas and Kidney Transplantation Center, University of Pisa, Pisa, Italy

**B297**      **Quantifying Patient Perspectives On Paired Kidney Exchange**  
M. Duda<sup>1</sup>, M. Houston<sup>1</sup>, D. Collins<sup>1</sup>, P. Porrett<sup>2</sup>, <sup>1</sup>*Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA*, <sup>2</sup>*Hospital of the University of Pennsylvania, Philadelphia, PA*

**B298**      **Distribution And Outcomes Of Donor Right Kidneys In A National Paired Kidney Exchange Program**  
G. Roll<sup>1</sup>, W. Irish<sup>2</sup>, M. Cooper<sup>3</sup>, M. Ronin<sup>4</sup>, G. Hill<sup>5</sup>, A. D. Waterman<sup>6</sup>, D. B. Leaser<sup>2</sup>, <sup>1</sup>*UCSF, San Francisco, CA*, <sup>2</sup>*ECU, Greenville, NC*, <sup>3</sup>*Georgetown Univ, Washington, DC*, <sup>4</sup>*NKR, Babylon, CA*, <sup>5</sup>*NKR, Babylon, NY*, <sup>6</sup>*UCLA and Terasaki Research Institute, Los Angeles, CA*

**B299**      **Compatible Pairs And Non-directed Living Donors Enhance Paired Exchange Kidney Transplantation: Single-center Experience**  
L. Jaber, C. Tiletile, J. Bellingham, N. Garg, A. Hassoun, H. Mahanty, N. Neidlinger, A. Sandhu, P. Patel, W. Bry, S. Katznelson, V. Peddi, *California Pacific Medical Center, San Francisco, CA*

## Poster Session B: Liver Retransplantation and Other Complications

---

**B300**      **Clinical Impact of Spontaneous Portosystemic Shunts on the Short Term Outcome of Liver Transplantation**  
E. A. Rodriguez<sup>1</sup>, R. M. Perez<sup>2</sup>, N. Zhang<sup>3</sup>, E. S. Lim<sup>3</sup>, C. R. Miller<sup>4</sup>, M. A. Schwartz<sup>2</sup>, A. J. McGirr<sup>4</sup>, A. Srinivasan<sup>5</sup>, W. R. Hewitt<sup>5</sup>, A. C. Silva<sup>4</sup>, J. Rakela<sup>1</sup>, H. E. Vargas<sup>1</sup>, <sup>1</sup>*Transplant Hepatology, Mayo Clinic Arizona, Phoenix, AZ*, <sup>2</sup>*Mayo Clinic School of Medicine, Mayo Clinic Arizona, Phoenix, AZ*, <sup>3</sup>*Division of Health Sciences Research, Mayo Clinic Arizona, Phoenix, AZ*, <sup>4</sup>*Radiology, Mayo Clinic Arizona, Phoenix, AZ*, <sup>5</sup>*Transplant Surgery, Mayo Clinic Arizona, Phoenix, AZ*

**B301**      **Incisional Ventral Hernia Repair (IVHR) in Post Liver Transplant Recipients (OLT) through a Robotic-Assisted Intervention (RAI): Initial Single-Center Experience**  
A. Mejia, C. G. Fasola, A. Stegall, *Liver Transplantation, Methodist Dallas Medical Center, Dallas, TX*

**B302**      **Guideline Adherence for Secondary Prevention of Stroke and Atherosclerotic Cardiovascular Disease among Liver Transplant Recipients**  
P. T. Campbell<sup>1</sup>, M. Kosirog<sup>1</sup>, S. Montag<sup>2</sup>, S. Connolly<sup>1</sup>, A. Daud<sup>3</sup>, A. Das<sup>1</sup>, S. Pine<sup>1</sup>, D. Finn<sup>3</sup>, J. Levitsky<sup>1</sup>, J. L. Holl<sup>4</sup>, D. M. Lloyd-Jones<sup>5</sup>, L. B. VanWagner<sup>6</sup>, <sup>1</sup>*Division of GI and Hepatology, Department of Medicine, Northwestern University, Chicago, IL*, <sup>2</sup>*Department of Preventive Medicine, Northwestern University, Chicago, IL*, <sup>3</sup>*Center for Healthcare Studies, Northwestern University, Chicago, IL*, <sup>4</sup>*Department of Pediatrics and Center for Healthcare Studies, Northwestern University, Chicago, IL*, <sup>5</sup>*Departments of Preventive Medicine and Medicine-Cardiology, Northwestern University, Chicago, IL*, <sup>6</sup>*Division of GI and Hepatology, Department of Medicine and Department of Preventive Medicine, Northwestern University, Chicago, IL*

**B303**      **Early Cognitive Improvement One Month after Liver Transplant Measured by the NIH Toolbox**  
M. Kim<sup>1</sup>, J. D. Peipert<sup>2</sup>, K. J. Reid<sup>1</sup>, E. M. Liotta<sup>1</sup>, M. B. Maas<sup>1</sup>, D. R. Ganger<sup>3</sup>, P. C. Zee<sup>1</sup>, D. P. Ladner<sup>4</sup>, <sup>1</sup>*Neurology, Northwestern University, Chicago, IL*, <sup>2</sup>*Medical Social Sciences, Northwestern University, Chicago, IL*, <sup>3</sup>*Medicine, Northwestern University, Chicago, IL*, <sup>4</sup>*Surgery, Northwestern University, Chicago, IL*

**B304**      **Measuring of Outcomes in Liver Transplant Patients with or without Splenectomy: A Meta Analysis**  
M. Chen, B. Huang, Y. Zhang, W. Ju, X. He, *Transplant Center, Sun Yat-sen University, Guangzhou, China*

**B305**      **Immediate Post-Operative Extubation Decreases Pulmonary Complications in Liver Transplant Patients**  
M. Safwan, C. Acho, Y. Morita, V. Fernandez, D. Galusca, M. Abouljoud, A. Yoshida, J. El-Bashir, S. Nagai, *Henry Ford Health System, Detroit, MI*

- B306 † Outcomes Following Open Inguinal Hernia Repair in Liver Transplant versus Cirrhotic Patients**  
N. Siegel, A. Kernodle, S. DiBrito, T. Ishaque, D. Segev, J. Garonzik-Wang, *Johns Hopkins, Baltimore, MD*
- B307 Patients With Biliary Complications Following Orthotopic Liver Transplantation Can Be Successfully Managed By Serial Endoscopic Retrograde Cholangiopancreatography**  
R. Kaur, I. C. Morales, D. Dhillon, M. S. Ilias, S. Nagai, D. Venkat, A. Yoshida, S. Jafri, *Henry Ford Hospital, Detroit, MI*
- B308 Transplant Provider Adherence to Cardiovascular Disease Primary Prevention Guidelines in Liver Transplant Recipients**  
M. Kosirog<sup>1</sup>, P. T. Campbell<sup>1</sup>, S. Montag<sup>2</sup>, S. Connolly<sup>1</sup>, A. Daud<sup>3</sup>, A. Das<sup>1</sup>, S. Pine<sup>1</sup>, D. Finn<sup>3</sup>, J. Levitsky<sup>1</sup>, J. L. Holl<sup>4</sup>, D. M. Lloyd-Jones<sup>5</sup>, L. B. VanWagner<sup>6</sup>, <sup>1</sup>*Division of GI and Hepatology, Department of Medicine, Northwestern Medicine, Chicago, IL*, <sup>2</sup>*Department of Preventative Medicine, Northwestern Medicine, Chicago, IL*, <sup>3</sup>*Center for Healthcare Studies, Northwestern Medicine, Chicago, IL*, <sup>4</sup>*Department of Pediatrics and Center for Healthcare Studies, Northwestern Medicine, Chicago, IL*, <sup>5</sup>*Department of Preventive Medicine and Division of Cardiology, Department of Medicine, Northwestern Medicine, Chicago, IL*, <sup>6</sup>*Division of GI and Hepatology, Department of Medicine and Department of Preventive Medicine, Northwestern Medicine, Chicago, IL*
- B309 Allograft Quality Impacts Simultaneous Liver Kidney Transplant Survival Outcomes in Recipients That Undergo Liver Re-Transplantation**  
J. Reyes, M. Eerhart, C. Blanton, P. Chlebeck, E. Polyak, Y. Yankol, L. Fernandez, *Department of Surgery, University of Wisconsin - Madison, Madison, WI*
- B310 Variables Associated with Intracardiac Thrombus during Orthotopic Liver Transplant: A Retrospective Single-Center Study**  
M. Groose<sup>1</sup>, J. Mezrich<sup>2</sup>, L. Hammel<sup>1</sup>, <sup>1</sup>*Department of Anesthesiology, University of Wisconsin, Madison, WI*, <sup>2</sup>*Department of Surgery, University of Wisconsin, Madison, WI*
- B311 Nodular Regenerative Hyperplasia after Liver Transplant - It is All in the Presentation**  
A. K. Chen<sup>1</sup>, S. Yamaguchi<sup>2</sup>, C. Praglin<sup>2</sup>, E. Agudelo<sup>2</sup>, F. K. Yao<sup>2</sup>, S. M. Syed<sup>2</sup>, G. R. Roll<sup>2</sup>, <sup>1</sup>*University of California, San Francisco - Fresno, Fresno, CA*, <sup>2</sup>*University of California, San Francisco, San Francisco, CA*
- B312 Management of Dyslipidemia after Liver Transplantation**  
S. S. Patel<sup>1</sup>, V. A. Rodriguez<sup>2</sup>, M. B. Siddiqui<sup>1</sup>, M. Faridnia<sup>3</sup>, F. Lin<sup>4</sup>, J. Laurenzano<sup>4</sup>, J. Clinton<sup>4</sup>, A. Chandrakumaran<sup>3</sup>, T. Reichman<sup>5</sup>, C. Bhati<sup>5</sup>, M. S. Siddiqui<sup>1</sup>, <sup>1</sup>*Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA*, <sup>2</sup>*Department of Bio-statistics, Virginia Commonwealth University, Richmond, VA*, <sup>3</sup>*Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA*, <sup>4</sup>*Virginia Commonwealth University, Richmond, VA*, <sup>5</sup>*Department of Transplant Surgery, Virginia Commonwealth University, Richmond, VA*
- B313 Etiology of Liver Disease Affects Weight Gain after Liver Transplant**  
A. Chandrakumaran<sup>1</sup>, M. B. Siddiqui<sup>2</sup>, S. Patel<sup>2</sup>, F. Lin<sup>3</sup>, J. Laurenzano<sup>2</sup>, J. Clinton<sup>2</sup>, T. Reichman<sup>4</sup>, C. Bhati<sup>4</sup>, M. S. Siddiqui<sup>2</sup>, <sup>1</sup>*Internal Medicine, Virginia Commonwealth University, Richmond, VA*, <sup>2</sup>*Gastroenterology & Hepatology, Virginia Commonwealth University, Richmond, VA*, <sup>3</sup>*Virginia Commonwealth University, Richmond, VA*, <sup>4</sup>*Transplant Surgery, Virginia Commonwealth University, Richmond, VA*



- B314 Redefining Cirrhotic Cardiomyopathy; A Shifting Paradigm**  
M. J. Izzy<sup>1</sup>, M. Angirekula<sup>2</sup>, M. Leise<sup>2</sup>, A. Allen<sup>2</sup>, K. Watt<sup>2</sup>, <sup>1</sup>*Gastroenterology and Hepatology, Vanderbilt University Medical Center, Nashville, TN*, <sup>2</sup>*Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN*
- B315 † Unplanned Pregnancies after Liver Transplant Are Associated with Adverse Pregnancy Outcomes**  
M. Sarkar<sup>1</sup>, L. A. Coscia<sup>2</sup>, D. Kliniewski<sup>2</sup>, S. Rao<sup>3</sup>, S. Constantinescu<sup>4</sup>, M. J. Moritz<sup>5</sup>, <sup>1</sup>*Medicine, University of California San Francisco, San Francisco, PA*, <sup>2</sup>*Gift of Life Institute, Transplant Pregnancy Registry International, Philadelphia, PA*, <sup>3</sup>*Medicine, University of Virginia Health System, Charlottesville, VA*, <sup>4</sup>*Medicine, Lewis Katz Temple University School of Medicine, Philadelphia, PA*, <sup>5</sup>*Surgery, Lehigh Valley Health Network, Allentown, PA*
- B316 Treatment of Cardiovascular Risk Factors Improves Long Term Outcome Post Liver Transplantation**  
S. Alghamdi, O. Altayar, T. Zhu, A. Bayudan, J. Fleckenstein, M. Lisker-Melman, J. Crippin, A. Flores, *Washington University in St Louis, Saint Louis, MO*
- B317 † Impact of Hepatitis C Viremia on Post-Transplant Diabetes Mellitus Development in Liver Transplant Recipients**  
K. Klein<sup>1</sup>, J. Nelson<sup>2</sup>, B. Crowther<sup>1</sup>, C. Guerra<sup>3</sup>, E. Kincaide<sup>1</sup>, K. V. Speeg<sup>4</sup>, N. Alkhouri<sup>5</sup>, R. Hall<sup>1</sup>, <sup>1</sup>*University Health System, The University of Texas at Austin, College of Pharmacy, Pharmacotherapy Division, Austin, TX*, <sup>2</sup>*The University of Texas Health Science Center at San Antonio, San Antonio, TX*, <sup>3</sup>*The University of Texas Health Science Center at San Antonio, University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX*, <sup>4</sup>*University Health System, The University of Texas Health Science Center at San Antonio, San Antonio, TX*, <sup>5</sup>*University Health System, The University of Texas Health Science Center at San Antonio, Texas Liver Institute, San Antonio, TX*
- B318 Incidence and Risks for Non-alcoholic Fatty Liver Disease and Steatohepatitis Post Liver Transplant: Systematic Review and Meta-Analysis**  
N. Saeed<sup>1</sup>, P. Sharma<sup>2</sup>, L. Glass<sup>2</sup>, C. Shannon<sup>2</sup>, C. Sonnenday<sup>2</sup>, M. Konerman<sup>2</sup>, <sup>1</sup>*Beaumont Hospital, Ann Arbor, MI*, <sup>2</sup>*University of Michigan, Ann Arbor, MI*
- B319 Multimodal Analgesia Reduces Opioid Use after Liver Transplantation**  
K. Tong, W. Nolan, D. O'Sullivan, H. Kutzler, *Hartford Hospital, Hartford, CT*
- B320 Pleural Effusion In Liver Transplantation Associated With Worse Hospital Outcomes And Lower Patient Survival**  
C. Vega<sup>1</sup>, J. Clouse<sup>2</sup>, A. Cabrales<sup>1</sup>, W. Bush<sup>1</sup>, C. Kubal<sup>1</sup>, R. S. Mangus<sup>2</sup>, <sup>1</sup>*Indiana University, Indianapolis, IN*, <sup>2</sup>*Surgery, Indiana University, Indianapolis, IN*
- B321 Analyzing The Effect Of Liver Transplantation On Myocardial Strain Using Speckle Tracking Echocardiography In Nonalcoholic Steatohepatitis (NASH) Patients**  
A. Chhatriwala, M. Lam, E. Kim, S. Raissi, N. Mazumder, J. Thomas, H. Maddur, M. Rinella, *Northwestern Memorial Hospital, Chicago, IL*
- B322 Perioperative Lactate Levels Are Sensitive Marker to Predict Early Allograft Dysfunction and Short-Term Graft Failure after Liver Transplant**  
K. Takahashi<sup>1</sup>, S. Nagai<sup>2</sup>, K. Collins<sup>2</sup>, M. Rizzari<sup>2</sup>, M. Safwan<sup>2</sup>, S. Jafri<sup>3</sup>, T. Oda<sup>1</sup>, A. Yoshida<sup>2</sup>, M. Abouljoud<sup>2</sup>, <sup>1</sup>*Surgery, University of Tsukuba, Tsukuba, Japan*, <sup>2</sup>*Surgery, Henry Ford Hospital, Detroit, MI*, <sup>3</sup>*Gastroenterology, Henry Ford Hospital, Detroit, MI*
- B323 Osmotic Demyelination Syndrome after Liver Transplantation- Etiology and Treatment Options**  
P. Mihaylov<sup>1</sup>, D. Soma<sup>2</sup>, D. Kuruppu<sup>2</sup>, B. Ekser<sup>2</sup>, R. Mangus<sup>2</sup>, J. Fridell<sup>2</sup>, R. Snook<sup>2</sup>, C. Kubal<sup>2</sup>, <sup>1</sup>*Indiana Univ School of Medicine, Pavia University School of Medicine, Indianapolis, IN*, <sup>2</sup>*Indiana Univ School of Medicine, Indianapolis, IN*



**B324 † Proximal Splenic Artery Embolization Is A Safe And Effective Tool To Treat Two Sides Of The Same Coin After Liver Transplant: Persistent High Hepatic Artery Resistive Index And Refractory Ascites And Hydrothorax Due To Portal Hyperperfusion**

L. Lomaglio, H. Matsushima, A. Simioni, G. D'Amico, T. Diago Uso, K. Hashimoto, B. Egtesad, M. Fujiki, F. Aucejo, K. Sasaki, C. Kwon, C. Coppa, M. Bayona Molano, C. Miller, C. Quintini, *Cleveland Clinic, Cleveland, OH*

**B325 Multidisciplinary Practitioner Perspectives on Cardiovascular Disease Guideline Interventions in Liver Transplant Recipients**

M. Kosirog<sup>1</sup>, L. Adamski<sup>1</sup>, A. Daud<sup>2</sup>, D. Finn<sup>2</sup>, D. Gregory<sup>1</sup>, D. M. Lloyd-Jones<sup>3</sup>, J. L. Holl<sup>4</sup>, L. B. VanWagner<sup>5</sup>, <sup>1</sup>Medicine-GI & Hepatology, Northwestern University, Chicago, IL, <sup>2</sup>Center for Healthcare Studies, Northwestern University, Chicago, IL, <sup>3</sup>Medicine-Cardiology and Preventive Medicine, Northwestern University, Chicago, IL, <sup>4</sup>Pediatrics & Center for Healthcare Studies, Northwestern University, Chicago, IL, <sup>5</sup>Medicine-GI & Hepatology and Preventive Medicine, Northwestern University, Chicago, IL

**B326 Poor Practitioner Adherence to Clinical Tobacco Use Guidelines in Liver Transplant Recipients**

M. Kosirog<sup>1</sup>, P. T. Campbell<sup>1</sup>, S. Montag<sup>2</sup>, S. Connolly<sup>1</sup>, A. Daud<sup>3</sup>, A. Das<sup>1</sup>, S. Pine<sup>1</sup>, D. Finn<sup>3</sup>, J. Levitsky<sup>1</sup>, J. L. Holl<sup>4</sup>, D. Lloyd-Jones<sup>5</sup>, L. B. VanWagner<sup>6</sup>, <sup>1</sup>Division of GI and Hepatology, Department of Medicine, Northwestern Medicine, Chicago, IL, <sup>2</sup>Department of Preventive Medicine, Northwestern Medicine, Chicago, IL, <sup>3</sup>Center for Healthcare Studies, Northwestern Medicine, Chicago, IL, <sup>4</sup>Department of Pediatrics & Center for Healthcare Studies, Northwestern Medicine, Chicago, IL, <sup>5</sup>Departments of Preventive Medicine and Medicine-Cardiology, Northwestern Medicine, Chicago, IL, <sup>6</sup>Division of GI and Hepatology, Department of Medicine and Department of Preventive Medicine, Northwestern Medicine, Chicago, IL

**B327 Bile Duct Anastomosis over Intraluminal Plastic Biliary Stent in Liver Transplant: Clinical Outcome**

H. Samant<sup>1</sup>, K. Patel<sup>1</sup>, W. Manatsathit<sup>2</sup>, N. Singh<sup>1</sup>, H. S. Amiri<sup>3</sup>, G. Zibari<sup>3</sup>, <sup>1</sup>Louisiana State University and Health Science Center, Shreveport, LA, <sup>2</sup>University of Nebraska Medical Center, Omaha, NE, <sup>3</sup>John C McDonald Transplant Center, Shreveport, LA

**B328 Anticoagulation in Post-Liver Transplant Recipients with Portal Vein Thrombosis**

L. Schumacher<sup>1</sup>, L. Lindberg<sup>1</sup>, D. Alonso<sup>2</sup>, R. Gilroy<sup>3</sup>, J. Krong<sup>4</sup>, L. Dong<sup>4</sup>, S. LeCorchick<sup>1</sup>, <sup>1</sup>Department of Pharmacy, Intermountain Medical Center, Murray, UT, <sup>2</sup>Transplant Surgery, Intermountain Medical Center, Murray, UT, <sup>3</sup>Transplant Hepatology, Intermountain Medical Center, Murray, UT, <sup>4</sup>Department of Transplant, Intermountain Medical Center, Murray, UT

**Poster Session B: Liver: Living Donors and Partial Grafts**

**B329 Complications of Interposition Grafts for Middle Hepatic Vein Reconstruction in Living Donor Liver Transplantation**

S. Kim, G. Chun, I. Song, *Division of Hepatobiliary and Liver Transplantation, Department of Surgery, Chungnam National University Hospital, Daejeon, Korea, Republic of*

**B330 Five Years after Right Hepatectomy for Living Liver Donation: Donor State of Health**

D. P. Hoyer, E. Malamutmann, G. Bagias, A. Oezcelik, *General, Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany*

**B331 Patient Response to a Formal Living Donor Liver Transplant Educational Program**

P. Narayanan, C. Palumbo, K. Ventura, R. Tomlin, L. Hammers, M. Joyce, D. Wuerth, D. Haakinson, S. Kulkarni, D. Mulligan, S. Emre, A. Liapakis, *Transplantation Center, Yale-New Haven Hospital, New Haven, CT*

- B332 Absorbable Mesh Placement to Prevent Incisional Hernias after Donor Hepatectomy**  
D. von Ahrens<sup>1</sup>, R. Hwang<sup>2</sup>, T. Kato<sup>2</sup>, J. Emond<sup>2</sup>, A. Griesemer<sup>2</sup>, B. Samstein<sup>1</sup>,  
<sup>1</sup>*Surgery, New York Presbyterian Weill Cornell, New York, NY*, <sup>2</sup>*Surgery, New York Presbyterian Columbia University Medical Center, New York, NY*
- B333 Clinical Outcomes of Living versus Deceased Donor Liver Transplantation for Primary Sclerosing Cholangitis: A Multicenter 15 Year Experience**  
O. Y. Mousa<sup>1</sup>, K. D. Watt<sup>1</sup>, J. K. Heimbach<sup>2</sup>, A. P. Keaveny<sup>3</sup>, J. E. Eaton<sup>1</sup>, D. M. Harnois<sup>3</sup>, B. Taner<sup>3</sup>, E. J. Carey<sup>4</sup>, A. A. Moss<sup>4</sup>, C. B. Rosen<sup>5</sup>, T. Taner<sup>5</sup>,  
<sup>1</sup>*Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN*, <sup>2</sup>*Department of Surgery, Mayo Clinic, Rochester, MN*, <sup>3</sup>*Department of Transplant, Mayo Clinic, Jacksonville, FL*, <sup>4</sup>*Department of Transplant, Mayo Clinic, Scottsdale, AZ*, <sup>5</sup>*Department of Transplant, Mayo Clinic, Rochester, MN*
- B334 Clinical Outcomes of Patients with Portal Vein Tumor Thrombi after Living Donor Liver Transplantation**  
D. Kim, *Surgery, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Korea, Republic of*
- B335 The Experience of Somatostatin to Prevent Small-for-Size Syndrome in Patients with Small Graft in Living Donor Liver Transplantation**  
D. Kim, K. Yoon, H. Jo, W. Kang, *Korea University College of Medicine, Seoul, Korea, Republic of*
- B336 † Inferior Graft and Patient Survival Following Offspring to Parent Living Donor Liver Transplantation**  
R. A. Choudhury, A. Dagan, H. Yaffe, D. Yoeli, E. A. Pomfret, T. L. Nydam,  
*Transplant Surgery, University of Colorado, Aurora, CO*
- B337 Near-Miss Events during Donor Left Liver Lobe Hepatectomy: A Potential Quality-Control to Assess Donor Safety in Living Donor Liver Transplantation Programs**  
E. BONACCORSI-RIANI, V. Daudré-Vignier, O. Ciccarelli, L. Coubeau, S. Iesari, R. Tambucci, C. De Magnee, A. Pire, R. Reding, *Cliniques universitaires Saint Luc - Université Catholique de Louvain, Brussels, Belgium*
- B338 Novel Cell-Free and Concentrated Ascites Reinfusion Therapy for Management of Refractory Ascites in Liver Transplant Candidates**  
K. Sato, M. Ohira, Y. Imaoka, S. Hashimoto, H. Tahara, K. Ide, T. Kobayashi, Y. Tanaka, H. Ohdan,  
*Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan*
- B339 Risk Factors for Post-Transplant Outcomes in Living and Deceased Donor Liver Transplantation. An Analysis of UNOS Registry**  
T. Kitajima, S. Nagai, K. Collins, M. Rizzari, A. Yoshida, M. Abouljoud,  
*Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI*
- B340 Adult-to-Adult Living-Donor Liver Transplantation: Towards a Prediction of Three-Month Survival Combining Graft-to-Recipient Weight and MELD in a Caucasian Population**  
S. Iesari, R. Reding, J. Lerut, E. Bonaccorsi-Riani, L. Coubeau, O. Ciccarelli, *Abdominal Surgery and Transplant Department, Université Catholique de Louvain, Brussels, Belgium*
- B341 † Totally Robotic Donor Hepatectomy: Feasibility And Early Outcomes**  
Y. Cheah, C. J. Simon, W. D. Lewis, R. L. Jenkins, M. E. Akoad, *Lahey Hospital & Medical Center, Burlington, MA*

- B342 Learning Curve for Living Donor Laparoscopic Left Lateral Sectionectomy**  
R. Hwang<sup>1</sup>, D. von Ahrens<sup>2</sup>, A. Griesemer<sup>1</sup>, T. Kato<sup>1</sup>, J. Emond<sup>1</sup>, D. Cherqui<sup>3</sup>, B. Samstein<sup>2</sup>, <sup>1</sup>Department of Surgery, Columbia University Medical Center, New York, NY, <sup>2</sup>Department of Surgery, Weill Cornell Medicine, New York, NY, <sup>3</sup>Department of Surgery, Paul Brousse Hospital - Université Paris Sud, Villejuif, France
- B343 Pulmonary Complications in Living Liver Donors**  
D. Esendagli<sup>1</sup>, E. Ayvazoglu Soy<sup>2</sup>, E. Kupeli<sup>1</sup>, A. Akdur<sup>2</sup>, S. Yildirim<sup>2</sup>, A. Torgay<sup>3</sup>, S. Boyacioglu<sup>4</sup>, M. Haberal<sup>2</sup>, <sup>1</sup>Pulmonary Diseases, Baskent University, Ankara, Turkey, <sup>2</sup>Transplantation, Baskent University, Ankara, Turkey, <sup>3</sup>Anesthesiology, Baskent University, Ankara, Turkey, <sup>4</sup>Gastroenterology, Baskent University, Ankara, Turkey
- B344 Higher Incidence of Coagulation Complications in Live Liver Donation**  
B. Movahedi, p. Mahboub, N. Kim, P. Martins, A. Bozorgzadeh, *Surgery, UMass Memorial Medical Center, Worcester, MA*
- B345 Impact of Donor Abdominal Aortic Calcification on Bile Duct Complications of Recipients after Living Donor Liver Transplantation; a Retrospective Study**  
Y. Imaoka, M. Ohira, K. Sato, H. Tahara, K. Ide, Y. Tanaka, H. Ohdan, *Hiroshima University Hospital, Hiroshima, Japan*
- B346 Ligation of the Proximal Splenic Vein to Keep Adequate Portal Flow in Patients with Large Splenorenal Shunts during Living Donor Liver Transplantation**  
C. Cheng, *Department of General Surgery, Chang Gung Memorial Hospital at Linkou, Kwei-Shan Township, Taoyuan, Taiwan*
- B347 Early Allograft Dysfunction Does Not Predict Graft or Patient Survival in Recipients of Living Donor Liver Transplantation**  
H. J. Braun, J. L. Dodge, J. D. Grab, N. L. Ascher, J. P. Roberts, *University of California, San Francisco, San Francisco, CA*
- B348 Insertion of Internal Stent in Duct-to-Duct Biliary Reconstruction to Reduce Bile Duct Complication in Living Donor Liver Transplantation**  
H. Choi<sup>1</sup>, G. Na<sup>2</sup>, <sup>1</sup>Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of, <sup>2</sup>Surgery, Bucheon St. Mary's Hospital, The Catholic University of Korea, Bucheon, Korea, Republic of
- B349 Impact of a Liver Waitlist Candidate LDLT Educational Outreach Program on Referrals and Outcomes of Donor Evaluation**  
C. Saroli Palumbo, J. Batisti, R. Batra, J. Dopico, D. Haakinson, L. Hughes, M. Joyce, S. Klein, S. Kulkarni, D. Mulligan, P. Narayanan, M. Schilsky, R. Tomlin, K. Ventura, S. Emre, A. Liapakis, *Yale, New Haven, CT*
- B350 Correlations between Preoperative Hepatic Venous Pressure Gradient and Graft Hemodynamics after Reperfusion in Living Donor Liver Transplantation**  
H. Matsushima, M. Fujiki, K. Sasaki, F. Aucejo, T. Diago Uso, C. Kwon, B. Eghtesad, C. Miller, C. Quintini, K. Hashimoto, *General Surgery, Digestive Disease & Surgery Institute, Cleveland Clinic, Cleveland Clinic, Cleveland, OH*
- B351 Management of Orphan Ducts After Pediatric Living Donor Liver Transplantation**  
N. Celik<sup>1</sup>, A. Ganoza<sup>2</sup>, A. Khanna<sup>2</sup>, G. Bond<sup>2</sup>, K. Soltys<sup>2</sup>, R. Sindhi<sup>2</sup>, J. Crowley<sup>3</sup>, A. Humar<sup>1</sup>, G. Mazariegos<sup>2</sup>, <sup>1</sup>Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>2</sup>Hillman Center for Pediatric Transplantation, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, <sup>3</sup>Department of Radiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA
- B352 Donor Exclusions and Shifting Trends in Living Liver Donor Evaluations: A Single Center Experience**  
S. Ganesh, M. Molinari, A. Tevar, C. Hughes, A. Humar, *Transplant Surgery, UPMC, Pittsburgh, PA*

- B353 Case Series Of Total Laparoscopic-hand Assisted Living Donor Right Hepatectomy: First 19 Cases At A Single Center In Usa**  
P. N. Martins<sup>1</sup>, B. Movahedi<sup>2</sup>, D. Litwin<sup>2</sup>, A. Bozorgzadeh<sup>2</sup>, <sup>1</sup>*Surgery, Division of Transplantation, University of Massachusetts, Worcester, MA, <sup>2</sup>Surgery, Division of Transplantation, University of Massachusetts, Worcester, MA*
- B354 Expansion Of The Use Of Left Lobe Grafts In Adult Liver Transplantation In The United States: Different Strategy Between Deceased And Living Donor Grafts**  
M. Fujiki, H. Matsushima, K. Sasaki, C. Quintini, F. Aucejo, T. Diago, B. Eghtesad, C. Miller, K. Hashimoto, *Cleveland Clinic Foundation, Cleveland, OH*
- B355 Meld Score / Grwr Ratio (meldgr) Can Predict Surgical Outcomes And Prognosis Of The Recipients In Adult-to-adult Living Donor Liver Transplantation**  
A. Tanemura, A. Hayasaki, T. Fujii, Y. Iizawa, H. Kato, Y. Murata, N. Kuriyama, Y. Azumi, M. Kishiwada, S. Mizuno, M. Usui, H. Sakurai, S. Isaji, *Hepatobiliary Pancreatic and Transplant Surgery, Mie University, Tsu, Japan*
- B356 † Drug Metabolizing Capacity Of The Liver In Liver Donors Recovers Fully By One Month Post Donation**  
M. Miah<sup>1</sup>, X. Wu<sup>1</sup>, I. H. Shaik<sup>1</sup>, H. J. Johnson<sup>1</sup>, S. Ganesh<sup>2</sup>, M. Molinari<sup>2</sup>, A. D. Tevar<sup>2</sup>, C. Hughes<sup>2</sup>, A. Humar<sup>2</sup>, R. Venkataramanan<sup>1</sup>, <sup>1</sup>*Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA*

## Poster Session C: Histocompatibility and Immunogenetics

Poster Viewing: 6:00 pm - 7:00 pm  
Presenters in Attendance: 6:00 pm - 7:00 pm  
Hall C & D

A# indicates the board location where the poster will be displayed.

† Those posters identified as an ATC Poster of Distinction by this symbol have received review scores that place them in the top 10% of their category. The Planning Committee encourages you to make them a priority when you visit the poster session.

- C1**      **Activation of Renal Fibroblasts by Anti-Major Histocompatibility Complex Antibody: A Missing Link in Allograft Fibrosis**  
M. B. Oliver<sup>1</sup>, J. Chen<sup>2</sup>, A. Zmijewska<sup>1</sup>, R. B. Mannon<sup>1</sup>, <sup>1</sup>Medicine, Division of Nephrology, The University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, The University of Alabama at Birmingham, Birmingham, AL
- C2**      **Intra-Operative Kinetics of Anti-HLA Antibodies in Simultaneous Liver-Kidney Transplantation**  
M. Kueht, P. Jindra, M. Cusick, N. Galvan, A. Rana, J. Goss, *Baylor College of Medicine, Houston, TX*
- C3**      **Impact Of Donor And Recipient Race On Kidney Transplant Survivals Evaluated By The Physiochemically-calculated Hla Immunogenicity**  
S. Stepkowski, B. Mierzejewska, M. Rees, *University of Toledo, Toledo, OH*
- C4**      **Patients with Immunological Diseases or on Peritoneal Dialysis Are Prone to False Positive Flow Cytometry Cross Match**  
Q. Xu<sup>1</sup>, A. House<sup>2</sup>, S. Leckie<sup>1</sup>, L. Gunaratnam<sup>2</sup>, P. Luke<sup>3</sup>, A. Jevnikar<sup>2</sup>, <sup>1</sup>Pathology and Lab Medicine, London Health Science Center, London, ON, Canada, <sup>2</sup>Medicine, Western University, London, ON, Canada, <sup>3</sup>Surgery, Western University, London, ON, Canada

- C5**      **Report of 20 HLA Matchmaker Eplets Present on Denatured Class I HLA Molecules**  
R. de Marco<sup>1</sup>, A. C. Lima<sup>2</sup>, N. F. Pereira<sup>2</sup>, M. Gerbase-DeLima<sup>1</sup>, <sup>1</sup>Immunogenetics Institute, AFIP, Sao Paulo, SP, Brazil, <sup>2</sup>Immunogenetics Laboratory, Universidade Federal do Paraná, Curitiba, PR, Brazil

- C6**      **Improving Pre-Kidney Transplantation Laboratory Utilization in an Era of Increasing Waitlist Size**  
G. K. Mahowald<sup>1</sup>, B. Kimball<sup>2</sup>, N. Elias<sup>2</sup>, E. Heher<sup>3</sup>, T. Girouard<sup>1</sup>, S. L. Saidman<sup>1</sup>, V. Pattanayak<sup>1</sup>, <sup>1</sup>Pathology, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Transplant Surgery, Massachusetts General Hospital, Boston, MA, <sup>3</sup>Nephrology, Massachusetts General Hospital, Boston, MA

- C7**      **Correlation of Crossmatch Predictions with Actual Results and Clinical Outcomes**  
R. Forbes<sup>1</sup>, B. Concepcion<sup>1</sup>, S. Fossey<sup>2</sup>, <sup>1</sup>Vanderbilt University Medical Center, Nashville, TN, <sup>2</sup>Dialysis Clinic, Inc, Nashville, TN

- C8 †**      **Anti-Complement Component 5 Antibody Based Immunosuppression Induced Accommodation in ABO Incompatible Heart Transplantation**  
S. Park<sup>1</sup>, S. Lee<sup>1</sup>, J. Hwang<sup>1</sup>, J. Ryu<sup>2</sup>, T. Koo<sup>2</sup>, C. Ahn<sup>3</sup>, J. Yang<sup>4</sup>, <sup>1</sup>Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of, <sup>2</sup>Transplantation Center, Seoul National University Hospital, Seoul, Korea, Republic of, <sup>3</sup>Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of, <sup>4</sup>Department of Surgery, Seoul National University Hospital, Seoul, Korea, Republic of



**Poster Session C: Immunosuppression  
Preclinical Studies**

---

- C9**      **Comparison of Tacrolimus or Cyclosporine Combined with Methotrexate for Graft versus Host Disease Prophylaxis after Allogeneic Hematopoietic Cell Transplantation: A Meta-Analysis**  
M. Chen, B. Huang, Y. Zhang, W. Ju, X. He, *Transplant Center, Sun Yat-sen University, Guangzhou, China*
- C10**      **Exendin-4 for Donor Treatment in a Brain-Death Model of Kidney Transplantation**  
H. Yang<sup>1</sup>, L. Luo<sup>1</sup>, X. Li<sup>1</sup>, C. Long<sup>1</sup>, Y. Shi<sup>2</sup>, Y. Xiong<sup>3</sup>, M. Chen<sup>4</sup>, J. Gao<sup>5</sup>, H. Li<sup>6</sup>, Z. Wang<sup>6</sup>, <sup>1</sup>*Department of Organ Transplantation, People's Hospital of Jiangxi Province, Nanchang, China,* <sup>2</sup>*Department of Pathology, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China,* <sup>3</sup>*Department of Neurology, People's Hospital of Jiangxi Province, Nanchang, China,* <sup>4</sup>*Department of Vascular Surgery, People's Hospital of Jiangxi Province, Nanchang, China,* <sup>5</sup>*Department of Vascular Surgery, People's hospital of Jiangxi Province, Nanchang, China,* <sup>6</sup>*Department of Urologic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China*
- C11**      **Bespoke Immunosuppression: Prolonging Transplant Survival through Enhanced T-cell Activation Induced Cell Death**  
R. Costello<sup>1</sup>, R. J. Ingram<sup>1</sup>, D. Longley<sup>2</sup>, J. McDaid<sup>3</sup>, <sup>1</sup>*WWIEM, QUB, Belfast, United Kingdom,* <sup>2</sup>*CCRCB, QUB, Belfast, United Kingdom,* <sup>3</sup>*Renal Transplantation, Belfast City Hospital, Belfast, United Kingdom*
- C12**      **A Novel Apparatus Mimicking Hypertensive Kidney With Primary Cultured Human Kidney Cells Using Rotational Force: Application To In Vitro Drug Screening In Kidney Transplant Recipients**  
Y. Kim<sup>1</sup>, S. Lee<sup>2</sup>, J. Moon<sup>1</sup>, J. Kim<sup>1</sup>, M. Yu<sup>3</sup>, C. Lee<sup>4</sup>, Y. Kim<sup>1</sup>, S. Yang<sup>5</sup>, J. Jeong<sup>1</sup>, J. Seon<sup>1</sup>, <sup>1</sup>*Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of,* <sup>2</sup>*Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of,* <sup>3</sup>*Internal Medicine, Hanyang University Medical Center, Seoul, Korea, Republic of,* <sup>4</sup>*Internal Medicine, Cheju Halla General Hospital, Cheju, Korea, Republic of,* <sup>5</sup>*Kidney Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of*
- C13**      **Store-Operated/Calcium Release Activated Calcium Channel Orai3 is a Novel Target for Immunoregulation**  
D. Shankaranarayanan<sup>1</sup>, M. Lagman<sup>1</sup>, V. Sharma<sup>1</sup>, C. Li<sup>1</sup>, M. Cassidy<sup>1</sup>, C. Snopkowski<sup>1</sup>, H. Yang<sup>1</sup>, T. Muthukumar<sup>1</sup>, K. Machaca<sup>2</sup>, M. Suthanthiran<sup>1</sup>, <sup>1</sup>*WCMC, New York, NY,* <sup>2</sup>*WCMC, Doha, Qatar*
- C14**      **Neutralization of Interleukin-6 by ALD518-P18 (Murine Clazakizumab) Attenuates Donor Specific Antibody Responses in a Mouse Model of Allogeneic Sensitization: A Report of Dosage Finding Study**  
I. Kim, G. Wu, N. Chai, T. Brennan, A. Klein, S. Jordan, *Cedars-Sinai Med Ctr, Los Angeles, CA*
- C15**      **Effects of Thalidomide and Dexamethasone Co-Treatment on CD8+ T Cells**  
J. Kim<sup>1</sup>, E. Kim<sup>2</sup>, Y. Cho<sup>1</sup>, H. Lee<sup>1</sup>, M. Kim<sup>3</sup>, Y. Kim<sup>3</sup>, K. Huh<sup>3</sup>, B. Kim<sup>4</sup>, <sup>1</sup>*The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Korea, Republic of,* <sup>2</sup>*Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea, Republic of,* <sup>3</sup>*Department of Transplantation Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of,* <sup>4</sup>*Nephrology Division, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of*

- C16** **Eupatilin Ameliorates Tacrolimus Induced Nephrotoxicity via Inhibiting Apoptosis**  
H. J. Jang, C. S. Park, M. Y. Oh, *Surgery, University of Ulsan, Gangneung Asan Hospital, Gangneung, Korea, Republic of*
- C17 †** **Bortezomib Attenuates the Progression of Epithelial to Mesenchymal Transition through Smurf1 Akt mTOR P70S6K Pathway in Rat Allograft Renal Interstitial Fibrosis Model**  
R. Tan, Z. Wang, S. Fei, Z. Han, J. Tao, X. Ju, M. Gu, *No.300 Guangzhou Road of Nanjing, Nanjing, China*
- C18** **Resistance of T Follicular Helper Cells to Depletion by Anti-Thymocyte Globulin**  
M. Pérez-Sáez<sup>1</sup>, N. Murakami<sup>2</sup>, T. J. Borges<sup>2</sup>, P. T. Sage<sup>2</sup>, J. Pascual<sup>1</sup>, L. V. Riella<sup>2</sup>, <sup>1</sup>*Nephrology, Hospital del Mar, Barcelona, Spain*, <sup>2</sup>*Brigham and Women's Hospital, Harvard Medical School, Boston, MA*

### Poster Session C: Innate Immunity; Chemokines, Cytokines, Complement

- C19** **C1q Dominant Deposits in Renal Transplant Biopsies Are Not Associated with Allograft Dysfunction**  
A. Babu<sup>1</sup>, S. Williamson<sup>2</sup>, N. Khoury<sup>1</sup>, M. Safwan<sup>1</sup>, A. Patel<sup>1</sup>, <sup>1</sup>*Transplant Institute, Henry Ford Hospitals, Detroit, MI*, <sup>2</sup>*Pathology Surgical, Henry Ford Hospitals, Detroit, MI*

- C20** **Targeting Pyroptosis in Brain-Dead Donors Improves Renal Function after Transplantation in Rat**  
H. Yang<sup>1</sup>, Y. Shi<sup>2</sup>, X. Li<sup>1</sup>, L. Luo<sup>1</sup>, C. Long<sup>1</sup>, Y. Xiong<sup>3</sup>, M. Chen<sup>4</sup>, J. Gao<sup>4</sup>, H. Li<sup>5</sup>, Z. Wang<sup>5</sup>, <sup>1</sup>*Department of Organ Transplantation, People's Hospital of Jiangxi Province, Nanchang, China*, <sup>2</sup>*Department of Pathology, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China*, <sup>3</sup>*Department of Neurology, People's Hospital of Jiangxi Province, Nanchang, China*, <sup>4</sup>*Department of Vascular Surgery, People's Hospital of Jiangxi Province, Nanchang, China*, <sup>5</sup>*Department of Urologic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China*
- C21 †** **Transplantation Alone Induces Myeloid-Derived Suppressor Cells Which Can Suppress T Cell Responses**  
Y. Lee, T. Zhang, J. S. Bromberg, J. R. Scalea, *University of Maryland, Baltimore, MD*
- C22** **Soluble Fibrinogen-Like Protein 2 Regulates MDSCs Differentiation and Function in Allograft Immunity**  
C. Yang, *Urology, Zhongshan Hospital, Fudan University, Shanghai, China*
- C23 †** **Recipient Myeloid Notch1 Disruption Shifts Neutrophil towards Anti-Inflammatory Phenotype and Protects Liver Grafts from Ischemia-Reperfusion Injury**  
S. Kageyama<sup>1</sup>, H. Hirao<sup>1</sup>, K. Kadono<sup>1</sup>, K. Nakamura<sup>1</sup>, K. J. Dery<sup>1</sup>, T. Ito<sup>2</sup>, D. Oncel<sup>1</sup>, J. Aziz<sup>1</sup>, B. Ke<sup>1</sup>, F. M. Kaldas<sup>2</sup>, R. W. Busuttil<sup>2</sup>, J. W. Kupiec-Weglinski<sup>1</sup>, <sup>1</sup>*Dumont-UCLA Transplant Center, UCLA, Los Angeles, CA*, <sup>2</sup>*Surgery, Ronald Reagan UCLA Medical Center, UCLA, Los Angeles, CA*
- C24** **Ikaros/IRF4 Signaling Regulates SIRT1-Mediated Macrophage M2 Shift in Liver Ischemia-Reperfusion Injury: From Mouse-to-Human**  
K. Kadono<sup>1</sup>, K. Nakamura<sup>1</sup>, H. Hirao<sup>1</sup>, S. Kageyama<sup>1</sup>, K. J. Dery<sup>1</sup>, T. Ito<sup>1</sup>, J. Aziz<sup>1</sup>, X. Li<sup>2</sup>, B. Ke<sup>1</sup>, R. W. Busuttil<sup>1</sup>, J. W. Kupiec-Weglinski<sup>1</sup>, <sup>1</sup>*Dumont-UCLA Transplant Center, UCLA, Los Angeles, CA*, <sup>2</sup>*NIEHS, Durham, NC*

- C25 Cellular Sources of Cytokine Production during Cold Ischemia Induced AKI after Kidney Transplant**  
S. Jain<sup>1</sup>, R. Plenter<sup>2</sup>, T. Nydam<sup>2</sup>, A. Jani<sup>1</sup>,  
*<sup>1</sup>Renal Division, University of Colorado, Aurora, CO, <sup>2</sup>Transplant Microsurgery Program, University of Colorado, Aurora, CO*
- C26 mTOR Inhibitors Enhance Antitumor Activity of Liver Resident NK Cells**  
J. Saparbay, Y. Tanaka, A. Seidakhmetov, H. Ohdan, *Gastroenterology and transplant Surgery, Hiroshima University, Hiroshima, Japan*
- C27 Cyclo (his-pro) Protects Against Gentamicin Induced Cell Apoptosis And Cisplatin Induced Acute Kidney Injury Through Inhibiting P53 Mediated Apoptotic Pathway.**  
Y. Kim<sup>1</sup>, J. Moon<sup>1</sup>, J. Jeong<sup>1</sup>, J. Kim<sup>1</sup>, S. Lee<sup>1</sup>, M. Yu<sup>2</sup>, C. Lee<sup>3</sup>, Y. Kim<sup>1</sup>, S. Yang<sup>4</sup>, *<sup>1</sup>Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of, <sup>2</sup>Internal Medicine, Hanyang University Medical Center, Seoul, Korea, Republic of, <sup>3</sup>Internal Medicine, Cheju Halla General Hospital, Cheju, Korea, Republic of, <sup>4</sup>Kidney Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of*
- C28 Alteration in Local Complement Activation in First 24h Post-Lung Transplantation (LTx) Helps Identify Recipients Developing Primary Graft Dysfunction**  
H. Kulkarni<sup>1</sup>, M. Elvington<sup>2</sup>, L. Ma<sup>1</sup>, M. Cano<sup>1</sup>, K. Pugh<sup>3</sup>, R. Hachem<sup>1</sup>, J. Atkinson<sup>2</sup>, A. Gelman<sup>3</sup>, *<sup>1</sup>Pulmonary and Critical Care Medicine, Washington University, Saint Louis, MO, <sup>2</sup>Rheumatology, Washington University, Saint Louis, MO, <sup>3</sup>Surgery, Washington University, Saint Louis, MO*
- C29 Myeloid Derived Suppressor Cells (MDSC) Home to the Allograft and Can Control T Cell Responses**  
Y. S. Lee, T. Zhang, J. S. Bromberg, J. R. Scalea, *University of Maryland, Baltimore, MD*
- C30 Murine Cytomegalovirus Infection Down-Regulates Receptor Tyrosine Kinase MerTK on Macrophages to Abrogate Allograft Tolerance**  
S. Yu, A. Dangi, M. Burnette, X. Luo, *Division of Nephrology, Department of Medicine, Duke Transplant Center, Duke University Medical Center, Durham, NC*
- C31 The Potential Role of IL-33/ST2 Pathway in Renal Allograft Rejection**  
M. Yu<sup>1</sup>, Y. Kim<sup>2</sup>, J. Moon<sup>2</sup>, S. Lee<sup>2</sup>, H. Lee<sup>2</sup>, D. Kim<sup>2</sup>, C. Lee<sup>3</sup>, Y. Kim<sup>2</sup>, S. Yang<sup>2</sup>, *<sup>1</sup>Hanyang University Guri Hospital, Guri, Korea, Republic of, <sup>2</sup>Seoul National University Hospital, Seoul, Korea, Republic of, <sup>3</sup>Cheju Halla General Hospital, Jeju, Korea, Republic of*
- C32 Inhibition of CXCR3 Expression through Blockade of STAT3 Alpha Signaling Down-Regulate Inflammation of Renal Ischemia-Reperfusion Injury**  
J. Kim<sup>1</sup>, J. Park<sup>2</sup>, K. Yoo<sup>2</sup>, J. Moon<sup>1</sup>, J. Jeong<sup>1</sup>, C. Lee<sup>3</sup>, Y. Kim<sup>1</sup>, S. Yang<sup>4</sup>, *<sup>1</sup>Seoul National University College of Medicine, Seoul, Korea, Republic of, <sup>2</sup>Dongguk University College of Medicine, Gyeonggi-do, Korea, Republic of, <sup>3</sup>Cheju Halla General Hospital, Cheju, Jeju-do, Korea, Republic of, <sup>4</sup>Kidney Research Institute, Seoul National University, Seoul, Korea, Republic of*
- C33 Hyperglycemia Aggravates Acute Liver Injury by Promoting Macrophage NLRP3 Activation via AMPK/mTOR-Dependent Autophagy Inhibition**  
H. ZHOU, Q. Wang, R. Liu, S. Zhou, F. Cheng, X. Wang, L. Lu, *The First Affiliated Hospital of Nanjing Medical University, Nanjing, China*
- C34 Deficiency of IRE1a Ameliorates Renal Allograft Injury via Remodeling of Graft-Infiltrating Macrophages**  
L. Qiu<sup>1</sup>, J. Wang<sup>1</sup>, X. Yeap<sup>1</sup>, S. Han<sup>1</sup>, F. Zheng<sup>1</sup>, D. Fang<sup>2</sup>, Z. J. Zhang<sup>1</sup>, *<sup>1</sup>Comprehensive Transplant Center, Department of Surgery, Northwestern University, Chicago, IL, <sup>2</sup>Department of Pathology, Northwestern University, Chicago, IL*

- C35** **EBV Latent Proteins Encode for Peptides That Prevent Natural Killer Cell Inhibition**  
B. Mbiribindi<sup>1</sup>, J. K. Pena<sup>1</sup>, O. Hatton<sup>2</sup>, C. Romero Moreno<sup>1</sup>, C. O. Esquivel<sup>1</sup>, O. M. Martinez<sup>1</sup>, S. M. Krams<sup>1</sup>, <sup>1</sup>*Department of Surgery/ Division of Abdominal Transplant, Stanford University - School of Medicine, Stanford, CA*, <sup>2</sup>*Department of Molecular Biology, Colorado College, Colorado Springs, CO*
- C36 †** **Blockade of C3aR1 Signaling Suppresses Alloreactive CD8+ T Cell Immunity and Prolongs Murine Cardiac Allograft Survival**  
J. Horwitz, D. Mathern, P. Heeger, *Icahn School of Medicine at Mount Sinai, NY, NY*
- C37** **Recipient TIM4 Expression is Essential for Hepatocellular Function in Liver Transplantation**  
K. Kadono, S. Kageyama, H. Hirao, K. Nakamura, K. J. Dery, D. Oncel, T. Ito, B. Ke, F. M. Kaldas, R. W. Busuttil, J. W. Kupiec-Weglinski, *Dumont-UCLA Transplant Center, UCLA, Los Angeles, CA*
- C38** **Peripheral Blood Chemokine Levels in Kidney Allograft Rejection**  
E. Van Loon, D. Schols, S. Claes, M. Naesens, *University Hospitals Leuven, Leuven, Belgium*
- C39** **CHOP Deficiency Attenuated Acute Liver Injury by Promoting Macrophage M2 Polarization via ATG5-Mediated Autophagy Activation**  
H. Zhou, R. Liu, Q. Wang, C. Shi, F. Cheng, X. Wang, L. Lu, *The First Affiliated Hospital of Nanjing Medical University, Nanjing, China*
- C40** **Initial Peritoneal sST2 Levels Are Associated with Peritoneal Failure and ST2 Blockade Mitigates TGF- $\beta$  and High Glucose-Induced Peritoneal Fibrosis**  
Y. Kim<sup>1</sup>, S. Lee<sup>1</sup>, M. Yu<sup>1</sup>, H. Lee<sup>1</sup>, Y. Kim<sup>1</sup>, C. Lee<sup>2</sup>, R. Cha<sup>3</sup>, S. Yang<sup>4</sup>, <sup>1</sup>*Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of*, <sup>2</sup>*Internal Medicine, Cheju Halla General Hospital, Cheju, Korea, Republic of*, <sup>3</sup>*Internal Medicine, National Medical Center, Seoul, Korea, Republic of*, <sup>4</sup>*kidney Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of*
- C41** **Interferon Sensitivity Promotes Recovery from Acetaminophen Induced Liver Injury**  
S. Datta, T. Hamilton, G. C. Sen, *Inflammation and Immunity, Cleveland Clinic Foundation, Cleveland, OH*
- C42** **Expansion of Myeloid Derived Suppressor Cells Following Alum Administration**  
A. G. Cuenca, N. J. Feeney, K. Deng, C. G. Rickert, J. F. Markmann, *Massachusetts General Hospital, Boston, MA*
- C43** **Endothelial Cells Do Not Regulate Expression of CD46, CD55 and CD59 in the Presence of Anti-HLA Class I and 11 Antibodies**  
A. Babu<sup>1</sup>, T. Pham<sup>2</sup>, M. Hamdorf<sup>2</sup>, V. Jucaud<sup>2</sup>, M. Everly<sup>2</sup>, S. Daga<sup>3</sup>, D. Mitchell<sup>4</sup>, <sup>1</sup>*Transplant Institute, Henry Ford Hospitals, Detroit, MI*, <sup>2</sup>*Terasaki Research Institute, Los Angeles, CA*, <sup>3</sup>*University of Warwick, Coventry, United Kingdom*, <sup>4</sup>*Medical Sciences, University of Warwick, Coventry, United Kingdom*

### Poster Session C: Kidney Complications: Late Graft Failure

- C44** **Meet Your Mate: Lessons Gleaned from Analysis of 154 Paired Kidneys Transplanted at a Single Center**  
M. Lubetzky<sup>1</sup>, M. Aull<sup>2</sup>, K. Rhee<sup>1</sup>, S. Sultan<sup>2</sup>, S. Kapur<sup>2</sup>, <sup>1</sup>*Division of Nephrology, New York, NY*, <sup>2</sup>*Surgery, NYP-Weill Cornell, New York, NY*



- C45**      **The Clinical Outcomes of Kidney Transplant Recipients with Early Graft Failure: A Nationwide Study in South Korea**  
 Y. Kim<sup>1</sup>, S. Kwon<sup>1</sup>, S. Park<sup>1</sup>, J. Moon<sup>1</sup>, J. Seon<sup>1</sup>, J. Kim<sup>1</sup>, M. Yu<sup>2</sup>, K. Han<sup>3</sup>, D. Kim<sup>1</sup>, Y. Kim<sup>1</sup>, H. Lee<sup>1</sup>, <sup>1</sup>Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of, <sup>2</sup>Internal Medicine, Hanyang University Medical Center, Seoul, Korea, Republic of, <sup>3</sup>Medical Statistics, Catholic University of Korea, Seoul, Korea, Republic of
- C46**      **The Inverted Renal CD4/CD8 Ratio Associated with the Development of Transplant Glomerulopathy and Arteriosclerosis**  
 B. H. Ozdemir<sup>1</sup>, F. N. Ozdemir<sup>2</sup>, A. Ok Atılgan<sup>1</sup>, E. Akcay<sup>1</sup>, M. Haberal<sup>3</sup>, <sup>1</sup>Pathology, Baskent University, Ankara, Turkey, <sup>2</sup>Nephrology, Baskent University, Ankara, Turkey, <sup>3</sup>Transplantation, Baskent University, Ankara, Turkey
- C47**      **Does Proton Pump Inhibitor Use Affect Renal Function in Kidney Transplant Recipients?**  
 K. Schütte-Nütgen<sup>1</sup>, D. J. Flothow<sup>1</sup>, B. Suwelack<sup>1</sup>, R. Schmidt<sup>2</sup>, H. Pavenstädt<sup>1</sup>, S. Reuter<sup>1</sup>, <sup>1</sup>Department of Internal Medicine D, University Hospital Münster, Münster, Germany, <sup>2</sup>Institute of Biostatistics and Clinical Research, University Hospital Münster, Münster, Germany
- C48 †**     **The Study on the DNA Methylation Dynamic Changes after Renal Transplantation**  
 C. Zhu, H. Jiang, J. Chen, *Nephrology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China*
- C49 †**     **Characterization Of Microscopic Hematuria Following Renal Transplant**  
 M. L. McDonald<sup>1</sup>, T. N. Duong<sup>2</sup>, N. Datta<sup>2</sup>, H. A. Gritsch<sup>1</sup>, S. Bunnapradist<sup>2</sup>, <sup>1</sup>Department of Urology, Kidney and Pancreas Transplant Programs, UCLA, Los Angeles, CA, <sup>2</sup>Division of Nephrology, Kidney and Pancreas Programs, UCLA, Los Angeles, CA
- C50 †**     **FK506 Influence Glucose Metabolism by Short Chain Fatty Acid**  
 W. Jiao<sup>1</sup>, Z. Zhang<sup>1</sup>, L. Liu<sup>2</sup>, X. Hu<sup>1</sup>, <sup>1</sup>Urology, Capital Medical University Beijing Chaoyang Hospital, Beijing, China, <sup>2</sup>GI Divison, West China Hospital, Beijing, China
- C51**      **Breakthrough Changes in the Access to Transplantation for the Patients with Atypical Hemolytic Uremic Syndrome in the Eculizumab Era**  
 J. Zuber, M. Frimat, P. Gatault, N. Kamar, L. Couzi, N. Jourde-Chiche, V. Chatelet, S. Caillard, R. Gaisne, D. Bertrand, J. Bamoulid, M. Louis, C. Pouteil-Noble, C. Legendre, M. Peraldi, E. Rondeau, M. Le Quintrec, V. Frémeaux-Bacchi, *On behalf of the French aHUS Study Group, France, France*
- C52**      **Comparison of Oral Microbiome in Stable vs Declining Kidney Function in Renal Transplant Recipients**  
 J. Wu<sup>1</sup>, A. Muthusamy<sup>2</sup>, G. Al-Ghalith<sup>3</sup>, B. Wu<sup>4</sup>, B. Guo<sup>4</sup>, W. Guan<sup>4</sup>, D. Knights<sup>3</sup>, W. Oetting<sup>5</sup>, D. Schladt<sup>2</sup>, R. Remmel<sup>5</sup>, P. Jacobson<sup>5</sup>, A. K. Sharma<sup>6</sup>, A. Matas<sup>7</sup>, A. Israni<sup>1</sup>, D. Skaar<sup>8</sup>, <sup>1</sup>Nephrology, Hennepin Healthcare, Minneapolis, MN, <sup>2</sup>Hennepin Health Research Institute, Minneapolis, MN, <sup>3</sup>Computer Science, University of Minnesota, Minneapolis, MN, <sup>4</sup>Biostatistics, University of Minnesota, Minneapolis, MN, <sup>5</sup>Pharmacy, University of Minnesota, Minneapolis, MN, <sup>6</sup>Animal Science, University of Minnesota, Minneapolis, MN, <sup>7</sup>Surgery, University of Minnesota, Minneapolis, MN, <sup>8</sup>Denistry, University of Minnesota, Minneapolis, MN
- C53**      **Kidney Transplant Outcome between Identical Twins in USA from 2001-2017**  
 D. R. Jorgensen, S. Hariharan, *Starzl Transplant Institute, Univ of Pittsburgh Med Center, Pittsburgh, PA*
- C54**      **Postoperative Telemonitoring Following Kidney Transplantation: Effects on Early Hospital Readmissions and Graft Outcomes**  
 N. Elfadawy, V. Humphreville, A. Padiyar, E. Sanchez, N. Sarabu, *University hospitals of Cleveland, Cleveland, OH*



- C55 Association of Histological Findings in Renal Graft Biopsy with Non-Adherence to Immunosuppressive Treatment**  
 B. D. Cardoso<sup>1</sup>, J. Montagner<sup>2</sup>, K. Pegas<sup>3</sup>, R. Kist<sup>4</sup>, J. Neumann<sup>5</sup>, H. S. Pinheiro<sup>6</sup>, V. D. Garcia<sup>4</sup>, E. Keitel<sup>1</sup>, <sup>1</sup>Department of Nephrology and Kidney Transplantation/ Post Graduation Program in Pathology, Irmandade Santa Casa de Misericórdia/ Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil, <sup>2</sup>Transplant Immunology Laboratory,, Irmandade Santa Casa de Misericórdia, Porto Alegre, Brazil, <sup>3</sup>Department of Pathology, Irmandade Santa Casa de Misericórdia, Porto Alegre, Brazil, <sup>4</sup>Department of Nephrology and Kidney Transplantation, Irmandade Santa Casa de Misericórdia, Porto Alegre, Brazil, <sup>5</sup>Transplant Immunology Laboratory, Irmandade Santa Casa de Misericórdia, Porto Alegre, Brazil, <sup>6</sup>Renal Transplant Unit, NIEPEN/NIDEAL (UFJF), Porto Alegre, Brazil
- C56 Clinical Features of IgA Nephropathy Recurrence after Kidney Transplantation**  
 H. HIGUCHI<sup>1</sup>, K. Hotta<sup>2</sup>, H. Harada<sup>1</sup>, Y. Wada<sup>1</sup>, A. Mitsuke<sup>1</sup>, D. Iwami<sup>2</sup>, N. Shinohara<sup>2</sup>, <sup>1</sup>Urology and Kidney transplant surgery, Sapporo General Hospital, Sapporo, Japan, <sup>2</sup>Urology, Hokkaido University, Sapporo, Japan
- C57 † Outcome of Renal Transplantation in Systemic Amyloidosis**  
 S. Law<sup>1</sup>, L. Helen<sup>2</sup>, T. Resk<sup>2</sup>, A. Wechalekar<sup>2</sup>, J. Gillmore<sup>2</sup>, R. Motallebzadeh<sup>1</sup>, <sup>1</sup>Renal Medicine, Royal Free Hospital, London, United Kingdom, <sup>2</sup>UCL Division of Medicine, National Amyloidosis Centre, London, United Kingdom
- C58 Pregnancy after Renal Transplantation**  
 A. Schwarz<sup>1</sup>, F. Keller<sup>2</sup>, H. Haller<sup>1</sup>, <sup>1</sup>Nephrology Department, Hannover Medical School, Hannover, Germany, <sup>2</sup>Nephrology Department, University Hospital Ulm, Ulm, Germany
- C59 Pregnancy Outcomes in Kidney Transplant Recipients**  
 H. SHIRAKAWA<sup>1</sup>, S. WAKAI<sup>2</sup>, K. UNAGAMI<sup>3</sup>, K. OMOTO<sup>4</sup>, T. SHIMIZU<sup>4</sup>, Y. KAKUTA<sup>5</sup>, M. OKUMI<sup>5</sup>, H. ISHIDA<sup>5</sup>, M. OGAWA<sup>6</sup>, K. TANABE<sup>5</sup>, <sup>1</sup>Urology, Ohkubo Hospital, Tokyo, Japan, <sup>2</sup>Nephrology, Ohkubo Hospital, Tokyo, Japan, <sup>3</sup>Nephrology, Tokyo Women's Medical University, Tokyo, Japan, <sup>4</sup>Urology, Toda Central General Hospital, Saitama, Japan, <sup>5</sup>Urology, Tokyo Women's Medical University, Tokyo, Japan, <sup>6</sup>Obstetrics and Gynecology, Tokyo Women's Medical University, Tokyo, Japan
- C60 † Living Kidney Donor Time Zero Biopsy Findings Predict Graft Loss in the Recipient**  
 N. Issa<sup>1</sup>, C. Lopez<sup>1</sup>, A. Denic<sup>1</sup>, J. J. Larson<sup>1</sup>, R. Narasimhan<sup>1</sup>, L. Archila<sup>1</sup>, S. S. Taler<sup>1</sup>, H. Chakker<sup>2</sup>, J. Augustine<sup>3</sup>, M. Stegall<sup>4</sup>, A. Rule<sup>1</sup>, <sup>1</sup>Nephrology, Mayo Clinic, Rochester, MN, <sup>2</sup>Nephrology, Mayo Clinic, Phoenix, AZ, <sup>3</sup>Nephrology, Cleveland Clinic, Cleveland, OH, <sup>4</sup>Transplantation, Mayo Clinic, Rochester, MN
- C61 Leukopenia in Older Kidney Transplant Recipients is Associated with Decreased Allograft Survival and Increased Patient Survival**  
 R. Rodriguez, A. Price, K. Soliman, R. Vinaya, D. Lazarus, M. Casey, M. Labonte, L. Erbe, M. Shearer, D. Taber, M. Posadas Salas, *Transplant Nephrology, Medical University of South Carolina, Charleston, SC*
- C62 Beneficial Association between Renin-Angiotensin-Aldosterone-System Blockade Usage and Graft Prognosis in Allograft Immunoglobulin A Nephropathy**  
 S. Park<sup>1</sup>, C. Baek<sup>2</sup>, M. Yu<sup>3</sup>, Y. Kim<sup>1</sup>, J. Moon<sup>1</sup>, H. Go<sup>2</sup>, Y. Kim<sup>2</sup>, J. Lee<sup>4</sup>, S. Min<sup>1</sup>, J. Ha<sup>1</sup>, K. Moon<sup>1</sup>, Y. Kim<sup>1</sup>, C. Ahn<sup>1</sup>, S. Park<sup>2</sup>, H. Lee<sup>1</sup>, <sup>1</sup>Seoul National University Hospital, Seoul, Korea, Republic of, <sup>2</sup>Asan Medical Center, Seoul, Korea, Republic of, <sup>3</sup>Hanyang University Hospital, Seoul, Korea, Republic of, <sup>4</sup>Seoul National University Hospital, Boramae Medical Center, Seoul, Korea, Republic of

- C63 Clinical Importance of the Updated Oxford Classification in Allograft IgA Nephropathy**  
S. Park<sup>1</sup>, H. Go<sup>2</sup>, C. Baek<sup>2</sup>, J. Jeong<sup>1</sup>, Y. Kim<sup>1</sup>, Y. Kim<sup>1</sup>, Y. Kim<sup>2</sup>, J. Lee<sup>3</sup>, S. Min<sup>1</sup>, J. Ha<sup>1</sup>, E. Song<sup>1</sup>, Y. Kim<sup>1</sup>, S. Park<sup>2</sup>, K. Moon<sup>1</sup>, H. Lee<sup>1</sup>, <sup>1</sup>Seoul National University Hospital, Seoul, Korea, Republic of, <sup>2</sup>Asan Medical Center, Seoul, Korea, Republic of, <sup>3</sup>Seoul National University Hospital, Boramae Medical Center, Seoul, Korea, Republic of
- C64 † Don't Believe the Hype: Machine Learning-Based Prediction of Kidney Transplant Outcomes**  
S. Bae, D. Segev, Johns Hopkins University, Baltimore, MD
- C65 Subtherapeutic Low Tacrolimus Trough Levels ( $\leq 3.5$  Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.**  
J. Arreola Guerra<sup>1</sup>, R. Reyes Acevedo<sup>2</sup>, A. Chew Wong<sup>1</sup>, F. Haro Alcalde<sup>1</sup>, L. Zuñiga Macias<sup>1</sup>, R. Delgadillo Castañeda<sup>2</sup>, R. Villafan<sup>3</sup>, <sup>1</sup>Internal Medicine and Nephrology, Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico, <sup>2</sup>Transplantation, Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico, <sup>3</sup>Universidad Autonoma de Aguascalientes, Aguascalientes, Mexico
- C66 Contemporary Predictors and Impact on Survival of Early Readmission after Kidney Transplant: Analysis of the Nationwide Readmission Database**  
N. Elfadawy, N. Tashtish, S. Al-kind, D. Hricik, E. Sanchez, N. Sarabu, University hospitals of Cleveland, Cleveland, OH
- C67 Prevalence of Recurrent and De Novo Glomerular Diseases after Renal Transplantation: A Single Center Experience**  
M. Ajaimy, O. Mohammed, E. Akalin, Montefiore-Einstein Transplant Center, Scarsdale, NY
- C68 Mesangiopathic Glomerulonephritis in Kidney Transplants**  
G. Towns, G. Agarwal, S. Ong, R. Mundra, C. Kew, UAB, Birmingham, AL
- C69 Low Incidence of Acute Renal Failure with Minimal Prophylaxis after Iodinated-Contrast TC in Ambulatory Renal Transplant Patients**  
C. Jimenez<sup>1</sup>, S. Afonso<sup>1</sup>, M. O. Lopez<sup>1</sup>, M. E. Gonzalez<sup>1</sup>, M. J. Santana<sup>1</sup>, A. Santiago<sup>2</sup>, M. A. Vaca<sup>1</sup>, M. Ferreira<sup>1</sup>, R. Selgas<sup>1</sup>, <sup>1</sup>Nephrology, Hospital Universitario La Paz, Madrid, Spain, <sup>2</sup>Radiology, Hospital Universitario La Paz, Madrid, Spain
- C70 Association Of Clinical Characteristics With Rate Of Kidney Transplant Function Decline In The 2 Years Prior To Allograft Loss**  
L. A. Binari, P. E. Thorne, J. L. Morse, T. G. Stewart, R. C. Forbes, K. Rabb, L. Lipworth, K. Abdel-Kader, B. P. Concepcion, Vanderbilt University Medical Center, Nashville, TN
- C71 Calcineurin Inhibitors and Long-Term Outcomes of Kidney Transplantation from Thai Transplant Registry**  
S. Udomkarnjananun, N. Townamchai, Y. Avihingsanon, K. Praditpornsilpa, Chulalongkorn University, Bangkok, Thailand
- C72 Development of a Novel Linear Model for Predicting Recipient's Post-Transplant Serum Creatinine Level after Living Donor Kidney Transplantation: A Multicenter Cross-Validation Study**  
S. Kim, S. Kim, J. Rhu, Y. Chung, S. Lee, K. Lee, J. Kim, G. Choi, J. Park, S. Lee, J. Joh, Transplantation, Samsung Medical Center, Seoul, Korea, Republic of
- C73 Tibetans and Hans Have Comparable Transplant Outcomes- A Propensity Score Matched Cohort Analysis**  
T. Lin, Y. Jiang, T. Song, Y. Fan, Organ transplantation center, Urology department, Urology research institute, WestChina Hospital, Sichuan University, Chengdu, China

- C74**      **Changes in Body Mass Index and Outcomes after Kidney Transplantation: A Single Centre, Retrospective, Observational Study**  
A. Arshad<sup>1</sup>, J. Hodson<sup>2</sup>, K. Khalil<sup>1</sup>, A. Sharif<sup>3</sup>, <sup>1</sup>University of Birmingham, Birmingham, United Kingdom, <sup>2</sup>Queen Elizabeth Hospital, Edgbaston, Birmingham, UK, Institute of Translational Medicine, Birmingham, United Kingdom, <sup>3</sup>Queen Elizabeth Hospital Birmingham, UK, Department of Nephrology and Transplantation, Birmingham, United Kingdom
- C75**      **Clinical Outcomes and Risk Factors for Delayed or Slow Graft Function in an Adult, Urban Renal Transplant Population**  
K. Tejani, Z. Hajjiri, E. Benedetti, A. Lichvar, University of Illinois at Chicago, Chicago, IL
- C76**      **The Safety Of Adjuvant Chemotherapy In Kidney Transplant Patients With Urothelial Carcinoma**  
Z. Wang, J. Xiao, Y. Zhu, J. Lin, Y. Guo, Y. Tian, Capital Medical University, Beijing Friendship Hospital, Beijing, China
- C77**      **Development of a Recurrence Risk Score in IgA Nephropathy after Kidney Transplantation: Role of Recipient Age and HLA-B Mismatch**  
L. M. Rodas Marin<sup>1</sup>, E. Ruiz<sup>2</sup>, A. García<sup>3</sup>, M. Blasco<sup>1</sup>, P. Ventura<sup>1</sup>, E. de Sousa<sup>1</sup>, O. Viñas<sup>4</sup>, F. Diekmann<sup>1</sup>, L. Quintana<sup>1</sup>, <sup>1</sup>Nephrology and Renal Transplantation, Hospital Clinic, Barcelona, Spain, <sup>2</sup>Immunology, Hospital Clinic, Barcelona, Spain, <sup>3</sup>Pathology, Hospital Clinic, Barcelona, Spain, <sup>4</sup>Immunology, Hospital Clinic, Barcelona, Spain
- C78**      **Differential Diagnosis of Membranous Nephropathy Occurs after Bone Marrow Transplantation and Renal Transplantation**  
L. Guo<sup>1</sup>, H. Wang<sup>1</sup>, Y. Tan<sup>2</sup>, J. Shen<sup>1</sup>, R. Wang<sup>1</sup>, J. Wu<sup>1</sup>, J. Chen<sup>1</sup>, <sup>1</sup>Kidney Disease Center, First Affiliated Hospital of Zhejiang University, Hangzhou, China, <sup>2</sup>First Affiliated Hospital of Zhejiang University, Hangzhou, China
- C79**      **Anti-HLA Antibodies Are Associated with Deterioration in Long-Term Renal Function Independently of Donor Specificity**  
T. Mueller<sup>1</sup>, P. Cippa<sup>2</sup>, R. van Breemen<sup>1</sup>, S. von Moos<sup>1</sup>, <sup>1</sup>University Hospital Zurich, Zurich, Switzerland, <sup>2</sup>Ospedale Regionale di Lugano Civico, Lugano, Switzerland
- C80**      **Risk Factors for Sensitization in the Failing Allograft: A Multi-Center Experience**  
M. Lubetzky<sup>1</sup>, O. Mohammed<sup>2</sup>, N. Hauser<sup>1</sup>, R. Friedlander<sup>1</sup>, V. Sharma<sup>1</sup>, A. Colovai<sup>2</sup>, T. Muthukumar<sup>1</sup>, J. Lee<sup>1</sup>, E. Akalin<sup>2</sup>, D. Dadhania<sup>1</sup>, <sup>1</sup>Division of Nephrology, Weil Cornell, New York, NY, <sup>2</sup>Division of Nephrology, Montefiore Medical Center, New York, NY
- C81**      **Clinicopathologic Assessment of Monoclonal Immunoglobulin (Ig) Associated Renal Disease in the Kidney Allograft**  
J. Kamal<sup>1</sup>, R. J. Crew<sup>1</sup>, X. Ye<sup>2</sup>, J. Swanson<sup>3</sup>, G. Appel<sup>1</sup>, G. Markowitz<sup>4</sup>, V. D'Agati<sup>4</sup>, I. Batal<sup>4</sup>, <sup>1</sup>Nephrology, Columbia University Medical Center, NEW YORK, NY, <sup>2</sup>Nephrology, Hartford Hospital, Hartford, CT, <sup>3</sup>Surgery, Christiana Hospital, Newark, DE, <sup>4</sup>Pathology, Columbia University Medical Center, NEW YORK, NY
- C82**      **Effects of Co-Morbidities on Kidney Transplantation Outcome in South Korea: A Nationwide-Population Based Study**  
M. Yu<sup>1</sup>, S. Park<sup>2</sup>, J. Moon<sup>2</sup>, J. Jeong<sup>2</sup>, J. Kim<sup>2</sup>, Y. Kim<sup>2</sup>, K. Han<sup>3</sup>, Y. Kim<sup>2</sup>, H. Lee<sup>2</sup>, <sup>1</sup>Hanyang University Guri Hospital, Guri, Korea, Republic of, <sup>2</sup>Seoul National University Hospital, Seoul, Korea, Republic of, <sup>3</sup>College of Medicine, Catholic University, Seoul, Korea, Republic of
- C83**      **Pregnancy in Renal Transplant Recipients A Single Center Retrospective Study**  
O. PISCORAN<sup>1</sup>, K. Bhatia<sup>1</sup>, T. Augustine<sup>1</sup>, S. Kopargaonkar<sup>2</sup>, J. Gillham<sup>2</sup>, <sup>1</sup>Renal Transplantation, Manchester Foundation Trust, MRI, Manchester, United Kingdom, <sup>2</sup>Manchester Foundation Trust, MRI, Manchester, United Kingdom

- C84**      **The Interaction between Post-Transplant Anemia and Allograft Function in Kidney Transplantation**  
Y. Kakuta<sup>1</sup>, M. Okumi<sup>1</sup>, T. Kanzawa<sup>1</sup>, K. Unagami<sup>2</sup>, H. Ishida<sup>2</sup>, K. Tanabe<sup>1</sup>, <sup>1</sup>*Urology, Tokyo Women's Medical University, Tokyo, Japan*, <sup>2</sup>*Organ Transplant Medicine, Tokyo Women's Medical University, Tokyo, Japan*
- C85 †**      **Interstitial CD68+ Cells Infiltration and Kidney Graft Outcome**  
E. Paoletti<sup>1</sup>, E. Bussalino<sup>2</sup>, L. Marsano<sup>1</sup>, D. Bellino<sup>1</sup>, R. Russo<sup>1</sup>, A. Parodi<sup>1</sup>, G. Garibotto<sup>2</sup>, J. L. Ravetti<sup>3</sup>, <sup>1</sup>*Nephrology, Dialysis, and Transplantation, Policlinico San Martino Genova, Genova, Italy*, <sup>2</sup>*Nephrology, Dialysis, and Transplantation, University of Genoa, Genova, Italy*, <sup>3</sup>*Pathology, Policlinico San Martino Genova, Genova, Italy*
- C86 †**      **The Association of Estimated Glomerular Filtration Rate at One Year Post-Kidney Transplant with Graft Loss is Not Modified by Delayed Graft Function**  
J. Gill, M. Kadatz, J. Gill, *University of British Columbia, Vancouver, BC, Canada*
- C87 †**      **Impact of Delayed Graft Function on Allograft Survival in DCD versus DBD Kidneys**  
T. Ishaque, A. B. Massie, J. Ruck, C. Holscher, J. G. Wang, D. L. Segev, *Surgery, Johns Hopkins School of Medicine, Baltimore, MD*
- C88**      **Frailty and Causes of Morbidity and Mortality in Kidney Transplant Recipients**  
L. Greco, S. Kaur, K. Lau, A. Fagenson, A. Di Carlo, S. Karhadkar, *Surgery, Temple University Hospital, Philadelphia, PA*
- C89**      **A National Cohort Validation of Graft Outcomes of Elderly Kidney Transplant Recipients**  
I. Bajjoka, A. Yaldo, C. Crombez, M. Abouljoud, *Henry Ford Transplant Institute, Detroit, MI*
- C90**      **Recipient and Donor Factors at the Time of Transplant as Predictors of Graft Outcomes**  
K. Soliman<sup>1</sup>, V. Rohan<sup>2</sup>, S. Zemin<sup>1</sup>, A. Price<sup>1</sup>, A. P. Salas<sup>1</sup>, D. Lazarus<sup>1</sup>, M. Casey<sup>3</sup>, D. J. Taber<sup>2</sup>, V. Rao<sup>3</sup>, <sup>1</sup>*Medicine, Medical University of South Carolina, Charleston, SC*, <sup>2</sup>*Surgery, Medical University of South Carolina, Charleston, SC*, <sup>3</sup>*Medicine and Surgery, Medical University of South Carolina, Charleston, SC*
- C91**      **The Role of Recipient Weight in Renal Transplantation Revisited; Not Quite the Obesity Paradox**  
A. Asderakis, R. Tahawar, T. Sabah, U. Khalid, M. Stephens, *Cardiff Transplant Unit, University Hospital of Wales, Cardiff, United Kingdom*
- C92 †**      **Impact of Acute Kidney Injury in Elderly Deceased Donor on the Post-Transplant Clinical Outcomes**  
J. Kim<sup>1</sup>, J. Lee<sup>2</sup>, Y. Kim<sup>3</sup>, K. Jin<sup>4</sup>, S. Han<sup>4</sup>, Y. Hong<sup>1</sup>, Y. Chang<sup>1</sup>, S. Kim<sup>1</sup>, H. Yoon<sup>5</sup>, C. Yang<sup>2</sup>, W. Park<sup>4</sup>, B. Chung<sup>2</sup>, <sup>1</sup>*Internal Medicine, Daejeon St. Mary's Hospital, Daejeon, Korea, Republic of*, <sup>2</sup>*Internal Medicine, Seoul St. Mary's Hospital, Seoul, Korea, Republic of*, <sup>3</sup>*Internal Medicine, Uijeongbu St. Mary's Hospital, Uijeongbu, Korea, Republic of*, <sup>4</sup>*Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of*, <sup>5</sup>*Internal Medicine, Incheon St. Mary's Hospital, Incheon, Korea, Republic of*
- Poster Session C: Tissue Engineering & Technology**
- C93 †**      **Systematic Testing and Specificity Mapping of Alloantigen-Specific Chimeric Antigen Receptors in T Regulatory Cells**  
C. Lamarche, N. Dawson, P. Bergqvist, R. Hoeppli, M. Mojibian, V. Feung, Q. Huang, J. Gillies, P. Orban, M. Levings, *University of British Columbia, Vancouver, BC, Canada*
- C94**      **Regeneration of Kidney with a Novel Biomimetic Vascular Scaffold**  
S. Min<sup>1</sup>, H. Mo<sup>1</sup>, A. Han<sup>1</sup>, J. Ha<sup>1</sup>, J. Yoo<sup>2</sup>, <sup>1</sup>*Seoul National University Hospital, Seoul 110-744, Korea, Republic of*, <sup>2</sup>*Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC*



- C95**      **Modeling Patients as Dynamical Systems: Evaluating the Efficiency of Kidney Transplantation through Multi-Stage Data Envelopment Analysis**  
 F. J. Santos Arteaga<sup>1</sup>, D. Di Caprio<sup>2</sup>, D. Cucchiari<sup>3</sup>, J. M. Campistol<sup>3</sup>, F. Oppenheimer<sup>3</sup>, F. Diekmann<sup>3</sup>, I. Revuelta<sup>3</sup>,  
<sup>1</sup>Faculty of Economics and Management, Free University of Bolzano, Bolzano, Italy, <sup>2</sup>Department of Mathematics and Statistics, York University, Toronto, ON, Canada, <sup>3</sup>Department of Nephrology and Kidney Transplant, Hospital Clinic, Barcelona, Spain
- C96**      **Towards 3D-Bioprinting of Bionic Pancreas: Effect of Pressure on the Viability of Pancreatic Islets**  
 M. Klak, K. Kosowska, E. Majdanska, T. Dobrzanski, A. Berman, L. Kaczynski, P. Kowalska, M. Gomolka, M. Wszola, Foundation for Research and Science Development, Warsaw, Poland
- C97**      **Scaffold-Free 3D-Bioprinting of Human Extrahepatic Bile Duct**  
 K. Saglam<sup>1</sup>, W. Zhang<sup>1</sup>, L. J. Smith<sup>2</sup>, A. Isidan<sup>1</sup>, A. M. Chen<sup>1</sup>, R. A. Naqvi<sup>1</sup>, E. Gramelspacher<sup>1</sup>, P. Li<sup>1</sup>, B. Ekser<sup>1</sup>,  
<sup>1</sup>Transplant Division, Department of Surgery, Indiana University, Indianapolis, IN, <sup>2</sup>3D-Bioprinting Core, Indiana University School of Medicine, Indianapolis, IN
- C98**      **Lymphotoxin Beta Receptor Determines Lymph Node Structure for Treg Migration and Suppression of Graft Rejection**  
 V. Saxena, W. Piao, L. Li, C. M. Paluskiewicz, Y. Xiong, T. Simon, J. S. Bromberg, U Maryland, Baltimore, MD
- C99**      **Balance between Low DNA Concentration and Structural Damage of Extracellular Matrix during Recellularization Procedure as a Key to Successful Recellularization**  
 A. Berman, A. Adamiok, G. Tynicki, L. Kaczynski, M. Gomolka, M. Klak, M. Wszola, Foundation of Research and Science Development, Warsaw, Poland

## Poster Session C: Kidney Psychosocial

- C100 †**      **Comparison of Planned vs. Unplanned Pregnancies in Female Kidney Transplant Recipients**  
 S. Rao<sup>1</sup>, L. A. Coscia<sup>2</sup>, D. Kliniewski<sup>2</sup>, S. Constantinescu<sup>3</sup>, M. J. Moritz<sup>4</sup>,  
<sup>1</sup>Medicine, University of Virginia Health System, Charlottesville, VA, <sup>2</sup>Gift of Life Institute, Transplant Pregnancy Registry International, Philadelphia, PA, <sup>3</sup>Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, <sup>4</sup>Surgery, Lehigh Valley Health Network, Allentown, PA
- C101**      **Quantifying Opioid Use after Renal Transplantation**  
 B. C. Noell, J. R. Brown, K. T. Cooper, A. M. Wagner, A. Kupsco, V. Casingal, Transplant Center, Carolinas Medical Center, Charlotte, NC
- C102**      **Better Health-Related Quality of Life in Kidney Transplant Patients over Time Compared with Those in Chronic Kidney Disease Patients at Similar Renal Function**  
 J. Ryu<sup>1</sup>, T. Koo<sup>1</sup>, K. Oh<sup>2</sup>, C. Ahn<sup>3</sup>, J. Yang<sup>1</sup>,  
<sup>1</sup>Organ transplant center, Seoul National University Hospital, Seoul, Korea, Republic of, <sup>2</sup>Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of, <sup>3</sup>Organ Transplant Center; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of
- C103 †**      **Assessment of Health-Related Quality of Life and Graft Failure among Kidney Transplant Patients in the Benefit and Benefit-EXT Trials**  
 I. Purnajo<sup>1</sup>, J. L. Beaumont<sup>1</sup>, M. Polinsky<sup>2</sup>, E. Alemas<sup>2</sup>, M. J. Everly<sup>1</sup>, <sup>1</sup>Terasaki Research Institute, Los Angeles, CA, <sup>2</sup>Bristol Myers Squibb, Princeton, NJ
- C104**      **simplifyKDPI: An Animated Video to Educate Kidney Transplant Candidates about the Kidney Donor Profile Index**  
 K. Bonner, R. Seibert, L. Kayler, SUNY Buffalo/ECMC, Buffalo, NY



- C105 Social Determinants of Quality of Life in Patients Evaluated for Kidney Transplant**  
H. Wesselman<sup>1</sup>, S. Wang<sup>2</sup>, C. J. Chang<sup>2</sup>, J. R. Pleis<sup>3</sup>, K. Kendall<sup>2</sup>, E. Croswell<sup>2</sup>, M. Dew<sup>2</sup>, M. L. Unruh<sup>4</sup>, R. Shapiro<sup>5</sup>, L. Myaskovsky<sup>4</sup>, <sup>1</sup>University of Notre Dame, Notre Dame, IN, <sup>2</sup>University of Pittsburgh, Pittsburgh, PA, <sup>3</sup>US Centers for Disease Control and Prevention, Hyattsville, MD, <sup>4</sup>Department of Internal Medicine, University of New Mexico, School of Medicine, Albuquerque, NM, <sup>5</sup>Icahn School of Medicine, New York, NY
- C106 Natural Evolution Of Tacrolimus Intra-patient Variability Among Renal Transplant Recipients**  
K. Zheng, S. Tremblay, N. S. Ejaz, N. K. Wilson, K. Hoffman, T. Kaur, M. Anand, E. S. Woodle, R. R. Alloway, T. E. Kaiser, University of Cincinnati, Cincinnati, OH
- C107 Return to Work after Sick Leave in Kidney Transplant Recipients: A 365-Day Cohort of the Japan Academic Consortium of Kidney Transplantation (JACK) Study**  
K. Miyake<sup>1</sup>, M. Okumi<sup>1</sup>, K. Unagami<sup>2</sup>, Y. Kakuta<sup>1</sup>, M. Furusawa<sup>1</sup>, K. Omoto<sup>3</sup>, T. Shimizu<sup>3</sup>, M. Endo<sup>4</sup>, H. Ishida<sup>2</sup>, K. Tanabe<sup>1</sup>, <sup>1</sup>Urology, Tokyo Women's Medical University, Sinjuku, Japan, <sup>2</sup>Organ Transplant Medicine, Tokyo Women's Medical University, Sinjuku, Japan, <sup>3</sup>Urology, Toda Chuo General Hospital, Saitama, Japan, <sup>4</sup>Public Health, Juntendo University, Bunkyo, Japan
- C108 † A Retrospective Matched Case-Control Study of Medical and Psychiatric Outcomes in Kidney Transplant Recipients with Bipolar Disorder**  
A. GOSWAMI BANERJEE<sup>1</sup>, S. Hamel<sup>2</sup>, R. Weinrieb<sup>1</sup>, S. Dave<sup>1</sup>, V. Johnson<sup>3</sup>, D. Sawinski<sup>4</sup>, J. Trofe-Clark<sup>3</sup>, <sup>1</sup>Psychiatry, Univ. of Pennsylvania, Philadelphia, PA, <sup>2</sup>Vanderbilt Univ. Medical Center, Nashville, TN, <sup>3</sup>Pharmacy, Hospital of the Univ. of Pennsylvania, Philadelphia, PA, <sup>4</sup>Renal, Univ. of Pennsylvania, Philadelphia, PA
- C109 Early Post-transplant Weight Gain In Inner-city Kidney Transplant Recipients (ktrs) Does Not Remit And Is Associated With Poor Food Quality, Stress And Anxiety.**  
A. Myrie, J. Leong, J. Fazli, Y. Akivis, C. Wilson, M. Markell, SUNY Downstate Medical Center, Brooklyn, NY
- C110 Exploration of the Stanford Integrated Psychosocial Assessment for Transplant with Psychosocial and Medical Outcomes in Kidney/Kidney-Pancreas Transplant Recipients**  
G. Chen<sup>1</sup>, C. Bell<sup>2</sup>, P. Loughhead<sup>1</sup>, B. Ibeche<sup>2</sup>, J. S. Bynon<sup>2</sup>, D. R. Hall<sup>2</sup>, A. M. De Golovine<sup>2</sup>, A. Edwards<sup>2</sup>, W. A. Dar<sup>2</sup>, <sup>1</sup>Memorial Hermann Hospital, Houston, TX, <sup>2</sup>The University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX
- C111 Clinical Utility of the Edmonton Symptom Assessment System to Screen for Depression and Anxiety in Kidney Transplant Recipients**  
E. Tang, S. Dano, A. Ayub, V. Li, I. Escudero, N. Ullah, N. Edwards, M. Novak, I. Mucsi, University Health Network, Toronto, ON, Canada
- C112 Acceptability of Animated Video Medium to Educate Kidney Transplant Patients**  
K. Bonner, M. Cobler- Lichter, N. Crenesse-Cozien, L. Lewis, T. Feeley, L. Kayler, University at Buffalo, Buffalo, NY
- C113 Identification of Relevant Renal Transplant Patient Reported Symptoms That Could Be Used for New Patient Reported Outcome Development**  
I. Purnajo<sup>1</sup>, J. Beaumont<sup>1</sup>, M. Polinsky<sup>2</sup>, E. Alemao<sup>2</sup>, M. J. Everly<sup>1</sup>, <sup>1</sup>Terasaki Research Institute, Los Angeles, CA, <sup>2</sup>Bristol Myers Squibb, Princeton, NJ
- C114 Nutritional Literacy and Diet Quality in a Cohort of Inner-City Kidney Transplant Recipients (KTRs)**  
S. Leventer, G. Yang, J. Leong, K. Lembrikova, C. Wilson, M. Markell, Nephrology/Medicine, SUNY Downstate Medical Center, Brooklyn, NY

- C115 Engaging Friends and Family in the Care of the Kidney Transplant Candidate: Identifying Needs and Barriers**  
A. Hart<sup>1</sup>, M. Bruin<sup>2</sup>, M. Partin<sup>3</sup>, A. Matas<sup>4</sup>, A. Israni<sup>1</sup>, <sup>1</sup>Medicine, Hennepin Healthcare, University of Minnesota, Minneapolis, MN, <sup>2</sup>Design, University of Minnesota, Minneapolis, MN, <sup>3</sup>Medicine, Minneapolis VA, University of Minnesota, Minneapolis, MN, <sup>4</sup>Surgery, University of Minnesota, Minneapolis, MN
- C116 Attitude towards Organ Donation among Medical Students: Relationship to Knowledge and Beliefs**  
A. Cerrato, M. Salifu, M. Markell, Nephrology/Medicine, SUNY Downstate Medical Center, Brooklyn, NY
- C117 Renal Transplantation and Sleep: What do Patients Distress for?**  
L. Long, J. Liu, J. Xie, J. Yan, The Third Xiangya hospital of Central South University, ChangSha, China
- C118 Health Utility And Social Distress In Kidney Transplant (KT) Recipients**  
S. Macanovic<sup>1</sup>, D. Li<sup>1</sup>, B. Liao<sup>1</sup>, I. Escudero<sup>1</sup>, V. Shah<sup>2</sup>, A. Nagee<sup>2</sup>, A. Che<sup>2</sup>, R. Khairalla<sup>2</sup>, M. Novak<sup>3</sup>, I. Mucsi<sup>1</sup>, <sup>1</sup>Division of Nephrology and Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, <sup>2</sup>University of Western Ontario, London, ON, Canada, <sup>3</sup>Centre for Mental Health, University Health Network, Toronto, ON, Canada
- C119 Self-reported Marijuana Use In Kidney Transplant Candidates And Its Association With Access To Transplantation**  
S. Rodriguez Ramirez, E. Tang, O. Famure, A. Bansal, J. Kim, I. Mucsi, Kidney Transplant, Toronto General Hospital, Toronto, ON, Canada
- C120 Lower Stanford Integrated Psychosocial Assessment (SIPAT) for Transplantation Score is Predictive of Successful Listing for Kidney Transplant Candidates**  
A. Kumar<sup>1</sup>, J. Salaway<sup>2</sup>, M. Dorris<sup>2</sup>, J. Newman<sup>3</sup>, A. Doyle<sup>1</sup>, S. Rao<sup>1</sup>, <sup>1</sup>Nephrology, University of Virginia, Charlottesville, VA, <sup>2</sup>Transplant, University of Virginia, Charlottesville, VA, <sup>3</sup>University of Virginia, Charlottesville, VA
- C121 Pre-Kidney Transplant Patient Education: Information Retention is Associated with Improved Waitlist Outcomes**  
S. Patel, J. Ptasinski-Anderson, G. Dela Torre, S. Akkina, Transplant Nephrology, Loyola University Medical Center, Maywood, IL
- C122 Pre Transplant Intact FGF 23 Modifies Post-Transplant Improvement in Cognition**  
J. A. Klein<sup>1</sup>, A. Jurgensen<sup>1</sup>, J. Stubbs<sup>1</sup>, P. Rowe<sup>1</sup>, D. Cibrik<sup>1</sup>, W. Brooks<sup>2</sup>, J. Burns<sup>3</sup>, Z. Lauer<sup>4</sup>, A. Gupta<sup>1</sup>, <sup>1</sup>Nephrology, University of Kansas Medical Center, Kansas City, KS, <sup>2</sup>KU Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, KS, <sup>3</sup>Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, KS, <sup>4</sup>Internal Medicine, University of Kansas Medical Center, Kansas City, KS
- C123 Impact of Clinical Trial Enrollment on Renal Transplant Outcomes**  
T. Shertel, A. Eisenhart, Saint Barnabas Medical Center, Livingston, NJ
- C124 Capturing Stories about Living Kidney Donation Using Storytelling Capture Technology: A Feasibility Assessment**  
A. D. Waterman<sup>1</sup>, C. S. Anderson<sup>1</sup>, O. N. Ranasinghe<sup>1</sup>, Y. Cui<sup>2</sup>, S. Brecher<sup>1</sup>, W. Balliet<sup>3</sup>, <sup>1</sup>Division of Nephrology, UCLA School of Medicine, Los Angeles, CA, <sup>2</sup>Terasaki Research Institute, Los Angeles, CA, <sup>3</sup>Division of Bio-behavioral Medicine, Medical University of South Carolina, Charleston, SC

**C125** **Kidney Transplant Education outside the Transplant Center - Initial Experience with an On-Line Transplant Education Hub**  
D. Belenko<sup>1</sup>, C. Richardson<sup>1</sup>, A. Li<sup>1</sup>, N. Edwards<sup>1</sup>, J. Lam<sup>1</sup>, A. D. Waterman<sup>2</sup>, A. Garg<sup>3</sup>, M. Novak<sup>4</sup>, I. Mucsi<sup>1</sup>, <sup>1</sup>*Division of Nephrology and Multi-Organ Transplant Program, Toronto, ON, Canada*, <sup>2</sup>*Division of Nephrology, University of California, Los Angeles, CA*, <sup>3</sup>*Division of Nephrology, Western University, London, ON, Canada*, <sup>4</sup>*Centre for Mental Health, University Health Network, Toronto, ON, Canada*

**C126** **Is Narrative Storytelling Ethical to Use to Educate the Public about Living Donation? Transplant Professionals Weigh In**  
W. Balliet<sup>1</sup>, L. Holland-Carter<sup>1</sup>, S. N. Maurer<sup>1</sup>, M. P. Salas<sup>1</sup>, C. S. Anderson<sup>2</sup>, O. N. Ranasinghe<sup>2</sup>, A. D. Waterman<sup>2</sup>, <sup>1</sup>*Division of Bio-behavioral Medicine, Medical University of South Carolina, Charleston, SC*, <sup>2</sup>*Division of Nephrology, UCLA School of Medicine, Los Angeles, CA*

### **Poster Session C: Kidney Technical**

**C127** **Impact of Transplant Ureteral Stricture Location and Type of Ureteral Revision on Long-Term Graft Survival and Patient Outcomes in Kidney Transplantation**  
C. Shepherd<sup>1</sup>, R. Cameron<sup>2</sup>, C. Holbrooks<sup>2</sup>, A. Lin<sup>3</sup>, S. Nadig<sup>3</sup>, J. McGillicuddy<sup>3</sup>, D. Dubay<sup>3</sup>, D. Taber<sup>3</sup>, P. Baliga<sup>3</sup>, V. Rohan<sup>3</sup>, <sup>1</sup>*Urology, Medical University of South Carolina, Charleston, SC*, <sup>2</sup>*College of Medicine, Medical University of South Carolina, Charleston, SC*, <sup>3</sup>*Transplant Surgery, Medical University of South Carolina, Charleston, SC*

**C128 †** **Efficacious Home Processing of Urine for Messenger RNA Profiling: A Point-of-Care Approach for Molecular Monitoring of Kidney Transplant Recipients**  
C. Snopkowski<sup>1</sup>, C. Li<sup>1</sup>, S. Albakry<sup>1</sup>, B. Botticelli<sup>1</sup>, M. Cassidy<sup>1</sup>, J. Lee<sup>1</sup>, M. Lubetzky<sup>1</sup>, D. Dadhania<sup>1</sup>, H. Yang<sup>1</sup>, R. Ding<sup>1</sup>, T. Muthukumar<sup>1</sup>, M. Suthanthiran<sup>2</sup>, <sup>1</sup>*WCM, NYC, NY*, <sup>2</sup>*WCM, New York, NY*

**C129 †** **Identification of Rare Genetic Disorders in Kidney Transplantation Recipients with Un-Diagnosed Nephropathy through NGS Approach**  
G. Castellano, M. Giliberti, P. Pontrelli, M. Gigante, S. Diella, M. Accetturo, E. Stea, A. Mitrotti, L. Gesualdo, *Emergency and Organ Transplantation, University of Bari, Bari, Italy*

**C130** **The Impact of Reduction of Warm Ischemia on DCD Kidney Transplantation Outcomes**  
S. Aquil, D. Wonjoon, M. Levine, R. Al Ogaili, A. Sener, P. Luke, *Department of Surgery, Multi Organ Transplant Program, Western University Hospital, LHSC, London, ON, Canada*

**C131** **Preoperative Simulation and Rehearsal of Robotic Living Donor Transplant Nephrectomy Using Patient Specific 3D Printed Hydrogel Models**  
R. Kashyap<sup>1</sup>, G. Wu<sup>2</sup>, R. Melnyk<sup>2</sup>, E. Coppola<sup>2</sup>, S. Farooq<sup>2</sup>, T. Holler<sup>2</sup>, M. Thompson<sup>3</sup>, M. Dokus<sup>1</sup>, J. Taylor<sup>4</sup>, R. Hernandez<sup>1</sup>, J. Joseph<sup>2</sup>, A. Ghazi<sup>2</sup>, <sup>1</sup>*Transplant Surgery, University of Rochester Medical Center, Rochester, NY*, <sup>2</sup>*Urology, University of Rochester Medical Center, Rochester, NY*, <sup>3</sup>*Intuitive Surgical, Sunnyvale, CA*, <sup>4</sup>*Nephrology, University of Rochester Medical Center, Rochester, NY*

**C132 †** **Interpretable Post-Transplant Graft Failure Prediction Using Decision Tree Neural Networks**  
J. N. Valdez<sup>1</sup>, T. Fu<sup>1</sup>, J. Hogan<sup>2</sup>, S. Adhikary<sup>1</sup>, M. Arenson<sup>2</sup>, R. Zhang<sup>2</sup>, X. Zhang<sup>3</sup>, K. Li<sup>2</sup>, A. B. Adams<sup>2</sup>, R. E. Patzer<sup>2</sup>, J. Sun<sup>1</sup>, <sup>1</sup>*Georgia Institute of Technology, Atlanta, GA*, <sup>2</sup>*Emory University, Atlanta, GA*, <sup>3</sup>*University of Michigan, Ann Arbor, MI*

**C133** **Body Mass Index Alone Should Not Be Used to Exclude Potential Kidney Transplant Recipients**  
D. Harriman, V. Gurram, A. Farney, G. Orlando, A. Reeves-Daniel, A. Mena-Gutierrez, C. Jay, R. Stratta, J. Rogers, *Wake Forest Baptist Medical Center, Winston-Salem, NC*

- C134 Primary Uretero-Ureterostomy In Organ Transplants**  
H. Shokouh-Amiri, B. Samant, N. Singh, R. McMillan, D. Aultman, T. Siskron, H. Samant, G. Zibari, *Willis-Knighton Regional Transplant Center, Shreveport, LA*
- C135 Diagnostic Efficacy of Color Doppler Ultrasound on Recipients with Transplanted Renal Artery Stenosis: A Single Center Experience**  
Y. Yang, Z. Wang, S. Fei, H. Chen, L. Sun, Z. Han, J. Tao, X. Ju, R. Tao, M. Gu, *No.300 Guangzhou Road of Nanjing, Nanjing, China*
- C136 Successful Repair of Kidney Graft Artery Rupture Secondary to Infection Using a Preprocessed Homologous 'Y'-Shaped Iliac Artery**  
G. Liu, X. Wang, J. Wu, W. Peng, R. Wang, H. Huang, J. Chen, *Kidney Disease Center, First Affiliated Hospital of Zhejiang University, Hangzhou, China*
- C137 Quantitative Measuring of Iliac Artery Calcification in Renal Transplantation**  
C. Choi<sup>1</sup>, A. Han<sup>2</sup>, S. Ahn<sup>2</sup>, M. Ahn<sup>1</sup>, S. Min<sup>2</sup>, J. Ha<sup>2</sup>, <sup>1</sup>*Transplantation and vascular surgery, Chungnam National University Hospital, Daejeon, Korea, Republic of,* <sup>2</sup>*Transplantation and vascular surgery, Seoul National University Hospital, Seoul, Korea, Republic of*
- C138 The Effects Of Simultaneously Training Additional Surgeons In The Living Donor Robotic Assisted Kidney Transplant**  
J. D. Stracke, M. Safwan, L. Malinzak, A. Yoshida, *Henry Ford Hospital, Detroit, MI*
- C139 Impact of Ureteral Stent on Urinary Tract Complications after Deceased Donor Renal Transplantation**  
L. Zheng, H. Jia, H. Chen, J. Wu, *Kidney disease center, The First Affiliated Hospital, College Of Medicine, Zhejiang University, Hangzhou, China*
- C140 Prediction of Renal Allograft Chronic Rejection Using a Model Based on Contrast Enhanced Ultrasonography**  
C. Yang<sup>1</sup>, T. Zhu<sup>1</sup>, W. He<sup>2</sup>, <sup>1</sup>*Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China,* <sup>2</sup>*Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China*
- C141 Kidney Grafts Ultrasound Guided Biopsy Performed By Nephrologist. Regaining Technique And Improving Results**  
J. Juega, M. Perez, L. Cañas, J. Soler, M. Troya, I. Bancu, R. Lauzurica, *Nephrology, Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain*
- C142 † Simultaneous Recipient Iliac Endarterectomy and Renal Transplantation: A Propensity Score Matched Study**  
O. Okoye, M. Spaggiari, J. Almario, V. Qiao, K. Tulla, P. Di Cocco, E. Benedetti, I. Tzvetanov, *General surgery, University of Illinois at Chicago, Chicago, IL*
- C143 Analysis of Lactic Acid Response in Renal Transplant Patients**  
A. A. Henderson<sup>1</sup>, H. Ahmed<sup>2</sup>, M. R. Wakefield<sup>1</sup>, <sup>1</sup>*Surgery/Urology, University of Missouri School of Medicine, Columbia, MO,* <sup>2</sup>*University of Missouri School of Medicine, Columbia, MO*
- C144 † Near-Infrared Fluorescence Imaging with ZW800-1 Dye to Assess Donor Kidneys While on Ex-Vivo Normothermic Machine Perfusion**  
A. S. Arykbaeva<sup>1</sup>, K. M. Rozenberg<sup>2</sup>, M. L. Lo Faro<sup>2</sup>, J. Hunter<sup>2</sup>, J. B. Doppenberg<sup>1</sup>, A. R. Valentijn<sup>3</sup>, A. G. Terwisscha van Scheltinga<sup>3</sup>, H. Putter<sup>4</sup>, I. P. Alwayn<sup>1</sup>, J. V. Frangioni<sup>5</sup>, J. Burggraaf<sup>6</sup>, A. L. Vahrmeijer<sup>1</sup>, R. J. Ploeg<sup>2</sup>, V. A. Huurman<sup>1</sup>, <sup>1</sup>*Department of Surgery, Leiden University Medical Center, Leiden, Netherlands,* <sup>2</sup>*Nuffield Department of Surgical Sciences, Oxford, United Kingdom,* <sup>3</sup>*Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands,* <sup>4</sup>*Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands,* <sup>5</sup>*Curadel, LCC, Marlborough, MA,* <sup>6</sup>*Centre for Human Drug Research, Leiden, Netherlands*



**C145 Arteriovenous Fistula Ligation In Stable Renal Transplant Patients Does Not Adversely Influence Graft Function**  
A. Han, S. Ahn, S. Min, S. Min, S. Kim, J. Ha, *Department of Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of*

**C146 Retroperitoneoscopic Native Nephrectomy in Renal Transplant Recipients with Autosomal Dominant Polycystic Kidney Disease**  
K. Hotta<sup>1</sup>, D. Iwami<sup>2</sup>, J. Furumido<sup>2</sup>, K. Morita<sup>3</sup>, T. Tanabe<sup>4</sup>, T. Mochizuki<sup>4</sup>, H. Higuchi<sup>2</sup>, N. Iwahara<sup>2</sup>, T. Abe<sup>2</sup>, K. Kanagawa<sup>4</sup>, N. Shinohara<sup>2</sup>, <sup>1</sup>*Hokkaido University Hospital, Sapporo, Japan*, <sup>2</sup>*Urology, Hokkaido University Hospital, Sapporo, Japan*, <sup>3</sup>*Urology, Kushiro City General Hospital, Kushiro, Japan*, <sup>4</sup>*Urology, Asahikawa City General Hospital, Asahikawa, Japan*

**C147 Novel Cooling Device for Kidney Transplant Surgery**  
A. Dergham<sup>1</sup>, L. Witherspoon<sup>2</sup>, T. A. Skinner<sup>2</sup>, <sup>1</sup>*Department of Medicine, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada*, <sup>2</sup>*Division of Urology, Department of Surgery, The Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada*

### Poster Session C: Kidney: Acute Cellular Rejection

---

**C148 † Borderline Changes in Kidney Allografts Represents a Non-Homogenous Cohort with Different Outcome**  
P. Hrubá<sup>1</sup>, J. Malusková<sup>1</sup>, Z. Krejčík<sup>2</sup>, M. Merkerová-Dostalová<sup>2</sup>, V. Stranecký<sup>3</sup>, J. Klema<sup>4</sup>, K. Osicková<sup>1</sup>, M. Wohlfahrtová<sup>1</sup>, E. Honsova<sup>1</sup>, O. Viklický<sup>1</sup>, <sup>1</sup>*Institute for Clinical and Experimental Medicine, Prague, Czech Republic*, <sup>2</sup>*Institute of Hematology and Blood Transfusion, Prague, Czech Republic*, <sup>3</sup>*Institute of Inherited Metabolic Disorders, Prague, Czech Republic*, <sup>4</sup>*Czech Technical University, Prague, Czech Republic*

**C149 † Perioperative Blood Transfusion and Risk for Post-Transplant Sensitization and Rejection**  
A. Chung<sup>1</sup>, M. Kleman<sup>1</sup>, T. Pesavento<sup>1</sup>, M. Abdel-Rasoul<sup>2</sup>, R. Daloul<sup>1</sup>, <sup>1</sup>*Internal Medicine, Division of Nephrology, The Ohio State University, Columbus, OH*, <sup>2</sup>*Center for Biostatistics and Bioinformatics, The Ohio State University, Columbus, OH*

**C150 † Microcirculation Inflammation with TCMR is Associated with Poor Graft Outcomes in Kidney Transplant Recipients (KTRs) without ABMR**  
A. Cherukuri, S. Tandukar, S. Hariharan, R. Mehta, *UPMC, Pittsburgh, PA*

**C151 The Molecular Pathology of Immune Checkpoint Inhibitor-Associated Renal Allograft Rejection: Overlap with Acute Interstitial Nephritis**  
B. Adam<sup>1</sup>, C. Boils<sup>2</sup>, L. Bu<sup>3</sup>, K. Renaudin<sup>4</sup>, K. Wen<sup>1</sup>, M. Mengel<sup>1</sup>, <sup>1</sup>*University of Alberta, Edmonton, AB, Canada*, <sup>2</sup>*Arkana Labs, Little Rock, AR*, <sup>3</sup>*University of Minnesota, Minneapolis, MN*, <sup>4</sup>*CHU Nantes, Nantes, France*

**C152 Subclinical Rejection is Common on Surveillance Biopsies in Children with Kidney Transplant**  
S. Gattis<sup>1</sup>, R. Liverman<sup>1</sup>, A. Serluco<sup>1</sup>, J. Yin<sup>1</sup>, J. Hogan<sup>2</sup>, S. Jernigan<sup>2</sup>, R. George<sup>2</sup>, P. D. Winterberg<sup>2</sup>, R. Garro<sup>2</sup>, <sup>1</sup>*Children's Healthcare of Atlanta, Atlanta, GA*, <sup>2</sup>*Department of Pediatrics, Emory University School of Medicine, Atlanta, GA*

**C153 Periphery Blood ddcfDNA Can Significantly Differentiate Acute Humoral Rejection from Banff's Type I Acute Rejection in Kidney Transplantation**  
R. Wang<sup>1</sup>, T. Jiang<sup>2</sup>, J. Shen<sup>1</sup>, J. Ge<sup>3</sup>, W. Lei<sup>1</sup>, X. Yang<sup>3</sup>, H. Deng<sup>1</sup>, W. Kong<sup>1</sup>, J. Zhou<sup>1</sup>, <sup>1</sup>*Kidney Disease Center, First Affiliated Hospital of Zhejiang University, Hangzhou, China*, <sup>2</sup>*Organ diagnosis company, Suzhou, China*, <sup>3</sup>*Organ Diagnosis Company, Suzhou, China*



- C154** **Role of Molecular Microscope in the Interpretation of Endarteritis and Acute Thrombotic Microangiopathy**  
M. Ciszek<sup>1</sup>, A. Perkowska-Ptasińska<sup>1</sup>, D. Deborska-Materkowska<sup>1</sup>, A. Debska-Slizien<sup>2</sup>, P. F. Halloran<sup>3</sup>, M. Myslak<sup>4</sup>,  
<sup>1</sup>Warsaw Medical Univeristy, Warsaw, Poland, <sup>2</sup>Gdansk Medical University, Gdansk, Poland, <sup>3</sup>ATAGC, University of Alberta, Edmonton AB, AB, Canada, <sup>4</sup>Pomeranian Medical University, Szczecin, Poland
- C155** **Urinary Microtubule-Associated Protein Light Chain3 and Neutrophil Gelatinase-Associated Lipocalin, as Potential Noninvasive Biomarkers for Subclinical Rejection at 3 Months after Kidney Transplantation**  
S. Tajima<sup>1</sup>, R. Fu<sup>2</sup>, M. Fukuda<sup>2</sup>, K. Suetsugu<sup>2</sup>, Y. Okabe<sup>3</sup>, S. Masuda<sup>1</sup>,  
<sup>1</sup>Pharmacy, Kyushu University Hospital, Fukuoka, Japan, <sup>2</sup>Clinical Pharmacology and Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan, <sup>3</sup>Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
- C156** **Severe Acute Rejection In Human Leukocyte Antigen Identical Renal Transplants: Reviving Mixed Lymphocyte Culture**  
P. Rajendran<sup>1</sup>, M. Cusick<sup>2</sup>, S. Dhingra<sup>3</sup>, B. Murthy<sup>1</sup>,  
<sup>1</sup>Baylor College of Medicine, Houston, TX, <sup>2</sup>Division of Abdominal Transplantation, Baylor College of Medicine, Houston, TX, <sup>3</sup>Pathology, Baylor College of Medicine, Houston, TX
- C157** **Combination of Ketoconazole and Tacrolimus Increases the Risk of Kidney Transplant Rejection in African Americans**  
M. E. Sharshir, A. Zhang, E. Khan, B. Zhang, S. Giusti, R. Zhang, *Nephrology, Tulane University, New Orleans, LA*
- C158** **In Depth Look at Acute Rejections in LCP-Tacrolimus (LCPT; Envarsus XR) and Immediate-Release Tacrolimus (IR-Tac)-Treated De Novo Kidney Transplant Recipients**  
A. Condon<sup>1</sup>, M. Mujtaba<sup>2</sup>, S. J. Patel<sup>3</sup>, D. R. Stevens<sup>3</sup>, U. Meier-Kriesche<sup>3</sup>,  
<sup>1</sup>University of New Mexico Hospitals, Albuquerque, NM, <sup>2</sup>University of Texas Medical Branch, Galveston, TX, <sup>3</sup>Veloxis Pharmaceuticals Inc., Cary, NC
- C159** **Utility of a Novel dd-cfDNA Test to Detect Injury in Renal Post-Transplant Patients**  
J. Peabody<sup>1</sup>, P. Billings<sup>2</sup>, Z. Demko<sup>2</sup>, D. Paculdo<sup>1</sup>, M. Tran<sup>1</sup>, S. Moshkevich<sup>2</sup>, C. Valdenor<sup>1</sup>,  
<sup>1</sup>QURE Healthcare, San Francisco, CA, <sup>2</sup>Natera, Inc., San Carlos, CA
- C160** **Effects of Proton Pump Inhibitors on Allograft Rejection and Adverse Effects in Kidney Transplant Recipients: A Systemic Review and Meta-Analysis**  
B. Boonpheng<sup>1</sup>, C. Thongprayoon<sup>2</sup>, M. A. Mao<sup>3</sup>, W. Cheungpasitporn<sup>4</sup>,  
<sup>1</sup>Internal Medicine, East Tennessee State University, Johnson City, TN, TN, <sup>2</sup>Nephrology, Mayo Clinic, Rochester, MN, MN, <sup>3</sup>Nephrology, Mayo Clinic, Rochester, MN, <sup>4</sup>Internal Medicine, University of Mississippi Medical Center, Jackson, MI, MS
- C161** **Outcomes of Phenotypes in Early Subclinical Inflammation (SCI) Determined by Presence of Interstitial Inflammation with or without Concomitant Tubulitis**  
R. Mehta, S. Tandukar, D. Jorgensen, I. Owoyemi, P. Sood, A. Tevar, S. Hariharan,  
*University of Pittsburgh Medical Center, Pittsburgh, PA*
- C162** **Decreased Rejection and Higher Graft Survival in Pediatric Deceased Donors**  
P. Budhiraja<sup>1</sup>, D. Rotich<sup>2</sup>, J. Mahnken<sup>2</sup>, A. Ilahe<sup>1</sup>, A. Naik<sup>3</sup>, D. Cibrik<sup>1</sup>,  
<sup>1</sup>Nephrology, University of Kansas Medical Center, Kansas City, KS, <sup>2</sup>Statistics, University of Kansas, Kansas City, KS, <sup>3</sup>Nephrology, University of Michigan, Ann Arbor, MI

- C163 Inpatient versus Outpatient Management of Hyperglycemia in Post-Transplant Patients Following High Dose Steroid Pulses for Acute Rejection**  
J. L. Wisniewski<sup>1</sup>, W. Bruneau<sup>2</sup>, E. A. Cohen<sup>2</sup>, <sup>1</sup>University of Connecticut, School of Pharmacy, Storrs, CT, <sup>2</sup>Yale New Haven Hospital, New Haven, CT
- C164 Outcome of Treated Cellular Rejection (CMR) in Renal Transplant Patients**  
N. Raj, S. Jackson, S. Riad, R. Spong, V. Vakil, A. Matas, D. Keys, *University of Minnesota, Minneapolis, MN*
- C165 Atypical Hemolytic Uremic Syndrome Concomitant Complement Factor H Gene Variations Leading to Early Renal Allograft Loss: Multicenter Cases Report from China**  
J. Wen<sup>1</sup>, Z. Jin<sup>2</sup>, N. Gong<sup>3</sup>, X. Xu<sup>4</sup>, <sup>1</sup>Jinling Hospital, Nanjing, Jiangsu, China, <sup>2</sup>Department of Renal Transplantation, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, China, <sup>3</sup>Organ Transplantation, Organ Transplantation Key Laboratory of the Ministry of Education, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, <sup>4</sup>The First Hospital Affiliated to Army Medical University, Beijing, China
- C166 Continuous 24-Hour vs. Daily Antithymocyte Globulin (ATG) Infusions for Treatment of Renal Allograft Rejection: Preliminary Results of a Prospective Trial**  
S. J. Patel, S. Kuten, R. Knight, J. Nolte-Fong, D. Nguyen, E. Graviss, A. Gaber, *Methodist Hospital, Houston, TX*
- C167 Comparison of Long-Term Outcomes between Alemtuzumab and Rabbit Anti-Thymocyte Globulin for Acute Kidney Allograft Rejection**  
M. van der Zwan, M. C. Clahsen-van Groningen, D. L. Roelen, M. W. van den Hoogen, M. Van Agteren, J. I. Roodnat, C. C. Baan, D. A. Hesselink, *Erasmus MC, Rotterdam, Netherlands*
- C168 Impact of T-cell Mediated Allograft Inflammation within First-Year after Kidney Transplantation: An Analysis of Paired Biopsies from a Single Center Study**  
S. Tandukar, R. Mehta, I. Owoyemi, D. Jorgensen, P. Sood, S. Hariharan, *Division of Transplant Nephrology, Thomas E. Starzl Transplant Institute, University of Pittsburgh Medical Center, Pittsburgh, PA*
- C169 Early And Late Borderline Lesions Exhibit Differential Outcomes In Renal Transplant Recipients**  
N. K. Wilson<sup>1</sup>, S. Tremblay<sup>1</sup>, P. Lee<sup>1</sup>, S. Bumb<sup>1</sup>, R. R. Alloway<sup>1</sup>, A. R. Shields<sup>2</sup>, M. Cardi<sup>2</sup>, E. S. Woodle<sup>1</sup>, <sup>1</sup>University of Cincinnati, Cincinnati, OH, <sup>2</sup>The Christ Hospital, Cincinnati, OH
- C170 Borderline Lesions Following Lymphocyte Depletion: Effect of Treatment**  
N. Wilson<sup>1</sup>, S. Tremblay<sup>1</sup>, P. Lee<sup>1</sup>, S. Bumb<sup>1</sup>, R. R. Alloway<sup>1</sup>, J. Kremer<sup>2</sup>, A. R. Shields<sup>2</sup>, E. S. Woodle<sup>1</sup>, <sup>1</sup>University of Cincinnati, Cincinnati, OH, <sup>2</sup>The Christ Hospital, Cincinnati, OH
- C171 The Impact of Early Subtherapeutic Tacrolimus Troughs with Alemtuzumab Induction**  
L. Bowman<sup>1</sup>, E. Yanqui<sup>1</sup>, C. Truong<sup>1</sup>, R. Baliga<sup>2</sup>, A. Brueckner<sup>1</sup>, <sup>1</sup>Tampa General Hospital, Tampa, FL, <sup>2</sup>Florida Kidney Physicians, Tampa, FL
- C172 The Crucial Role of Molecular Microscope in the Interpretation of Ambiguous Lesions Such as Banff Borderline Changes and Tubulo-Interstitial Inflammation Accompanying PVAN**  
D. Deborska-Materkowska<sup>1</sup>, A. Perkowska-Ptasinska<sup>1</sup>, M. Ciszek<sup>1</sup>, P. F. Halloran<sup>2</sup>, M. Myslak<sup>3</sup>, <sup>1</sup>Warsaw Medical University, Warsaw, Poland, <sup>2</sup>ATAGC, University of Alberta, Edmonton AB, AB, Canada, <sup>3</sup>Pomeranian Medical University, Szczecin, Poland

**C173** **Impact of T-cell Mediated Allograft Rejection and Antibody Mediated Rejection within the First Year after Kidney Transplantation**  
I. Owoyemi, D. Jorgensen, S. Tandukar, R. Mehta, S. Hariharan, *Thomas E. Starzl Institute of Transplantation and Division of Transplant Nephrology, UPMC, Pittsburgh, PA*

**C174 †** **A Prospective, Randomized, Multicenter Trial of Bela-Based CNI Free and Steroid Withdrawal Immunosuppression: Best Trial Two Year Characterization of Rejection and Renal Function**  
A. Wiseman<sup>1</sup>, A. R. Shields<sup>2</sup>, R. R. Alloway<sup>2</sup>, D. Kaufman<sup>3</sup>, J. P. Leone<sup>4</sup>, A. J. Matas<sup>5</sup>, P. West-Thielke<sup>6</sup>, J. Lipscomb<sup>2</sup>, E. King<sup>2</sup>, E. S. Woodle for the BEST Study Group<sup>2</sup>, <sup>1</sup>*University of Colorado School of Medicine, Denver, CO*, <sup>2</sup>*University of Cincinnati, Cincinnati, OH*, <sup>3</sup>*University of Wisconsin, Madison, WI*, <sup>4</sup>*Tampa General, Tampa, FL*, <sup>5</sup>*University of Minnesota, Minneapolis, MN*, <sup>6</sup>*University of Illinois, Chicago, Chicago, IL*

### Poster Session C: Kidney: Cardiovascular and Metabolic

**C175** **Effect of Renal Function on Asymmetric Dimethylarginine (ADMA) Homeostasis in Kidney Donors and Recipients**  
M. Y. Said<sup>1</sup>, R. M. Douwes<sup>1</sup>, M. van Londen<sup>1</sup>, I. Minović<sup>1</sup>, A. Frenay<sup>2</sup>, M. H. de Borst<sup>1</sup>, E. van den Berg<sup>1</sup>, M. R. Heiner-Fokkema<sup>3</sup>, A. A. Kayacelebi<sup>4</sup>, A. Bollenbach<sup>4</sup>, H. van Goor<sup>5</sup>, G. J. Navis<sup>1</sup>, D. Tsikas<sup>4</sup>, S. J. Bakker<sup>1</sup>, <sup>1</sup>*Internal medicine, University Medical Center Groningen, Groningen, Netherlands*, <sup>2</sup>*Gynecology and Obstetrics, Amsterdam University Medical Center, Amsterdam, Netherlands*, <sup>3</sup>*Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands*, <sup>4</sup>*Inst. of Toxicology, Core Unit Proteomics, Hannover Medical School, Hannover, Germany*, <sup>5</sup>*Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands*

**C176** **Sex Specific Regulation of Podocyte-Specific Genes and Proteins Determines Glomerular Response to mTOR Inhibition**  
A. Kusch<sup>1</sup>, O. AIDiab<sup>2</sup>, D. Gürgen<sup>2</sup>, C. Sünkel<sup>3</sup>, F. Grahammer<sup>4</sup>, M. Rinschen<sup>5</sup>, T. Huber<sup>4</sup>, N. Rajewsky<sup>3</sup>, D. Dragun<sup>2</sup>, <sup>1</sup>*Medizinische Klinik m. S. Nephrologie und Internistische Intensivmedizin, Charité Universitätsmedizin Berlin, Berlin, Germany*, <sup>2</sup>*Medizinische Klinik m. S. Nephrologie und internistische Intensivmedizin, Charité Universitätsmedizin Berlin, Berlin, Germany*, <sup>3</sup>*Max-Delbrück Center for Molecular Medicine, Berlin, Germany*, <sup>4</sup>*III. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg - Eppendorf, Hamburg, Germany*, <sup>5</sup>*CECAD Research Center, Universitätsklinikum Köln, Köln, Germany*

**C177** **Use of GLP-1 Receptor Agonists in Kidney Transplant Recipients with Type 2 Diabetes**  
A. Kukla, J. Hill, M. Merzkani, A. Bentall, E. Lorenz, W. Park, P. Shah, N. Issa, M. Stegall, *Mayo Clinic, Rochester, MN*

**C178** **Prevention of Diabetic Nephropathy after Kidney Transplantation Requires More Than Pursuing Low Levels of Glycated Hemoglobin**  
M. Coemans, E. Van Loon, E. Lerut, D. Kuypers, B. Sprangers, P. Gillard, C. Mathieu, G. Verbeke, M. Naesens, *KU Leuven, Leuven, Belgium*

**C179** **Hypoadiponectinemia is Associated with Low Handgrip Strength in Renal Transplant Recipients**  
M. Lee<sup>1</sup>, B. Hsu<sup>2</sup>, <sup>1</sup>*Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan*, <sup>2</sup>*Nephrology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan*

**C180** **BMI Changes and Its Impact on Long Term Follow-Up in Kidney Transplant Recipients**  
P. A. Miarka, D. Cieniawski, E. Ignacak, A. Prokop, A. Hodun, K. Krzanowska, M. Kuzniewski, *Dept. of Nephrology, Jagiellonian University Medical College, Krakow, Poland*

- C181 Normal Coronary Angiogram Pre-Transplant Does Not Predict Cardiac Events in Diabetic Kidney Transplant Recipients**  
 F. Aziz, A. Mulay, M. Anders, S. Parajuli, D. Mandelbrot, A. Djamali, *University of Wisconsin, Madison, WI*
- C182 Impact of Prolonged Venous Thromboembolism Prophylaxis on 30-Day Hemostatic Outcomes Following Kidney Transplantation in Patients with Hypercoagulable Risk Factors**  
 V. Behbahani, A. Santeusano, S. Ames, R. Shapiro, *Mount Sinai Hospital, New York, NY*
- C183 Renal Function, Albuminuria, and the Risk of Hemorrhage and Thrombosis after Kidney Transplantation**  
 N. N. Lam<sup>1</sup>, P. Ravani<sup>2</sup>, R. R. Quinn<sup>2</sup>, M. Tonelli<sup>2</sup>, F. Ye<sup>1</sup>, B. R. Hemmelgarn<sup>2</sup>, M. M. Sood<sup>3</sup>, <sup>1</sup>*University of Alberta, Edmonton, AB, Canada*, <sup>2</sup>*University of Calgary, Calgary, AB, Canada*, <sup>3</sup>*University of Ottawa, Ottawa, ON, Canada*
- C184 Pharmacist-Led Management of Post-Transplant Hyperglycemia Reduces Hospitalizations**  
 V. H. Do<sup>1</sup>, I. Figueroa<sup>2</sup>, A. Elshafie<sup>3</sup>, R. Belfort De Aguiar<sup>3</sup>, D. Haakinson<sup>3</sup>, E. Cohen<sup>1</sup>, <sup>1</sup>*Yale New Haven Hospital, New Haven, CT*, <sup>2</sup>*Western New England School of Pharmacy, Springfield, MA*, <sup>3</sup>*Yale School of Medicine, New Haven, CT*
- C185 † Speckle Echo Pre and Post Kidney Transplant: A Pilot Study**  
 M. Olivares-Perez<sup>1</sup>, Y. Gao<sup>1</sup>, A. Webber<sup>1</sup>, F. Ghahghaie<sup>1</sup>, M. Lassen<sup>2</sup>, A. Qasim<sup>1</sup>, M. Park<sup>1</sup>, <sup>1</sup>*University California, San Francisco, San Francisco, CA*, <sup>2</sup>*University of Copenhagen, Copenhagen, Denmark*
- C186 Effect of Paricalcitol on Markers of Inflammation in De Novo Renal Transplant Recipients**  
 H. K. Pihlstrøm<sup>1</sup>, T. Ueland<sup>2</sup>, A. E. Michelsen<sup>2</sup>, G. Mjøen<sup>1</sup>, K. Midtvedt<sup>1</sup>, H. Holdaas<sup>1</sup>, <sup>1</sup>*Department of Surgery, Inflammation Medicine and Transplantation, Oslo University Hospital, Oslo, Norway*, <sup>2</sup>*Institute for Clinical Medicine, University of Oslo, Oslo, Norway*
- C187 Effect of Severe Diarrhea on Kidney Transplant Outcomes**  
 J. Kim, J. Ha, Y. Kim, S. Han, *Seoul National University Hospital, Seoul, Korea, Republic of*
- C188 Alterations in Brain Metabolites before and after Kidney Transplant**  
 A. Gupta<sup>1</sup>, P. Lee<sup>2</sup>, R. Lepping<sup>3</sup>, A. Jurgensen<sup>1</sup>, J. Klein<sup>1</sup>, P. Adany<sup>4</sup>, D. Cibrik<sup>1</sup>, J. Burns<sup>5</sup>, W. Brooks<sup>3</sup>, I. Choi<sup>6</sup>, <sup>1</sup>*Division of Nephrology, The Kidney Institute, University of Kansas Medical Center, Kansas City, KS*, <sup>2</sup>*Hoglund Brain Imaging Center, Department of Molecular & Integrative Physiology, University of Kansas Medical Center, Kansas City, KS*, <sup>3</sup>*Hoglund Brain Imaging Center, Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, KS*, <sup>4</sup>*Hoglund Brain Imaging Center, University of Kansas Medical Center, Kansas City, KS*, <sup>5</sup>*Alzheimer's Disease Center, Department of Neurology, University of Kansas Medical Center, Kansas City, KS*, <sup>6</sup>*Hoglund Brain Imaging Center, Department of Neurology, University of Kansas Medical Center, Kansas City, KS*
- C189 Serum Apolipoproteins B and A1 Predict the Development of Late Post-Transplant Diabetes Mellitus in Prevalent Adult Kidney Transplant Recipients**  
 R. Malyala, L. Rapi, M. Nash, G. Prasad, *St Michael's Hospital, University of Toronto, Toronto, ON, Canada*
- C190 Similar Quality in Chronic Kidney Disease Multidisciplinary Follow-Up between Kidney Transplant and Pre-Dialysis Patients**  
 M. Carminatti, N. M. Fernandes, F. A. Colugnati, H. Sanders-Pinheiro, *Nephrology, UFJF, Juiz de Fora, Brazil*
- C191 Partial Parathyroidectomy And Allograft Function In Renal Transplant Patients**  
 M. Gao<sup>1</sup>, E. Vilayur<sup>1</sup>, D. Ferreira<sup>2</sup>, C. Bendinelli<sup>1</sup>, C. Sankoorikal<sup>1</sup>, <sup>1</sup>*John Hunter Hospital, New Lambton Heights, Australia*, <sup>2</sup>*Liverpool Hospital, Liverpool, Australia*



- C192 Impact of Pre-Kidney Transplant Cinacalcet Use on Post-Transplant Outcomes**  
L. Bowman<sup>1</sup>, S. Lloyd<sup>2</sup>, J. Buggs<sup>1</sup>, H. Pearson<sup>1</sup>, R. Baliga<sup>3</sup>, E. Rogers<sup>1</sup>, A. Kumar<sup>4</sup>, <sup>1</sup>Tampa General Hospital, Tampa, FL, <sup>2</sup>University of Florida, Gainesville, FL, <sup>3</sup>Florida Kidney Physicians, Tampa, FL, <sup>4</sup>University of South Florida, Tampa, FL
- C193 † Tacrolimus Activated BMP Signaling Acts in Synergy with Stress-Activated FOXO1 to Induce Loss of Beta-Cell Function and Identity**  
J. Trinañes<sup>1</sup>, P. ten Dijke<sup>2</sup>, T. J. Rabelink<sup>3</sup>, E. J. de Koning<sup>4</sup>, F. Carlotti<sup>1</sup>, A. P. de Vries<sup>1</sup>, <sup>1</sup>Transplant Center, Leiden University Medical Center, Leiden, Netherlands, <sup>2</sup>Molecular Cell Biology, Leiden University Medical Center, Leiden, Netherlands, <sup>3</sup>of Nephrology, Leiden University Medical Center, Leiden, Netherlands, <sup>4</sup>Nephrology, Leiden University Medical Center, Leiden, Netherlands
- C194 Effects of Statin Use on Cardiovascular Outcome in Patients with Renal Transplantation**  
J. Kim<sup>1</sup>, K. Park<sup>1</sup>, S. Park<sup>1</sup>, M. Yu<sup>2</sup>, Y. Kim<sup>1</sup>, K. Kim<sup>1</sup>, M. Park<sup>3</sup>, H. Lee<sup>1</sup>, <sup>1</sup>Seoul National University Hospital, Seoul, Korea, Republic of, <sup>2</sup>Hanyang University Guri Hospital, Gyeonggi-do, Korea, Republic of, <sup>3</sup>Samsung Medical Center, Seoul, Korea, Republic of
- C195 † A Comparison of the Safety and Efficacy of Apixaban Use in Renal Transplant vs. Non-Renal Transplant Recipients**  
T. Loosier, K. Gutierrez, A. James, A. Dodson, University of Alabama at Birmingham Hospital, Birmingham, AL
- C196 Novel Oral Anticoagulants in Kidney Transplantation: Results from a Pilot Study**  
J. Leon, J. Zuber, L. Amrouche, D. Anglicheau, G. Divard, C. Legendre, R. Sberro-Soussan, Adult Transplantation, Necker Hospital, Paris, France
- C197 Alterations in Cerebral Blood Flow before and after Kidney Transplantation**  
A. Gupta<sup>1</sup>, I. Choi<sup>2</sup>, R. Lepping<sup>3</sup>, P. Adany<sup>4</sup>, A. Jurgensen<sup>1</sup>, J. Klein<sup>1</sup>, D. Cibrik<sup>1</sup>, J. Burns<sup>5</sup>, W. Brooks<sup>2</sup>, P. Lee<sup>2</sup>, <sup>1</sup>Division of Nephrology, The Kidney Institute, University of Kansas Medical Center, Kansas City, KS, <sup>2</sup>Hoglund Brain Imaging Center, Department of Molecular & Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, <sup>3</sup>Hoglund Brain Imaging Center, Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, KS, <sup>4</sup>Hoglund Brain Imaging Center, University of Kansas Medical Center, Kansas City, KS, <sup>5</sup>Alzheimer's Disease Center, Department of Neurology, University of Kansas Medical Center, Kansas City, KS
- C198 Kidney Transplant Outcomes among Patients with Obstructive Sleep Apnea**  
R. Tiwari, B. Lyu, S. Alagusundaramoorthy, B. C. Astor, D. Mandelbrot, S. Parajuli, University of Wisconsin, Madison, WI
- C199 Successful Kidney Transplant Improves Glucose Tolerance - A Paradoxical Report From A Single Center**  
A. Mitsuke, H. Harada, H. Higuchi, N. Fukuzawa, H. Tanaka, T. Hirano, T. Sekii, Kidney Transplantation Surgery, Sapporo City General Hospital, Sapporo, Japan
- C200 BMI Influence on the Outcomes of Renal Transplant**  
V. Bianchi, I. D. Kostakis, T. Kasimatis, C. Flach, P. Paraskeva, C. Callaghan, B. Phillips, N. Karydis, N. Kessarar, F. Calder, I. Loukopoulos, Department of Transplantation, Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, London, United Kingdom
- C201 Predictors Of Persistent Hyperparathyroidism After Successful Kidney Transplant: A Single Center Pilot Study**  
S. Ong, K. Wille, F. Saad, C. Kew, University of Alabama, Birmingham, AL



- C202 Diastolic Blood Pressure Derived from Twenty Four Hour Ambulatory Blood Pressure Monitoring Predicts Survival after Kidney Transplantation**  
I. Basdeo, H. Wadei, M. Prendergast, M. Mai, C. Oshel, T. Jarmi, *Transplant, Mayo Clinic, Jacksonville, FL*
- C203 Rituximab Protects against Development of Atherosclerotic Cardiovascular Disease after Kidney Transplantation, a Propensity Matched Analysis**  
D. Kim, J. Lee, J. Lee, B. Kim, M. Kim, S. Soon II, Y. Kim, K. Huh, S. Kim, D. Joo, K. In, E. Kim, *Severance hospital, Seoul, Korea, Republic of*
- C204 Cardiac Risk Assessment in Kidney Transplant Candidates: Clinical Usefulness of Different Guidelines**  
A. Velioglu<sup>1</sup>, S. Mehdiyev<sup>1</sup>, H. Arikan<sup>1</sup>, E. Asicioglu<sup>1</sup>, A. Cincin<sup>2</sup>, S. Tuglular<sup>1</sup>, <sup>1</sup>*Nephrology, Marmara University School of Medicine, Istanbul, Turkey*, <sup>2</sup>*Cardiology, Marmara University School of Medicine, Istanbul, Turkey*
- C205 Efficacy And Safety Of Febuxostat In Renal Transplant Recipients With Hyperuricemia**  
L. Liu<sup>1</sup>, J. Jiang<sup>1</sup>, Q. Fu<sup>2</sup>, S. Long<sup>3</sup>, H. Zhang<sup>2</sup>, X. Su<sup>2</sup>, J. Li<sup>2</sup>, C. Wu<sup>2</sup>, R. Deng<sup>2</sup>, W. Zhang<sup>3</sup>, C. Wang<sup>2</sup>, <sup>1</sup>*Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China*, <sup>2</sup>*Organ transplant center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China*, <sup>3</sup>*Information Data Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China*
- C206 Good Outcomes of Octagenerian Kidney-Transplant Recipients: A Single-Center Experience**  
S. Sultan, M. Aull, M. Lubetzky, A. Watkins, S. Kapur, *New York Presbyterian / Weill Cornell, New York, NY*
- C207 † Long-term Impact of Antihypertensive Treatment and Tacrolimus Dose in Renal Allograft Recipients 5 Years Post-Transplantation**  
D. Rush<sup>1</sup>, S. Cockfield<sup>2</sup>, S. Wilson<sup>3</sup>, J. Schwartz<sup>4</sup>, <sup>1</sup>*University of Manitoba, Winnipeg, MB, Canada*, <sup>2</sup>*University of Alberta Hospital, Edmonton, AB, Canada*, <sup>3</sup>*Astellas Pharma Global Development, Northbrook, IL*, <sup>4</sup>*Astellas Pharma US, Northbrook, IL*
- C208 Daily Use of a Muscle Pump Activator Device Reduces Hospitalization and Improves Graft Function Post Transplantation: A Randomized Controlled Trial**  
W. Xie, S. Aquil, K. Pacoli, R. Al-Ogaili, P. Luke, A. Sener, *London Health Sciences Center, London, Ontario, Canada, London, ON, Canada*
- C209 Intracerebral Hemorrhage in Renal Transplant Recipients with Autosomal Dominant Polycystic Kidney Disease: A Nationwide Analysis**  
W. Cheungpasitporn<sup>1</sup>, C. Thongprayoon<sup>2</sup>, P. Ungprasert<sup>3</sup>, K. Wijarnpreecha<sup>4</sup>, F. T. Chebib<sup>2</sup>, P. T. Kroner<sup>4</sup>, <sup>1</sup>*Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS*, <sup>2</sup>*Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN*, <sup>3</sup>*Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand*, <sup>4</sup>*Department of Medicine, Mayo Clinic, Jacksonville, FL*
- C210 When to Hold: Apixaban in Renal Transplant Recipients**  
V. H. Do<sup>1</sup>, D. Haakinson<sup>2</sup>, K. D. Belfield<sup>1</sup>, <sup>1</sup>*Yale New Haven Hospital, New Haven, CT*, <sup>2</sup>*Yale School of Medicine, New Haven, CT*
- C211 Long-Term Outcomes of Older Kidney-Transplant Recipients: A Single-Center Experience**  
S. Sultan, M. Aull, M. Lubetzky, A. Watkins, S. Kapur, *Weill Cornell Medical College, New York, NY*

- C212**     **Dialysis Lowers Pulmonary Embolism Mortality Risk in Kidney Transplantation**  
 B. Javaid, A. Gilbert, G. Vranic, J. Moore, B. Thomas, P. Abrams, S. Ghasemian, J. Verbese, S. Yi, M. Cooper, *MedStar Georgetown Transplant Institute, Georgetown University School of Medicine, Washington, DC*
- C213**     **Insulin Resistance as a Surrogate Marker for Post-Transplantation Diabetes Mellitus**  
 D. D. de Lucena, É. B. Rangel, J. R. de Sá, J. O. Medina-Pestana, *Department of Medicine, Division of Nephrology, Federal University of São Paulo, São Paulo, Brazil*
- C214**     **Serum Adipocyte Fatty Acid Binding Protein Level is Negatively Associated with Vascular Reactivity Index Measured by Digital Thermal Monitoring in Kidney Transplant Patients**  
 M. Lee<sup>1</sup>, B. Hsu<sup>2</sup>, <sup>1</sup>*Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan,* <sup>2</sup>*Nephrology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan*
- C215**     **Antihypertensive Medication Requirements with Native Nephrectomy and Kidney Transplantation**  
 J. Buggs<sup>1</sup>, J. Sykes<sup>2</sup>, S. Lloyd<sup>2</sup>, E. Rogers<sup>1</sup>, L. Wang<sup>3</sup>, J. Wei<sup>3</sup>, J. Zhang<sup>3</sup>, A. Kumar<sup>3</sup>, R. Liu<sup>3</sup>, V. Bowers<sup>1</sup>, <sup>1</sup>*Tampa General Hospital, Tampa, FL,* <sup>2</sup>*University of Florida, Gainesville, FL,* <sup>3</sup>*University of South Florida, Tampa, FL*
- C216**     **Postoperative Atrial Fibrillation in Kidney Transplant Recipients: A Retrospective Study Evaluating Risk of Anticoagulation**  
 P. Serrano Rodriguez<sup>1</sup>, A. Vijayakumar<sup>2</sup>, P. D. Strassle<sup>3</sup>, K. Szempruch<sup>1</sup>, C. S. Desai<sup>1</sup>, A. Vijay<sup>1</sup>, A. H. Toledo<sup>1</sup>, D. A. Gerber<sup>1</sup>, <sup>1</sup>*Abdominal Transplant Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC,* <sup>2</sup>*School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC,* <sup>3</sup>*General Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC*

- C217**     **The Comparison of Glycemic Profiles during Post-Operative Early Period between Liver and Kidney Transplantation Assessed by Continuous Glucose Monitoring System**  
 H. Yu<sup>1</sup>, H. Jin<sup>2</sup>, S. Lee<sup>2</sup>, J. Yang<sup>1</sup>, S. Park<sup>2</sup>, S. Ahn<sup>1</sup>, H. Hwang<sup>1</sup>, <sup>1</sup>*Surgery, Chonbuk National University Medical School and Hospital, Jeonju, Korea, Republic of,* <sup>2</sup>*Internal Medicine, Chonbuk National University Medical School and Hospital, Jeonju, Korea, Republic of*

### Poster Session C: Kidney: Pediatrics

- C218**     **Low Dose Thymoglobulin Has No Disadvantages to Standard Higher Dose: A Report of the Midwest Pediatric Nephrology Consortium**  
 I. Ashoor<sup>1</sup>, R. Beyl<sup>2</sup>, C. Gupta<sup>3</sup>, A. Jain<sup>4</sup>, S. Kiessling<sup>5</sup>, H. Patel<sup>6</sup>, J. Sherbotie<sup>7</sup>, D. J. Weaver Jr<sup>8</sup>, R. Zahr<sup>9</sup>, V. Dharnidharka<sup>10</sup>, <sup>1</sup>*LSU Health, New Orleans, LA,* <sup>2</sup>*Pennington Biomedical Research Center, Baton Rouge, LA,* <sup>3</sup>*Children's National Medical Center, Washington, DC,* <sup>4</sup>*Wayne State University, Detroit, MI,* <sup>5</sup>*University of Kentucky, Lexington, KY,* <sup>6</sup>*Nationwide Children's Hospital, Columbus, OH,* <sup>7</sup>*University of Utah SOM, Salt Lake City, UT,* <sup>8</sup>*Levine Children's Hospital, Charlotte, NC,* <sup>9</sup>*University of Tennessee, Memphis, TN,* <sup>10</sup>*Washington University, St. Louis, MO*
- C219**     **Growth and Function of En Bloc Kidney Transplantation: A Single-Center Experience**  
 H. Mo<sup>1</sup>, J. Ha<sup>1</sup>, A. Han<sup>1</sup>, S. Min<sup>1</sup>, S. Min<sup>1</sup>, S. Ahn<sup>1</sup>, I. Ha<sup>2</sup>, H. Kang<sup>2</sup>, S. Kim<sup>3</sup>, <sup>1</sup>*Department of surgery, Seoul National University Hospital, Seoul, Korea, Republic of,* <sup>2</sup>*Pediatric Nephrology, Seoul National University Hospital, Seoul, Korea, Republic of,* <sup>3</sup>*Department of surgery, Myongji Hospital, Seoul, Korea, Republic of*

- C220 Epitope-Based Matching in Pediatric Kidney Transplantation**  
C. Boussard<sup>1</sup>, M. Ould Rabah<sup>2</sup>, O. Boyer<sup>2</sup>, M. Macher<sup>1</sup>, J. Taupin<sup>3</sup>, J. Hogan<sup>4</sup>,  
<sup>1</sup>Department of Pediatric Nephrology, Robert Debre hospital, APHP, Paris, France, <sup>2</sup>Department of Pediatric Nephrology, Necker Enfants-Malades, APHP, Paris, France, <sup>3</sup>Department of Immunology, Saint-Louis Hospital, APHP, Paris, France, <sup>4</sup>Transplant Research Center, Department of Surgery, Emory University, ATLANTA, GA
- C221 Implementation of a Longitudinal Comprehensive Multidisciplinary Transition Program and Seminar - Safely Making the Long Leap to the Adult World**  
M. Moss, E. Steinberg, A. Sikora, K. McKinnon, J. Goebel, M. Bock, *Children's Hospital Colorado, Aurora, CO*
- C222 † Hit Me with Your Best Shot! Multidisciplinary Team Approach to Live Vaccination Administration in Pediatric Transplant Candidates**  
H. Corbo, K. Sprott, N. Pilch, K. Twombly, D. Taber, *Medical University of South Carolina, Charleston, SC*
- C223 The Utility of Donor and Recipient BK Virus Antibody Testing Prior to Renal Transplantation in Risk Assessment for Developing BK Viremia**  
N. Donmez, S. I. Al-Akash, *Driscoll Children's Hospital, Corpus Christi, TX*
- C224 Transport Medium Fluid Cultures in Paediatric Renal Transplantation: Are We Ready to Make a Consensus on Prophylaxis?**  
D. Furnell<sup>1</sup>, S. Boyle<sup>1</sup>, N. Kessar<sup>2</sup>, S. D. Marks<sup>1</sup>, J. Stojanovic<sup>1</sup>, <sup>1</sup>Nephrology, Great Ormond Street Hospital, London, United Kingdom, <sup>2</sup>Transplantation, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
- C225 HLA-DR Upregulation in Pediatric Kidney Transplant Biopsies**  
O. Moussa, S. Self, E. Bruner, K. Twombly, *Medical University of South Carolina, Charleston, SC*
- C226 Racial Disparities in Documentation of Non-Adherence and Its Relation to Rejection in Pediatric Kidney Transplant Recipients**  
T. Melanson, J. Hogan, K. Maroney, R. Patzer, R. George, *Emory University, Atlanta, GA*
- C227 Requirements Of A Successful Pediatric To Adult Transition Program For Kidney Transplant Recipients. A Single Center Experience.**  
H. Youness, D. Zepeda-Orozco, L. Harshman, S. Kuppachi, *UIHC, Iowa City, IA*
- C228 Anti-ebv Antibody (ebv-ab) And Ebv-specific Cytotoxic T Cell (ebv-tc) Positivity Are Essential To Control Viremia In Seronegative (sero[-]) Pediatric Kidney Transplant Recipients (ped Ktx Pts).**  
B. Shin, H. Pizzo, D. Puliyanda, A. Petrosyan, D. Lovato, S. C. Jordan, M. Toyoda, *Cedars-Sinai Medical Center, Los Angeles, CA*
- C229 Ganciclovir Based Prophylaxis against Cytomegalovirus Viremia in Pediatric Renal Transplant Patients: A Systematic Review and Meta-Analysis**  
B. CHATANI<sup>1</sup>, W. Glaberson<sup>2</sup>, Z. Nemeth<sup>3</sup>, L. Tamariz<sup>4</sup>, I. A. Gonzalez<sup>1</sup>, <sup>1</sup>Pediatric Infectious Disease, University of Miami Miller School of Medicine, Miami, FL, <sup>2</sup>Pediatric Nephrology, University of Miami Miller School of Medicine, Miami, FL, <sup>3</sup>Health Informatics, University of Miami Miller School of Medicine, Miami, FL, <sup>4</sup>Population Health and Computation Medicine, University of Miami Miller School of Medicine, Miami, FL
- C230 Circulating De Novo Donor Specific Antibodies and Carotid Intima-Media Thickness in Pediatric Kidney Transplant Recipients**  
K. Sgambat<sup>1</sup>, S. Clauss<sup>2</sup>, A. Moudgil<sup>1</sup>, <sup>1</sup>Nephrology, Children's National, Washington DC, DC, <sup>2</sup>Cardiology, Children's National, Washington DC, DC

- C231 Efficacy and Safety of Everolimus in Pediatric Renal Transplantation**  
T. Sandes-Freitas<sup>1</sup>, B. Pantoja<sup>2</sup>, M. Custódio<sup>2</sup>, A. Goersch Silva<sup>3</sup>, R. Costa<sup>2</sup>, M. Sales<sup>3</sup>, R. Esmeraldo<sup>3</sup>, <sup>1</sup>Hospital Geral de Fortaleza / Federal University of Ceara, Fortaleza, Brazil, <sup>2</sup>Federal University of Ceará, Fortaleza, Brazil, <sup>3</sup>Hospital Geral de Fortaleza, Fortaleza, Brazil
- C232 Anti-cmv Antibody (cmv-ab) And Cmv-specific Cytotoxic T Cell (cmv-tc) Positivity Are Essential To Control Severe Viremia In Seronegative (sero[-]) Pediatric Kidney Transplant Recipients (ped Ktx Pts).**  
B. Shin, H. Pizzo, D. Puliyanda, A. Petrosyan, D. Lovato, S. C. Jordan, M. Toyoda, Cedars-Sinai Medical Center, Los Angeles, CA
- C233 † Consistent High Burden of Arteriosclerosis in Pediatric Kidney Transplant Recipients**  
K. Ostendorf<sup>1</sup>, N. Memaran<sup>1</sup>, B. Borchert-Mörlins<sup>1</sup>, J. von der Born<sup>1</sup>, E. Bauer<sup>1</sup>, A. von Wick<sup>1</sup>, J. Oh<sup>2</sup>, M. J. Kemper<sup>3</sup>, R. Büscher<sup>4</sup>, B. M. Schmidt<sup>5</sup>, A. Melk<sup>1</sup>, <sup>1</sup>Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany, <sup>2</sup>Pediatric Nephrology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, <sup>3</sup>Department of Pediatrics, Asklepios Klinik Nord - Heidberg, Hamburg, Germany, <sup>4</sup>Pediatric Nephrology, University Hospital, Essen, Germany, <sup>5</sup>Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
- C234 Are Protocol Biopsies Necessary for Pediatric Renal Transplant Recipients?**  
E. Allred, E. Ingulli, Pediatrics, UCSD, San Diego, CA
- C235 The Response to Human Papillomavirus Vaccination in Pediatric Patients before and after Kidney Transplantation**  
C. Nailescu<sup>1</sup>, R. D. Nelson<sup>2</sup>, K. Twombly<sup>3</sup>, P. S. Verghese<sup>4</sup>, A. S. Chishti<sup>5</sup>, M. Mills<sup>6</sup>, J. E. Slaven<sup>7</sup>, J. D. Mahan<sup>8</sup>, M. L. Shew<sup>1</sup>, <sup>1</sup>Riley Hospital for Children, Indianapolis, IN, <sup>2</sup>Primary Children's Hospital, Salt Lake City, UT, <sup>3</sup>MUSC Children's Hospital, Charleston, SC, <sup>4</sup>Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, <sup>5</sup>Kentucky Children's Hospital, Lexington, KY, <sup>6</sup>C.S. Mott Children's Hospital, Ann Arbor, MI, <sup>7</sup>Indiana University, Indianapolis, IN, <sup>8</sup>Nationwide Children's Hospital, Columbus, OH
- C236 Impact of Six-Month Surveillance Biopsies and Monitoring on 2-Year Outcomes in Pediatric Renal Transplant Recipients**  
J. Lyons<sup>1</sup>, D. Ranch<sup>2</sup>, R. Hall<sup>1</sup>, P. Maxwell<sup>1</sup>, K. Hitchman<sup>2</sup>, B. Crowther<sup>1</sup>, <sup>1</sup>University Health System, The University of Texas at Austin, College of Pharmacy, Pharmacotherapy Division, Austin, TX, The University of Texas Health Science Center at San Antonio, San Antonio, TX, <sup>2</sup>University Health System, The University of Texas Health Science Center at San Antonio, San Antonio, TX
- C237 Prevalence of Overweight and Obesity in Children after Kidney Transplantation. Risk Factors and Outcomes**  
M. L. Monteverde<sup>1</sup>, J. M. Velasco<sup>1</sup>, M. E. Izzo<sup>2</sup>, M. Mannarino<sup>2</sup>, J. P. Ibanez<sup>1</sup>, A. B. Chaparro<sup>1</sup>, C. E. Vezzani<sup>1</sup>, <sup>1</sup>Nephrology, Hospital de Pediatria JP Garrahan, Buenos Aires, Argentina, <sup>2</sup>Food and Nutrition, Hospital de Pediatria JP Garrahan, Buenos Aires, Argentina
- C238 Long-term Outcomes And The Feasibility Of Kidney Retransplantation In Pediatric Survivors Of Post-transplant Lymphoproliferative Disease**  
S. Kizilbash, P. Verghese, B. Chavers, University of Minnesota, Minneapolis, MN



- C239 † Cytokine Profiles in Children after Pediatric Kidney Transplantation with Acute Cellular Compared to Chronic Active Antibody-Mediated Rejection**  
N. Borsum, T. Ahlenstiel-Grunow, L. Pape, *Pediatric Nephrology, Hannover Medical School, Hannover, Germany*
- C240 EBV Viremia and Development of EBV Specific Cytotoxic T-cells in Pediatric Renal Transplant Recipients**  
H. Pizzo, D. Puliyaanda, B. Shin, M. Toyoda, S. Jordan, *Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA*
- C241 † Differences in Graft Survival for Pediatric and Adult Kidney Recipients Followed and Lost to Follow-Up**  
A. M. Robinson<sup>1</sup>, E. K. Hsu<sup>2</sup>, S. M. Bartosh<sup>3</sup>, D. E. Stewart<sup>1</sup>, G. V. Mazariegos<sup>4</sup>, <sup>1</sup>*United Network for Organ Sharing, Richmond, VA*, <sup>2</sup>*Seattle Children's Hospital, Seattle, WA*, <sup>3</sup>*University of Wisconsin Hospital and Clinics, Madison, WI*, <sup>4</sup>*Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA*
- C242 Prevalence of Diabetes after Transplant in a Single Center**  
L. J. Koh<sup>1</sup>, W. P. Yau<sup>2</sup>, M. Than<sup>1</sup>, K. H. Ng<sup>1</sup>, A. Vathsala<sup>3</sup>, H. K. Yap<sup>1</sup>, <sup>1</sup>*Paediatrics, National University Health System, Singapore, Singapore*, <sup>2</sup>*Pharmacy, National University of Singapore, Singapore, Singapore*, <sup>3</sup>*NUCOT, National University Health System, Singapore, Singapore*
- C243 Quantitative Epstein-Barr Virus Viral Load Monitoring in Pediatric Kidney Transplantation**  
C. Metran<sup>1</sup>, M. E. Araujo<sup>1</sup>, R. Cardoso<sup>1</sup>, G. Araujo<sup>1</sup>, T. De Paula<sup>1</sup>, L. Cristofani<sup>2</sup>, F. Pentead<sup>3</sup>, M. F. Pereira<sup>3</sup>, A. Watanabe<sup>1</sup>, <sup>1</sup>*Pediatric Nephrology, ICr HC FMUSP, São Paulo, Brazil*, <sup>2</sup>*Pediatric Oncology, ICr HC FMUSP, São Paulo, Brazil*, <sup>3</sup>*Pediatric Infectology, ICr HC FMUSP, São Paulo, Brazil*
- C244 Timeline for Resuming Physical Activities after Renal Transplantation: A Mid West Pediatric Nephrology Consortium Study**  
P. Baddi<sup>1</sup>, H. Patel<sup>2</sup>, H. Janjua<sup>3</sup>, D. Y. Kim<sup>4</sup>, A. Jain<sup>5</sup>, <sup>1</sup>*Beaumont Children's Hospital, Royal Oak, MI*, <sup>2</sup>*Nationwide Children's Hospital, Columbus, OH*, <sup>3</sup>*Cleveland Clinic Children's Hospital, Cleveland, OH*, <sup>4</sup>*Children's Hospital of Michigan and Henry Ford Hospital, Detroit, MI*, <sup>5</sup>*Children's Hospital of Michigan, Detroit, MI*
- C245 Successful Kidney Transplantation in a Small Child with an Atretic Inferior Vena Cava**  
J. A. Geha<sup>1</sup>, J. D. Geha<sup>1</sup>, M. Goss<sup>1</sup>, M. L. Kueht<sup>1</sup>, R. T. Cotton<sup>1</sup>, J. A. Goss<sup>1</sup>, A. Rana<sup>1</sup>, C. A. O'Mahony<sup>1</sup>, P. Srivaths<sup>2</sup>, E. Brewer<sup>2</sup>, N. N. Galvan<sup>1</sup>, <sup>1</sup>*Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX*, <sup>2</sup>*Department of Pediatrics, Baylor College of Medicine, Houston, TX*
- C246 Utilization of Small Pediatric Donor Kidneys to Improve Access to Kidney Transplantation for Underappreciated Uremic Children in China**  
X. Su<sup>1</sup>, W. Shang<sup>2</sup>, L. Liu<sup>1</sup>, Y. Feng<sup>2</sup>, H. Zhang<sup>1</sup>, J. Li<sup>1</sup>, Q. Fu<sup>1</sup>, X. Pang<sup>2</sup>, G. Feng<sup>2</sup>, C. Wang<sup>1</sup>, <sup>1</sup>*Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China*, <sup>2</sup>*Kidney Transplantation Unit, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China*
- C247 † Long-Term Outcome and Surgical Complications Following Live-Donor Kidney Transplantation in Children Weighting Less Than 15 Kg: A Single Center Experience in Japan**  
Y. Aoki<sup>1</sup>, H. Satoh<sup>2</sup>, Z. Matsui<sup>2</sup>, R. Hamada<sup>3</sup>, R. Harada<sup>3</sup>, M. Muramatsu<sup>4</sup>, Y. Hamasaki<sup>4</sup>, S. Shishido<sup>4</sup>, <sup>1</sup>*Urology and Kidney Transplantation, Tokyo Metropolitan Children's Medical Center, Fuchu-shi, Tokyo, Japan*, <sup>2</sup>*Urology and Kidney Transplantation, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan*, <sup>3</sup>*Nephrology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan*, <sup>4</sup>*Nephrology, Toho University Faculty of Medicine, Tokyo, Japan*



- C248 The Importance of BMP4 Gene Defects in Renal Transplant Patients with CAKUT**  
E. Baskin<sup>1</sup>, V. Sahin<sup>1</sup>, Y. Terzi<sup>2</sup>, K. Gulleroglu<sup>1</sup>, N. Uslu<sup>3</sup>, A. Akdur<sup>4</sup>, G. Moray<sup>4</sup>, F. Sahin<sup>2</sup>, M. Haberal<sup>4</sup>, <sup>1</sup>*Pediatric Nephrology, Baskent University, Ankara, Turkey*, <sup>2</sup>*Genetics, Baskent University, Ankara, Turkey*, <sup>3</sup>*Radiology, Baskent University, Ankara, Turkey*, <sup>4</sup>*Transplantation, Baskent University, Ankara, Turkey*
- C249 En Bloc Kidney Transplant from Infant Donors Less Than 5kg into Adult Recipients**  
Z. Wang, Q. Xia, M. Wang, H. Li, J. Liu, J. Liu, J. Liu, *Urology, Union hospital, Wuhan, China*
- C250 Post-Transplant Lymphoproliferative Disorders in Pediatric Renal Transplant Recipients: Case Series of 5 Patients**  
M. E. Araujo<sup>1</sup>, C. Metran<sup>1</sup>, R. Cardoso<sup>1</sup>, G. Araujo<sup>1</sup>, T. De Paula<sup>1</sup>, L. Cristofani<sup>2</sup>, M. F. Pereira<sup>3</sup>, D. David<sup>4</sup>, A. Watanabe<sup>1</sup>, <sup>1</sup>*Pediatric Nephrology, ICr HC FMUSP, São Paulo, Brazil*, <sup>2</sup>*Pediatric Oncology, ICr HC FMUSP, São Paulo, Brazil*, <sup>3</sup>*Pediatric Infectology, ICr HC FMUSP, São Paulo, Brazil*, <sup>4</sup>*Anatomopathology, HC FMUSP, São Paulo, Brazil*

### Poster Session C: Kidney: Polyoma

- C251 † Immunosuppression Reduction after Diagnosis of Sustained BK Viremia and the Risk of Allograft Rejection, Allograft Loss and Mortality**  
F. A. Al Dhufairi<sup>1</sup>, M. Shokoohi<sup>2</sup>, A. M. Jevnikar<sup>1</sup>, A. A. House<sup>1</sup>, D. Kumar<sup>3</sup>, S. M. Hosseini-Moghaddam<sup>1</sup>, <sup>1</sup>*Department of Medicine, Western University, London Health Sciences Centre, London, ON, Canada*, <sup>2</sup>*Epidemiology and Biostatistics, Western University, London, ON, Canada*, <sup>3</sup>*Department of Medicine, University Of Toronto, University Health Network, Toronto, ON, Canada*
- C252 The Association of BK Virus Infection and Risk of Subsequent Cytomegalovirus Infection after Renal Transplant**  
M. R. Jorgenson, J. L. Descourouez, B. Lyu, B. C. Astor, C. M. Saddler, S. Parajuli, *University of Wisconsin, Madison, WI*

- C253 Predictive Factors for BK Nephropathy in Renal Transplant Recipients with BK Viruria**  
I. Alshaer, M. Bottomley, S. Mehta, J. Galante, I. Roberts, E. Sharples, *Renal, Oxford University Hospitals, Oxford, United Kingdom*
- C254 Incidence, Risk Factors, Outcomes and Clinical Management of BK Viremia in the Modern Era of Kidney Transplantation**  
J. Kim, *Toronto General Hospital, Toronto, ON, Canada*
- C255 Tandem Mass Tags Based Liquid Chromatography/ Mass Spectrometry Analysis of Quantitative Proteomic Changes in Renal Allograft Biopsies with Polyomavirus BK Nephropathy**  
F. Fang, P. Liu, L. Song, Y. Zhao, G. Zeng, G. Tseng, K. Xiao, P. Randhawa, *University of Pittsburgh, Pittsburgh, PA*
- C256 † Prospective BK Virus Screening in the Early Post-Kidney Transplant Period: A Single Center Experience**  
N. Parrish<sup>1</sup>, S. Stander<sup>2</sup>, M. Anand<sup>2</sup>, B. G. Abu Jawdeh<sup>2</sup>, A. Govil<sup>2</sup>, <sup>1</sup>*UC Med Ctr, Cincinnati, OH*, <sup>2</sup>*U Cincinnati, Cincinnati, OH*
- C257 Development of De Novo Antibody in Renal Transplant Recipients with BK Viremia Managed with Immunosuppression Reduction**  
M. Raijmakers<sup>1</sup>, A. Shetty<sup>2</sup>, R. Hod Dvorai<sup>2</sup>, A. Tambur<sup>2</sup>, M. G. Ison<sup>2</sup>, <sup>1</sup>*University of Santiago, Santiago, Chile*, <sup>2</sup>*Northwestern University Comprehensive Transplant Center, Chicago, IL*
- C258 † Late Onset J C Virus Allograft Nephropathy**  
M. Samra, I. Tang, S. Setty, *University of Illinois Health, Chicago, IL*
- C259 Prolonged Fluoroquinolone Prophylaxis to Prevent BK Viremia in Kidney Transplant Recipients**  
S. A. Muhsin<sup>1</sup>, S. J. Ripley<sup>2</sup>, M. L. Jacobs<sup>3</sup>, K. Safa<sup>1</sup>, D. M. Wojciechowski<sup>1</sup>, <sup>1</sup>*Nephrology Division, MGH, Boston, MA*, <sup>2</sup>*Cancer Center, MGH, Boston, MA*, <sup>3</sup>*Wake Forest University School of Medicine, Winston-Salem, NC*

- C260 † Polyomavirus Genotypes In Renal Transplant Recipients In The United States**  
 N. Khoury<sup>1</sup>, C. Thongprayoon<sup>2</sup>, N. Leeaphorn<sup>3</sup>, J. Bruminhent<sup>4</sup>, W. Cheungpasitporn<sup>5</sup>, <sup>1</sup>Henry Ford Transplant Institute, Detroit, MI, <sup>2</sup>Mayo Clinic, Rochester, MN, <sup>3</sup>University of Missouri, Kansas, MO, <sup>4</sup>Mahidol University, Bangkok, Thailand, <sup>5</sup>University of Mississippi, Jackson, MS
- C261 † Cidofovir for BK Nephropathy Rescue Treatment: A Single Center Experience**  
 J. Slatinska<sup>1</sup>, E. Honsova<sup>2</sup>, T. Rohal<sup>1</sup>, A. Slavcev<sup>3</sup>, P. Hruby<sup>4</sup>, O. Viklicky<sup>1</sup>, <sup>1</sup>Nephrology, IKEM, Prague, Czech Republic, <sup>2</sup>Pathology, IKEM, Prague, Czech Republic, <sup>3</sup>Immunology, IKEM, Prague, Czech Republic, <sup>4</sup>Transplant Laboratory, IKEM, Prague, Czech Republic
- C262 Evaluation Of BK Polyomavirus Monitoring And Management In Kidney Transplant Recipients**  
 M. Tomeczkiewicz, S. Mondal, N. Sulejmani, B. Summers, T. Larson, A. Jantz, Henry Ford Hospital, Detroit, MI
- C263 Early Diagnosis of BK Virus Nephropathy Can Retrieve Kidney Allografts by Simple Reduction in Immunosuppressive Agents**  
 N. Iwahara, D. Iwami, K. Hotta, H. Okada, N. Shinohara, Hokkaido University, Sapporo, Japan
- C264 Low Specific Gravity Of First Morning Urine Predicts Bkvn in Kidney Transplant Recipients With Bk Viruria**  
 G. Huang<sup>1</sup>, X. Chen<sup>1</sup>, Z. Wang<sup>2</sup>, Y. Nuertai<sup>2</sup>, W. Chen<sup>3</sup>, S. Yang<sup>3</sup>, P. Chen<sup>4</sup>, C. Wang<sup>1</sup>, <sup>1</sup>Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, <sup>2</sup>Department of Clinical Medicine, Sun Yat-sen University Zhongshan School of Medicine, Guangzhou, China, <sup>3</sup>Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, <sup>4</sup>Department of Clinical Laboratory, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- C265 Protocol Cidofovir for Refractory Polyomavirus Associated Nephropathy in Kidney Transplant Recipients**  
 J. Clark, A. Haririan, University of Maryland Medical Center, Baltimore, MD
- C266 Are Ureteric Stents a Risk Factor for Bk Virus Activation in Kidney Transplantation?**  
 L. Tran, R. Akiki, A. Gautam, Surgery-Section of Transplant Surgery, Boston University School of Medicine, Boston, MA
- C267 BK Virus Infection among Kidney Transplant Recipients with High Immunological Risk and Strong Immunosuppression**  
 G. Ledesma, M. O. Lopez, G. Carreño, M. J. Santana, M. A. Vaca, E. Gonzalez, C. Jimenez, Nephrology, Hospital Universitario La Paz, Madrid, Spain
- C268 † Characteristics of Patients with Early vs Late BK Viremia after Kidney Transplantation**  
 S. Rehman<sup>1</sup>, J. Pryor<sup>2</sup>, A. Olyaei<sup>3</sup>, M. Stack<sup>1</sup>, D. Norman<sup>1</sup>, J. Lockridge<sup>1</sup>, <sup>1</sup>Medicine/Nephrology, Oregon Health and Science University, Portland, OR, <sup>2</sup>Oregon Health and Science University, Portland, OR, <sup>3</sup>Pharmacy, Oregon Health and Science University, Portland, OR
- Poster Session C: Liver: MELD, Allocation and Donor Issues (DCD/ECD)**
- C269 Impact of Revised Policy for Hepatocellular Carcinoma MELD Exception Points on Recurrence after Liver Transplantation**  
 P. Le<sup>1</sup>, L. McClelland<sup>1</sup>, K. Knapp<sup>1</sup>, T. Xu<sup>1</sup>, S. Pelletier<sup>2</sup>, <sup>1</sup>University of Virginia, Charlottesville, VA, <sup>2</sup>Surgery, University of Virginia, Charlottesville, VA
- C270 Impact of MELD-Na Course (Delta MELD-Na) on Outcome after Liver Transplantation**  
 G. Silberhumer<sup>1</sup>, G. Gyoeri<sup>1</sup>, L. Unger<sup>2</sup>, G. Harpain<sup>1</sup>, <sup>1</sup>Transplant Surgery, Medical University Vienna, Vienna, Austria, <sup>2</sup>Institute for Mathematics and Bioscience, Medical University Vienna, Vienna, Austria

- C271 Donor Hepatitis C Seropositivity Confers Poorer Post-transplant Outcomes In Recipients Of Marginal Livers In The Post-hepatitis C Treatment Era**  
M. B. Shah, M. Gupta, X. Mei, R. Gedaly, *University of Kentucky, Lexington, KY*
- C272 Use, Safety and Effectiveness of Hepatitis B Virus NAT-Positive Donor Livers in the Current Era**  
T. C. Lee, K. Safdar, L. K. Winer, M. C. Morris, A. Kassam, K. Lockett, R. Quillin III, K. Bari, N. Anwar, S. A. Shah, *University of Cincinnati, Cincinnati, OH*
- C273 Finding Opportunities for Increased Donation after Circulatory Death Liver Utilization: Results of an American Society of Transplant Surgeons/ Association of Organ Procurement Organizations Survey**  
M. Hobeika<sup>1</sup>, R. Glazner<sup>2</sup>, D. Foley<sup>1</sup>, S. Hanish<sup>1</sup>, C. Quintini<sup>1</sup>, E. Eidbo<sup>2</sup>, D. Axelrod<sup>1</sup>, <sup>1</sup>*American Society of Transplant Surgeons DCD Task Force, Arlington, VA*, <sup>2</sup>*Association of Organ Procurement Organizations, Vienna, VA*
- C274 Microsteatosis in Livers from Donation after Circulatory Death (DCD) Donors is Associated with Inferior Graft and Patient Survival Following Liver Transplantation (LTX)**  
N. Bath, G. Levenson, D. Foley, *University of Wisconsin, Madison, WI*
- C275 Donor - Recipient Size Mismatch Has No Impact on Outcomes after Deceased Donor Whole Liver Transplantation: A Single Center Analysis**  
A. Cabrales<sup>1</sup>, R. Mangus<sup>1</sup>, B. Ekser<sup>1</sup>, L. Timsina<sup>1</sup>, J. Fridell<sup>1</sup>, P. Mihaylov<sup>1</sup>, T. Nikumbh<sup>1</sup>, M. Ghabril<sup>2</sup>, M. Lacerda<sup>2</sup>, C. Kubal<sup>1</sup>, <sup>1</sup>*Department of Surgery, Indiana University Hospital, Indianapolis, IN*, <sup>2</sup>*Division of Digestive & Liver Disorders, Indiana University Hospital, Indianapolis, IN*
- C276 The Utility Of Intraoperative Vascular Anastomotic Inflow Measurements In Donation After Circulatory Death (DCD) Liver Transplantation**  
A. Nair, L. Coromina Hernandez, K. Sasaki, C. Kwon, T. Diago Uso, M. Fujiki, F. Aucejo, K. Hashimoto, B. Eghtesad, C. Miller, C. Quintini, *Cleveland Clinic, Cleveland, OH*
- C277 Risk Factors for Graft Loss Vary with Recipient MELD Score in Liver Transplantation**  
J. A. Steggerda<sup>1</sup>, M. B. Bloom<sup>1</sup>, T. Todo<sup>2</sup>, T. V. Brennan<sup>2</sup>, N. N. Nissen<sup>2</sup>, A. S. Klein<sup>2</sup>, I. K. Kim<sup>2</sup>, <sup>1</sup>*Surgery, Cedars-Sinai Medical Center, Los Angeles, Los Angeles, CA*, <sup>2</sup>*Transplant Surgery, Cedars-Sinai Medical Center, Los Angeles, Los Angeles, CA*
- C278 Moving from Local Allocation to National Allocation Using Gravity Model**  
F. Bayer<sup>1</sup>, B. Audry<sup>2</sup>, C. Antoine<sup>2</sup>, C. Jasseron<sup>2</sup>, C. Legeais<sup>2</sup>, O. Bastien<sup>2</sup>, C. Jacquelinet<sup>1</sup>, <sup>1</sup>*Agence de la biomedecine and INSERM U1018, Saint-Denis la Plaine and Villejuif, France*, <sup>2</sup>*Agence de la biomedecine, Saint-Denis la Plaine, France*
- C279 MELD-Na Alterations on the Liver Transplant Waiting List and Its Impact on Listing Outcome**  
G. Silberhumer<sup>1</sup>, G. Gyoeri<sup>1</sup>, L. Baumann<sup>1</sup>, S. Zehetmayer<sup>2</sup>, T. Soliman<sup>1</sup>, G. Berlakovich<sup>1</sup>, <sup>1</sup>*Transplant Surgery, Medical University Vienna, Vienna, Austria*, <sup>2</sup>*Statistics Department, Medical University Vienna, Vienna, Austria*
- C280 Geographic Disparities in Liver Supply/ Demand Ratio within Fixed-Distance and Fixed-Person Circles**  
C. Haugen<sup>1</sup>, T. Ishaque<sup>1</sup>, A. Sapirstein<sup>1</sup>, D. Segev<sup>1</sup>, S. Gentry<sup>2</sup>, <sup>1</sup>*JHU, Baltimore, MD*, <sup>2</sup>*USNA, Baltimore, MD*

- C281**      **Share 21 Rather Than Share 15: Balancing Transplant Opportunity without Compromising Waitlist Outcomes**  
S. Nagai<sup>1</sup>, L. C. Chau<sup>1</sup>, M. Abouljoud<sup>1</sup>, K. Collins<sup>1</sup>, S. Jafri<sup>2</sup>, M. Safwan<sup>1</sup>, D. Moonka<sup>2</sup>, <sup>1</sup>*Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI*, <sup>2</sup>*Gastroenterology, Henry Ford Hospital, Detroit, MI*
- C282**      **The Power of Young Donor Liver; Elixir of Life for Sick Liver Transplant Recipient**  
J. Kusakabe<sup>1</sup>, J. McVey<sup>2</sup>, D. J. Firl<sup>2</sup>, M. Fujiki<sup>2</sup>, F. N. Aucejo<sup>2</sup>, C. Quintini<sup>2</sup>, K. Hashimoto<sup>2</sup>, K. Sasaki<sup>2</sup>, <sup>1</sup>*Kyoto University Graduate School of Medicine, Kyoto, Japan*, <sup>2</sup>*Cleveland Clinic Foundation, Department of General Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH*
- C283**      **Identifying a Clinically Relevant Cut-Off for Height That is Associated with a Higher Risk of Waitlist Mortality in Liver Transplant Candidates**  
J. Ge, J. C. Lai, *University of California - San Francisco, San Francisco, CA*
- C284**      **Early Allograft Dysfunction in High Acuity Liver Transplant Recipients**  
T. Ito, M. Lu, A. Murray, D. S. Graham, J. DiNorcia, V. G. Agopian, H. Yersiz, D. G. Farmer, R. W. Busuttill, F. M. Kaldas, *Department of Surgery, The Dumont-UCLA Transplant Center, Los Angeles, CA*
- C285**      **Impact Of Aggressive Utilization Of Liver Allografts On Outcomes**  
A. Rana, M. Kueht, N. Galvan, R. Cotton, C. O'Mahony, J. Goss, *Baylor College of Medicine, Houston, TX*
- C286**      **Patients With Persistently Low MELD-Na Scores Continue To Be At Risk Of Liver Related Death**  
N. Mazumder, K. Atiemo, S. Montag, A. Daud, A. Kho, M. Abecassis, J. Levitsky, D. Ladner, *Northwestern Memorial Hospital, Chicago, IL*
- C287**      **Increasing the Number of Liver Transplants through Active Review of Offers Turned Down**  
M. L. Melcher, C. A. Bonham, A. Gallo, W. Concepcion, I. Jacobson, C. O. Esquivel, *Stanford University, Palo Alto, CA*
- C288 †**    **Validation Of The Optimized Prediction Of Mortality (Opom) Machine Learning Model For Non-hepatocellular Carcinoma Candidates Awaiting Liver Transplant**  
L. Lau<sup>1</sup>, X. Xie<sup>2</sup>, F. Jia<sup>2</sup>, P. D. Greig<sup>1</sup>, T. C. Chan<sup>2</sup>, <sup>1</sup>*Multi-Organ Transplant, Department of Surgery, University of Toronto, Toronto, ON, Canada*, <sup>2</sup>*Mechanical and Industrial Engineering, University of Toronto, Toronto, ON, Canada*
- C289 †**    **Taking a Step toward Standardization: Results of an American Society of Transplant Surgeons/Association of Organ Procurement Organizations Survey of Donation after Circulatory Death Liver Recovery Practices**  
M. Hobeika<sup>1</sup>, R. Glazner<sup>2</sup>, D. Foley<sup>1</sup>, S. Hanish<sup>1</sup>, C. Quintini<sup>1</sup>, E. Eidbo<sup>2</sup>, D. Axelrod<sup>1</sup>, <sup>1</sup>*American Society of Transplant Surgeons DCD Task Force, Arlington, VA*, <sup>2</sup>*Association of Organ Procurement Organizations, Vienna, VA*
- C290**      **Factors Associated with the Acceptance of Livers for Liver Transplantation: Validation of the Discard Risk Index in the Eurotransplant Region**  
J. D. Boer<sup>1</sup>, H. Putter<sup>2</sup>, J. J. Blok<sup>3</sup>, N. Cambridge<sup>1</sup>, S. Van den Berg<sup>1</sup>, U. Samuel<sup>1</sup>, G. Berlakovich<sup>4</sup>, M. Guba<sup>5</sup>, A. E. Braat<sup>3</sup>, <sup>1</sup>*Eurotransplant International Foundation, Leiden, Netherlands*, <sup>2</sup>*Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands*, <sup>3</sup>*Transplant Center, Leiden University Medical Center, Leiden, Netherlands*, <sup>4</sup>*Medical University of Vienna, Vienna, Austria*, <sup>5</sup>*Hospital of the University of Munich, Munich, Germany*



- C291** **Analysis Of Public Health Service Increased Risk Donors Shows No Viral Transmission In Liver Transplant Recipients And Similar Graft / Patient Survival When Compared To Non-increased Risk Donors**  
A. Amin, T. Ito, D. Ng, R. McMillan, J. DiNorcia, V. Agopian, F. Kaldas, H. Yersiz, R. Busuttil, D. Farmer, *Department of Surgery, The Dumont-UCLA Transplant Center, Los Angeles, CA*
- C292** **Gender Disparities In Cirrhosis: New Findings In A Large Pretransplant Population**  
N. Mazumder, K. Atiemo, A. Daud, L. Zhao, M. Abecassis, J. Levitsky, D. P. Ladner, *Northwestern Memorial Hospital, Chicago, IL*
- C293** **The Feasibility Of Donation After Cardiac Death In Liver Transplantation: A Registry Analysis**  
A. C. Gruessner, R. Misawa, A. Masi, Z. Moghadamyeghaneh, J. F. Renz, R. W. Gruessner, *SUNY Downstate Medical Center, Brooklyn, NY*
- C294** **Increasing Incidence and Transplantation of Individuals Listed with Alcoholic Liver Disease**  
E. L. Godfrey<sup>1</sup>, A. Rana<sup>2</sup>, J. A. Goss<sup>2</sup>, <sup>1</sup>*Department of Student Affairs, Baylor College of Medicine, Houston, TX*, <sup>2</sup>*Division of Abdominal Transplantation, Baylor College of Medicine, Houston, TX*
- C295** **Twin Epidemics: Drug Overdoses And Suicides Are Increasingly Fueling The United States Donor Liver Supply**  
M. Goss<sup>1</sup>, M. Kueht<sup>1</sup>, N. Galvan<sup>1</sup>, J. Reece<sup>2</sup>, A. Rana<sup>1</sup>, <sup>1</sup>*Baylor College of Medicine, Houston, TX*, <sup>2</sup>*Southwest Transplant Alliance, Dallas, TX*
- C296** **Impact of Enteric Vancomycin Resistant Enterococcus Colonization on Waitlist Outcomes among Liver Transplant Candidates**  
E. Aldag, R. Pedersen, V. Gunabushanam, A. Sahajpal, T. J. Dilworth, *Aurora St Luke's Medical Center, Milwaukee, WI*
- C297** **When to Transplant for Wilson's Disease: A Review**  
M. Flanagan, S. Koohmaraie, M. Kueht, R. Cotton, C. O'Mahony, A. Rana, J. Goss, N. Galvan, *Baylor College of Medicine, Houston, TX*
- C298** **Liver Transplantation in Acute Hepatic Insufficiency Induced by Imatinib**  
A. I. David<sup>1</sup>, D. N. Alvarenga de Rezende<sup>2</sup>, M. C. Fantauzzi<sup>3</sup>, T. Di Santi<sup>3</sup>, N. C. Confuorto<sup>3</sup>, G. T. Martinho<sup>3</sup>, P. S. Antunes<sup>3</sup>, <sup>1</sup>*GI Surgery/Transplant, Hospital Samaritano de Sao Paulo, Sao Paulo, Brazil*, <sup>2</sup>*GI Surgery/Transplant, Faculdade de Ciências Médicas da Santa Casa de São Paulo, Sao Paulo, Brazil*, <sup>3</sup>*Faculdade de Ciências Médicas da Santa Casa de São Paulo, Sao Paulo, Brazil*
- C299** **Liver Circle-Based Allocation: LSAM Modeling Results**  
D. Schladt<sup>1</sup>, T. Weaver<sup>1</sup>, J. Pyke<sup>1</sup>, A. Herreid<sup>1</sup>, B. Thompson<sup>1</sup>, B. Kasiske<sup>1</sup>, J. Snyder<sup>1</sup>, W. Kim<sup>2</sup>, J. Lake<sup>3</sup>, A. Israni<sup>1</sup>, J. Heimbach<sup>4</sup>, <sup>1</sup>*SRTR, Minneapolis, MN*, <sup>2</sup>*Stanford Univ, Stanford, CA*, <sup>3</sup>*Univ of Minnesota, Minneapolis, MN*, <sup>4</sup>*Mayo Clinic, Rochester, MN*
- C300** **The Impact of Share 35 on Living Donor Liver Transplant Utilization in the United States: Analysis of UNOS Data**  
H. J. Braun, J. L. Dodge, J. D. Grab, R. Hirose, P. G. Stock, N. L. Ascher, *University of California, San Francisco, San Francisco, CA*
- C301 †** **Liver Transplant Candidates Derive a Survival Benefit from Accepting a Macrosteatotic Liver**  
K. Jackson, M. Bowring, C. Haugen, C. Holscher, L. Liyanage, S. Ottmann, B. Philosophe, A. Massie, D. Segev, A. Cameron, J. Garonzik-Wang, *Johns Hopkins University, Baltimore, MD*



## Poster Session C: Liver: Pediatrics

- C302 † Development and Implementation of a Pediatric Transplant Consortium**  
K. Soltys<sup>1</sup>, S. K. Rasmussen<sup>2</sup>, J. Squires<sup>3</sup>, R. Sindhi<sup>1</sup>, S. Pelletier<sup>2</sup>, K. Brayman<sup>2</sup>, M. Angelis<sup>4</sup>, T. Chin<sup>4</sup>, R. Teaster<sup>2</sup>, J. Oberholzer<sup>2</sup>, R. Gonzalez-Peralta<sup>5</sup>, B. Friedman<sup>4</sup>, D. Hupp<sup>6</sup>, M. Mendoza<sup>7</sup>, P. A. Eicker<sup>6</sup>, J. Middleton<sup>7</sup>, G. Mazariegos<sup>1</sup>, <sup>1</sup>*Transplant Surgery, Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, PA*, <sup>2</sup>*Charles O. Strickler Transplant Center, University of Virginia, Charlottesville, VA*, <sup>3</sup>*Hepatology, Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, PA*, <sup>4</sup>*AdventHealth Transplant Institute, Florida Hospital, Orlando, FL*, <sup>5</sup>*AdventHealth for Children, Florida Hospital, Orlando, FL*, <sup>6</sup>*Nursing, Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, PA*, <sup>7</sup>*Hepatology, University of Virginia, Charlottesville, VA*
- C303 Case Series: Anti-Thymocyte Globulin as a Treatment for Steroid-Refractory Severe Acute Hepatitis in Children**  
A. L. Peters, A. Miethke, K. Campbell, *Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*
- C304 Pediatric Liver Transplantation during the Opioid Epidemic: UNOS Analysis of Organ Availability and Outcomes**  
J. Chu<sup>1</sup>, J. Franke<sup>2</sup>, C. Almy<sup>1</sup>, R. Annunziato<sup>2</sup>, R. Arnon<sup>1</sup>, <sup>1</sup>*Recanati/Miller Transplant Institute, Icahn School of Medicine at Mount Sinai, New York, NY*, <sup>2</sup>*Psychology, Fordham University, New York, NY*
- C305 De Novo Hepatitis B Virus Infection after Pediatric Living Donor Liver Transplantation: Risk Factors, Recognition and Prevention Strategies**  
G. Gu, Q. Xia, *Renji Hospital, Shanghai, China*
- C306 Deceased Donor Predictors for Pediatric Liver Allograft Utilization and Outcome of the Use of Paediatric Donor Livers in Adult Recipients**  
S. Huang, C. Sun, X. He, Z. Guo, G. Chen, *Organ Transplant Center, the First Affiliated Hospital of SYSU, Guangzhou, China*
- C307 Management and Outcome of Hepatic Artery Thrombosis in Pediatric Liver Transplantation**  
A. Channaoui, R. Tambucci, A. Pire, C. de Magnée, R. Reding, *Pediatric Surgery and Transplantation Unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium*
- C308 Silent Allograft Fibrosis in 10-Year Post-Transplantation Histology of Pediatric Liver Transplantation: Is It Really Silent?**  
S. Lee, S. Lee, J. Rhu, Y. Chung, S. Kim, K. Lee, S. Lee, J. Kim, G. Choi, J. Park, S. Kim, J. Joh, *Transplantation, Samsung Medical Center, Seoul, Korea, Republic of*
- C309 Intraoperative Blood Loss and Transfusion during Pediatric Liver Transplantation: A Single Center Experience**  
J. A. Villarreal<sup>1</sup>, D. Yoeli<sup>2</sup>, J. Yoeli<sup>3</sup>, R. Ackah<sup>4</sup>, R. Sigireddi<sup>1</sup>, M. Kueht<sup>1</sup>, N. Galvan<sup>1</sup>, R. Cotton<sup>1</sup>, A. Rana<sup>1</sup>, C. O'Mahony<sup>1</sup>, J. Goss<sup>1</sup>, <sup>1</sup>*Surgery, Baylor College of Medicine, Houston, TX*, <sup>2</sup>*Surgery, University of Colorado School of Medicine, Denver, CO*, <sup>3</sup>*Pediatrics, University of Colorado School of Medicine, Denver, CO*, <sup>4</sup>*Surgery, The Ohio State University College of Medicine, Columbus, OH*
- C310 † Organ Procurement Organization Surgeon Improves Utilization of Livers from Pediatric Donors**  
M. MacConmara<sup>1</sup>, J. Reese<sup>2</sup>, T. Anthony<sup>2</sup>, A. Aqul<sup>3</sup>, S. Hanish<sup>1</sup>, P. Vagefi<sup>1</sup>, D. Desai<sup>1</sup>, C. Hwang<sup>1</sup>, <sup>1</sup>*Surgery (Division of Surgical Transplantation), UT Southwestern Medical Center, Dallas, TX*, <sup>2</sup>*Southwest Transplant Alliance, Dallas, TX*, <sup>3</sup>*Childrens Medical Center, Dallas, TX*
- C311 Metabolic Liver Transplantation - Can We Afford It?**  
N. Yazigi<sup>1</sup>, W. Fujiwara<sup>2</sup>, <sup>1</sup>*Transplant Institute, MedStar Georgetown University Hospital, Washington, DC*, <sup>2</sup>*Georgetown University Medical School, Washington, DC*

- C312 Repeat Liver Transplantation after Failed First Transplant in Childhood: Development of a Retransplant Risk Index**  
 M. Gupta<sup>1</sup>, M. Barry<sup>2</sup>, M. Levine<sup>3</sup>, K. Olthoff<sup>3</sup>, A. Shaked<sup>3</sup>, P. Abt<sup>3</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of California, San Francisco, San Francisco, CA, <sup>3</sup>University of Pennsylvania, Philadelphia, PA
- C313 500 Pediatric Liver Transplants At A Freestanding Pediatric Hospital - Where It Is Done Best**  
 A. Rana, M. Kueht, N. Galvan, R. Cotton, C. O'Mahony, J. Goss, Baylor College of Medicine, Houston, TX
- C314 Biliary Atresia Patients Receiving Liver Transplantation Reflect Changing Birth Demographics in the United States between 1987-2018**  
 R. Sindhi, K. Soltys, G. Mazariegos, G. Bond, A. Khanna, P. McKiernan, Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, PA
- C315 Living Donor vs. Deceased Donor Liver Transplantation for Pediatric Patients with Metabolic Liver Disease**  
 G. Gu, Q. Xia, Renji Hospital, Shanghai, China
- C316 Metabolic Liver Transplant: A Single Cooperative 2002-2017**  
 N. Yazigi<sup>1</sup>, K. Chapman<sup>2</sup>, <sup>1</sup>Transplantation, MedStar Georgetown University Hospital, Washington, DC, <sup>2</sup>Transplantation, Children's National Rare Disease Institute, Washington, DC
- C317 Liver Transplantation in Children with Type 1 and Type 2 Autoimmune Hepatitis**  
 I. G. Roepe, J. A. Goss, T. Miloh, Department of Student Affairs, Baylor College of Medicine, Houston, TX
- C318 Independent Risk Factors for Discard of Pediatric Liver Allografts**  
 T. H. Malik<sup>1</sup>, J. Goss<sup>2</sup>, N. T. Galvan<sup>2</sup>, M. L. Kueht II<sup>2</sup>, A. Rana<sup>3</sup>, <sup>1</sup>Department of Student Affairs, Baylor College of Medicine, Houston, TX, <sup>2</sup>Department of Abdominal Transplantation, Baylor College of Medicine, Houston, TX, <sup>3</sup>Division of Abdominal Transplantation, Baylor College of Medicine, Houston, TX

## Poster Session C: Lung: All Topics

- C319 Obesity Induced IL-18 Production Impairs FOXP3+ Treg Function and Increases Risk of Primary Graft Dysfunction in Lung Transplant Recipients**  
 W. W. Hancock<sup>1</sup>, T. Zhang<sup>1</sup>, U. H. Beier<sup>1</sup>, A. Samanta<sup>1</sup>, R. Han<sup>1</sup>, L. Wang<sup>1</sup>, J. Jiao<sup>1</sup>, J. M. Diamond<sup>2</sup>, D. S. Wilkes<sup>3</sup>, D. J. Lederer<sup>4</sup>, R. A. Simmons<sup>2</sup>, J. D. Christie<sup>2</sup>, T. Akimova<sup>2</sup>, <sup>1</sup>Children's Hospital of Philadelphia, Philadelphia, PA, <sup>2</sup>University of Pennsylvania, Philadelphia, PA, <sup>3</sup>University of Virginia, Charlottesville, VA, <sup>4</sup>Columbia University, New York, NY
- C320 † Correlation between Gene Expression and Histology in Transbronchial Lung Transplant Biopsies**  
 B. Adam, K. Du, S. Rotich, M. Mengel, University of Alberta, Edmonton, AB, Canada
- C321 Impact of the 2013 Change in Definition of Increased Risk Donors on Lung Transplant Outcomes**  
 C. J. Lehr<sup>1</sup>, R. Lopez<sup>2</sup>, S. Arrigain<sup>2</sup>, J. D. Schold<sup>2</sup>, M. Valapour<sup>1</sup>, <sup>1</sup>Respiratory Institute, Cleveland Clinic, Cleveland, OH, <sup>2</sup>Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
- C322 Molecular Features of Rejection in Endobronchial Mucosa Biopsies**  
 M. D. Parkes, K. M. Halloran, J. Chang, P. F. Halloran and The INTERLUNG Study Group, University of Alberta, Edmonton, AB, Canada
- C323 Oral Ribavirin Therapy for Respiratory Syncytial Virus (RSV) in Lung Transplant Recipients: The Impact of Policy Implementation on Cost and Appropriate Use**  
 B. Berak, N. Sulejmani, A. Jantz, T. Larson, S. Davis, B. Summers, Henry Ford Hospital, Detroit, MI
- C324 † Cellular And Molecular Characteristics Of Intra-graft Lymphoid Aggregates In Chronic Lung Allograft Dysfunction**  
 E. Miyamoto<sup>1</sup>, S. Juvet<sup>1</sup>, D. Hwang<sup>2</sup>, S. Keshavjee<sup>1</sup>, T. Martinu<sup>1</sup>, <sup>1</sup>Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, <sup>2</sup>Sunnybrook Health Sciences Centre, Toronto, ON, Canada

- C325 Treprostinil as a Bridge Therapy to Heart-Lung Transplants with Severe Pulmonary Arterial Hypertension**  
C. Ju, Q. Lian, B. Wei, X. Xu, J. He, R. Chen, *State Key Lab of the Respiratory Disease, Guangzhou Institute of Respiratory Disease, Guangzhou, China*
- C326 Caregiving before Thoracic Transplantation--A Qualitative Inquiry**  
C. C. Kennedy<sup>1</sup>, J. Ridgeway<sup>1</sup>, E. Stevens<sup>1</sup>, J. Kirsch<sup>2</sup>, K. Carroll<sup>1</sup>, J. Griffin<sup>1</sup>, R. Benzo<sup>1</sup>, <sup>1</sup>Mayo Clinic, Rochester, MN, <sup>2</sup>University of Florida-Gainesville, Gainesville, FL
- C327 Efficacy and Safety of Alemtuzumab versus Basiliximab Induction in Lung Transplantation**  
J. Choe, J. Au, A. Diamond, C. Ruggia-Check, S. Sehgal, F. Cordova, N. Shigemura, S. Keshavamurthy, Y. Toyoda, *Temple University Hospital, Philadelphia, PA*
- C328 The Impact Of Early Statin Use Following Lung Transplantation On The Development Of Bronchiolitis Obliterans Syndrome**  
B. Lindner<sup>1</sup>, S. Strout<sup>1</sup>, P. Shah<sup>2</sup>, <sup>1</sup>Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, <sup>2</sup>Department of Pulmonology, The Johns Hopkins Hospital, Baltimore, MD
- C329 Impact Of Inhaled Vasodilator Therapy On Early Morbidity And Mortality After Lung Transplant**  
M. Tomeczko<sup>1</sup>, A. Wexler<sup>1</sup>, M. Patel<sup>2</sup>, J. Fernandez-Castillo<sup>2</sup>, J. Rusniak<sup>1</sup>, E. Mancl<sup>3</sup>, S. Quddus<sup>2</sup>, <sup>1</sup>Department of Pharmacy, Loyola University Medical Center, Maywood, IL, <sup>2</sup>Division of Pulmonary and Critical Care, Loyola University Medical Center, Maywood, IL, <sup>3</sup>Loyola University Medical Center, Maywood, IL
- C330 Outcomes for Lung Transplantation Recipients with Non-Alcoholic Fatty Liver Disease**  
A. J. Trindade<sup>1</sup>, P. Burkett<sup>1</sup>, S. El-Chemaly<sup>1</sup>, N. Hashemi<sup>2</sup>, T. Thaniyavarn<sup>1</sup>, H. R. Mallidi<sup>3</sup>, H. J. Goldberg<sup>1</sup>, <sup>1</sup>Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, <sup>2</sup>Gastroenterology and Hepatology, Brigham and Women's Hospital, Boston, MA, <sup>3</sup>Division of Thoracic and Cardiovascular Surgery, Brigham and Women's Hospital, Boston, MA
- C331 Impact of Size Mismatch on Long-Term Graft Survival after Orthotopic Liver Transplantation**  
K. Kamrani<sup>1</sup>, A. Okoh<sup>2</sup>, A. Mathur<sup>3</sup>, L. Brown<sup>4</sup>, <sup>1</sup>Dept. of Surgery, Monmouth Medical Center, Long Branch, NJ, <sup>2</sup>Dept. of Medicine, Newark Beth Israel Medical Center, Newark, NJ, <sup>3</sup>Div. of Transplant Surgery, Mayo Clinic, Scottsdale, AZ, <sup>4</sup>Div. of Liver Transplant Surgery, University Hospital, Newark, NJ
- C332 Patient-Reported Self-Management in Lung Transplant Candidates**  
C. C. Kennedy<sup>1</sup>, M. Budev<sup>2</sup>, S. Chandrashekar<sup>3</sup>, D. Erasmus<sup>4</sup>, E. D. Lease<sup>5</sup>, D. Levine<sup>6</sup>, K. Thompson<sup>1</sup>, E. Stevens<sup>1</sup>, R. Benzo<sup>1</sup>, <sup>1</sup>Mayo Clinic, Rochester, MN, <sup>2</sup>Cleveland Clinic, Cleveland, OH, <sup>3</sup>University of Florida-Gainesville, Gainesville, FL, <sup>4</sup>Mayo Clinic, Jacksonville, FL, <sup>5</sup>University of Washington, Seattle, WA, <sup>6</sup>University of Texas Health Science Center San Antonio, San Antonio, TX
- C333 Lung Allocation Score Should Be Implemented in China**  
C. Ju, Q. Lian, B. Wei, X. Xu, R. Chen, J. He, *State Key Lab of the Respiratory Disease, Guangzhou Institute of Respiratory Disease, Guangzhou, China*
- C334 Assessment Of Glomerular Filtration Rate Among Lung Transplant Candidates**  
S. Akkina<sup>1</sup>, S. Hou<sup>2</sup>, D. Jain Arwindekar<sup>2</sup>, A. Desai<sup>2</sup>, <sup>1</sup>Loyola University Medical Center, Maywood, IL, <sup>2</sup>Medicine, Loyola University Medical Center, Maywood, IL

- C335 † The Molecular Features of Chronic Lung Allograft Dysfunction (CLAD) in Transbronchial and Endobronchial Mucosa Biopsies**  
M. D. Parkes<sup>1</sup>, K. M. Halloran<sup>1</sup>, J. Chang<sup>2</sup>, P. F. Halloran and the INTERLUNG study group<sup>1</sup>, <sup>1</sup>University of Alberta, Edmonton, AB, Canada, <sup>2</sup>ATAGC, University of Alberta, Edmonton, AB, Canada
- C336 Azole Use and Fungal Pathogens in Cystic Fibrosis versus Non-Cystic Fibrosis Lung Transplant Recipients**  
F. J. Marco Canosa<sup>1</sup>, K. Brizendine<sup>2</sup>, H. Hassouna<sup>3</sup>, <sup>1</sup>Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, <sup>2</sup>Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, <sup>3</sup>Infectious Disease, Spectrum Health Infectious Disease, Grand Rapids, MI
- C337 Simulation of DSA-Free Lung Allocation**  
M. Skeans<sup>1</sup>, J. Pyke<sup>1</sup>, K. Audette<sup>1</sup>, R. Lehman<sup>2</sup>, K. Uccellini<sup>2</sup>, K. M. Chan<sup>3</sup>, E. D. Lease<sup>4</sup>, R. Daly<sup>5</sup>, M. Valapour<sup>6</sup>, <sup>1</sup>SRTR, Minneapolis, MN, <sup>2</sup>OPTN, Richmond, VA, <sup>3</sup>Univ. of Michigan, Ann Arbor, MI, <sup>4</sup>Univ. of WA, Seattle, WA, <sup>5</sup>Mayo Clinic, Rochester, MN, <sup>6</sup>Cleveland Clinic Foundation, Cleveland, OH
- C338 Effect of Enoxaparin Prophylaxis on Early VTE Post Lung Transplant**  
S. Marshall<sup>1</sup>, K. Tsveybel<sup>1</sup>, S. Boukedes<sup>1</sup>, P. Burkett<sup>2</sup>, R. Chepuri<sup>2</sup>, A. Coppolino<sup>3</sup>, M. Divo<sup>2</sup>, S. El-Chemaly<sup>2</sup>, S. Keller<sup>2</sup>, J. Kennedy<sup>2</sup>, H. Mallidi<sup>3</sup>, G. Mody<sup>3</sup>, T. Thaniyavarn<sup>2</sup>, A. Trindade<sup>2</sup>, K. Townsend<sup>1</sup>, H. Goldberg<sup>2</sup>, <sup>1</sup>Lung Transplant, Brigham & Women's Hospital, Boston, MA, <sup>2</sup>Pulmonary Division, Brigham & Women's Hospital, Boston, MA, <sup>3</sup>Thoracic Surgery, Brigham & Women's Hospital, Boston, MA
- C339 † Lung Transplantation in the Elderly Patients with Multi-Comorbidities**  
N. Shigemura, Y. Toyoda, Temple University Health System / Lewis Katz School of Medicine, Philadelphia, PA
- C340 Simulation vs. Reality: 250NM as First Unit of Lung Allocation**  
M. Skeans<sup>1</sup>, J. Pyke<sup>1</sup>, C. Lehr<sup>2</sup>, R. Lehman<sup>3</sup>, K. Uccellini<sup>3</sup>, K. M. Chan<sup>4</sup>, E. D. Lease<sup>5</sup>, R. Daly<sup>6</sup>, M. Valapour<sup>2</sup>, <sup>1</sup>SRTR, Minneapolis, MN, <sup>2</sup>Cleveland Clinic Foundation, Cleveland, OH, <sup>3</sup>OPTN, Richmond, VA, <sup>4</sup>Univ. of Michigan, Ann Arbor, MI, <sup>5</sup>Univ. of WA, Seattle, WA, <sup>6</sup>Mayo Clinic, Rochester, MN
- C341 Synergistic Effect of HLA Eplet Mismatch Load and CMV Viremia on Clinical Antibody-Mediated Rejection in Lung Transplantation**  
Y. Im<sup>1</sup>, S. Yeramaneeni<sup>2</sup>, Y. Yim<sup>3</sup>, J. Dodderer<sup>4</sup>, M. Askar<sup>1</sup>, H. J. Huang<sup>5</sup>, <sup>1</sup>Baylor University Medical Center, Dallas, TX, <sup>2</sup>Baylor Scott & White Health, Dallas, TX, <sup>3</sup>Ross University School of Medicine, Portsmouth, Dominica, <sup>4</sup>Texas Tech University Health Sciences Center, El Paso, TX, <sup>5</sup>Houston Methodist Hospital, Houston, TX
- C342 Comparison of Basiliximab and Alemtuzumab for Lung Transplant Induction**  
S. Mietz<sup>1</sup>, D. Roe<sup>2</sup>, E. Lushin<sup>1</sup>, E. Anderson<sup>1</sup>, C. Hage<sup>2</sup>, <sup>1</sup>Pharmacy, Indiana University Health, Indianapolis, IN, <sup>2</sup>Pulmonary Critical Care, Indiana University Health, Indianapolis, IN
- C343 Pediatric Heart and Lung Graft Loss during the "High-Risk Age Window"**  
J. Long<sup>1</sup>, J. Motter<sup>1</sup>, K. R. Jackson<sup>1</sup>, M. Kosztowski<sup>1</sup>, B. Orandi<sup>2</sup>, X. Luo<sup>1</sup>, K. Van Arendonk<sup>3</sup>, A. Massie<sup>1</sup>, E. Bush<sup>1</sup>, R. S. Higgins<sup>1</sup>, D. L. Segev<sup>1</sup>, J. M. Garonzik-Wang<sup>1</sup>, <sup>1</sup>Johns Hopkins School of Medicine, Baltimore, MD, <sup>2</sup>University Of Alabama at Birmingham, Birmingham, AL, <sup>3</sup>Children's Hospital of Wisconsin-Milwaukee Campus, Milwaukee, WI
- C344 Anti-Fungal Prophylaxis in Lung Transplant: A Systematic Review/Meta-Analysis**  
K. Pennington, M. Baqir, P. Erwin, H. Murad, R. Razonable, C. C. Kennedy, Mayo Clinic, Rochester, MN



- C345**     **Frailty is Highly Prevalent in Lung Transplant Candidates and Varies by Frailty Tool**  
A. O'Boye, K. Leitner, M. Kelly, J. Wright, J. Lee, M. Sala, R. Tomic, S. Bhorade, *Northwestern Memorial Hospital, Chicago, IL*
- C346**     **Inadequate (ax) Transbronchial Biopsies Are Not Associated With Clad Or Death After Lung Transplantation**  
L. Levy<sup>1</sup>, E. Huszti<sup>2</sup>, J. Tikkanen<sup>3</sup>, R. Ghany<sup>3</sup>, S. Keshavjee<sup>3</sup>, T. Martinu<sup>3</sup>, <sup>1</sup>Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada, <sup>2</sup>Biostatistics Research Unit, University Health Network, University of Toronto, Toronto, ON, Canada, <sup>3</sup>Lung transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada
- C347**     **Effect of Donor-Recipient Serologic CMV Matching on 1-Year Post-Lung Transplant Outcomes**  
H. Ehrenfeld, M. Manson, R. Yau, *Pharmacy, CHI St. Luke's Health Baylor St. Luke's Medical Center, Houston, TX*
- C348**     **Pre-Transplant Patient and Caregiver Assessments: A Systematic Review and Meta-Analysis**  
J. Lau, A. A. Rmilah, R. Mendpara, P. J. Erwin, C. C. Kennedy, *Mayo Clinic, Rochester, MN*
- C349**     **Clinical Outcomes of Using mTOR Inhibitors with Reduced Dose of Calcineurin Inhibitors in Lung Transplant Recipients: A Single Center Experience**  
M. Frawley<sup>1</sup>, J. Leedy<sup>1</sup>, A. James<sup>1</sup>, A. Salter<sup>1</sup>, V. Rusanov<sup>2</sup>, <sup>1</sup>Department of Pharmacy, UAB Hospital, Birmingham, AL, <sup>2</sup>Division of Pulmonary, Allergy, and Critical Care Medicine, UAB Hospital, Birmingham, AL
- C351 †**    **Robotic Kidney Transplantation For Obese Patients: First Year Experience In Single Institute**  
S. Lee<sup>1</sup>, L. A. Cantrell<sup>2</sup>, A. Agarwal<sup>1</sup>, S. K. Rasmussen<sup>1</sup>, S. Pelletier<sup>1</sup>, K. Brayman<sup>1</sup>, J. Oberholzer<sup>1</sup>, <sup>1</sup>Division of Transplant Surgery, Department of Surgery, University of Virginia Health Sciences Center, Charlottesville, VA, <sup>2</sup>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health Sciences Center, Charlottesville, VA
- C352**     **Multi-Disciplinary Considerations Concerning the Impacts of Kidney Transplantation on Cervical and Lumbar Spinal Fusion Operations**  
L. Mugge, C. Gallagher, W. Qu, A. Caras, N. Henkel, O. Ekwenna, J. Ortiz, *The University of Toledo Medical Center, Toledo, OH*
- C353 †**    **Large Series Of Liver Transplantation In Patients With Portal Vein Thrombosis**  
Y. Cheah, C. J. Simon, R. L. Jenkins, M. E. Akoad, *Lahey Hospital & Medical Center, Burlington, MA*
- C354 †**    **Hepatopancreatobiliary Training In Transplant Fellowships: H And B, Maybe?**  
R. Borscheid<sup>1</sup>, A. Saharia<sup>2</sup>, E. Cho<sup>1</sup>, F. Lewis<sup>1</sup>, H. Osman<sup>1</sup>, J. Kurtz<sup>1</sup>, D. Jeyarajah<sup>1</sup>, A. Gaber<sup>2</sup>, <sup>1</sup>Methodist Richardson Medical Center, Richardson, TX, <sup>2</sup>Houston Methodist Hospital, Houston, TX
- C355**     **Short and Long Term Outcomes of Retrograde vs Antegrade Reperfusion of Liver Transplants. A Propensity Matched Pair Analysis**  
H. Sharma, B. Shrum, D. Quan, A. Skaro, W. Wall, V. McAlister., *Transplant Surgery, University of Western Ontario, London, ON, Canada*

## Poster Session C: Surgical Issues: All Organs

---

- C350 †**    **Surgical Site Complications in Kidney Transplant Recipients: Incidence and Outcomes in the Modern Era**  
J. S. Kim, *Toronto General Hospital, Toronto, ON, Canada*



- C356**      **Minimally Invasive Kidney Transplantation Using a Novel Intraoperative Cryogenic Circulatory Cooling Device**  
H. Dai, L. Peng, L. Song, Z. Tang, N. Wu, C. Fang, M. Nie, T. Li, Y. Zheng, X. Xie, S. Yu, *Department of Urological Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, China*
- C357**      **Severe Hyponatremia with Intraoperative Desmopressin Use in (Deceased and Living Donor) Renal Transplant Recipients**  
M. Gill, S. Kuppachi, C. Thomas, *Division of Nephrology, University of Iowa Hospital and Clinics, Iowa City, IA*
- C358**      **Robotic Pancreas Kidney Transplantation For Type 1 Diabetic Patient With End stage Renal Disease: First Year Experience In Single Institute**  
S. Lee<sup>1</sup>, L. A. Cantrell<sup>2</sup>, A. Agarwal<sup>1</sup>, S. K. Rasmussen<sup>1</sup>, S. Pelletier<sup>1</sup>, K. Brayman<sup>1</sup>, J. Oberholzer<sup>1</sup>, <sup>1</sup>*Division of Transplant Surgery, Department of Surgery, University of Virginia Health Sciences Center, Charlottesville, VA*, <sup>2</sup>*Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health Sciences Center, Charlottesville, VA*
- C359**      **Significant Implications of Prior Transplantation on Treatment and Outcomes of Patients Suffering from Traumatic Brain Injury**  
L. Mugge, W. Qu, C. Gallagher, A. Caras, N. Henkel, O. Ekwenna, J. Ortiz, *The University of Toledo Medical Center, Toledo, OH*
- C360**      **Panniculectomy at the Time of Living Donor Renal Transplantation: An Eight Year Experience**  
L. M. Ngaage<sup>1</sup>, A. Elegbede<sup>2</sup>, K. K. Tasidina<sup>1</sup>, S. Gebran<sup>3</sup>, E. Rada<sup>1</sup>, A. J. Nam<sup>3</sup>, J. R. Scalea<sup>4</sup>, S. Niederhaus<sup>4</sup>, D. Singh<sup>1</sup>, J. S. Bromberg<sup>4</sup>, S. T. Bartlett<sup>4</sup>, Y. M. Rasko<sup>1</sup>, <sup>1</sup>*Department of Plastic Surgery, University of Maryland Medical Center, Baltimore, MD*, <sup>2</sup>*Department of Plastic & Reconstructive Surgery, Johns Hopkins Hospital / University of Maryland Medical Center, Baltimore, MD*, <sup>3</sup>*Division of Plastic & Reconstructive Surgery, R Adams Cowley Shock Trauma Center, Baltimore, MD*, <sup>4</sup>*Department of Transplant Surgery, University of Maryland Medical Center, Baltimore, MD*
- C361**      **Passive Venovenous Bypass Instead Of Centrifugal Pump Is Feasible And Low Cost For Experimental Pig Liver Transplant**  
J. A. Kalil, M. Sanchez-Galvez, M. Hertl, E. Schadde, *Surgery, Rush University Medical Center, Chicago, IL*
- C362**      **Tracheostomy Following Liver Transplantation**  
J. Almario, O. Okoye, M. Spaggiari, K. Jacob, P. Di Cocco, E. Benedetti, I. Tzvetanov, *Surgery, University of Illinois at Chicago, Chicago, IL*
- C363**      **Hepatic Artery Anastomosis Post-Operative Anatomy Influences Doppler Ultrasound Systolic Acceleration Time after Liver Transplantation**  
R. A. Choudhury, A. Yule, K. Conzen, E. A. Pomfret, T. L. Nydam, *Transplant Surgery, University of Colorado, Aurora, CO*
- C364**      **Ex Vivo Resection And Autologous Liver Transplantation As Management Concept For Extensive Malignancy**  
K. Bruestle<sup>1</sup>, A. Griesemer<sup>2</sup>, S. Lobritto<sup>2</sup>, M. Martinez<sup>2</sup>, J. Vittorio<sup>2</sup>, D. Yamashiro<sup>2</sup>, E. Bacha<sup>3</sup>, T. Kato<sup>2</sup>, <sup>1</sup>*Columbia Center for Translational Immunology, Columbia University, New York City, NY*, <sup>2</sup>*Columbia Center for Liver Disease and Transplantation, Columbia University Medical Center, New York City, NY*, <sup>3</sup>*Morgan Stanley Children's Hospital, Columbia University Medical Center, New York City, NY*

- C365 Outcome Differences in Urine Leak Repair Modality Post Kidney Transplantation**  
J. Buggs<sup>1</sup>, V. Gamarra<sup>2</sup>, E. Rogers<sup>1</sup>, R. Watson<sup>1</sup>, J. Sokolich<sup>1</sup>, H. Pearson<sup>1</sup>, J. Huang<sup>1</sup>, A. Kumar<sup>2</sup>, V. Bowers<sup>1</sup>, <sup>1</sup>Tampa General Hospital, Tampa, FL, <sup>2</sup>University of South Florida, Tampa, FL
- C366 Single-Port Robotic Kidney Transplantation: Initial Pre-Clinical Experience Using the SP Surgical System**  
M. Eltemamy, J. Garisto, R. Bertolo, E. Miller, A. Wee, J. Kaouk, *Cleveland Clinic, Cleveland, OH*
- C367 Endovascular Repair Of Abdominal Aortic Aneurysms In Kidney Transplant Recipients**  
S. Kwon<sup>1</sup>, D. Jung<sup>1</sup>, Y. Kim<sup>1</sup>, S. Park<sup>2</sup>, S. Yoon<sup>2</sup>, <sup>1</sup>Department of Vascular and Transplant Surgery, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of, <sup>2</sup>Department of Vascular and Transplant Surgery, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of
- C368 Incisional Hernia Repair Post Liver and or Kidney Transplantation**  
J. Buggs<sup>1</sup>, A. Brando<sup>2</sup>, J. Sokolich<sup>1</sup>, E. Rogers<sup>1</sup>, A. Kumar<sup>3</sup>, V. Bowers<sup>1</sup>, <sup>1</sup>Tampa General Hospital, Tampa, FL, <sup>2</sup>University of Tampa, Tampa, FL, <sup>3</sup>University of South Florida, Tampa, FL

## Poster Session D: Quality Assurance Process Improvement & Regulatory Issues

Poster Viewing: 6:00 pm - 7:00 pm  
Presenters in Attendance: 6:00 pm - 7:00 pm  
Hall C & D

A# indicates the board location where the poster will be displayed.

† Those posters identified as an ATC Poster of Distinction by this symbol have received review scores that place them in the top 10% of their category. The Planning Committee encourages you to make them a priority when you visit the poster session.

- D1**      **Availability of Psychiatric and Chemical Dependency Treatment Services at US Hospitals Providing Transplantations**  
S. K. Niazi<sup>1</sup>, A. Spaulding<sup>2</sup>, T. Schneekloth<sup>3</sup>, A. Keaveny<sup>4</sup>, A. Vasquez<sup>1</sup>, E. Vargas<sup>2</sup>, T. Rummans<sup>1</sup>, C. Taner<sup>5</sup>,  
<sup>1</sup>Psychiatry & Psychology, Mayo Clinic, Jacksonville, FL, <sup>2</sup>Health Services Research, Mayo Clinic, Jacksonville, FL, <sup>3</sup>Psychiatry & Psychology, Mayo Clinic, Rochester, MN, <sup>4</sup>Hepatology, Mayo Clinic, Jacksonville, FL, <sup>5</sup>Transplantation, Mayo Clinic, Jacksonville, FL
- D2 †**    **Predicting Post Liver Transplant 30-Day Readmission Using Deep Neural Network Model**  
S. K. Niazi<sup>1</sup>, H. O. Park<sup>2</sup>, R. E. Carter<sup>3</sup>, A. Keaveny<sup>4</sup>, T. Schneekloth<sup>5</sup>, A. Spaulding<sup>6</sup>, D. Harnois<sup>4</sup>, P. F. Moreno-Franco<sup>7</sup>, E. Vargas<sup>6</sup>, T. Rummans<sup>1</sup>, C. Taner<sup>7</sup>, <sup>1</sup>Psychiatry & Psychology, Mayo Clinic, Jacksonville, FL, <sup>2</sup>Enterprise Analytics, Mayo Clinic, Rochester, MN, <sup>3</sup>Health Sciences Research, Mayo Clinic, Jacksonville, FL, <sup>4</sup>GI & Hepatology, Mayo Clinic, Jacksonville, FL, <sup>5</sup>Psychiatry & Psychology, Mayo Clinic, Rochester, MN, <sup>6</sup>Health Services Research, Mayo Clinic, Jacksonville, FL, <sup>7</sup>Transplantation, Mayo Clinic, Jacksonville, FL
- D3**      **Utility of Protocol Ultrasound Surveillance in Liver Transplantation**  
N. Kemmer<sup>1</sup>, W. McClellan<sup>2</sup>, D. Patino<sup>3</sup>, E. Rogers<sup>1</sup>, A. Kumar<sup>2</sup>, J. Buggs<sup>1</sup>, <sup>1</sup>Tampa General Hospital, Tampa, FL, <sup>2</sup>University of South Florida, Tampa, FL, <sup>3</sup>University of Tampa, Tampa, FL

- D4**      **Listening to the Patients Voice for Developing Transplant Education**  
S. Brown, H. Li, D. Tsapepas, *Renal Transplant, Columbia University Medical Center, New York, NY*

- D5**      **Evaluation Of Workplace Environment In Transplant Medicine: Harassment Should Not Be The “Reality Of Life”**  
M. Reilly<sup>1</sup>, T. Branstool<sup>1</sup>, S. Gregory<sup>1</sup>, T. R. Pearson<sup>2</sup>, T. S. Purnell<sup>3</sup>, G. Gunasekaran<sup>4</sup>, B. Kelly<sup>5</sup>, P. N. Martins<sup>6</sup>, C. M. Mobley<sup>7</sup>, S. M. Black<sup>8</sup>, E. C. Maynard<sup>9</sup>, D. C. Simpson<sup>10</sup>, M. B. Shah<sup>11</sup>, O. Ekwenna<sup>1</sup>, J. Locke<sup>12</sup>, J. Ortiz<sup>1</sup>, <sup>1</sup>Surgical Transplant, University of Toledo College of Medicine and Life Sciences, Toledo, OH, <sup>2</sup>Froedtert and the Medical College of Wisconsin, Milwaukee, WI, <sup>3</sup>Johns Hopkins School of Medicine, Baltimore, MD, <sup>4</sup>Mount Sinai Medical Center, New York, NY, <sup>5</sup>DCI Donor Services, Nashville, TN, <sup>6</sup>University of Massachusetts, Amherst, MA, <sup>7</sup>Houston Methodist, Houston, TX, <sup>8</sup>The Ohio State University, Columbus, OH, <sup>9</sup>Oregon Health and Science University, Portland, OR, <sup>10</sup>Northwestern University, Evanston, IL, <sup>11</sup>University of Kentucky, Lexington, KY, <sup>12</sup>University of Alabama at Birmingham, Birmingham, AL

- D6 †**    **The Use of Mobile Software for Real-Time, Secure, Team-Based Procurement and Transplantation Team Communication to Improve the Deceased Donor Organ Transplantation Process**  
E. Pahl, *HealthTech Solutions, Inc., Coralville, IA*

- D7 †**    **Integration Of Business Intelligence (BI) Solution In Tertiary Renal Transplant Centre To Drive Clinical Decisions.**  
M. Heer, S. Yausis, P. R. Trevillian, *Newcastle Transplant Unit, John Hunter Hospital, Newcastle, Australia*

- D8 The Medical Intensive Liver Unit: A Novel Multi-disciplinary Program For The Intensive Care Of Patients With Advanced Liver Disease**  
C. C. Lindenmeyer<sup>1</sup>, G. Flocco<sup>1</sup>, A. Sobotka<sup>1</sup>, L. Kokoczka<sup>2</sup>, B. Dolan<sup>2</sup>, C. Strauser<sup>2</sup>, C. Romero-Marrero<sup>1</sup>, E. Mireles-Cabodevila<sup>2</sup>, H. Khouli<sup>2</sup>, C. Quintini<sup>3</sup>, A. Kapoor<sup>2</sup>, <sup>1</sup>Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, OH, <sup>2</sup>Department of Critical Care Medicine, Cleveland Clinic, Cleveland, OH, <sup>3</sup>Transplantation Center, Cleveland Clinic, Cleveland, OH
- D9 A Cost Saving Quality Improvement Project in Solid Organ Transplant Population Following Tacrolimus Switch from Prograf® to Adoport® Immunosuppression - A Single Centre Experience**  
L. Mulreid, M. Vincent, L. Laycock, A. Summers, S. Bhutani, Manchester Royal Infirmary, Manchester, United Kingdom
- D10 Initial Single-Center Results from the Pilot Transplant Quality Improvement Project in Liver Transplant**  
A. Zarinsefat, S. M. Syed, R. Hirose, UC San Francisco, San Francisco, CA
- D11 QA of MMR/VZV Protocol-Driven Serologic Screening and Infectious Disease Consultation (IDC) Are Strongly Recommended in Heart, Lung, Liver (HLL) SOTs**  
Z. Seckin, L. Brumble, C. Libertin, Mayo Clinic, Jacksonville, FL
- D12 The Effect Of Missed Hemodialysis Treatment Prior To Transplant**  
A. Padiyar<sup>1</sup>, A. Agrawal<sup>1</sup>, D. Hricik<sup>1</sup>, N. Sarabu<sup>1</sup>, A. Jittirat<sup>1</sup>, K. Yadav<sup>2</sup>, E. Sanchez<sup>2</sup>, M. Debroy<sup>2</sup>, V. Humphreville<sup>2</sup>, J. Rabets<sup>2</sup>, A. Palanisamy<sup>2</sup>, K. Chavin<sup>2</sup>, <sup>1</sup>Medicine, Nephrology, University Hospitals Cleveland Medical Center, Cleveland, OH, <sup>2</sup>Transplant Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH
- D13 Sensitivity of 5-Tier System to Unadjusted Confounding**  
N. Salkowski, A. Wey, J. Snyder, SRTR, Minneapolis, MN
- D14 Performance Improvement Initiative: Ambulatory Tool to Improve Tacrolimus Inpatient Variability (IPV) Monitoring in Kidney & Liver Transplant Recipients**  
T. E. Kaiser<sup>1</sup>, N. S. Ejaz<sup>1</sup>, S. Tremblay<sup>1</sup>, N. J. Parrish<sup>2</sup>, S. Schinasi<sup>2</sup>, J. Harris<sup>2</sup>, A. Govil<sup>1</sup>, N. Anwar<sup>1</sup>, R. R. Alloway<sup>1</sup>, <sup>1</sup>University of Cincinnati, Cincinnati, OH, <sup>2</sup>UC Health, Cincinnati, OH
- D15 Mortality around the One-Year Survival Metric after Liver Transplantation in the United States**  
C. Blebea<sup>1</sup>, P. Chatterjee<sup>2</sup>, A. Nathan<sup>1</sup>, J. Diamond<sup>1</sup>, H. J. Goldberg<sup>2</sup>, A. Courtwright<sup>1</sup>, <sup>1</sup>Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Brigham and Women's Hospital, Boston, MA
- D16 Poor Nutritional And Bone-mineral Density Parameters Pretransplant Predict Complications Posttransplant**  
A. Padiyar<sup>1</sup>, A. Agrawal<sup>1</sup>, D. Hricik<sup>1</sup>, J. Kerner<sup>2</sup>, J. Benavides<sup>2</sup>, N. Sarabu<sup>1</sup>, A. Jittirat<sup>1</sup>, K. Yadav<sup>2</sup>, E. Sanchez<sup>2</sup>, M. DeBroy<sup>2</sup>, V. Humphreville<sup>2</sup>, J. Rabets<sup>2</sup>, A. Palanisamy<sup>2</sup>, K. Chavin<sup>2</sup>, <sup>1</sup>Medicine, Nephrology, University Hospitals Cleveland Medical Center, Cleveland, OH, <sup>2</sup>Transplant Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH
- D17 Use of an Ideal Body Weight-Based Rabbit Anti-Thymocyte Globulin Dosing Protocol in Kidney Transplant Recipients to Decrease Cost and Maintain Outcomes at a Large Academic Medical Center**  
L. J. Myhre<sup>1</sup>, R. J. Bubik<sup>1</sup>, K. T. Peterson<sup>1</sup>, H. A. Personett<sup>1</sup>, S. A. Crow<sup>1</sup>, P. G. Dean<sup>2</sup>, <sup>1</sup>Pharmacy, Mayo Clinic, Rochester, MN, <sup>2</sup>Transplantation Surgery, Mayo Clinic, Rochester, MN
- D18 Characterization Of Increased Risk Donor Post-transplant Viral Surveillance Protocol At A Comprehensive Transplant Center**  
J. Dann, W. Ally, S. Pelletier, C. Sifri, A. Agarwal, University of Virginia Health System, Charlottesville, VA

**D19 The Dry Weight Revealed!, What Transplanted Kidneys Teach Us about the (Dry Weight).**

M. Hamid<sup>1</sup>, S. Oyewolle-Eletu<sup>2</sup>, G. Gudleski<sup>2</sup>, K. Speta<sup>3</sup>, J. Kumar<sup>1</sup>, S. Chang<sup>1</sup>, <sup>1</sup>*Nephrology-Transplant, State University of New York at Buffalo (SUNY) Buffalo, Buffalo, NY*, <sup>2</sup>*Jacob's School of Medicine, State University of New York at Buffalo (SUNY) Buffalo, Buffalo, NY*, <sup>3</sup>*Nephrology-Transplant, Erie County Medical Center, Buffalo, NY*

**D20 † Kidney & Pancreas Transplant Waitlist Management - A Tiered System Approach**

H. L. Busch, *Transplant, UCI Health, Orange, CA*

**D21 Build It, They Will Come: Surgical Renal Outpatient Infusion Room Decreases Readmission Rates**

J. Truckenbrod<sup>1</sup>, K. DeWall<sup>1</sup>, M. Jones<sup>1</sup>, E. VanLith<sup>1</sup>, M. Anderson<sup>1</sup>, L. Jaeger<sup>1</sup>, M. Phillips<sup>2</sup>, W. Kendall<sup>1</sup>, L. Burris<sup>1</sup>, T. Thambi<sup>1</sup>, <sup>1</sup>*Transplant, Sanford USD Medical Center and Hospital, Sioux Falls, SD*, <sup>2</sup>*Surgical Renal, Sanford USD Medical Center and Hospital, Sioux Falls, SD*

**D22 Pharmacist Impact on Vaccinations Rates in Cardiothoracic Transplant Recipients**

K. Zaborowski, J. Dederling, R. Felkner, *William S. Middleton Memorial Veterans Hospital, Madison, WI*

**D23 A Cytomegalovirus Antiviral Stewardship Program at a Large Transplant Center**

M. Jorgenson<sup>1</sup>, J. Descourouez<sup>1</sup>, D. Felix<sup>1</sup>, C. Saddler<sup>2</sup>, J. Smith<sup>2</sup>, D. Mandelbrot<sup>2</sup>, <sup>1</sup>*UW Health, Madison, WI*, <sup>2</sup>*University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI*

**D24 Beyond Medication Education: Opportunities for Improvement in Health Education of Solid Organ Transplant Recipients**

Y. J. Bababekov, Y. Hsu, C. G. Rickert, Y. Hung, J. A. Fishman, J. F. Markmann, L. Dageforde, D. C. Chang, H. Yeh, *Department of Surgery, Massachusetts General Hospital, Boston, MA*

**D25 Development of an Aggressiveness Report Card**

L. Liyanage, M. Kosztowski, S. Bae, K. Jackson, C. Holscher, A. Massie, N. Desai, M. Henderson, D. Segev, J. Garonzik-Wang, *Johns Hopkins, Baltimore, MD*

**D26 The Impact of Changes in OPTN Oversight of Kidney Programs on Organ Yield and Offer Acceptance Practices**

A. Wey<sup>1</sup>, N. Salkowski<sup>1</sup>, B. Carrico<sup>2</sup>, S. Sheppard<sup>2</sup>, B. Kasiske<sup>1</sup>, B. Thompson<sup>1</sup>, A. Israni<sup>1</sup>, J. Snyder<sup>1</sup>, <sup>1</sup>*SRTR, Minneapolis, MN*, <sup>2</sup>*OPTN, Richmond, VA*

**D27 Perception Of Hospital Staff On Transplant: Pre And Post-intervention**

J. Wise<sup>1</sup>, A. Sarvestani<sup>1</sup>, K. Briggs<sup>2</sup>, J. Malik<sup>2</sup>, M. Ott<sup>3</sup>, L. Markham<sup>3</sup>, H. Wilkins<sup>3</sup>, D. Neel<sup>2</sup>, C. Richart<sup>4</sup>, J. Foxworth<sup>1</sup>, M. Moncure<sup>2</sup>, <sup>1</sup>*University of Missouri - Kansas City, Kansas City, MO*, <sup>2</sup>*Department of Surgery, University of Missouri - Kansas City, Kansas City, MO*, <sup>3</sup>*Midwest Transplant Network, Kansas City, MO*, <sup>4</sup>*Northeast Georgia Medical Center, Gainesville, GA*

**D28 Evaluating Potentially Inappropriate Prescribing in Older Kidney Transplant Recipients**

L. DeVietro<sup>1</sup>, B. Richardson<sup>2</sup>, E. A. Cohen<sup>3</sup>, A. H. Toledo<sup>4</sup>, E. Marin<sup>5</sup>, K. R. Szempruch<sup>6</sup>, <sup>1</sup>*University of St. Joseph School of Pharmacy, Hartford, CT*, <sup>2</sup>*University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC*, <sup>3</sup>*Pharmacy, Yale New Haven Hospital, New Haven, CT*, <sup>4</sup>*Surgery-Transplant, University of North Carolina Medical Center, Chapel Hill, NC*, <sup>5</sup>*Nephrology, Yale New Haven Hospital, New Haven, CT*, <sup>6</sup>*Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC*

**D29 Page Kidney Phenomenon in a Trauma Patient: A Case Report and Recommendations for Management**

M. M. Estrada, D. R. Hall, W. Dar, J. S. Bynon, *University of Texas Health Science Center at Houston, Houston, TX*



**D30**      **Impact of Case Scheduling on Hospital Cost and Length of Stay in Living Donor Kidney Recipients**  
J. Yu<sup>1</sup>, L. A. Dageforde<sup>2</sup>, M. B. Doyle<sup>1</sup>, A. S. Khan<sup>1</sup>, W. C. Chapman<sup>1</sup>, Y. Lin<sup>1</sup>, S. Shenoy<sup>1</sup>, T. Alhamad<sup>3</sup>, T. A. Horwedel<sup>4</sup>, J. R. Wellen<sup>1</sup>, <sup>1</sup>*Surgery, Washington University School of Medicine, St. Louis, MO*, <sup>2</sup>*Surgery, Massachusetts General Hospital, Boston, MA*, <sup>3</sup>*Medicine, Washington University School of Medicine, St. Louis, MO*, <sup>4</sup>*Barnes-Jewish Hospital, St. Louis, MO*

**D31**      **Early Readmission After Renal Transplant As A Valuable Quality Measure**  
S. Kim<sup>1</sup>, A. Osband<sup>1</sup>, B. Merhi<sup>2</sup>, G. Bayliss<sup>2</sup>, R. Gohh<sup>2</sup>, P. Morrissey<sup>1</sup>, <sup>1</sup>*Surgery, Rhode Island Hospital, Providence, RI*, <sup>2</sup>*Nephrology, Rhode Island Hospital, Providence, RI*

**D32**      **Liver Waitlist Dropout and Transplant Rates for Metropolitan vs. Non-Metropolitan Candidates**  
D. Schladt<sup>1</sup>, T. Weaver<sup>1</sup>, J. Pyke<sup>1</sup>, A. Herreid<sup>1</sup>, B. Thompson<sup>1</sup>, B. Kasiske<sup>1</sup>, J. Snyder<sup>1</sup>, W. Kim<sup>2</sup>, J. Lake<sup>3</sup>, A. Israni<sup>1</sup>, <sup>1</sup>*SRTR, Minneapolis, MN*, <sup>2</sup>*Stanford Univ, Stanford, CA*, <sup>3</sup>*Univ of Minnesota, Minneapolis, MN*

**D33**      **How Well Do Kidney Transplant Patients Understand Their Medications and Does Real-Time Assessment of Knowledge Improve Retention of Information?**  
B. Clark<sup>1</sup>, B. Sirandas<sup>1</sup>, T. Larson<sup>2</sup>, A. Carlson<sup>1</sup>, C. Truax<sup>1</sup>, D. D. Ramirez<sup>1</sup>, L. Smith<sup>1</sup>, I. Hall<sup>1</sup>, <sup>1</sup>*University of Utah Health, Salt Lake City, UT*, <sup>2</sup>*Henry Ford Hospital, Detroit, MI*

#### **Poster Session D: Stem Cell, Cellular Therapies and Regenerative Medicine**

---

**D34**      **Costimulatory Blockade and Allo-Specific Treg Therapy for Liver Transplant Recipients: Preclinical Data**  
L. Contreras-Ruiz<sup>1</sup>, K. Shimozaawa<sup>2</sup>, R. Zhang<sup>1</sup>, L. Turka<sup>3</sup>, J. F. Markmann<sup>3</sup>, E. C. Guinan<sup>2</sup>, <sup>1</sup>*Medical Oncology, Dana-Farber Cancer Institute, Boston, MA*, <sup>2</sup>*Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA*, <sup>3</sup>*Center of Transplantation Sciences, Massachusetts General Hosp., Boston, MA*

**D35**      **Immune Cells Composition of Humanized Mouse Kidney Compared to Normal Human Kidney**  
S. Noel<sup>1</sup>, J. T. Kurzhagen<sup>1</sup>, S. Lee<sup>1</sup>, M. Sadasivam<sup>2</sup>, A. R. Hamad<sup>2</sup>, P. M. Pierorazio<sup>3</sup>, H. Rabb<sup>1</sup>, <sup>1</sup>*Medicine, Johns Hopkins University, Baltimore, MD*, <sup>2</sup>*Pathology, Johns Hopkins University, Baltimore, MD*, <sup>3</sup>*Urology, Johns Hopkins University, Baltimore, MD*

**D36**      **Full and Sustained Donor Hematopoietic Chimerism after an Isolated Kidney Transplantation**  
J. Zuber<sup>1</sup>, O. Boyer<sup>1</sup>, B. Neven<sup>1</sup>, E. Six<sup>2</sup>, R. Berthaud<sup>1</sup>, M. Ould Rabah<sup>1</sup>, S. Sobrino<sup>2</sup>, C. Lagresle<sup>2</sup>, I. André-Schmutz<sup>2</sup>, M. Cavazzana<sup>1</sup>, S. Blanche<sup>1</sup>, R. Salomon<sup>1</sup>, <sup>1</sup>*Paris Descartes University, Paris, France*, <sup>2</sup>*Inserm UMRS 1163, Paris, France*

**D37**      **Responder B Cell Depletion Increased Allo-Reactive Regulatory T Cells Generated in Allo-Anergization**  
N. Tanimine<sup>1</sup>, L. Contreras-Ruiz<sup>2</sup>, K. Deng<sup>1</sup>, N. Feeney<sup>1</sup>, C. Rickert<sup>1</sup>, K. Lee<sup>1</sup>, E. Guinan<sup>3</sup>, J. Markmann<sup>1</sup>, <sup>1</sup>*Department of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA*, <sup>2</sup>*Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA*, <sup>3</sup>*Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA*

**D38**      **RNA Splicing and Lineage Progression: Identification of an Integrated Splicing Pattern in Endodermal Lineage Progression**  
J. Fair<sup>1</sup>, N. Liu<sup>1</sup>, S. G. Widen<sup>2</sup>, W. S. Fagg<sup>1</sup>, <sup>1</sup>*Surgery, University of Texas Medical Branch, Galveston, TX*, <sup>2</sup>*Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX*

**D39**      **Pluripotent Stem Cell Differentiation: Delaying Forward Differentiation Signals Maintains Definitive Endoderm Phenotype for Cellular Transplantation**  
J. Fair<sup>1</sup>, M. M. Shoja<sup>1</sup>, N. Liu<sup>1</sup>, I. Patrikeev<sup>2</sup>, M. Motamedi<sup>2</sup>, W. S. Fagg<sup>1</sup>, <sup>1</sup>*Surgery, University of Texas Medical Branch, Galveston, TX*, <sup>2</sup>*Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX*

**D40 †** **Generation of Thymic Epithelial Cells from Induced Pluripotent Stem Cells to Prolong Allograft Survival**  
R. Otsuka, H. Wada, H. Tsuji, A. Sasaki, T. Murata, M. Baghdadi, K. Seino, *Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido, Japan*

## Poster Session D: Tolerance / Immune Deviation

---

**D41** **Analysis and Regulation of Immune Reaction in the Transplantation from MHC Homozygous Donors to Heterozygous Recipients with Minor Antigen Mismatches**  
T. Murata, H. Wada, R. Otsuka, H. Tsuji, A. Sasaki, M. Baghdadi, K. Seino, *Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan*

**D42** **In Vivo/In Situ Behaviour of Allogeneic Spleen versus Bone Marrow Cells in Wild-Type Neonatal Mice: Insights into Robust Transplant Tolerance Induction**  
R. A. Bascom, K. Tao, L. J. West, *Pediatrics, University of Alberta, Edmonton, AB, Canada*

**D43** **MHC Cross-Dressing in Mixed Hematopoietic Chimerism**  
B. Gonzalez Nolasco<sup>1</sup>, M. Wang<sup>1</sup>, W. Orent<sup>1</sup>, A. Prunevieuille<sup>1</sup>, K. Pruner<sup>1</sup>, J. O<sup>1</sup>, J. Paster<sup>1</sup>, J. C. Madsen<sup>2</sup>, G. Benichou<sup>1</sup>, <sup>1</sup>*Department of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA*, <sup>2</sup>*Department of Surgery, Center for Transplantation Sciences, Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA*

**D44** **Heart En Bloc Thymus Cotransplantation in NHPs**  
J. O<sup>1</sup>, W. Sommer<sup>2</sup>, K. Pruner<sup>3</sup>, J. T. Paster<sup>4</sup>, I. M. Hanekamp<sup>1</sup>, A. Dehnadi<sup>1</sup>, I. Rosales<sup>1</sup>, R. N. Smith<sup>1</sup>, R. B. Colvin<sup>1</sup>, G. Benichou<sup>1</sup>, J. S. Allan<sup>1</sup>, J. C. Madsen<sup>1</sup>, <sup>1</sup>*Center for Transplantation Sciences, MGH, Boston, MA*, <sup>2</sup>*Hannover Medical School, Hannover, Germany*, <sup>3</sup>*University of Washington, Seattle, WA*, <sup>4</sup>*MGH, Boston, MA*

**D45** **Ablation of Interferon Regulatory Factor 4 in T Cells Induces “Memory” of Transplant Tolerance That is Irreversible by Immune Checkpoint Blockade**  
H. Zhang<sup>1</sup>, J. Wu<sup>2</sup>, D. Zou<sup>3</sup>, W. Chen<sup>3</sup>, <sup>1</sup>*The second Xiangya Hospital, Changsha, China*, <sup>2</sup>*Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China*, <sup>3</sup>*Immunobiology & Transplant Science Center, Houston Methodist Research Institute, Houston, TX*

**D46 †** **Kidney Allografts Induce Systemic Tolerance of Heart Allografts and is Dependent on Foxp3+ Cells**  
C. Yang<sup>1</sup>, J. Ge<sup>1</sup>, P. S. Russell<sup>1</sup>, J. C. Madsen<sup>1</sup>, A. Alessandrini<sup>1</sup>, R. B. Colvin<sup>2</sup>, <sup>1</sup>*Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA*, <sup>2</sup>*Department of Pathology, Massachusetts General Hospital, Boston, MA*

**D47** **Depleting Laminin  $\alpha 5$  in Lymph Node Stromal Cells Promotes Transplant Tolerance**  
L. Li, M. Shirkey, W. Piao, Y. Xiong, V. Saxena, T. Zhang, N. Toney, C. Paluskievicz, J. S. Bromberg, *Surgery, U. Maryland, Baltimore, Baltimore, MD*

**D48** **B7H1 Expression is Crucial for Tolerance Induction in Mouse Liver Transplantation**  
M. Morita<sup>1</sup>, S. Datta<sup>1</sup>, C. Miller<sup>2</sup>, T. Hamilton<sup>1</sup>, K. Hashimoto<sup>3</sup>, <sup>1</sup>*Inflammation & Immunity, Lerner Research Institution, Cleveland, OH*, <sup>2</sup>*General surgery, Liver Transplant Center, Cleveland Clinic, Cleveland, OH*, <sup>3</sup>*General Surgery, Liver Transplant Center, Cleveland Clinic, Cleveland, OH*

- D49 Donor Brain Death Affects Tolerance Induction in Non-Human Primates**  
W. Sommer<sup>1</sup>, J. M. O<sup>2</sup>, K. B. Pruner<sup>3</sup>, J. T. Paster<sup>3</sup>, A. Bean<sup>3</sup>, A. Dehnadi<sup>3</sup>, I. M. Hanekamp<sup>3</sup>, I. Rosales<sup>4</sup>, R. N. Smith<sup>4</sup>, R. B. Colvin<sup>4</sup>, G. Benichou<sup>3</sup>, J. S. Allan<sup>3</sup>, T. Kawai<sup>3</sup>, J. C. Madsen<sup>5</sup>, <sup>1</sup>Department of Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany, <sup>2</sup>Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, <sup>3</sup>Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, <sup>4</sup>Department of Pathology, Massachusetts General Hospital, Boston, MA, <sup>5</sup>Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA
- D50 A Novel Method for Ex Vivo Treg Expansion via Human iNKT Cell Activation**  
R. Ishii<sup>1</sup>, I. Masako<sup>1</sup>, H. Katsumata<sup>1</sup>, T. Kanzawa<sup>1</sup>, T. Yamakawa<sup>1</sup>, H. Ishigooka<sup>1</sup>, T. Hirai<sup>1</sup>, K. Saiga<sup>1</sup>, M. Okumi<sup>1</sup>, Y. Ishii<sup>2</sup>, K. Tanabe<sup>1</sup>, <sup>1</sup>Urology, Tokyo Women's Medical University, Tokyo, Japan, <sup>2</sup>Vaccine Innovation Laboratory RIKEN Cluster for Science, Technology and Innovation Hub (RCSTI), Kanagawa, Japan
- D51 IL-21 Induces the Transformation of Th Cell Subsets in Acute Rejection after Kidney Transplantation**  
H. Deng, R. Wang, J. Shen, J. Chen, Kidney Disease Center, First Affiliated Hospital of Zhejiang University, Hangzhou, China
- D52 Increased Frequency of Myeloid-Derived Suppressor Cells Contributing to Prolong Skin Allograft Survival in Aged Mice**  
W. Lee, Y. Wang, T. Wu, C. Cheng, C. Lee, T. Wu, H. Chou, K. Chan, General Surgery, Chang-gung Hospital, Taoyuan, Taiwan
- D53 The Effects of Chronic Kidney Disease on Antiviral T Cell Response**  
R. L. Crepeau<sup>1</sup>, H. Li<sup>2</sup>, L. P. Daley-Bauer<sup>3</sup>, M. L. Ford<sup>1</sup>, P. D. Winterberg<sup>2</sup>, <sup>1</sup>Emory Transplant Center, Atlanta, GA, <sup>2</sup>Pediatrics, Emory University School of Medicine, Atlanta, GA, <sup>3</sup>Microbiology & Immunology, Emory University School of Medicine, Atlanta, GA
- D54 T Cell-Intrinsic Dysfunction in Donor-Specific Transplantation Tolerance**  
C. M. McIntosh<sup>1</sup>, M. L. Miller<sup>2</sup>, Y. Wang<sup>1</sup>, A. Chong<sup>3</sup>, M. Alegre<sup>1</sup>, <sup>1</sup>Department of Medicine, University of Chicago, Chicago, IL, <sup>2</sup>Department of Immunology, University of Pittsburgh, Pittsburgh, PA, <sup>3</sup>Department of Surgery, University of Chicago, Chicago, IL
- D55 † Endogenous Erythropoietin is Required for Spontaneous Acceptance of Murine Renal Allografts**  
J. Horwitz, P. Cravedi, P. Heeger, Icahn School of Medicine at Mount Sinai, NY, NY
- D56 Tolerance to ABO A-Antigen Following Treatment of Infant Mice with A-Expressing MHC-Identical Erythrocytes**  
B. Motyka<sup>1</sup>, J. Fersovich<sup>1</sup>, M. Sulzer<sup>1</sup>, I. Adam<sup>1</sup>, J. Pearcey<sup>1</sup>, K. Tao<sup>1</sup>, C. W. Cairo<sup>2</sup>, P. J. Cowan<sup>3</sup>, L. J. West<sup>1</sup>, <sup>1</sup>Dept Pediatrics, Alberta Transplant Institute, Canadian Donation and Transplant Research Program, University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Department of Chemistry, University of Alberta, Edmonton, AB, Canada, <sup>3</sup>Immunology Research Centre, St Vincent's Hospital, Melbourne, Australia
- D57 Bcl-2/Bcl-xL Inhibition by Navitoclax vs. Bcl-2 Alone Inhibition by Venetoclax for Induction of Mixed Chimerism in Non-Human Primates**  
H. Sasaki<sup>1</sup>, D. Ma<sup>1</sup>, T. Oura<sup>1</sup>, A. Dehnadi<sup>1</sup>, I. Rosales<sup>2</sup>, B. Cosimi<sup>1</sup>, P. Cippa<sup>3</sup>, T. Fehr<sup>3</sup>, T. Kawai<sup>1</sup>, <sup>1</sup>Surgery, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Pathology, Massachusetts General Hospital, Boston, MA, <sup>3</sup>Medicine, University of Zurich, Zurich, Switzerland
- D58 ECDI-Treated Donor Leukocytes in Primate Cardiac Allograft Recipients**  
Z. Alikhassy Habibabady<sup>1</sup>, T. Zhang<sup>2</sup>, W. Sun<sup>2</sup>, X. Cheng<sup>2</sup>, L. Burdorf<sup>1</sup>, I. Tatarov<sup>2</sup>, S. Sendil<sup>2</sup>, I. Behroozfard<sup>2</sup>, B. Cerel<sup>1</sup>, D. Parsell<sup>2</sup>, R. N. Pierson III<sup>1</sup>, X. Luo<sup>3</sup>, A. M. Azimzadeh<sup>1</sup>, <sup>1</sup>Surgery, Massachusetts General Hospital and Harvard School of Medicine, Boston, MA, <sup>2</sup>Surgery, University of Maryland School of Medicine, Baltimore, MD, <sup>3</sup>Duke Transplant Center, Duke University, Durham, NC

- D59 Immunologically Tolerant Liver Transplant Recipients Are Characterized by Donor-Specific Hypo Responsiveness of Circulating T-cells**  
A. A. Duizendstra<sup>1</sup>, R. J. Knegt de<sup>1</sup>, M. G. Betjes<sup>2</sup>, M. P. Peppelenbosch<sup>1</sup>, N. H. Litjens<sup>2</sup>, J. Kwekkeboom<sup>1</sup>,  
<sup>1</sup>Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, Netherlands, <sup>2</sup>Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands
- D60 Deficiency of the Transcription Factor Satb1 in T Cells Promotes Solid Organ Allograft Survival**  
P. K. Gupta<sup>1</sup>, M. L. Miller<sup>2</sup>, L. Chen<sup>1</sup>, Y. Wang<sup>1</sup>, J. Conejo-Garcia<sup>3</sup>, A. Chong<sup>1</sup>, M. Alegre<sup>1</sup>, <sup>1</sup>University of Chicago, Chicago, IL, <sup>2</sup>University of Pittsburgh, Pittsburgh, PA, <sup>3</sup>Moffitt Cancer Center & Research Institute, Tampa, FL
- D61 Prevention of Diabetes in the NOD Mice Reconstituted with Bone Marrow Cells from Allogeneic CD4 Knockout, CD8 Knockout or B-Cell Knockout B6 Mice**  
Y. Huang, H. Xu, Y. Wen, S. Ildstad, University of Louisville, Louisville, KY
- D62 Superiority of Donor-Specifically vs. Polyclonally Expanded Regulatory T Cells in Controlling Graft Rejection in the NSG Mouse Human Skin Graft Model**  
J. H. Voss<sup>1</sup>, F. Zheng<sup>1</sup>, M. D. Jendrisak<sup>2</sup>, J. R. Leventhal<sup>1</sup>, Z. J. Zhang<sup>1</sup>, J. M. Mathew<sup>1</sup>, <sup>1</sup>Surgery – Comprehensive Transplant Center, Northwestern University, Chicago, IL, <sup>2</sup>Gift of Hope Organ & Tissue Donor Network, Itasca, IL
- D63 Comparative Use of Single mTOR vs Dual mTOR/PI3K Inhibition in Regulatory T Cell Expansion for Clinical Application in Transplantation**  
R. Gedaly-Eidelman, F. Marti, L. Turcios, E. Chacon, D. Valvi, University of Kentucky, Lexington, KY
- D64 Dichotomous Role Of Donor T Cells In The Efficacy Of Tolerogenic Therapies For Transplant Rejection**  
M. Iglesias Lozano, D. Bibicheff, M. Chicco, G. Brandacher, G. Raimondi, Plastic Surgery, Johns Hopkins University, Baltimore, MD
- D65 † Acquired Resistance to Transplantation Tolerance as a Result of Prior Pregnancy Requires B Cells**  
D. V. Tran, A. N. Suah, S. Khiew, J. S. Young, Q. Wang, D. Yin, M. Alegre, A. S. Chong, Departments of Surgery and Medicine, University of Chicago, Chicago, IL
- D66 Chimeric Allografts Induced by Stem Cell Mobilizing Agents in a Mouse Model of Kidney Transplantation: Role of CD133 Stem Cells**  
J. Zhou, I. Qi, A. Ahmadi, R. Wesson, A. Cameron, J. Burdick, Z. Sun, Johns Hopkins University School of Medicine, Baltimore, MD
- D67 Allograft Survival is Influenced by Gut Microbiota-Dependent Modulation of Innate Immunity**  
V. Saxena<sup>1</sup>, Y. Xiong<sup>1</sup>, L. Hittle<sup>1</sup>, L. Li<sup>1</sup>, T. Simon<sup>2</sup>, W. Piao<sup>1</sup>, C. C. Brinkman<sup>1</sup>, E. M. Smyth<sup>1</sup>, T. Zhang<sup>1</sup>, C. Wagner<sup>1</sup>, C. M. Palusckievicz<sup>1</sup>, W. F. Fricke<sup>3</sup>, E. F. Mongodin<sup>1</sup>, J. S. Bromberg<sup>1</sup>, <sup>1</sup>U Maryland, Baltimore, MD, <sup>2</sup>Institut de Pharmacologie Moléculaire et Cellulaire, Université Côte d'Azur, CNRS, Valbonne, France, <sup>3</sup>Institute of Biological Chemistry and Nutrition, U Hohenheim, Stuttgart, Germany
- D68 Generation of Human/Pig Hybrid Thymus to Achieve Immune Tolerance to Pig Antigens with Optimal Immune Function**  
M. Khosravi Maharlooei, H. Li, M. Holzl, A. Vecchione, A. Misra, A. Ruiz, R. Madley, G. Nauman, N. Danzl, G. Zhao, K. Yamada, M. Sykes, Columbia University, New York, NY
- D69 † Circulating Exosomes with Cardiac Self-Antigens (Cardiac Myosin and Vimentin) and De Novo Development of Antibodies to Cardiac Self-Antigens Precedes Chronic Cardiac Allograft Rejection**  
R. Ravichandran, Y. Itabashi, W. Liu, T. Mohanakumar, Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ



**D70**      **Role of RIPK3 in Chronic Rejection Following Human Lung Transplantation**  
S. Angara, R. Ravichandran, H. Sodawalla, M. Smith, R. Bremner, T. Mohanakumar, *Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*

**D76**      **Xenorejection of Porcine Islets in Humanized Mice is Dominated by a Human Th17 Cytokine Immune Response**  
F. T. Lee<sup>1</sup>, A. Dangi<sup>2</sup>, M. Burnette<sup>2</sup>, B. Hering<sup>3</sup>, X. Luo<sup>2</sup>, <sup>1</sup>*Transplant Surgery, Northwestern University, Chicago, IL*, <sup>2</sup>*Nephrology, Duke University, Durham, NC*, <sup>3</sup>*Diabetes Institute, University of Minnesota, Minneapolis, MN*

### **Poster Session D: Xenotransplantation**

**D71**      **Novel Insights into Blocking the IL-6 / IL-6 Receptor Pathway after Pig Kidney Xenotransplantation in Baboons**  
H. Hara<sup>1</sup>, G. Zhang<sup>1</sup>, H. Iwase<sup>1</sup>, T. Yamamoto<sup>1</sup>, D. Ayares<sup>2</sup>, D. E. Eckhoff<sup>1</sup>, D. K. Cooper<sup>1</sup>, <sup>1</sup>*Surgery, University of Alabama at Birmingham, Birmingham, AL*, <sup>2</sup>*Revivicor Inc., Blacksburg, VA*

**D77**      **Prevention of Islet Allo- and Xenograft Rejection with Immunoglobulin M Immunotherapy**  
M. Ma, P. Chhabra, K. Brayman, *Surgery, University of Virginia, Charlottesville, VA*

**D72**      **Indicators of Impending Pig Organ Xenograft Failure: Relevance to Clinical Xenotransplantation**  
H. Iwase<sup>1</sup>, A. Jagdale<sup>1</sup>, T. Yamamoto<sup>1</sup>, G. Zhang<sup>1</sup>, Q. Li<sup>1</sup>, J. Foote<sup>1</sup>, D. Ayares<sup>2</sup>, H. Hara<sup>1</sup>, D. K. Cooper<sup>1</sup>, <sup>1</sup>*University of Alabama at Birmingham, Birmingham, AL*, <sup>2</sup>*Revivicor, Inc., Blacksburg, VA*

**D78**      **Investigation and Regulation of Induced Anti-Pig Antibody Production in GTKO Pig-to-Cynomolgus Monkey Artery Retransplantation**  
S. Hurh<sup>1</sup>, E. Lee<sup>1</sup>, J. Jeong<sup>2</sup>, G. Lee<sup>1</sup>, S. Park<sup>1</sup>, S. Ahn<sup>3</sup>, S. Min<sup>3</sup>, C. Ahn<sup>4</sup>, <sup>1</sup>*Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of*, <sup>2</sup>*Department of Nephrology, Ajou University School of Medicine, Suwon, Korea, Republic of*, <sup>3</sup>*Department of Surgery, Seoul National University Hospital, Seoul, Korea, Republic of*, <sup>4</sup>*Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of*

**D73**      **Graft-Infiltrating Regulatory T Cells Are Associated with Long Term Cardiac Xenograft Survival**  
A. K. Singh<sup>1</sup>, G. Braileanu<sup>1</sup>, A. Hersfield<sup>1</sup>, L. DiChiacchio<sup>1</sup>, T. Zhang<sup>1</sup>, I. Tatarov<sup>1</sup>, D. Parsell<sup>1</sup>, B. Lewis<sup>1</sup>, F. Sentz<sup>1</sup>, D. Ayares<sup>2</sup>, M. Mohiuddin<sup>1</sup>, <sup>1</sup>*Department of Surgery, School of Medicine, University of Maryland Baltimore, Baltimore, MD*, <sup>2</sup>*Revivicor, Inc, Blacksburg, VA*

**D79**      **Donor-Specific Tregs Prolong Peripheral Chimerism in Baboons Receiving GalTKO hCD47-tg Porcine Peripheral Blood Stem Cells**  
N. P. Llore<sup>1</sup>, J. Stern<sup>1</sup>, G. Pierre<sup>1</sup>, E. Lopes<sup>1</sup>, D. Ekanayake-Alper<sup>1</sup>, P. Alonso-Guallart<sup>1</sup>, K. Bruestle<sup>1</sup>, H. Sakai<sup>1</sup>, D. Ayares<sup>2</sup>, M. Lorber<sup>2</sup>, R. Hawley<sup>1</sup>, D. H. Sachs<sup>1</sup>, M. Sykes<sup>1</sup>, A. D. Griesemer<sup>1</sup>, <sup>1</sup>*Columbia Center for Translational Immunology, New York, NY*, <sup>2</sup>*United Therapeutics, Silver Springs, MD*

**D74**      **TMA Development in Kidney and Heart Xenografts Treated with Anti-CD40 or Anti-CD154 Antibodies**  
D. H. Ma<sup>1</sup>, H. Sasaki<sup>1</sup>, J. M. O<sup>1</sup>, K. Ahrens<sup>1</sup>, D. Becerra<sup>1</sup>, C. G. Rickert<sup>1</sup>, D. M. Detelich<sup>1</sup>, T. Oura<sup>1</sup>, W. Somer<sup>1</sup>, I. Rosales<sup>2</sup>, R. N. Pierson<sup>1</sup>, J. Markmann<sup>1</sup>, J. C. Madsen<sup>1</sup>, T. Kawai<sup>1</sup>, <sup>1</sup>*Surgery, MGH, Boston, MA*, <sup>2</sup>*Pathology, MGH, Boston, MA*

**D80**      **TCR Transgenes to Understand Human Xenotolerance Induction**  
G. Nauman, C. Borsotti, N. Danzl, M. Khosravi-Maharlooeei, H. Li, E. Chavez, Y. Yang, M. Sykes, *Columbia Center for Translational Immunology, New York, NY*

**D75 †**      **Targeted Epitope Mutagenesis as a Strategy to Decrease Xenoantibody Binding**  
J. Ladowski, G. Martens, Z. Wang, L. Reyes, M. Tector, J. Tector, *University of Alabama-Birmingham, Birmingham, AL*



- D81**      **Perioperative Cardiac Xenograft Dysfunction after Orthotopic Transplantation is for Real**  
M. Mohiuddin<sup>1</sup>, A. Singh<sup>1</sup>, L. DiChiacchio<sup>1</sup>, D. Kaczorowski<sup>1</sup>, B. Lewis<sup>1</sup>, T. Zhang<sup>1</sup>, F. Sentz<sup>1</sup>, I. Tatarov<sup>1</sup>, D. Parsell<sup>1</sup>, P. Odonkor<sup>1</sup>, E. Strauss<sup>1</sup>, B. Williams<sup>1</sup>, K. Deatrck<sup>1</sup>, D. Ayares<sup>2</sup>, B. Griffith<sup>1</sup>, S. Bartlett<sup>1</sup>, <sup>1</sup>Department of Surgery, University of Maryland Baltimore, Baltimore, MD, <sup>2</sup>Revivacor, Inc, Blacksburg, VA
- D82**       **$\alpha$ -1,3-galactosyltransferase Knockout Porcine Tissue And Organ May Reduce The Risks Of Antibody Mediated Rejection Via Less Rhesus Igm Cross-reactivity.**  
J. Yoon, B. Ezekian, M. Manook, J. Kwun, S. Knechtle, Duke Transplant Center, Durham, NC
- D83**      **Inhibition of Sialidase Activity and Galectin Binding Reduces Xenogeneic Neutrophil-Endothelial Adhesion**  
B. M. Cerel<sup>1</sup>, B. M. French<sup>2</sup>, D. G. Harris<sup>2</sup>, C. Laird<sup>2</sup>, L. Burdorf<sup>1</sup>, X. Cheng<sup>2</sup>, C. Feng<sup>3</sup>, A. S. Cross<sup>4</sup>, S. E. Goldblum<sup>4</sup>, G. R. Vasta<sup>3</sup>, R. N. Pierson III<sup>1</sup>, A. M. Azimzadeh<sup>1</sup>, <sup>1</sup>Department of Surgery, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, <sup>3</sup>Department of Microbiology and Immunology, and Institute of Marine and Environmental Technology, University of Maryland School of Medicine, Baltimore, MD, <sup>4</sup>Department of Medicine Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD
- D84 †**      **Prolonged Heterotopic Cardiac Xenograft Survival from Thrombomodulin Expressing Multigene Donor Pig**  
A. K. Singh<sup>1</sup>, L. DiChiacchio<sup>1</sup>, T. Zhang<sup>1</sup>, A. Hersfield<sup>1</sup>, I. Tatarov<sup>1</sup>, D. Parsell<sup>1</sup>, B. Lewis<sup>1</sup>, F. Sentz<sup>1</sup>, D. Ayares<sup>2</sup>, M. Mohiuddin<sup>1</sup>, <sup>1</sup>Department of Surgery, University of Maryland Baltimore, Baltimore, MD, <sup>2</sup>Revivacor, Inc, Blacksburg, VA
- D85 †**      **Absence of Antibodies in Human Neonates and Infants to Gtko/cmahko/ $\beta$ 4galnt2ko (Triple Gene Knockout) Pig Cells: Relevance to Cardiac Xenotransplantation for Complex Congenital Heart Disease**  
H. Hara<sup>1</sup>, Q. Li<sup>1</sup>, C. A. Banks<sup>1</sup>, T. Yamamoto<sup>1</sup>, D. Ayares<sup>2</sup>, D. C. Cleveland<sup>1</sup>, D. K. Cooper<sup>1</sup>, <sup>1</sup>Surgery, University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>Revivacor Inc., Blacksburg, VA
- D86**      **The Effect of Intravenous Immunoglobulin on Human Complement-Dependent Cytotoxicity of Pig Cells: Benefit? Or Harm?**  
T. Yamamoto<sup>1</sup>, Q. Li<sup>1</sup>, A. Banks<sup>1</sup>, H. Iwase<sup>1</sup>, D. Ayares<sup>2</sup>, D. K. Cooper<sup>1</sup>, H. Hara<sup>1</sup>, <sup>1</sup>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>Revivacor, Blacksburg, VA
- D87**      **Ex-vivo Xenoperfusion Of Wild Type And Galtko.hcd55 Pig Livers With Human Whole Blood**  
D. Detelich, C. Rickert, C. Eymard, C. Carroll, S. Kimura, H. Yeh, J. Markmann, Massachusetts General Hospital, Boston, MA
- D88**      **Donor Derived Neoplasia: Will It Be a Risk after Clinical Pig Organ Xenotransplantation?**  
A. Jagdale<sup>1</sup>, H. Iwase<sup>1</sup>, E. Klein<sup>2</sup>, D. Cooper<sup>1</sup>, <sup>1</sup>Surgery, University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>Surgery, University of Pittsburgh, Pittsburgh, PA
- Poster Session D: Kidney Acute Antibody Mediated Rejection**
- D89**      **Reduced Intensity Induction Therapy in Patients Undergoing Repeat Kidney Transplants**  
K. Linhares, M. Cristelli, C. Felipe, L. Viana, H. Proença, R. E. de Marco, J. Pestana, H. Tedesco, Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil

- D90 International Multicenter Study Evaluating Clinical Outcomes Associated with Acute Antibody-Mediated Rejection**  
S. Corman<sup>1</sup>, I. Hirji<sup>2</sup>, E. Brouwer<sup>2</sup>, S. H. Park<sup>1</sup>, C. Macahilig<sup>3</sup>, A. Vergani<sup>2</sup>, T. Bo<sup>2</sup>, P. Wolthoff<sup>3</sup>, P. Keown<sup>4</sup>, <sup>1</sup>Pharmerit International, Bethesda, MD, <sup>2</sup>Shire, Cambridge, MA, <sup>3</sup>Medical Data Analytics, Parsippany, NJ, <sup>4</sup>University of British Columbia, Vancouver, BC, Canada
- D91 Impact of Granulocyte Colony Stimulating Factor on Clinical Outcomes in Kidney Transplant Recipients with Neutropenia**  
H. Yao<sup>1</sup>, A. Alam<sup>2</sup>, R. Sapir-Pichhadze<sup>2</sup>, D. D'Arienza<sup>3</sup>, D. Baran<sup>2</sup>, S. Sandal<sup>2</sup>, M. Cantarovich<sup>2</sup>, <sup>1</sup>Critical Care Medicine, McGill University Health Center, Montreal, QC, Canada, <sup>2</sup>Nephrology and Multi-Organ Transplant Program, McGill University Health Center, Montreal, QC, Canada, <sup>3</sup>Medicine, McGill University Health Center, Montreal, QC, Canada
- D92 Yellow Fever and Renal Transplantation: Influence of Vaccination and Infection on the Emergence of Antibody-Mediated Rejection**  
M. V. Sousa<sup>1</sup>, R. L. Zollner<sup>2</sup>, R. S. Stucchi<sup>3</sup>, I. F. Boin<sup>4</sup>, E. C. Ataide<sup>4</sup>, M. Mazzali<sup>1</sup>, <sup>1</sup>Department of Internal Medicine - Division of Nephrology, University of Campinas, Campinas, Brazil, <sup>2</sup>Department of Internal Medicine, University of Campinas, Campinas, Brazil, <sup>3</sup>Department of Internal Medicine - Division of Infectious Diseases, University of Campinas, Campinas, Brazil, <sup>4</sup>Surgery Department, University of Campinas, Campinas, Brazil
- D93 ABMR In Low-single Dose Thymoglobulin Induction Protocol In Renal Transplant Recipients From A Tertiary Care Centre In A Developing Country**  
R. Parthasarathy<sup>1</sup>, M. Mohammed<sup>1</sup>, P. Koshy<sup>2</sup>, I. Pradeep<sup>2</sup>, M. Mathew<sup>1</sup>, G. Abraham<sup>1</sup>, <sup>1</sup>Nephrology, Madras Medical Mission, Chennai, India, <sup>2</sup>Pathology, Madras Medical Mission, Chennai, India
- D94 Is Pre-transplant Plasmapheresis For Patients With Insignificant Abo Blood Type Antibody In Abo Blood Type Incompatible Kidney Transplant Necessary? - A Japanese Single Center Study.**  
M. Miyazaki, A. Mitsuke, H. Higuchi, N. Fukuzawa, H. Tanaka, T. Hirano, T. Seki, H. Harada, *Urology and Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Hokkaido, Japan*
- D95 † Post-Transplant Anti- A Titer >1:128 in A2-Incompatible Kidney Recipients is Associated with Subclinical Antibody Mediated Rejection**  
V. Kumar, D. Williams, P. MacLennan, M. Mustian, B. Orandi, L. Williams, J. Locke, *University of Alabama at Birmingham, Birmingham, AL*
- D96 A Clinical Analysis for Low-Dose Immunoglobulin United with Plasmapheresis in High Sensitization Renal Transplantation Recipients**  
L. Xu<sup>1</sup>, J. Zhang<sup>2</sup>, <sup>1</sup>Chinese PLA General Hospital Eighth Medical Centre, Beijing, China, <sup>2</sup>Nursing Department, Chinese PLA General Hospital, Beijing, China
- D97 Daratumumab for Treatment of Antibody-Mediated Rejection in a Kidney Transplant Recipient**  
S. C. Jordan<sup>1</sup>, R. Vescio<sup>2</sup>, M. Toyoda<sup>3</sup>, N. Ammerman<sup>1</sup>, E. Huang<sup>1</sup>, A. Peng<sup>1</sup>, S. Sethi<sup>1</sup>, R. Najjar<sup>1</sup>, K. Lim<sup>1</sup>, A. Vo<sup>1</sup>, <sup>1</sup>Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA, <sup>2</sup>Cedars-Sinai Medical Ctr, Los Angeles, CA, <sup>3</sup>Transplant Immunology Lab, Cedars-Sinai Medical Ctr, Los Angeles, CA
- D98 Cluster Analysis of Microvascular Inflammation in Indication Biopsies Unveils Distinct Pathological and Immunological Phenotypes with Prognostic Implications**  
J. Malheiro<sup>1</sup>, A. Silva<sup>1</sup>, S. Santos<sup>1</sup>, S. Tafulo<sup>2</sup>, L. Martins<sup>1</sup>, L. Dias<sup>1</sup>, A. Castro-Henriques<sup>1</sup>, <sup>1</sup>Centro Hospitalar do Porto, Porto, Portugal, <sup>2</sup>IPST\_Porto, Porto, Portugal

- D99 Effect of Race and Antibody-Mediated Injury on Outcomes after Early Subclinical Inflammation**  
E. P. Kasik, M. E. Seifert, M. Bernard, G. Agarwal, H. Fatima, R. Gaston, B. Julian, C. Kew, V. Kumar, S. Mehta, S. Ong, F. Rosenblum, G. Towns, R. B. Mannon, *University of Alabama, Birmingham, AL*
- D100 † De Novo Complement-Activating Donor Specific Antibodies in Pediatric Renal Transplant Recipients Are Highly Responsive to Therapy**  
V. Sigurjonsdottir, A. Chaudhuri, P. Grimm, *Pediatric Nephrology, Stanford, Los Altos, CA*
- D101 Association between CD19-Positive Rate and Antibody-Mediated Rejection Following Rituximab Administration in Kidney Transplant Recipients**  
K. Nanmoku, T. Shinzato, T. Kubo, T. Shimizu, T. Yagisawa, *Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan*
- D102 Pre-emptive Ivig For Dsa Positive Living Donor Kidney Transplant Recipients**  
B. Abdalla<sup>1</sup>, D. Kellner<sup>2</sup>, A. Diaz<sup>2</sup>, Y. Zheng<sup>3</sup>, E. Reed<sup>4</sup>, Q. J. Zhang<sup>4</sup>, <sup>1</sup>*Medicine, Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, CA*, <sup>2</sup>*David Geffen School of Medicine at UCLA, Los Angeles, CA*, <sup>3</sup>*UCLA Immunogenetics Center, Los Angeles, CA*, <sup>4</sup>*Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA*
- D103 Incidence of De Novo Donor Specific Antibodies and Treatment Response for AMR in Pediatric Kidney Transplant Recipients**  
S. Gattis<sup>1</sup>, R. Liverman<sup>1</sup>, A. Serluco<sup>1</sup>, J. Yin<sup>1</sup>, H. C. Sullivan<sup>2</sup>, R. A. Bray<sup>3</sup>, H. M. Gebel<sup>3</sup>, S. Jernigan<sup>4</sup>, R. George<sup>4</sup>, P. D. Winterberg<sup>4</sup>, R. Garro<sup>4</sup>, <sup>1</sup>*Children's Healthcare of Atlanta, Atlanta, GA*, <sup>2</sup>*Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA*, <sup>3</sup>*Emory University Hospital, Atlanta, GA*, <sup>4</sup>*Department of Pediatrics, Emory University School of Medicine, Atlanta, GA*
- D104 Evaluation Of Complement-related Factors In Tma Post-kidney Transplantation: A Retrospective Multicenter Study**  
N. Fujiyama<sup>1</sup>, M. Tasaki<sup>2</sup>, H. Harada<sup>3</sup>, K. Tsutahara<sup>4</sup>, A. Matsumoto<sup>5</sup>, Y. Hara<sup>6</sup>, M. Okumi<sup>7</sup>, K. Saito<sup>2</sup>, Y. Watarai<sup>8</sup>, N. Inoue<sup>9</sup>, N. Wakamiya<sup>9</sup>, S. Satoh<sup>1</sup>, <sup>1</sup>*Center for Kidney Disease and Transplantation, Akita University Hospital, Akita, Japan*, <sup>2</sup>*Department of Urology, Niigata University, Niigata, Japan*, <sup>3</sup>*Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan*, <sup>4</sup>*Department of Urology, Osaka General Medical Center, Osaka, Japan*, <sup>5</sup>*Department of Urology, The University of Tokyo, Tokyo, Japan*, <sup>6</sup>*Department of Nephrology, Shinsyu University Hospital, Shinsyu, Japan*, <sup>7</sup>*Department of Urology, Tokyo Women's Medical University, Tokyo, Japan*, <sup>8</sup>*Department of Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan*, <sup>9</sup>*The Japanese Association for Complement Research, Osaka, Japan*
- D105 † Infectious Complications after Treatment of Antibody-Mediated Kidney Allograft Rejection: A National Cohort Study**  
N. Perrottet<sup>1</sup>, D. Golshayan<sup>2</sup>, O. Manuel<sup>2</sup>, V. Aubert<sup>2</sup>, M. Koller<sup>3</sup>, K. Hadaya<sup>4</sup>, L. Bühler<sup>4</sup>, T. Mueller<sup>5</sup>, U. Huynh-Do<sup>6</sup>, S. Dahdal<sup>6</sup>, I. Binet<sup>7</sup>, M. Dickenmann<sup>3</sup>, S. Schaub<sup>3</sup>, J. Steiger<sup>3</sup>, M. Pascual<sup>2</sup>, M. Fernández-Ruiz<sup>2</sup>, <sup>1</sup>*Pharmacy, CHUV, Lausanne, Switzerland*, <sup>2</sup>*CHUV, Lausanne, Switzerland*, <sup>3</sup>*USB, Basel, Switzerland*, <sup>4</sup>*HUG, Geneva, Switzerland*, <sup>5</sup>*USZ, Zurich, Switzerland*, <sup>6</sup>*Inselspital, Bern, Switzerland*, <sup>7</sup>*KSSG, St. Gallen, Switzerland*
- D106 Outcomes Of Treatment Of Late Vs Early Acute Antibody-mediated Rejection In Renal Transplant Recipients - A Single Center Experience**  
R. Prashar, N. Sulejmani, A. Patel, *Henry Ford Transplant Institute, Detroit, MI*

- D107 Immediate Post Reperfusion In Vivo Transcriptional Responses of Individual Human Renal Allograft Cell Populations to Circulating Anti-Angiotensin II Type I Receptor Antibody**  
C. M. Castro -Rojas<sup>1</sup>, N. Salomonis<sup>2</sup>, K. Chetal<sup>2</sup>, R. R. Alloway<sup>3</sup>, E. Woodle<sup>3</sup>, D. A. Hildeman<sup>1</sup>, <sup>1</sup>Immunobiology, Cincinnati Children's Hospital, Cincinnati, OH, <sup>2</sup>Biomedical Informatics, Cincinnati Children's Hospital, Cincinnati, OH, <sup>3</sup>Transplantation, University of Cincinnati College of Medicine, Cincinnati, OH
- D108 Adjunctive Therapy With Tocilizumab For Treatment Of Acute Antibody Mediated Rejection - 2 Year Experience**  
K. Venkatachalam, R. Delos Santos, B. Heady, A. Malone, T. Alhamad, Washington University, St. Louis, MO
- D109 Do Outcomes Differ in Glomerulitis Predominant Antibody Mediated Rejection and Peritubular capillaritis Predominant Antibody Mediated Rejection?**  
S. Sethi<sup>1</sup>, J. Hou<sup>2</sup>, M. Lin<sup>2</sup>, Y. Ren<sup>2</sup>, A. Peng<sup>1</sup>, R. Najjar<sup>1</sup>, A. Vo<sup>1</sup>, S. Jordan<sup>1</sup>, M. Haas<sup>2</sup>, E. Huang<sup>1</sup>, <sup>1</sup>Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA, <sup>2</sup>Pathology, Cedars Sinai Medical Center, Los Angeles, CA
- D110 Peritubular Capillary C4d Positivity in Renal Allograft Biopsies: Implications for Allograft Survival**  
A. Bailey, S. Tremblay, A. R. Shields, J. Wang, R. Alloway, E. S. Woodle, Transplant Surgery, University of Cincinnati, Cincinnati, OH
- D111 Donor-Derived Cell-Free DNA (dd-cfDNA) Course after Rejection in Pediatric Kidney Transplant Recipients**  
R. D. Swinford<sup>1</sup>, A. M. De Golovine<sup>1</sup>, C. Bell<sup>1</sup>, A. Pai<sup>1</sup>, A. R. Edwards<sup>1</sup>, S. Connor<sup>2</sup>, J. S. Bynon<sup>1</sup>, <sup>1</sup>Pediatrics, UTHealth, McGovern Medical School, University of Texas at Houston, Houston, TX, <sup>2</sup>Transplantation, Memorial Hermann Hospital, Houston, TX
- D112 Use of Eculizumab for Active Antibody-Mediated Rejection That Occurs Early Post-Kidney Transplantation: A Consecutive Series of 15 Cases**  
E. Tan<sup>1</sup>, B. J. Andrew<sup>2</sup>, P. G. Dean<sup>2</sup>, M. F. Shaheen<sup>1</sup>, M. D. Stegall<sup>2</sup>, C. A. Schinstock<sup>2</sup>, <sup>1</sup>Division of Transplantation Surgery, Mayo Clinic Rochester, Rochester, MN, <sup>2</sup>The William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic Rochester, Rochester, MN
- D113 Is HLA Donor-Specific Antibody (DSA)-C3d+ Assay a Potential Predictor of Subclinical Antibody Mediated Damage in the Renal Graft?**  
A. G. Contreras<sup>1</sup>, M. I. Solis-G<sup>1</sup>, C. Ramirez-Espinoza<sup>1</sup>, J. Hernandez-Rosales<sup>2</sup>, M. Vilatoba-Chapa<sup>1</sup>, R. Cruz-Martínez<sup>1</sup>, J. Granados<sup>1</sup>, L. E. Morales-Buenrostro<sup>3</sup>, J. Alberú<sup>1</sup>, J. M. Arreola-Guerra<sup>4</sup>, <sup>1</sup>Transplantation, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico, <sup>2</sup>Department of Histocompatibility, Laboratorio Clinico del Campestre, Mexico City, Mexico, <sup>3</sup>Nephrology-Mineral Metabolism, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico, <sup>4</sup>Internal Medicine, Centenario Hospital Miguel Hidalgo, Mexico City, Mexico
- D114 Induction Therapy Modulated by the Absence of Preformed Donor-Specific Antibodies (DSAs) Regardless of the Level of Sensitization**  
M. Cristelli, K. Linhares, R. de Marco, L. Viana, C. Felipe, M. Gaspar, C. Peixoto, G. Marcelo Gomes, J. Toniato Rezende, K. Nunes Ficher, L. Alfaro Villanueva, V. Lima, M. Gerbase de Lima, J. Medina Pestana, H. Tedesco Silva Junior, Núcleo de Ensino e Pesquisa, Hospital do Rim, São Paulo, Brazil



**Poster Session D: Liver: Hepatocellular Carcinoma and Other Malignancies**

- D115 † Peri-Operative Basiliximab is Not Associated with Post-Transplant Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients**  
D. Salerno<sup>1</sup>, N. Lange<sup>1</sup>, E. Simoneau<sup>2</sup>, C. Sammons<sup>3</sup>, D. Bley<sup>1</sup>, R. S. Brown Jr<sup>4</sup>, J. Emond<sup>2</sup>, K. Halazun<sup>5</sup>, <sup>1</sup>Pharmacy, NewYork-Presbyterian Hospital, New York, NY, <sup>2</sup>Surgery, Columbia University Irving Medical Center, New York, NY, <sup>3</sup>Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>4</sup>Medicine, Weill Cornell Medicine, New York, NY, <sup>5</sup>Surgery, Weill Cornell Medicine, New York, NY
- D116 † Long Term Outcomes of Patients Transplanted for Hepatocellular Carcinoma with Human Immunodeficiency Virus Infection**  
R. Gedaly-Eidelman, E. Chacon, P. Eman, M. Gupta, J. Berger, A. El-Husseini, X. Mei, F. Marti, L. Turcios, M. Shah, University of Kentucky, Lexington, KY
- D117 Outcomes of Liver Transplantation for Hepatocellular Carcinoma in Septuagenarians**  
M. Najjar<sup>1</sup>, K. Bruestle<sup>1</sup>, P. Jiang<sup>1</sup>, E. Lieberman<sup>1</sup>, R. Hwang<sup>1</sup>, A. Mathur<sup>1</sup>, E. C. Verna<sup>1</sup>, A. Griesemer<sup>1</sup>, B. Samstein<sup>2</sup>, T. Kato<sup>1</sup>, Y. M. Saenger<sup>1</sup>, K. J. Halazun<sup>2</sup>, J. C. Emond<sup>1</sup>, <sup>1</sup>Columbia University Medical Center, New York, NY, <sup>2</sup>Weill Cornell Medicine, New York, NY
- D118 † Policy Changes in Liver Graft Allocation for Hepatocellular Carcinoma in the USA: Improved Survival for African American Recipients**  
M. Molinari<sup>1</sup>, D. Jorgensen<sup>1</sup>, A. Tevar<sup>1</sup>, C. Hughes<sup>1</sup>, A. Humar<sup>1</sup>, N. Jonassaint<sup>2</sup>, <sup>1</sup>Surgery, University of Pittsburgh Medical Centre, Pittsburgh, PA, <sup>2</sup>Medicine, University of Pittsburgh Medical Centre, Pittsburgh, PA
- D119 Long Term Impact of Intraoperative Autologous Blood Transfusion on HCC Recurrence in Liver Transplantation**  
G. Kelly<sup>1</sup>, J. L. Pasko<sup>1</sup>, E. Dewey<sup>2</sup>, E. Maynard<sup>1</sup>, S. L. Orloff<sup>1</sup>, C. Enestvedt<sup>1</sup>, <sup>1</sup>Division of Abdominal Transplant, OHSU, Portland, OR, <sup>2</sup>Department of General Surgery, OHSU, Portland, OR
- D120 Outcome Of Living Donor Liver Transplantation In Elderly Patients >65 Years With And Without Hepatocellular Carcinomas: A Retroepsective Analysis**  
A. Thorat, L. Jeng, S. Hsu, H. Yang, C. Yeh, T. Chen, K. Poon, P. Li, Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan
- D121 Favorable Outcome of Pathologic Downstaging by Locoregional Treatment for Hepatocellular Carcinoma in Liver Transplantation**  
D. Kim, J. Lee, S. Kim, K. In, D. Joo, S. Kim, M. Kim, Severance hospital, Seoul, Korea, Republic of
- D122 Tumor Necrosis as a Result to Pre-Transplant Bridging Treatment for Hepatocellular Carcinoma and Its Effect on Post-Transplant Outcome**  
S. Radunz<sup>1</sup>, A. Kirschner<sup>1</sup>, J. M. Theysohn<sup>2</sup>, C. Schotten<sup>3</sup>, T. Benkö<sup>1</sup>, <sup>1</sup>General, Visceral and Transplant Surgery, University Hospital Essen, Essen, Germany, <sup>2</sup>Diagnostic and Interventional Radiology and Neurroradiology, University Hospital Essen, Essen, Germany, <sup>3</sup>Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany
- D123 Resource Utilization in Hepatocellular Carcinoma Liver Transplantation before and after the Six Month Wait Time**  
J. Sokolich<sup>1</sup>, W. McClellan<sup>2</sup>, J. Buggs<sup>1</sup>, E. Rogers<sup>1</sup>, K. Barber<sup>1</sup>, K. Cocuy<sup>1</sup>, A. Kumar<sup>2</sup>, <sup>1</sup>Tampa General Hospital, Tampa, FL, <sup>2</sup>University of South Florida, Tampa, FL
- D124 Hepatocellular Carcinoma in Fontan Liver Disease**  
V. Lamm<sup>1</sup>, J. Wedd<sup>2</sup>, C. Haydek<sup>2</sup>, C. Obineme<sup>2</sup>, A. Noll<sup>2</sup>, H. Veeramachaneni<sup>2</sup>, M. Muftah<sup>2</sup>, R. Ford<sup>2</sup>, <sup>1</sup>Internal Medicine, Emory, Atlanta, GA, <sup>2</sup>Emory, Atlanta, GA



**D125 Clinical Presentation After Hepatitis B Recurrence In Liver Transplant Patients**

W. Lee, C. Cheng, T. Wu, Y. Wang, C. Lee, T. Wu, H. Chou, K. Chan, *Chang-Gung Hospital, Taoyuan, Taiwan*

**Poster Session D: Liver: Immunosuppression and Rejection**

---

**D126 Rituximab Desensitization to Liver Transplantation Recipients with Preformed Donor Specific Antibodies to Prevent Antibody Mediated Rejection**

Y. Ogura, M. Shizuku, N. Kurata, K. Jobara, H. Kamei, *Transplantation Surgery, Nagoya University Hospital, Nagoya City, Japan*

**D127 Donor Lymphocyte Chimerism and Homozygosity Are Critical Indicators for Timely and Accurate Diagnosis of Acute Graft vs. Host Disease after Liver Transplantation**

A. Zhang, B. Eghtesad, *Cleveland Clinic Foundation, Cleveland, OH*

**D128 High Prevalence of De Novo Donor-Specific Antibodies during Rejection after Liver Transplantation**

J. Colmenero, N. Flores, A. Diaz, M. Vasquez, P. Ruiz, G. Crespo, J. Martorell, M. Navasa, *Liver Transplant Unit, Hospital Clinic Barcelona, Barcelona, Spain*

**D129 Nivolumab-Induced Rejection of a Liver Allograft: PD-1 Inhibition Thwarts Liver Allograft Resistance to Humoral Rejection**

B. T. Lee, H. Han, S. Chopra, A. J. Ahearn, *Surgery, USC Keck School of Medicine, Los Angeles, CA*

**D130 Immunologic Impact Of Native Kidney Function On Liver Transplant Patients**

M. Mujtaba, S. Merwat, J. Fair, M. Bilal, A. Chatila, R. Kulkarni, J. Zou, S. Hussain, A. Gamilla-Crudo, *Univ. of Texas Medical Branch, Galveston, TX*

**D131 † Fatal Graft versus Host Disease in Liver Transplantation. An Analysis of UNOS Registry**

S. Nagai<sup>1</sup>, A. Yoshida<sup>1</sup>, R. Salgia<sup>2</sup>, M. Abouljoud<sup>1</sup>, D. Moonka<sup>2</sup>, <sup>1</sup>*Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI*, <sup>2</sup>*Gastroenterology, Henry Ford Hospital, Detroit, MI*

**D132 Assessing the Effectiveness of Early Maintenance Immunosuppression Practices in Liver Transplantation**

T. Bittermann, R. Hubbard, J. Lewis, D. Goldberg, *University of Pennsylvania, Philadelphia, PA*

**D133 Natural Course Of Tacrolimus Intra-patient Variability In Liver Transplant Recipients**

N. Wilson, S. Tremblay, N. S. Ejaz, K. Zheng, J. Garrett, S. A. Shah, R. R. Alloway, T. E. Kaiser, *University of Cincinnati, Cincinnati, OH*

**D134 Karnofsky Performance Score as a Predictor of Acute Cellular Rejection Post Liver Transplantation**

N. Kapila<sup>1</sup>, K. Al Khalloufi<sup>2</sup>, F. Salomon<sup>3</sup>, K. Kapila<sup>4</sup>, A. Gupta<sup>3</sup>, X. B. Zervos<sup>2</sup>, <sup>1</sup>*Gastroenterology and Hepatology, Cleveland Clinic Florida, Weston, FL*, <sup>2</sup>*Transplant, Cleveland Clinic Florida, Weston, FL*, <sup>3</sup>*Internal Medicine, Cleveland Clinic Florida, Weston, FL*, <sup>4</sup>*Internal Medicine, University of Miami/JFK Medical Center, Atlantis, FL*

**D135 Discovery and Validation of Blood Genomic Signatures of Acute Rejection in Liver Transplant Recipients**

J. Levitsky<sup>1</sup>, N. Bridges<sup>2</sup>, J. Odum<sup>2</sup>, M. Brown<sup>2</sup>, D. Ikle<sup>3</sup>, B. Armstrong<sup>3</sup>, A. Demetris<sup>4</sup>, S. Asrani<sup>5</sup>, G. Klintmalm<sup>5</sup>, T. Schiano<sup>6</sup>, A. Moss<sup>7</sup>, K. Chavin<sup>8</sup>, C. Miller<sup>9</sup>, M. Kandpal<sup>10</sup>, L. Zhao<sup>10</sup>, S. Kurian<sup>11</sup>, M. Abecassis<sup>10</sup>, <sup>1</sup>*Div of Gastroenterology & Comprehensive Tx Cnt, Chicago, IL*, <sup>2</sup>*NIAID, Bethesda, MD*, <sup>3</sup>*Rho, Chapel Hill, NC*, <sup>4</sup>*UPMC, Pittsburgh, PA*, <sup>5</sup>*Baylor, Dallas, TX*, <sup>6</sup>*Mount Sinai, New York, NY*, <sup>7</sup>*Mayo Arizona, Phoenix, AZ*, <sup>8</sup>*Case Western, Cleveland, OH*, <sup>9</sup>*Cleveland Clinic, Cleveland, OH*, <sup>10</sup>*Comprehensive Transplant Center, Chicago, IL*, <sup>11</sup>*Scripps, San Diego, CA*

**D136 Induction Immunosuppression Practices in Liver Transplantation are Variable and Predict Post-Transplant Survival**

T. Bittermann<sup>1</sup>, R. Hubbard<sup>2</sup>, J. Lewis<sup>1</sup>, D. Goldberg<sup>1</sup>, <sup>1</sup>*Gastroenterology, University of Pennsylvania, Philadelphia, PA*, <sup>2</sup>*University of Pennsylvania, Philadelphia, PA*

- D137 Leukopenia at the Time of Liver Transplantation: Medication Tolerance and Clinical Outcomes**  
E. Tiao<sup>1</sup>, J. Casale<sup>1</sup>, J. LaMattina<sup>2</sup>, S. Hammad<sup>1</sup>, <sup>1</sup>Pharmacy, University of Maryland Medical Center, Baltimore, MD, <sup>2</sup>Surgery, University of Maryland School of Medicine, Baltimore, MD
- D138 Early Everolimus Conversion For Renal Protection In Liver Transplantation: The Sooner The Better?**  
M. Tomieczkovicz, N. Sulejmani, A. Jantz, B. Summers, T. Larson, R. Salgia, *Henry Ford Health System, Detroit, MI*
- D139 Immunologic Outcomes In Recipients Of Orthotopic Liver Transplant Induced Only With Steroids**  
S. N. Merwat, A. T. Chatila, M. Bilal, R. Kulkarni, H. L. Stevenson, J. H. Fair, S. K. Merwat, T. Kozlowski, M. A. Mujtaba, *The University of Texas Medical Branch, Galveston, TX*

**Poster Session D: Lymphocyte Biology: Signaling, Co-Stimulation, Regulation**

- D140 Anti-CD272 Antibody (6B2) Induced Indefinite Survival of Fully MHC-Mismatched Murine Cardiac Allograft**  
E. Yin, M. Uchiyama, Y. Yamamoto, M. Niimi, *Teikyo University, Tokyo, Japan*
- D141 Gene Expression Profiles in CD8+ T Cells in Chronic Antibody-Mediated Rejection (CAMR) of Kidney Transplantation**  
P. Pontrelli<sup>1</sup>, F. Rascio<sup>2</sup>, M. Accetturo<sup>1</sup>, G. Castellano<sup>1</sup>, S. Simone<sup>1</sup>, G. Stallone<sup>2</sup>, L. Gesualdo<sup>1</sup>, G. Grandaliano<sup>2</sup>, <sup>1</sup>Department of Emergency, and Organ Transplantation, Nephrology, Dialysis and Transplantation Unit, University of Bari, Bari, Italy, <sup>2</sup>Dept. of Surgical and Medical Sciences, Nephrology Unit, University of Foggia, Foggia, Italy

- D142 Sphingosine 1-Phosphate Receptors and CCR7 Sequentially Coordinate T Cell Migration**  
Y. Xiong<sup>1</sup>, W. Piao<sup>1</sup>, C. Brinkman<sup>1</sup>, J. Kulinski<sup>2</sup>, A. Olivera<sup>2</sup>, A. Cartier<sup>3</sup>, T. Hla<sup>4</sup>, K. Hippen<sup>5</sup>, B. Blazar<sup>5</sup>, S. Schwab<sup>6</sup>, J. Bromberg<sup>1</sup>, <sup>1</sup>Surgery, UMB, Baltimore, MD, <sup>2</sup>NIH, Bethesda, MD, <sup>3</sup>Boston Children's hospital, Boston, MA, <sup>4</sup>Boston Children's hospital, Boston, MD, <sup>5</sup>U.Minnesota, Minneapolis, MN, <sup>6</sup>NYU, NY, NY

- D143 Thymoglobulin Induction with Tacrolimus and Everolimus Maintenance Therapy in Elderly Kidney Transplantation Results in Prolonged Lymphocyte Depletion and Do Not Favor Regulatory Profile**  
E. David-Neto<sup>1</sup>, G. Ramos de Freitas<sup>1</sup>, M. Fernandes<sup>1</sup>, F. Agena<sup>1</sup>, F. Brambate Carvalhinho Lemos<sup>1</sup>, F. Jota de Paula<sup>1</sup>, V. Coelho<sup>2</sup>, N. Zocoler Galante<sup>1</sup>, <sup>1</sup>Renal Transplantation Service, Hospital das Clínicas - University of São Paulo School of Medicine, Sao Paulo, Brazil, <sup>2</sup>Laboratory of Immunology – LIM 19, Heart Institute - University of São Paulo School of Medicine, Sao Paulo, Brazil

- D144 Inhibition of Th1 and Th17 Cell Differentiation and Prolonged Graft Survival through NFAT Pathway Downregulation**  
C. Dai<sup>1</sup>, R. Tan<sup>1</sup>, B. Yang<sup>1</sup>, J. Markmann<sup>2</sup>, D. Chen<sup>1</sup>, L. Wei<sup>1</sup>, Z. Chen<sup>1</sup>, <sup>1</sup>Institute of Organ Transplantation, Wuhan, China, <sup>2</sup>Division of Transplantation, Boston, American Samoa

- D145 Examination of a Novel Immunoregulatory Marker in Kidney and Lung Transplant Recipients**  
A. D. Desai<sup>1</sup>, G. J. Kavalam<sup>2</sup>, A. Chandraker<sup>2</sup>, S. Tripathi<sup>2</sup>, <sup>1</sup>Harvard Summer Research Program for Kidney Medicine, Harvard Medical School,, Boston, MA, <sup>2</sup>Schuster Family Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

- D146** **Peripheral Blood Regulatory T Cells In The Folow In The Kidney-transplant Patients**  
M. A. Carmona-Escamilla<sup>1</sup>, G. Queipo<sup>2</sup>, L. A. Garcia-Mosqueda<sup>3</sup>, R. Lascurain<sup>4</sup>,  
<sup>1</sup>Nephrology, Pemex, CDMX, Mexico, <sup>2</sup>Genetics, Hospital General, CDMX, Mexico, <sup>3</sup>UNAM, CDMX, Mexico, <sup>4</sup>Inmunologia, UNAM, CDMX, Mexico
- D147** **A Mouse Model of Vascularized Heterotopic Spleen Transplantation for Studying Lymphocyte Biology and Transplant Immunity**  
L. Qiu<sup>1</sup>, J. Wang<sup>2</sup>, R. Fernandez<sup>3</sup>, X. Yeap<sup>1</sup>, S. Han<sup>1</sup>, F. Zheng<sup>1</sup>, C. Lin<sup>2</sup>, Z. J. Zhang<sup>1</sup>, <sup>1</sup>Comprehensive Transplant Center, Department of Surgery, Northwestern University, Chicago, IL, <sup>2</sup>Northwestern University, Chicago, IL, <sup>3</sup>Department of Surgery, Northwestern University, Chicago, IL
- D148** **Treg Lymphotoxin and Lymphatic Endothelial Cell Lymphotoxin Receptor Interactions Are Required for Treg Stability and Allograft Protection**  
V. Saxena, W. Piao, L. Li, C. M. Paluskievicz, Y. Xiong, T. Simon, J. S. Bromberg, U Maryland, Baltimore, MD
- D149** **Phenotypic and Functional Analysis of Non-Activated and Allo-Activated Eomesodermin+ CD8+ T Cells in Humans and Nonhuman Primates**  
A. Perez Gutierrez<sup>1</sup>, A. W. Thomson<sup>2</sup>, D. M. Metes<sup>2</sup>, M. B. Ezzelarab<sup>2</sup>,  
<sup>1</sup>Transplantation Institute, University of Chicago Medicine, Chicago, IL, <sup>2</sup>Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA
- D150 †** **CD4 T Cell is Essential in an Innate-Immune Driven Ischemia-Reperfusion Injury in Mouse and Human**  
S. Kageyama<sup>1</sup>, K. Kadono<sup>1</sup>, H. Hirao<sup>1</sup>, K. Nakamura<sup>1</sup>, T. Ito<sup>2</sup>, K. J. Dery<sup>1</sup>, D. Oncel<sup>1</sup>, R. A. Sosa<sup>3</sup>, E. F. Reed<sup>3</sup>, F. M. Kaldas<sup>2</sup>, R. W. Busuttil<sup>2</sup>, J. W. Kupiec-Weglinski<sup>1</sup>, Y. Zhai<sup>1</sup>, <sup>1</sup>Surgery, Dumont-UCLA Transplant Center, Los Angeles, CA, <sup>2</sup>Surgery, Ronald Reagan UCLA Medical Center, Los Angeles, CA, <sup>3</sup>Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA
- D151 †** **A Regulatory T Cell-Intrinsic Role for Ikaros in Acquired Transplant Tolerance**  
R. M. Thomas, L. Wang, W. W. Hancock, A. D. Wells, The Children's Hospital of Philadelphia, Philadelphia, PA
- D152 †** **Rcor1 and Regulation of Foxp3+ T-Regulatory Cells In Vitro and In Vivo**  
Y. Xiong, L. Wang, R. Han, W. W. Hancock, Children's Hospital of Philadelphia, Philadelphia, PA
- D153** **Cd45rb Mediates Cd8+T Cell Persistence In An Allogeneic Heterologous Immune Response**  
S. M. Krummey, A. B. Morris, M. L. Ford, Emory Transplant Center, Atlanta, GA
- D154** **Evaluating Allo-Specific CD57+ T Cells during Memory and Proliferative Responses**  
A. Lucander, H. Xu, A. Kirk, Department of Surgery, Duke University, Durham, NC
- D155** **High-Throughput Immune Synapse Detection as a Tool for the Measurement of T Cell Alloreactivity**  
S. Moshkelgosh, S. C. Juvet, UHN, Toronto, ON, Canada
- D156** **IL-10+ Plasma Cells Are Not Required for Breg Activity and Are Counterbalanced by Novel Pro-Inflammatory Plasma Cells**  
Q. Ding, Y. Zhou, Z. Song, L. Zeng, D. Rothstein, University of Pittsburgh, Pittsburgh, PA
- D157** **EBV+ PTLD Cell Lines Secrete Exosomes Containing microRNAs That Alter Immune Responses**  
S. Syed, E. Maloney, A. Hui, O. Martinez, S. Krams, Stanford Univ School of Med, Stanford, CA
- D158** **IFNAR Signaling Augments Plasmacytoid Dendritic Cell Activation during Costimulation Independent Rejection**  
J. Habib, D. Mathews, Y. Dong, A. Stephenson, A. Ghosh, C. Breeden, A. Adams, Surgery, Emory University, Atlanta, GA

- D159 S1PR1 and S1PR4 Regulate T Cell Migration into Afferent Lymphatics**  
Y. Xiong<sup>1</sup>, W. Piao<sup>1</sup>, C. Brinkman<sup>1</sup>, L. Li<sup>1</sup>, J. Kulinski<sup>2</sup>, A. Olivera<sup>2</sup>, A. Cartier<sup>3</sup>, T. Hla<sup>4</sup>, K. Hippen<sup>5</sup>, B. Blazar<sup>6</sup>, S. Schwab<sup>7</sup>, J. Bromberg<sup>1</sup>, <sup>1</sup>*Surgery, UMB, Baltimore, MD*, <sup>2</sup>*NIH, Bethesda, MD*, <sup>3</sup>*Boston Children's hospital, Boston, MA*, <sup>4</sup>*Boston Children's, Boston, MA*, <sup>5</sup>*U.Minnesota, Minneapolis, MN*, <sup>6</sup>*U.Minnesota, Minneapolis, MD*, <sup>7</sup>*NYU, NY, NY*
- D160 Laminin Dependent T Cell Migration Determines Allograft Survival**  
L. Li, M. Shirkey, W. Piao, Y. Xiong, V. Saxena, T. Zhang, B. M. Cerel, C. Paluskievicz, J. S. Bromberg, *Surgery, U. Maryland, Baltimore, Baltimore, MD*
- D161 Novel Role of Qa-1-Restricted Immunoregulation in Murine Cardiac Transplantation**  
J. Y. Choi<sup>1</sup>, S. K. Eskandari<sup>1</sup>, J. Assaker<sup>1</sup>, I. Sulkaj<sup>1</sup>, S. Cai<sup>1</sup>, H. Allos<sup>1</sup>, M. Uehara<sup>1</sup>, M. Mohammad<sup>1</sup>, B. S. Al Dulaijan<sup>1</sup>, A. Bano<sup>1</sup>, E. Al Huassain<sup>1</sup>, H. I. Cantor<sup>2</sup>, J. R. Azzi<sup>1</sup>, <sup>1</sup>*Medicine, Brigham and Women's Hospital, Boston, MA*, <sup>2</sup>*Dana-Farbar Cancer Institute, Boston, MA*
- D162 In Vivo Treg Expansion under Costimulation Blockade Targets Early Rejection and Improves Long-Term Outcome**  
C. Schwarz<sup>1</sup>, B. Mahr<sup>2</sup>, L. Unger<sup>1</sup>, N. Pilat<sup>2</sup>, H. Regele<sup>3</sup>, T. Wekerle<sup>2</sup>, <sup>1</sup>*Dept. of Surg. / Div. of Transplantation, Medical University Vienna, Vienna, Austria*, <sup>2</sup>*Dept. of Surg. / Section of Transplantation Immunology, Medical University Vienna, Vienna, Austria*, <sup>3</sup>*Clinical Institute of Pathology, Medical University Vienna, Vienna, Austria*
- D163 The Adapter Protein TSAd Regulates Mitochondrial Lck Activity and is Potent to Enhance Immunoregulation Following Transplantation**  
J. Wedel<sup>1</sup>, M. P. Stack<sup>1</sup>, T. Seto<sup>1</sup>, K. Liu<sup>1</sup>, I. E. Stillman<sup>2</sup>, D. M. Briscoe<sup>1</sup>, <sup>1</sup>*Transplant Research Program, Boston Children's Hospital, Harvard Medical School, Boston, MA*, <sup>2</sup>*Department of Pathology, Beth Israel Deaconess Center, Harvard Medical School, Boston, MA*
- D164 Novel In Vitro Germinal Center Culture System Demonstrates More Aggressive B Cell to Plasma Blast Differentiation in Allosensitized Nonhuman Primates**  
P. Schroder, J. Yoon, R. Schmitz, Z. Fitch, J. Kwun, S. J. Knechtle, *Department of Surgery, Duke University Medical Center, Durham, NC*
- D165 The Immunomodulatory Role of Type I Interferons in Alloimmunity**  
I. Sulkaj, H. Allos, S. K. Eskandari, J. M. Safadi, J. Y. Choi, B. S. Al Dulaijan, E. Al-Hussain, S. Cai, J. R. Azzi, *Medicine, Brigham and Women's Hospital, Boston, MA*
- D166 Prolonged Cold Ischemic Storage Induces Allograft Necro-Inflammation That Increases Graft Susceptibility to T Cell Mediated Rejection**  
N. Chun<sup>1</sup>, R. Ang<sup>1</sup>, J. Horwitz<sup>1</sup>, R. Fairchild<sup>2</sup>, W. Baldwin III<sup>2</sup>, A. Ting<sup>1</sup>, P. S. Heeger<sup>1</sup>, <sup>1</sup>*Icahn School of Medicine at Mount Sinai, New York, NY*, <sup>2</sup>*Cleveland Clinic, Cleveland, OH*
- D167 Early T Cell Infiltration is Modulated by PD-1/PD-L1 Interactions in Kidney Graft**  
Y. Shim, R. Fan, N. Dvorina, W. Baldwin, *Inflammation and Immunity, Lerner Research Institute, Cleveland, OH*
- Poster Session D: Non-Organ Specific: Disparities to Outcome and Access to Healthcare**
- D168 The Role of Non-Traditional Environmental Factors in Long-Term Outcomes of Liver Transplantation**  
J. Buggs<sup>1</sup>, D. Patino<sup>2</sup>, B. Evans<sup>1</sup>, C. Anderson<sup>1</sup>, C. Delfavero<sup>1</sup>, E. Rogers<sup>1</sup>, A. Alsina<sup>1</sup>, A. Kumar<sup>3</sup>, <sup>1</sup>*Tampa General Hospital, Tampa, FL*, <sup>2</sup>*University of Tampa, Tampa, FL*, <sup>3</sup>*University of South Florida, Tampa, FL*



- D169 A Video Intervention to Increase Organ Donor Registration (ODR) at the Department of Motorized Vehicles (DMV)**  
D. A. DuBay<sup>1</sup>, T. Morinelli<sup>1</sup>, D. Redden<sup>2</sup>, N. Ivankova<sup>2</sup>, I. Herbey<sup>3</sup>, C. L. Holt<sup>4</sup>, L. Siminoff<sup>5</sup>, M. Fouad<sup>2</sup>, Z. Su<sup>6</sup>, M. Martin<sup>7</sup>,  
<sup>1</sup>Surgery, Medical University of South Carolina, Charleston, SC, <sup>2</sup>University of Alabama at Birmingham, Birmingham, AL, <sup>3</sup>Surgery, University of Alabama at Birmingham, Birmingham, AL, <sup>4</sup>University of Maryland, College Park, MD, <sup>5</sup>Temple University, Philadelphia, PA, <sup>6</sup>Medical University of South Carolina, Charleston, SC, <sup>7</sup>University of Tennessee Health Sciences Center, Memphis, TN
- D170 Kidney Transplant Outcomes in Recipients with Physical Impairments**  
A. G. Thomas<sup>1</sup>, J. Ruck<sup>2</sup>, N. Chu<sup>2</sup>, D. Agoons<sup>2</sup>, A. Shaffer<sup>2</sup>, C. Haugen<sup>2</sup>, H. Ying<sup>2</sup>, B. Swenor<sup>2</sup>, S. Norman<sup>3</sup>, J. Garonzik-Wang<sup>2</sup>, D. Segev<sup>2</sup>, M. McAdams-DeMarco<sup>2</sup>, <sup>1</sup>Epidemiology, UNC Chapel Hill, Chapel Hill, NC, <sup>2</sup>Johns Hopkins University, Baltimore, MD, <sup>3</sup>University of Michigan, Ann Arbor, MI
- D171 BK Virus Infection Disparity between Black and Other Races; Do Not Blame the Mycophenolic Acid**  
N. Raj<sup>1</sup>, R. Spong<sup>1</sup>, S. Jackson<sup>2</sup>, V. Vakil<sup>1</sup>, D. Keys<sup>1</sup>, E. Finger<sup>3</sup>, S. Riad<sup>1</sup>, <sup>1</sup>Medicine, University of Minnesota, Minneapolis, MN, <sup>2</sup>Complex Care Analytics, Fairview Health Services, Minneapolis, MN, <sup>3</sup>Surgery, University of Minnesota, Minneapolis, MN
- D172 The C-Statistic Provides No Information on the Accuracy of Program Evaluations or the Presence of Unmeasured Confounders**  
A. Wey, N. Salkowski, B. Kasiske, M. Skeans, S. Gustafson, A. Israni, J. Snyder, SRTR, Minneapolis, MN
- D173 Modeling Multiple Registrations and the Impact at the National and Regional Scale**  
C. Harvey, R. Weigel, Computational Science and Informatics, George Mason University, Fairfax, VA
- D174 Waitlisted for Lung Transplant and the Role of Patient Travel Distance: A National Cohort Study**  
W. Tsuang, S. Arrigain, R. Lopez, M. Snair, K. McCurry, M. Budev, J. Schold, Cleveland Clinic, Cleveland, OH
- D175 Opioid Use Policies and Practices in Liver Transplant and Lung Transplant Candidates: A Comparison of National Surveys**  
H. Bruschwein<sup>1</sup>, V. Andersen<sup>1</sup>, H. Patel<sup>2</sup>, S. S. Rogal<sup>3</sup>, J. N. Fleming<sup>4</sup>, <sup>1</sup>University of Virginia, Charlottesville, VA, <sup>2</sup>University of North Carolina, Chapel Hill, NC, <sup>3</sup>University of Pittsburgh, Pittsburgh, PA, <sup>4</sup>Medical University of South Carolina, Charleston, SC
- D176 Access to Deceased Donor Liver Transplant for Candidates in Hawaii and Puerto Rico**  
A. M. Robinson<sup>1</sup>, I. K. Kim<sup>2</sup>, A. K. Mathur<sup>3</sup>, S. E. Rosas<sup>4</sup>, <sup>1</sup>United Network for Organ Sharing, Richmond, VA, <sup>2</sup>Cedars-Sinai Medical Center, Los Angeles, CA, <sup>3</sup>Mayo Clinic Arizona, Phoenix, AZ, <sup>4</sup>Joslin Diabetes Center, Harvard Medical School, Boston, MA
- D177 Racial and Ethnic Differences in Physician Trust and Hypertension Treatment Adherence among Living Kidney Donors in the United States**  
J. S. Wilson Jr<sup>1</sup>, L. Cooper<sup>2</sup>, M. Johnson<sup>2</sup>, M. Waldram<sup>2</sup>, Y. Yu<sup>2</sup>, J. Perkins<sup>2</sup>, D. Crews<sup>2</sup>, N. Lacy<sup>3</sup>, M. Henderson<sup>2</sup>, A. Massie<sup>2</sup>, K. Lentine<sup>4</sup>, D. Segev<sup>2</sup>, T. Purnell<sup>2</sup>, <sup>1</sup>Williams College, Williamstown, MA, <sup>2</sup>Johns Hopkins University, Baltimore, MD, <sup>3</sup>North Carolina State University, Raleigh, NC, <sup>4</sup>St. Louis University, St. Louis, MO
- D178 † Patterns of Emergency Department (ED) Utilization between Transplant and Non-Transplant Centers and Impact on Clinical Outcomes in Kidney Recipients**  
H. Perkins, N. Patel, V. Rohan, Z. Su, D. DuBay, J. McGillicuddy, D. Taber, MUSC, Charleston, SC



- D179**      **Timing Matters: Improving Prediction of Hospital Readmission Post Kidney Transplantation**  
J. Hogan<sup>1</sup>, M. Arenson<sup>1</sup>, S. Adhikary<sup>2</sup>, K. Li<sup>1</sup>, X. Zhang<sup>1</sup>, R. Zhang<sup>1</sup>, J. Valdez<sup>3</sup>, J. Sun<sup>3</sup>, A. B. Adams<sup>1</sup>, R. E. Patzer<sup>1</sup>,  
<sup>1</sup>*Transplant Research Center, Department of Surgery, Emory University, Atlanta, GA*,  
<sup>2</sup>*Transplant Research Center, Department of Surgery, Georgia Technology Institute, Atlanta, GA*,  
<sup>3</sup>*Georgia Technology Institute, Atlanta, GA*
- D180**      **The Association of Health Literacy with Physical and Mental Health-Related Quality of Life in Organ Transplant Candidates**  
K. Chapin<sup>1</sup>, S. Rega<sup>1</sup>, L. Dageforde<sup>2</sup>, D. Moore<sup>1</sup>, M. Via<sup>1</sup>, I. D. Feurer<sup>1</sup>,  
<sup>1</sup>*Vanderbilt Transplant Center, Vanderbilt University Medical Center, Nashville, TN*,  
<sup>2</sup>*Transplant Surgery, Massachusetts General Hospital, Boston, MA*
- D181**      **Developing a Patient Specific Search: Feedback from Kidney Transplant Candidates and Recipients**  
W. T. McKinney<sup>1</sup>, M. J. Bruin<sup>2</sup>, C. R. Schaffhausen<sup>1</sup>, S. Chu<sup>2</sup>, J. Snyder<sup>3</sup>, A. Matas<sup>4</sup>, B. Kasiske<sup>5</sup>, A. K. Israni<sup>1</sup>,  
<sup>1</sup>*Nephrology, Hennepin Healthcare Research Institute, Minneapolis, MN*,  
<sup>2</sup>*College of Design, University of Minnesota, St. Paul, MN*,  
<sup>3</sup>*Scientific Registry of Transplant Recipients, Hennepin Healthcare Research Institute, Minneapolis, MN*,  
<sup>4</sup>*Department of Surgery, University of Minnesota, Minneapolis, MN*,  
<sup>5</sup>*Department of Medicine, Hennepin Healthcare, Minneapolis, MN*
- D182**      **Variations in Recipient and Donor Clinical Characteristics between Kidney Transplant Centers**  
W. T. McKinney<sup>1</sup>, M. Bruin<sup>2</sup>, S. Chu<sup>2</sup>, D. Schladt<sup>3</sup>, J. Snyder<sup>3</sup>, A. Matas<sup>4</sup>, B. Kasiske<sup>5</sup>, A. K. Israni<sup>3</sup>,  
<sup>1</sup>*Nephrology, Hennepin Healthcare Research Institute, Minneapolis, MN*,  
<sup>2</sup>*College of Design, University of Minnesota, St. Paul, MN*,  
<sup>3</sup>*Scientific Registry of Transplant Recipients, Hennepin Healthcare Research Institute, Minneapolis, MN*,  
<sup>4</sup>*Department of Surgery, University of Minnesota, Minneapolis, MN*,  
<sup>5</sup>*Department of Medicine, Hennepin Healthcare, Minneapolis, MN*
- D183**      **Excellent Outcomes in Liver Transplantation under Charity Care: An Opportunity to Mitigate Socio-Economic Disparities in Access to Transplantation**  
F. Paterno<sup>1</sup>, J. Rosado<sup>1</sup>, R. Olivo<sup>2</sup>, S. Gavzy<sup>1</sup>, L. Brown<sup>1</sup>, D. Wilson<sup>1</sup>, B. Koneru<sup>1</sup>, N. Pysopoulos<sup>2</sup>, J. V. Guarrera<sup>1</sup>,  
<sup>1</sup>*Department of Surgery, Division of Transplant and Hepatobiliary Surgery, Rutgers New Jersey Medical School, Newark, NJ*,  
<sup>2</sup>*Department of Medicine, Division of Hepatology, Rutgers New Jersey Medical School, Newark, NJ*
- D184**      **The Impact of Race on Metabolic, Graft and Patient Outcomes after Pancreatic Transplantation**  
V. S. Rohan, S. N. Nadig, J. McGillicuddy, V. Rao, D. Dubay, K. Soliman, P. Baliga, D. Taber,  
*Transplant Surgery, Medical University of South Carolina, Charleston, SC*
- D185**      **Insurance Status Impacts Treatment for Hepatocellular Carcinoma**  
L. Sobotka<sup>1</sup>, A. Hinton<sup>2</sup>, L. Conteh<sup>1</sup>,  
<sup>1</sup>*Gastroenterology, Hepatology and Nutrition, The Ohio State Wexner Medical Center, Columbus, OH*,  
<sup>2</sup>*The Ohio State University, Columbus, OH*
- D186**      **Gait Speed Predicts Kidney Transplant Candidate Mortality**  
M. N. Harhay<sup>1</sup>, K. Ranganna<sup>1</sup>, L. B. Levin Mizrahi<sup>1</sup>, G. Xiao<sup>2</sup>, G. Malat<sup>2</sup>, S. Guy<sup>2</sup>, D. Reich<sup>2</sup>, P. P. Reese<sup>3</sup>,  
<sup>1</sup>*Medicine, Drexel University College of Medicine, Philadelphia, PA*,  
<sup>2</sup>*Surgery, Drexel University College of Medicine, Philadelphia, PA*,  
<sup>3</sup>*Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA*
- D187**      **Barriers to Kidney Transplant Wait Listing among HIV Positive Patients with Advanced Kidney Disease**  
S. M. Boyle<sup>1</sup>, K. Fehr<sup>1</sup>, C. Deering<sup>2</sup>, A. Raza<sup>1</sup>, M. Harhay<sup>1</sup>, G. Malat<sup>3</sup>, K. Ranganna<sup>1</sup>, D. Lee<sup>1</sup>,  
<sup>1</sup>*Drexel University, Philadelphia, PA*,  
<sup>2</sup>*University of Toledo, Toledo, OH*,  
<sup>3</sup>*Hahnemann University Hospital, Philadelphia, PA*

- D188**      **Lack of Linguistically and Culturally Tailored Initiatives in Kidney Transplant Programs in the United States**  
S. Carbanaru<sup>1</sup>, A. Ortiz<sup>2</sup>, C. Ortiz<sup>3</sup>, J. Ortiz<sup>3</sup>, J. Locke<sup>4</sup>, J. Caicedo<sup>1</sup>,  
<sup>1</sup>Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, <sup>2</sup>University of California, Los Angeles, Los Angeles, CA, <sup>3</sup>Department of Surgery, University of Toledo College of Medicine & Life Sciences, Toledo, OH, <sup>4</sup>University of Alabama at Birmingham, Birmingham, AL
- D189 †**    **Kidney Transplantation after Sleeve Gastrectomy in the Morbidly Obese Candidate: Results of a Five-Year Experience**  
Y. Kim, A. J. Bailey, M. C. Morris, J. Hlavaty, M. C. Cuffy, E. S. Woodle, S. A. Shah, T. S. Diwan, *Department of Surgery, University of Cincinnati, Cincinnati, OH*
- D190**      **Does Ethnicity Impact Elderly Kidney Transplant Recipient Outcomes?**  
 I. Bajjoka, A. Yaldo, S. Serra, S. Foley, C. Crombez, M. Abouljoud, *Henry Ford Transplant Institute, Detroit, MI*
- D191**      **Limited Accessibility of Kidney Transplantation in Rural Residents: A Nationwide Data of South Korea**  
J. Kim<sup>1</sup>, K. Park<sup>1</sup>, S. Park<sup>1</sup>, M. Yu<sup>2</sup>, Y. Kim<sup>1</sup>, J. Jeong<sup>1</sup>, K. Kim<sup>1</sup>, M. Park<sup>3</sup>, H. Lee<sup>1</sup>, <sup>1</sup>Seoul National University Hospital, Seoul, Korea, Republic of, <sup>2</sup>Hanyang University Guri Hospital, Gyeonggi-do, Korea, Republic of, <sup>3</sup>Samsung Medical Center, Seoul, Korea, Republic of
- D192**      **Impact Of Transplant Center And Regional Characteristics On Racial Disparities On Readmission After Kidney Transplantation**  
J. Hogan<sup>1</sup>, K. Li<sup>1</sup>, R. Zhang<sup>1</sup>, J. Sun<sup>2</sup>, A. B. Adams<sup>1</sup>, R. E. Patzer<sup>1</sup>, <sup>1</sup>Transplant Research Center, Department of Surgery, Emory University, ATLANTA, GA, <sup>2</sup>College of Computing, Georgia Technology Institute, ATLANTA, GA

## Poster Session D: Non-Organ Specific: Economics & Ethics

---

- D193**      **Forensic Transplant Psychiatry: Ethical Issues and the Unique Assessment Needs of Candidates with Forensic Psychiatric Problems**  
D. Banayan, S. Gershan, *Rush University Medical Center, Chicago, IL*
- D194**      **The Changing Paradigm of Ethics in Uterus Transplantation: A Systematic Review**  
L. M. Ngaage<sup>1</sup>, S. Ike<sup>2</sup>, A. Elegbede<sup>3</sup>, S. Gebran<sup>4</sup>, C. J. Vercler<sup>5</sup>, F. Liang<sup>4</sup>, E. M. Rada<sup>1</sup>, C. Cooney<sup>3</sup>, R. J. Redett<sup>3</sup>, Y. M. Rasko<sup>1</sup>, <sup>1</sup>Division of Plastic Surgery, University of Maryland Medical Center, Baltimore, MD, <sup>2</sup>London North West University Healthcare Trust, London, United Kingdom, <sup>3</sup>Department of Plastic & Reconstructive Surgery, Johns Hopkins Hospital / University of Maryland Medical Center, Baltimore, MD, <sup>4</sup>Division of Plastic & Reconstructive Surgery, R Adams Cowley Shock Trauma Center, Baltimore, MD, <sup>5</sup>Plastic Surgery Section, University of Michigan, Ann Arbor, MI
- D195**      **Barriers to Listing for Kidney Transplantation in LMICs: A Single Center Retrospective Cohort Study in Brazil**  
Y. Yu<sup>1</sup>, G. Ferreira<sup>2</sup>, A. Saha<sup>1</sup>, M. Henderson<sup>1</sup>, D. Segev<sup>1</sup>, J. Bastos<sup>2</sup>, V. Colares<sup>2</sup>, A. Massie<sup>1</sup>, <sup>1</sup>Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD, <sup>2</sup>Santa Casa de Misericordia de Juiz de Fora, Juiz de Fora, Brazil
- D196**      **Economic Evaluation of Kidney Transplantation in the Elderly Stratified by Donor Quality**  
M. Kadatz<sup>1</sup>, S. Klarenbach<sup>2</sup>, J. S. Gill<sup>1</sup>, J. Gill<sup>1</sup>, <sup>1</sup>Nephrology, University of British Columbia, Vancouver, BC, Canada, <sup>2</sup>Nephrology, University of Alberta, Edmonton, AB, Canada
- D197**      **Costs In Contemporary Transplant Practice**  
M. Wyld, T. Ying, K. Wyburn, S. Chadban, *Renal Department, Royal Prince Alfred Hospital, Camperdown, Australia*

- D198**     **How Much Does Graft Function Cost Us? A Financial Analysis of Delayed Graft Function in Kidney Transplant Recipients**  
A. Yaldo, I. Bajjoka, C. Crombez, M. Abouljoud, *Henry Ford Transplant Institute, Detroit, MI*
- D199**     **The Centennial Allograft? Observation Of Greater Than 100-year Allograft Survival Is More Common Among Liver Allograft Recipients Than Renal Allograft Recipients.**  
J. F. Renz, A. C. Gruessner, R. C. Misawa, A. Masi, R. W. Gruessner, *SUNY Downstate Medical Center, Brooklyn, NY*
- D200**     **Cost-Effectiveness Analysis of Renal Replacement Therapy Strategies in Haiti**  
J. S. Pyda<sup>1</sup>, L. James<sup>2</sup>, J. J. Kim<sup>2</sup>, K. Khwaja<sup>1</sup>, M. Shrimel<sup>3</sup>, <sup>1</sup>*Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA*, <sup>2</sup>*Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA*, <sup>3</sup>*Program in Global Surgery and Social Change, Harvard Medical School, Boston, MA*
- D201**     **Healthcare Resource Utilization and Associated Costs of Cytomegalovirus Management among Solid Organ Transplant Recipients**  
W. Y. Cheng<sup>1</sup>, P. Thompson-Leduc<sup>1</sup>, H. Cheung<sup>1</sup>, R. Avery<sup>2</sup>, T. Bo<sup>3</sup>, S. Chavan<sup>3</sup>, M. Duh<sup>1</sup>, I. Hirji<sup>3</sup>, <sup>1</sup>*Analysis Group, Inc., Boston, MA*, <sup>2</sup>*Johns Hopkins University, Baltimore, MD*, <sup>3</sup>*Shire, Cambridge, MA*
- D202 †**    **High Health Care Utilizers in Kidney Transplantation: Do You Know Your Frequent Flyers?**  
E. Weeda<sup>1</sup>, Z. Su<sup>2</sup>, D. Taber<sup>3</sup>, J. Bian<sup>2</sup>, T. A. Morinelli<sup>4</sup>, N. A. Pilch<sup>5</sup>, P. D. Mauldin<sup>2</sup>, D. A. DuBay<sup>4</sup>, <sup>1</sup>*Department of Clinical Pharmacy and Outcomes Sciences, Medical University of South Carolina, Charleston, SC*, <sup>2</sup>*General Internal Medicine and Geriatrics, Medical University of South Carolina, Charleston, SC*, <sup>3</sup>*Surgery and Ralph H. Johnson VAMC, Medical University of South Carolina, Charleston, SC*, <sup>4</sup>*Surgery, Medical University of South Carolina, Charleston, SC*, <sup>5</sup>*Clinical Pharmacy and Outcomes Sciences, Medical University of South Carolina, Charleston, SC*

- D203**     **The Use of Focus Groups to Explore the Public Attitudes on the Use of Imminent Death Donation**  
P. Moolchandani<sup>1</sup>, R. Ackah<sup>2</sup>, L. Washburn<sup>1</sup>, D. O'Connor<sup>1</sup>, E. L. Godfrey<sup>1</sup>, T. Galván<sup>1</sup>, A. Rana<sup>1</sup>, J. A. Goss<sup>1</sup>, <sup>1</sup>*Division Of Abdominal Transplantation, Michael E. DeBakey Department Of Surgery, Baylor College of Medicine, Houston, TX*, <sup>2</sup>*Department of Surgery, Ohio State University, Columbus, OH*
- D204**     **A Financial Analysis of Elderly Kidney Transplant Recipients**  
A. Yaldo, I. Bajjoka, C. Crombez, M. Abouljoud, *Henry Ford Transplant Institute, Detroit, MI*

**Poster Session D: Non-Organ Specific: Pharmacogenomics / Pharmacokinetics**

- D205 †**    **Gut Microbiota May Affect a Variability of Tacrolimus Trough Levels in Kidney Transplant Recipients**  
J. Kim<sup>1</sup>, H. Cho<sup>2</sup>, J. Park<sup>3</sup>, M. Kwak<sup>4</sup>, B. Kim<sup>4</sup>, J. Lee<sup>5</sup>, D. Kim<sup>1</sup>, B. Kim<sup>6</sup>, Y. Kim<sup>1</sup>, H. Lee<sup>1</sup>, <sup>1</sup>*Seoul National University Hospital, Seoul, Korea, Republic of*, <sup>2</sup>*Chungbuk National University Hospital, Cheongju, Korea, Republic of*, <sup>3</sup>*Kangwon National University Hospital, Chuncheon, Korea, Republic of*, <sup>4</sup>*Chunlab Inc., Seoul, Korea, Republic of*, <sup>5</sup>*Seoul National University Boramae Hospital, Seoul, Korea, Republic of*, <sup>6</sup>*Hallym University, Chuncheon, Korea, Republic of*
- D206**     **Time to First Therapeutic Tacrolimus Trough in Kidney Transplant Recipients: A Comparison of a Weight Based versus a Non-Weight Based Dosing Strategy**  
M. Chunduru, K. Schnelle, S. Zhao, L. Wei, R. Daloul, *Ohio State Wexner Medical Center, Columbus, OH*

- D207**      **The Reduced Tacrolimus Metabolism Rate and Its Association with Estimated Glomerular Filtration Rate and Interstitial Fibrosis: A Study Using Korean Organ Transplantation Registry (KOTRY) Dataset**  
 J. Jeong<sup>1</sup>, H. Ro<sup>2</sup>, T. Koo<sup>3</sup>, J. Yang<sup>3</sup>, M. Kim<sup>4</sup>, S. Shin<sup>5</sup>, J. Park<sup>6</sup>, T. Ban<sup>7</sup>, S. Han<sup>8</sup>, T. Kim<sup>9</sup>, C. Ahn<sup>10</sup>, <sup>1</sup>*Ajou University School of Medicine, Suwon, Korea, Republic of*, <sup>2</sup>*Gachon University, Incheon, Korea, Republic of*, <sup>3</sup>*Seoul National University Hospital, Seoul, Korea, Republic of*, <sup>4</sup>*Yonsei University College of Medicine, Seoul, Korea, Republic of*, <sup>5</sup>*Asan Medical Center, Seoul, Korea, Republic of*, <sup>6</sup>*Samsung Medical Center, Seoul, Korea, Republic of*, <sup>7</sup>*Seoul St Mary's Hospital, Seoul, Korea, Republic of*, <sup>8</sup>*Keimyung University School of Medicine, Daegu, Korea, Republic of*, <sup>9</sup>*Inje University, Busan Paik Hospital, Busan, Korea, Republic of*, <sup>10</sup>*Seoul National University College of Medicine, Seoul, Korea, Republic of*
- D208**      **mTOR Inhibitors Associated with Higher Cardiovascular Adverse Events - A Large Population Database Analysis**  
 V. N. Nguyen<sup>1</sup>, R. Abagyan<sup>2</sup>, S. Tsunoda<sup>2</sup>, <sup>1</sup>*Pharmacy, UC San Diego Health, San Diego, CA*, <sup>2</sup>*Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA*
- D209**      **Impact of Everolimus Therapy on HIV Persistence and Gene Expression in Transplant Patients**  
 A. Zarinsefat<sup>1</sup>, C. Schreiner<sup>1</sup>, C. Cameron<sup>2</sup>, S. Chu<sup>1</sup>, M. P. Busch<sup>1</sup>, T. Liegler<sup>1</sup>, S. G. Deeks<sup>1</sup>, T. J. Henrich<sup>1</sup>, P. G. Stock<sup>1</sup>, <sup>1</sup>*UC San Francisco, San Francisco, CA*, <sup>2</sup>*Case Western Reserve University, Cleveland, OH*
- D210**      **Evaluation of Mycophenolate Mofetil Exposure in Renal Transplant Recipients**  
 M. C. Ott<sup>1</sup>, S. Mietz<sup>2</sup>, S. Chang<sup>3</sup>, <sup>1</sup>*Department of Pharmaceutical Services, Erie County Medical Center, Buffalo, NY*, <sup>2</sup>*Department of Pharmacy, Indiana University Health, Indianapolis, IN*, <sup>3</sup>*Department of Medicine, Jacobs School of Medicine & Biomedical Sciences, Buffalo, NY*
- D211**      **Safety and Efficacy of Anti Xa Inhibitors Post-Transplant with Concomitant Calcineurin Inhibitors**  
 K. A. McMurry<sup>1</sup>, J. Shuster<sup>2</sup>, K. Bain<sup>2</sup>, T. Horwedel<sup>3</sup>, J. Hartupée<sup>2</sup>, <sup>1</sup>*Michigan Medicine, Ann Arbor, MI*, <sup>2</sup>*Barnes-Jewish Hospital, St. Louis, MO*, <sup>3</sup>*Veloxis Pharmaceuticals, Cary, NC*
- D212 †**      **Apixaban Therapy Is Safe And Effective In Most Organ Transplant Populations**  
 A. Brown, S. Palkimas, W. Ally, *University of Virginia Health System, Charlottesville, VA*
- D213**      **The lncRNA-mRNA Co-Expression Analysis in Acetaminophen-Induced Liver Injury**  
 J. Zheng, F. Xue, *Liver Surgery and Liver Transplantation Center, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China*
- D214**      **Clinical Utility of a Pharmacogenomic Testing Tool among Kidney Transplant Recipients**  
 S. LeCorchick, L. Lindberg, W. Stapley, S. Anand, D. Morris, T. Srinivas, *Kidney/Pancreas Transplant Program, Intermountain Medical Center, Murray, UT*
- D215 †**      **CURATE.AI: Personalized Liver Transplant Tacrolimus Dosing**  
 A. Zarrinpar<sup>1</sup>, T. Kee<sup>2</sup>, P. Wang<sup>3</sup>, J. Khong<sup>3</sup>, U. Kim<sup>1</sup>, J. Chong<sup>2</sup>, J. B. Jeong<sup>3</sup>, A. T. Truong<sup>2</sup>, S. Tan<sup>2</sup>, B. K. Betzler<sup>2</sup>, W. Ng<sup>2</sup>, C. Ho<sup>3</sup>, D. Ho<sup>2</sup>, <sup>1</sup>*Surgery, University of Florida, Gainesville, FL*, <sup>2</sup>*National University of Singapore, Singapore, Singapore*, <sup>3</sup>*UCLA, Los Angeles, CA*
- D216**      **Anti-Xa Level Monitoring for Treatment Dose Enoxaparin in Liver/Intestine Transplant Recipients**  
 J. Sullivan, J. Jebrock, J. Revollo, M. Perez, J. Garcia, T. Beduschi, *Jackson Memorial Hospital, Miami, FL*
- D217**      **Direct Oral Anticoagulants: An Evaluation of the Safety and Efficacy in Solid Organ Transplant Recipients**  
 T. Pasley, A. Logan, A. Brueckner, L. Bowman, A. Silverman, A. Rumore, *Tampa General Hospital, Tampa, FL*



**Poster Session D: Non-Organ Specific:  
Public Policy & Allocation**

**D218 † Organ Donation Rates And Transplantation Activity Comparing Opt-out Versus Opt-in Systems: A Cross-sectional Study Of Oecd Countries**

A. Arshad<sup>1</sup>, M. Babiker<sup>2</sup>, B. Anderson<sup>2</sup>, A. Sharif<sup>2</sup>, <sup>1</sup>University of Birmingham, Birmingham, United Kingdom, <sup>2</sup>Queen Elizabeth Hospital, Department of Nephrology and Transplantation, Birmingham, United Kingdom

**D219 † Neighborhood Deprivation is Associated with Decreased Rates of Organ Donor Designation**

S. I. Wadhvani<sup>1</sup>, J. Bucuvalas<sup>2</sup>, C. Brokamp<sup>1</sup>, M. A. Bhuiyan<sup>1</sup>, J. C. Lai<sup>3</sup>, A. Beck<sup>1</sup>, <sup>1</sup>Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>2</sup>Icahn School of Medicine at Mount Sinai, New York, NY, <sup>3</sup>University of California San Francisco, San Francisco, CA

**D220 Do Reimbursement Programs Increase The Number Of Living Organ Donations?**

A. Siddique<sup>1</sup>, J. Ortiz<sup>2</sup>, S. Fry-Revere<sup>2</sup>, V. Apte<sup>2</sup>, Y. Jin<sup>3</sup>, N. Koizumi<sup>1</sup>, <sup>1</sup>Schar School of Policy and Government, George Mason University, Arlington, VA, <sup>2</sup>University of Toledo Hospital, Toledo, OH, <sup>3</sup>The State University of New Jersey, New Brunswick, NJ

**D221 Specific Reasons for Public Health Service (PHS) Increased Risk (IR) Designation Had Little Influence on Doctors' Kidney Offer Acceptance Decisions in Controlled "Lab" Experiment**

D. Stewart<sup>1</sup>, J. Rosendale<sup>1</sup>, H. McGehee<sup>1</sup>, J. Schold<sup>2</sup>, J. Lindemans<sup>3</sup>, J. Kessler<sup>4</sup>, C. Sullivan<sup>4</sup>, K. Mekeel<sup>5</sup>, R. Stratta<sup>6</sup>, R. Formica<sup>7</sup>, D. Klassen<sup>1</sup>, <sup>1</sup>UNOS, Richmond, VA, <sup>2</sup>CCF, Cleveland, OH, <sup>3</sup>Duke, Durham, NC, <sup>4</sup>Wharton, Philadelphia, PA, <sup>5</sup>UCSD, San Diego, CA, <sup>6</sup>Wake Forest, Winston-Salem, NC, <sup>7</sup>Yale, New Haven, CT

**D222 National Landscape of Donors Allocated through the Hope Act in the United States**

A. R. Wilk<sup>1</sup>, R. Hunter<sup>2</sup>, M. A. McBride<sup>2</sup>, D. K. Klassen<sup>2</sup>, <sup>1</sup>Research, United Network for Organ Sharing, Richmond, VA, <sup>2</sup>United Network for Organ Sharing, Richmond, VA

**D223 Unfavorable Donor after Cardiac Death Characteristics in Lung Transplantation: An Analysis of the UNOS Registry**

A. Y. Choi<sup>1</sup>, O. K. Jawitz<sup>2</sup>, V. Raman<sup>2</sup>, Y. Barac<sup>2</sup>, M. S. Mulvihill<sup>2</sup>, C. Moore<sup>2</sup>, M. G. Hartwig<sup>2</sup>, <sup>1</sup>Duke University School of Medicine, Durham, NC, <sup>2</sup>Department of Surgery, Duke University Medical Center, Durham, NC

**D224 Different Options Available For Patients Registered In A Kidney Paired Donation (KPD) Program**

S. Stepkowski, B. Mierzejewska, M. Rees, University of Toledo, Toledo, OH

**D225 Exploring Perceptions of Organ Procurement: Need for a Formal Medical Student Curriculum**

L. Winer<sup>1</sup>, M. Vivero<sup>2</sup>, B. Scully<sup>3</sup>, A. Cortez<sup>1</sup>, A. Kassam<sup>1</sup>, J. Kuethe<sup>1</sup>, R. Nowygrod<sup>3</sup>, J. Emond<sup>3</sup>, R. C. Quillin III<sup>1</sup>, <sup>1</sup>Surgery, University of Cincinnati, Cincinnati, OH, <sup>2</sup>Surgery, Brigham and Women's Hospital, Boston, MA, <sup>3</sup>Surgery, Columbia University, New York City, NY

**D226 Modeling the Effect of Presumed Consent on Waitlist Candidate Quantities**

L. DeRoos<sup>1</sup>, W. Marrero<sup>1</sup>, M. Lavieri<sup>1</sup>, D. Hutton<sup>2</sup>, N. Parikh<sup>3</sup>, <sup>1</sup>Industrial and Operations Engineering, University of Michigan, Ann Arbor, MI, <sup>2</sup>School of Public Health, University of Michigan, Ann Arbor, MI, <sup>3</sup>Department of Internal Medicine, University of Michigan, Ann Arbor, MI

**D227 A Collaborative AI Framework to Improve the MELD Exception Request Policy Process**

A. M. Placona, S. M. Noreen, R. Carrico, Research, United Network for Organ Sharing, Henrico, VA



- D228 Identifying the Proverbial “Needle in the Arm” with Natural Language Processing**  
G. R. Vece, J. Foutz, A. Placona,  
*Department of Research, United Network for Organ Sharing, Richmond, VA*
- D229 Identifying Barriers to Organ Donation among Asians Americans**  
M. T. Li, G. C. Hillyer, S. Mohan,  
*Columbia University Medical Center, New York, NY*
- D230 † A Pilot Study of Organ Donor Registration among Persons Living with HIV (PLWH)**  
D. Bhamidipati<sup>1</sup>, P. Veldkamp<sup>2</sup>, L. Despines<sup>1</sup>, C. Sullivan<sup>3</sup>, S. Stuart<sup>3</sup>, D. McMahon<sup>2</sup>, G. Haidar<sup>2</sup>, <sup>1</sup>UPMC, Pittsburgh, PA, <sup>2</sup>Division of Infectious Diseases, UPMC, Pittsburgh, PA, <sup>3</sup>Center for Organ Recovery and Education, Pittsburgh, PA
- D231 Lower Alcohol Taxes Are Associated with Increased Liver Transplant Listing**  
N. T. Shen<sup>1</sup>, M. Raver<sup>1</sup>, N. Hutchison<sup>1</sup>, A. Jesudian<sup>1</sup>, J. Bray<sup>2</sup>, B. Schackman<sup>3</sup>, R. S. Brown<sup>1</sup>, <sup>1</sup>Medicine; Division of Gastroenterology and Hepatology, New York Presbyterian Hospital - Weill Cornell, New York, NY, <sup>2</sup>Economics, University of North Carolina at Greensboro, Greensboro, NC, Greensboro, NC, <sup>3</sup>Healthcare Policy and Research, Weill Cornell Medicine, New York, NY
- D232 A Multi National Study Ofkidney Transplantation In Inmates**  
Y. Qazi, A. Mahajan, D. Bahl, F. Jan, Keck Medical Center at USC, Los Angeles, CA
- D234 Multicenter Experience Evaluating Outcomes of HCV-Seropositive Donors to HCV-Seronegative Recipients Liver Transplantation**  
K. Wijarnpreecha<sup>1</sup>, B. Aqel<sup>2</sup>, S. Pungpapong<sup>1</sup>, C. Taner<sup>3</sup>, K. Reddy<sup>4</sup>, M. Leise<sup>5</sup>, R. Dickson<sup>2</sup>, <sup>1</sup>Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, <sup>2</sup>Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ, <sup>3</sup>Transplant, Mayo Clinic, Jacksonville, FL, <sup>4</sup>Transplant and Hepatobiliary Surgery, Mayo Clinic, Scottsdale, AZ, <sup>5</sup>Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
- D235 Real World Impact of HCV Viremic Solid Organs on Waitlist Times**  
N. Kapila<sup>1</sup>, A. Ur Rahman<sup>1</sup>, K. Gupta<sup>2</sup>, K. Al Khalloufi<sup>3</sup>, E. Navas<sup>3</sup>, D. Reino<sup>3</sup>, S. Ebaid<sup>3</sup>, N. Agarwal<sup>3</sup>, J. Shaw<sup>3</sup>, C. Murgas<sup>3</sup>, S. Rhazouani<sup>3</sup>, A. Zeeshan<sup>3</sup>, A. Tzakis<sup>3</sup>, C. Sheffield<sup>3</sup>, J. Vanatta<sup>3</sup>, X. Zervos<sup>3</sup>, <sup>1</sup>Gastroenterology and Hepatology, Cleveland Clinic Florida, Weston, FL, <sup>2</sup>Internal Medicine, University of Miami/JFK Consortium, Atlantis, FL, <sup>3</sup>Transplant, Cleveland Clinic Florida, Weston, FL
- D236 Timing, Duration, and Source of Hepatitis C Virus (HCV) Antibodies (Ab) among HCV-Negative Recipients of an Organ from an HCV-Infected Donor**  
P. Porrett<sup>1</sup>, P. Reese<sup>1</sup>, E. Blumberg<sup>1</sup>, P. Abt<sup>1</sup>, R. Bloom<sup>1</sup>, K. Reddy<sup>1</sup>, V. Holzmayer<sup>2</sup>, K. Coller<sup>2</sup>, M. Kuhns<sup>2</sup>, G. Cloherty<sup>2</sup>, D. Goldberg<sup>1</sup>, <sup>1</sup>University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Abbott Labs, Chicago, IL
- D237 Renal Function between Tenofovir and Entecavir in Post-Liver Transplanted Hepatitis B Patients**  
S. Kim, J. Kim, S. Lee, J. Rhu, Y. Chung, S. Kim, J. Joh, S. Lee, G. Choi, J. Park, S. Lee, K. Lee, *Transplantation, Samsung Medical Center, Seoul, Korea, Republic of*
- Poster Session D: Non-Organ Specific: Viral Hepatitis**
- D233 Hepatitis C Antibody Positive (HCV Ab+)/Nucleic Acid Test Negative (NAT -) Deceased Donor Kidney Transplantation into Hepatitis C Negative (HCV -) Recipients: Is It Safe?**  
Y. Taehwan, A. Rajab, G. Bumgardner, t. Pesavento, R. Daloul, A. Michaels, K. Washburn, A. El-Hinnawi, *Ohio State University, Columbus, OH*

- D238 Hepatitis A Hospitalizations among Kidney Transplant Recipients in the United States: A Nationwide Study**  
 W. Cheungpasitporn<sup>1</sup>, C. Thongprayoon<sup>2</sup>, P. Ungprasert<sup>3</sup>, K. Wijarnpreecha<sup>4</sup>, P. T. Kroner<sup>4</sup>, <sup>1</sup>Nephrology, University of Mississippi Medical Center, Jackson, MS, <sup>2</sup>Nephrology and Hypertension, Mayo Clinic, Rochester, MN, <sup>3</sup>Nephrology, University of Mississippi Medical Center, Bangkok, Thailand, <sup>4</sup>Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL
- D239 REHANNA: Renal Transplants in Hepatitis C Negative Recipients with Nucleic Acid Positive Donors with Short Course Direct Acting Antiviral Prophylaxis**  
 C. Durand, B. Barnaba, D. Brown, N. Bair, F. Naqvi, M. Bowring, D. Segev, M. Sulkowski, N. Desai, Johns Hopkins University School of Medicine, Baltimore, MD
- D240 † Introduction of Universal Hepatitis E RNA Screening in Deceased Organ Donors - The UK Experience**  
 I. Ushiro-Lumb<sup>1</sup>, K. Tettmar<sup>1</sup>, I. Johannessen<sup>2</sup>, K. Simpson<sup>2</sup>, I. Hart<sup>3</sup>, J. Timms<sup>4</sup>, A. Hale<sup>5</sup>, S. Ijaz<sup>6</sup>, R. Tedder<sup>6</sup>, J. Forsythe<sup>1</sup>, <sup>1</sup>NHS Blood and Transplant, London, United Kingdom, <sup>2</sup>Royal Infirmary of Edinburgh, Edinburgh, United Kingdom, <sup>3</sup>Royal Liverpool University Hospital, Liverpool, United Kingdom, <sup>4</sup>University Hospitals Coventry and Warwickshire, Coventry, United Kingdom, <sup>5</sup>Public Health England, Leeds, United Kingdom, <sup>6</sup>Public Health England, London, United Kingdom
- D241 The Treatment of Hepatitis C Virus (HCV) with Direct Acting Antiviral (DAA) Treatment in the Post Orthotopic Liver Transplant (OLT) Patient is Safe and Efficacious**  
 P. Brown<sup>1</sup>, Z. Demertzis<sup>1</sup>, S. Jafri<sup>2</sup>, <sup>1</sup>Internal Medicine, Henry Ford Health System, Detroit, MI, <sup>2</sup>Gastroenterology and Hepatology, Henry Ford Health System, Detroit, MI
- D242 Evaluating Hepatitis C Treatment after Solid Organ Transplantation**  
 A. J. Burgos<sup>1</sup>, R. Yau<sup>1</sup>, C. Tunwar<sup>2</sup>, J. A. Goss<sup>3</sup>, S. Khaderi<sup>3</sup>, N. L. Sussman<sup>4</sup>, <sup>1</sup>Pharmacy, CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, TX, <sup>2</sup>CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, TX, <sup>3</sup>Division of Abdominal Transplantation, Baylor College of Medicine, Houston, TX, <sup>4</sup>Abdominal Transplant & Liver Disease, Baylor College of Medicine, Houston, TX
- D243 Listing Practices and Graft Utilization Lag behind Supply of Hepatitis C Positive Deceased Donors for Liver and Kidney Transplant**  
 C. E. Kling<sup>1</sup>, J. D. Perkins<sup>2</sup>, S. W. Biggins<sup>3</sup>, C. Johnson<sup>4</sup>, A. P. Limaye<sup>5</sup>, L. Sibulesky<sup>1</sup>, <sup>1</sup>Division of Transplant Surgery, University of Washington Medical Center, Seattle, WA, <sup>2</sup>Division of Transplant Surgery and Clinical and Bio-Analytics Transplant Laboratory, University of Washington Medical Center, Seattle, WA, <sup>3</sup>Divisions of Gastroenterology and Hepatology and Center for Liver Investigation Fostering DiscovERY, University of Washington Medical Center, Seattle, WA, <sup>4</sup>Division of Nephrology, University of Washington Medical Center, Seattle, WA, <sup>5</sup>Division of Infectious Disease, University of Washington Medical Center, Seattle, WA
- D244 Impact of DAA Treatment on Graft Fibrosis in HCV Positive Liver Transplantation**  
 J. Wellington<sup>1</sup>, A. Ma<sup>2</sup>, S. Kottlilil<sup>3</sup>, J. Husson<sup>3</sup>, E. Wilson<sup>3</sup>, D. Bruno<sup>4</sup>, <sup>1</sup>Gastroenterology & Hepatology, University of Maryland, Baltimore, MD, <sup>2</sup>Internal Medicine, University of Maryland, Baltimore, MD, <sup>3</sup>Institute of Human Virology, Division of Clinical Care and Research, University of Maryland, Baltimore, MD, <sup>4</sup>Transplant Surgery, University of Maryland, Baltimore, MD
- D245 Long-Term Efficacy of Direct-Acting Antiviral Agents**  
 J. Zhang, W. Sun, J. Lin, Y. Tian, L. Ma, L. Zhang, Y. Zhu, Beijing Friendship Hospital, Capital Medical University, Beijing, China

**D246**      **Excellent Success with Safety and Efficacy of Direct-Acting Anti-Viral HCV Drugs in Kidney Transplant Recipients Using an Evolving Regimen. A Single Institution Experience**  
*A. Sharfuddin, S. A. Hussain, T. Taber, D. Mishler, O. Adebisi, M. S. Yaqub, Indiana University School of Medicine, Indianapolis, IN*

**Poster Session D: Non-Organ Specific: Organ Preservation/Ischemia Reperfusion Injury**

---

**D247**      **Redox State of HMGB1 Drives Ischemia-Reperfusion Injury in Human Liver Transplantation**  
*R. A. Sosa<sup>1</sup>, A. Q. Terry<sup>1</sup>, J. Nevarez-Mejia<sup>1</sup>, M. Rossetti<sup>1</sup>, B. V. Naini<sup>1</sup>, V. M. Groysberg<sup>1</sup>, F. M. Kaldas<sup>2</sup>, R. W. Busuttil<sup>2</sup>, D. W. Gjertson<sup>1</sup>, J. W. Kupiec-Weglinski<sup>2</sup>, E. F. Reed<sup>1</sup>, <sup>1</sup>Pathology & Laboratory Medicine, UCLA, Los Angeles, CA, <sup>2</sup>Surgery, UCLA, Los Angeles, CA*

**D248 †**    **Notch1 Signaling Protects Liver Grafts from Ischemia Reperfusion Injury: From Mouse to Human**  
*K. Kadono, S. Kageyama, H. Hirao, K. Nakamura, T. Ito, K. J. Dery, D. Oncel, B. Ke, F. M. Kaldas, R. W. Busuttil, J. W. Kupiec-Weglinski, Surgery, Dumont-UCLA Transplant Center, Los Angeles, CA*

**D249**      **Organ-Specific Injury and Recovery Mechanisms in Post-Transplant Ischemia Reperfusion Injury**  
*S. Bontha<sup>1</sup>, A. Bajwa<sup>1</sup>, L. Gallon<sup>2</sup>, J. Eason<sup>3</sup>, D. Maluf<sup>1</sup>, V. Mas<sup>4</sup>, <sup>1</sup>UTHSC, Memphis, TN, <sup>2</sup>Northwestern University, Chicago, IL, <sup>3</sup>Director of Transplant Institute UTHSC, Memphis, TN, <sup>4</sup>Director of Transplant Research Institute, Memphis, TN*

**D250**      **CXCL12-CXCR4-Mediated Chemotaxis is a Potential Mechanism for Monocyte Recruitment in Ischemia-Reperfusion Injury in Orthotopic Liver Transplant Patients**  
*A. Q. Terry<sup>1</sup>, R. A. Sosa<sup>1</sup>, B. V. Naini<sup>1</sup>, V. Groysberg<sup>1</sup>, F. M. Kaldas<sup>2</sup>, R. W. Busuttil<sup>2</sup>, D. Gjertson<sup>1</sup>, J. Kupiec-Weglinski<sup>2</sup>, E. F. Reed<sup>1</sup>, <sup>1</sup>Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA, <sup>2</sup>Surgery, University of California, Los Angeles, Los Angeles, CA*

**D251**      **Urine Recirculation Maintains Hemodynamics and Enhances Function in Normothermic Kidney Perfusion**  
*A. Weissenbacher<sup>1</sup>, C. D. Ceresa<sup>2</sup>, D. Voyce<sup>3</sup>, J. Hunter<sup>2</sup>, R. Ploeg<sup>2</sup>, C. C. Coussios<sup>4</sup>, P. Friend<sup>2</sup>, <sup>1</sup>Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria, <sup>2</sup>Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom, <sup>3</sup>OrganOx Limited, Oxford, United Kingdom, <sup>4</sup>Oxford Institute of Biomedical Engineering, University of Oxford, Oxford, United Kingdom*

**D252**      **The Effect of the Beneficial Activity of  $\alpha$ -Lipoic Acid Treatment Depend on the Quality of the Graft Kidneys**  
*F. Osella<sup>1</sup>, N. Ambrosi<sup>2</sup>, G. Werber<sup>1</sup>, F. Caro<sup>2</sup>, S. Beltramino<sup>1</sup>, I. Cabrera<sup>1</sup>, G. Hilchenbach<sup>1</sup>, L. Diaz Alvarez<sup>1</sup>, C. Incardona<sup>3</sup>, E. Chuluyan<sup>2</sup>, D. Casadei<sup>1</sup>, <sup>1</sup>Instituto de Trasplante y Alta Complejidad, Buenos Aires, Argentina, <sup>2</sup>CEFYO, UBA, Buenos Aires, Argentina, <sup>3</sup>GADOR S.A., Buenos Aires, Argentina*

**D253**      **Partial Freezing: Subzero Whole Liver Preservation In The Presence Of Ice**  
*S. E. Cronin<sup>1</sup>, C. A. Pendexter<sup>1</sup>, R. J. deVries<sup>1</sup>, S. Kimura<sup>2</sup>, S. Ozer<sup>1</sup>, P. D. Banik<sup>1</sup>, S. Nagpal<sup>1</sup>, H. Yeh<sup>2</sup>, S. N. Tessier<sup>1</sup>, K. Uygun<sup>1</sup>, M. Toner<sup>1</sup>, <sup>1</sup>Center for Engineering in Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, <sup>2</sup>Transplant Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA*

**D254 Assessing Discarded Human Liver Quality with Normothermic Ex-Vivo Liver Perfusion**

F. Zhou, M. Xu, S. Garcia-Aroz, G. A. Upadhyaya, Y. Lin, W. C. Chapman, *Surgery, Washington University in St. Louis, St. Louis, MO*

**D255 Apparatus and Method to Facilitate In-Situ Cold Perfusion of Abdominal Organs in DCD Donors**

M. Jendrisak, *Gift of Hope Organ & Tissue Donor Network, Itasca, IL*

**D256 † C1 Esterase Inhibitor (C1INH) Treatment at Kidney Transplant Improves Long-Term Outcomes in Patients at Risk for Ischemia/Reperfusion Injury & Delayed Graft Function**

S. Jordan<sup>1</sup>, E. Huang<sup>2</sup>, N. Ammerman<sup>1</sup>, J. Choi<sup>1</sup>, O. Aubert<sup>3</sup>, S. Kumar<sup>1</sup>, A. Loupy<sup>4</sup>, A. Peng<sup>1</sup>, I. Kim<sup>1</sup>, R. Najjar<sup>1</sup>, D. Puliyaanda<sup>1</sup>, T. Brennan<sup>1</sup>, S. Sethi<sup>1</sup>, A. Vo<sup>1</sup>, <sup>1</sup>*Cedars Sinai Medical Ctr, West Hollywood, CA*, <sup>2</sup>*Comprehensive Transplant Center, Cedars Sinai Medical Ctr, West Hollywood, CA*, <sup>3</sup>*Biostatistics Department, Paris Translational Research Center for Organ Transplantation, Paris, France*, <sup>4</sup>*Biostatistics, Paris Translational Research Center for Organ Transplantation, Paris, France*

**D257 Early Allograft Dysfunction in the Setting of Histologic Ischemia Reperfusion Injury Following Liver Transplantation: Analysis of Predictors and Outcomes**

T. Ito, J. Aziz, V. G. Agopian, S. Younan, J. DiNorcia, H. Yersiz, D. G. Farmer, R. W. Busuttil, F. M. Kaldas, *Department of Surgery, The Dumont-UCLA Transplant Center, Los Angeles, CA*

**D258 Correlation between Gene Expression and Cardiac Function in Ex Vivo Perfused Porcine Hearts**

S. Rotich, N. Herbers, S. Hatami, J. Nagendran, M. Mengel, D. Freed, B. Adam, *University of Alberta, Edmonton, AB, Canada*

**D259 Predicting Graft Function And Long-term Outcomes Following Kidney Transplantation Using An Intraoperative Tissue Oximetry Sensor**

H. Lau, A. Shimomura, E. Tantisattamo, U. G. Reddy, D. Dafoe, H. Ichii, *University of California Irvine, Orange, CA*

**D260 Comprehensive and Combined Transcriptomic and Proteomic Analysis Reveals Key Factors Underlying Ischemia-Reperfusion Injury in Human Liver Transplantation**

S. Huang, X. He, C. Sun, Z. Guo, W. Ju, Z. Zhu, Q. Zhao, G. Chen, *Organ Transplant Center, the First Affiliated Hospital of SYSU, Guangzhou, China*

**D261 Innate Immunity in Brain Dead Donors: Implications of Necroptosis in Kidney Allograft Outcomes**

A. Ang<sup>1</sup>, A. Zmijewska<sup>2</sup>, T. M. Stevens<sup>3</sup>, J. Murphy<sup>1</sup>, R. B. Mannon<sup>2</sup>, <sup>1</sup>*School of Medicine, UAB, Birmingham, AL*, <sup>2</sup>*Medicine/Nephrology, UAB, Birmingham, AL*, <sup>3</sup>*Pathology, UAB, Birmingham, AL*

**D262 Protective Effect of Ischemic-Free Liver Transplantation Technique on Distant Multiple Organ Function**

L. Wang<sup>1</sup>, Z. Guo<sup>1</sup>, L. Yang<sup>2</sup>, W. Xiong<sup>2</sup>, S. Huang<sup>1</sup>, T. Zhang<sup>2</sup>, Y. Tang<sup>1</sup>, Z. Zhang<sup>1</sup>, Z. Zhu<sup>1</sup>, C. Zhu<sup>1</sup>, X. He<sup>1</sup>, <sup>1</sup>*Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China*, <sup>2</sup>*Department of Anesthesiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China*

**Poster Session D: Pancreas and Islet: All Topics**

**D263 † Obese Simultaneous Pancreas And Kidney Transplant Recipients In Type 2 Diabetes Have Similar Risks Of Pancreas Failure As Non-obese**

T. Alhamad<sup>1</sup>, K. Espinoza<sup>1</sup>, J. R. Wellen<sup>1</sup>, S. Chang<sup>1</sup>, D. C. Brennan<sup>2</sup>, K. L. Lentine<sup>3</sup>, <sup>1</sup>*Washington University in St. Louis, St. Louis, MO*, <sup>2</sup>*Johns Hopkins University, Baltimore, MD*, <sup>3</sup>*Saint Louis University, St. Louis, MO*



- D264 † Donor-Derived Cell-Free DNA for Surveillance in Simultaneous Pancreas and Kidney Transplant Recipients, Can We Extrapolate from Kidney Transplant Alone?**  
 O. K. Olaitan<sup>1</sup>, S. Loeb<sup>1</sup>, E. Hetterman<sup>2</sup>, V. Peev<sup>1</sup>, S. Saltzberg<sup>1</sup>, M. Hertl<sup>1</sup>, S. Dholakia<sup>2</sup>, <sup>1</sup>Rush University Medical Center, Chicago, IL, <sup>2</sup>CareDx, Brisbane, CA
- D265 † Predicting Metabolic Outcomes in Islet Autotransplantation before Transplantation**  
 M. A. Kanak, P. Saravanan, J. Kalivarathan, Y. Shindo, M. F. Levy, Virginia Commonwealth University, Richmond, VA
- D266 † Excellent Outcome in African-American (AA), Type 1 and Type 2 Diabetic Recipients after Simultaneous Pancreas and Kidney Transplantation (SPK)**  
 A. Gruessner, S. Saggi, R. W. Gruessner, SUNY Downstate Medical Center, Brooklyn, NY
- D267 † Utilization of LCP-Tacrolimus (ENVARUS XR) in Simultaneous Pancreas and Kidney (SPK) Transplant Recipients**  
 J. Torabi, A. Campbell, E. Akalin, M. Ajaimy, Y. Azzi, C. Pynadath, L. Liriano-Ward, J. P. Rocca, J. A. Graham, Montefiore Medical Center, Bronx, NY
- D268 † Comparison of Portal vs Systemic Venous Drained Pancreas Transplantation Alone Matched by Propensity Score Analysis**  
 E. Vistoli, N. Napoli, F. Palumbo, E. Kauffmann, V. Perrone, S. Iacopi, C. Lombardo, G. Amorese, P. Marchetti, U. Boggi, Pancreas and Kidney Transplantation Center, University of Pisa, Pisa, Italy
- D269 Thymoglobulin Efficacy: The Role of Dosing on Viral Infection and Rejection in Pancreas Transplantation**  
 H. Sarumi, B. Johnson, S. Jackson, S. Hogan, J. Fisher, S. Riad, R. Kandaswamy, T. Pruett, Transplant Surgery, University of Minnesota Medical Center, Minneapolis, MN
- D270 Outcomes Of Simultaneous Pancreas/ kidney Transplantation In Bmi Extremes**  
 A. Al-Kurd, M. Safwan, D. Kim, M. Abouljoud, S. Nagai, Henry Ford Hospital, Detroit, MI
- D271 What Are Factors That Can Influence The High Immunological Graft Loss Rate In Young Pancreas Transplant Recipients**  
 A. C. Gruessner, J. Renz, S. Saggi, R. W. Gruessner, SUNY Downstate Medical Center, Brooklyn, NY
- D272 Kidney Allograft Survival Among Kidney-pancreas Recipients Compared To Solitary Kidney Recipients: A Mate Analysis Of The Unos/optn Database**  
 O. K. Serrano<sup>1</sup>, R. Kandaswamy<sup>2</sup>, E. B. Finger<sup>2</sup>, <sup>1</sup>Hartford Hospital, Hartford, CT, <sup>2</sup>Surgery, University of Minnesota, Minneapolis, MN
- D273 Contrast-Enhanced Ultrasonography Predicts Insulin Secretion Ability at 1 Year after Pancreas Transplantation**  
 N. Aida<sup>1</sup>, T. Kenmochi<sup>1</sup>, T. Ito<sup>1</sup>, K. Kurihara<sup>1</sup>, A. Kawai<sup>1</sup>, T. Nishikawa<sup>2</sup>, I. Hiratsuka<sup>3</sup>, M. Shibata<sup>3</sup>, A. Suzuki<sup>3</sup>, M. Hasegawa<sup>4</sup>, M. Kusaka<sup>5</sup>, M. Hoshinaga<sup>5</sup>, <sup>1</sup>Transplantation and Regenerative Medicine, Fujita Health University, Toyoake, Japan, <sup>2</sup>Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Toyoake, Japan, <sup>3</sup>Endocrinology and Metabolism, Fujita Health University, Toyoake, Japan, <sup>4</sup>Nephrology, Fujita Health University, Toyoake, Japan, <sup>5</sup>Urology, Fujita Health University, Toyoake, Japan
- D274 Impact of Glycemic Control on Long Term Graft and Patient Outcomes after Pancreas Transplantation**  
 V. S. Rohan<sup>1</sup>, K. Soliman<sup>1</sup>, V. Kalbhavi<sup>2</sup>, S. N. Nadig<sup>1</sup>, A. Lin<sup>1</sup>, V. Rao<sup>1</sup>, D. Taber<sup>1</sup>, <sup>1</sup>Transplant Surgery, Medical University of South Carolina, Charleston, SC, <sup>2</sup>Central Michigan University, Mount Pleasant, MI
- D275 Early Pancreas Loss in Simultaneous Pancreas Kidney Transplants: Does It Matter for the Kidney?**  
 D. Das, J. Huskey, R. Heilman, K. S. Reddy, A. Moss, J. Harbell, C. Jadlowiec, Mayo Clinic AZ, Phoenix, AZ



- D276** **Impact of Transplant Surgery Advanced Practice Providers in the Management of Pancreas Transplant Recipients**  
E. A. Herriman, J. M. Sharp, K. J. Brown, J. R. Montgomery, J. C. Magee, J. D. Punch, R. S. Sung, K. J. Woodside, *Section of Transplantation, Department of Surgery, University of Michigan, Ann Arbor, MI*
- D277** **The Incidence of Fungal Infections in Pancreas Transplant Recipients in the Absence of Systemic Antifungal Prophylaxis**  
S. Shaikh<sup>1</sup>, M. Cooper<sup>1</sup>, A. Nolan<sup>1</sup>, P. Abrams<sup>2</sup>, <sup>1</sup>MedStar Georgetown University Hospital, Washington, DC, <sup>2</sup>MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC
- D278** **Safety and Efficacy of Peri-Operative Sublingual Tacrolimus in Pancreas Transplant as Compared to Oral Tacrolimus**  
N. Patel, C. Perez, D. Taber, V. Kalbavi, V. Rohan, *MUSC, Charleston, SC*
- D279** **Pancreas Allograft Importation Should Be Fostered by Any Transplant Center Challenged by Excessively Long Waitlist Times**  
J. Torabi, J. P. Rocca, L. Lirano, Y. Azzizi, M. Ajaimy, C. Pynadath, E. Akalin, M. Kinkhabwala, J. A. Graham, *Montefiore Medical Center, Bronx, NY*
- D280** **Blockade of IL-1 $\beta$  and TNF- $\alpha$  Does Not Significantly Pose Risk or Affect Outcomes in Patients Infused with Microbial-Positive Autologous Islet Preparations**  
K. Kumano<sup>1</sup>, C. Darden<sup>2</sup>, S. Vasu<sup>1</sup>, M. Lawrence<sup>1</sup>, B. Naziruddin<sup>3</sup>, A. Gupta<sup>3</sup>, E. Beecher<sup>3</sup>, N. Onaca<sup>3</sup>, <sup>1</sup>Baylor Scott and White Research Institute, Dallas, TX, <sup>2</sup>Baylor University, Waco, TX, <sup>3</sup>Baylor Simmons Transplant Institute, Dallas, TX
- D281** **Management of Post Operative Pain after Pancreas Transplant - Liposomal Bupivacaine Injection or Continuous Catheter Infiltration Reduces Daily Opioid Usage**  
S. Nagaraju, Y. Yeap, R. Mangus, J. Fridell, J. Wolfe, J. Powelson, *Indiana University School of Medicine, Indianapolis, IN*
- D282** **Risk Predictive Strategy to Expand Pancreas Donor Selection**  
J. W. Mensink<sup>1</sup>, K. M. Ooms - de Vries<sup>2</sup>, V. A. Huurman<sup>1</sup>, R. A. Pol<sup>3</sup>, I. P. Alwayn<sup>1</sup>, A. E. Braat<sup>1</sup>, <sup>1</sup>Department of Surgery; Division of Transplantation, Leiden University Medical Center, Leiden, Netherlands, <sup>2</sup>Dutch Transplant Foundation, Leiden, Netherlands, <sup>3</sup>Department of Surgery; Division of Transplantation, University Medical Center Groningen, Groningen, Netherlands
- D283** **Intra-Abdominal Hypertension in Simultaneous Pancreas-Kidney Transplantation**  
T. Ameen, G. Papadakis, R. Punjala, N. Karydis, *Nephrology and Transplantation, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom*
- D284** **Fibrosis Scoring Correlates with Progression of Chronic Pancreatitis, Islet Isolation Yields and Transplant Outcomes in Patients Undergoing Islet Autotransplantation**  
Y. Liu<sup>1</sup>, J. SoRelle<sup>2</sup>, K. Kumano<sup>3</sup>, S. Vasu<sup>3</sup>, M. Lawrence<sup>4</sup>, A. Gupta<sup>1</sup>, N. Onaca<sup>1</sup>, E. Beecher<sup>1</sup>, B. Naziruddin<sup>4</sup>, <sup>1</sup>Baylor Simmons Transplant Institute, Dallas, TX, <sup>2</sup>UTSouthwestern Medical Center, Dallas, TX, <sup>3</sup>Baylor Scott and White Research Institute, Dallas, TX, <sup>4</sup>Baylor University Medical Ctr, Dallas, TX
- D285** **Fasting Blood Glucose: A Simple and Reliable Marker to Predict Late Pancreas Graft Failure**  
D. Cantarovitch<sup>1</sup>, M. Ollivier<sup>2</sup>, L. Chaillous<sup>2</sup>, B. Cariou<sup>2</sup>, J. Branchereau<sup>1</sup>, G. Karam<sup>1</sup>, <sup>1</sup>Nephrology and Transplantation, ITUN, Nantes, France, <sup>2</sup>Endocrinology, Institut du Thorax, Nantes, France

- D286** **New-Onset Diabetes after Kidney Transplantation: Risk Factors and Early Graft Function Outcome**  
Z. Li, W. Peng, J. Chen, *Kidney Disease Center, First Affiliated Hospital of Zhejiang University, Hangzhou, China*
- D287** **Outcomes of Total Pancreatectomy and Islet Autotransplantation, a Single Center Experience**  
A. Rajab<sup>1</sup>, J. Buss<sup>1</sup>, L. F. Lara<sup>2</sup>, S. Meng<sup>3</sup>, K. Kuntz<sup>4</sup>, D. Conwell<sup>2</sup>, P. A. Hart<sup>2</sup>, K. Washburn<sup>1</sup>, <sup>1</sup>*Transplant Surgery, The Ohio State University, Columbus, OH*, <sup>2</sup>*Gastroenterology, Hepatology and Nutrition, The Ohio State University, Columbus, OH*, <sup>3</sup>*Endocrinology, Diabetes and Metabolism, The Ohio State University, Columbus, OH*, <sup>4</sup>*Psychiatry and Behavioral Health, The Ohio State University, Columbus, OH*
- D288** **Variable Outcomes of Recurrent Autoimmune Diabetes Post Pancreas Transplant Treated with Rituximab**  
K. Venkatachalam, A. Markwardt, B. Heady, T. Alhamad, A. Malone, *Washington University, St. Louis, MO*
- D289** **Comparison of Functional  $\beta$ -cell Function and Insulin Sensitivity of Functioning Pancreas Transplant According to Pre-Transplant Matsuda's Index**  
S. Shin, Y. Ko, D. Kim, J. Kim, H. Kwon, J. Choi, J. Jung, Y. Kim, D. Han, *Division of Kidney and Pancreas Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of*
- D290** **Should Preceding Solo-Kidney Transplantation for Patients with Type 1 Diabetes with End Stage Renal Failure Be Carried Out?**  
T. Ito, T. Kenmochi, K. Kurihara, A. Kawai, N. Aida, *Transplantation and Regenerative Medicine, Fujita Health University, School of Medicine., Aichi, Japan*
- D291** **Quality of Life After Islet/Pancreas Transplantation in Insulin Dependent Diabetic Patients: A Systematic Review of the Literature.**  
I. Mosca<sup>1</sup>, S. Knight<sup>2</sup>, S. Mittal<sup>3</sup>, P. J. Friend<sup>1</sup>, <sup>1</sup>*Nuffield Department of Surgical Sciences, University of Oxford, Oxford Transplant Centre, Oxford, United Kingdom*, <sup>2</sup>*Nuffield Department of Surgical Sciences, Simon Knight, Oxford, United Kingdom*, <sup>3</sup>*Nuffield Department of Surgical Sciences, Shruti Mittal, Oxford, United Kingdom*
- D292** **The Need for Diabetic Medications after Pancreas Transplantation**  
A. Bhansali, O. El Shamy, M. Menon, R. Shapiro, V. Delaney, G. De Boccardo, *Mount Sinai Hospital, New York, NY*
- D293** **Can Cxcl8 Inhibitor (reparixin) Improve Islet Engraftment And Clinical Outcomes After Islet Allotransplantation? University Of Chicago Preliminary Results From A Phase 3 Multicenter Randomized, Double-blinded, Prospective Study.**  
P. Bachul<sup>1</sup>, K. Golab<sup>1</sup>, L. Basto<sup>1</sup>, L. Wang<sup>1</sup>, M. Tibudan<sup>1</sup>, J. Golebiewska<sup>2</sup>, M. Para<sup>1</sup>, L. Perea<sup>1</sup>, F. Antic<sup>1</sup>, J. Fung<sup>1</sup>, P. Witkowski<sup>1</sup>, <sup>1</sup>*University of Chicago Medicine, Chicago, IL*, <sup>2</sup>*Medical University of Gdansk, Gdansk, Poland*
- D294** **Pancreas Transplantation Outcomes - A Single Center Experience 400 Cases**  
J. CHOI, J. Kim, H. Kwon, S. Shin, Y. Kim, D. Han, *Division of Kidney & Pancreas Transplantation, Department of Surgery, Asan Medical Center, Seoul, Korea, Republic of*
- D295** **Pre-Operative C-Peptide Predicts Weight Gain after Pancreas Transplantation**  
J. Torabi, J. P. Rocca, E. Kestenbaum, M. Ajaimy, M. Kinkhabwala, J. A. Graham, *Montefiore Medical Center, Bronx, NY*
- D296** **Correlates of Significant Weight Changes Following Pancreas Alone Transplantation**  
A. Arunachalam, F. Aziz, N. Garg, M. Mohamed, A. Djamali, J. Odorico, D. Mandelbrot, S. Parajuli, *University of Wisconsin, Madison, WI*

- D297**     **Optimizing Patient Blood Management in Simultaneous Kidney and Pancreas Transplantation**  
 D. P. Al-Adra, J. Odorico, D. Kaufman, R. Redfield, J. P. Connor, *University of Wisconsin, Madison, WI*
- D298**     **Outcomes of Portal Vein Extension Grafts in Pancreas Transplantation: A Single-Centre Analysis**  
 S. R. Punjala, B. L. Phillips, N. Karydis, F. Calder, C. J. Callaghan, *Department of Nephrology, Renal Transplantation and Urology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom*
- D299**     **Use of Belatacept in Pancreas Transplantation**  
 P. D. Uva, A. Quevedo, J. Roses, R. Pilotti, E. Chuluyan, D. Casadei, *Kidney/Pancreas Transplantation, ITAC - Nephrology, Buenos Aires, Argentina*

**Poster Session D: Psychosocial and Treatment Adherence**

---

- D300**     **Pictogram Tool to Improve Medication Adherence in Heart Transplant Families with Limited English Proficiency and Low Health Literacy**  
 A. C. Rothkopf<sup>1</sup>, J. Chen<sup>2</sup>, N. Jasiak-Panek<sup>3</sup>, K. Le<sup>3</sup>, A. Joong<sup>4</sup>, L. J. Addonizio<sup>1</sup>, <sup>1</sup>*Pediatric Cardiology, Columbia University, New York, NY*, <sup>2</sup>*Department of Pharmacy, Columbia University, New York, NY*, <sup>3</sup>*Department of Pharmacy, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL*, <sup>4</sup>*Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL*
- D301**     **Correlation between Self-Reported Medication Adherence and Side Effects in Transplant Recipients**  
 T. Harrison<sup>1</sup>, K. Foster<sup>1</sup>, N. Patel<sup>1</sup>, H. Meadows<sup>1</sup>, C. Perez<sup>1</sup>, H. Corbo<sup>1</sup>, J. Fleming<sup>1</sup>, N. Pilch<sup>1</sup>, D. DuBay<sup>2</sup>, J. McGillicuddy<sup>2</sup>, S. Nadig<sup>2</sup>, V. Rohan<sup>2</sup>, D. Taber<sup>1</sup>, <sup>1</sup>*Pharmacy Services, Medical University of South Carolina, Charleston, SC*, <sup>2</sup>*Transplant Surgery, Medical University of South Carolina, Charleston, SC*

- D302**     **Transplant Regimen Adherence For Kidney Recipients By Engaging Information Technologies: The Take It Trial**  
 D. P. Ladner<sup>1</sup>, M. S. Wolf<sup>2</sup>, <sup>1</sup>*Surgery, Northwestern Medicine, Chicago, IL*, <sup>2</sup>*General Internal Medicine, Northwestern University, Chicago, IL*
- D303**     **What Do We Not Know about Long Term Liver Transplant Patients? A Look at Side Effect Burden and Medication Adherence**  
 K. Foster<sup>1</sup>, C. Perez<sup>1</sup>, T. Harrison<sup>1</sup>, H. Corbo<sup>1</sup>, N. Patel<sup>1</sup>, D. Taber<sup>1</sup>, H. Meadows<sup>1</sup>, J. Fleming<sup>1</sup>, D. DuBay<sup>2</sup>, J. McGillicuddy<sup>2</sup>, N. Pilch<sup>1</sup>, <sup>1</sup>*Department of Pharmacy Services, -Medical University of South Carolina, -Charleston, SC*, <sup>2</sup>*Division of Transplant Surgery, Department of Surgery, -Medical University of South Carolina, -Charleston, SC*
- D304**     **Developing a Patient Reported Outcome Measure for Assessment of Calcineurin Inhibitor-Related Symptoms**  
 J. L. Beaumont<sup>1</sup>, I. Purnajo<sup>1</sup>, M. Polinsky<sup>2</sup>, E. Alemao<sup>2</sup>, M. J. Everly<sup>1</sup>, <sup>1</sup>*Terasaki Research Institute, Los Angeles, CA*, <sup>2</sup>*Bristol Myers Squibb, Princeton, NJ*
- D305**     **ALcohol Relapse after Liver Transplantation**  
 B. Movahedi, p. Mahboub, P. Martings, A. Bozorgzadeh, *Surgery, UMass Memorial Medical Center, Worcester, MA*
- D306**     **Immunosuppressant Adherence in Adult Heart Transplant Recipients: An Analysis of Pharmacy Claims and Organ Procurement and Transplantation Network Data**  
 W. S. Cherikh<sup>1</sup>, A. R. Wilk<sup>1</sup>, J. Maghirang<sup>1</sup>, E. A. Witt<sup>2</sup>, H. Kirkham<sup>3</sup>, S. Boghani<sup>2</sup>, N. Hira<sup>4</sup>, G. Pietradoni<sup>2</sup>, D. K. Klassen<sup>1</sup>, <sup>1</sup>*United Network for Organ Sharing, Richmond, VA*, <sup>2</sup>*Walgreens Co, Deerfield, IL*, <sup>3</sup>*Walgreens Co, Deerfield, IL*, <sup>4</sup>*AllianceRx Walgreens Prime, Orlando, FL*

Poster Session D  
 Tuesday, June 4

- D307** “What I Wish I Would Have Known....”  
**Patient Impressions of Transplant Education**  
K. Collins<sup>1</sup>, A. Yaldo<sup>1</sup>, E. Rubinstein<sup>1</sup>, K. Kippen<sup>2</sup>, H. Olden<sup>2</sup>, S. Nagai<sup>1</sup>, M. Abouljoud<sup>1</sup>, <sup>1</sup>Henry Ford Transplant Institute, Detroit, MI, <sup>2</sup>Henry Ford, Detroit, MI
- D308** **Exercise for Solid Organ Transplant Candidates and Recipients: A Joint Position Statement of the Canadian Society of Transplantation (CST) and Canadian Network for Rehabilitation and Exercise for Solid Organ Transplant Optimal Recovery (CAN-RESTORE)**  
T. Janaudis-Ferreira<sup>1</sup>, S. Mathur<sup>2</sup>, R. Deliva<sup>3</sup>, N. Howes<sup>4</sup>, C. Patterson<sup>5</sup>, A. Råke<sup>6</sup>, S. So<sup>5</sup>, L. Wickerson<sup>7</sup>, M. White<sup>6</sup>, Y. Avitzur<sup>5</sup>, O. Johnston<sup>8</sup>, N. Heywood<sup>9</sup>, S. Singh<sup>7</sup>, S. Holdsworth<sup>10</sup>, <sup>1</sup>School of Physical and Occupational Therapy, McGill University, Montreal, QC, Canada, <sup>2</sup>University of Toronto, Toronto, ON, Canada, <sup>3</sup>The Hospital for Sick Children, Toronto, ON, Canada, <sup>4</sup>London Health Sciences Centre, London, ON, Canada, <sup>5</sup>The Hospital For Sick Children, Toronto, ON, Canada, <sup>6</sup>University of Montreal Hospital Centre, Montreal, QC, Canada, <sup>7</sup>University Health Network, Toronto, ON, Canada, <sup>8</sup>Vancouver General Hospital, Vancouver, BC, Canada, <sup>9</sup>McGill University Health Centre, Montreal, QC, Canada, <sup>10</sup>Canadian Donation and Transplantation Research Program, Edmonton, AB, Canada
- D309** **Immunosuppressant Adherence in Adult Liver Transplant Recipients in the United States**  
W. S. Cherikh<sup>1</sup>, A. R. Wilk<sup>1</sup>, J. Maghirang<sup>1</sup>, E. A. Witt<sup>2</sup>, H. Kirkham<sup>2</sup>, S. Boghani<sup>2</sup>, N. Hira<sup>3</sup>, G. Pietradoni<sup>2</sup>, D. K. Klassen<sup>1</sup>, <sup>1</sup>United Network for Organ Sharing, Richmond, VA, <sup>2</sup>Walgreen Co, Deerfield, IL, <sup>3</sup>AllianceRx Walgreens Prime, Orlando, FL
- D310** **Parental Anxiety and Depression Rates across Pediatric Solid Organ Transplant Populations**  
A. M. Lofton<sup>1</sup>, A. Wille<sup>1</sup>, E. A. Steinberg<sup>2</sup>, C. Buchanan<sup>2</sup>, <sup>1</sup>Psychiatry, Children's Hospital Colorado, Aurora, CO, <sup>2</sup>Psychiatry, University of Colorado SOM, Children's Hospital Colorado, Aurora, CO
- D311** **Prevalence of Non-Adherence to Immunosuppressive Medications in Kidney Transplant Recipients, Barriers and Predictors**  
S. Taj<sup>1</sup>, H. Baghaffar<sup>2</sup>, D. Alnajjar<sup>2</sup>, N. Almashabi<sup>3</sup>, S. Ismail<sup>4</sup>, <sup>1</sup>King Saud Bin Abdulaziz University For Health Sciences, Jeddah, Saudi Arabia, <sup>2</sup>Ibn Sina College, Jeddah, Saudi Arabia, <sup>3</sup>Umm Al-Qura University, Makkah, Saudi Arabia, <sup>4</sup>Pharmaceutical Care Department, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia
- D312 †** **Evaluating the Predictive Utility of the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) for Post-Transplant Outcomes in Moderate to High-Risk Liver Transplant Candidates**  
P. Sheiner, S. Spence, D. Gleason, J. Riley, M. Einstein, E. UrtasunSotil, C. Rochon, B. Maneckshana, O. Serrano, Hartford Hospital, Hartford, CT
- D313** **Transition from Pediatric to Adult Care of Kidney Transplant Recipients: A Retrospective Analysis of a French Monocentric Cohort**  
M. Mazloun<sup>1</sup>, M. Charbit<sup>2</sup>, O. Aubert<sup>1</sup>, D. Anglicheau<sup>1</sup>, A. Scemla<sup>1</sup>, R. Salomon<sup>2</sup>, P. Krug<sup>2</sup>, C. Legendre<sup>1</sup>, R. Sberro-Soussan<sup>1</sup>, <sup>1</sup>Adult Nephrology and Renal Transplantation Department, Necker Hospital, Paris, France, <sup>2</sup>Pediatric Nephrology and Renal Transplantation Department, Necker Hospital, Paris, France
- D314 †** **Impact of an mHealth, Electronic Pillbox Intervention on Tacrolimus Variability in Kidney Transplantation: Results of a Prospective Randomized Clinical Trial**  
J. W. McGillicuddy, L. Sox, J. Chandler, F. Treiber, D. Taber, Medical University of South Carolina, Charleston, SC
- D315 †** **Determining the Role of Insurance Coverage at the Time of Renal Transplantation as a Predictor of Medication Misadventure**  
D. Wilkerson, P. Klem, Pharmacy, University of Colorado Skaggs School of Pharmacy, Aurora, CO



**D316**      **Pregnancy Outcomes by Conception Age in Female Liver Transplant Recipients**  
M. Sarkar<sup>1</sup>, L. A. Coscia<sup>2</sup>, D. Kliniewski<sup>2</sup>, S. Rao<sup>3</sup>, S. Constantinescu<sup>4</sup>, M. J. Moritz<sup>5</sup>,  
<sup>1</sup>Medicine, University of California San Francisco, San Francisco, CA, <sup>2</sup>Gift of Life Institute, Transplant Pregnancy Registry International, Philadelphia, PA, <sup>3</sup>Medicine, University of Virginia Health System, Charlottesville, VA, <sup>4</sup>Lewis Katz School of Medicine, Temple University, Philadelphia, PA, <sup>5</sup>Surgery, Lehigh Valley Health Network, Allentown, PA

**D317**      **Lifelong Immunosuppression, I Am Sure We Told Them That?: Long Term Medication Adherence in Liver Transplant Patients**  
K. Foster<sup>1</sup>, C. Perez<sup>1</sup>, T. Harrison<sup>1</sup>, H. Corbo<sup>1</sup>, N. Patel<sup>1</sup>, J. Fleming<sup>1</sup>, H. Meadows<sup>1</sup>, D. Taber<sup>1</sup>, D. DuBay<sup>2</sup>, J. McGillicuddy<sup>2</sup>, N. Pilch<sup>1</sup>, <sup>1</sup>Department of Pharmacy Services, -Medical University of South Carolina, -Charleston, SC, <sup>2</sup>Division of Transplant Surgery, Department of Surgery, -Medical University of South Carolina, -Charleston, SC

**D318**      **Multilevel Correlates of Immunosuppressive Nonadherence in Kidney Transplant Patients - The Multicenter ADHERE BRAZIL Study**  
H. Sanders-Pinheiro<sup>1</sup>, F. A. Colugnati<sup>1</sup>, K. Denhaerynck<sup>2</sup>, E. O. Marsicano<sup>1</sup>, J. O. Medina<sup>3</sup>, S. De Geest<sup>2</sup>, A. ADHERE BRAZIL Study team<sup>1</sup>, <sup>1</sup>Nephrology, Federal University of Juiz de Fora, Juiz de Fora, Brazil, <sup>2</sup>Institute of Nursing Science, Department of Public Health, University of Basel, Basel, Switzerland, <sup>3</sup>Hospital do Rim e Hipertensão/Nephrology, Federal University of São Paulo, São Paulo, Brazil

**D319**      **Characteristics Associated with Immunosuppressant Adherence after Deceased Donor Kidney Transplant**  
A. R. Wilk<sup>1</sup>, W. S. Cherikh<sup>1</sup>, J. Maghirang<sup>1</sup>, E. A. Witt<sup>2</sup>, H. Kirkham<sup>2</sup>, S. Boghani<sup>2</sup>, N. Hira<sup>3</sup>, G. Pietradoni<sup>2</sup>, D. K. Klassen<sup>1</sup>,  
<sup>1</sup>United Network for Organ Sharing, Richmond, VA, <sup>2</sup>Walgreen Co, Deerfield, IL, <sup>3</sup>AllianceRx Walgreens Prime, Orlando, FL

**D320**      **Caregiving in Thoracic Transplantation--A SR/MA**  
A. A. Rmilah, J. Lau, R. Mendpara, P. Erwin, C. C. Kennedy, *Mayo Clinic, Rochester, MN*

**D321**      **Pilot Testing Of A Novel Transition Program**  
J. Uze, N. Yazigi, *Transplantation, MedStar Georgetown University Hospital, Washington, DC*

**D322**      **Correlation between Self-Reported Medication Adherence and Side Effects in Cardiothoracic Transplant Recipients**  
T. Harrison<sup>1</sup>, N. Patel<sup>1</sup>, H. Corbo<sup>1</sup>, K. Foster<sup>1</sup>, H. Meadows<sup>1</sup>, N. Pilch<sup>1</sup>, C. Perez<sup>1</sup>, J. Fleming<sup>1</sup>, D. Judge<sup>2</sup>, L. Paoletti<sup>3</sup>, D. Taber<sup>1</sup>, <sup>1</sup>Pharmacy Services, Medical University of South Carolina, Charleston, SC, <sup>2</sup>Cardiology, Medical University of South Carolina, Charleston, SC, <sup>3</sup>Pulmonary & Critical Care Medicine, Medical University of South Carolina, Charleston, SC

**D323**      **Stakeholder Perspectives in Peer Mentoring Program for Pediatric Solid Organ Transplant Recipients**  
C. Strachan, M. Paton, J. Reason, S. Amaral, *Nephrology, Children's Hospital of Philadelphia, Philadelphia, PA*

**D324**      **A Pilot Study of the mDOT Platform for Immunosuppression Adherence in Adult Kidney Transplant Recipients**  
J. Langlee, L. Lees, A. Saha, D. Helfer, M. Waldram, A. Love, F. Rivera, A. Massie, D. Segev, D. Brennan, M. Henderson, *Johns Hopkins School of Medicine, Baltimore, MD*

## Poster Session D: PTLD/Malignancies: All Topics

---

**D325**      **Screening for Renal Cell Masses in Kidney Transplant**  
H. E. Fernandez, D. Tsapepas, D. J. Cohen, M. Sumit, L. E. Ratner, *Columbia University MC, New York, NY*



- D326 Post-Transplant Cancer Following Living Donor HLA-Incompatible Kidney Transplantation**  
 J. D. Motter<sup>1</sup>, K. Jackson<sup>1</sup>, S. Bae<sup>1</sup>, X. Luo<sup>1</sup>, J. Long<sup>1</sup>, L. Kucirka<sup>1</sup>, B. Orandi<sup>2</sup>, A. Muzaale<sup>1</sup>, J. Coresh<sup>1</sup>, J. Garonzik-Wang<sup>1</sup>, D. Segev<sup>1</sup>, A. Massie<sup>1</sup>, <sup>1</sup>*Johns Hopkins University, Baltimore, MD*, <sup>2</sup>*University of Alabama, Birmingham, AL*
- D327 Racial Differences in Cancer Mortality for Kidney Transplant Recipients**  
 K. Cordrey, J. Motter, A. Kernodle, K. Jackson, M. Camp, T. Purnell, D. Segev, J. Garonzik Wang, *Johns Hopkins University, Baltimore, MD*
- D328 The Impact of Acute Rejection in Heart Transplantation on Post-Transplant Malignancy**  
 K. Kamrani<sup>1</sup>, A. Okoh<sup>2</sup>, D. Hanos<sup>1</sup>, M. Camacho<sup>1</sup>, M. Zucker<sup>2</sup>, K. Clarke<sup>1</sup>, <sup>1</sup>*Dept. of Surgery, Newark Beth Israel Medical Center, Newark, NJ*, <sup>2</sup>*Dept. of Medicine, Newark Beth Israel Medical Center, Newark, NJ*
- D329 Post-Transplant Cancer and Graft Failure in Kidney Transplant Recipients**  
 J. Kim, J. Ha, S. Min, H. Lee, Y. Kim, S. Han, *Seoul National University Hospital, Seoul, Korea, Republic of*
- D330 Characteristics And Outcomes Of Early Onset Cancers After Kidney Transplantation**  
 W. Lim<sup>1</sup>, E. Au<sup>2</sup>, A. Krishnan<sup>1</sup>, G. Wong<sup>2</sup>, <sup>1</sup>*Sir Charles Gairdner Hospital, Perth, Australia*, <sup>2</sup>*University of Sydney & Westmead Hospital, Sydney, Australia*
- D331 Impact of Everolimus on Secondary Nonmelanoma Skin Cancer Prevention in Solid Organ Transplant Recipients**  
 B. Clark<sup>1</sup>, D. D. Ramirez<sup>1</sup>, A. Carlson<sup>1</sup>, B. Sirandas<sup>1</sup>, C. Truax<sup>1</sup>, L. Smith<sup>1</sup>, I. Hall<sup>2</sup>, <sup>1</sup>*Solid Organ Transplant, University of Utah Health, Salt Lake City, UT*, <sup>2</sup>*Nephrology and Hypertension, University of Utah Health, Salt Lake City, UT*
- D332 † Steadily Dropping Malignancy Rates after Pediatric Kidney Transplantation Have Now Reversed in the Most Recent Era: A Report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS)**  
 V. Dharnidharka<sup>1</sup>, C. Cramer<sup>2</sup>, A. Chua<sup>3</sup>, A. Moudgil<sup>4</sup>, K. Martz<sup>5</sup>, T. Blydt-Hansen<sup>6</sup>, J. Smith<sup>7</sup>, A. Neu, on behalf of the NAPRTCS Investigators<sup>8</sup>, <sup>1</sup>*Washington University in St. Louis, Saint Louis, MO*, <sup>2</sup>*Mayo Clinic, Rochester, MN*, <sup>3</sup>*Duke University, Durham, NC*, <sup>4</sup>*Children's National Medical Center, Washington, DC*, <sup>5</sup>*Emmes Corporation, Rockville, MD*, <sup>6</sup>*BC Children's Hospital, Vancouver, BC, Canada*, <sup>7</sup>*Seattle Children's Hospital, Seattle, WA*, <sup>8</sup>*Johns Hopkins University, Baltimore, MD*
- D333 Whole Body CT Imaging in Deceased Donor Screening**  
 J. W. Mensink<sup>1</sup>, R. A. Pol.<sup>2</sup>, W. N. Nijboer<sup>1</sup>, J. de Jonge<sup>3</sup>, K. M. Ooms - de Vries<sup>4</sup>, M. F. van der Jagt<sup>5</sup>, M. C. van de Poll<sup>6</sup>, I. P. Alwayn<sup>1</sup>, A. E. Braat<sup>1</sup>, <sup>1</sup>*Department of Surgery; Division of Transplantation, Leiden University Medical Center, Leiden, Netherlands*, <sup>2</sup>*Department of Surgery; Division of Transplantation, University Medical Center Groningen, Groningen, Netherlands*, <sup>3</sup>*Department of Surgery; Division of Transplantation, Erasmus Medical Center, Rotterdam, Netherlands*, <sup>4</sup>*Dutch Transplant Foundation, Leiden, Netherlands*, <sup>5</sup>*Department of Surgery; Division of Transplantation, University Medical Center St. Radboud, Nijmegen, Netherlands*, <sup>6</sup>*Department of Surgery and Department of Intensive Care, Maastricht University Medical Center, Maastricht, Netherlands*
- D334 Epstein Barr Virus DNA Integration in B Cell Lymphomas of Post-Transplant Lymphoproliferative Disorder**  
 M. C. McPherson, O. M. Martinez, *Surgery, Division of Abdominal Transplant, Stanford University School of Medicine, Stanford, CA*
- D335 Genomic Variations in Epstein Barr Virus are Associated with Post-Transplant Lymphoproliferative Disorder**  
 M. Arvedson, E. Maloney, C. Esquivel, O. Martinez, S. Krams, *Stanford Univ School of Med, Stanford, CA*

**D336** **Post-Transplant Lymphoproliferative Disorders after Living-Donor Liver Transplantation: A Retrospective Cohort Study in 1,900 Cases of Single Center Experience**  
T. Tajima<sup>1</sup>, K. Hata<sup>1</sup>, H. Haga<sup>2</sup>, M. Nishikori<sup>3</sup>, J. Kusakabe<sup>1</sup>, I. Tamaki<sup>1</sup>, T. Ito<sup>1</sup>, T. Kaido<sup>1</sup>, A. Takaori-Kondo<sup>3</sup>, S. Uemoto<sup>1</sup>,  
<sup>1</sup>*Div. of HBP Surgery and Transplantation, Dept. of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan*, <sup>2</sup>*Dept. of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan*, <sup>3</sup>*Dept. of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan*

**D337** **Genome-Wide Profiling of BK Polyomavirus Integration in Urothelial Carcinoma of Kidney Transplant Recipients Reveals a Potential Microhomology or Nonhomologous End Joining Mediated Integration Mechanism**  
Y. Jin<sup>1</sup>, Y. Zhou<sup>1</sup>, W. Deng<sup>1</sup>, R. Lee<sup>2</sup>, Y. Liu<sup>1</sup>, M. Blute<sup>3</sup>, R. Liu<sup>1</sup>, N. Elias<sup>4</sup>, F. Fu<sup>1</sup>, B. Guan<sup>1</sup>, J. Geng<sup>1</sup>, J. Ma<sup>5</sup>, J. Zhou<sup>5</sup>, N. Liu<sup>5</sup>, C. Wu<sup>6</sup>, Y. Miao<sup>1</sup>,  
<sup>1</sup>*Nanfang Hospital, Southern Medical University, Guangzhou, China*, <sup>2</sup>*Departments of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA*, <sup>3</sup>*Departments of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA*, <sup>4</sup>*Departments of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA*, <sup>5</sup>*Mygenostics Co., Beijing, China*, <sup>6</sup>*Departments of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA*

**D338** **Sirolimus in Geriatric Kidney Transplantation: Modification of Outcomes by Pre-Transplant History of Malignancy or Cardiovascular Disease**  
H. Ibrahim<sup>1</sup>, C. Chen<sup>2</sup>, K. Alquadan<sup>3</sup>, X. Wen<sup>4</sup>, K. L. Womer<sup>3</sup>, A. H. Santos Jr<sup>1</sup>,  
<sup>1</sup>*College of Medicine, Div. of Nephrology, Hypertension & Renal Transplantation, Univ. of Florida, Gainesville, FL*, <sup>2</sup>*College of Pharmacy, Univ. of Florida, Gainesville, FL*, <sup>3</sup>*College of Medicine, Div. of Nephrology, Hypertension & Renal Transplantation, Univ. of Florida, Gainesville, FL*, <sup>4</sup>*College of Pharmacy, Univ. of Rhode Island, Kingston, RI*

**D339** **Organ Vigilance in Germany: Malignancy Transmission from Organ Donor to Recipient**  
K. Moench, A. Rahmel, A. P. Barreiros, *German Foundation for Organtransplantation, Frankfurt, Germany*

**D340** **Incidence and Mortality of Renal Cell Carcinoma after Kidney Transplantation: A Meta-Analysis**  
A. Chewcharat<sup>1</sup>, C. Thongprayoon<sup>2</sup>, B. Boonpheng<sup>3</sup>, A. Torres-Ortiz<sup>4</sup>, M. A Mao<sup>2</sup>, N. J Khoury<sup>5</sup>, W. Cheungpasitporn<sup>4</sup>,  
<sup>1</sup>*Harvard T.H. Chan, Boston, MA*, <sup>2</sup>*Mayo Clinic, Rochester, MN*, <sup>3</sup>*East Tennessee State University, Johnson City, TN*, <sup>4</sup>*University of Mississippi Medical Center, Jackson, MS*, <sup>5</sup>*Henry Ford Hospital, Detroit, MI*

**D341** **Kidney Transplant Outcomes in Patients with ESRD Due to Myeloma**  
A. Riaz, A. Khalil, M. S. Yaqub, T. Taber, O. Adebiyi, A. Sharfuddin,  
*Indiana University School of Medicine, Indianapolis, IN*

**D342** **Retrospective Nested Case Control Study of the Impact of Immunosuppression on Post Transplant Malignancy among Adult Heart Transplant Patients**  
S. Crow, R. J. Bubik, S. S. Kushwaha, K. C. Mara, R. A. Dierkhising, N. L. Pereira,  
*Mayo Clinic, Rochester, MN*

**D343 †** **Long Term Follow-Up of the Use of Checkpoint Inhibitors in Kidney Transplant Recipients**  
K. Venkatachalam, R. Delos Santos, T. Alhamad, *Transplant nephrology, Washington University, St. Louis, MO*

## Poster Session D: Small Bowel: All Topics

**D344** **First Report and Mechanistic Analysis of Chronic GVHD after Solid Organ Transplantation**  
J. Weiner, N. Svetlicky, J. Schmidt, J. Kang, M. Sadat, A. Karaballa, S. Moturi, O. Aguirre, J. Hawksworth, C. Matsumoto, T. Fishbein, A. Kroemer, *Georgetown University Hospital, Washington, DC*

**D345** **Ninety-Day Complications in 214 Intestinal Transplant Patients: A Calvien-Dindo Analysis and Assessment of Long Term Outcomes**  
A. Zimmerman, J. Hawksworth, A. Kroemer, P. Radkani, K. Khan, S. Kaufman, N. Yazigi, S. Subramanian, T. Fishbein, C. Matsumoto, *Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC*

**D346** **Post-transplant Lymphoproliferative Disorder Following Intestine Transplantation: Contemporary Single Center Experience**  
A. Zimmerman, J. Hawksworth, A. Kroemer, P. Radkani, K. Khan, S. Kaufman, N. Yazigi, S. Subramanian, T. Fishbein, C. Matsumoto, *Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC*

**D347** **A Multicenter Study Of mTOR Inhibitor Use In Intestine And Multivisceral Transplantation**  
M. C. Segovia<sup>1</sup>, A. Mavis<sup>1</sup>, J. Boike<sup>2</sup>, Y. Patel<sup>1</sup>, T. Schiano<sup>3</sup>, S. Jafri<sup>4</sup>, <sup>1</sup>Duke, Durham, NC, <sup>2</sup>NWU, Chicago, IL, <sup>3</sup>Mt Sinai, NY, NY, <sup>4</sup>Henry Ford, Detroit, MI

**D348** **Clostridium difficile Infection Mimics Intestinal Acute Cellular Rejection in Pediatric Multivisceral Transplant - A Case Series**  
D. A. Cheung<sup>1</sup>, T. Beduschi<sup>2</sup>, A. Tekin<sup>2</sup>, G. Selvaggi<sup>2</sup>, R. M. Vianna<sup>2</sup>, J. Garcia<sup>1</sup>, <sup>1</sup>Pediatric Gastroenterology, University of Miami, Miami, FL, <sup>2</sup>Surgery, Division of Liver/GI Transplant, University of Miami, Miami, FL

**D349** **Biomarkers in Multivisceral and Intestinal Transplantation**  
D. A. Cheung<sup>1</sup>, J. Garcia<sup>1</sup>, T. Beduschi<sup>2</sup>, A. H. Langshaw<sup>1</sup>, K. L. Arheart<sup>3</sup>, I. A. Gonzalez<sup>4</sup>, <sup>1</sup>Pediatric Gastroenterology, University of Miami, Miami, FL, <sup>2</sup>Surgery, Division of Liver/GI Transplant, University of Miami, Miami, FL, <sup>3</sup>Public Health Sciences, Division of Biostatistics, University of Miami, Miami, FL, <sup>4</sup>Pediatric Infectious Diseases and Immunology, University of Miami, Miami, FL

**D350** **Viral Enteritis in Intestinal Transplant Recipients**  
A. Servais, M. Vacha, D. F. Florescu, M. Keck, *Nebraska Medicine, Omaha, NE*

**D351 †** **Effects of Major Liver Allocation Policy Changes on Waitlist Outcomes in Multivisceral Transplantation**  
S. Nagai<sup>1</sup>, M. Rizzari<sup>1</sup>, Y. Muszkat<sup>2</sup>, K. Collins<sup>1</sup>, A. Yoshida<sup>1</sup>, S. Jafri<sup>2</sup>, M. Abouljoud<sup>1</sup>, <sup>1</sup>Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI, <sup>2</sup>Gastroenterology, Henry Ford Hospital, Detroit, MI

## Poster Session D: Tolerance: Clinical Studies

---

**D352** **Identification of Adult Liver Transplant Recipients Eligible to Participate in an Immunosuppression Withdrawal Trial Employing Non-Invasive Assessments of Allograft Status**  
J. Vionnet<sup>1</sup>, R. Miquel<sup>1</sup>, A. Douiri<sup>1</sup>, M. Elstad<sup>1</sup>, E. Kodela<sup>1</sup>, A. Quaglia<sup>2</sup>, J. Wall<sup>1</sup>, P. Ruiz Martin<sup>1</sup>, E. B. Riani<sup>3</sup>, J. Leithead<sup>4</sup>, A. Marshall<sup>2</sup>, M. Navasa<sup>5</sup>, P. Ruiz<sup>5</sup>, J. Ferguson<sup>6</sup>, K. Simpson<sup>7</sup>, A. Pascher<sup>8</sup>, E. Jaeckel<sup>9</sup>, R. Bishop<sup>10</sup>, F. Nevens<sup>11</sup>, S. Masson<sup>12</sup>, A. Sanchez-Fueyo<sup>1</sup>, <sup>1</sup>King's College London, London, United Kingdom, <sup>2</sup>Royal Free, London, United Kingdom, <sup>3</sup>St-Luc, Brussels, Belgium, <sup>4</sup>Addenbrookes, Cambridge, United Kingdom, <sup>5</sup>Hospital Clinic, Barcelona, Spain, <sup>6</sup>Queen Elizabeth, Birmingham, United Kingdom, <sup>7</sup>Royal Infirmary, Edinburgh, United Kingdom, <sup>8</sup>Charité, Berlin, Germany, <sup>9</sup>Hannover Medical School, Hannover, Germany, <sup>10</sup>Leeds NHS Trust, Leeds, United Kingdom, <sup>11</sup>UZ Leuven, Leuven, Belgium, <sup>12</sup>Hepatology, Newcastle, United Kingdom

**D353** **Inflammation and Fibrosis Are Observed in 34% of Clinically Stable Adult Liver Transplant Recipients**  
L. Sun<sup>1</sup>, J. Levitsky<sup>2</sup>, S. Feng<sup>3</sup>, A. Humar<sup>4</sup>, A. J. Demetris<sup>4</sup>, J. Emond<sup>5</sup>, A. Shaked<sup>6</sup>, G. Klintmalm<sup>7</sup>, K. Mason<sup>8</sup>, M. DesMarais<sup>1</sup>, A. Priore<sup>9</sup>, N. Bridges<sup>9</sup>, B. E. Burrell<sup>10</sup>, S. Chandran<sup>3</sup>, J. Markmann<sup>11</sup>, <sup>1</sup>ITN, San Francisco, CA, <sup>2</sup>Northwestern, Chicago, IL, <sup>3</sup>UCSF, San Francisco, CA, <sup>4</sup>UPMC, Pittsburg, PA, <sup>5</sup>Columbia, New York, NY, <sup>6</sup>UPenn, Philadelphia, PA, <sup>7</sup>Baylor, Dallas, TX, <sup>8</sup>Rho, Chapel Hill, NC, <sup>9</sup>NAID, Bethesda, MD, <sup>10</sup>ITN, Bethesda, MD, <sup>11</sup>MGH, Boston, MA

**D354** **A Novel Protocol to Produce Massive Amounts of Autologous Thymus-Derived Treg Cells (ThyTreg) to Be Employed as Cellular Therapy in Heart Transplanted Children: A New Paradigm for the Prevention of Graft Rejection**  
 E. Bernaldo de Quirós<sup>1</sup>, R. López<sup>1</sup>, V. Pérez<sup>1</sup>, M. Clemente<sup>2</sup>, J. Gil-Jaurena<sup>3</sup>, M. Camino<sup>4</sup>, N. Gil<sup>4</sup>, E. Panadero<sup>4</sup>, C. Medrano<sup>4</sup>, M. Pion<sup>1</sup>, R. Correa-Rocha<sup>1</sup>,  
<sup>1</sup>Laboratory of Immune-regulation, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain, <sup>2</sup>Cell Culture Unit, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain, <sup>3</sup>Pediatric Cardiac Surgery Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain, <sup>4</sup>Pediatric Cardiology Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain

**D355 †** **Mismatched Antibody Epitopes and the Development of HLA-DQ De Novo DSA during Immunosuppression Withdrawal in Liver Transplant Recipients**  
 V. Jucaud<sup>1</sup>, A. Shaked<sup>2</sup>, M. DesMarais<sup>3</sup>, P. Sayre<sup>4</sup>, S. Feng<sup>4</sup>, J. Levitsky<sup>5</sup>, M. Everly<sup>1</sup>,  
<sup>1</sup>Terasaki Research Institute, Los Angeles, CA, <sup>2</sup>University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Immune Tolerance Network, San Francisco, CA, <sup>4</sup>University of California San Francisco, San Francisco, CA, <sup>5</sup>Northern Western University, Chicago, IL

### Poster Session D: Late Breaking

**D356** **Paradoxical Liver Simulated Allocation Model (LSAM) Projections for Changes to Waitlist Mortality under Acuity Circle Distribution Model**  
 R. Lynch<sup>1</sup>, K. Ross<sup>1</sup>, S. Karp<sup>2</sup>,  
<sup>1</sup>Emory, Atlanta, GA, <sup>2</sup>Vanderbilt, Nashville, TN

**D357** **Recipient Predictors of Post-Donation End Stage Renal Disease in Living Kidney Donors**  
 J. Wainright<sup>1</sup>, A. Robinson<sup>1</sup>, A. Wilk<sup>1</sup>, D. Klassen<sup>2</sup>, W. Cherikh<sup>1</sup>, L. Cartwright<sup>1</sup>, D. Stewart<sup>1</sup>,  
<sup>1</sup>Research, UNOS, Richmond, VA, <sup>2</sup>UNOS, Richmond, VA

**D358** **Transplantation of Hepatitis C Virus Positive Donor Kidneys into Hepatitis C Negative Older Recipients**  
 J. A. Graham<sup>1</sup>, M. Ajaimy<sup>2</sup>, J. Torabi<sup>1</sup>, T. Powell<sup>3</sup>, J. Weiss<sup>4</sup>, T. Weinstein<sup>5</sup>, S. Greenstein<sup>1</sup>, O. Andacoglu<sup>1</sup>, A. Campbell<sup>6</sup>, J. Carrero<sup>1</sup>, J. Laponese<sup>1</sup>, M. Kinkhabwala<sup>1</sup>, E. Akalin<sup>2</sup>, J. P. Rocca<sup>1</sup>,  
<sup>1</sup>Surgery, Montefiore Medical Center, Bronx, NY, <sup>2</sup>Medicine, Montefiore Medical Center, Bronx, NY, <sup>3</sup>Epidemiology and Psychiatry, Montefiore Medical Center, Bronx, NY, <sup>4</sup>Medical Affairs, Montefiore Medical Center, Bronx, NY, <sup>5</sup>Risk & Loss Prevention, Montefiore Medical Center, Bronx, NY, <sup>6</sup>Pharmacy, Montefiore Medical Center, Bronx, NY

**D359** **EBV+ PTLD in the Modern Immunosuppression Era: Role of EBV Serology and DNAemia-Preliminary Data from CTOT-C06**  
 O. M. Martinez<sup>1</sup>, S. M. Krams<sup>1</sup>, M. A. Robien<sup>2</sup>, M. Lapasaran<sup>1</sup>, S. D. Boyd<sup>1</sup>, B. Armstrong<sup>3</sup>, C. Twist<sup>4</sup>, K. Weinberg<sup>1</sup>, D. Gratzinger<sup>1</sup>, B. Tan<sup>1</sup>, M. Sever<sup>3</sup>, D. Ikle<sup>3</sup>, M. Brown<sup>2</sup>, D. Bernstein<sup>1</sup>, C. O. Esquivel<sup>1</sup>,  
<sup>1</sup>Stanford University Sch of Med, Stanford, CA, <sup>2</sup>NIAID/NIH, Rockville, MD, <sup>3</sup>Rho, Chapel Hill, NC, <sup>4</sup>Roswell Park, Buffalo, NY

**D360** **Specific Donor/Recipient HLA Disparities are Associated with Better Long-Term Kidney Allograft Survival among 4-, 5-, and 6-HLA (A/B/DR)-Mismatched Pairs**  
 D. Bekbolsynov, H. Zhang, B. Mierzejewska, M. Rees, K. Xu, S. Stepkowski,  
 University of Toledo, Toledo, OH

**D361** **The Influential Yet Highly Variable Role of Biopsy Findings on Kidney Offer Acceptance Decisions: An Organ Offer Simulation Study**  
 D. Stewart<sup>1</sup>, J. Rosendale<sup>1</sup>, H. McGehee<sup>1</sup>, I. Hall<sup>2</sup>, G. Gupta<sup>3</sup>, K. Reddy<sup>4</sup>, B. Kasiske<sup>5</sup>, K. Andreoni<sup>6</sup>, D. Klassen<sup>1</sup>,  
<sup>1</sup>UNOS, Richmond, VA, <sup>2</sup>Univ of Utah, Salt Lake City, UT, <sup>3</sup>VCU, Richmond, VA, <sup>4</sup>Mayo, Phoenix, AZ, <sup>5</sup>HCMC, Minneapolis, MN, <sup>6</sup>Univ of Florida, Gainesville, FL



- D362 The Rapidly Aging Population of Liver Transplant Patients with Hepatocellular Carcinoma**  
J. B. Rubin, G. Cullaro, N. Mehta, J. C. Lai, *Division of Gastroenterology & Hepatology, UCSF, San Francisco, CA*
- D363 Comparison of Simultaneous Pancreas kidney Transplantation to Kidney Transplantation Alone for Type 2 Diabetes with End Stage Renal Disease**  
Y. Fu, Z. Shen, *Kidney&Pancreas Transplant, Tianjin First Center Hospital, Tianjin, China*
- D364 Targeting Syk Signaling in Myeloid Cells Protects against Liver Fibrosis and Hepatocarcinogenesis**  
A. Torres-Hernandez, W. Wang, G. Miller, *Surgery, NYU School of Medicine, New York, NY*
- D365 Willingness to Acquire Donor-Derived Hepatitis C Infection May Reduce Waitlist Mortality for Heart Transplant Candidates**  
B. E. Lonze, A. Reyentovich, N. Moazami, D. E. Smith, C. Gidea, R. A. Montgomery, *NYU Langone Transplant Institute, New York, NY*
- D366 The First Human Organ Transported by Drone and Steps Forward to Large Scale Organ Drone Use in the USA**  
J. R. Scalea<sup>1</sup>, M. Scassero<sup>2</sup>, N. Wereley<sup>3</sup>, *<sup>1</sup>Surgery, University of Maryland, Baltimore, MD, <sup>2</sup>UAS Test Site, University of Maryland, California, MD, <sup>3</sup>Aerospace Engineering, University of Maryland, College Park, MD*
- D367 A Step-Wise Desensitization Using Rituximab&Bortezomib Combined with Antithymocyte Globulin for Highly Sensitized Kidney Transplant Candidates**  
H. Ohdan, K. Ide, M. Ohira, H. Tahara, Y. Tanaka, *Hiroshima University, Hiroshima, Japan*
- D368 Clinical Trial of Allogeneic Islet Transplantation in the Treatment of Diabetes after Renal Transplantation**  
W. liang, M. Hu, G. Peng, D. Zhou, C. Zeng, W. Zhou, q. Ye, Z. Wang, *Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases, Wuhan, China*
- D369 † Outcomes Analysis of U.S. Transplant Centers Performing High Volumes of Hard to Place Kidneys**  
Y. Qazi<sup>1</sup>, D. Bahl<sup>2</sup>, N. Mehta<sup>3</sup>, Z. Haddad<sup>4</sup>, M. Smogorzewski<sup>4</sup>, *<sup>1</sup>USC, Los Angeles, CA, <sup>2</sup>UC Davis, Sacramento, CA, <sup>3</sup>UC Berkeley, Berkeley, CA, <sup>4</sup>Keck Medical Center At USC, Los Angeles, CA*
- D370 Impact of the Pediatric End-Stage Liver Disease Growth Failure Threshold on Waitlist Mortality in Children Awaiting Liver Transplant**  
S. M. Swenson, J. P. Roberts, S. Rhee, E. R. Perito, *University of California, San Francisco, San Francisco, CA*
- D371 Supercooling Preservation Prolonged Mouse Cardiac Graft Cold Ischemia Time**  
W. Que<sup>1</sup>, X. Hu<sup>1</sup>, M. Fujino<sup>1</sup>, Y. Yamada<sup>2</sup>, L. Zhong<sup>3</sup>, X. Li<sup>1</sup>, *<sup>1</sup>Division of Transplantation Immunology, National Research Institute for Child Health and Development, Tokyo, Japan, <sup>2</sup>Technican Co., Ltd., Kanagawa, Japan, <sup>3</sup>Department of Surgery, Shanghai General Hospital, shanghai Jiao Tong University School of Medicine, Shanghai, China*
- D372 Mycophenolate Mofetil versus Azathioprine in Kidney Transplant Recipients on Steroid-Free Low-Dose Cyclosporine Immunosuppression: The ATHENA Trial**  
P. Cravedi<sup>1</sup>, P. Ruggenti<sup>2</sup>, E. Gotti<sup>2</sup>, A. Plati<sup>2</sup>, S. Sandrini<sup>3</sup>, N. Bossini<sup>3</sup>, F. Citterio<sup>4</sup>, E. Minetti<sup>5</sup>, D. Montanaro<sup>6</sup>, R. Tardanico<sup>3</sup>, E. Sabadini<sup>2</sup>, F. Gaspari<sup>7</sup>, A. Villa<sup>7</sup>, F. Peraro<sup>7</sup>, G. Remuzzi<sup>7</sup>, *<sup>1</sup>Mount Sinai, New York, NY, <sup>2</sup>ASST Ospedale Papa Giovanni XXIII, Bergamo, Italy, <sup>3</sup>ASST degli Spedali Civili, Brescia, Italy, <sup>4</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, <sup>5</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>6</sup>Presidio Ospedaliero Universitario Santa Maria della Misericordia, Udine, Italy, <sup>7</sup>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy*
- D373 Platelets Stimulate Liver Regeneration in a 30% Partial Liver Transplantation Model in Rat**  
C. Liang, K. Takahashi, T. Oda, N. Ohkohchi, *University of Tsukuba, Tsukuba, Japan*



- D374** **Impact of Steroid-Free Protocol on Incidence of Posttransplantation Diabetes Mellitus: A Prospective, Randomized, Multicenter, Open-Label, Controlled Trial in Renal Transplant Recipients**  
 J. Ekberg<sup>1</sup>, S. Baid-Agrawal<sup>1</sup>, B. Jespersen<sup>2</sup>, R. Källén<sup>3</sup>, E. Rafael<sup>3</sup>, K. Skov<sup>2</sup>, P. Lindnér<sup>1</sup>, <sup>1</sup>*Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden*, <sup>2</sup>*Department of Nephrology, Aarhus University Hospital, Skejby, Denmark*, <sup>3</sup>*Department of Transplantation, Skane University Hospital, Malmoe, Sweden*
- D375** **Blood Profiling Reflects a Significant Down-Regulation in Oxidative Phosphorylation Following Renal Transplantation with DCD and AKI Allografts**  
 S. Walker<sup>1</sup>, L. Cox<sup>2</sup>, C. Langefeld<sup>2</sup>, B. Freedman<sup>2</sup>, A. Farney<sup>2</sup>, J. Rogers<sup>2</sup>, C. Jay<sup>2</sup>, R. Stratta<sup>2</sup>, G. Orlando<sup>2</sup>, <sup>1</sup>*Wake Forest Institute for Regenerative Medicine, Winston Salem, NC*, <sup>2</sup>*Wake Forest Baptist Medical Center, Winston Salem, NC*
- D376** **Utilization of Hepatitis C Donors is Safe and Cost Effective**  
 J. Shaw, D. Reino, N. Kapila, K. Al Khalloufi, S. Ebaid, S. Rhazouani, X. Zervos, J. Vanatta, N. Agrawal, *Cleveland Clinic, Weston, FL*
- D377** **Vimentin Inhibition Improves Post-Transplant Survival in a Mouse Renal Transplant Model**  
 R. Lopez-Soler<sup>1</sup>, Z. Zhang<sup>2</sup>, H. Chin<sup>3</sup>, J. Wang<sup>4</sup>, K. Ridge<sup>5</sup>, <sup>1</sup>*Albany Medical College, Albany, NY*, <sup>2</sup>*Microsurgery Core, Comprehensive Transplant Center, Northwestern University, Feinberg School of Medicine, Chicago, IL*, <sup>3</sup>*Molecular and Cellular Physiology, Albany Medical College, Albany, NY*, <sup>4</sup>*Microsurgery Core, Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL*, <sup>5</sup>*Northwestern University, Feinberg School of Medicine, Chicago, IL*
- D378** **Towards Human Leukocyte Antigen Immunogenicity Assessment at the Individual Patient Level**  
 H. Copley<sup>1</sup>, H. McDowell<sup>2</sup>, D. Pinelli<sup>2</sup>, A. R. Tambur<sup>2</sup>, V. Kosmoliaptis<sup>1</sup>, <sup>1</sup>*Department of Surgery, University of Cambridge, Cambridge, United Kingdom*, <sup>2</sup>*Department of Surgery, Feinberg School of Medicine, Comprehensive Transplant Center, Northwestern University, Chicago, IL*
- D379** **Organ Procurement Organization Performance is Not Related to Educational Spending**  
 J. P. Roberts<sup>1</sup>, J. Bragg-Gresham<sup>2</sup>, P. Held<sup>3</sup>, <sup>1</sup>*Univ of California-San Francisco, San Francisco, CA*, <sup>2</sup>*Nephrology, University of Michigan, Ann Arbor, MI*, <sup>3</sup>*Stanford University, Stanford, CA*
- D380** **Human Neutrophil Function against Pathogens in Solid Organ and Stem Cell Transplant Recipients**  
 N. Barros, N. Alexander, Z. Dagher, S. Knooihuizen, A. Viens, A. R. Hopke, D. Irimia, M. K. Mansour, *Transplant Infectious Diseases, Massachusetts General Hospital, Boston, MA*
- D381** **Impact of Previous Hepatic Resection on the Outcome of Liver Transplantation: A Case-Control Analysis**  
 M. Serenari, M. Paterno, A. D. Pinna, M. Ravaioli, E. Prospero, M. Del Gaudio, C. Zanfi, V. Bertuzzo, G. Frascaroli, M. Cescon, *University of Bologna, Bologna, Italy*

- D382 Pathologic Vascular Invasion Correlates with Worse Outcome in Hepatoblastoma Patients Treated with Liver Transplantation - A Hepatoblastoma Transplant Consortium Study**  
 T. H. Malik<sup>1</sup>, H. Zhu<sup>2</sup>, T. Ha<sup>3</sup>, S. Commander<sup>4</sup>, C. Trautz<sup>5</sup>, R. Sindhi<sup>5</sup>, S. Kim<sup>6</sup>, K. Vakili<sup>6</sup>, N. Vachharajani<sup>7</sup>, W. Chapman<sup>7</sup>, A. Griesemer<sup>8</sup>, M. Martinez<sup>8</sup>, J. A. Goss<sup>9</sup>, S. Vasudevan<sup>10</sup>, <sup>1</sup>Baylor College of Medicine, Houston, TX, <sup>2</sup>Texas Children's Hospital, Houston, TX, <sup>3</sup>Department of Surgery, Baylor College of Medicine, Houston, TX, <sup>4</sup>Department of Surgery, Duke University School of Medicine, Durham, NC, <sup>5</sup>Department of Surgery, University of Pittsburgh, Pittsburgh, PA, <sup>6</sup>Department of Surgery, Boston Children's Hospital, Boston, MA, <sup>7</sup>Department of Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO, <sup>8</sup>Department of Surgery, NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY, <sup>9</sup>Division of Abdominal Transplantation, Baylor College of Medicine, Houston, TX, <sup>10</sup>Department of Pediatric Surgery, Texas Children's Hospital, Houston, TX
- D383 Pediatric Liver Transplantation for Metabolic Disorders without Intrinsic Liver Disease: A 25 Year Experience**  
 P. Vuong, L. Lee, N. Mineyev, S. Conlon, R. Shetty, W. Concepcion, C. A. Bonham, A. Gallo, T. Pham, S. Busque, M. L. Melcher, G. M. Enns, C. O. Esquivel, Stanford University Medical Center, Palo Alto, CA
- D384 † Complete Robotic-Assisted Kidney Transplantation: Our Initial Experience**  
 A. Khan, C. Bhati, T. Reichman, A. Cotterell, D. Kumar, G. Gupta, L. Kamal, A. King, A. Sharma, M. Levy, VCU Medical Center, Richmond, VA
- D385 Ex Vivo Assessment of Marginal Human Kidneys Using Computed Tomography**  
 M. K. Harris<sup>1</sup>, J. R. DiRito<sup>2</sup>, H. Liu<sup>3</sup>, N. Boutagy<sup>3</sup>, C. Liu<sup>4</sup>, S. Hosgood<sup>2</sup>, D. Mulligan<sup>1</sup>, M. L. Nicholson<sup>2</sup>, A. Sinusas<sup>3</sup>, D. Haakinson<sup>1</sup>, G. T. Tietjen<sup>1</sup>, <sup>1</sup>Surgery, Yale School of Medicine, New Haven, CT, <sup>2</sup>Surgery, University of Cambridge, Cambridge, United Kingdom, <sup>3</sup>Yale Translational Research Imaging Center, New Haven, CT, <sup>4</sup>Radiology, Yale School of Medicine, New Haven, CT
- D386 Breaking Concepts: 10-year Follow-Up of the Everolimus versus Azathioprine Heart Transplant Multi-National Study**  
 J. A. Kobashigawa<sup>1</sup>, R. Starling<sup>2</sup>, E. Passano<sup>1</sup>, P. Bernhardt<sup>3</sup>, B. Azarbal<sup>1</sup>, R. Cheng<sup>1</sup>, F. Esmailian<sup>1</sup>, K. Khush<sup>4</sup>, D. Mancini<sup>5</sup>, J. Patel<sup>1</sup>, T. Sato<sup>1</sup>, S. Varnous<sup>6</sup>, <sup>1</sup>Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA, <sup>2</sup>Cleveland Clinic, Cleveland, OH, <sup>3</sup>Novartis Pharmaceuticals, Basel, Switzerland, <sup>4</sup>Stanford University, Palo Alto, CA, <sup>5</sup>Mount Sinai, New York, NY, <sup>6</sup>APHP, Pitié-Salpêtrière, Sorbonne University, Paris, France
- D387 Development and Validation of a Capillary Blood Mitra-Based Assay for the Quantitative Determination of Advagraf® Concentrations in Transplant Patients**  
 N. Undre<sup>1</sup>, I. Dawson<sup>2</sup>, V. Aluvihare<sup>3</sup>, N. Kamar<sup>4</sup>, F. Saliba<sup>5</sup>, N. Torpey<sup>6</sup>, S. Anaokar<sup>7</sup>, G. Kazeem<sup>1</sup>, <sup>1</sup>Astellas Pharma Europe Ltd, Chertsey, United Kingdom, <sup>2</sup>Covance Laboratories, Harrogate, United Kingdom, <sup>3</sup>Kings College Hospital, London, United Kingdom, <sup>4</sup>CHU Rangueil, Toulouse, France, <sup>5</sup>Hôpital Paul-Brousse, Villejuif, France, <sup>6</sup>Addenbrookes Hospital, Cambridge, United Kingdom, <sup>7</sup>Astellas Pharma Europe Ltd, Surrey, United Kingdom

- D388 Renal Cell Carcinoma in Dialysis Patients: Criteria for Transplant Wait List Inclusion**  
D. B. Laskar<sup>1</sup>, J. Zeng<sup>1</sup>, S. Sharma<sup>2</sup>, M. T. Smith Jr<sup>3</sup>, A. D. Nicastri<sup>1</sup>, D. Levitan<sup>4</sup>, R. Maglantay<sup>1</sup>, D. John<sup>3</sup>, S. R. Gottesman<sup>1</sup>, <sup>1</sup>Pathology, SUNY Downstate Medical Center, Brooklyn, NY, <sup>2</sup>Transplant Surgery, NYP/Columbia University Medical Center, New York, NY, <sup>3</sup>Surgery, SUNY Downstate Medical Center, Brooklyn, NY, <sup>4</sup>Pathology & Laboratory Medicine, NYP/Weill Cornell Medical Center, New York, NY
- D389 The Pregnancy Experiences of Uterus Transplant Recipients**  
A. E. Wall, L. Johannesson, G. Testa, A. Warren, Baylor University Medical Center, Dallas, TX
- D390 Effects of Pretreated Bortezomib on Renal Function after Renal Ischemia - Reperfusion Injury in Mice**  
X. Zheng, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
- D391 Perioperative Blood Transfusion Significantly Increases Inpatient Morbidity and Mortality in Renal Transplant Recipients: 15-year Experience**  
K. Mahendraraj<sup>1</sup>, G. Medrano del Rosal<sup>1</sup>, M. Kruse<sup>1</sup>, R. Shah<sup>1</sup>, T. Katsichtis<sup>1</sup>, T. Brennan<sup>2</sup>, N. Nissen<sup>2</sup>, T. Todo<sup>2</sup>, K. Kosari<sup>2</sup>, A. Klein<sup>2</sup>, I. Kim<sup>2</sup>, <sup>1</sup>Surgery, Lincoln Medical Center, New York, NY, <sup>2</sup>Transplant Surgery, Cedars-Sinai Medical Center, Los Angeles, CA
- D392 The Therapeutic Potential of Ex Vivo Induced Monocytic Myeloid-Derived Suppressor Cells from Bone Marrow in a Mouse Cardiac Allotransplantation Model**  
K. Uchida, K. Fujimoto, E. Yin, H. Bashuda, K. Okumura, K. Takeda, Juntendo University Atopy Research Center, Tokyo, Japan
- D393 The High Burden of Vaccine Preventable Infections Following Pediatric Solid Organ Transplant**  
A. G. Feldman<sup>1</sup>, B. L. Beaty<sup>2</sup>, D. Curtis<sup>3</sup>, E. Juarez-Colunga<sup>2</sup>, A. Kempe<sup>4</sup>, <sup>1</sup>Pediatric Gastroenterology, Hepatology and Nutrition, University of Colorado, Aurora, CO, <sup>2</sup>University of Colorado, Aurora, CO, <sup>3</sup>Pediatric Infectious Diseases, University of Colorado, Aurora, CO, <sup>4</sup>Pediatrics, University of Colorado, Aurora, CO
- D394 The Use of High Volume Perioperative Normal Saline Increases the Risk of Delayed Graft Function after Kidney Transplantation**  
K. Kolodzie<sup>1</sup>, O. S. Cakmakkaya<sup>2</sup>, E. S. Boparai<sup>3</sup>, M. Tavakol<sup>4</sup>, J. Feiner<sup>1</sup>, C. U. Niemann<sup>5</sup>, <sup>1</sup>Anesthesia & Perioperative Care, University of California San Francisco, San Francisco, CA, <sup>2</sup>Dept. of Medical Education, University Istanbul – Cerrahpasa, Istanbul, Turkey, <sup>3</sup>School of Medicine, George Washington University, Washington, DC, <sup>4</sup>Dept. of Surgery, Division of Transplantation, University of California San Francisco, San Francisco, CA, <sup>5</sup>Anesthesia & Perioperative Care, and Dept. of Surgery, Division of Transplantation, University of California San Francisco, San Francisco, CA
- D395 Clinical Features and Prognosis of Diffuse Intrahepatic Biliary Stricture in Adult ABO-Incompatible Living Donor Liver Transplantation**  
J. Kwon, G. Song, S. Hwang, K. Kim, C. Ahn, D. Moon, T. Ha, D. Jung, G. Park, Y. Yoon, H. Cho, I. Jeong, J. Choi, S. Yoo, S. Lee, Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
- D396 Restrictive Medicaid Policies Reduce Access to Liver Transplant for Alcohol-Associated Liver Disease**  
B. P. Lee, V. Eric, P. Mark, J. Dodge, N. Terrault, UCSF, SF, CA
- D397 Actual Outcomes and Technical Feasibility of Living Donor-Related Liver Re-Transplantation**  
W. Kim<sup>1</sup>, G. Song<sup>2</sup>, S. Lee<sup>2</sup>, <sup>1</sup>Korea University Guro Hospital, Seoul, Korea, Republic of, <sup>2</sup>Asan Medical Center, Seoul, Korea, Republic of

- D398 The Important Roles of Dendritic Cells in Transplantation**  
T. Ueno<sup>1</sup>, M. M. McGrath<sup>1</sup>, M. Y. Yeung<sup>1</sup>, S. Cai<sup>1</sup>, Y. Ueno<sup>1</sup>, T. Yokoyama<sup>2</sup>, Y. Kihara<sup>2</sup>, O. Konno<sup>2</sup>, Y. Nakamura<sup>2</sup>, H. Iwamoto<sup>2</sup>, A. K. Chandraker<sup>1</sup>,  
<sup>1</sup>Medicine, Renal Division, Brigham and Women's Hospital, Transplantation Research Center, Boston, MA, <sup>2</sup>Kidney Transplantation Surgery, Tokyo Medical University, Hachioji Medical Center, Tokyo, Japan
- D399 Single-center Retrospective Analysis of Prophylaxis and Treatment of Pneumocystis Carinii Pneumonia in Patients with Poor Renal Function**  
Y. Fu, J. Pan, Z. Shen, *Kidney-Pancreas Transplant Department., Tianjin First Central Hospital, Tianjin, China*
- D400 Retrospective Evaluation of Optimal Cmv Prophylaxis Regimens in Lung Transplant Patients: Analysis of Patient Outcomes Pre and Post Protocol Dosing Alterations**  
J. Hunt, A. Nasar, R. Walia, L. Cherrier, *St. Joseph Hospital and Medical Center, Phoenix, AZ*
- D401 Combined Thoracic-Liver Transplants Using Normothermic Machine Perfusion for Liver Preservation: A Case Series**  
M. Rizzari, K. Crombez, S. Nagai, J. Stracke, A. Al-Kurd, K. Collins, A. Yoshida, M. Abouljoud, *Henry Ford Transplant Institute, Detroit, MI*
- D402 Effects of IVIG Therapy and FcγR Polymorphisms on BK Virus Nephropathy in Kidney Transplant Recipients**  
D. I. Min<sup>1</sup>, Y. Chang<sup>2</sup>, T. Shah<sup>3</sup>, <sup>1</sup>Western Univ of Health Sciences, Los Angeles, CA, <sup>2</sup>Mendez National Institute of Transplantation Foundation, Los Angeles, CA, <sup>3</sup>St. Vincent Medical Center, Los Angeles, CA
- D403 Costs of Kidney Recoveries Varies Dramatically across Organ Procurement Organizations**  
J. P. Roberts<sup>1</sup>, J. Bragg-Gresham<sup>2</sup>, P. J. Held<sup>3</sup>, <sup>1</sup>Univ of California-San Francisco, San Francisco, CA, <sup>2</sup>University of Michigan, Ann Arbor, MI, <sup>3</sup>Stanford, Stanford, CA
- D404 Associations between State-Level Donor Designation Rate and Organ Procurement Organization Characteristics and Outcomes**  
J. Bragg-Gresham<sup>1</sup>, P. Held<sup>2</sup>, J. P. Roberts<sup>3</sup>, <sup>1</sup>Kidney Epidemiology and Cost Center, Univ of Michigan, Ann Arbor, MI, <sup>2</sup>Stanford University, Stanford, CA, <sup>3</sup>University of California San Francisco, San Francisco, CA
- D405 Challenges to Inpatient Management Post Abdominal Wall Transplant (AWT) - From App's Perspective**  
K. Hattori, D. Sudan, K. Ravindra, *Duke University hospital, Durham, NC*
- D406 Immunization Status at the Time of Pediatric Liver Transplant: A 1-year Study through The Society of Pediatric Liver Transplantation**  
A. G. Feldman<sup>1</sup>, A. Kempe<sup>2</sup>, B. L. Beaty<sup>3</sup>, R. Torres<sup>1</sup>, D. Curtis<sup>4</sup>, S. S. Sundaram<sup>1</sup>, <sup>1</sup>Pediatric Gastroenterology, Hepatology and Nutrition, University of Colorado, Aurora, CO, <sup>2</sup>Pediatrics, University of Colorado, Aurora, CO, <sup>3</sup>University of Colorado, Aurora, CO, <sup>4</sup>Pediatric Infectious Diseases, University of Colorado, Aurora, CO
- D407 Barriers to Pre-Transplant Immunization: A Qualitative Study of Pediatric Liver-Transplant Stakeholders**  
A. G. Feldman<sup>1</sup>, R. Marsh<sup>2</sup>, A. Kempe<sup>3</sup>, M. Morris<sup>2</sup>, <sup>1</sup>Pediatric Gastroenterology, Hepatology and Nutrition, University of Colorado, Aurora, CO, <sup>2</sup>University of Colorado, Aurora, CO, <sup>3</sup>Pediatrics, University of Colorado, Aurora, CO
- D408 Organ Transportation by Drone: Surgeon Perspectives**  
T. Talaie<sup>1</sup>, R. Barth<sup>2</sup>, J. R. Scalea<sup>1</sup>, <sup>1</sup>University of Maryland, Baltimore, MD, <sup>2</sup>Surgery, University of Maryland, Baltimore, MD

- D409**      **Variable Glycosylations of Anti-HLA Antibodies Detected with Single Antigen Beads in Kidney Transplant Recipients**  
Y. Chang<sup>1</sup>, N. Lemp<sup>2</sup>, J. Ciciarelli<sup>1</sup>, T. Shah<sup>3</sup>, D. Min<sup>4</sup>, <sup>1</sup>Mendez National Institute of Transplantation Foundation, Los Angeles, CA, <sup>2</sup>Transplantation Research, Mendez National Institute of Transplantation Foundation, Los Angeles, CA, <sup>3</sup>St. Vincent Medical Center, Los Angeles, CA, <sup>4</sup>Western Univ of Health Sciences, Pomona, CA
- D410**      **Differences in the Cost of Kidney Organ Recovery by Organ Procurement Organization Size**  
P. J. Held<sup>1</sup>, J. Bragg-Gresham<sup>2</sup>, J. P. Roberts<sup>3</sup>, <sup>1</sup>Stanford University, Stanford, CA, <sup>2</sup>Univ of Michigan, Michigan, MI, <sup>3</sup>Univ of California-San Francisco, San Francisco, CA
- D411**      **Differences in the Cost of Recovering Organs over Time**  
J. P. Roberts<sup>1</sup>, J. Bragg-Gresham<sup>2</sup>, P. Held<sup>3</sup>, <sup>1</sup>Univ of California-San Francisco, San Francisco, CA, <sup>2</sup>Univ of Michigan, Ann Arbor, CA, <sup>3</sup>Stanford University, Stanford, CA